<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<corpus source="miRNA-corpus">
    <document id="miRNA-corp.d0" origId="21295623">
        <sentence id="miRNA-corp.d0.s0" origId="21295623.s0" text="Identification of blood microRNAs associated to Parkinsońs disease.  ">
            <entity charOffset="24-32" id="miRNA-corp.d0.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="48-66" id="miRNA-corp.d0.s0.e1" text="Parkinsońs disease" type="Diseases"/>
            <entity charOffset="34-43" id="miRNA-corp.d0.s0.e2" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d0.s0.e0" e2="miRNA-corp.d0.s0.e1" id="miRNA-corp.d0.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s1" origId="21295623.s4" text="While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients. ">
            <entity charOffset="85-86" id="miRNA-corp.d0.s1.e0" text="PD" type="Diseases"/>
            <entity charOffset="6-10" id="miRNA-corp.d0.s1.e1" text="miR-1" type="Specific_miRNAs"/>
            <entity charOffset="13-18" id="miRNA-corp.d0.s1.e2" text="miR-22" type="Specific_miRNAs"/>
            <entity charOffset="25-30" id="miRNA-corp.d0.s1.e3" text="miR-29" type="Specific_miRNAs"/>
            <entity charOffset="111-118" id="miRNA-corp.d0.s1.e4" text="miR-16-2" type="Specific_miRNAs"/>
            <entity charOffset="122-129" id="miRNA-corp.d0.s1.e5" text="miR-26a2" type="Specific_miRNAs"/>
            <entity charOffset="136-141" id="miRNA-corp.d0.s1.e6" text="miR30a" type="Specific_miRNAs"/>
            <entity charOffset="32-71" id="miRNA-corp.d0.s1.e7" text="expression levels allowed to distinguish" type="Relation_Trigger"/>
            <entity charOffset="181-188" id="miRNA-corp.d0.s1.e8" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d0.s1.e1" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s1.e2" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s1.e3" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s1.e4" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s1.e5" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s1.e6" e2="miRNA-corp.d0.s1.e0" id="miRNA-corp.d0.s1.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s2" origId="21295623.s3" text="They form two groups according to their expression profile in control, non-treated, early-onset and treated Parkinson's disease subjects. ">
            <entity charOffset="108-126" id="miRNA-corp.d0.s2.e0" text="Parkinson's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s3" origId="21295623.s2" text="A set of six differentially expressed microRNAs were identified. ">
            <entity charOffset="38-46" id="miRNA-corp.d0.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-36" id="miRNA-corp.d0.s3.e1" text="differentially expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s4" origId="21295623.s1" text="The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD). ">
            <entity charOffset="77-81" id="miRNA-corp.d0.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-130" id="miRNA-corp.d0.s4.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="133-134" id="miRNA-corp.d0.s4.e2" text="PD" type="Diseases"/>
            <entity charOffset="98-107" id="miRNA-corp.d0.s4.e3" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d0.s4.e0" e2="miRNA-corp.d0.s4.e1" id="miRNA-corp.d0.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d0.s4.e0" e2="miRNA-corp.d0.s4.e2" id="miRNA-corp.d0.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d0.s5" origId="21295623.s5" text="This study is innovative in contributing to the development of effective PD biomarkers.   ">
            <entity charOffset="73-74" id="miRNA-corp.d0.s5.e0" text="PD" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d1" origId="19703993">
        <sentence id="miRNA-corp.d1.s0" origId="19703993.s8" text="This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.   ">
            <entity charOffset="151-158" id="miRNA-corp.d1.s0.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="69-84" id="miRNA-corp.d1.s0.e1" text="meningioma tumor" type="Diseases"/>
            <entity charOffset="231-241" id="miRNA-corp.d1.s0.e2" text="meningiomas" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s0.e0" e2="miRNA-corp.d1.s0.e1" id="miRNA-corp.d1.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s0.e0" e2="miRNA-corp.d1.s0.e2" id="miRNA-corp.d1.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s1" origId="19703993.s6" text="A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples. ">
            <entity charOffset="61-68" id="miRNA-corp.d1.s1.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="116-125" id="miRNA-corp.d1.s1.e1" text="meningioma" type="Diseases"/>
            <entity charOffset="94-105" id="miRNA-corp.d1.s1.e2" text="beta-catenin" type="Genes/Proteins"/>
            <entity charOffset="43-56" id="miRNA-corp.d1.s1.e3" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="78-89" id="miRNA-corp.d1.s1.e4" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="9-19" id="miRNA-corp.d1.s1.e5" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="110-114" id="miRNA-corp.d1.s1.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d1.s1.e0" e2="miRNA-corp.d1.s1.e1" id="miRNA-corp.d1.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s1.e0" e2="miRNA-corp.d1.s1.e2" id="miRNA-corp.d1.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s2" origId="19703993.s7" text="Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways. ">
            <entity charOffset="6-13" id="miRNA-corp.d1.s2.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="112-121" id="miRNA-corp.d1.s2.e1" text="E-cadherin" type="Genes/Proteins"/>
            <entity charOffset="68-72" id="miRNA-corp.d1.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-87" id="miRNA-corp.d1.s2.e3" text="meningiomas" type="Diseases"/>
            <entity charOffset="51-66" id="miRNA-corp.d1.s2.e4" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="131-142" id="miRNA-corp.d1.s2.e5" text="beta-catenin" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e2" e2="miRNA-corp.d1.s2.e1" id="miRNA-corp.d1.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e2" e2="miRNA-corp.d1.s2.e3" id="miRNA-corp.d1.s2.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s2.e2" e2="miRNA-corp.d1.s2.e5" id="miRNA-corp.d1.s2.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e1" id="miRNA-corp.d1.s2.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e3" id="miRNA-corp.d1.s2.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s2.e0" e2="miRNA-corp.d1.s2.e5" id="miRNA-corp.d1.s2.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s3" origId="19703993.s5" text="miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer. ">
            <entity charOffset="0-7" id="miRNA-corp.d1.s3.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="38-49" id="miRNA-corp.d1.s3.e1" text="beta-catenin" type="Genes/Proteins"/>
            <entity charOffset="65-90" id="miRNA-corp.d1.s3.e2" text="inhibiting its translation" type="Relation_Trigger"/>
            <entity charOffset="96-103" id="miRNA-corp.d1.s3.e3" text="blocking" type="Relation_Trigger"/>
            <entity charOffset="22-36" id="miRNA-corp.d1.s3.e4" text="directly target" type="Relation_Trigger"/>
            <entity charOffset="109-120" id="miRNA-corp.d1.s3.e5" text="beta-catenin" type="Genes/Proteins"/>
            <entity charOffset="165-170" id="miRNA-corp.d1.s3.e6" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s3.e0" e2="miRNA-corp.d1.s3.e1" id="miRNA-corp.d1.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s3.e0" e2="miRNA-corp.d1.s3.e5" id="miRNA-corp.d1.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s3.e0" e2="miRNA-corp.d1.s3.e6" id="miRNA-corp.d1.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s4" origId="19703993.s4" text="Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation. ">
            <entity charOffset="18-25" id="miRNA-corp.d1.s4.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="117-125" id="miRNA-corp.d1.s4.e1" text="cyclin D1" type="Genes/Proteins"/>
            <entity charOffset="100-111" id="miRNA-corp.d1.s4.e2" text="beta-catenin" type="Genes/Proteins"/>
            <entity charOffset="30-40" id="miRNA-corp.d1.s4.e3" text="meningiomas" type="Diseases"/>
            <entity charOffset="0-13" id="miRNA-corp.d1.s4.e4" text="Downregulation" type="Relation_Trigger"/>
            <entity charOffset="76-95" id="miRNA-corp.d1.s4.e5" text="increased expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e1" id="miRNA-corp.d1.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e2" id="miRNA-corp.d1.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s4.e0" e2="miRNA-corp.d1.s4.e3" id="miRNA-corp.d1.s4.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s5" origId="19703993.s3" text="Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation. ">
            <entity charOffset="16-23" id="miRNA-corp.d1.s5.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="75-78" id="miRNA-corp.d1.s5.e1" text="ZEB1" type="Genes/Proteins"/>
            <entity charOffset="130-139" id="miRNA-corp.d1.s5.e2" text="E-cadherin" type="Genes/Proteins"/>
            <entity charOffset="0-11" id="miRNA-corp.d1.s5.e3" text="Upregulation" type="Relation_Trigger"/>
            <entity charOffset="25-48" id="miRNA-corp.d1.s5.e4" text="decreased the expression" type="Relation_Trigger"/>
            <entity charOffset="106-125" id="miRNA-corp.d1.s5.e5" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="162-171" id="miRNA-corp.d1.s5.e6" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e2" id="miRNA-corp.d1.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s5.e0" e2="miRNA-corp.d1.s5.e1" id="miRNA-corp.d1.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s6" origId="19703993.s2" text="Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo. ">
            <entity charOffset="19-26" id="miRNA-corp.d1.s6.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="38-47" id="miRNA-corp.d1.s6.e1" text="meningioma" type="Diseases"/>
            <entity charOffset="0-14" id="miRNA-corp.d1.s6.e2" text="Elevated levels" type="Relation_Trigger"/>
            <entity charOffset="28-36" id="miRNA-corp.d1.s6.e3" text="inhibited" type="Relation_Trigger"/>
            <entity charOffset="81-85" id="miRNA-corp.d1.s6.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s6.e0" e2="miRNA-corp.d1.s6.e1" id="miRNA-corp.d1.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s6.e0" e2="miRNA-corp.d1.s6.e4" id="miRNA-corp.d1.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s7" origId="19703993.s1" text="Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth. ">
            <entity charOffset="329-336" id="miRNA-corp.d1.s7.e0" text="miR-200a" type="Specific_miRNAs"/>
            <entity charOffset="322-326" id="miRNA-corp.d1.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="247-254" id="miRNA-corp.d1.s7.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="257-261" id="miRNA-corp.d1.s7.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-10" id="miRNA-corp.d1.s7.e4" text="Meningiomas" type="Diseases"/>
            <entity charOffset="178-201" id="miRNA-corp.d1.s7.e5" text="neurofibromatosis type 2" type="Diseases"/>
            <entity charOffset="308-320" id="miRNA-corp.d1.s7.e6" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="91-100" id="miRNA-corp.d1.s7.e7" text="associated" type="Relation_Trigger"/>
            <entity charOffset="162-171" id="miRNA-corp.d1.s7.e8" text="associated" type="Relation_Trigger"/>
            <entity charOffset="42-53" id="miRNA-corp.d1.s7.e9" text="brain tumors" type="Diseases"/>
            <entity charOffset="236-245" id="miRNA-corp.d1.s7.e10" text="meningioma" type="Diseases"/>
            <entity charOffset="91-100" id="miRNA-corp.d1.s7.e11" text="associated" type="Relation_Trigger"/>
            <entity charOffset="36-40" id="miRNA-corp.d1.s7.e12" text="human" type="Species"/>
            <entity charOffset="230-234" id="miRNA-corp.d1.s7.e13" text="human" type="Species"/>
            <entity charOffset="342-346" id="miRNA-corp.d1.s7.e14" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e0" e2="miRNA-corp.d1.s7.e4" id="miRNA-corp.d1.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e0" e2="miRNA-corp.d1.s7.e5" id="miRNA-corp.d1.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e0" e2="miRNA-corp.d1.s7.e9" id="miRNA-corp.d1.s7.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e0" e2="miRNA-corp.d1.s7.e10" id="miRNA-corp.d1.s7.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e0" e2="miRNA-corp.d1.s7.e14" id="miRNA-corp.d1.s7.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e1" e2="miRNA-corp.d1.s7.e4" id="miRNA-corp.d1.s7.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e1" e2="miRNA-corp.d1.s7.e5" id="miRNA-corp.d1.s7.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e1" e2="miRNA-corp.d1.s7.e9" id="miRNA-corp.d1.s7.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e1" e2="miRNA-corp.d1.s7.e10" id="miRNA-corp.d1.s7.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e1" e2="miRNA-corp.d1.s7.e14" id="miRNA-corp.d1.s7.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e2" e2="miRNA-corp.d1.s7.e4" id="miRNA-corp.d1.s7.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e2" e2="miRNA-corp.d1.s7.e5" id="miRNA-corp.d1.s7.p11" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e2" e2="miRNA-corp.d1.s7.e9" id="miRNA-corp.d1.s7.p12" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e2" e2="miRNA-corp.d1.s7.e10" id="miRNA-corp.d1.s7.p13" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e2" e2="miRNA-corp.d1.s7.e14" id="miRNA-corp.d1.s7.p14" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e3" e2="miRNA-corp.d1.s7.e4" id="miRNA-corp.d1.s7.p15" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e3" e2="miRNA-corp.d1.s7.e5" id="miRNA-corp.d1.s7.p16" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e3" e2="miRNA-corp.d1.s7.e9" id="miRNA-corp.d1.s7.p17" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e3" e2="miRNA-corp.d1.s7.e10" id="miRNA-corp.d1.s7.p18" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s7.e3" e2="miRNA-corp.d1.s7.e14" id="miRNA-corp.d1.s7.p19" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d1.s8" origId="19703993.s0" text="Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.  ">
            <entity charOffset="14-26" id="miRNA-corp.d1.s8.e0" text="microRNA-200a" type="Specific_miRNAs"/>
            <entity charOffset="77-86" id="miRNA-corp.d1.s8.e1" text="E-cadherin" type="Genes/Proteins"/>
            <entity charOffset="31-41" id="miRNA-corp.d1.s8.e2" text="meningiomas" type="Diseases"/>
            <entity charOffset="0-12" id="miRNA-corp.d1.s8.e3" text="Downregulated" type="Relation_Trigger"/>
            <entity charOffset="111-122" id="miRNA-corp.d1.s8.e4" text="beta-catenin" type="Genes/Proteins"/>
            <entity charOffset="92-101" id="miRNA-corp.d1.s8.e5" text="activating" type="Relation_Trigger"/>
            <entity charOffset="52-56" id="miRNA-corp.d1.s8.e6" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d1.s8.e0" e2="miRNA-corp.d1.s8.e1" id="miRNA-corp.d1.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s8.e0" e2="miRNA-corp.d1.s8.e2" id="miRNA-corp.d1.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d1.s8.e0" e2="miRNA-corp.d1.s8.e4" id="miRNA-corp.d1.s8.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d1.s8.e0" e2="miRNA-corp.d1.s8.e6" id="miRNA-corp.d1.s8.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d2" origId="20936480">
        <sentence id="miRNA-corp.d2.s0" origId="20936480.s10" text="These data support the hypothesis that patterns of miRNA expression in cortical GM may contribute to AD pathogenetically, because the aggregate change in miRNA expression observed early in the disease would be predicted to cause profound changes in gene expression.   ">
            <entity charOffset="51-55" id="miRNA-corp.d2.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="154-158" id="miRNA-corp.d2.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-102" id="miRNA-corp.d2.s0.e2" text="AD" type="Diseases"/>
            <entity charOffset="238-263" id="miRNA-corp.d2.s0.e3" text="changes in gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d2.s0.e0" e2="miRNA-corp.d2.s0.e2" id="miRNA-corp.d2.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s0.e1" e2="miRNA-corp.d2.s0.e2" id="miRNA-corp.d2.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s1" origId="20936480.s0" text="Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter.  ">
            <entity charOffset="12-19" id="miRNA-corp.d2.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-70" id="miRNA-corp.d2.s1.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="72-76" id="miRNA-corp.d2.s1.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d2.s1.e0" e2="miRNA-corp.d2.s1.e1" id="miRNA-corp.d2.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s2" origId="20936480.s1" text="MicroRNA (miRNA) expression was assessed in human cerebral cortical gray matter (GM) and white matter (WM) in order to provide the first insights into the difference between GM and WM miRNA repertoires across a range of Alzheimer's disease (AD) pathology. ">
            <entity charOffset="0-7" id="miRNA-corp.d2.s2.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-14" id="miRNA-corp.d2.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-188" id="miRNA-corp.d2.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="220-238" id="miRNA-corp.d2.s2.e3" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="241-242" id="miRNA-corp.d2.s2.e4" text="AD" type="Diseases"/>
            <entity charOffset="44-48" id="miRNA-corp.d2.s2.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d2.s2.e0" e2="miRNA-corp.d2.s2.e3" id="miRNA-corp.d2.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s2.e0" e2="miRNA-corp.d2.s2.e4" id="miRNA-corp.d2.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s2.e1" e2="miRNA-corp.d2.s2.e3" id="miRNA-corp.d2.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s2.e1" e2="miRNA-corp.d2.s2.e4" id="miRNA-corp.d2.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s2.e2" e2="miRNA-corp.d2.s2.e3" id="miRNA-corp.d2.s2.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s2.e2" e2="miRNA-corp.d2.s2.e4" id="miRNA-corp.d2.s2.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s3" origId="20936480.s2" text="RNA was isolated separately from GM and WM portions of superior and middle temporal cerebral cortex (N = 10 elderly females, postmortem interval &lt; 4 h). "/>
        <sentence id="miRNA-corp.d2.s4" origId="20936480.s3" text="miRNA profiling experiments were performed using state-of-the-art Exiqon(©) LNA-microarrays. ">
            <entity charOffset="0-4" id="miRNA-corp.d2.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s5" origId="20936480.s4" text="A subset of miRNAs that appeared to be strongly expressed according to the microarrays did not appear to be conventional miRNAs according to Northern blot analyses. ">
            <entity charOffset="12-17" id="miRNA-corp.d2.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-126" id="miRNA-corp.d2.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s6" origId="20936480.s5" text="Some well-characterized miRNAs were substantially enriched in WM as expected. ">
            <entity charOffset="24-29" id="miRNA-corp.d2.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s7" origId="20936480.s6" text="However, most of the miRNA expression variability that correlated with the presence of early AD-related pathology was seen in GM. ">
            <entity charOffset="21-25" id="miRNA-corp.d2.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-94" id="miRNA-corp.d2.s7.e1" text="AD" type="Diseases"/>
            <entity charOffset="27-64" id="miRNA-corp.d2.s7.e2" text="expression variability that correlated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d2.s7.e0" e2="miRNA-corp.d2.s7.e1" id="miRNA-corp.d2.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s8" origId="20936480.s7" text="We confirm that downregulation of a set of miRNAs in GM (including several miR-15/107 genes and miR-29 paralogs) correlated strongly with the density of diffuse amyloid plaques detected in adjacent tissue. ">
            <entity charOffset="43-48" id="miRNA-corp.d2.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-29" id="miRNA-corp.d2.s8.e1" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="96-101" id="miRNA-corp.d2.s8.e2" text="miR-29" type="Specific_miRNAs"/>
            <entity charOffset="113-122" id="miRNA-corp.d2.s8.e3" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="161-175" id="miRNA-corp.d2.s8.e4" text="amyloid plaques" type="Diseases"/>
            <entity charOffset="75-84" id="miRNA-corp.d2.s8.e5" text="miR-15/107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d2.s8.e2" e2="miRNA-corp.d2.s8.e4" id="miRNA-corp.d2.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s8.e5" e2="miRNA-corp.d2.s8.e4" id="miRNA-corp.d2.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s8.e0" e2="miRNA-corp.d2.s8.e4" id="miRNA-corp.d2.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s9" origId="20936480.s8" text="A few miRNAs were differentially expressed in WM, including miR-212 that is downregulated in AD and miR-424 which is upregulated in AD. ">
            <entity charOffset="6-11" id="miRNA-corp.d2.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="18-41" id="miRNA-corp.d2.s9.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="76-88" id="miRNA-corp.d2.s9.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="117-127" id="miRNA-corp.d2.s9.e3" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="132-133" id="miRNA-corp.d2.s9.e4" text="AD" type="Diseases"/>
            <entity charOffset="93-94" id="miRNA-corp.d2.s9.e5" text="AD" type="Diseases"/>
            <entity charOffset="100-106" id="miRNA-corp.d2.s9.e6" text="miR-424" type="Specific_miRNAs"/>
            <entity charOffset="60-66" id="miRNA-corp.d2.s9.e7" text="miR-212" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d2.s9.e0" e2="miRNA-corp.d2.s9.e4" id="miRNA-corp.d2.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s9.e0" e2="miRNA-corp.d2.s9.e5" id="miRNA-corp.d2.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s9.e6" e2="miRNA-corp.d2.s9.e4" id="miRNA-corp.d2.s9.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s9.e6" e2="miRNA-corp.d2.s9.e5" id="miRNA-corp.d2.s9.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s9.e7" e2="miRNA-corp.d2.s9.e4" id="miRNA-corp.d2.s9.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s9.e7" e2="miRNA-corp.d2.s9.e5" id="miRNA-corp.d2.s9.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d2.s10" origId="20936480.s9" text="The expression of certain miRNAs correlates with other miRNAs across different cases, and particular subsets of miRNAs are coordinately expressed in relation to AD-related pathology. ">
            <entity charOffset="26-31" id="miRNA-corp.d2.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="55-60" id="miRNA-corp.d2.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-117" id="miRNA-corp.d2.s10.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-42" id="miRNA-corp.d2.s10.e3" text="expression of certain miRNAs correlates" type="Relation_Trigger"/>
            <entity charOffset="161-162" id="miRNA-corp.d2.s10.e4" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d2.s10.e0" e2="miRNA-corp.d2.s10.e4" id="miRNA-corp.d2.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s10.e1" e2="miRNA-corp.d2.s10.e4" id="miRNA-corp.d2.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d2.s10.e2" e2="miRNA-corp.d2.s10.e4" id="miRNA-corp.d2.s10.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d3" origId="21537368">
        <sentence id="miRNA-corp.d3.s0" origId="21537368.s11" text="Remarks are also provided to point out the unanswered questions and to outline the new directions for the future research of the field.   "/>
        <sentence id="miRNA-corp.d3.s1" origId="21537368.s10" text="Speculations on the development of miRNAs as potential therapeutic targets are also presented. ">
            <entity charOffset="35-40" id="miRNA-corp.d3.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-73" id="miRNA-corp.d3.s1.e1" text="potential therapeutic targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s2" origId="21537368.s6" text="These small molecules act by repressing the expression of either the proapoptotic or antiapoptotic genes to produce antiapoptotic or proapoptotic effects. "/>
        <sentence id="miRNA-corp.d3.s3" origId="21537368.s7" text="Appealing evidence has been accumulating for the involvement of miRNAs in human diseases associated with apoptotic cell death and the potential of miRNAs as novel therapeutic targets for the treatment of the diseases. ">
            <entity charOffset="147-152" id="miRNA-corp.d3.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-69" id="miRNA-corp.d3.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="163-181" id="miRNA-corp.d3.s3.e2" text="therapeutic targets" type="Relation_Trigger"/>
            <entity charOffset="89-98" id="miRNA-corp.d3.s3.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="74-78" id="miRNA-corp.d3.s3.e4" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s4" origId="21537368.s4" text="The importance of miRNAs has steadily gained appreciation and miRNA biology has exploded into a massive swell of interest with enormous range and potential in almost every biological discipline because of their widespread expression and diverse functions in both animals and humans. ">
            <entity charOffset="18-23" id="miRNA-corp.d3.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-66" id="miRNA-corp.d3.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="275-280" id="miRNA-corp.d3.s4.e2" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s5" origId="21537368.s5" text="It has been established that miRNAs are critical regulators of apoptosis of various cell types. ">
            <entity charOffset="29-34" id="miRNA-corp.d3.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-58" id="miRNA-corp.d3.s5.e1" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s6" origId="21537368.s2" text="Tremendous efforts have been made to improve our understanding of the molecular mechanisms and signaling pathways involved in apoptosistic cell death. "/>
        <sentence id="miRNA-corp.d3.s7" origId="21537368.s3" text="Once ignored completely or overlooked as cellular detritus, microRNAs (miRNAs) that were discovered only a decade ago, have recently taken many by surprise. ">
            <entity charOffset="60-68" id="miRNA-corp.d3.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-76" id="miRNA-corp.d3.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s8" origId="21537368.s0" text="MicroRNA: A matter of life or death.  ">
            <entity charOffset="0-7" id="miRNA-corp.d3.s8.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s9" origId="21537368.s1" text="Progressive cell loss due to apoptosis is a pathological hallmark implicated in a wide spectrum of degenerative diseases such as heart disease, atherosclerotic arteries and hypertensive vessels, Alzheimer's disease and other neurodegenerative disorders. ">
            <entity charOffset="195-213" id="miRNA-corp.d3.s9.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="173-184" id="miRNA-corp.d3.s9.e1" text="hypertensive" type="Diseases"/>
            <entity charOffset="129-141" id="miRNA-corp.d3.s9.e2" text="heart disease" type="Diseases"/>
            <entity charOffset="225-251" id="miRNA-corp.d3.s9.e3" text="neurodegenerative disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s10" origId="21537368.s8" text="This editorial aims to convey this message and to boost up the research interest by providing a timely, comprehensive overview on regulation of apoptosis by miRNAs and a synopsis on the pathophysiologic implications of this novel regulatory network based on the currently available data in the literature. ">
            <entity charOffset="157-162" id="miRNA-corp.d3.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="130-139" id="miRNA-corp.d3.s10.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="230-239" id="miRNA-corp.d3.s10.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d3.s11" origId="21537368.s9" text="It begins with a brief introduction to apoptosis and miRNAs, followed by the description of the fundamental aspects of miRNA biogenesis and action, and the role of miRNAs in regulating apoptosis of cancer cells and cardiovascular cells. ">
            <entity charOffset="119-123" id="miRNA-corp.d3.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="164-169" id="miRNA-corp.d3.s11.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-58" id="miRNA-corp.d3.s11.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="174-183" id="miRNA-corp.d3.s11.e3" text="regulating" type="Relation_Trigger"/>
            <entity charOffset="198-203" id="miRNA-corp.d3.s11.e4" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d3.s11.e2" e2="miRNA-corp.d3.s11.e4" id="miRNA-corp.d3.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s11.e0" e2="miRNA-corp.d3.s11.e4" id="miRNA-corp.d3.s11.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d3.s11.e1" e2="miRNA-corp.d3.s11.e4" id="miRNA-corp.d3.s11.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d4" origId="15509239">
        <sentence id="miRNA-corp.d4.s0" origId="15509239.s2" text="METHODS: We prospectively collected surgical outcome data for 2 to 11 years for 134 consecutive patients who specifically had MTLE and unilateral HS, according to magnetic resonance imaging (MRI) and confirmed by histopathology. ">
            <entity charOffset="126-129" id="miRNA-corp.d4.s0.e0" text="MTLE" type="Diseases"/>
            <entity charOffset="146-147" id="miRNA-corp.d4.s0.e1" text="HS" type="Diseases"/>
            <entity charOffset="96-103" id="miRNA-corp.d4.s0.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s1" origId="15509239.s1" text="PURPOSE: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE. ">
            <entity charOffset="43-71" id="miRNA-corp.d4.s1.e0" text="mesial temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="103-106" id="miRNA-corp.d4.s1.e1" text="MTLE" type="Diseases"/>
            <entity charOffset="80-100" id="miRNA-corp.d4.s1.e2" text="hippocampal sclerosis" type="Diseases"/>
            <entity charOffset="108-109" id="miRNA-corp.d4.s1.e3" text="HS" type="Diseases"/>
            <entity charOffset="171-173" id="miRNA-corp.d4.s1.e4" text="TLE" type="Diseases"/>
            <entity charOffset="29-36" id="miRNA-corp.d4.s1.e5" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s2" origId="15509239.s0" text="Survival analysis of the surgical outcome of temporal lobe epilepsy due to hippocampal sclerosis.  ">
            <entity charOffset="45-66" id="miRNA-corp.d4.s2.e0" text="temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="75-95" id="miRNA-corp.d4.s2.e1" text="hippocampal sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s3" origId="15509239.s7" text="Of the patients tested, 26% of those operated on the left side and 22% of those operated on the right had postoperative decline of &gt;1 SD in verbal or visual memory, respectively. ">
            <entity charOffset="7-14" id="miRNA-corp.d4.s3.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s4" origId="15509239.s8" text="CONCLUSIONS: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.   ">
            <entity charOffset="95-102" id="miRNA-corp.d4.s4.e0" text="patients" type="Species"/>
            <entity charOffset="131-134" id="miRNA-corp.d4.s4.e1" text="MTLE" type="Diseases"/>
            <entity charOffset="136-137" id="miRNA-corp.d4.s4.e2" text="HS" type="Diseases"/>
            <entity charOffset="27-33" id="miRNA-corp.d4.s4.e3" text="seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s5" origId="15509239.s5" text="RESULTS: Kaplan-Meier estimates of complete seizure freedom (Engel's class IA) for years 1, 2, 5, and 10 were 85%, 77%, 74%, and 66%, and of Engel's class I were 89%, 86%, 83%, and 81%. ">
            <entity charOffset="44-50" id="miRNA-corp.d4.s5.e0" text="seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s6" origId="15509239.s6" text="Only nine (6.7%) patients had outcome classes III or IV at any point during follow-up. ">
            <entity charOffset="17-24" id="miRNA-corp.d4.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d4.s7" origId="15509239.s3" text="Sixty-five had postoperative neuropsychological testing. "/>
        <sentence id="miRNA-corp.d4.s8" origId="15509239.s4" text="Outcome was analyzed by using Engel's classification (a) through Kaplan-Meier estimated survival curves (as a function of the time to seizure recurrence), (b) as percentage of patients in each outcome class on a yearly basis, and (c) at the last updated follow-up. ">
            <entity charOffset="134-140" id="miRNA-corp.d4.s8.e0" text="seizure" type="Diseases"/>
            <entity charOffset="176-183" id="miRNA-corp.d4.s8.e1" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d5" origId="20667897">
        <sentence id="miRNA-corp.d5.s0" origId="20667897.s10" text="Western blot analysis of human glioblastoma specimens showed high levels of PKM2 protein, but none was observed in normal brain samples. ">
            <entity charOffset="76-79" id="miRNA-corp.d5.s0.e0" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="31-42" id="miRNA-corp.d5.s0.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="61-87" id="miRNA-corp.d5.s0.e2" text="high levels of PKM2 protein" type="Relation_Trigger"/>
            <entity charOffset="25-29" id="miRNA-corp.d5.s0.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s1" origId="20667897.s12" text="Our data suggest PKM2 inhibition as a therapy for glioblastoma, with the potential for minimal toxicity to the brain.   ">
            <entity charOffset="17-20" id="miRNA-corp.d5.s1.e0" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="50-61" id="miRNA-corp.d5.s1.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="22-31" id="miRNA-corp.d5.s1.e2" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s2" origId="20667897.s11" text="Strikingly, cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326. ">
            <entity charOffset="125-131" id="miRNA-corp.d5.s2.e0" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="69-75" id="miRNA-corp.d5.s2.e1" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="38-41" id="miRNA-corp.d5.s2.e2" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="117-120" id="miRNA-corp.d5.s2.e3" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="23-33" id="miRNA-corp.d5.s2.e4" text="high levels" type="Relation_Trigger"/>
            <entity charOffset="43-64" id="miRNA-corp.d5.s2.e5" text="expressed lower levels" type="Relation_Trigger"/>
            <entity charOffset="103-112" id="miRNA-corp.d5.s2.e6" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d5.s2.e0" e2="miRNA-corp.d5.s2.e2" id="miRNA-corp.d5.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s2.e0" e2="miRNA-corp.d5.s2.e3" id="miRNA-corp.d5.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s2.e1" e2="miRNA-corp.d5.s2.e2" id="miRNA-corp.d5.s2.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s2.e1" e2="miRNA-corp.d5.s2.e3" id="miRNA-corp.d5.s2.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s3" origId="20667897.s1" text="Emerging studies have identified microRNAs (miRNAs) as possible therapeutic tools for the treatment of glioma, the most aggressive brain tumor. ">
            <entity charOffset="103-108" id="miRNA-corp.d5.s3.e0" text="glioma" type="Diseases"/>
            <entity charOffset="131-141" id="miRNA-corp.d5.s3.e1" text="brain tumor" type="Diseases"/>
            <entity charOffset="33-41" id="miRNA-corp.d5.s3.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-49" id="miRNA-corp.d5.s3.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="137-141" id="miRNA-corp.d5.s3.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e2" e2="miRNA-corp.d5.s3.e0" id="miRNA-corp.d5.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e2" e2="miRNA-corp.d5.s3.e1" id="miRNA-corp.d5.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e2" e2="miRNA-corp.d5.s3.e4" id="miRNA-corp.d5.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e3" e2="miRNA-corp.d5.s3.e0" id="miRNA-corp.d5.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e3" e2="miRNA-corp.d5.s3.e1" id="miRNA-corp.d5.s3.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s3.e3" e2="miRNA-corp.d5.s3.e4" id="miRNA-corp.d5.s3.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s4" origId="20667897.s0" text="Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.  ">
            <entity charOffset="0-17" id="miRNA-corp.d5.s4.e0" text="Pyruvate kinase M2" type="Genes/Proteins"/>
            <entity charOffset="56-67" id="miRNA-corp.d5.s4.e1" text="microRNA-326" type="Specific_miRNAs"/>
            <entity charOffset="99-104" id="miRNA-corp.d5.s4.e2" text="glioma" type="Diseases"/>
            <entity charOffset="24-29" id="miRNA-corp.d5.s4.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="38-54" id="miRNA-corp.d5.s4.e4" text="tumor-suppressive" type="Relation_Trigger"/>
            <entity charOffset="73-81" id="miRNA-corp.d5.s4.e5" text="regulates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d5.s4.e1" e2="miRNA-corp.d5.s4.e0" id="miRNA-corp.d5.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s4.e1" e2="miRNA-corp.d5.s4.e2" id="miRNA-corp.d5.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s5" origId="20667897.s2" text="Their important targets in this tumor are not well understood. ">
            <entity charOffset="16-22" id="miRNA-corp.d5.s5.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="32-36" id="miRNA-corp.d5.s5.e1" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s6" origId="20667897.s3" text="We recently found that the Notch pathway is a target of miRNA-326. ">
            <entity charOffset="56-64" id="miRNA-corp.d5.s6.e0" text="miRNA-326" type="Specific_miRNAs"/>
            <entity charOffset="46-51" id="miRNA-corp.d5.s6.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s7" origId="20667897.s4" text="Ectopic expression of miRNA-326 in glioma and glioma stem cells induced their apoptosis and reduced their metabolic activity. ">
            <entity charOffset="22-30" id="miRNA-corp.d5.s7.e0" text="miRNA-326" type="Specific_miRNAs"/>
            <entity charOffset="35-40" id="miRNA-corp.d5.s7.e1" text="glioma" type="Diseases"/>
            <entity charOffset="0-17" id="miRNA-corp.d5.s7.e2" text="Ectopic expression" type="Relation_Trigger"/>
            <entity charOffset="46-51" id="miRNA-corp.d5.s7.e3" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d5.s7.e0" e2="miRNA-corp.d5.s7.e1" id="miRNA-corp.d5.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d5.s7.e0" e2="miRNA-corp.d5.s7.e3" id="miRNA-corp.d5.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s8" origId="20667897.s5" text="Computational target gene prediction revealed pyruvate kinase type M2 (PKM2) as another target of miRNA-326. ">
            <entity charOffset="98-106" id="miRNA-corp.d5.s8.e0" text="miRNA-326" type="Specific_miRNAs"/>
            <entity charOffset="46-68" id="miRNA-corp.d5.s8.e1" text="pyruvate kinase type M2" type="Genes/Proteins"/>
            <entity charOffset="71-74" id="miRNA-corp.d5.s8.e2" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="88-93" id="miRNA-corp.d5.s8.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="14-19" id="miRNA-corp.d5.s8.e4" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d5.s8.e0" e2="miRNA-corp.d5.s8.e1" id="miRNA-corp.d5.s8.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s8.e0" e2="miRNA-corp.d5.s8.e2" id="miRNA-corp.d5.s8.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s9" origId="20667897.s6" text="PKM2 has recently been shown to play a key role in cancer cell metabolism. ">
            <entity charOffset="0-3" id="miRNA-corp.d5.s9.e0" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="51-56" id="miRNA-corp.d5.s9.e1" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s10" origId="20667897.s7" text="To investigate whether it might be a functionally important target of miR-326, we used RNA interference to knockdown PKM2 expression in glioma cells. ">
            <entity charOffset="70-76" id="miRNA-corp.d5.s10.e0" text="miR-326" type="Specific_miRNAs"/>
            <entity charOffset="117-120" id="miRNA-corp.d5.s10.e1" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="136-141" id="miRNA-corp.d5.s10.e2" text="glioma" type="Diseases"/>
            <entity charOffset="60-65" id="miRNA-corp.d5.s10.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d5.s10.e0" e2="miRNA-corp.d5.s10.e1" id="miRNA-corp.d5.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d5.s10.e0" e2="miRNA-corp.d5.s10.e2" id="miRNA-corp.d5.s10.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s11" origId="20667897.s8" text="Transfection of the established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels, and activated AMP-activated protein kinase. ">
            <entity charOffset="66-69" id="miRNA-corp.d5.s11.e0" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="32-37" id="miRNA-corp.d5.s11.e1" text="glioma" type="Diseases"/>
            <entity charOffset="43-48" id="miRNA-corp.d5.s11.e2" text="glioma" type="Diseases"/>
            <entity charOffset="170-178" id="miRNA-corp.d5.s11.e3" text="activated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d5.s12" origId="20667897.s9" text="The cytotoxic effects exhibited by PKM2 knockdown in glioma and glioma stem cells were not observed in transformed human astrocytes. ">
            <entity charOffset="35-38" id="miRNA-corp.d5.s12.e0" text="PKM2" type="Genes/Proteins"/>
            <entity charOffset="53-58" id="miRNA-corp.d5.s12.e1" text="glioma" type="Diseases"/>
            <entity charOffset="64-69" id="miRNA-corp.d5.s12.e2" text="glioma" type="Diseases"/>
            <entity charOffset="115-119" id="miRNA-corp.d5.s12.e3" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d6" origId="20678503">
        <sentence id="miRNA-corp.d6.s0" origId="20678503.s5" text="Membership in this group is defined based on sequence similarity near the mature miRNAs' 5' end: all include the sequence AGCAGC. ">
            <entity charOffset="81-86" id="miRNA-corp.d6.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s1" origId="20678503.s4" text="Here we provide an overview of the following: (1) the evolution of miR-15/107 group member genes; (2) the expression levels of miRNAs in mammalian tissues; (3) evidence for overlapping gene-regulatory functions by different miRNAs; (4) the normal biochemical pathways regulated by miR-15/107 group miRNAs; and (5) the roles played by these miRNAs in human diseases. ">
            <entity charOffset="67-76" id="miRNA-corp.d6.s1.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="281-290" id="miRNA-corp.d6.s1.e1" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="127-132" id="miRNA-corp.d6.s1.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="224-229" id="miRNA-corp.d6.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="298-303" id="miRNA-corp.d6.s1.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="340-345" id="miRNA-corp.d6.s1.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="268-276" id="miRNA-corp.d6.s1.e6" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="350-354" id="miRNA-corp.d6.s1.e7" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s2" origId="20678503.s7" text="While all vertebrates studied to date express miR-15a, miR-15b, miR-16, miR-103, and miR-107, mammals alone are known to express miR-195, miR-424, miR-497, miR-503, and miR-646. ">
            <entity charOffset="46-52" id="miRNA-corp.d6.s2.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="55-61" id="miRNA-corp.d6.s2.e1" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="64-69" id="miRNA-corp.d6.s2.e2" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="72-78" id="miRNA-corp.d6.s2.e3" text="miR-103" type="Specific_miRNAs"/>
            <entity charOffset="85-91" id="miRNA-corp.d6.s2.e4" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="129-135" id="miRNA-corp.d6.s2.e5" text="miR-195" type="Specific_miRNAs"/>
            <entity charOffset="138-144" id="miRNA-corp.d6.s2.e6" text="miR-424" type="Specific_miRNAs"/>
            <entity charOffset="147-153" id="miRNA-corp.d6.s2.e7" text="miR-497" type="Specific_miRNAs"/>
            <entity charOffset="156-162" id="miRNA-corp.d6.s2.e8" text="miR-503" type="Specific_miRNAs"/>
            <entity charOffset="169-175" id="miRNA-corp.d6.s2.e9" text="miR-646" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s3" origId="20678503.s6" text="Phylogeny of this group of miRNAs is incomplete; thus, a definitive taxonomic classification (e.g., designation as a &quot;superfamily&quot;) is currently not possible. ">
            <entity charOffset="27-32" id="miRNA-corp.d6.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s4" origId="20678503.s9" text="We present data on the expression of all known miR-15/107 group members in human cerebral cortical gray matter and white matter using new miRNA profiling microarrays. ">
            <entity charOffset="47-56" id="miRNA-corp.d6.s4.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="138-142" id="miRNA-corp.d6.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d6.s4.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s5" origId="20678503.s8" text="Multiple different miRNAs in the miR-15/107 group are expressed at moderate to high levels in human tissues. ">
            <entity charOffset="33-42" id="miRNA-corp.d6.s5.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="19-24" id="miRNA-corp.d6.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-89" id="miRNA-corp.d6.s5.e2" text="high levels" type="Relation_Trigger"/>
            <entity charOffset="94-98" id="miRNA-corp.d6.s5.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s6" origId="20678503.s0" text="The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.  ">
            <entity charOffset="4-13" id="miRNA-corp.d6.s6.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="24-31" id="miRNA-corp.d6.s6.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="95-99" id="miRNA-corp.d6.s6.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s7" origId="20678503.s1" text="The miR-15/107 group of microRNA (miRNA) gene is increasingly appreciated to serve key functions in humans. ">
            <entity charOffset="4-13" id="miRNA-corp.d6.s7.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="24-31" id="miRNA-corp.d6.s7.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="34-38" id="miRNA-corp.d6.s7.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-105" id="miRNA-corp.d6.s7.e3" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s8" origId="20678503.s2" text="These miRNAs regulate gene expression involved in cell division, metabolism, stress response, and angiogenesis in vertebrate species. ">
            <entity charOffset="6-11" id="miRNA-corp.d6.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-36" id="miRNA-corp.d6.s8.e1" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s9" origId="20678503.s3" text="The miR-15/107 group has also been implicated in human cancers, cardiovascular disease and neurodegenerative disease, including Alzheimer's disease. ">
            <entity charOffset="4-13" id="miRNA-corp.d6.s9.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="128-146" id="miRNA-corp.d6.s9.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="64-85" id="miRNA-corp.d6.s9.e2" text="cardiovascular disease" type="Diseases"/>
            <entity charOffset="55-61" id="miRNA-corp.d6.s9.e3" text="cancers" type="Diseases"/>
            <entity charOffset="91-115" id="miRNA-corp.d6.s9.e4" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="49-53" id="miRNA-corp.d6.s9.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d6.s9.e0" e2="miRNA-corp.d6.s9.e1" id="miRNA-corp.d6.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s9.e0" e2="miRNA-corp.d6.s9.e2" id="miRNA-corp.d6.s9.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s9.e0" e2="miRNA-corp.d6.s9.e3" id="miRNA-corp.d6.s9.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s9.e0" e2="miRNA-corp.d6.s9.e4" id="miRNA-corp.d6.s9.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s10" origId="20678503.s12" text="In conclusion, the miR-15/107 group of miRNA genes is a fascinating topic of study for evolutionary biologists, miRNA biochemists, and clinically oriented translational researchers alike.   ">
            <entity charOffset="19-28" id="miRNA-corp.d6.s10.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="39-43" id="miRNA-corp.d6.s10.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-116" id="miRNA-corp.d6.s10.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s11" origId="20678503.s11" text="We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted by miR-16 and miR-103 and also support the importance of the mature miRNAs' 5' seed region in mRNA target recognition. ">
            <entity charOffset="98-103" id="miRNA-corp.d6.s11.e0" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="109-115" id="miRNA-corp.d6.s11.e1" text="miR-103" type="Specific_miRNAs"/>
            <entity charOffset="163-168" id="miRNA-corp.d6.s11.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-93" id="miRNA-corp.d6.s11.e3" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="194-199" id="miRNA-corp.d6.s11.e4" text="target" type="Relation_Trigger"/>
            <entity charOffset="34-39" id="miRNA-corp.d6.s11.e5" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d6.s11.e0" e2="miRNA-corp.d6.s11.e5" id="miRNA-corp.d6.s11.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s11.e1" e2="miRNA-corp.d6.s11.e5" id="miRNA-corp.d6.s11.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d6.s11.e2" e2="miRNA-corp.d6.s11.e5" id="miRNA-corp.d6.s11.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d6.s12" origId="20678503.s10" text="There is extensive overlap in the mRNAs targeted by miR-15/107 group members. ">
            <entity charOffset="52-61" id="miRNA-corp.d6.s12.e0" text="miR-15/107" type="Specific_miRNAs"/>
            <entity charOffset="40-47" id="miRNA-corp.d6.s12.e1" text="targeted" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d7" origId="21449035">
        <sentence id="miRNA-corp.d7.s0" origId="21449035.s0" text="Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease.  ">
            <entity charOffset="81-99" id="miRNA-corp.d7.s0.e0" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="13-17" id="miRNA-corp.d7.s0.e1" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="68-70" id="miRNA-corp.d7.s0.e2" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s1" origId="21449035.s3" text="METHODS: To normalize the GAD67 expression in the striatum after dopamine depletion, we developed several lentiviral vectors that express RNA interference (RNAi) directed against GAD67 mitochondrial RNA. ">
            <entity charOffset="26-30" id="miRNA-corp.d7.s1.e0" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="179-183" id="miRNA-corp.d7.s1.e1" text="GAD67" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s2" origId="21449035.s4" text="The vectors were injected into the striatum of hemiparkinsonian rats and the level of GAD67 protein as well as a marker of neuronal activity, mtCO1, was analyzed using western blots. ">
            <entity charOffset="86-90" id="miRNA-corp.d7.s2.e0" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="142-146" id="miRNA-corp.d7.s2.e1" text="mtCO1" type="Genes/Proteins"/>
            <entity charOffset="64-67" id="miRNA-corp.d7.s2.e2" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s3" origId="21449035.s1" text="BACKGROUND: Dopamine depletion of the striatum is one of the hallmarks of Parkinson's disease. ">
            <entity charOffset="74-92" id="miRNA-corp.d7.s3.e0" text="Parkinson's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s4" origId="21449035.s2" text="The loss of dopamine upregulates GAD67 expression in the striatal projection neurons and causes other changes in the activity of the basal ganglia circuit. ">
            <entity charOffset="33-37" id="miRNA-corp.d7.s4.e0" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="21-48" id="miRNA-corp.d7.s4.e1" text="upregulates GAD67 expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s5" origId="21449035.s7" text="Using a lentiviral vectors with a synthetic miRNA scaffold to deliver RNAi, we were able to normalize the GAD67 protein levels in the parkinsonian rat striatum. ">
            <entity charOffset="44-48" id="miRNA-corp.d7.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="106-110" id="miRNA-corp.d7.s5.e1" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="147-149" id="miRNA-corp.d7.s5.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d7.s5.e0" e2="miRNA-corp.d7.s5.e1" id="miRNA-corp.d7.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s6" origId="21449035.s8" text="In addition, we were able to normalize the increased neural activity, which resulted from the loss of dopamine as measured by the marker mtCO1. ">
            <entity charOffset="137-141" id="miRNA-corp.d7.s6.e0" text="mtCO1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s7" origId="21449035.s5" text="RESULTS: Unilateral lesions of the dopamine neurons in substantia nigra resulted in an increased level of GAD67 protein in the ipsilateral striatum. ">
            <entity charOffset="106-110" id="miRNA-corp.d7.s7.e0" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="87-118" id="miRNA-corp.d7.s7.e1" text="increased level of GAD67 protein" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s8" origId="21449035.s6" text="Furthermore, we detected significantly higher levels of mtCO1, after dopamine depletion in the striatum. ">
            <entity charOffset="56-60" id="miRNA-corp.d7.s8.e0" text="mtCO1" type="Genes/Proteins"/>
            <entity charOffset="39-51" id="miRNA-corp.d7.s8.e1" text="higher levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s9" origId="21449035.s9" text="CONCLUSIONS: We conclude that RNAi directed against GAD67 may be a valid approach to correct the dysregulation of the basal ganglia circuit in a rat model of Parkinson's disease. ">
            <entity charOffset="52-56" id="miRNA-corp.d7.s9.e0" text="GAD67" type="Genes/Proteins"/>
            <entity charOffset="158-176" id="miRNA-corp.d7.s9.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="97-109" id="miRNA-corp.d7.s9.e2" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="145-147" id="miRNA-corp.d7.s9.e3" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d7.s10" origId="21449035.s10" text="The possibility to correct for a loss of dopamine using nondopamimetic tools is interesting because it may be more directed towards the casual mechanisms of the motor symptoms. "/>
        <sentence id="miRNA-corp.d7.s11" origId="21449035.s11" text="Copyright © 2011 John Wiley &amp; Sons, Ltd.   "/>
    </document>
    <document id="miRNA-corp.d8" origId="20228028">
        <sentence id="miRNA-corp.d8.s0" origId="20228028.s10" text="Out of the 5 positive samples, one was an HTLV, three HTLV-1 and one HTLV-2. "/>
        <sentence id="miRNA-corp.d8.s1" origId="20228028.s11" text="These blood donors were residents of Posadas, Eldorado and Oberá, with no risk antecedents. "/>
        <sentence id="miRNA-corp.d8.s2" origId="20228028.s12" text="This study demonstrates the presence of HTLV-1/2 in a population of Misiones with a prevalence rate similar to those reported among blood donors from non-endemic areas.   "/>
        <sentence id="miRNA-corp.d8.s3" origId="20228028.s0" text="[Seroprevalence of HTLV-1/2 in blood donors from Misiones Province].  "/>
        <sentence id="miRNA-corp.d8.s4" origId="20228028.s6" text="The aim of this study was to estimate the seroprevalence of HTLV-1/2 in a blood donor population from Misiones province. "/>
        <sentence id="miRNA-corp.d8.s5" origId="20228028.s5" text="They are transmitted through sex contact, parenterally and from mother to child. ">
            <entity charOffset="74-78" id="miRNA-corp.d8.s5.e0" text="child" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s6" origId="20228028.s8" text="HTLV-1/2 screening was performed with ELISA and particle agglutination, and reactive samples were confirmed by Western Blot. "/>
        <sentence id="miRNA-corp.d8.s7" origId="20228028.s7" text="A total of 6912 accepted blood donations in 2008 were analyzed. "/>
        <sentence id="miRNA-corp.d8.s8" origId="20228028.s2" text="It is endemic worldwide, including the North of Argentina where both associated diseases have also been detected. ">
            <entity charOffset="69-78" id="miRNA-corp.d8.s8.e0" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s9" origId="20228028.s1" text="Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP). ">
            <entity charOffset="0-4" id="miRNA-corp.d8.s9.e0" text="Human" type="Species"/>
            <entity charOffset="126-146" id="miRNA-corp.d8.s9.e1" text="Adult T-cell Leukemia" type="Diseases"/>
            <entity charOffset="149-151" id="miRNA-corp.d8.s9.e2" text="ATL" type="Diseases"/>
            <entity charOffset="158-185" id="miRNA-corp.d8.s9.e3" text="HTLV-1 Associated Mielopathy" type="Diseases"/>
            <entity charOffset="190-217" id="miRNA-corp.d8.s9.e4" text="Tropical Spastic Paraparesis" type="Diseases"/>
            <entity charOffset="220-222" id="miRNA-corp.d8.s9.e5" text="HAM" type="Diseases"/>
            <entity charOffset="224-226" id="miRNA-corp.d8.s9.e6" text="TSP" type="Diseases"/>
            <entity charOffset="61-65" id="miRNA-corp.d8.s9.e7" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s10" origId="20228028.s4" text="Both retroviruses are endemic in native populations of The Americas, Africa and at-risk populations. "/>
        <sentence id="miRNA-corp.d8.s11" origId="20228028.s3" text="No etiologic role has been described for HTLV-2, although it has been associated with HAM/TSP-like neurologic syndromes. ">
            <entity charOffset="70-79" id="miRNA-corp.d8.s11.e0" text="associated" type="Relation_Trigger"/>
            <entity charOffset="86-88" id="miRNA-corp.d8.s11.e1" text="HAM" type="Diseases"/>
            <entity charOffset="90-92" id="miRNA-corp.d8.s11.e2" text="TSP" type="Diseases"/>
            <entity charOffset="99-118" id="miRNA-corp.d8.s11.e3" text="neurologic syndromes" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d8.s12" origId="20228028.s9" text="From the total, 5 samples resulted seropositive with a final prevalence of 0.00072. "/>
    </document>
    <document id="miRNA-corp.d9" origId="19406203">
        <sentence id="miRNA-corp.d9.s0" origId="19406203.s4" text="The results suggest (a) that unless specifically stabilized, certain brain-enriched miRNAs represent a rapidly executed signaling system employing highly transient effectors of CNS gene expression, and (b) that in AD temporal lobe neocortex specific brain miRNAs are significantly up-regulated in abundance and strongly correlate with the presence of AD-type neuropatholgical change.   ">
            <entity charOffset="214-215" id="miRNA-corp.d9.s0.e0" text="AD" type="Diseases"/>
            <entity charOffset="84-89" id="miRNA-corp.d9.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="256-261" id="miRNA-corp.d9.s0.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="281-292" id="miRNA-corp.d9.s0.e3" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="320-328" id="miRNA-corp.d9.s0.e4" text="correlate" type="Relation_Trigger"/>
            <entity charOffset="147-195" id="miRNA-corp.d9.s0.e5" text="highly transient effectors of CNS gene expression" type="Relation_Trigger"/>
            <entity charOffset="351-352" id="miRNA-corp.d9.s0.e6" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d9.s0.e1" e2="miRNA-corp.d9.s0.e6" id="miRNA-corp.d9.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s0.e1" e2="miRNA-corp.d9.s0.e0" id="miRNA-corp.d9.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s0.e2" e2="miRNA-corp.d9.s0.e6" id="miRNA-corp.d9.s0.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s0.e2" e2="miRNA-corp.d9.s0.e0" id="miRNA-corp.d9.s0.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s1" origId="19406203.s3" text="In short PMI Alzheimer's disease (AD)-affected temporal lobe neocortex, miRNA-9, miRNA-125b and miRNA-146a were found to be significantly up-regulated, an effect that was not seen in several related neurological disorders. ">
            <entity charOffset="13-31" id="miRNA-corp.d9.s1.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="72-78" id="miRNA-corp.d9.s1.e1" text="miRNA-9" type="Specific_miRNAs"/>
            <entity charOffset="81-90" id="miRNA-corp.d9.s1.e2" text="miRNA-125b" type="Specific_miRNAs"/>
            <entity charOffset="96-105" id="miRNA-corp.d9.s1.e3" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="34-35" id="miRNA-corp.d9.s1.e4" text="AD" type="Diseases"/>
            <entity charOffset="138-149" id="miRNA-corp.d9.s1.e5" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="199-220" id="miRNA-corp.d9.s1.e6" text="neurological disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e1" e2="miRNA-corp.d9.s1.e0" id="miRNA-corp.d9.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e1" e2="miRNA-corp.d9.s1.e6" id="miRNA-corp.d9.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e1" e2="miRNA-corp.d9.s1.e4" id="miRNA-corp.d9.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e2" e2="miRNA-corp.d9.s1.e0" id="miRNA-corp.d9.s1.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e2" e2="miRNA-corp.d9.s1.e6" id="miRNA-corp.d9.s1.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e2" e2="miRNA-corp.d9.s1.e4" id="miRNA-corp.d9.s1.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e3" e2="miRNA-corp.d9.s1.e0" id="miRNA-corp.d9.s1.p6" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e3" e2="miRNA-corp.d9.s1.e6" id="miRNA-corp.d9.s1.p7" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d9.s1.e3" e2="miRNA-corp.d9.s1.e4" id="miRNA-corp.d9.s1.p8" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s2" origId="19406203.s2" text="In these studies, miRNA array and Northern blot based tracking of specific miRNA abundances and decay kinetics in human neural (HN) cells in primary culture and in short post-mortem interval (PMI, approximately 1h) human brain tissues showed a limited stability and relatively short half-life ( approximately 1-3.5h) for specific brain-enriched miRNAs. ">
            <entity charOffset="18-22" id="miRNA-corp.d9.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d9.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="345-350" id="miRNA-corp.d9.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="114-118" id="miRNA-corp.d9.s2.e3" text="human" type="Species"/>
            <entity charOffset="215-219" id="miRNA-corp.d9.s2.e4" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s3" origId="19406203.s1" text="Micro-RNA (miRNA) mediated regulation of messenger RNA (mRNA) complexity in the central nervous system (CNS) is emerging as a critical factor in the control of CNS-specific gene expression during development, plasticity, aging and disease. ">
            <entity charOffset="0-8" id="miRNA-corp.d9.s3.e0" text="Micro-RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d9.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-36" id="miRNA-corp.d9.s3.e2" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d9.s4" origId="19406203.s0" text="Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex.  ">
            <entity charOffset="74-92" id="miRNA-corp.d9.s4.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d9.s4.e1" text="Micro-RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-41" id="miRNA-corp.d9.s4.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d9.s4.e1" e2="miRNA-corp.d9.s4.e0" id="miRNA-corp.d9.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d10" origId="19568434">
        <sentence id="miRNA-corp.d10.s0" origId="19568434.s10" text="While confirmation is required, this study suggests that microRNA mutations can contribute to schizophrenia.   ">
            <entity charOffset="57-64" id="miRNA-corp.d10.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-106" id="miRNA-corp.d10.s0.e1" text="schizophrenia" type="Diseases"/>
            <pair e1="miRNA-corp.d10.s0.e0" e2="miRNA-corp.d10.s0.e1" id="miRNA-corp.d10.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s1" origId="19568434.s7" text="One ultra-rare variant was identified in a control sample (with a history of depression) (8/193 versus 1/191, p = 0.02 by one-sided Fisher's exact test, odds ratio = 8.2). ">
            <entity charOffset="77-86" id="miRNA-corp.d10.s1.e0" text="depression" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s2" origId="19568434.s8" text="These variants were not found in an additional 7,197 control X-chromosomes. "/>
        <sentence id="miRNA-corp.d10.s3" origId="19568434.s9" text="CONCLUSIONS: Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression levels. ">
            <entity charOffset="80-84" id="miRNA-corp.d10.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-112" id="miRNA-corp.d10.s3.e1" text="miRNA precursors demonstrate loss" type="Relation_Trigger"/>
            <entity charOffset="36-56" id="miRNA-corp.d10.s3.e2" text="ectopically expressed" type="Relation_Trigger"/>
            <entity charOffset="147-171" id="miRNA-corp.d10.s3.e3" text="altered expression levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s4" origId="19568434.s3" text="In addition, components required for miRNA processing and/or function have also been implicated in X-linked mental retardation, neurological and neoplastic diseases, pointing to the wide ranging involvement of miRNAs in disease. ">
            <entity charOffset="37-41" id="miRNA-corp.d10.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="210-215" id="miRNA-corp.d10.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-125" id="miRNA-corp.d10.s4.e2" text="X-linked mental retardation" type="Diseases"/>
            <entity charOffset="145-163" id="miRNA-corp.d10.s4.e3" text="neoplastic diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d10.s4.e0" e2="miRNA-corp.d10.s4.e2" id="miRNA-corp.d10.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s4.e0" e2="miRNA-corp.d10.s4.e3" id="miRNA-corp.d10.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s4.e1" e2="miRNA-corp.d10.s4.e2" id="miRNA-corp.d10.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s4.e1" e2="miRNA-corp.d10.s4.e3" id="miRNA-corp.d10.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s5" origId="19568434.s4" text="METHODS AND FINDINGS: To explore the role of miRNAs in schizophrenia, 59 microRNA genes on the X-chromosome were amplified and sequenced in males with (193) and without (191) schizophrenia spectrum disorders to test the hypothesis that ultra-rare mutations in microRNA collectively contribute to the risk of schizophrenia. ">
            <entity charOffset="45-50" id="miRNA-corp.d10.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-80" id="miRNA-corp.d10.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="260-267" id="miRNA-corp.d10.s5.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="175-187" id="miRNA-corp.d10.s5.e3" text="schizophrenia" type="Diseases"/>
            <entity charOffset="308-320" id="miRNA-corp.d10.s5.e4" text="schizophrenia" type="Diseases"/>
            <entity charOffset="55-67" id="miRNA-corp.d10.s5.e5" text="schizophrenia" type="Diseases"/>
            <entity charOffset="113-121" id="miRNA-corp.d10.s5.e6" text="amplified" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d10.s5.e0" e2="miRNA-corp.d10.s5.e3" id="miRNA-corp.d10.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e0" e2="miRNA-corp.d10.s5.e4" id="miRNA-corp.d10.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e0" e2="miRNA-corp.d10.s5.e5" id="miRNA-corp.d10.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e1" e2="miRNA-corp.d10.s5.e3" id="miRNA-corp.d10.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e1" e2="miRNA-corp.d10.s5.e4" id="miRNA-corp.d10.s5.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e1" e2="miRNA-corp.d10.s5.e5" id="miRNA-corp.d10.s5.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e2" e2="miRNA-corp.d10.s5.e3" id="miRNA-corp.d10.s5.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e2" e2="miRNA-corp.d10.s5.e4" id="miRNA-corp.d10.s5.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s5.e2" e2="miRNA-corp.d10.s5.e5" id="miRNA-corp.d10.s5.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s6" origId="19568434.s5" text="Here we provide the first association of microRNA gene dysfunction with schizophrenia. ">
            <entity charOffset="41-48" id="miRNA-corp.d10.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-84" id="miRNA-corp.d10.s6.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="26-36" id="miRNA-corp.d10.s6.e2" text="association" type="Relation_Trigger"/>
            <entity charOffset="55-65" id="miRNA-corp.d10.s6.e3" text="dysfunction" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d10.s6.e0" e2="miRNA-corp.d10.s6.e1" id="miRNA-corp.d10.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s7" origId="19568434.s6" text="Eight ultra-rare variants in the precursor or mature miRNA were identified in eight distinct miRNA genes in 4% of analyzed males with schizophrenia. ">
            <entity charOffset="53-57" id="miRNA-corp.d10.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-97" id="miRNA-corp.d10.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="134-146" id="miRNA-corp.d10.s7.e2" text="schizophrenia" type="Diseases"/>
            <pair e1="miRNA-corp.d10.s7.e1" e2="miRNA-corp.d10.s7.e2" id="miRNA-corp.d10.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d10.s7.e0" e2="miRNA-corp.d10.s7.e2" id="miRNA-corp.d10.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s8" origId="19568434.s0" text="Evidence for X-chromosomal schizophrenia associated with microRNA alterations.  ">
            <entity charOffset="57-64" id="miRNA-corp.d10.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-50" id="miRNA-corp.d10.s8.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="13-39" id="miRNA-corp.d10.s8.e2" text="X-chromosomal schizophrenia" type="Diseases"/>
            <pair e1="miRNA-corp.d10.s8.e0" e2="miRNA-corp.d10.s8.e2" id="miRNA-corp.d10.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s9" origId="19568434.s1" text="BACKGROUND: Schizophrenia is a severe disabling brain disease affecting about 1% of the population. ">
            <entity charOffset="12-24" id="miRNA-corp.d10.s9.e0" text="Schizophrenia" type="Diseases"/>
            <entity charOffset="48-60" id="miRNA-corp.d10.s9.e1" text="brain disease" type="Diseases"/>
            <entity charOffset="12-24" id="miRNA-corp.d10.s9.e2" text="Schizophrenia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d10.s10" origId="19568434.s2" text="Individual microRNAs (miRNAs) affect moderate downregulation of gene expression. ">
            <entity charOffset="11-19" id="miRNA-corp.d10.s10.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-27" id="miRNA-corp.d10.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-78" id="miRNA-corp.d10.s10.e2" text="downregulation of gene expression" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d11" origId="19909260">
        <sentence id="miRNA-corp.d11.s0" origId="19909260.s10" text="We will describe the evidence that disruption to the REST regulon brought about by a loss of interaction between REST and mutHtt may be a key contributory factor in the widespread dysregulation of gene expression in HD.   ">
            <entity charOffset="216-217" id="miRNA-corp.d11.s0.e0" text="HD" type="Diseases"/>
            <entity charOffset="53-56" id="miRNA-corp.d11.s0.e1" text="REST" type="Genes/Proteins"/>
            <entity charOffset="113-116" id="miRNA-corp.d11.s0.e2" text="REST" type="Genes/Proteins"/>
            <entity charOffset="180-211" id="miRNA-corp.d11.s0.e3" text="dysregulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s1" origId="19909260.s0" text="Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.  ">
            <entity charOffset="83-102" id="miRNA-corp.d11.s1.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="0-28" id="miRNA-corp.d11.s1.e1" text="Transcriptional dysregulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s2" origId="19909260.s1" text="HD (Huntington's disease) is a late onset heritable neurodegenerative disorder that is characterized by neuronal dysfunction and death, particularly in the cerebral cortex and medium spiny neurons of the striatum. ">
            <entity charOffset="0-1" id="miRNA-corp.d11.s2.e0" text="HD" type="Diseases"/>
            <entity charOffset="4-23" id="miRNA-corp.d11.s2.e1" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="52-77" id="miRNA-corp.d11.s2.e2" text="neurodegenerative disorder" type="Diseases"/>
            <entity charOffset="104-123" id="miRNA-corp.d11.s2.e3" text="neuronal dysfunction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s3" origId="19909260.s2" text="This is followed by progressive chorea, dementia and emotional dysfunction, eventually resulting in death. ">
            <entity charOffset="32-37" id="miRNA-corp.d11.s3.e0" text="chorea" type="Diseases"/>
            <entity charOffset="40-47" id="miRNA-corp.d11.s3.e1" text="dementia" type="Diseases"/>
            <entity charOffset="53-73" id="miRNA-corp.d11.s3.e2" text="emotional dysfunction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s4" origId="19909260.s3" text="HD is caused by an expanded CAG repeat in the first exon of the HD gene that results in an abnormally elongated polyQ (polyglutamine) tract in its protein product, Htt (Huntingtin). ">
            <entity charOffset="0-1" id="miRNA-corp.d11.s4.e0" text="HD" type="Diseases"/>
            <entity charOffset="164-166" id="miRNA-corp.d11.s4.e1" text="Htt" type="Genes/Proteins"/>
            <entity charOffset="169-178" id="miRNA-corp.d11.s4.e2" text="Huntingtin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s5" origId="19909260.s4" text="Wild-type Htt is largely cytoplasmic; however, in HD, proteolytic N-terminal fragments of Htt form insoluble deposits in both the cytoplasm and nucleus, provoking the idea that mutHtt (mutant Htt) causes transcriptional dysfunction. ">
            <entity charOffset="50-51" id="miRNA-corp.d11.s5.e0" text="HD" type="Diseases"/>
            <entity charOffset="10-12" id="miRNA-corp.d11.s5.e1" text="Htt" type="Genes/Proteins"/>
            <entity charOffset="90-92" id="miRNA-corp.d11.s5.e2" text="Htt" type="Genes/Proteins"/>
            <entity charOffset="192-194" id="miRNA-corp.d11.s5.e3" text="Htt" type="Genes/Proteins"/>
            <entity charOffset="220-230" id="miRNA-corp.d11.s5.e4" text="dysfunction" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s6" origId="19909260.s5" text="While a number of specific transcription factors and co-factors have been proposed as mediators of mutHtt toxicity, the causal relationship between these Htt/transcription factor interactions and HD pathology remains unknown. ">
            <entity charOffset="196-197" id="miRNA-corp.d11.s6.e0" text="HD" type="Diseases"/>
            <entity charOffset="154-156" id="miRNA-corp.d11.s6.e1" text="Htt" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s7" origId="19909260.s6" text="Previous work has highlighted REST [RE1 (repressor element 1)-silencing transcription factor] as one such transcription factor. ">
            <entity charOffset="30-33" id="miRNA-corp.d11.s7.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="36-91" id="miRNA-corp.d11.s7.e1" text="RE1 (repressor element 1)-silencing transcription factor" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s8" origId="19909260.s9" text="Recent evidence has also shown that REST regulates transcription of regulatory miRNAs (microRNAs), many of which are known to regulate neuronal gene expression and are dysregulated in HD. Thus repression of miRNAs constitutes a second, indirect mechanism by which REST can alter the neuronal transcriptome in HD. ">
            <entity charOffset="79-84" id="miRNA-corp.d11.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-95" id="miRNA-corp.d11.s8.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="207-212" id="miRNA-corp.d11.s8.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-185" id="miRNA-corp.d11.s8.e3" text="HD" type="Diseases"/>
            <entity charOffset="309-310" id="miRNA-corp.d11.s8.e4" text="HD" type="Diseases"/>
            <entity charOffset="36-39" id="miRNA-corp.d11.s8.e5" text="REST" type="Genes/Proteins"/>
            <entity charOffset="264-267" id="miRNA-corp.d11.s8.e6" text="REST" type="Genes/Proteins"/>
            <entity charOffset="41-49" id="miRNA-corp.d11.s8.e7" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="168-179" id="miRNA-corp.d11.s8.e8" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="68-77" id="miRNA-corp.d11.s8.e9" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="126-158" id="miRNA-corp.d11.s8.e10" text="regulate neuronal gene expression" type="Relation_Trigger"/>
            <entity charOffset="193-202" id="miRNA-corp.d11.s8.e11" text="repression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d11.s8.e0" e2="miRNA-corp.d11.s8.e3" id="miRNA-corp.d11.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e0" e2="miRNA-corp.d11.s8.e4" id="miRNA-corp.d11.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e0" e2="miRNA-corp.d11.s8.e5" id="miRNA-corp.d11.s8.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s8.e0" e2="miRNA-corp.d11.s8.e6" id="miRNA-corp.d11.s8.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s8.e1" e2="miRNA-corp.d11.s8.e3" id="miRNA-corp.d11.s8.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e1" e2="miRNA-corp.d11.s8.e4" id="miRNA-corp.d11.s8.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e1" e2="miRNA-corp.d11.s8.e5" id="miRNA-corp.d11.s8.p6" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s8.e1" e2="miRNA-corp.d11.s8.e6" id="miRNA-corp.d11.s8.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s8.e2" e2="miRNA-corp.d11.s8.e3" id="miRNA-corp.d11.s8.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e2" e2="miRNA-corp.d11.s8.e4" id="miRNA-corp.d11.s8.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d11.s8.e2" e2="miRNA-corp.d11.s8.e5" id="miRNA-corp.d11.s8.p10" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d11.s8.e2" e2="miRNA-corp.d11.s8.e6" id="miRNA-corp.d11.s8.p11" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s9" origId="19909260.s8" text="Many of its direct target genes are known or suspected to have a role in HD pathogenesis, including BDNF (brain-derived neurotrophic factor). ">
            <entity charOffset="73-74" id="miRNA-corp.d11.s9.e0" text="HD" type="Diseases"/>
            <entity charOffset="100-103" id="miRNA-corp.d11.s9.e1" text="BDNF" type="Genes/Proteins"/>
            <entity charOffset="106-138" id="miRNA-corp.d11.s9.e2" text="brain-derived neurotrophic factor" type="Genes/Proteins"/>
            <entity charOffset="19-24" id="miRNA-corp.d11.s9.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d11.s10" origId="19909260.s7" text="REST is a master regulator of neuronal genes, repressing their expression. ">
            <entity charOffset="0-3" id="miRNA-corp.d11.s10.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="17-25" id="miRNA-corp.d11.s10.e1" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="46-72" id="miRNA-corp.d11.s10.e2" text="repressing their expression" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d12" origId="20219352">
        <sentence id="miRNA-corp.d12.s0" origId="20219352.s1" text="BACKGROUND: The aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers. ">
            <entity charOffset="39-47" id="miRNA-corp.d12.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-55" id="miRNA-corp.d12.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-34" id="miRNA-corp.d12.s0.e2" text="aberrant expression" type="Relation_Trigger"/>
            <entity charOffset="61-70" id="miRNA-corp.d12.s0.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="109-115" id="miRNA-corp.d12.s0.e4" text="cancers" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s0.e0" e2="miRNA-corp.d12.s0.e4" id="miRNA-corp.d12.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s0.e1" e2="miRNA-corp.d12.s0.e4" id="miRNA-corp.d12.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s1" origId="20219352.s2" text="In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults. ">
            <entity charOffset="26-30" id="miRNA-corp.d12.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-77" id="miRNA-corp.d12.s1.e1" text="astrocytoma" type="Diseases"/>
            <entity charOffset="106-124" id="miRNA-corp.d12.s1.e2" text="intracranial tumour" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s1.e0" e2="miRNA-corp.d12.s1.e1" id="miRNA-corp.d12.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s1.e0" e2="miRNA-corp.d12.s1.e2" id="miRNA-corp.d12.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s2" origId="20219352.s3" text="METHODS: We screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR. ">
            <entity charOffset="51-56" id="miRNA-corp.d12.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-110" id="miRNA-corp.d12.s2.e1" text="astrocytoma" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s2.e0" e2="miRNA-corp.d12.s2.e1" id="miRNA-corp.d12.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s3" origId="20219352.s4" text="The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples. ">
            <entity charOffset="26-31" id="miRNA-corp.d12.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-109" id="miRNA-corp.d12.s3.e1" text="astrocytoma" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s3.e0" e2="miRNA-corp.d12.s3.e1" id="miRNA-corp.d12.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s4" origId="20219352.s5" text="The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis. ">
            <entity charOffset="23-27" id="miRNA-corp.d12.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-14" id="miRNA-corp.d12.s4.e1" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="53-63" id="miRNA-corp.d12.s4.e2" text="astrocytoma" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s4.e0" e2="miRNA-corp.d12.s4.e2" id="miRNA-corp.d12.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s5" origId="20219352.s6" text="RESULTS: After a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples. ">
            <entity charOffset="67-72" id="miRNA-corp.d12.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="141-151" id="miRNA-corp.d12.s5.e1" text="astrocytoma" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s5.e0" e2="miRNA-corp.d12.s5.e1" id="miRNA-corp.d12.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s6" origId="20219352.s7" text="Unsupervised clustering analysis further revealed the great potential of the 7-miRNA profile to differentiate between tumours and normal brain tissues. ">
            <entity charOffset="118-124" id="miRNA-corp.d12.s6.e0" text="tumours" type="Diseases"/>
            <entity charOffset="79-83" id="miRNA-corp.d12.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d12.s6.e1" e2="miRNA-corp.d12.s6.e0" id="miRNA-corp.d12.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s7" origId="20219352.s8" text="The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease. ">
            <entity charOffset="38-49" id="miRNA-corp.d12.s7.e0" text="astrocytomas" type="Diseases"/>
            <entity charOffset="4-18" id="miRNA-corp.d12.s7.e1" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="67-76" id="miRNA-corp.d12.s7.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="23-33" id="miRNA-corp.d12.s7.e3" text="hsa-miR-137" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d12.s7.e3" e2="miRNA-corp.d12.s7.e0" id="miRNA-corp.d12.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s8" origId="20219352.s0" text="The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.  ">
            <entity charOffset="81-91" id="miRNA-corp.d12.s8.e0" text="astrocytoma" type="Diseases"/>
            <entity charOffset="11-20" id="miRNA-corp.d12.s8.e1" text="hsa-miR-21" type="Specific_miRNAs"/>
            <entity charOffset="23-34" id="miRNA-corp.d12.s8.e2" text="hsa-miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="40-51" id="miRNA-corp.d12.s8.e3" text="hsa-miR-106a" type="Specific_miRNAs"/>
            <entity charOffset="56-76" id="miRNA-corp.d12.s8.e4" text="prognostic indicators" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d12.s8.e1" e2="miRNA-corp.d12.s8.e0" id="miRNA-corp.d12.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s8.e2" e2="miRNA-corp.d12.s8.e0" id="miRNA-corp.d12.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d12.s8.e3" e2="miRNA-corp.d12.s8.e0" id="miRNA-corp.d12.s8.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s9" origId="20219352.s9" text="Using Kaplan-Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival. ">
            <entity charOffset="70-81" id="miRNA-corp.d12.s9.e0" text="hsa-miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="52-65" id="miRNA-corp.d12.s9.e1" text="low expression" type="Relation_Trigger"/>
            <entity charOffset="103-117" id="miRNA-corp.d12.s9.e2" text="high expression" type="Relation_Trigger"/>
            <entity charOffset="151-160" id="miRNA-corp.d12.s9.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="122-131" id="miRNA-corp.d12.s9.e4" text="hsa-miR-21" type="Specific_miRNAs"/>
            <entity charOffset="86-97" id="miRNA-corp.d12.s9.e5" text="hsa-miR-106a" type="Specific_miRNAs"/>
            <entity charOffset="172-178" id="miRNA-corp.d12.s9.e6" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s10" origId="20219352.s11" text="CONCLUSIONS: Our results suggest a great potential for the use of miRNA profiling as a powerful diagnostic and prognostic marker in defining the signature of astrocytomas and in predicting the post-surgical outcome.   ">
            <entity charOffset="66-70" id="miRNA-corp.d12.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="158-169" id="miRNA-corp.d12.s10.e1" text="astrocytomas" type="Diseases"/>
            <pair e1="miRNA-corp.d12.s10.e0" e2="miRNA-corp.d12.s10.e1" id="miRNA-corp.d12.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d12.s11" origId="20219352.s10" text="Moreover, Cox proportional hazard regression analysis revealed that this prognostic impact was independent of other clinicopathological factors. "/>
    </document>
    <document id="miRNA-corp.d13" origId="20591823">
        <sentence id="miRNA-corp.d13.s0" origId="20591823.s6" text="Expression profiling showed strong miRNA and isomiR expression deregulation in HD, most being common to both FC and ST. ">
            <entity charOffset="35-39" id="miRNA-corp.d13.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-80" id="miRNA-corp.d13.s0.e1" text="HD" type="Diseases"/>
            <entity charOffset="52-74" id="miRNA-corp.d13.s0.e2" text="expression deregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d13.s0.e0" e2="miRNA-corp.d13.s0.e1" id="miRNA-corp.d13.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s1" origId="20591823.s5" text="Around 80-90% of the miRNAs presented modifications in the 3'-terminus mainly in the form of trimming and/or as nucleotide addition variants, while the 5'-terminus of the miRNAs was specially protected from changes. ">
            <entity charOffset="21-26" id="miRNA-corp.d13.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="171-176" id="miRNA-corp.d13.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s2" origId="20591823.s4" text="Deep sequencing revealed length and sequence heterogeneity (IsomiRs) for the vast majority of miRNAs. ">
            <entity charOffset="94-99" id="miRNA-corp.d13.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s3" origId="20591823.s3" text="More than 80% of the small-RNAs were annotated as microRNAs (miRNAs) in all samples. ">
            <entity charOffset="50-58" id="miRNA-corp.d13.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-66" id="miRNA-corp.d13.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s4" origId="20591823.s2" text="We have applied the Illumina massively parallel sequencing to deeply analyze the small RNA populations of two different forebrain areas, the frontal cortex (FC) and the striatum (ST) of healthy individuals and individuals with HD. ">
            <entity charOffset="227-228" id="miRNA-corp.d13.s4.e0" text="HD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s5" origId="20591823.s1" text="Huntington disease (HD) is a neurodegenerative disorder that predominantly affects neurons of the forebrain. ">
            <entity charOffset="0-17" id="miRNA-corp.d13.s5.e0" text="Huntington disease" type="Diseases"/>
            <entity charOffset="20-21" id="miRNA-corp.d13.s5.e1" text="HD" type="Diseases"/>
            <entity charOffset="29-54" id="miRNA-corp.d13.s5.e2" text="neurodegenerative disorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s6" origId="20591823.s0" text="A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing.  ">
            <entity charOffset="12-16" id="miRNA-corp.d13.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-61" id="miRNA-corp.d13.s6.e1" text="Huntington's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d13.s6.e0" e2="miRNA-corp.d13.s6.e1" id="miRNA-corp.d13.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s7" origId="20591823.s9" text="Our results show that miRNA variability is a ubiquitous phenomenon in the adult human brain, which may influence gene expression in physiological and pathological conditions.   ">
            <entity charOffset="22-26" id="miRNA-corp.d13.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-84" id="miRNA-corp.d13.s7.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s8" origId="20591823.s8" text="The putative targets of deregulated miRNAs and seed-region IsomiRs strongly suggest that their altered expression contributes to the aberrant gene expression in HD. ">
            <entity charOffset="36-41" id="miRNA-corp.d13.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="161-162" id="miRNA-corp.d13.s8.e1" text="HD" type="Diseases"/>
            <entity charOffset="24-34" id="miRNA-corp.d13.s8.e2" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="95-112" id="miRNA-corp.d13.s8.e3" text="altered expression" type="Relation_Trigger"/>
            <entity charOffset="13-19" id="miRNA-corp.d13.s8.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="133-156" id="miRNA-corp.d13.s8.e5" text="aberrant gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d13.s8.e0" e2="miRNA-corp.d13.s8.e1" id="miRNA-corp.d13.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d13.s9" origId="20591823.s7" text="The analysis of the upstream regulatory regions in co-regulated miRNAs suggests a role for RE1-Silencing Transcription Factor (REST) and P53 in miRNAs downregulation in HD. ">
            <entity charOffset="64-69" id="miRNA-corp.d13.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="144-149" id="miRNA-corp.d13.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-124" id="miRNA-corp.d13.s9.e2" text="RE1-Silencing Transcription Factor" type="Genes/Proteins"/>
            <entity charOffset="127-130" id="miRNA-corp.d13.s9.e3" text="REST" type="Genes/Proteins"/>
            <entity charOffset="137-139" id="miRNA-corp.d13.s9.e4" text="P53" type="Genes/Proteins"/>
            <entity charOffset="169-170" id="miRNA-corp.d13.s9.e5" text="HD" type="Diseases"/>
            <entity charOffset="151-164" id="miRNA-corp.d13.s9.e6" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="29-38" id="miRNA-corp.d13.s9.e7" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="51-62" id="miRNA-corp.d13.s9.e8" text="co-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d13.s9.e0" e2="miRNA-corp.d13.s9.e2" id="miRNA-corp.d13.s9.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e0" e2="miRNA-corp.d13.s9.e3" id="miRNA-corp.d13.s9.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e0" e2="miRNA-corp.d13.s9.e4" id="miRNA-corp.d13.s9.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e0" e2="miRNA-corp.d13.s9.e5" id="miRNA-corp.d13.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d13.s9.e1" e2="miRNA-corp.d13.s9.e2" id="miRNA-corp.d13.s9.p4" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e1" e2="miRNA-corp.d13.s9.e3" id="miRNA-corp.d13.s9.p5" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e1" e2="miRNA-corp.d13.s9.e4" id="miRNA-corp.d13.s9.p6" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d13.s9.e1" e2="miRNA-corp.d13.s9.e5" id="miRNA-corp.d13.s9.p7" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d14" origId="12640204">
        <sentence id="miRNA-corp.d14.s0" origId="12640204.s8" text="To determine the role of possible pathogenic cofactors such as geographic, ethnic, genetic, and cultural features, further pertinent surveys are required in subtropical northwestern Argentina.   ">
            <entity charOffset="75-80" id="miRNA-corp.d14.s0.e0" text="ethnic" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s1" origId="12640204.s7" text="Considering the HAM/TSP cluster described here plus previously reported isolated cases in neighboring Salta Province, we speculate that the Puna Jujeña region and regions in that vicinity would be a microepidemic focus of disease. ">
            <entity charOffset="16-18" id="miRNA-corp.d14.s1.e0" text="HAM" type="Diseases"/>
            <entity charOffset="20-22" id="miRNA-corp.d14.s1.e1" text="TSP" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s2" origId="12640204.s6" text="Therefore, the long-term presence of virus in Jujuy natives may be taken for granted. "/>
        <sentence id="miRNA-corp.d14.s3" origId="12640204.s5" text="In contrast to the Andean region of Bolivia, where high HTLV-I seroprevalence is in part attributable to Japanese immigrants, the Jujuy population mainly consists of aborigines, mestizos, and European descendants. "/>
        <sentence id="miRNA-corp.d14.s4" origId="12640204.s4" text="No history of risk factors was disclosed, except for a single transfusion in 1 patient. ">
            <entity charOffset="79-85" id="miRNA-corp.d14.s4.e0" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s5" origId="12640204.s3" text="Most patients (9/11) were born in Cochinoca Department, located in an Andes highland area called Puna Jujeña, situated at more that 3400 m above sea level. ">
            <entity charOffset="5-12" id="miRNA-corp.d14.s5.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s6" origId="12640204.s2" text="Accordingly, a clinically diagnosed and serologically confirmed cluster of cases in 1 man and 10 women, including 2 sisters, is described here. ">
            <entity charOffset="86-88" id="miRNA-corp.d14.s6.e0" text="man" type="Species"/>
            <entity charOffset="97-101" id="miRNA-corp.d14.s6.e1" text="women" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s7" origId="12640204.s1" text="Compared with other regions in Argentina, greater human T-cell lymphotropic virus type I (HTLV-I) seroprevalence has been reported in Jujuy Province, where it reaches 2.32% in the general population, so that a search for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) cases deserved to be carried out. ">
            <entity charOffset="50-54" id="miRNA-corp.d14.s7.e0" text="human" type="Species"/>
            <entity charOffset="221-248" id="miRNA-corp.d14.s7.e1" text="HTLV-I-associated myelopathy" type="Diseases"/>
            <entity charOffset="250-277" id="miRNA-corp.d14.s7.e2" text="tropical spastic paraparesis" type="Diseases"/>
            <entity charOffset="280-282" id="miRNA-corp.d14.s7.e3" text="HAM" type="Diseases"/>
            <entity charOffset="284-286" id="miRNA-corp.d14.s7.e4" text="TSP" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d14.s8" origId="12640204.s0" text="A cluster of human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Jujuy, Argentina.  ">
            <entity charOffset="13-72" id="miRNA-corp.d14.s8.e0" text="human T-cell lymphotropic virus type I-associated myelopathy" type="Diseases"/>
            <entity charOffset="74-101" id="miRNA-corp.d14.s8.e1" text="tropical spastic paraparesis" type="Diseases"/>
            <entity charOffset="13-17" id="miRNA-corp.d14.s8.e2" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d15" origId="21522051">
        <sentence id="miRNA-corp.d15.s0" origId="21522051.s2" text="DESIGN: : Cross-sectional study. "/>
        <sentence id="miRNA-corp.d15.s1" origId="21522051.s1" text="OBJECTIVE: : To compare presentation of Alzheimer disease (AD) at the time of initial evaluation at a university specialty clinic across three ethnoracial groups in order to understand similarities and differences in the demographic, clinical, cognitive, psychiatric, and biologic features. ">
            <entity charOffset="40-56" id="miRNA-corp.d15.s1.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="59-60" id="miRNA-corp.d15.s1.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s2" origId="21522051.s0" text="Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center.  ">
            <entity charOffset="59-77" id="miRNA-corp.d15.s2.e0" text="Alzheimer's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s3" origId="21522051.s9" text="The apolipoprotein E-4 genotype was not associated with AD in the Latino cohort. ">
            <entity charOffset="56-57" id="miRNA-corp.d15.s3.e0" text="AD" type="Diseases"/>
            <entity charOffset="4-19" id="miRNA-corp.d15.s3.e1" text="apolipoprotein E" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s4" origId="21522051.s8" text="Greater severity of symptoms was not accounted for by a difference in lag time between onset of symptoms and initial evaluation. "/>
        <sentence id="miRNA-corp.d15.s5" origId="21522051.s7" text="There was more depression in the Latinos compared with African Americans and WNHs. ">
            <entity charOffset="15-24" id="miRNA-corp.d15.s5.e0" text="depression" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s6" origId="21522051.s6" text="In particular, the largely immigrant Puerto Rican Latino group had an earlier age of onset of AD, more cognitive impairment, and greater severity of cognitive impairment at the time of initial evaluation in the setting of low average education and socioeconomic status. ">
            <entity charOffset="103-122" id="miRNA-corp.d15.s6.e0" text="cognitive impairment" type="Diseases"/>
            <entity charOffset="149-168" id="miRNA-corp.d15.s6.e1" text="cognitive impairment" type="Diseases"/>
            <entity charOffset="94-95" id="miRNA-corp.d15.s6.e2" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s7" origId="21522051.s5" text="RESULTS: : Differences among ethnoracial groups were found for nearly all variables of interest. "/>
        <sentence id="miRNA-corp.d15.s8" origId="21522051.s4" text="MEASUREMENTS: : Demographic variables and age of onset of AD, as well as cognitive, functional, and mood impairments at the time of initial presentation and frequencies of apolipoprotein E genotypes, were compared across groups. ">
            <entity charOffset="105-115" id="miRNA-corp.d15.s8.e0" text="impairments" type="Relation_Trigger"/>
            <entity charOffset="58-59" id="miRNA-corp.d15.s8.e1" text="AD" type="Diseases"/>
            <entity charOffset="172-187" id="miRNA-corp.d15.s8.e2" text="apolipoprotein E" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d15.s9" origId="21522051.s3" text="PARTICIPANTS: : A total of 1,341 self-identified African American, Latino (primarily of Caribbean origin), and white non-Hispanic (&quot;WNH&quot;) subjects were recruited from primary care sites or by referral by primary care physicians. "/>
        <sentence id="miRNA-corp.d15.s10" origId="21522051.s11" text="Important potential confounds need to be considered and future research comparing immigrant and nonimmigrant Latino groups will be necessary to elucidate the highly significant differences reported.   "/>
        <sentence id="miRNA-corp.d15.s11" origId="21522051.s10" text="CONCLUSIONS: : Minority groups in Philadelphia, especially Latinos, exhibit a more severe profile of AD at the time of presentation than WNHs. ">
            <entity charOffset="101-102" id="miRNA-corp.d15.s11.e0" text="AD" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d16" origId="16373485">
        <sentence id="miRNA-corp.d16.s0" origId="16373485.s4" text="Furthermore, methods to profile miRNAs from formalin-fixed, paraffin-embedded (FFPE) archival tissues or to study their cellular and subcellular localization in FFPE tissues have been lacking. ">
            <entity charOffset="32-37" id="miRNA-corp.d16.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s1" origId="16373485.s5" text="Here we report the coordinated miRNA expression analysis from the tissue level to the subcellular level, using the RAKE (RNA-primed, array-based, Klenow Enzyme) miRNA microarray platform in conjunction with Locked Nucleic Acid (LNA)-based in situ hybridization (LNA-ISH) on archival FFPE human brains and oligodendroglial tumors. ">
            <entity charOffset="31-35" id="miRNA-corp.d16.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="161-165" id="miRNA-corp.d16.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="305-327" id="miRNA-corp.d16.s1.e2" text="oligodendroglial tumors" type="Diseases"/>
            <entity charOffset="288-292" id="miRNA-corp.d16.s1.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d16.s1.e0" e2="miRNA-corp.d16.s1.e2" id="miRNA-corp.d16.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d16.s1.e1" e2="miRNA-corp.d16.s1.e2" id="miRNA-corp.d16.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s2" origId="16373485.s6" text="The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAs in human diseases.   ">
            <entity charOffset="23-28" id="miRNA-corp.d16.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="159-164" id="miRNA-corp.d16.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="169-173" id="miRNA-corp.d16.s2.e2" text="human" type="Species"/>
            <entity charOffset="137-146" id="miRNA-corp.d16.s2.e3" text="accelerate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s3" origId="16373485.s0" text="RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.  ">
            <entity charOffset="24-31" id="miRNA-corp.d16.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-77" id="miRNA-corp.d16.s3.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s4" origId="16373485.s1" text="microRNAs (miRNAs) are small (approximately 22 nucleotide) regulatory RNAs which play fundamental roles in many biological processes. ">
            <entity charOffset="0-8" id="miRNA-corp.d16.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d16.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-68" id="miRNA-corp.d16.s4.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s5" origId="16373485.s2" text="Recent studies have shown that the expression of many miRNAs is altered in various human tumors and some miRNAs may function as oncogenes or tumor suppressor genes. ">
            <entity charOffset="54-59" id="miRNA-corp.d16.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="105-110" id="miRNA-corp.d16.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-70" id="miRNA-corp.d16.s5.e2" text="expression of many miRNAs is altered" type="Relation_Trigger"/>
            <entity charOffset="89-94" id="miRNA-corp.d16.s5.e3" text="tumors" type="Diseases"/>
            <entity charOffset="141-156" id="miRNA-corp.d16.s5.e4" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="83-87" id="miRNA-corp.d16.s5.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d16.s5.e0" e2="miRNA-corp.d16.s5.e3" id="miRNA-corp.d16.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d16.s5.e1" e2="miRNA-corp.d16.s5.e3" id="miRNA-corp.d16.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d16.s6" origId="16373485.s3" text="However, with the exception of glioblastoma multiforme, the expression of miRNAs in brain tumors is unknown. ">
            <entity charOffset="74-79" id="miRNA-corp.d16.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-53" id="miRNA-corp.d16.s6.e1" text="glioblastoma multiforme" type="Diseases"/>
            <entity charOffset="84-95" id="miRNA-corp.d16.s6.e2" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d16.s6.e0" e2="miRNA-corp.d16.s6.e1" id="miRNA-corp.d16.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d16.s6.e0" e2="miRNA-corp.d16.s6.e2" id="miRNA-corp.d16.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d17" origId="21551949">
        <sentence id="miRNA-corp.d17.s0" origId="21551949.s5" text="Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction. ">
            <entity charOffset="25-31" id="miRNA-corp.d17.s0.e0" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="105-108" id="miRNA-corp.d17.s0.e1" text="MCAO" type="Diseases"/>
            <entity charOffset="7-59" id="miRNA-corp.d17.s0.e2" text="concentrations of miR-124 were significantly elevated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d17.s0.e0" e2="miRNA-corp.d17.s0.e1" id="miRNA-corp.d17.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s1" origId="21551949.s6" text="Thus, plasma concentration of miR-124 provides a promising candidate biomarker for early detection of cerebral infarction.   ">
            <entity charOffset="102-120" id="miRNA-corp.d17.s1.e0" text="cerebral infarction" type="Diseases"/>
            <entity charOffset="30-36" id="miRNA-corp.d17.s1.e1" text="miR-124" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d17.s1.e1" e2="miRNA-corp.d17.s1.e0" id="miRNA-corp.d17.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s2" origId="21551949.s3" text="In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases. ">
            <entity charOffset="15-19" id="miRNA-corp.d17.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-73" id="miRNA-corp.d17.s2.e1" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="221-241" id="miRNA-corp.d17.s2.e2" text="neurological diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d17.s2.e1" e2="miRNA-corp.d17.s2.e2" id="miRNA-corp.d17.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s2.e0" e2="miRNA-corp.d17.s2.e2" id="miRNA-corp.d17.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s3" origId="21551949.s4" text="We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat. ">
            <entity charOffset="95-113" id="miRNA-corp.d17.s3.e0" text="cerebral infarction" type="Diseases"/>
            <entity charOffset="126-144" id="miRNA-corp.d17.s3.e1" text="cerebral infarction" type="Diseases"/>
            <entity charOffset="60-64" id="miRNA-corp.d17.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="161-192" id="miRNA-corp.d17.s3.e3" text="middle cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="195-198" id="miRNA-corp.d17.s3.e4" text="MCAO" type="Diseases"/>
            <entity charOffset="208-210" id="miRNA-corp.d17.s3.e5" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d17.s3.e2" e2="miRNA-corp.d17.s3.e0" id="miRNA-corp.d17.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s3.e2" e2="miRNA-corp.d17.s3.e3" id="miRNA-corp.d17.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s3.e2" e2="miRNA-corp.d17.s3.e4" id="miRNA-corp.d17.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d17.s3.e2" e2="miRNA-corp.d17.s3.e1" id="miRNA-corp.d17.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s4" origId="21551949.s1" text="MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes. ">
            <entity charOffset="0-8" id="miRNA-corp.d17.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d17.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="111-124" id="miRNA-corp.d17.s4.e2" text="downregulating" type="Relation_Trigger"/>
            <entity charOffset="126-131" id="miRNA-corp.d17.s4.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s5" origId="21551949.s2" text="Recently, plasma miRNAs have been investigated as biomarkers for various diseases. ">
            <entity charOffset="17-22" id="miRNA-corp.d17.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d17.s6" origId="21551949.s0" text="Plasma miR-124 as a biomarker for cerebral infarction.  ">
            <entity charOffset="34-52" id="miRNA-corp.d17.s6.e0" text="cerebral infarction" type="Diseases"/>
            <entity charOffset="7-13" id="miRNA-corp.d17.s6.e1" text="miR-124" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d17.s6.e1" e2="miRNA-corp.d17.s6.e0" id="miRNA-corp.d17.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d18" origId="15883265">
        <sentence id="miRNA-corp.d18.s0" origId="15883265.s8" text="The basis for the younger age at symptom onset remains obscure.   "/>
        <sentence id="miRNA-corp.d18.s1" origId="15883265.s7" text="CONCLUSIONS: An earlier age at symptom onset suggests that US mainland Latino individuals may experience an increased burden of AD compared with Anglo individuals. ">
            <entity charOffset="128-129" id="miRNA-corp.d18.s1.e0" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s2" origId="15883265.s2" text="OBJECTIVE: To compare the age at AD symptom onset in Latino and Anglo individuals. ">
            <entity charOffset="33-34" id="miRNA-corp.d18.s2.e0" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s3" origId="15883265.s1" text="BACKGROUND: Latino individuals are the largest minority group and the fastest growing population group in the United States, yet there are few studies comparing the clinical features of Alzheimer disease (AD) in this population with those found in Anglo (white non-Latino) patients. ">
            <entity charOffset="186-202" id="miRNA-corp.d18.s3.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="205-206" id="miRNA-corp.d18.s3.e1" text="AD" type="Diseases"/>
            <entity charOffset="273-280" id="miRNA-corp.d18.s3.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s4" origId="15883265.s0" text="Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals.  ">
            <entity charOffset="17-33" id="miRNA-corp.d18.s4.e0" text="Alzheimer disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s5" origId="15883265.s6" text="RESULTS: After adjusting for center, sex, and years of education, Latino patients had a mean age at symptom onset 6.8 years earlier (95% confidence interval, 3.5-10.3 years earlier) than Anglo patients. ">
            <entity charOffset="73-80" id="miRNA-corp.d18.s5.e0" text="patients" type="Species"/>
			<entity charOffset="193-200" id="miRNA-corp.d18.s5.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s6" origId="15883265.s5" text="PATIENTS: We evaluated 119 Latino and 55 Anglo patients who had a diagnosis of AD. MAIN OUTCOME MEASURE: Age at symptom onset. ">
            <entity charOffset="79-80" id="miRNA-corp.d18.s6.e0" text="AD" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d18.s6.e1" text="PATIENTS" type="Species"/>
            <entity charOffset="47-54" id="miRNA-corp.d18.s6.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d18.s7" origId="15883265.s4" text="SETTING: Five National Institute on Aging-sponsored Alzheimer's Disease Centers with experience evaluating Spanish-speaking individuals. "/>
        <sentence id="miRNA-corp.d18.s8" origId="15883265.s3" text="DESIGN: Cross-sectional assessment using standardized methods to collect and compare age at AD symptom onset, demographic variables, and medical variables. ">
            <entity charOffset="92-93" id="miRNA-corp.d18.s8.e0" text="AD" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d19" origId="19351822">
        <sentence id="miRNA-corp.d19.s0" origId="19351822.s9" text="We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.   ">
            <entity charOffset="17-25" id="miRNA-corp.d19.s0.e0" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="165-180" id="miRNA-corp.d19.s0.e1" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="131-133" id="miRNA-corp.d19.s0.e2" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-107" id="miRNA-corp.d19.s0.e3" text="aberrant expression" type="Relation_Trigger"/>
            <entity charOffset="109-121" id="miRNA-corp.d19.s0.e4" text="amplification" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s0.e0" e2="miRNA-corp.d19.s0.e1" id="miRNA-corp.d19.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s0.e2" e2="miRNA-corp.d19.s0.e1" id="miRNA-corp.d19.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s1" origId="19351822.s8" text="Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. ">
            <entity charOffset="149-151" id="miRNA-corp.d19.s1.e0" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="64-66" id="miRNA-corp.d19.s1.e1" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="8-16" id="miRNA-corp.d19.s1.e2" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="0-27" id="miRNA-corp.d19.s1.e3" text="Ectopic miR-17/92 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s1.e2" e2="miRNA-corp.d19.s1.e0" id="miRNA-corp.d19.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s1.e2" e2="miRNA-corp.d19.s1.e1" id="miRNA-corp.d19.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s2" origId="19351822.s7" text="In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. ">
            <entity charOffset="42-45" id="miRNA-corp.d19.s2.e0" text="Gli1" type="Genes/Proteins"/>
            <entity charOffset="14-16" id="miRNA-corp.d19.s2.e1" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="56-64" id="miRNA-corp.d19.s2.e2" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="27-31" id="miRNA-corp.d19.s2.e3" text="N-myc" type="Genes/Proteins"/>
            <entity charOffset="48-75" id="miRNA-corp.d19.s2.e4" text="induced miR-17/92 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s2.e2" e2="miRNA-corp.d19.s2.e3" id="miRNA-corp.d19.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s2.e2" e2="miRNA-corp.d19.s2.e0" id="miRNA-corp.d19.s2.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s2.e2" e2="miRNA-corp.d19.s2.e1" id="miRNA-corp.d19.s2.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s3" origId="19351822.s6" text="Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. ">
            <entity charOffset="56-58" id="miRNA-corp.d19.s3.e0" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="34-36" id="miRNA-corp.d19.s3.e1" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="214-222" id="miRNA-corp.d19.s3.e2" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="174-189" id="miRNA-corp.d19.s3.e3" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="204-233" id="miRNA-corp.d19.s3.e4" text="increased miR-17/92 expression" type="Relation_Trigger"/>
            <entity charOffset="159-161" id="miRNA-corp.d19.s3.e5" text="Shh" type="Genes/Proteins"/>
            <entity charOffset="20-29" id="miRNA-corp.d19.s3.e6" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s3.e2" e2="miRNA-corp.d19.s3.e0" id="miRNA-corp.d19.s3.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s3.e2" e2="miRNA-corp.d19.s3.e3" id="miRNA-corp.d19.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s3.e2" e2="miRNA-corp.d19.s3.e5" id="miRNA-corp.d19.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s3.e2" e2="miRNA-corp.d19.s3.e1" id="miRNA-corp.d19.s3.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s4" origId="19351822.s5" text="Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. ">
            <entity charOffset="81-83" id="miRNA-corp.d19.s4.e0" text="MYC" type="Genes/Proteins"/>
            <entity charOffset="85-88" id="miRNA-corp.d19.s4.e1" text="MYCN" type="Genes/Proteins"/>
            <entity charOffset="26-34" id="miRNA-corp.d19.s4.e2" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="0-15" id="miRNA-corp.d19.s4.e3" text="Medulloblastomas" type="Diseases"/>
            <entity charOffset="40-51" id="miRNA-corp.d19.s4.e4" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="62-99" id="miRNA-corp.d19.s4.e5" text="elevated levels of MYC/MYCN expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e3" id="miRNA-corp.d19.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e0" id="miRNA-corp.d19.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s4.e2" e2="miRNA-corp.d19.s4.e1" id="miRNA-corp.d19.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s5" origId="19351822.s4" text="Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. ">
            <entity charOffset="14-22" id="miRNA-corp.d19.s5.e0" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="55-70" id="miRNA-corp.d19.s5.e1" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="178-192" id="miRNA-corp.d19.s5.e2" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="0-34" id="miRNA-corp.d19.s5.e3" text="Expression of miR-17/92 was highest" type="Relation_Trigger"/>
            <entity charOffset="72-81" id="miRNA-corp.d19.s5.e4" text="associated" type="Relation_Trigger"/>
            <entity charOffset="88-97" id="miRNA-corp.d19.s5.e5" text="activation" type="Relation_Trigger"/>
            <entity charOffset="106-119" id="miRNA-corp.d19.s5.e6" text="sonic hedgehog" type="Genes/Proteins"/>
            <entity charOffset="122-124" id="miRNA-corp.d19.s5.e7" text="Shh" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s5.e0" e2="miRNA-corp.d19.s5.e1" id="miRNA-corp.d19.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s5.e0" e2="miRNA-corp.d19.s5.e2" id="miRNA-corp.d19.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s5.e0" e2="miRNA-corp.d19.s5.e6" id="miRNA-corp.d19.s5.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s5.e0" e2="miRNA-corp.d19.s5.e7" id="miRNA-corp.d19.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s6" origId="19351822.s3" text="Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. ">
            <entity charOffset="138-146" id="miRNA-corp.d19.s6.e0" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="203-217" id="miRNA-corp.d19.s6.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="39-47" id="miRNA-corp.d19.s6.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-54" id="miRNA-corp.d19.s6.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="193-198" id="miRNA-corp.d19.s6.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-104" id="miRNA-corp.d19.s6.e5" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="173-191" id="miRNA-corp.d19.s6.e6" text="highly up-regulated" type="Relation_Trigger"/>
            <entity charOffset="83-87" id="miRNA-corp.d19.s6.e7" text="human" type="Species"/>
            <pair e1="miRNA-corp.d19.s6.e0" e2="miRNA-corp.d19.s6.e1" id="miRNA-corp.d19.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e0" e2="miRNA-corp.d19.s6.e5" id="miRNA-corp.d19.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e2" e2="miRNA-corp.d19.s6.e1" id="miRNA-corp.d19.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e2" e2="miRNA-corp.d19.s6.e5" id="miRNA-corp.d19.s6.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e3" e2="miRNA-corp.d19.s6.e1" id="miRNA-corp.d19.s6.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e3" e2="miRNA-corp.d19.s6.e5" id="miRNA-corp.d19.s6.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e1" id="miRNA-corp.d19.s6.p6" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s6.e4" e2="miRNA-corp.d19.s6.e5" id="miRNA-corp.d19.s6.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s7" origId="19351822.s2" text="We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray. ">
            <entity charOffset="45-53" id="miRNA-corp.d19.s7.e0" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="24-36" id="miRNA-corp.d19.s7.e1" text="amplification" type="Relation_Trigger"/>
            <entity charOffset="91-116" id="miRNA-corp.d19.s7.e2" text="pediatric medulloblastomas" type="Diseases"/>
            <entity charOffset="258-272" id="miRNA-corp.d19.s7.e3" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="252-256" id="miRNA-corp.d19.s7.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d19.s7.e0" e2="miRNA-corp.d19.s7.e2" id="miRNA-corp.d19.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s7.e0" e2="miRNA-corp.d19.s7.e3" id="miRNA-corp.d19.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s8" origId="19351822.s1" text="Medulloblastoma is the most common malignant pediatric brain tumor, and mechanisms underlying its development are poorly understood. ">
            <entity charOffset="0-14" id="miRNA-corp.d19.s8.e0" text="Medulloblastoma" type="Diseases"/>
            <entity charOffset="55-65" id="miRNA-corp.d19.s8.e1" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d19.s9" origId="19351822.s0" text="The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.  ">
            <entity charOffset="4-12" id="miRNA-corp.d19.s9.e0" text="miR-17/92" type="Specific_miRNAs"/>
            <entity charOffset="108-121" id="miRNA-corp.d19.s9.e1" text="sonic hedgehog" type="Genes/Proteins"/>
            <entity charOffset="67-82" id="miRNA-corp.d19.s9.e2" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="99-103" id="miRNA-corp.d19.s9.e3" text="N-myc" type="Genes/Proteins"/>
            <entity charOffset="29-40" id="miRNA-corp.d19.s9.e4" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="45-58" id="miRNA-corp.d19.s9.e5" text="sonic hedgehog" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e0" e2="miRNA-corp.d19.s9.e1" id="miRNA-corp.d19.s9.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e0" e2="miRNA-corp.d19.s9.e2" id="miRNA-corp.d19.s9.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d19.s9.e0" e2="miRNA-corp.d19.s9.e3" id="miRNA-corp.d19.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d19.s9.e0" e2="miRNA-corp.d19.s9.e5" id="miRNA-corp.d19.s9.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d20" origId="20130213">
        <sentence id="miRNA-corp.d20.s0" origId="20130213.s0" text="MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.  ">
            <entity charOffset="23-30" id="miRNA-corp.d20.s0.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="0-7" id="miRNA-corp.d20.s0.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-81" id="miRNA-corp.d20.s0.e2" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="9-49" id="miRNA-corp.d20.s0.e3" text="regulation of IFN-beta protein expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d20.s0.e1" e2="miRNA-corp.d20.s0.e0" id="miRNA-corp.d20.s0.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s1" origId="20130213.s5" text="In primary primate macrophages, the main cell type implicated in HIV and SIV infection in the CNS, specific miRNAs reduce, whereas miRNA inhibitors enhance, IFN-beta protein production. ">
            <entity charOffset="157-164" id="miRNA-corp.d20.s1.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="108-113" id="miRNA-corp.d20.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="137-146" id="miRNA-corp.d20.s1.e2" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="65-85" id="miRNA-corp.d20.s1.e3" text="HIV and SIV infection" type="Diseases"/>
            <pair e1="miRNA-corp.d20.s1.e1" e2="miRNA-corp.d20.s1.e3" id="miRNA-corp.d20.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d20.s1.e1" e2="miRNA-corp.d20.s1.e0" id="miRNA-corp.d20.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s2" origId="20130213.s6" text="The potential biologic significance of this regulation is supported by evidence of an apparent negative feedback loop, with increased expression of three IFN-beta-regulating miRNAs by primate macrophages exposed to recombinant IFN-beta or stimulated to produce IFN-beta. ">
            <entity charOffset="261-268" id="miRNA-corp.d20.s2.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="227-234" id="miRNA-corp.d20.s2.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="174-179" id="miRNA-corp.d20.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="154-161" id="miRNA-corp.d20.s2.e3" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="124-143" id="miRNA-corp.d20.s2.e4" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="44-53" id="miRNA-corp.d20.s2.e5" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d20.s2.e2" e2="miRNA-corp.d20.s2.e0" id="miRNA-corp.d20.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d20.s2.e2" e2="miRNA-corp.d20.s2.e1" id="miRNA-corp.d20.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d20.s2.e2" e2="miRNA-corp.d20.s2.e3" id="miRNA-corp.d20.s2.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s3" origId="20130213.s7" text="Thus, miRNAs may contribute significantly to the regulation of IFN-beta in innate immune responses.   ">
            <entity charOffset="6-11" id="miRNA-corp.d20.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="63-70" id="miRNA-corp.d20.s3.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="49-58" id="miRNA-corp.d20.s3.e2" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d20.s3.e0" e2="miRNA-corp.d20.s3.e1" id="miRNA-corp.d20.s3.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s4" origId="20130213.s1" text="IFN-beta production is an inaugural event in the innate immune response to viral infections, with relatively small fold changes in IFN-beta expression resulting in the activation of important antiviral signaling cascades. ">
            <entity charOffset="0-7" id="miRNA-corp.d20.s4.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="131-138" id="miRNA-corp.d20.s4.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="168-177" id="miRNA-corp.d20.s4.e2" text="activation" type="Relation_Trigger"/>
            <entity charOffset="75-90" id="miRNA-corp.d20.s4.e3" text="viral infections" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s5" origId="20130213.s2" text="In our rapid SIV/macaque model of HIV encephalitis, the virus enters the CNS within 4 d of infection, accompanied by a marked IFN-beta response that wanes as SIV replication is controlled. ">
            <entity charOffset="34-49" id="miRNA-corp.d20.s5.e0" text="HIV encephalitis" type="Diseases"/>
            <entity charOffset="126-133" id="miRNA-corp.d20.s5.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="91-99" id="miRNA-corp.d20.s5.e2" text="infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s6" origId="20130213.s3" text="The centrality of IFN-beta to the innate antiviral response in the CNS combines with the potential inflammatory damage associated with long-term activation of this pathway to suggest that IFN-beta may be subject to regulatory fine-tuning in addition to well-established transcriptional and message stability mechanisms of regulation. ">
            <entity charOffset="18-25" id="miRNA-corp.d20.s6.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="188-195" id="miRNA-corp.d20.s6.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="119-128" id="miRNA-corp.d20.s6.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="145-154" id="miRNA-corp.d20.s6.e3" text="activation" type="Relation_Trigger"/>
            <entity charOffset="215-224" id="miRNA-corp.d20.s6.e4" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="322-331" id="miRNA-corp.d20.s6.e5" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d20.s7" origId="20130213.s4" text="In this paper, we present for the first time evidence that microRNAs (miRNAs), including miR-26a, -34a, -145, and let-7b, may directly regulate IFN-beta in human and macaque cells. ">
            <entity charOffset="114-119" id="miRNA-corp.d20.s7.e0" text="let-7b" type="Specific_miRNAs"/>
            <entity charOffset="144-151" id="miRNA-corp.d20.s7.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="59-67" id="miRNA-corp.d20.s7.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-75" id="miRNA-corp.d20.s7.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-142" id="miRNA-corp.d20.s7.e4" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="89-107" id="miRNA-corp.d20.s7.e5" text="miR-26a, -34a, -145" type="Specific_miRNAs"/>
            <entity charOffset="156-160" id="miRNA-corp.d20.s7.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d20.s7.e2" e2="miRNA-corp.d20.s7.e1" id="miRNA-corp.d20.s7.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d20.s7.e3" e2="miRNA-corp.d20.s7.e1" id="miRNA-corp.d20.s7.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d20.s7.e5" e2="miRNA-corp.d20.s7.e1" id="miRNA-corp.d20.s7.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d20.s7.e0" e2="miRNA-corp.d20.s7.e1" id="miRNA-corp.d20.s7.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d21" origId="18525125">
        <sentence id="miRNA-corp.d21.s0" origId="18525125.s0" text="Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways.  ">
            <entity charOffset="18-22" id="miRNA-corp.d21.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-53" id="miRNA-corp.d21.s0.e1" text="Alzheimer's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s0.e0" e2="miRNA-corp.d21.s0.e1" id="miRNA-corp.d21.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s1" origId="18525125.s1" text="MicroRNAs have essential functional roles in brain development and neuronal specification but their roles in neurodegenerative diseases such as Alzheimer's disease (AD) is unknown. ">
            <entity charOffset="0-8" id="miRNA-corp.d21.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="144-162" id="miRNA-corp.d21.s1.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="165-166" id="miRNA-corp.d21.s1.e2" text="AD" type="Diseases"/>
            <entity charOffset="109-134" id="miRNA-corp.d21.s1.e3" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e0" e2="miRNA-corp.d21.s1.e3" id="miRNA-corp.d21.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e0" e2="miRNA-corp.d21.s1.e1" id="miRNA-corp.d21.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s1.e0" e2="miRNA-corp.d21.s1.e2" id="miRNA-corp.d21.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s2" origId="18525125.s2" text="Using a sensitive qRT-PCR platform we identified regional and stage-specific deregulation of miRNA expression in AD patient brains. ">
            <entity charOffset="93-97" id="miRNA-corp.d21.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="113-114" id="miRNA-corp.d21.s2.e1" text="AD" type="Diseases"/>
            <entity charOffset="77-108" id="miRNA-corp.d21.s2.e2" text="deregulation of miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="116-122" id="miRNA-corp.d21.s2.e3" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d21.s2.e0" e2="miRNA-corp.d21.s2.e1" id="miRNA-corp.d21.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s3" origId="18525125.s3" text="We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity. ">
            <entity charOffset="94-102" id="miRNA-corp.d21.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="151-152" id="miRNA-corp.d21.s3.e1" text="AD" type="Diseases"/>
            <entity charOffset="212-229" id="miRNA-corp.d21.s3.e2" text="insulin resistance" type="Diseases"/>
            <entity charOffset="212-218" id="miRNA-corp.d21.s3.e3" text="insulin" type="Genes/Proteins"/>
            <entity charOffset="76-86" id="miRNA-corp.d21.s3.e4" text="deregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d21.s3.e0" e2="miRNA-corp.d21.s3.e1" id="miRNA-corp.d21.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s3.e0" e2="miRNA-corp.d21.s3.e2" id="miRNA-corp.d21.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s3.e0" e2="miRNA-corp.d21.s3.e3" id="miRNA-corp.d21.s3.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d21.s4" origId="18525125.s4" text="We additionally recovered miRNAs from cerebrospinal fluid and discovered AD-specific miRNA changes consistent with their role as potential biomarkers of disease.   ">
            <entity charOffset="26-31" id="miRNA-corp.d21.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-89" id="miRNA-corp.d21.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-74" id="miRNA-corp.d21.s4.e2" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d21.s4.e0" e2="miRNA-corp.d21.s4.e2" id="miRNA-corp.d21.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d21.s4.e1" e2="miRNA-corp.d21.s4.e2" id="miRNA-corp.d21.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d22" origId="21062284">
        <sentence id="miRNA-corp.d22.s0" origId="21062284.s9" text="In sum, our results suggest that specific miRNAs are involved in the fine-tuning of APP alternative splicing in neurons. ">
            <entity charOffset="42-47" id="miRNA-corp.d22.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-86" id="miRNA-corp.d22.s0.e1" text="APP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s0.e0" e2="miRNA-corp.d22.s0.e1" id="miRNA-corp.d22.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s1" origId="21062284.s8" text="Finally, we show that miR-124 is down-regulated in AD brain. ">
            <entity charOffset="33-46" id="miRNA-corp.d22.s1.e0" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="22-28" id="miRNA-corp.d22.s1.e1" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="51-52" id="miRNA-corp.d22.s1.e2" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d22.s1.e1" e2="miRNA-corp.d22.s1.e2" id="miRNA-corp.d22.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s2" origId="21062284.s7" text="Furthermore, PTBP1 levels correlate with the presence of APP exons 7 and 8, while PTBP2 levels correlate with the skipping of these exons during neuronal differentiation. ">
            <entity charOffset="19-34" id="miRNA-corp.d22.s2.e0" text="levels correlate" type="Relation_Trigger"/>
            <entity charOffset="88-103" id="miRNA-corp.d22.s2.e1" text="levels correlate" type="Relation_Trigger"/>
            <entity charOffset="57-59" id="miRNA-corp.d22.s2.e2" text="APP" type="Genes/Proteins"/>
            <entity charOffset="82-86" id="miRNA-corp.d22.s2.e3" text="PTBP2" type="Genes/Proteins"/>
            <entity charOffset="13-17" id="miRNA-corp.d22.s2.e4" text="PTBP1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s3" origId="21062284.s6" text="Similar results were obtained by depletion of endogenous polypyrimidine tract binding protein 1 (PTBP1) in cells, a recognized miR-124 target gene. ">
            <entity charOffset="57-92" id="miRNA-corp.d22.s3.e0" text="polypyrimidine tract binding protein" type="Genes/Proteins"/>
            <entity charOffset="97-101" id="miRNA-corp.d22.s3.e1" text="PTBP1" type="Genes/Proteins"/>
            <entity charOffset="127-133" id="miRNA-corp.d22.s3.e2" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="135-140" id="miRNA-corp.d22.s3.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d22.s3.e2" e2="miRNA-corp.d22.s3.e0" id="miRNA-corp.d22.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s3.e2" e2="miRNA-corp.d22.s3.e1" id="miRNA-corp.d22.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s4" origId="21062284.s0" text="In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs.  ">
            <entity charOffset="69-77" id="miRNA-corp.d22.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-46" id="miRNA-corp.d22.s4.e1" text="amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="8-17" id="miRNA-corp.d22.s4.e2" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d22.s4.e0" e2="miRNA-corp.d22.s4.e1" id="miRNA-corp.d22.s4.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s5" origId="21062284.s1" text="The β-amyloid peptide that accumulate in Alzheimer's disease (AD) brain derive from proteolytic processing of the amyloid precursor protein (APP). ">
            <entity charOffset="41-59" id="miRNA-corp.d22.s5.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="62-63" id="miRNA-corp.d22.s5.e1" text="AD" type="Diseases"/>
            <entity charOffset="114-138" id="miRNA-corp.d22.s5.e2" text="amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="141-143" id="miRNA-corp.d22.s5.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="4-20" id="miRNA-corp.d22.s5.e4" text="β-amyloid peptide" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s6" origId="21062284.s4" text="Here, we present evidence that, besides APP expression regulation, miRNAs are equally involved in the regulation of neuronal APP mRNA alternative splicing. ">
            <entity charOffset="67-72" id="miRNA-corp.d22.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-64" id="miRNA-corp.d22.s6.e1" text="expression regulation" type="Relation_Trigger"/>
            <entity charOffset="102-111" id="miRNA-corp.d22.s6.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="40-42" id="miRNA-corp.d22.s6.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="125-127" id="miRNA-corp.d22.s6.e4" text="APP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s6.e0" e2="miRNA-corp.d22.s6.e3" id="miRNA-corp.d22.s6.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s6.e0" e2="miRNA-corp.d22.s6.e4" id="miRNA-corp.d22.s6.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s7" origId="21062284.s5" text="Lack of miRNAs in post-mitotic neurons in vivo is associated with APP exons 7 and 8 inclusion, while ectopic expression of miR-124, an abundant neuronal-specific miRNA, reversed these effects in cultured neurons. ">
            <entity charOffset="8-13" id="miRNA-corp.d22.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="162-166" id="miRNA-corp.d22.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-118" id="miRNA-corp.d22.s7.e2" text="ectopic expression" type="Relation_Trigger"/>
            <entity charOffset="66-68" id="miRNA-corp.d22.s7.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="123-129" id="miRNA-corp.d22.s7.e4" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="50-59" id="miRNA-corp.d22.s7.e5" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d22.s7.e4" e2="miRNA-corp.d22.s7.e3" id="miRNA-corp.d22.s7.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s7.e0" e2="miRNA-corp.d22.s7.e3" id="miRNA-corp.d22.s7.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s7.e1" e2="miRNA-corp.d22.s7.e3" id="miRNA-corp.d22.s7.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s8" origId="21062284.s2" text="Recent evidence suggest that microRNAs (miRNAs) participate in the post-transcriptional regulation of APP expression. ">
            <entity charOffset="29-37" id="miRNA-corp.d22.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-45" id="miRNA-corp.d22.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-115" id="miRNA-corp.d22.s8.e2" text="regulation of APP expression" type="Relation_Trigger"/>
            <entity charOffset="102-104" id="miRNA-corp.d22.s8.e3" text="APP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s8.e0" e2="miRNA-corp.d22.s8.e3" id="miRNA-corp.d22.s8.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s8.e1" e2="miRNA-corp.d22.s8.e3" id="miRNA-corp.d22.s8.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s9" origId="21062284.s3" text="Because gene dosage effects of the APP gene can cause genetic AD, dysregulation of the miRNA network could contribute significantly to disease. ">
            <entity charOffset="66-78" id="miRNA-corp.d22.s9.e0" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="35-37" id="miRNA-corp.d22.s9.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="62-63" id="miRNA-corp.d22.s9.e2" text="AD" type="Diseases"/>
            <entity charOffset="87-91" id="miRNA-corp.d22.s9.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d22.s9.e3" e2="miRNA-corp.d22.s9.e1" id="miRNA-corp.d22.s9.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s9.e3" e2="miRNA-corp.d22.s9.e2" id="miRNA-corp.d22.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d22.s10" origId="21062284.s10" text="Since abnormal neuronal splicing of APP affects β-amyloid peptide production, these results could contribute to the understanding of the implication of miRNAs in brain health and disease.   ">
            <entity charOffset="152-157" id="miRNA-corp.d22.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-38" id="miRNA-corp.d22.s10.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="50-64" id="miRNA-corp.d22.s10.e2" text="amyloid peptide" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s10.e0" e2="miRNA-corp.d22.s10.e1" id="miRNA-corp.d22.s10.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d22.s10.e0" e2="miRNA-corp.d22.s10.e2" id="miRNA-corp.d22.s10.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d23" origId="21157891">
        <sentence id="miRNA-corp.d23.s0" origId="21157891.s10" text="A greater understanding of aberrant miRNA expression in pediatric brain tumors may aid in the development of novel therapies. ">
            <entity charOffset="36-40" id="miRNA-corp.d23.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-77" id="miRNA-corp.d23.s0.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="27-51" id="miRNA-corp.d23.s0.e2" text="aberrant miRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d23.s0.e0" e2="miRNA-corp.d23.s0.e1" id="miRNA-corp.d23.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s1" origId="21157891.s11" text="The characterization of tumor-specific miRNA signatures may aid in the discovery of biomarkers with diagnostic or prognostic utility.   ">
            <entity charOffset="39-43" id="miRNA-corp.d23.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-28" id="miRNA-corp.d23.s1.e1" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s1.e0" e2="miRNA-corp.d23.s1.e1" id="miRNA-corp.d23.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s2" origId="21157891.s3" text="The present study provides an initial survey of miRNA expression in pediatric central nervous system (CNS) malignancies including atypical teratoid/rhabdoid tumor, ependymoma, glioblastoma, medulloblastoma, and pilocytic astrocytoma. ">
            <entity charOffset="48-52" id="miRNA-corp.d23.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="164-173" id="miRNA-corp.d23.s2.e1" text="ependymoma" type="Diseases"/>
            <entity charOffset="176-187" id="miRNA-corp.d23.s2.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="190-204" id="miRNA-corp.d23.s2.e3" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="211-231" id="miRNA-corp.d23.s2.e4" text="pilocytic astrocytoma" type="Diseases"/>
            <entity charOffset="148-161" id="miRNA-corp.d23.s2.e5" text="rhabdoid tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e0" e2="miRNA-corp.d23.s2.e1" id="miRNA-corp.d23.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e0" e2="miRNA-corp.d23.s2.e2" id="miRNA-corp.d23.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e0" e2="miRNA-corp.d23.s2.e3" id="miRNA-corp.d23.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e0" e2="miRNA-corp.d23.s2.e4" id="miRNA-corp.d23.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s2.e0" e2="miRNA-corp.d23.s2.e5" id="miRNA-corp.d23.s2.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s3" origId="21157891.s4" text="PROCEDURE: MicroRNA expression in pediatric brain tumors and normal tissue controls was examined by microarray. ">
            <entity charOffset="11-18" id="miRNA-corp.d23.s3.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-55" id="miRNA-corp.d23.s3.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s3.e0" e2="miRNA-corp.d23.s3.e1" id="miRNA-corp.d23.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s4" origId="21157891.s1" text="BACKGROUND: A better understanding of pediatric brain tumor biology is needed to assist in the development of less toxic therapies and to provide better markers for disease stratification. ">
            <entity charOffset="48-58" id="miRNA-corp.d23.s4.e0" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s5" origId="21157891.s2" text="MicroRNAs (miRNA) may play a significant role in brain tumor biology. ">
            <entity charOffset="0-8" id="miRNA-corp.d23.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d23.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-59" id="miRNA-corp.d23.s5.e2" text="brain tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s5.e0" e2="miRNA-corp.d23.s5.e2" id="miRNA-corp.d23.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s5.e1" e2="miRNA-corp.d23.s5.e2" id="miRNA-corp.d23.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s6" origId="21157891.s7" text="When further examined by qRT-PCR, these miRNAs demonstrated differential expression that significantly correlated with the microarray findings. ">
            <entity charOffset="40-45" id="miRNA-corp.d23.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-82" id="miRNA-corp.d23.s6.e1" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="73-112" id="miRNA-corp.d23.s6.e2" text="expression that significantly correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s7" origId="21157891.s8" text="Distinctive miRNA expression profiles were also observed in the different pediatric brain tumor types. ">
            <entity charOffset="12-16" id="miRNA-corp.d23.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-94" id="miRNA-corp.d23.s7.e1" text="brain tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s7.e0" e2="miRNA-corp.d23.s7.e1" id="miRNA-corp.d23.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s8" origId="21157891.s5" text="Three aberrantly expressed miRNAs were further studied in a larger cohort by quantitative real-time PCR (qRT-PCR). ">
            <entity charOffset="27-32" id="miRNA-corp.d23.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="6-25" id="miRNA-corp.d23.s8.e1" text="aberrantly expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s9" origId="21157891.s6" text="RESULTS: MicroRNA-129, miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray. ">
            <entity charOffset="95-105" id="miRNA-corp.d23.s9.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="51-74" id="miRNA-corp.d23.s9.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="9-20" id="miRNA-corp.d23.s9.e2" text="MicroRNA-129" type="Specific_miRNAs"/>
            <entity charOffset="23-32" id="miRNA-corp.d23.s9.e3" text="miR-142-5p" type="Specific_miRNAs"/>
            <entity charOffset="39-44" id="miRNA-corp.d23.s9.e4" text="miR-25" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d23.s9.e2" e2="miRNA-corp.d23.s9.e0" id="miRNA-corp.d23.s9.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s9.e3" e2="miRNA-corp.d23.s9.e0" id="miRNA-corp.d23.s9.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d23.s9.e4" e2="miRNA-corp.d23.s9.e0" id="miRNA-corp.d23.s9.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s10" origId="21157891.s9" text="CONCLUSIONS: MicroRNAs are differentially expressed between pediatric CNS neoplasms and normal tissue suggesting that they may play a significant role in oncogenesis. ">
            <entity charOffset="13-21" id="miRNA-corp.d23.s10.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-50" id="miRNA-corp.d23.s10.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="74-82" id="miRNA-corp.d23.s10.e2" text="neoplasms" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s10.e0" e2="miRNA-corp.d23.s10.e2" id="miRNA-corp.d23.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d23.s11" origId="21157891.s0" text="Survey of MicroRNA expression in pediatric brain tumors.  ">
            <entity charOffset="10-17" id="miRNA-corp.d23.s11.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-54" id="miRNA-corp.d23.s11.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d23.s11.e0" e2="miRNA-corp.d23.s11.e1" id="miRNA-corp.d23.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d24" origId="21302725">
        <sentence id="miRNA-corp.d24.s0" origId="21302725.s3" text="The authors reviewed the records of nineteen consecutive children with newly diagnosed IIH in order to compare demographic characteristics, clinical pictures and ophthalmologic aspects as optic disc evaluation and visual field evaluation, as well as treatment modalities and follow up. ">
            <entity charOffset="57-64" id="miRNA-corp.d24.s0.e0" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d24.s1" origId="21302725.s4" text="Beside obesity and female gender, potential alternative risk factors remains to be investigated, which need a good collaboration between neuro-ophthalmologists and pediatric neurologists.   ">
            <entity charOffset="7-13" id="miRNA-corp.d24.s1.e0" text="obesity" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d24.s2" origId="21302725.s1" text="Idiopathic intracranial hypertension (IIH) is a clinical condition characterized by elevated intracranial pressure and absence of clinical, laboratory or radiographic evidence of central nervous system infection, vascular malformation, intracranial space occupying lesion or hydrocephalus. ">
            <entity charOffset="84-113" id="miRNA-corp.d24.s2.e0" text="elevated intracranial pressure" type="Diseases"/>
            <entity charOffset="0-35" id="miRNA-corp.d24.s2.e1" text="Idiopathic intracranial hypertension" type="Diseases"/>
            <entity charOffset="38-40" id="miRNA-corp.d24.s2.e2" text="IIH" type="Diseases"/>
            <entity charOffset="275-287" id="miRNA-corp.d24.s2.e3" text="hydrocephalus" type="Diseases"/>
            <entity charOffset="265-270" id="miRNA-corp.d24.s2.e4" text="lesion" type="Diseases"/>
            <entity charOffset="213-233" id="miRNA-corp.d24.s2.e5" text="vascular malformation" type="Diseases"/>
            <entity charOffset="179-210" id="miRNA-corp.d24.s2.e6" text="central nervous system infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d24.s3" origId="21302725.s2" text="In the last years the raising understanding of pediatric IIH, especially concerning its demographics and epidemiology, has brought up to a redefinition of diagnostic criteria and reevaluation of pathogenesis and treatment. "/>
        <sentence id="miRNA-corp.d24.s4" origId="21302725.s0" text="Pediatric idiopathic intracranial hypertension: clinical and demographic features.  ">
            <entity charOffset="10-45" id="miRNA-corp.d24.s4.e0" text="idiopathic intracranial hypertension" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d25" origId="19175699">
        <sentence id="miRNA-corp.d25.s0" origId="19175699.s7" text="In this review, we summarise the current knowledge of miR-21 functions in human disease, with an emphasis on its regulation, oncogenic role, targets in human cancers, potential as a disease biomarker and novel therapeutic target in oncology.   ">
            <entity charOffset="54-59" id="miRNA-corp.d25.s0.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="141-147" id="miRNA-corp.d25.s0.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="210-227" id="miRNA-corp.d25.s0.e2" text="therapeutic target" type="Relation_Trigger"/>
            <entity charOffset="113-122" id="miRNA-corp.d25.s0.e3" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="158-164" id="miRNA-corp.d25.s0.e4" text="cancers" type="Diseases"/>
            <entity charOffset="74-78" id="miRNA-corp.d25.s0.e5" text="human" type="Species"/>
            <entity charOffset="152-156" id="miRNA-corp.d25.s0.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d25.s0.e0" e2="miRNA-corp.d25.s0.e4" id="miRNA-corp.d25.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s1" origId="19175699.s6" text="However, an miR-21 knockout mouse has not yet been generated, and the data about miR-21 functions in normal cells are still very limited. ">
            <entity charOffset="12-17" id="miRNA-corp.d25.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="81-86" id="miRNA-corp.d25.s1.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="28-32" id="miRNA-corp.d25.s1.e2" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s2" origId="19175699.s5" text="Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields, such as development, oncology, stem cell biology and aging, becoming one of the most studied miRNAs, along with let-7, miR-17-92 cluster ('oncomir-1'), miR-155 and a few others. ">
            <entity charOffset="130-135" id="miRNA-corp.d25.s2.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="318-326" id="miRNA-corp.d25.s2.e1" text="miR-17-92" type="Specific_miRNAs"/>
            <entity charOffset="311-315" id="miRNA-corp.d25.s2.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="351-357" id="miRNA-corp.d25.s2.e3" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="338-346" id="miRNA-corp.d25.s2.e4" text="oncomir-1" type="Specific_miRNAs"/>
            <entity charOffset="44-48" id="miRNA-corp.d25.s2.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="292-297" id="miRNA-corp.d25.s2.e6" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-123" id="miRNA-corp.d25.s2.e7" text="brain tumour glioblastoma" type="Diseases"/>
            <entity charOffset="77-88" id="miRNA-corp.d25.s2.e8" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="93-97" id="miRNA-corp.d25.s2.e9" text="human" type="Species"/>
            <pair e1="miRNA-corp.d25.s2.e0" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e4" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e5" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e6" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e1" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e2" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d25.s2.e3" e2="miRNA-corp.d25.s2.e7" id="miRNA-corp.d25.s2.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s3" origId="19175699.s4" text="Particular miRNAs emerge as principal regulators that control major cell functions in various physiological and pathophysiological settings. ">
            <entity charOffset="11-16" id="miRNA-corp.d25.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-47" id="miRNA-corp.d25.s3.e1" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s4" origId="19175699.s0" text="miR-21: a small multi-faceted RNA.  ">
            <entity charOffset="0-5" id="miRNA-corp.d25.s4.e0" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s5" origId="19175699.s1" text="More than 1000 microRNAs (miRNAs) are expressed in human cells, some tissue or cell type specific, others considered as house-keeping molecules. ">
            <entity charOffset="15-23" id="miRNA-corp.d25.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-31" id="miRNA-corp.d25.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-55" id="miRNA-corp.d25.s5.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s6" origId="19175699.s2" text="Functions and direct mRNA targets for some miRNAs have been relatively well studied over the last years. ">
            <entity charOffset="43-48" id="miRNA-corp.d25.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-32" id="miRNA-corp.d25.s6.e1" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d25.s7" origId="19175699.s3" text="Every miRNA potentially regulates the expression of numerous protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are equally important; diverse high-throughput screenings of various systems have identified a limited number of key functional miRNAs over and over again. ">
            <entity charOffset="6-10" id="miRNA-corp.d25.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="152-157" id="miRNA-corp.d25.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="287-292" id="miRNA-corp.d25.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-47" id="miRNA-corp.d25.s7.e3" text="regulates the expression" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d26" origId="21358093">
        <sentence id="miRNA-corp.d26.s0" origId="21358093.s8" text="Expression levels of select protein-coding genes and miRNAs could classify an independent set of medulloblastomas. ">
            <entity charOffset="97-112" id="miRNA-corp.d26.s0.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="53-58" id="miRNA-corp.d26.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d26.s0.e1" e2="miRNA-corp.d26.s0.e0" id="miRNA-corp.d26.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s1" origId="21358093.s9" text="Twelve of 31 medulloblastomas were found to overexpress genes belonging to the canonical WNT signaling pathway and carry a mutation in CTNNB1 gene. ">
            <entity charOffset="13-28" id="miRNA-corp.d26.s1.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="135-140" id="miRNA-corp.d26.s1.e1" text="CTNNB1" type="Genes/Proteins"/>
            <entity charOffset="44-54" id="miRNA-corp.d26.s1.e2" text="overexpress" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s2" origId="21358093.s4" text="In order to get a better understanding of medulloblastoma biology, miRNA profiling of medulloblastomas was carried out in parallel with expression profiling of protein-coding genes. ">
            <entity charOffset="86-101" id="miRNA-corp.d26.s2.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="67-71" id="miRNA-corp.d26.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-56" id="miRNA-corp.d26.s2.e2" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d26.s2.e1" e2="miRNA-corp.d26.s2.e0" id="miRNA-corp.d26.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s2.e1" e2="miRNA-corp.d26.s2.e2" id="miRNA-corp.d26.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s3" origId="21358093.s5" text="MATERIALS AND METHODS: miRNA profiling of medulloblastomas was carried out using Taqman Low Density Array v 1.0 having 365 human microRNAs. ">
            <entity charOffset="42-57" id="miRNA-corp.d26.s3.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="23-27" id="miRNA-corp.d26.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-137" id="miRNA-corp.d26.s3.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="123-127" id="miRNA-corp.d26.s3.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d26.s3.e1" e2="miRNA-corp.d26.s3.e0" id="miRNA-corp.d26.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s3.e2" e2="miRNA-corp.d26.s3.e0" id="miRNA-corp.d26.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s4" origId="21358093.s6" text="In parallel, genome-wide expression profiling of protein-coding genes was carried out using Affymetrix gene 1.0 ST arrays. "/>
        <sentence id="miRNA-corp.d26.s5" origId="21358093.s7" text="RESULTS: Both the profiling studies identified four molecular subtypes of medulloblastomas. ">
            <entity charOffset="74-89" id="miRNA-corp.d26.s5.e0" text="medulloblastomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s6" origId="21358093.s0" text="Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway.  ">
            <entity charOffset="34-49" id="miRNA-corp.d26.s6.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="12-19" id="miRNA-corp.d26.s6.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-60" id="miRNA-corp.d26.s6.e2" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d26.s6.e1" e2="miRNA-corp.d26.s6.e0" id="miRNA-corp.d26.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s7" origId="21358093.s1" text="AIM: Medulloblastoma is a malignant brain tumor that occurs predominantly in children. ">
            <entity charOffset="36-46" id="miRNA-corp.d26.s7.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="5-19" id="miRNA-corp.d26.s7.e1" text="Medulloblastoma" type="Diseases"/>
            <entity charOffset="77-84" id="miRNA-corp.d26.s7.e2" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s8" origId="21358093.s2" text="Current risk stratification based on clinical parameters is inadequate for accurate prognostication. "/>
        <sentence id="miRNA-corp.d26.s9" origId="21358093.s3" text="MicroRNA expression is known to be deregulated in various cancers and has been found to be useful in predicting tumor behavior. ">
            <entity charOffset="0-7" id="miRNA-corp.d26.s9.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-45" id="miRNA-corp.d26.s9.e1" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="58-64" id="miRNA-corp.d26.s9.e2" text="cancers" type="Diseases"/>
            <entity charOffset="112-116" id="miRNA-corp.d26.s9.e3" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d26.s9.e0" e2="miRNA-corp.d26.s9.e2" id="miRNA-corp.d26.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s9.e0" e2="miRNA-corp.d26.s9.e3" id="miRNA-corp.d26.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s10" origId="21358093.s10" text="A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas. ">
            <entity charOffset="222-237" id="miRNA-corp.d26.s10.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="12-17" id="miRNA-corp.d26.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="176-188" id="miRNA-corp.d26.s10.e2" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="24-31" id="miRNA-corp.d26.s10.e3" text="miR-193a" type="Specific_miRNAs"/>
            <entity charOffset="34-40" id="miRNA-corp.d26.s10.e4" text="miR-224" type="Specific_miRNAs"/>
            <entity charOffset="42-48" id="miRNA-corp.d26.s10.e5" text="miR-452" type="Specific_miRNAs"/>
            <entity charOffset="59-65" id="miRNA-corp.d26.s10.e6" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="67-73" id="miRNA-corp.d26.s10.e7" text="miR-183" type="Specific_miRNAs"/>
            <entity charOffset="75-80" id="miRNA-corp.d26.s10.e8" text="miR-96" type="Specific_miRNAs"/>
            <entity charOffset="95-102" id="miRNA-corp.d26.s10.e9" text="miR-148a" type="Specific_miRNAs"/>
            <entity charOffset="211-220" id="miRNA-corp.d26.s10.e10" text="associated" type="Relation_Trigger"/>
            <entity charOffset="138-148" id="miRNA-corp.d26.s10.e11" text="suppressive" type="Relation_Trigger"/>
            <entity charOffset="121-125" id="miRNA-corp.d26.s10.e12" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e1" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e1" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e3" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e3" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e4" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e4" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e5" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e5" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p7" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e6" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e6" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p9" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e7" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p10" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e7" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p11" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e8" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p12" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e8" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p13" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e9" e2="miRNA-corp.d26.s10.e12" id="miRNA-corp.d26.s10.p14" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s10.e9" e2="miRNA-corp.d26.s10.e0" id="miRNA-corp.d26.s10.p15" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s11" origId="21358093.s12" text="CONCLUSION: Expression level of tumor/metastasis suppressive miRNAs in the WNT signaling associated medulloblastomas is likely to determine their response to treatment, and thus, these miRNAs would be important biomarkers for risk stratification within the WNT signaling associated medulloblastomas.   ">
            <entity charOffset="282-297" id="miRNA-corp.d26.s11.e0" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="100-115" id="miRNA-corp.d26.s11.e1" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="61-66" id="miRNA-corp.d26.s11.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="185-190" id="miRNA-corp.d26.s11.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-98" id="miRNA-corp.d26.s11.e4" text="associated" type="Relation_Trigger"/>
            <entity charOffset="271-280" id="miRNA-corp.d26.s11.e5" text="associated" type="Relation_Trigger"/>
            <entity charOffset="49-59" id="miRNA-corp.d26.s11.e6" text="suppressive" type="Relation_Trigger"/>
            <entity charOffset="32-36" id="miRNA-corp.d26.s11.e7" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e2" e2="miRNA-corp.d26.s11.e7" id="miRNA-corp.d26.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e2" e2="miRNA-corp.d26.s11.e0" id="miRNA-corp.d26.s11.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e2" e2="miRNA-corp.d26.s11.e1" id="miRNA-corp.d26.s11.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e3" e2="miRNA-corp.d26.s11.e7" id="miRNA-corp.d26.s11.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e3" e2="miRNA-corp.d26.s11.e0" id="miRNA-corp.d26.s11.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s11.e3" e2="miRNA-corp.d26.s11.e1" id="miRNA-corp.d26.s11.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d26.s12" origId="21358093.s11" text="Exogenous expression of miR-193a and miR-224, two miRNAs that have the highest WNT pathway specific upregulation, was found to inhibit proliferation, increase radiation sensitivity and reduce anchorage-independent growth of medulloblastoma cells. ">
            <entity charOffset="50-55" id="miRNA-corp.d26.s12.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-111" id="miRNA-corp.d26.s12.e1" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="24-31" id="miRNA-corp.d26.s12.e2" text="miR-193a" type="Specific_miRNAs"/>
            <entity charOffset="37-43" id="miRNA-corp.d26.s12.e3" text="miR-224" type="Specific_miRNAs"/>
            <entity charOffset="224-238" id="miRNA-corp.d26.s12.e4" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="0-19" id="miRNA-corp.d26.s12.e5" text="Exogenous expression" type="Relation_Trigger"/>
            <entity charOffset="127-133" id="miRNA-corp.d26.s12.e6" text="inhibit" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d26.s12.e0" e2="miRNA-corp.d26.s12.e4" id="miRNA-corp.d26.s12.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s12.e2" e2="miRNA-corp.d26.s12.e4" id="miRNA-corp.d26.s12.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d26.s12.e3" e2="miRNA-corp.d26.s12.e4" id="miRNA-corp.d26.s12.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d27" origId="12325078">
        <sentence id="miRNA-corp.d27.s0" origId="12325078.s2" text="We now report clinical and genetic findings in nine additional European families with myoclonus-dystonia syndrome. ">
            <entity charOffset="86-112" id="miRNA-corp.d27.s0.e0" text="myoclonus-dystonia syndrome" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d27.s1" origId="12325078.s1" text="Mutations in the gene for epsilon-sarcoglycan (SGCE) have been found to cause myoclonus-dystonia syndrome. ">
            <entity charOffset="26-44" id="miRNA-corp.d27.s1.e0" text="epsilon-sarcoglycan" type="Genes/Proteins"/>
            <entity charOffset="47-50" id="miRNA-corp.d27.s1.e1" text="SGCE" type="Genes/Proteins"/>
            <entity charOffset="78-104" id="miRNA-corp.d27.s1.e2" text="myoclonus-dystonia syndrome" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d27.s2" origId="12325078.s4" text="Six novel and one previously known heterozygous SGCE mutations were identified. ">
            <entity charOffset="48-51" id="miRNA-corp.d27.s2.e0" text="SGCE" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d27.s3" origId="12325078.s3" text="The clinical presentation in 24 affecteds was homogeneous with myoclonus predominantly of neck and upper limbs in 23 of them and dystonia, presenting as cervical dystonia and/or writer's cramp, in 13 cases. ">
            <entity charOffset="129-136" id="miRNA-corp.d27.s3.e0" text="dystonia" type="Diseases"/>
            <entity charOffset="63-71" id="miRNA-corp.d27.s3.e1" text="myoclonus" type="Diseases"/>
            <entity charOffset="153-169" id="miRNA-corp.d27.s3.e2" text="cervical dystonia" type="Diseases"/>
            <entity charOffset="178-191" id="miRNA-corp.d27.s3.e3" text="writer's cramp" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d27.s4" origId="12325078.s5" text="SGCE deficiency seems to be the common pathogenetic mechanism in myoclonus-dystonia syndrome.   ">
            <entity charOffset="0-3" id="miRNA-corp.d27.s4.e0" text="SGCE" type="Genes/Proteins"/>
            <entity charOffset="65-91" id="miRNA-corp.d27.s4.e1" text="myoclonus-dystonia syndrome" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d27.s5" origId="12325078.s0" text="Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype.  ">
            <entity charOffset="0-26" id="miRNA-corp.d27.s5.e0" text="Myoclonus-dystonia syndrome" type="Diseases"/>
            <entity charOffset="29-47" id="miRNA-corp.d27.s5.e1" text="epsilon-sarcoglycan" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d28" origId="19343354">
        <sentence id="miRNA-corp.d28.s0" origId="19343354.s7" text="This review summarizes recent findings of miRNA study in brain tumors.   ">
            <entity charOffset="42-46" id="miRNA-corp.d28.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-68" id="miRNA-corp.d28.s0.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d28.s0.e0" e2="miRNA-corp.d28.s0.e1" id="miRNA-corp.d28.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s1" origId="19343354.s6" text="Several deregulated miRNAs uncovered in glioblastomas and medulloblastomas have their gene targets and the associated genetic pathways identified. ">
            <entity charOffset="20-25" id="miRNA-corp.d28.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-52" id="miRNA-corp.d28.s1.e1" text="glioblastomas" type="Diseases"/>
            <entity charOffset="58-73" id="miRNA-corp.d28.s1.e2" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="91-97" id="miRNA-corp.d28.s1.e3" text="targets" type="Relation_Trigger"/>
            <entity charOffset="8-18" id="miRNA-corp.d28.s1.e4" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="107-116" id="miRNA-corp.d28.s1.e5" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d28.s1.e0" e2="miRNA-corp.d28.s1.e1" id="miRNA-corp.d28.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d28.s1.e0" e2="miRNA-corp.d28.s1.e2" id="miRNA-corp.d28.s1.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s2" origId="19343354.s5" text="Moreover, specific miRNA subsets may have potential diagnostic and prognostic values in some brain tumors. ">
            <entity charOffset="19-23" id="miRNA-corp.d28.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-104" id="miRNA-corp.d28.s2.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d28.s2.e0" e2="miRNA-corp.d28.s2.e1" id="miRNA-corp.d28.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s3" origId="19343354.s4" text="Expression profiling has unveiled miRNA signatures that not only distinguish brain tumors from normal tissues, but can also differentiate histotypes or molecular subtypes with altered genetic pathways. ">
            <entity charOffset="34-38" id="miRNA-corp.d28.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-88" id="miRNA-corp.d28.s3.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d28.s3.e0" e2="miRNA-corp.d28.s3.e1" id="miRNA-corp.d28.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s4" origId="19343354.s3" text="Recent years have seen considerable progress in miRNA research in brain tumors, particularly in glioblastomas and medulloblastomas, providing novel insights into the pathogenesis of these malignant lesions. ">
            <entity charOffset="48-52" id="miRNA-corp.d28.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-77" id="miRNA-corp.d28.s4.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="96-108" id="miRNA-corp.d28.s4.e2" text="glioblastomas" type="Diseases"/>
            <entity charOffset="114-129" id="miRNA-corp.d28.s4.e3" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="188-204" id="miRNA-corp.d28.s4.e4" text="malignant lesions" type="Diseases"/>
            <pair e1="miRNA-corp.d28.s4.e0" e2="miRNA-corp.d28.s4.e1" id="miRNA-corp.d28.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d28.s4.e0" e2="miRNA-corp.d28.s4.e2" id="miRNA-corp.d28.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d28.s4.e0" e2="miRNA-corp.d28.s4.e3" id="miRNA-corp.d28.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d28.s4.e0" e2="miRNA-corp.d28.s4.e4" id="miRNA-corp.d28.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s5" origId="19343354.s2" text="Emerging evidence indicates that miRNAs play an important role in the development of human cancers, with their deregulation resulting in altered activity of downstream tumor suppressors, oncogenes and other signaling molecules. ">
            <entity charOffset="33-38" id="miRNA-corp.d28.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-97" id="miRNA-corp.d28.s5.e1" text="cancers" type="Diseases"/>
            <entity charOffset="111-122" id="miRNA-corp.d28.s5.e2" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="168-184" id="miRNA-corp.d28.s5.e3" text="tumor suppressors" type="Relation_Trigger"/>
            <entity charOffset="85-89" id="miRNA-corp.d28.s5.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d28.s5.e0" e2="miRNA-corp.d28.s5.e1" id="miRNA-corp.d28.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s6" origId="19343354.s1" text="MicroRNAs (miRNAs) are short non-protein-coding RNAs that function as key regulators of diverse biological processes through negative control on gene expression at the post-transcriptional level. ">
            <entity charOffset="0-8" id="miRNA-corp.d28.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d28.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-83" id="miRNA-corp.d28.s6.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d28.s7" origId="19343354.s0" text="Oncogenic role of microRNAs in brain tumors.  ">
            <entity charOffset="18-26" id="miRNA-corp.d28.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-42" id="miRNA-corp.d28.s7.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d28.s7.e0" e2="miRNA-corp.d28.s7.e1" id="miRNA-corp.d28.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d29" origId="18398004">
        <sentence id="miRNA-corp.d29.s0" origId="18398004.s6" text="Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression. ">
            <entity charOffset="95-120" id="miRNA-corp.d29.s0.e0" text="reduce HDh mRNA expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s1" origId="18398004.s7" text="Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA. ">
            <entity charOffset="42-68" id="miRNA-corp.d29.s1.e0" text="higher antisense RNA levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s2" origId="18398004.s8" text="These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain. ">
            <entity charOffset="132-136" id="miRNA-corp.d29.s2.e0" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s3" origId="18398004.s9" text="Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy. ">
            <entity charOffset="107-111" id="miRNA-corp.d29.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-104" id="miRNA-corp.d29.s3.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="211-220" id="miRNA-corp.d29.s3.e2" text="attenuated" type="Relation_Trigger"/>
            <entity charOffset="243-247" id="miRNA-corp.d29.s3.e3" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s4" origId="18398004.s0" text="Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.  ">
            <entity charOffset="11-16" id="miRNA-corp.d29.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s5" origId="18398004.s1" text="Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein. ">
            <entity charOffset="0-19" id="miRNA-corp.d29.s5.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="22-23" id="miRNA-corp.d29.s5.e1" text="HD" type="Diseases"/>
            <entity charOffset="160-169" id="miRNA-corp.d29.s5.e2" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="38-71" id="miRNA-corp.d29.s5.e3" text="dominant neurodegenerative disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s6" origId="18398004.s2" text="We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models. ">
            <entity charOffset="62-63" id="miRNA-corp.d29.s6.e0" text="HD" type="Diseases"/>
            <entity charOffset="87-96" id="miRNA-corp.d29.s6.e1" text="inhibitory" type="Relation_Trigger"/>
            <entity charOffset="103-111" id="miRNA-corp.d29.s6.e2" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="191-192" id="miRNA-corp.d29.s6.e3" text="HD" type="Diseases"/>
            <entity charOffset="120-124" id="miRNA-corp.d29.s6.e4" text="human" type="Species"/>
            <entity charOffset="194-198" id="miRNA-corp.d29.s6.e5" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s7" origId="18398004.s3" text="Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD. ">
            <entity charOffset="161-162" id="miRNA-corp.d29.s7.e0" text="HD" type="Diseases"/>
            <entity charOffset="65-66" id="miRNA-corp.d29.s7.e1" text="HD" type="Diseases"/>
            <entity charOffset="78-79" id="miRNA-corp.d29.s7.e2" text="HD" type="Diseases"/>
            <entity charOffset="26-34" id="miRNA-corp.d29.s7.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="59-63" id="miRNA-corp.d29.s7.e4" text="human" type="Species"/>
            <entity charOffset="72-76" id="miRNA-corp.d29.s7.e5" text="mouse" type="Species"/>
            <entity charOffset="146-150" id="miRNA-corp.d29.s7.e6" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s8" origId="18398004.s4" text="We screened 35 shRNAs in vitro and subsequently narrowed our focus to three candidates for in vivo testing. "/>
        <sentence id="miRNA-corp.d29.s9" origId="18398004.s5" text="Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three. ">
            <entity charOffset="103-124" id="miRNA-corp.d29.s9.e0" text="expression was reduced" type="Relation_Trigger"/>
            <entity charOffset="118-142" id="miRNA-corp.d29.s9.e1" text="reduced to similar levels" type="Relation_Trigger"/>
            <entity charOffset="69-73" id="miRNA-corp.d29.s9.e2" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d29.s10" origId="18398004.s10" text="Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.   ">
            <entity charOffset="90-99" id="miRNA-corp.d29.s10.e0" text="inhibitory" type="Relation_Trigger"/>
            <entity charOffset="6-10" id="miRNA-corp.d29.s10.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d30" origId="18684319">
        <sentence id="miRNA-corp.d30.s0" origId="18684319.s6" text="These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.   ">
            <entity charOffset="64-66" id="miRNA-corp.d30.s0.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="88-93" id="miRNA-corp.d30.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-83" id="miRNA-corp.d30.s0.e2" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="58-62" id="miRNA-corp.d30.s0.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d30.s0.e1" e2="miRNA-corp.d30.s0.e0" id="miRNA-corp.d30.s0.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s1" origId="18684319.s5" text="Over-expression of these miRNAs, but not control miRNAs, results in translational repression of APP mRNA and significantly reduces APP protein levels. ">
            <entity charOffset="96-98" id="miRNA-corp.d30.s1.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="131-133" id="miRNA-corp.d30.s1.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="25-30" id="miRNA-corp.d30.s1.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-54" id="miRNA-corp.d30.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-14" id="miRNA-corp.d30.s1.e4" text="Over-expression" type="Relation_Trigger"/>
            <entity charOffset="68-91" id="miRNA-corp.d30.s1.e5" text="translational repression" type="Relation_Trigger"/>
            <entity charOffset="123-148" id="miRNA-corp.d30.s1.e6" text="reduces APP protein levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d30.s1.e2" e2="miRNA-corp.d30.s1.e0" id="miRNA-corp.d30.s1.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d30.s1.e2" e2="miRNA-corp.d30.s1.e1" id="miRNA-corp.d30.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d30.s1.e3" e2="miRNA-corp.d30.s1.e0" id="miRNA-corp.d30.s1.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d30.s1.e3" e2="miRNA-corp.d30.s1.e1" id="miRNA-corp.d30.s1.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s2" origId="18684319.s3" text="Here we test the hypothesis that APP protein levels can be regulated by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role in regulating gene expression. ">
            <entity charOffset="33-35" id="miRNA-corp.d30.s2.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="72-77" id="miRNA-corp.d30.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-67" id="miRNA-corp.d30.s2.e2" text="levels can be regulated" type="Relation_Trigger"/>
            <entity charOffset="166-191" id="miRNA-corp.d30.s2.e3" text="regulating gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d30.s2.e1" e2="miRNA-corp.d30.s2.e0" id="miRNA-corp.d30.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s3" origId="18684319.s4" text="Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively regulate reporter gene expression. ">
            <entity charOffset="133-135" id="miRNA-corp.d30.s3.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="55-66" id="miRNA-corp.d30.s3.e1" text="hsa-mir-106a" type="Specific_miRNAs"/>
            <entity charOffset="72-83" id="miRNA-corp.d30.s3.e2" text="hsa-mir-520c" type="Specific_miRNAs"/>
            <entity charOffset="48-53" id="miRNA-corp.d30.s3.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-88" id="miRNA-corp.d30.s3.e4" text="bind" type="Relation_Trigger"/>
            <entity charOffset="158-190" id="miRNA-corp.d30.s3.e5" text="regulate reporter gene expression" type="Relation_Trigger"/>
            <entity charOffset="109-114" id="miRNA-corp.d30.s3.e6" text="target" type="Relation_Trigger"/>
            <entity charOffset="147-165" id="miRNA-corp.d30.s3.e7" text="negatively regulate" type="Relation_Trigger"/>
            <entity charOffset="10-14" id="miRNA-corp.d30.s3.e8" text="human" type="Species"/>
            <pair e1="miRNA-corp.d30.s3.e1" e2="miRNA-corp.d30.s3.e0" id="miRNA-corp.d30.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d30.s3.e2" e2="miRNA-corp.d30.s3.e0" id="miRNA-corp.d30.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d30.s3.e3" e2="miRNA-corp.d30.s3.e0" id="miRNA-corp.d30.s3.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s4" origId="18684319.s1" text="ABSTRACT: A number of studies have shown that increased APP levels, resulting from either a genomic locus duplication or alteration in APP regulatory sequences, can lead to development of early-onset dementias, including Alzheimer's disease (AD). ">
            <entity charOffset="56-58" id="miRNA-corp.d30.s4.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="200-208" id="miRNA-corp.d30.s4.e1" text="dementias" type="Diseases"/>
            <entity charOffset="221-239" id="miRNA-corp.d30.s4.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="242-243" id="miRNA-corp.d30.s4.e3" text="AD" type="Diseases"/>
            <entity charOffset="46-65" id="miRNA-corp.d30.s4.e4" text="increased APP levels" type="Relation_Trigger"/>
            <entity charOffset="139-148" id="miRNA-corp.d30.s4.e5" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s5" origId="18684319.s2" text="Therefore, understanding how APP levels are regulated could provide valuable insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD. ">
            <entity charOffset="159-160" id="miRNA-corp.d30.s5.e0" text="AD" type="Diseases"/>
            <entity charOffset="111-112" id="miRNA-corp.d30.s5.e1" text="AD" type="Diseases"/>
            <entity charOffset="29-31" id="miRNA-corp.d30.s5.e2" text="APP" type="Genes/Proteins"/>
            <entity charOffset="33-52" id="miRNA-corp.d30.s5.e3" text="levels are regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d30.s6" origId="18684319.s0" text="MicroRNAs can regulate human APP levels.  ">
            <entity charOffset="29-31" id="miRNA-corp.d30.s6.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="0-8" id="miRNA-corp.d30.s6.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-38" id="miRNA-corp.d30.s6.e2" text="regulate human APP levels" type="Relation_Trigger"/>
            <entity charOffset="23-27" id="miRNA-corp.d30.s6.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d30.s6.e1" e2="miRNA-corp.d30.s6.e0" id="miRNA-corp.d30.s6.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d31" origId="17111382">
        <sentence id="miRNA-corp.d31.s0" origId="17111382.s8" text="Predictive miRNAs could be potentially useful diagnostic markers, improving the classification of pituitary adenomas.   ">
            <entity charOffset="11-16" id="miRNA-corp.d31.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-115" id="miRNA-corp.d31.s0.e1" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s0.e0" e2="miRNA-corp.d31.s0.e1" id="miRNA-corp.d31.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s1" origId="17111382.s7" text="Several of the identified miRNAs are involved in cell proliferation and apoptosis, suggesting that their deregulated expression may be involved in pituitary tumorigenesis. ">
            <entity charOffset="26-31" id="miRNA-corp.d31.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="105-126" id="miRNA-corp.d31.s1.e1" text="deregulated expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s2" origId="17111382.s0" text="Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.  ">
            <entity charOffset="43-51" id="miRNA-corp.d31.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-95" id="miRNA-corp.d31.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="106-123" id="miRNA-corp.d31.s2.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="18-41" id="miRNA-corp.d31.s2.e3" text="differentially expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d31.s2.e0" e2="miRNA-corp.d31.s2.e2" id="miRNA-corp.d31.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s2.e1" e2="miRNA-corp.d31.s2.e2" id="miRNA-corp.d31.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s3" origId="17111382.s1" text="MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression by targeting mRNA. ">
            <entity charOffset="0-8" id="miRNA-corp.d31.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d31.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-85" id="miRNA-corp.d31.s3.e2" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s4" origId="17111382.s2" text="It has been demonstrated that miRNA expression is altered in many human cancers, suggesting that they may play a role in human neoplasia. ">
            <entity charOffset="30-34" id="miRNA-corp.d31.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-56" id="miRNA-corp.d31.s4.e1" text="expression is altered" type="Relation_Trigger"/>
            <entity charOffset="72-78" id="miRNA-corp.d31.s4.e2" text="cancers" type="Diseases"/>
            <entity charOffset="66-70" id="miRNA-corp.d31.s4.e3" text="human" type="Species"/>
            <entity charOffset="121-125" id="miRNA-corp.d31.s4.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d31.s4.e0" e2="miRNA-corp.d31.s4.e2" id="miRNA-corp.d31.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s5" origId="17111382.s3" text="To determine whether miRNA expression is altered in pituitary adenomas, we analyzed the entire miRNAome in 32 pituitary adenomas and in 6 normal pituitary samples by microarray and by Real-Time PCR. ">
            <entity charOffset="21-25" id="miRNA-corp.d31.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-69" id="miRNA-corp.d31.s5.e1" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="110-127" id="miRNA-corp.d31.s5.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="27-47" id="miRNA-corp.d31.s5.e3" text="expression is altered" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d31.s5.e0" e2="miRNA-corp.d31.s5.e1" id="miRNA-corp.d31.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s5.e0" e2="miRNA-corp.d31.s5.e2" id="miRNA-corp.d31.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s6" origId="17111382.s4" text="Here, we show that 30 miRNAs are differentially expressed between normal pituitary and pituitary adenomas. ">
            <entity charOffset="22-27" id="miRNA-corp.d31.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-104" id="miRNA-corp.d31.s6.e1" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="33-56" id="miRNA-corp.d31.s6.e2" text="differentially expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d31.s6.e0" e2="miRNA-corp.d31.s6.e1" id="miRNA-corp.d31.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s7" origId="17111382.s5" text="Moreover, 24 miRNAs were identified as a predictive signature of pituitary adenoma and 29 miRNAs were able to predict pituitary adenoma histotype. ">
            <entity charOffset="13-18" id="miRNA-corp.d31.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-95" id="miRNA-corp.d31.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-81" id="miRNA-corp.d31.s7.e2" text="pituitary adenoma" type="Diseases"/>
            <entity charOffset="118-134" id="miRNA-corp.d31.s7.e3" text="pituitary adenoma" type="Diseases"/>
            <pair e1="miRNA-corp.d31.s7.e0" e2="miRNA-corp.d31.s7.e2" id="miRNA-corp.d31.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s7.e0" e2="miRNA-corp.d31.s7.e3" id="miRNA-corp.d31.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s7.e1" e2="miRNA-corp.d31.s7.e2" id="miRNA-corp.d31.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d31.s7.e1" e2="miRNA-corp.d31.s7.e3" id="miRNA-corp.d31.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d31.s8" origId="17111382.s6" text="miRNA expression could differentiate micro- from macro-adenomas and treated from non-treated patient samples. ">
            <entity charOffset="0-4" id="miRNA-corp.d31.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="55-62" id="miRNA-corp.d31.s8.e1" text="adenomas" type="Diseases"/>
            <entity charOffset="93-99" id="miRNA-corp.d31.s8.e2" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d31.s8.e0" e2="miRNA-corp.d31.s8.e1" id="miRNA-corp.d31.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d32" origId="19415117">
        <sentence id="miRNA-corp.d32.s0" origId="19415117.s6" text="Comparison of mouse cerebellar development and medulloblastoma demonstrates a shared miRNA-mRNA co-expression program for brain-specific neurologic processes such as synaptic transmission and exocytosis, in which miRNA target expression increases with the accumulation of multiple miRNAs in developing cerebellum and decreases with the loss of these miRNAs in brain tumors. ">
            <entity charOffset="47-61" id="miRNA-corp.d32.s0.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="360-371" id="miRNA-corp.d32.s0.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="281-286" id="miRNA-corp.d32.s0.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="350-355" id="miRNA-corp.d32.s0.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="213-217" id="miRNA-corp.d32.s0.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-89" id="miRNA-corp.d32.s0.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="219-224" id="miRNA-corp.d32.s0.e6" text="target" type="Relation_Trigger"/>
            <entity charOffset="336-355" id="miRNA-corp.d32.s0.e7" text="loss of these miRNAs" type="Relation_Trigger"/>
            <entity charOffset="96-108" id="miRNA-corp.d32.s0.e8" text="co-expression" type="Relation_Trigger"/>
            <entity charOffset="226-245" id="miRNA-corp.d32.s0.e9" text="expression increases" type="Relation_Trigger"/>
            <entity charOffset="14-18" id="miRNA-corp.d32.s0.e10" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d32.s0.e5" e2="miRNA-corp.d32.s0.e0" id="miRNA-corp.d32.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e5" e2="miRNA-corp.d32.s0.e1" id="miRNA-corp.d32.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e2" e2="miRNA-corp.d32.s0.e0" id="miRNA-corp.d32.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e2" e2="miRNA-corp.d32.s0.e1" id="miRNA-corp.d32.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e3" e2="miRNA-corp.d32.s0.e0" id="miRNA-corp.d32.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e3" e2="miRNA-corp.d32.s0.e1" id="miRNA-corp.d32.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e4" e2="miRNA-corp.d32.s0.e0" id="miRNA-corp.d32.s0.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d32.s0.e4" e2="miRNA-corp.d32.s0.e1" id="miRNA-corp.d32.s0.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s1" origId="19415117.s7" text="These findings demonstrate the context-dependence of miRNA-mRNA co-expression.   ">
            <entity charOffset="64-76" id="miRNA-corp.d32.s1.e0" text="co-expression" type="Relation_Trigger"/>
            <entity charOffset="53-57" id="miRNA-corp.d32.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s2" origId="19415117.s4" text="Although miRNAs in general suppress target mRNA messages, many predicted miRNA targets demonstrate a significantly higher level of co-expression than non-target genes in developing cerebellum. ">
            <entity charOffset="9-14" id="miRNA-corp.d32.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-77" id="miRNA-corp.d32.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-34" id="miRNA-corp.d32.s2.e2" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="36-41" id="miRNA-corp.d32.s2.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="79-85" id="miRNA-corp.d32.s2.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="131-143" id="miRNA-corp.d32.s2.e5" text="co-expression" type="Relation_Trigger"/>
            <entity charOffset="115-126" id="miRNA-corp.d32.s2.e6" text="higher level" type="Relation_Trigger"/>
            <entity charOffset="36-41" id="miRNA-corp.d32.s2.e7" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s3" origId="19415117.s5" text="This phenomenon is tissue specific since it is not observed in developing lungs. "/>
        <sentence id="miRNA-corp.d32.s4" origId="19415117.s2" text="Towards that goal, we examined miRNA-mRNA interactions by measuring miRNA and mRNA in the same tissue during development and also in malignant conditions. ">
            <entity charOffset="68-72" id="miRNA-corp.d32.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-35" id="miRNA-corp.d32.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s5" origId="19415117.s3" text="We identified significant miRNA-mediated biological process categories in developing mouse cerebellum and lung using non-targeted mRNA expression as the negative control. ">
            <entity charOffset="26-30" id="miRNA-corp.d32.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-89" id="miRNA-corp.d32.s5.e1" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s6" origId="19415117.s0" text="Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy.  ">
            <entity charOffset="28-35" id="miRNA-corp.d32.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-54" id="miRNA-corp.d32.s6.e1" text="co-expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d32.s7" origId="19415117.s1" text="An association between enrichment and depletion of microRNA (miRNA) binding sites, 3' UTR length, and mRNA expression has been demonstrated in various developing tissues and tissues from different mature organs; but functional, context-dependent miRNA regulations have yet to be elucidated. ">
            <entity charOffset="51-58" id="miRNA-corp.d32.s7.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-65" id="miRNA-corp.d32.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="246-250" id="miRNA-corp.d32.s7.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-80" id="miRNA-corp.d32.s7.e3" text="binding sites" type="Relation_Trigger"/>
            <entity charOffset="252-262" id="miRNA-corp.d32.s7.e4" text="regulations" type="Relation_Trigger"/>
            <entity charOffset="3-13" id="miRNA-corp.d32.s7.e5" text="association" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d33" origId="19118166">
        <sentence id="miRNA-corp.d33.s0" origId="19118166.s1" text="The transcription factor REST silences neuronal gene expression in non-neuronal cells. ">
            <entity charOffset="25-28" id="miRNA-corp.d33.s0.e0" text="REST" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s1" origId="19118166.s0" text="The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease.  ">
            <entity charOffset="26-30" id="miRNA-corp.d33.s1.e0" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="49-52" id="miRNA-corp.d33.s1.e1" text="REST" type="Genes/Proteins"/>
            <entity charOffset="58-63" id="miRNA-corp.d33.s1.e2" text="CoREST" type="Genes/Proteins"/>
            <entity charOffset="89-108" id="miRNA-corp.d33.s1.e3" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="32-36" id="miRNA-corp.d33.s1.e4" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="17-24" id="miRNA-corp.d33.s1.e5" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-47" id="miRNA-corp.d33.s1.e6" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="72-84" id="miRNA-corp.d33.s1.e7" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d33.s1.e0" e2="miRNA-corp.d33.s1.e1" id="miRNA-corp.d33.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e0" e2="miRNA-corp.d33.s1.e2" id="miRNA-corp.d33.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e0" e2="miRNA-corp.d33.s1.e3" id="miRNA-corp.d33.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d33.s1.e4" e2="miRNA-corp.d33.s1.e1" id="miRNA-corp.d33.s1.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e4" e2="miRNA-corp.d33.s1.e2" id="miRNA-corp.d33.s1.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e4" e2="miRNA-corp.d33.s1.e3" id="miRNA-corp.d33.s1.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d33.s1.e5" e2="miRNA-corp.d33.s1.e1" id="miRNA-corp.d33.s1.p6" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e5" e2="miRNA-corp.d33.s1.e2" id="miRNA-corp.d33.s1.p7" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s1.e5" e2="miRNA-corp.d33.s1.e3" id="miRNA-corp.d33.s1.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s2" origId="19118166.s3" text="Polyglutamine expansions in huntingtin, which causes Huntington's disease (HD), abrogates REST-huntingtin binding. ">
            <entity charOffset="53-72" id="miRNA-corp.d33.s2.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="75-76" id="miRNA-corp.d33.s2.e1" text="HD" type="Diseases"/>
            <entity charOffset="90-93" id="miRNA-corp.d33.s2.e2" text="REST" type="Genes/Proteins"/>
            <entity charOffset="95-104" id="miRNA-corp.d33.s2.e3" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="28-37" id="miRNA-corp.d33.s2.e4" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="106-112" id="miRNA-corp.d33.s2.e5" text="binding" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s3" origId="19118166.s2" text="In neurons, the protein is sequestered in the cytoplasm in part through binding to huntingtin. ">
            <entity charOffset="83-92" id="miRNA-corp.d33.s3.e0" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="72-78" id="miRNA-corp.d33.s3.e1" text="binding" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s4" origId="19118166.s5" text="In this work, we found that levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased in HD patient cortices relative to healthy controls. ">
            <entity charOffset="106-107" id="miRNA-corp.d33.s4.e0" text="HD" type="Diseases"/>
            <entity charOffset="46-54" id="miRNA-corp.d33.s4.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d33.s4.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-101" id="miRNA-corp.d33.s4.e3" text="levels of several microRNAs (miRNAs) with upstream RE1 sites are decreased" type="Relation_Trigger"/>
            <entity charOffset="109-115" id="miRNA-corp.d33.s4.e4" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d33.s4.e1" e2="miRNA-corp.d33.s4.e0" id="miRNA-corp.d33.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d33.s4.e2" e2="miRNA-corp.d33.s4.e0" id="miRNA-corp.d33.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s5" origId="19118166.s4" text="Consequently, REST translocates to the nucleus, occupies RE1 repressor sequences and decreases neuronal gene expression. ">
            <entity charOffset="14-17" id="miRNA-corp.d33.s5.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="61-69" id="miRNA-corp.d33.s5.e1" text="repressor" type="Relation_Trigger"/>
            <entity charOffset="85-118" id="miRNA-corp.d33.s5.e2" text="decreases neuronal gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s6" origId="19118166.s6" text="Interestingly, one of these, the bifunctional brain enriched miR-9/miR-9*, targets two components of the REST complex: miR-9 targets REST and miR-9* targets CoREST. ">
            <entity charOffset="157-162" id="miRNA-corp.d33.s6.e0" text="CoREST" type="Genes/Proteins"/>
            <entity charOffset="119-123" id="miRNA-corp.d33.s6.e1" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="67-71" id="miRNA-corp.d33.s6.e2" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="61-65" id="miRNA-corp.d33.s6.e3" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="142-146" id="miRNA-corp.d33.s6.e4" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="75-81" id="miRNA-corp.d33.s6.e5" text="targets" type="Relation_Trigger"/>
            <entity charOffset="125-131" id="miRNA-corp.d33.s6.e6" text="targets" type="Relation_Trigger"/>
            <entity charOffset="149-155" id="miRNA-corp.d33.s6.e7" text="targets" type="Relation_Trigger"/>
            <entity charOffset="133-136" id="miRNA-corp.d33.s6.e8" text="REST" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e2" e2="miRNA-corp.d33.s6.e8" id="miRNA-corp.d33.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e2" e2="miRNA-corp.d33.s6.e0" id="miRNA-corp.d33.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e3" e2="miRNA-corp.d33.s6.e8" id="miRNA-corp.d33.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e3" e2="miRNA-corp.d33.s6.e0" id="miRNA-corp.d33.s6.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e4" e2="miRNA-corp.d33.s6.e8" id="miRNA-corp.d33.s6.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e4" e2="miRNA-corp.d33.s6.e0" id="miRNA-corp.d33.s6.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e1" e2="miRNA-corp.d33.s6.e8" id="miRNA-corp.d33.s6.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d33.s6.e1" e2="miRNA-corp.d33.s6.e0" id="miRNA-corp.d33.s6.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d33.s7" origId="19118166.s7" text="These data provide evidence for a double negative feedback loop between the REST silencing complex and the miRNAs it regulates.   ">
            <entity charOffset="107-112" id="miRNA-corp.d33.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-125" id="miRNA-corp.d33.s7.e1" text="regulates" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d34" origId="17478730">
        <sentence id="miRNA-corp.d34.s0" origId="17478730.s11" text="MiRNAs may be a new therapeutic target for proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation arteriopathy, and stroke.   ">
            <entity charOffset="162-167" id="miRNA-corp.d34.s0.e0" text="stroke" type="Diseases"/>
            <entity charOffset="0-5" id="miRNA-corp.d34.s0.e1" text="MiRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="83-97" id="miRNA-corp.d34.s0.e2" text="atherosclerosis" type="Diseases"/>
            <entity charOffset="20-37" id="miRNA-corp.d34.s0.e3" text="therapeutic target" type="Relation_Trigger"/>
            <entity charOffset="57-73" id="miRNA-corp.d34.s0.e4" text="vascular diseases" type="Diseases"/>
            <entity charOffset="144-155" id="miRNA-corp.d34.s0.e5" text="arteriopathy" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s0.e1" e2="miRNA-corp.d34.s0.e0" id="miRNA-corp.d34.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s0.e1" e2="miRNA-corp.d34.s0.e2" id="miRNA-corp.d34.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s0.e1" e2="miRNA-corp.d34.s0.e4" id="miRNA-corp.d34.s0.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s0.e1" e2="miRNA-corp.d34.s0.e5" id="miRNA-corp.d34.s0.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s1" origId="17478730.s10" text="The results suggest that miRNAs are novel regulatory RNAs for neointimal lesion formation. ">
            <entity charOffset="25-30" id="miRNA-corp.d34.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-51" id="miRNA-corp.d34.s1.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="62-78" id="miRNA-corp.d34.s1.e2" text="neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s1.e0" e2="miRNA-corp.d34.s1.e2" id="miRNA-corp.d34.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s2" origId="17478730.s1" text="MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate about 30% of the encoding genes of the human genome. ">
            <entity charOffset="0-8" id="miRNA-corp.d34.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d34.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-100" id="miRNA-corp.d34.s2.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="141-145" id="miRNA-corp.d34.s2.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s3" origId="17478730.s0" text="MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation.  ">
            <entity charOffset="0-7" id="miRNA-corp.d34.s3.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-98" id="miRNA-corp.d34.s3.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-128" id="miRNA-corp.d34.s3.e2" text="vascular neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s3.e0" e2="miRNA-corp.d34.s3.e2" id="miRNA-corp.d34.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s3.e1" e2="miRNA-corp.d34.s3.e2" id="miRNA-corp.d34.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s4" origId="17478730.s9" text="Western blot analysis demonstrated that PTEN and Bcl-2 were involved in miR-21-mediated cellular effects. ">
            <entity charOffset="40-43" id="miRNA-corp.d34.s4.e0" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="49-53" id="miRNA-corp.d34.s4.e1" text="Bcl-2" type="Genes/Proteins"/>
            <entity charOffset="72-77" id="miRNA-corp.d34.s4.e2" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d34.s4.e2" e2="miRNA-corp.d34.s4.e0" id="miRNA-corp.d34.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d34.s4.e2" e2="miRNA-corp.d34.s4.e1" id="miRNA-corp.d34.s4.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s5" origId="17478730.s8" text="MiR-21-mediated cellular effects were further confirmed in vivo in balloon-injured rat carotid arteries. ">
            <entity charOffset="0-5" id="miRNA-corp.d34.s5.e0" text="MiR-21" type="Specific_miRNAs"/>
            <entity charOffset="83-85" id="miRNA-corp.d34.s5.e1" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s6" origId="17478730.s7" text="Depletion of miR-21 resulted in decreased cell proliferation and increased cell apoptosis in a dose-dependent manner. ">
            <entity charOffset="13-18" id="miRNA-corp.d34.s6.e0" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s7" origId="17478730.s6" text="In vitro, the expression level of miR-21 in dedifferentiated vascular smooth muscle cells was significantly higher than that in fresh isolated differentiated cells. ">
            <entity charOffset="34-39" id="miRNA-corp.d34.s7.e0" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s8" origId="17478730.s5" text="Modulating an aberrantly overexpressed miRNA, miR-21, via antisense-mediated depletion (knock-down) had a significant negative effect on neointimal lesion formation. ">
            <entity charOffset="46-51" id="miRNA-corp.d34.s8.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="39-43" id="miRNA-corp.d34.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-37" id="miRNA-corp.d34.s8.e2" text="aberrantly overexpressed" type="Relation_Trigger"/>
            <entity charOffset="137-153" id="miRNA-corp.d34.s8.e3" text="neointimal lesion" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s8.e1" e2="miRNA-corp.d34.s8.e3" id="miRNA-corp.d34.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d34.s8.e0" e2="miRNA-corp.d34.s8.e3" id="miRNA-corp.d34.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s9" origId="17478730.s4" text="The aberrantly expressed miRNAs were further confirmed by Northern blot and quantitative real-time polymerase chain reaction. ">
            <entity charOffset="25-30" id="miRNA-corp.d34.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-23" id="miRNA-corp.d34.s9.e1" text="aberrantly expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s10" origId="17478730.s3" text="Using microarray analysis, we demonstrated for the first time that miRNAs are aberrantly expressed in the vascular walls after balloon injury. ">
            <entity charOffset="67-72" id="miRNA-corp.d34.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="127-140" id="miRNA-corp.d34.s10.e1" text="balloon injury" type="Diseases"/>
            <entity charOffset="78-97" id="miRNA-corp.d34.s10.e2" text="aberrantly expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d34.s10.e0" e2="miRNA-corp.d34.s10.e1" id="miRNA-corp.d34.s10.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d34.s11" origId="17478730.s2" text="However, the role of miRNAs in vascular disease is currently completely unknown. ">
            <entity charOffset="21-26" id="miRNA-corp.d34.s11.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-46" id="miRNA-corp.d34.s11.e1" text="vascular disease" type="Diseases"/>
            <pair e1="miRNA-corp.d34.s11.e0" e2="miRNA-corp.d34.s11.e1" id="miRNA-corp.d34.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d35" origId="12827450">
        <sentence id="miRNA-corp.d35.s0" origId="12827450.s0" text="Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease.     ">
            <entity charOffset="69-96" id="miRNA-corp.d35.s0.e0" text="familial Parkinson's disease" type="Diseases"/>
            <entity charOffset="33-37" id="miRNA-corp.d35.s0.e1" text="NR4A2" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d36" origId="19712440">
        <sentence id="miRNA-corp.d36.s0" origId="19712440.s9" text="In a pilot study we could show that hsa-miR-342-3p was also upregulated in brain samples of human type 1 and type 2 sporadic CJD. ">
            <entity charOffset="36-49" id="miRNA-corp.d36.s0.e0" text="hsa-miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="60-70" id="miRNA-corp.d36.s0.e1" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="109-127" id="miRNA-corp.d36.s0.e2" text="type 2 sporadic CJD" type="Diseases"/>
            <entity charOffset="92-96" id="miRNA-corp.d36.s0.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d36.s0.e0" e2="miRNA-corp.d36.s0.e2" id="miRNA-corp.d36.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s1" origId="19712440.s8" text="Our study revealed significant upregulation of hsa-miR-342-3p and hsa-miR-494 in the brains of BSE-infected macaques compared to non-infected animals. ">
            <entity charOffset="47-60" id="miRNA-corp.d36.s1.e0" text="hsa-miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="66-76" id="miRNA-corp.d36.s1.e1" text="hsa-miR-494" type="Specific_miRNAs"/>
            <entity charOffset="31-42" id="miRNA-corp.d36.s1.e2" text="upregulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s2" origId="19712440.s7" text="Shock-frozen brain sections of six BSE-infected and five non-infected macaques were used to validate regulated miRNA candidates by two independent qRT-PCR-based methods. ">
            <entity charOffset="111-115" id="miRNA-corp.d36.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-109" id="miRNA-corp.d36.s2.e1" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s3" origId="19712440.s6" text="We have applied miRNA-microarrays to identify deregulated miRNA candidates in brains of BSE-infected macaques. ">
            <entity charOffset="58-62" id="miRNA-corp.d36.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-56" id="miRNA-corp.d36.s3.e1" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="16-20" id="miRNA-corp.d36.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s4" origId="19712440.s5" text="Therefore, we hypothesized that miRNAs are also regulated in response to human prion disease. ">
            <entity charOffset="32-37" id="miRNA-corp.d36.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="48-56" id="miRNA-corp.d36.s4.e1" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="79-91" id="miRNA-corp.d36.s4.e2" text="prion disease" type="Diseases"/>
            <entity charOffset="73-77" id="miRNA-corp.d36.s4.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d36.s4.e0" e2="miRNA-corp.d36.s4.e2" id="miRNA-corp.d36.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s5" origId="19712440.s3" text="Among other functions they contribute to neuronal development and survival. "/>
        <sentence id="miRNA-corp.d36.s6" origId="19712440.s4" text="Recently, the lack of miRNA processing has been shown to promote neurodegeneration and deregulation of several miRNAs has been reported to be associated with Scrapie in mice. ">
            <entity charOffset="22-26" id="miRNA-corp.d36.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="111-116" id="miRNA-corp.d36.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="158-164" id="miRNA-corp.d36.s6.e2" text="Scrapie" type="Diseases"/>
            <entity charOffset="87-98" id="miRNA-corp.d36.s6.e3" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="142-151" id="miRNA-corp.d36.s6.e4" text="associated" type="Relation_Trigger"/>
            <entity charOffset="169-172" id="miRNA-corp.d36.s6.e5" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d36.s6.e0" e2="miRNA-corp.d36.s6.e2" id="miRNA-corp.d36.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s6.e1" e2="miRNA-corp.d36.s6.e2" id="miRNA-corp.d36.s6.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s7" origId="19712440.s1" text="ABSTRACT: The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD). ">
            <entity charOffset="149-173" id="miRNA-corp.d36.s7.e0" text="Creutzfeldt-Jakob disease" type="Diseases"/>
            <entity charOffset="176-178" id="miRNA-corp.d36.s7.e1" text="CJD" type="Diseases"/>
            <entity charOffset="77-82" id="miRNA-corp.d36.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-72" id="miRNA-corp.d36.s7.e3" text="differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d36.s7.e2" e2="miRNA-corp.d36.s7.e0" id="miRNA-corp.d36.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s7.e2" e2="miRNA-corp.d36.s7.e1" id="miRNA-corp.d36.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s8" origId="19712440.s2" text="MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting. ">
            <entity charOffset="0-8" id="miRNA-corp.d36.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d36.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-69" id="miRNA-corp.d36.s8.e2" text="regulating gene expression" type="Relation_Trigger"/>
            <entity charOffset="79-87" id="miRNA-corp.d36.s8.e3" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s9" origId="19712440.s0" text="Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease.  ">
            <entity charOffset="22-35" id="miRNA-corp.d36.s9.e0" text="hsa-miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="68-80" id="miRNA-corp.d36.s9.e1" text="prion disease" type="Diseases"/>
            <entity charOffset="16-20" id="miRNA-corp.d36.s9.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-11" id="miRNA-corp.d36.s9.e3" text="Upregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d36.s9.e0" e2="miRNA-corp.d36.s9.e1" id="miRNA-corp.d36.s9.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s9.e2" e2="miRNA-corp.d36.s9.e1" id="miRNA-corp.d36.s9.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d36.s10" origId="19712440.s10" text="With respect to the reported regulation of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a general phenomenon in late stage prion disease and might be used as a novel marker for animal and human TSEs.   ">
            <entity charOffset="112-125" id="miRNA-corp.d36.s10.e0" text="hsa-miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="48-52" id="miRNA-corp.d36.s10.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="169-181" id="miRNA-corp.d36.s10.e2" text="prion disease" type="Diseases"/>
            <entity charOffset="57-63" id="miRNA-corp.d36.s10.e3" text="Scrapie" type="Diseases"/>
            <entity charOffset="96-107" id="miRNA-corp.d36.s10.e4" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="29-38" id="miRNA-corp.d36.s10.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="240-243" id="miRNA-corp.d36.s10.e6" text="TSEs" type="Diseases"/>
            <entity charOffset="234-238" id="miRNA-corp.d36.s10.e7" text="human" type="Species"/>
            <entity charOffset="74-77" id="miRNA-corp.d36.s10.e8" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d36.s10.e1" e2="miRNA-corp.d36.s10.e2" id="miRNA-corp.d36.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e1" e2="miRNA-corp.d36.s10.e3" id="miRNA-corp.d36.s10.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e1" e2="miRNA-corp.d36.s10.e6" id="miRNA-corp.d36.s10.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e0" e2="miRNA-corp.d36.s10.e2" id="miRNA-corp.d36.s10.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e0" e2="miRNA-corp.d36.s10.e3" id="miRNA-corp.d36.s10.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d36.s10.e0" e2="miRNA-corp.d36.s10.e6" id="miRNA-corp.d36.s10.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d37" origId="20451497">
        <sentence id="miRNA-corp.d37.s0" origId="20451497.s0" text="Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.  ">
            <entity charOffset="50-57" id="miRNA-corp.d37.s0.e0" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="67-69" id="miRNA-corp.d37.s0.e1" text="TBP" type="Genes/Proteins"/>
            <entity charOffset="8-16" id="miRNA-corp.d37.s0.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-65" id="miRNA-corp.d37.s0.e3" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d37.s0.e0" e2="miRNA-corp.d37.s0.e1" id="miRNA-corp.d37.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d37.s0.e2" e2="miRNA-corp.d37.s0.e1" id="miRNA-corp.d37.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s1" origId="20451497.s1" text="We studied expression of 90 miRNAs in STHdh(Q111)/Hdh(Q111) cells, a model for Huntington's disease and compared with that obtained in STHdh(Q7)/Hdh(Q7) cells. ">
            <entity charOffset="79-98" id="miRNA-corp.d37.s1.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="28-33" id="miRNA-corp.d37.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d37.s1.e1" e2="miRNA-corp.d37.s1.e0" id="miRNA-corp.d37.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s2" origId="20451497.s2" text="Fifteen miRNAs were down regulated and 12 miRNAs were up regulated more than 2-fold. ">
            <entity charOffset="8-13" id="miRNA-corp.d37.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-47" id="miRNA-corp.d37.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-33" id="miRNA-corp.d37.s2.e2" text="down regulated" type="Relation_Trigger"/>
            <entity charOffset="54-65" id="miRNA-corp.d37.s2.e3" text="up regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s3" origId="20451497.s3" text="Such changes were statistically significant. "/>
        <sentence id="miRNA-corp.d37.s4" origId="20451497.s4" text="One hundred and forty-two genes are experimentally known targets of these altered miRNAs. ">
            <entity charOffset="82-87" id="miRNA-corp.d37.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-87" id="miRNA-corp.d37.s4.e1" text="altered miRNAs" type="Relation_Trigger"/>
            <entity charOffset="57-63" id="miRNA-corp.d37.s4.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s5" origId="20451497.s6" text="Using luciferase reporter assays with 3'-UTRs of TBP, over-expression and inhibition of miR-146a, we showed that miR-146a targets TBP. ">
            <entity charOffset="130-132" id="miRNA-corp.d37.s5.e0" text="TBP" type="Genes/Proteins"/>
            <entity charOffset="88-95" id="miRNA-corp.d37.s5.e1" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="113-120" id="miRNA-corp.d37.s5.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="49-51" id="miRNA-corp.d37.s5.e3" text="TBP" type="Genes/Proteins"/>
            <entity charOffset="122-128" id="miRNA-corp.d37.s5.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="54-68" id="miRNA-corp.d37.s5.e5" text="over-expression" type="Relation_Trigger"/>
            <entity charOffset="74-83" id="miRNA-corp.d37.s5.e6" text="inhibition" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d37.s5.e1" e2="miRNA-corp.d37.s5.e3" id="miRNA-corp.d37.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d37.s5.e1" e2="miRNA-corp.d37.s5.e0" id="miRNA-corp.d37.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d37.s5.e2" e2="miRNA-corp.d37.s5.e3" id="miRNA-corp.d37.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d37.s5.e2" e2="miRNA-corp.d37.s5.e0" id="miRNA-corp.d37.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s6" origId="20451497.s5" text="It has been predicted that miR-146a may target Tata Binding Protein (TBP). ">
            <entity charOffset="47-66" id="miRNA-corp.d37.s6.e0" text="Tata Binding Protein" type="Genes/Proteins"/>
            <entity charOffset="69-71" id="miRNA-corp.d37.s6.e1" text="TBP" type="Genes/Proteins"/>
            <entity charOffset="27-34" id="miRNA-corp.d37.s6.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="12-45" id="miRNA-corp.d37.s6.e3" text="predicted that miR-146a may target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d37.s6.e2" e2="miRNA-corp.d37.s6.e0" id="miRNA-corp.d37.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d37.s6.e2" e2="miRNA-corp.d37.s6.e1" id="miRNA-corp.d37.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d37.s7" origId="20451497.s7" text="Regulation of TBP by miR-146a may contribute to HD pathogenesis.   ">
            <entity charOffset="14-16" id="miRNA-corp.d37.s7.e0" text="TBP" type="Genes/Proteins"/>
            <entity charOffset="21-28" id="miRNA-corp.d37.s7.e1" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="48-49" id="miRNA-corp.d37.s7.e2" text="HD" type="Diseases"/>
            <entity charOffset="0-9" id="miRNA-corp.d37.s7.e3" text="Regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d37.s7.e1" e2="miRNA-corp.d37.s7.e2" id="miRNA-corp.d37.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d37.s7.e1" e2="miRNA-corp.d37.s7.e0" id="miRNA-corp.d37.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d38" origId="12884173">
        <sentence id="miRNA-corp.d38.s0" origId="12884173.s2" text="This is, to our knowledge, the first case of this kind found in Argentina and is additional evidence that HAM/TSP solely related to HTLV-II infection occurs in HTLV-I-negative subjects.   ">
            <entity charOffset="106-108" id="miRNA-corp.d38.s0.e0" text="HAM" type="Diseases"/>
            <entity charOffset="110-112" id="miRNA-corp.d38.s0.e1" text="TSP" type="Diseases"/>
            <entity charOffset="132-148" id="miRNA-corp.d38.s0.e2" text="HTLV-II infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s1" origId="12884173.s1" text="A case of neurological disease featuring human T lymphocyte virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was diagnosed by serological (Western blot) and molecular (polymerase chain reaction) criteria as related to human T lymphocyte virus (HTLV)-II infection. ">
            <entity charOffset="236-240" id="miRNA-corp.d38.s1.e0" text="human" type="Species"/>
            <entity charOffset="41-86" id="miRNA-corp.d38.s1.e1" text="human T lymphocyte virus-associated myelopathy" type="Diseases"/>
            <entity charOffset="88-115" id="miRNA-corp.d38.s1.e2" text="tropical spastic paraparesis" type="Diseases"/>
            <entity charOffset="118-120" id="miRNA-corp.d38.s1.e3" text="HAM" type="Diseases"/>
            <entity charOffset="122-124" id="miRNA-corp.d38.s1.e4" text="TSP" type="Diseases"/>
            <entity charOffset="236-279" id="miRNA-corp.d38.s1.e5" text="human T lymphocyte virus (HTLV)-II infection" type="Diseases"/>
            <entity charOffset="10-29" id="miRNA-corp.d38.s1.e6" text="neurological disease" type="Diseases"/>
            <entity charOffset="41-45" id="miRNA-corp.d38.s1.e7" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d38.s2" origId="12884173.s0" text="A possible case of myelopathy/tropical spastic paraparesis in an Argentinian woman with human T lymphocyte virus type II.  ">
            <entity charOffset="19-28" id="miRNA-corp.d38.s2.e0" text="myelopathy" type="Diseases"/>
            <entity charOffset="30-57" id="miRNA-corp.d38.s2.e1" text="tropical spastic paraparesis" type="Diseases"/>
            <entity charOffset="77-81" id="miRNA-corp.d38.s2.e2" text="woman" type="Species"/>
            <entity charOffset="88-92" id="miRNA-corp.d38.s2.e3" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d39" origId="16024602">
        <sentence id="miRNA-corp.d39.s0" origId="16024602.s5" text="Knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death. ">
            <entity charOffset="13-18" id="miRNA-corp.d39.s0.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="51-69" id="miRNA-corp.d39.s0.e1" text="triggers activation" type="Relation_Trigger"/>
            <entity charOffset="32-43" id="miRNA-corp.d39.s0.e2" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d39.s0.e0" e2="miRNA-corp.d39.s0.e2" id="miRNA-corp.d39.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s1" origId="16024602.s4" text="Our studies show markedly elevated miR-21 levels in human glioblastoma tumor tissues, early-passage glioblastoma cultures, and in six established glioblastoma cell lines (A172, U87, U373, LN229, LN428, and LN308) compared with nonneoplastic fetal and adult brain tissues and compared with cultured nonneoplastic glial cells. ">
            <entity charOffset="35-40" id="miRNA-corp.d39.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="26-47" id="miRNA-corp.d39.s1.e1" text="elevated miR-21 levels" type="Relation_Trigger"/>
            <entity charOffset="86-111" id="miRNA-corp.d39.s1.e2" text="early-passage glioblastoma" type="Diseases"/>
            <entity charOffset="52-75" id="miRNA-corp.d39.s1.e3" text="human glioblastoma tumor" type="Diseases"/>
            <entity charOffset="146-157" id="miRNA-corp.d39.s1.e4" text="glioblastoma" type="Diseases"/>
            <entity charOffset="52-56" id="miRNA-corp.d39.s1.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d39.s1.e0" e2="miRNA-corp.d39.s1.e2" id="miRNA-corp.d39.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s1.e0" e2="miRNA-corp.d39.s1.e3" id="miRNA-corp.d39.s1.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s1.e0" e2="miRNA-corp.d39.s1.e4" id="miRNA-corp.d39.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s2" origId="16024602.s6" text="Our data suggest that aberrantly expressed miR-21 may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.   ">
            <entity charOffset="43-48" id="miRNA-corp.d39.s2.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="22-41" id="miRNA-corp.d39.s2.e1" text="aberrantly expressed" type="Relation_Trigger"/>
            <entity charOffset="95-113" id="miRNA-corp.d39.s2.e2" text="blocking expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s3" origId="16024602.s1" text="MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by targeting the mRNA of protein-coding genes for either cleavage or repression of translation. ">
            <entity charOffset="0-8" id="miRNA-corp.d39.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d39.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="155-179" id="miRNA-corp.d39.s3.e2" text="repression of translation" type="Relation_Trigger"/>
            <entity charOffset="58-84" id="miRNA-corp.d39.s3.e3" text="regulate protein expression" type="Relation_Trigger"/>
            <entity charOffset="89-97" id="miRNA-corp.d39.s3.e4" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s4" origId="16024602.s0" text="MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.  ">
            <entity charOffset="0-10" id="miRNA-corp.d39.s4.e0" text="MicroRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="18-37" id="miRNA-corp.d39.s4.e1" text="antiapoptotic factor" type="Relation_Trigger"/>
            <entity charOffset="48-59" id="miRNA-corp.d39.s4.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="42-46" id="miRNA-corp.d39.s4.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d39.s4.e0" e2="miRNA-corp.d39.s4.e2" id="miRNA-corp.d39.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s5" origId="16024602.s3" text="Here we show that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21. ">
            <entity charOffset="114-119" id="miRNA-corp.d39.s5.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="58-69" id="miRNA-corp.d39.s5.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="107-111" id="miRNA-corp.d39.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-94" id="miRNA-corp.d39.s5.e3" text="over-expresses" type="Relation_Trigger"/>
            <entity charOffset="39-55" id="miRNA-corp.d39.s5.e4" text="human brain tumor" type="Diseases"/>
            <entity charOffset="58-69" id="miRNA-corp.d39.s5.e5" text="glioblastoma" type="Diseases"/>
            <entity charOffset="39-43" id="miRNA-corp.d39.s5.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d39.s5.e0" e2="miRNA-corp.d39.s5.e4" id="miRNA-corp.d39.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s5.e0" e2="miRNA-corp.d39.s5.e5" id="miRNA-corp.d39.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s5.e0" e2="miRNA-corp.d39.s5.e1" id="miRNA-corp.d39.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s5.e2" e2="miRNA-corp.d39.s5.e4" id="miRNA-corp.d39.s5.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s5.e2" e2="miRNA-corp.d39.s5.e5" id="miRNA-corp.d39.s5.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d39.s5.e2" e2="miRNA-corp.d39.s5.e1" id="miRNA-corp.d39.s5.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d39.s6" origId="16024602.s2" text="The roles of miRNAs in lineage determination and proliferation as well as the location of several miRNA genes at sites of translocation breakpoints or deletions has led to the speculation that miRNAs could be important factors in the development or maintenance of the neoplastic state. ">
            <entity charOffset="98-102" id="miRNA-corp.d39.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-18" id="miRNA-corp.d39.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="193-198" id="miRNA-corp.d39.s6.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d40" origId="19881909">
        <sentence id="miRNA-corp.d40.s0" origId="19881909.s5" text="Key microRNAs have been identified as essential for a variety of cellular events including cell lineage determination, proliferation, apoptosis, DNA repair, and cytoskeletal organization; most, if not all, acting to fine-tune gene expression at the post-transcriptional level in a host of cellular signaling networks. ">
            <entity charOffset="4-12" id="miRNA-corp.d40.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s1" origId="19881909.s4" text="Their discovery has evoked great excitement in biomedical research for their promise as potential disease biomarkers and therapeutic targets. ">
            <entity charOffset="121-139" id="miRNA-corp.d40.s1.e0" text="therapeutic targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s2" origId="19881909.s3" text="MicroRNAs are one of the major noncoding RNAs that function as negative regulators to silence or suppress gene expression via translational inhibition or message degradation. ">
            <entity charOffset="0-8" id="miRNA-corp.d40.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-120" id="miRNA-corp.d40.s2.e1" text="suppress gene expression" type="Relation_Trigger"/>
            <entity charOffset="126-149" id="miRNA-corp.d40.s2.e2" text="translational inhibition" type="Relation_Trigger"/>
            <entity charOffset="63-81" id="miRNA-corp.d40.s2.e3" text="negative regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s3" origId="19881909.s2" text="Unlike the familial forms of AD, the genetic and environmental risks factors identified for sporadic AD are extensive. ">
            <entity charOffset="29-30" id="miRNA-corp.d40.s3.e0" text="AD" type="Diseases"/>
            <entity charOffset="101-102" id="miRNA-corp.d40.s3.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s4" origId="19881909.s1" text="Understanding complex diseases such as sporadic Alzheimer disease (AD) has been a major challenge. ">
            <entity charOffset="48-64" id="miRNA-corp.d40.s4.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="67-68" id="miRNA-corp.d40.s4.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s5" origId="19881909.s0" text="MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.  ">
            <entity charOffset="0-7" id="miRNA-corp.d40.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-43" id="miRNA-corp.d40.s5.e1" text="Alzheimer Disease" type="Diseases"/>
            <entity charOffset="61-73" id="miRNA-corp.d40.s5.e2" text="CNS Disorders" type="Diseases"/>
            <entity charOffset="55-59" id="miRNA-corp.d40.s5.e3" text="Human" type="Species"/>
            <pair e1="miRNA-corp.d40.s5.e0" e2="miRNA-corp.d40.s5.e2" id="miRNA-corp.d40.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d40.s5.e0" e2="miRNA-corp.d40.s5.e1" id="miRNA-corp.d40.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s6" origId="19881909.s7" text="Here, the current understanding of the role of miRNAs in the central nervous system is reviewed with emphasis on their impact on the etiopathogenesis of sporadic AD.   ">
            <entity charOffset="47-52" id="miRNA-corp.d40.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="153-163" id="miRNA-corp.d40.s6.e1" text="sporadic AD" type="Diseases"/>
            <pair e1="miRNA-corp.d40.s6.e0" e2="miRNA-corp.d40.s6.e1" id="miRNA-corp.d40.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d40.s7" origId="19881909.s6" text="Dysfunctional microRNA-mediated regulation has been implicated in the pathogenesis of many disease states. ">
            <entity charOffset="14-21" id="miRNA-corp.d40.s7.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-41" id="miRNA-corp.d40.s7.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="0-12" id="miRNA-corp.d40.s7.e2" text="Dysfunctional" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d41" origId="18226108">
        <sentence id="miRNA-corp.d41.s0" origId="18226108.s0" text="MicroRNAs (miRNAs) in neurodegenerative diseases.  ">
            <entity charOffset="0-8" id="miRNA-corp.d41.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d41.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-47" id="miRNA-corp.d41.s0.e2" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e0" e2="miRNA-corp.d41.s0.e2" id="miRNA-corp.d41.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s0.e1" e2="miRNA-corp.d41.s0.e2" id="miRNA-corp.d41.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s1" origId="18226108.s2" text="Prior studies have shown that RNAs are pathologically altered during the inexorable course of some NDs. ">
            <entity charOffset="99-101" id="miRNA-corp.d41.s1.e0" text="NDs" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s2" origId="18226108.s1" text="Aging-related neurodegenerative diseases (NDs) are the culmination of many different genetic and environmental influences. ">
            <entity charOffset="14-39" id="miRNA-corp.d41.s2.e0" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="42-44" id="miRNA-corp.d41.s2.e1" text="NDs" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s3" origId="18226108.s4" text="miRNAs are brain-enriched, small ( approximately 22 nucleotides) non-coding RNAs that participate in mRNA translational regulation. ">
            <entity charOffset="0-5" id="miRNA-corp.d41.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="106-129" id="miRNA-corp.d41.s3.e1" text="translational regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s4" origId="18226108.s3" text="Recent evidence suggests that microRNAs (miRNAs) may be a contributing factor in neurodegeneration. ">
            <entity charOffset="30-38" id="miRNA-corp.d41.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-46" id="miRNA-corp.d41.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s5" origId="18226108.s6" text="Research about miRNAs in the context of neurodegeneration is accumulating rapidly, and the goal of this review is to provide perspective for these new data that may be helpful to specialists in either field. ">
            <entity charOffset="15-20" id="miRNA-corp.d41.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s6" origId="18226108.s5" text="Although discovered in the framework of worm development, miRNAs are now appreciated to play a dynamic role in many mammalian brain-related biochemical pathways, including neuroplasticity and stress responses. ">
            <entity charOffset="58-63" id="miRNA-corp.d41.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s7" origId="18226108.s8" text="Recently published studies pertaining to the roles of miRNAs in NDs--including Alzheimer's disease, Parkinson's disease and triplet repeat disorders-are described. ">
            <entity charOffset="54-59" id="miRNA-corp.d41.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-97" id="miRNA-corp.d41.s7.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="100-118" id="miRNA-corp.d41.s7.e2" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="64-66" id="miRNA-corp.d41.s7.e3" text="NDs" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s7.e0" e2="miRNA-corp.d41.s7.e1" id="miRNA-corp.d41.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s7.e0" e2="miRNA-corp.d41.s7.e2" id="miRNA-corp.d41.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d41.s7.e0" e2="miRNA-corp.d41.s7.e3" id="miRNA-corp.d41.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s8" origId="18226108.s7" text="An overview is provided about the normal functions for miRNAs, including some of the newer concepts related to the human brain. ">
            <entity charOffset="55-60" id="miRNA-corp.d41.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="115-119" id="miRNA-corp.d41.s8.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d41.s9" origId="18226108.s9" text="Finally, a discussion is included with theoretical syntheses and possible future directions in exploring the nexus between miRNA and ND research.   ">
            <entity charOffset="123-127" id="miRNA-corp.d41.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-134" id="miRNA-corp.d41.s9.e1" text="ND" type="Diseases"/>
            <pair e1="miRNA-corp.d41.s9.e0" e2="miRNA-corp.d41.s9.e1" id="miRNA-corp.d41.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d42" origId="21162128">
        <sentence id="miRNA-corp.d42.s0" origId="21162128.s1" text="Traumatic brain injury (TBI) initiates many different signaling cascades throughout the brain that impact both pathophysiological and neuroprotective processes. ">
            <entity charOffset="0-21" id="miRNA-corp.d42.s0.e0" text="Traumatic brain injury" type="Diseases"/>
            <entity charOffset="24-26" id="miRNA-corp.d42.s0.e1" text="TBI" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s1" origId="21162128.s0" text="Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury.  ">
            <entity charOffset="0-17" id="miRNA-corp.d42.s1.e0" text="Altered expression" type="Relation_Trigger"/>
            <entity charOffset="22-29" id="miRNA-corp.d42.s1.e1" text="miRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="72-93" id="miRNA-corp.d42.s1.e2" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="39-45" id="miRNA-corp.d42.s1.e3" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d42.s1.e1" e2="miRNA-corp.d42.s1.e2" id="miRNA-corp.d42.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s2" origId="21162128.s5" text="In situ localization of miR-21 transcripts indicates widespread expression in normal brain, with a pronounced increase in expression after TBI evident throughout the cortex and hippocampus, including the dentate gyrus and CA3 cell layer. ">
            <entity charOffset="110-131" id="miRNA-corp.d42.s2.e0" text="increase in expression" type="Relation_Trigger"/>
            <entity charOffset="24-29" id="miRNA-corp.d42.s2.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="139-141" id="miRNA-corp.d42.s2.e2" text="TBI" type="Diseases"/>
            <pair e1="miRNA-corp.d42.s2.e1" e2="miRNA-corp.d42.s2.e2" id="miRNA-corp.d42.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s3" origId="21162128.s4" text="We report that miR-21 expression is significantly up-regulated in the hippocampus after rodent TBI, with expression levels peaking by 3 days postinjury and returning to near sham levels by 15 days postinjury. ">
            <entity charOffset="22-61" id="miRNA-corp.d42.s3.e0" text="expression is significantly up-regulated" type="Relation_Trigger"/>
            <entity charOffset="15-20" id="miRNA-corp.d42.s3.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="95-97" id="miRNA-corp.d42.s3.e2" text="TBI" type="Diseases"/>
            <entity charOffset="105-129" id="miRNA-corp.d42.s3.e3" text="expression levels peaking" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d42.s3.e1" e2="miRNA-corp.d42.s3.e2" id="miRNA-corp.d42.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s4" origId="21162128.s3" text="MicroRNAs (miRNAs) are an important class of noncoding regulatory RNAs providing an epigenetic mechanism for the regulation of protein expression levels of target genes. ">
            <entity charOffset="0-8" id="miRNA-corp.d42.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d42.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="113-144" id="miRNA-corp.d42.s4.e2" text="regulation of protein expression" type="Relation_Trigger"/>
            <entity charOffset="55-64" id="miRNA-corp.d42.s4.e3" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="156-161" id="miRNA-corp.d42.s4.e4" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s5" origId="21162128.s2" text="Cellular mechanisms that can modulate these processes may play an important role in determining the nature and extent of the damage suffered after TBI and therefore influence overall outcome after injury. ">
            <entity charOffset="147-149" id="miRNA-corp.d42.s5.e0" text="TBI" type="Diseases"/>
            <entity charOffset="29-36" id="miRNA-corp.d42.s5.e1" text="modulate" type="Relation_Trigger"/>
            <entity charOffset="197-202" id="miRNA-corp.d42.s5.e2" text="injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s6" origId="21162128.s8" text="These results suggest that increased miR-21 expression in the hippocampus may influence multiple components of TBI pathophysiology.   ">
            <entity charOffset="111-113" id="miRNA-corp.d42.s6.e0" text="TBI" type="Diseases"/>
            <entity charOffset="27-53" id="miRNA-corp.d42.s6.e1" text="increased miR-21 expression" type="Relation_Trigger"/>
            <entity charOffset="37-42" id="miRNA-corp.d42.s6.e2" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d42.s6.e2" e2="miRNA-corp.d42.s6.e0" id="miRNA-corp.d42.s6.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s7" origId="21162128.s7" text="Analysis of these genes' annotated Gene Ontology molecular function and biological process terms revealed an overrepresentation of genes involved in enzyme-linked receptor signaling, transcriptional regulation, and developmental processes. ">
            <entity charOffset="183-208" id="miRNA-corp.d42.s7.e0" text="transcriptional regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d42.s8" origId="21162128.s6" text="We used a combination of the miRanda, TargetScan, and PicTar prediction algorithms to identify 99 potential target genes that possess miR-21 binding sites within their 3' untranslated regions. ">
            <entity charOffset="134-139" id="miRNA-corp.d42.s8.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="141-153" id="miRNA-corp.d42.s8.e1" text="binding sites" type="Relation_Trigger"/>
            <entity charOffset="98-113" id="miRNA-corp.d42.s8.e2" text="potential target" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d43" origId="18226107">
        <sentence id="miRNA-corp.d43.s0" origId="18226107.s6" text="MiRNA expression profiling of human tumors has led to the identification of signatures correlated with the tumor diagnosis, staging, progression, prognosis and response to treatment. ">
            <entity charOffset="0-4" id="miRNA-corp.d43.s0.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-41" id="miRNA-corp.d43.s0.e1" text="tumors" type="Diseases"/>
            <entity charOffset="107-111" id="miRNA-corp.d43.s0.e2" text="tumor" type="Diseases"/>
            <entity charOffset="87-96" id="miRNA-corp.d43.s0.e3" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="30-34" id="miRNA-corp.d43.s0.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d43.s0.e0" e2="miRNA-corp.d43.s0.e1" id="miRNA-corp.d43.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s0.e0" e2="miRNA-corp.d43.s0.e2" id="miRNA-corp.d43.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s1" origId="18226107.s7" text="MiRNA fingerprinting can therefore be added to the diagnostic and prognostic tools used by medical oncologists. ">
            <entity charOffset="0-4" id="miRNA-corp.d43.s1.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s2" origId="18226107.s8" text="Furthermore, new therapeutic strategies involving miRNA silencing or miRNA mimics could be proposed based on the roles of these small non-coding RNAs as oncogenes and tumor suppressors in brain tumors.   ">
            <entity charOffset="50-54" id="miRNA-corp.d43.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-73" id="miRNA-corp.d43.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="188-199" id="miRNA-corp.d43.s2.e2" text="brain tumors" type="Diseases"/>
            <entity charOffset="167-183" id="miRNA-corp.d43.s2.e3" text="tumor suppressors" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d43.s2.e0" e2="miRNA-corp.d43.s2.e2" id="miRNA-corp.d43.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s2.e1" e2="miRNA-corp.d43.s2.e2" id="miRNA-corp.d43.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s3" origId="18226107.s0" text="MicroRNA involvement in brain tumors: from bench to bedside.  ">
            <entity charOffset="0-7" id="miRNA-corp.d43.s3.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-35" id="miRNA-corp.d43.s3.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s3.e0" e2="miRNA-corp.d43.s3.e1" id="miRNA-corp.d43.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s4" origId="18226107.s1" text="MicroRNAs (miRNAs), a novel class of small non-coding RNAs, are effective post-transcriptional regulators of gene expression, exhibiting, when altered in human tumors, both oncogenic and tumor suppressive potential. ">
            <entity charOffset="0-8" id="miRNA-corp.d43.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d43.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="95-123" id="miRNA-corp.d43.s4.e2" text="regulators of gene expression" type="Relation_Trigger"/>
            <entity charOffset="187-203" id="miRNA-corp.d43.s4.e3" text="tumor suppressive" type="Relation_Trigger"/>
            <entity charOffset="160-165" id="miRNA-corp.d43.s4.e4" text="tumors" type="Diseases"/>
            <entity charOffset="154-158" id="miRNA-corp.d43.s4.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d43.s4.e0" e2="miRNA-corp.d43.s4.e4" id="miRNA-corp.d43.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s4.e1" e2="miRNA-corp.d43.s4.e4" id="miRNA-corp.d43.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s5" origId="18226107.s2" text="Recently, miRNA involvement in the pathophysiology of brain cancer has been assessed. ">
            <entity charOffset="10-14" id="miRNA-corp.d43.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-65" id="miRNA-corp.d43.s5.e1" text="brain cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s5.e0" e2="miRNA-corp.d43.s5.e1" id="miRNA-corp.d43.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s6" origId="18226107.s3" text="Aberrant gene expression is the main mechanism of miRNAs dysfunction in cancer, with abnormal expression levels of mature and/or precursor miRNA expression in tumor samples versus normal. ">
            <entity charOffset="50-55" id="miRNA-corp.d43.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="139-143" id="miRNA-corp.d43.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-23" id="miRNA-corp.d43.s6.e2" text="Aberrant gene expression" type="Relation_Trigger"/>
            <entity charOffset="85-110" id="miRNA-corp.d43.s6.e3" text="abnormal expression levels" type="Relation_Trigger"/>
            <entity charOffset="57-67" id="miRNA-corp.d43.s6.e4" text="dysfunction" type="Relation_Trigger"/>
            <entity charOffset="72-77" id="miRNA-corp.d43.s6.e5" text="cancer" type="Diseases"/>
            <entity charOffset="159-163" id="miRNA-corp.d43.s6.e6" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s6.e0" e2="miRNA-corp.d43.s6.e5" id="miRNA-corp.d43.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s6.e0" e2="miRNA-corp.d43.s6.e6" id="miRNA-corp.d43.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s6.e1" e2="miRNA-corp.d43.s6.e5" id="miRNA-corp.d43.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s6.e1" e2="miRNA-corp.d43.s6.e6" id="miRNA-corp.d43.s6.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s7" origId="18226107.s4" text="MiRNA germline and somatic mutations or polymorphisms in the protein coding messenger RNA targeted by miRNAs may also occur, contributing to cancer predisposition, initiation and/or progression. ">
            <entity charOffset="0-4" id="miRNA-corp.d43.s7.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-107" id="miRNA-corp.d43.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-97" id="miRNA-corp.d43.s7.e2" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="141-146" id="miRNA-corp.d43.s7.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s7.e0" e2="miRNA-corp.d43.s7.e3" id="miRNA-corp.d43.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s7.e1" e2="miRNA-corp.d43.s7.e3" id="miRNA-corp.d43.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d43.s8" origId="18226107.s5" text="If present in somatic cells, miRNA alterations may play a role in tumor initiation, while if present in germ line cells they could constitute a cancer predisposing event. ">
            <entity charOffset="29-33" id="miRNA-corp.d43.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-70" id="miRNA-corp.d43.s8.e1" text="tumor" type="Diseases"/>
            <entity charOffset="144-149" id="miRNA-corp.d43.s8.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d43.s8.e0" e2="miRNA-corp.d43.s8.e1" id="miRNA-corp.d43.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d43.s8.e0" e2="miRNA-corp.d43.s8.e2" id="miRNA-corp.d43.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d44" origId="20576953">
        <sentence id="miRNA-corp.d44.s0" origId="20576953.s7" text="RESULTS: We detected a total of 360 miRNAs. ">
            <entity charOffset="36-41" id="miRNA-corp.d44.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s1" origId="20576953.s6" text="Selective miRNAs then were synthesized and transfected into Neuro-2a cells before oxygen-glucose deprivation. ">
            <entity charOffset="10-15" id="miRNA-corp.d44.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s2" origId="20576953.s9" text="Transfections of some of these were neuroprotective in in vitro ischemia. ">
            <entity charOffset="64-71" id="miRNA-corp.d44.s2.e0" text="ischemia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s3" origId="20576953.s8" text="Two miRNA families, miR-200 and miR-182, were selectively upregulated at 3 hours after ischemic preconditioning. ">
            <entity charOffset="4-8" id="miRNA-corp.d44.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-26" id="miRNA-corp.d44.s3.e1" text="miR-200" type="Specific_miRNAs"/>
            <entity charOffset="32-38" id="miRNA-corp.d44.s3.e2" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="58-68" id="miRNA-corp.d44.s3.e3" text="upregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s4" origId="20576953.s2" text="Although miRNAs control a number of conditions and diseases, few neuroprotective miRNAs have been described. ">
            <entity charOffset="81-86" id="miRNA-corp.d44.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-14" id="miRNA-corp.d44.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s5" origId="20576953.s3" text="In this study, we investigated neuroprotective miRNAs induced early in ischemic preconditioning. ">
            <entity charOffset="47-52" id="miRNA-corp.d44.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s6" origId="20576953.s4" text="METHODS: Ischemic preconditioning or focal cerebral ischemia was induced in mice by transient occlusion of the middle cerebral artery for 15 or 120 minutes. ">
            <entity charOffset="37-59" id="miRNA-corp.d44.s6.e0" text="focal cerebral ischemia" type="Diseases"/>
            <entity charOffset="76-79" id="miRNA-corp.d44.s6.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s7" origId="20576953.s5" text="We prepared RNA samples from the ischemic cortex at 3 or 24 hours after the onset of ischemia. ">
            <entity charOffset="85-92" id="miRNA-corp.d44.s7.e0" text="ischemia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s8" origId="20576953.s0" text="MicroRNAs induced during ischemic preconditioning.  ">
            <entity charOffset="0-8" id="miRNA-corp.d44.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s9" origId="20576953.s1" text="BACKGROUND AND PURPOSE: MicroRNAs (miRNA) are single-stranded short RNA molecules that regulate gene expression by either degradation or translational repression of mRNA. ">
            <entity charOffset="137-160" id="miRNA-corp.d44.s9.e0" text="translational repression" type="Relation_Trigger"/>
            <entity charOffset="24-32" id="miRNA-corp.d44.s9.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-39" id="miRNA-corp.d44.s9.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-110" id="miRNA-corp.d44.s9.e3" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s10" origId="20576953.s10" text="Among them, miR-200b, miR-200c, and miR-429 targeted prolyl hydroxylase 2 and had the best neuroprotective effect. ">
            <entity charOffset="12-19" id="miRNA-corp.d44.s10.e0" text="miR-200b" type="Specific_miRNAs"/>
            <entity charOffset="22-29" id="miRNA-corp.d44.s10.e1" text="miR-200c" type="Specific_miRNAs"/>
            <entity charOffset="36-42" id="miRNA-corp.d44.s10.e2" text="miR-429" type="Specific_miRNAs"/>
            <entity charOffset="44-51" id="miRNA-corp.d44.s10.e3" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s11" origId="20576953.s11" text="CONCLUSIONS: Two miRNA families, miR-200 and miR-182, were upregulated early after ischemic preconditioning and the miR-200 family was neuroprotective mainly by downregulating prolyl hydroxylase 2 levels. ">
            <entity charOffset="17-21" id="miRNA-corp.d44.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-39" id="miRNA-corp.d44.s11.e1" text="miR-200" type="Specific_miRNAs"/>
            <entity charOffset="45-51" id="miRNA-corp.d44.s11.e2" text="miR-182" type="Specific_miRNAs"/>
            <entity charOffset="59-69" id="miRNA-corp.d44.s11.e3" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="161-174" id="miRNA-corp.d44.s11.e4" text="downregulating" type="Relation_Trigger"/>
            <entity charOffset="116-122" id="miRNA-corp.d44.s11.e5" text="miR-200" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d44.s12" origId="20576953.s12" text="These miRNAs may be useful in future research and therapeutic applications.   ">
            <entity charOffset="6-11" id="miRNA-corp.d44.s12.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d45" origId="15756081">
        <sentence id="miRNA-corp.d45.s0" origId="15756081.s10" text="A significant association with death was found for major adverse events, medical adverse events, and nosocomial infections, with adjusted odds ratio estimates of 3.74 [95% confidence interval (CI) 1.64-8.54], 3.71 (95% CI 1.61-8.53), and 3.22 (95% CI 1.21-8.59), respectively. ">
            <entity charOffset="101-121" id="miRNA-corp.d45.s0.e0" text="nosocomial infections" type="Diseases"/>
            <entity charOffset="14-24" id="miRNA-corp.d45.s0.e1" text="association" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s1" origId="15756081.s11" text="CONCLUSION: Adverse events, mostly severe, predominated among deceased patients, resulting mainly from diagnostic or therapeutic procedures and nursing activities. ">
            <entity charOffset="71-78" id="miRNA-corp.d45.s1.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s2" origId="15756081.s12" text="In spite of limitations concerning the observational retrospective nature of this study, we found that severe adverse events, medical adverse events, and nosocomial infections were significantly associated with death in stroke patients.   ">
            <entity charOffset="227-234" id="miRNA-corp.d45.s2.e0" text="patients" type="Species"/>
            <entity charOffset="154-174" id="miRNA-corp.d45.s2.e1" text="nosocomial infections" type="Diseases"/>
            <entity charOffset="220-225" id="miRNA-corp.d45.s2.e2" text="stroke" type="Diseases"/>
            <entity charOffset="195-204" id="miRNA-corp.d45.s2.e3" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s3" origId="15756081.s1" text="OBJECTIVES: To identify the occurrence of adverse events in stroke patients presenting to the emergency department of a tertiary university facility, and to disclose the categories of adverse events associated with death. ">
            <entity charOffset="67-74" id="miRNA-corp.d45.s3.e0" text="patients" type="Species"/>
            <entity charOffset="60-65" id="miRNA-corp.d45.s3.e1" text="stroke" type="Diseases"/>
            <entity charOffset="199-208" id="miRNA-corp.d45.s3.e2" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s4" origId="15756081.s0" text="Adverse events and death in stroke patients admitted to the emergency department of a tertiary university hospital.  ">
            <entity charOffset="35-42" id="miRNA-corp.d45.s4.e0" text="patients" type="Species"/>
            <entity charOffset="28-33" id="miRNA-corp.d45.s4.e1" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s5" origId="15756081.s7" text="Major adverse events equaled 54.1% of all events (659 episodes): 538 events in 143 cases and 121 in 65 controls. "/>
        <sentence id="miRNA-corp.d45.s6" origId="15756081.s6" text="RESULTS: Adverse events totaled 1218 and occurred in 295 patients: 932 events (76.5%) in 170 cases and 286 (23.5%) in 125 controls. ">
            <entity charOffset="57-64" id="miRNA-corp.d45.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s7" origId="15756081.s9" text="Nursing (38.4%) and medical (31%) adverse events represented the most common related professional categories. "/>
        <sentence id="miRNA-corp.d45.s8" origId="15756081.s8" text="Diagnostic or therapeutic procedures and nursing activities accounted for 55.2% of events. "/>
        <sentence id="miRNA-corp.d45.s9" origId="15756081.s3" text="The cases comprised 234 consecutive deaths and the controls 234 discharged patients, matched for primary diagnosis and admission period. ">
            <entity charOffset="75-82" id="miRNA-corp.d45.s9.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s10" origId="15756081.s2" text="METHODS: This matched case-control study enrolled 468 patients admitted with stroke to the emergency department from March 1996 to September 1999. ">
            <entity charOffset="54-61" id="miRNA-corp.d45.s10.e0" text="patients" type="Species"/>
            <entity charOffset="77-82" id="miRNA-corp.d45.s10.e1" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s11" origId="15756081.s5" text="The association with death was analysed by conditional logistic regression. ">
            <entity charOffset="4-14" id="miRNA-corp.d45.s11.e0" text="association" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d45.s12" origId="15756081.s4" text="Adverse events, detected by chart review, were classified according to the degree of severity, immediate causes, and professional category. "/>
    </document>
    <document id="miRNA-corp.d46" origId="20841486">
        <sentence id="miRNA-corp.d46.s0" origId="20841486.s8" text="These findings reveal a novel mechanism of targeted intercellular protein regulation between brain tumor cells.   ">
            <entity charOffset="93-103" id="miRNA-corp.d46.s0.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="43-50" id="miRNA-corp.d46.s0.e1" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="74-83" id="miRNA-corp.d46.s0.e2" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s1" origId="20841486.s2" text="Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that lacks homology in rat. ">
            <entity charOffset="71-75" id="miRNA-corp.d46.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-66" id="miRNA-corp.d46.s1.e1" text="cel-miR-67" type="Specific_miRNAs"/>
            <entity charOffset="28-38" id="miRNA-corp.d46.s1.e2" text="gliosarcoma" type="Diseases"/>
            <entity charOffset="100-102" id="miRNA-corp.d46.s1.e3" text="rat" type="Species"/>
            <entity charOffset="21-23" id="miRNA-corp.d46.s1.e4" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d46.s1.e1" e2="miRNA-corp.d46.s1.e2" id="miRNA-corp.d46.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d46.s1.e0" e2="miRNA-corp.d46.s1.e2" id="miRNA-corp.d46.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s2" origId="20841486.s3" text="Coculture of these cells with cells that expressed a luciferase reporter that contained a complementary sequence to cel-miR-67 resulted in significant suppression of luciferase expression. ">
            <entity charOffset="116-125" id="miRNA-corp.d46.s2.e0" text="cel-miR-67" type="Specific_miRNAs"/>
            <entity charOffset="151-186" id="miRNA-corp.d46.s2.e1" text="suppression of luciferase expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s3" origId="20841486.s0" text="Functional microRNA is transferred between glioma cells.  ">
            <entity charOffset="11-18" id="miRNA-corp.d46.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-48" id="miRNA-corp.d46.s3.e1" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d46.s3.e0" e2="miRNA-corp.d46.s3.e1" id="miRNA-corp.d46.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s4" origId="20841486.s1" text="MicroRNAs (miRNA) are single-stranded 17- to 27-nucleotide RNA molecules that regulate gene expression by posttranscriptional silencing of target mRNAs. ">
            <entity charOffset="0-8" id="miRNA-corp.d46.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d46.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-101" id="miRNA-corp.d46.s4.e2" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="139-144" id="miRNA-corp.d46.s4.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s5" origId="20841486.s6" text="Finally, in situ hybridization revealed the presence of cel-miR-67 in cel-miR-67-null 9L cells after coculture with cel-miR-67-expressing cells. ">
            <entity charOffset="56-65" id="miRNA-corp.d46.s5.e0" text="cel-miR-67" type="Specific_miRNAs"/>
            <entity charOffset="70-79" id="miRNA-corp.d46.s5.e1" text="cel-miR-67" type="Specific_miRNAs"/>
            <entity charOffset="116-125" id="miRNA-corp.d46.s5.e2" text="cel-miR-67" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s6" origId="20841486.s7" text="Our data show that miRNA transcribed in glioma cells can be transferred to adjacent cells and induces targeted inhibition of protein expression in the acceptor cells. ">
            <entity charOffset="19-23" id="miRNA-corp.d46.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-45" id="miRNA-corp.d46.s6.e1" text="glioma" type="Diseases"/>
            <entity charOffset="102-109" id="miRNA-corp.d46.s6.e2" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="111-142" id="miRNA-corp.d46.s6.e3" text="inhibition of protein expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d46.s6.e0" e2="miRNA-corp.d46.s6.e1" id="miRNA-corp.d46.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s7" origId="20841486.s4" text="This effect was also observed in the U87-MG human glioma cell line. ">
            <entity charOffset="50-55" id="miRNA-corp.d46.s7.e0" text="glioma" type="Diseases"/>
            <entity charOffset="44-48" id="miRNA-corp.d46.s7.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d46.s8" origId="20841486.s5" text="Moreover, luciferase suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junction communication regulates intercellular transfer of miRNA. ">
            <entity charOffset="174-178" id="miRNA-corp.d46.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="21-31" id="miRNA-corp.d46.s8.e1" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="37-45" id="miRNA-corp.d46.s8.e2" text="inhibited" type="Relation_Trigger"/>
            <entity charOffset="138-146" id="miRNA-corp.d46.s8.e3" text="regulates" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d47" origId="20507594">
        <sentence id="miRNA-corp.d47.s0" origId="20507594.s10" text="Moreover, bioinformatics analyses revealed a theoretical basis for many other potential interactions between natural antisense transcripts and miRNAs at the binding sites of the latter.   ">
            <entity charOffset="143-148" id="miRNA-corp.d47.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="157-169" id="miRNA-corp.d47.s0.e1" text="binding sites" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s1" origId="20507594.s2" text="In addition, mammalian genomes contain numerous natural antisense transcripts, most of which appear to be non-protein-coding RNAs (ncRNAs). "/>
        <sentence id="miRNA-corp.d47.s2" origId="20507594.s1" text="BACKGROUND: MicroRNAs (miRNAs) have the potential to regulate diverse sets of mRNA targets. ">
            <entity charOffset="12-20" id="miRNA-corp.d47.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d47.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-60" id="miRNA-corp.d47.s2.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="83-89" id="miRNA-corp.d47.s2.e3" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s3" origId="20507594.s0" text="Evidence for natural antisense transcript-mediated inhibition of microRNA function.  ">
            <entity charOffset="65-72" id="miRNA-corp.d47.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-60" id="miRNA-corp.d47.s3.e1" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s4" origId="20507594.s6" text="Indeed, miR-485-5p and BACE1-antisense compete for binding within the same region in the open reading frame of the BACE1 mRNA. ">
            <entity charOffset="8-17" id="miRNA-corp.d47.s4.e0" text="miR-485-5p" type="Specific_miRNAs"/>
            <entity charOffset="115-119" id="miRNA-corp.d47.s4.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="51-57" id="miRNA-corp.d47.s4.e2" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d47.s4.e0" e2="miRNA-corp.d47.s4.e1" id="miRNA-corp.d47.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s5" origId="20507594.s5" text="RESULTS: We report here that BACE1-antisense prevents miRNA-induced repression of BACE1 mRNA by masking the binding site for miR-485-5p. ">
            <entity charOffset="54-58" id="miRNA-corp.d47.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-119" id="miRNA-corp.d47.s5.e1" text="binding site" type="Relation_Trigger"/>
            <entity charOffset="82-86" id="miRNA-corp.d47.s5.e2" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="125-134" id="miRNA-corp.d47.s5.e3" text="miR-485-5p" type="Specific_miRNAs"/>
            <entity charOffset="68-77" id="miRNA-corp.d47.s5.e4" text="repression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d47.s5.e3" e2="miRNA-corp.d47.s5.e2" id="miRNA-corp.d47.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s5.e0" e2="miRNA-corp.d47.s5.e2" id="miRNA-corp.d47.s5.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s6" origId="20507594.s4" text="The BACE1-antisense transcript is markedly up-regulated in brain samples from Alzheimer's disease patients and promotes the stability of the (sense) BACE1 transcript. ">
            <entity charOffset="78-96" id="miRNA-corp.d47.s6.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="149-153" id="miRNA-corp.d47.s6.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="43-54" id="miRNA-corp.d47.s6.e2" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="98-105" id="miRNA-corp.d47.s6.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s7" origId="20507594.s3" text="We have recently identified and characterized a highly conserved non-coding antisense transcript for beta-secretase-1 (BACE1), a critical enzyme in Alzheimer's disease pathophysiology. ">
            <entity charOffset="148-166" id="miRNA-corp.d47.s7.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="119-123" id="miRNA-corp.d47.s7.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="101-116" id="miRNA-corp.d47.s7.e2" text="beta-secretase-1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s8" origId="20507594.s7" text="We observed opposing effects of BACE1-antisense and miR-485-5p on BACE1 protein in vitro and showed that Locked Nucleic Acid-antimiR mediated knockdown of miR-485-5p as well as BACE1-antisense over-expression can prevent the miRNA-induced BACE1 suppression. ">
            <entity charOffset="245-255" id="miRNA-corp.d47.s8.e0" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="239-243" id="miRNA-corp.d47.s8.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="52-61" id="miRNA-corp.d47.s8.e2" text="miR-485-5p" type="Specific_miRNAs"/>
            <entity charOffset="155-164" id="miRNA-corp.d47.s8.e3" text="miR-485-5p" type="Specific_miRNAs"/>
            <entity charOffset="193-207" id="miRNA-corp.d47.s8.e4" text="over-expression" type="Relation_Trigger"/>
            <entity charOffset="225-229" id="miRNA-corp.d47.s8.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-70" id="miRNA-corp.d47.s8.e6" text="BACE1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e2" e2="miRNA-corp.d47.s8.e1" id="miRNA-corp.d47.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e2" e2="miRNA-corp.d47.s8.e6" id="miRNA-corp.d47.s8.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e3" e2="miRNA-corp.d47.s8.e1" id="miRNA-corp.d47.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e3" e2="miRNA-corp.d47.s8.e6" id="miRNA-corp.d47.s8.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e5" e2="miRNA-corp.d47.s8.e1" id="miRNA-corp.d47.s8.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d47.s8.e5" e2="miRNA-corp.d47.s8.e6" id="miRNA-corp.d47.s8.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s9" origId="20507594.s8" text="We found that the expression of BACE1-antisense as well as miR-485-5p are dysregulated in RNA samples from Alzheimer's disease subjects compared to control individuals. ">
            <entity charOffset="74-85" id="miRNA-corp.d47.s9.e0" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="107-125" id="miRNA-corp.d47.s9.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="59-68" id="miRNA-corp.d47.s9.e2" text="miR-485-5p" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d47.s9.e2" e2="miRNA-corp.d47.s9.e1" id="miRNA-corp.d47.s9.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d47.s10" origId="20507594.s9" text="CONCLUSIONS: Our data demonstrate an interface between two distinct groups of regulatory RNAs in the computation of BACE1 gene expression. ">
            <entity charOffset="116-120" id="miRNA-corp.d47.s10.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="78-87" id="miRNA-corp.d47.s10.e1" text="regulatory" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d48" origId="19142192">
        <sentence id="miRNA-corp.d48.s0" origId="19142192.s8" text="The mRNA expression of the RNases Drosha and Dicer, cofactor Pasha, and the pre-miRNA transporter exportin-5, which modulate miRNA biogenesis, were not altered after transient middle cerebral artery occlusion. ">
            <entity charOffset="34-39" id="miRNA-corp.d48.s0.e0" text="Drosha" type="Genes/Proteins"/>
            <entity charOffset="45-49" id="miRNA-corp.d48.s0.e1" text="Dicer" type="Genes/Proteins"/>
            <entity charOffset="183-207" id="miRNA-corp.d48.s0.e2" text="cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="125-129" id="miRNA-corp.d48.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-107" id="miRNA-corp.d48.s0.e4" text="exportin-5" type="Genes/Proteins"/>
            <entity charOffset="116-123" id="miRNA-corp.d48.s0.e5" text="modulate" type="Relation_Trigger"/>
            <entity charOffset="80-84" id="miRNA-corp.d48.s0.e6" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d48.s0.e3" e2="miRNA-corp.d48.s0.e4" id="miRNA-corp.d48.s0.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e3" e2="miRNA-corp.d48.s0.e0" id="miRNA-corp.d48.s0.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e3" e2="miRNA-corp.d48.s0.e1" id="miRNA-corp.d48.s0.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e3" e2="miRNA-corp.d48.s0.e2" id="miRNA-corp.d48.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d48.s0.e6" e2="miRNA-corp.d48.s0.e4" id="miRNA-corp.d48.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e6" e2="miRNA-corp.d48.s0.e0" id="miRNA-corp.d48.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e6" e2="miRNA-corp.d48.s0.e1" id="miRNA-corp.d48.s0.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d48.s0.e6" e2="miRNA-corp.d48.s0.e2" id="miRNA-corp.d48.s0.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s1" origId="19142192.s9" text="Thus, the present studies indicate a critical role of miRNAs in controlling mRNA transcription and translation in the postischemic brain.   ">
            <entity charOffset="54-59" id="miRNA-corp.d48.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s2" origId="19142192.s5" text="Bioinformatics analysis indicated a correlation between miRNAs altered to several mRNAs known to mediate inflammation, transcription, neuroprotection, receptors function, and ionic homeostasis. ">
            <entity charOffset="56-61" id="miRNA-corp.d48.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-46" id="miRNA-corp.d48.s2.e1" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="105-116" id="miRNA-corp.d48.s2.e2" text="inflammation" type="Diseases"/>
            <pair e1="miRNA-corp.d48.s2.e0" e2="miRNA-corp.d48.s2.e2" id="miRNA-corp.d48.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s3" origId="19142192.s4" text="Of those, 17 showed &gt;5 fold change. "/>
        <sentence id="miRNA-corp.d48.s4" origId="19142192.s7" text="In silico analysis showed sequence complementarity of eight miRNAs induced after focal ischemia to 877 promoters indicating the possibility of noncoding RNA-induced activation of gene expression. ">
            <entity charOffset="60-65" id="miRNA-corp.d48.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-94" id="miRNA-corp.d48.s4.e1" text="focal ischemia" type="Diseases"/>
            <entity charOffset="165-174" id="miRNA-corp.d48.s4.e2" text="activation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d48.s4.e0" e2="miRNA-corp.d48.s4.e1" id="miRNA-corp.d48.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s5" origId="19142192.s6" text="Antagomir-mediated prevention of mir-145 expression led to an increased protein expression of its downstream target superoxide dismutase-2 in the postischemic brain. ">
            <entity charOffset="33-39" id="miRNA-corp.d48.s5.e0" text="mir-145" type="Specific_miRNAs"/>
            <entity charOffset="116-137" id="miRNA-corp.d48.s5.e1" text="superoxide dismutase-2" type="Genes/Proteins"/>
            <entity charOffset="62-89" id="miRNA-corp.d48.s5.e2" text="increased protein expression" type="Relation_Trigger"/>
            <entity charOffset="109-114" id="miRNA-corp.d48.s5.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d48.s5.e0" e2="miRNA-corp.d48.s5.e1" id="miRNA-corp.d48.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s6" origId="19142192.s1" text="MicroRNAs (miRNAs) are approximately 22 nucleotides long, noncoding RNAs that control cellular function by either degrading mRNAs or arresting their translation. ">
            <entity charOffset="0-8" id="miRNA-corp.d48.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d48.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s7" origId="19142192.s0" text="Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome.  ">
            <entity charOffset="0-23" id="miRNA-corp.d48.s7.e0" text="Transient focal ischemia" type="Diseases"/>
            <entity charOffset="63-65" id="miRNA-corp.d48.s7.e1" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s8" origId="19142192.s3" text="Of the 238 miRNAs evaluated, 8 showed increased and 12 showed decreased expression at least at 4 out of 5 reperfusion time points studied between 3 h and 3 days compared with sham. ">
            <entity charOffset="11-16" id="miRNA-corp.d48.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-81" id="miRNA-corp.d48.s8.e1" text="decreased expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d48.s9" origId="19142192.s2" text="To understand their functional significance in ischemic pathophysiology, we profiled miRNAs in adult rat brain as a function of reperfusion time after transient middle cerebral artery occlusion. ">
            <entity charOffset="85-90" id="miRNA-corp.d48.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="161-192" id="miRNA-corp.d48.s9.e1" text="middle cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="101-103" id="miRNA-corp.d48.s9.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d48.s9.e0" e2="miRNA-corp.d48.s9.e1" id="miRNA-corp.d48.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d49" origId="16325011">
        <sentence id="miRNA-corp.d49.s0" origId="16325011.s11" text="The possible use of RNAi in the treatment of spinocerebellar ataxia or amyotrophic lateral sclerosis, with its advantages and pitfalls and possible extensions to other diseases are discussed.   ">
            <entity charOffset="45-66" id="miRNA-corp.d49.s0.e0" text="spinocerebellar ataxia" type="Diseases"/>
            <entity charOffset="71-99" id="miRNA-corp.d49.s0.e1" text="amyotrophic lateral sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s1" origId="16325011.s10" text="RNAi has moved from a purely experimental technique to the stage of potential clinical applications. "/>
        <sentence id="miRNA-corp.d49.s2" origId="16325011.s3" text="RNAi utilises cellular machinery associated with the processing of naturally occurring micro RNA (miRNAs). ">
            <entity charOffset="87-95" id="miRNA-corp.d49.s2.e0" text="micro RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-103" id="miRNA-corp.d49.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-42" id="miRNA-corp.d49.s2.e2" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s3" origId="16325011.s2" text="RNAi has both admirers and detractors, but is undeniably a technique with great potential, which has come a long way in the short time since its discovery. "/>
        <sentence id="miRNA-corp.d49.s4" origId="16325011.s1" text="RNA interference has become the tool of choice to analyse the loss-of-function of individual genes and has been exploited to identify complex regulatory pathways following genomic screening. ">
            <entity charOffset="142-151" id="miRNA-corp.d49.s4.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s5" origId="16325011.s0" text="Design of shRNAs for RNAi-A lesson from pre-miRNA processing: possible clinical applications.  ">
            <entity charOffset="44-48" id="miRNA-corp.d49.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s6" origId="16325011.s8" text="The cellular processing of shRNAs shares common features with the biogenesis of naturally occurring miRNA such as cleavage by nuclear RNase Drosha, export from the nucleus, processing by a cytoplasmic RNase Dicer, and incorporation into the RNA-induced silencing complex (RISC). ">
            <entity charOffset="100-104" id="miRNA-corp.d49.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-145" id="miRNA-corp.d49.s6.e1" text="Drosha" type="Genes/Proteins"/>
            <entity charOffset="207-211" id="miRNA-corp.d49.s6.e2" text="Dicer" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d49.s6.e0" e2="miRNA-corp.d49.s6.e1" id="miRNA-corp.d49.s6.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d49.s6.e0" e2="miRNA-corp.d49.s6.e2" id="miRNA-corp.d49.s6.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s7" origId="16325011.s9" text="Each step has a crucial influence on the efficiency of RNAi and their consideration should be a part of a standard experimental design. "/>
        <sentence id="miRNA-corp.d49.s8" origId="16325011.s6" text="More recently an introduction of short approximately 22 nucleotide RNA duplexes has become the standard in short-term experiments, but is insufficient for long-term knock-down assays. "/>
        <sentence id="miRNA-corp.d49.s9" origId="16325011.s7" text="Long-term expression of siRNAs has been achieved by in vivo transcription from plasmids coding for short hairpin RNAs (shRNAs). "/>
        <sentence id="miRNA-corp.d49.s10" origId="16325011.s4" text="Effective use of RNAi requires detailed knowledge of the individual steps and the proteins involved, as well as the similarities and distinctions between miRNA and siRNA pathways. ">
            <entity charOffset="154-158" id="miRNA-corp.d49.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d49.s11" origId="16325011.s5" text="RNAi was originally induced by the introduction of long double stranded RNAs (dsRNAs) into cells in which the RNA was cleaved into short RNAs which effectively interfered with a transcription of cognate mRNA. "/>
    </document>
    <document id="miRNA-corp.d50" origId="19501075">
        <sentence id="miRNA-corp.d50.s0" origId="19501075.s9" text="Our microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury has shown that some microRNA such as miR-21 could be involved in the intricate process of TBI course.   ">
            <entity charOffset="142-147" id="miRNA-corp.d50.s0.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="82-103" id="miRNA-corp.d50.s0.e1" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="195-197" id="miRNA-corp.d50.s0.e2" text="TBI" type="Diseases"/>
            <entity charOffset="33-40" id="miRNA-corp.d50.s0.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="125-132" id="miRNA-corp.d50.s0.e4" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="56-58" id="miRNA-corp.d50.s0.e5" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d50.s0.e0" e2="miRNA-corp.d50.s0.e1" id="miRNA-corp.d50.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s0.e0" e2="miRNA-corp.d50.s0.e2" id="miRNA-corp.d50.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s0.e3" e2="miRNA-corp.d50.s0.e1" id="miRNA-corp.d50.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s0.e3" e2="miRNA-corp.d50.s0.e2" id="miRNA-corp.d50.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s0.e4" e2="miRNA-corp.d50.s0.e1" id="miRNA-corp.d50.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s0.e4" e2="miRNA-corp.d50.s0.e2" id="miRNA-corp.d50.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s1" origId="19501075.s6" text="Furthermore, we revealed global up-regulation of miR-21 expression within all the four time points post injury. ">
            <entity charOffset="49-54" id="miRNA-corp.d50.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="104-109" id="miRNA-corp.d50.s1.e1" text="injury" type="Diseases"/>
            <entity charOffset="32-44" id="miRNA-corp.d50.s1.e2" text="up-regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d50.s1.e0" e2="miRNA-corp.d50.s1.e1" id="miRNA-corp.d50.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s2" origId="19501075.s5" text="Our research revealed that 136 miRNAs were expressing at 6 h post injury, in which 13 miRNAs were more than 2-fold up-regulated, and 14 miRNAs were more than 2-fold down-regulated; 118 miRNAs were expressing at 24 h post injury, in which 4 miRNAs were more than 2-fold up-regulated, and 23 miRNAs were more than 2-fold down-regulated; 149 miRNAs were expressing at 48 h post injury, in which 16 miRNAs were more than 2-fold up-regulated, and 11 miRNAs were more than 2-fold down-regulated; and 203 miRNAs were expressing at 72 h post injury, in which 19 miRNAs were more than 2-fold up-regulated, and 5 miRNAs were more than 2-fold down-regulated. ">
            <entity charOffset="31-36" id="miRNA-corp.d50.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-91" id="miRNA-corp.d50.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="136-141" id="miRNA-corp.d50.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="185-190" id="miRNA-corp.d50.s2.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="240-245" id="miRNA-corp.d50.s2.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="290-295" id="miRNA-corp.d50.s2.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="339-344" id="miRNA-corp.d50.s2.e6" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="395-400" id="miRNA-corp.d50.s2.e7" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="445-450" id="miRNA-corp.d50.s2.e8" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="498-503" id="miRNA-corp.d50.s2.e9" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="554-559" id="miRNA-corp.d50.s2.e10" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="603-608" id="miRNA-corp.d50.s2.e11" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="115-126" id="miRNA-corp.d50.s2.e12" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="165-178" id="miRNA-corp.d50.s2.e13" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="66-71" id="miRNA-corp.d50.s2.e14" text="injury" type="Diseases"/>
            <entity charOffset="221-226" id="miRNA-corp.d50.s2.e15" text="injury" type="Diseases"/>
            <entity charOffset="375-380" id="miRNA-corp.d50.s2.e16" text="injury" type="Diseases"/>
            <entity charOffset="534-539" id="miRNA-corp.d50.s2.e17" text="injury" type="Diseases"/>
            <entity charOffset="269-280" id="miRNA-corp.d50.s2.e18" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="319-332" id="miRNA-corp.d50.s2.e19" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="424-435" id="miRNA-corp.d50.s2.e20" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="474-487" id="miRNA-corp.d50.s2.e21" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="583-594" id="miRNA-corp.d50.s2.e22" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="632-645" id="miRNA-corp.d50.s2.e23" text="down-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d50.s2.e0" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e0" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e0" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e0" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e1" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e1" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e1" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e1" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e2" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e2" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e2" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e2" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p11" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e3" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p12" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e3" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p13" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e3" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p14" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e3" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p15" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e4" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p16" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e4" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p17" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e4" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p18" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e4" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p19" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e5" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p20" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e5" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p21" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e5" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p22" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e5" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p23" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e6" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p24" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e6" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p25" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e6" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p26" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e6" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p27" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e7" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p28" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e7" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p29" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e7" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p30" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e7" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p31" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e8" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p32" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e8" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p33" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e8" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p34" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e8" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p35" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e9" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p36" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e9" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p37" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e9" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p38" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e9" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p39" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e10" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p40" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e10" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p41" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e10" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p42" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e10" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p43" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e11" e2="miRNA-corp.d50.s2.e14" id="miRNA-corp.d50.s2.p44" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e11" e2="miRNA-corp.d50.s2.e15" id="miRNA-corp.d50.s2.p45" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e11" e2="miRNA-corp.d50.s2.e16" id="miRNA-corp.d50.s2.p46" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s2.e11" e2="miRNA-corp.d50.s2.e17" id="miRNA-corp.d50.s2.p47" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s3" origId="19501075.s8" text="The qRT-PCR results indicated good consistency with the results of the microarray method. "/>
        <sentence id="miRNA-corp.d50.s4" origId="19501075.s7" text="Finally, we utilized qRT-PCR methods to verify the microarray results. "/>
        <sentence id="miRNA-corp.d50.s5" origId="19501075.s1" text="MicroRNAs (miRNAs) are very important regulators of biological processes such as development, cellular differentiation, and tumor generation. ">
            <entity charOffset="0-8" id="miRNA-corp.d50.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d50.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-47" id="miRNA-corp.d50.s5.e2" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="124-128" id="miRNA-corp.d50.s5.e3" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d50.s5.e0" e2="miRNA-corp.d50.s5.e3" id="miRNA-corp.d50.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d50.s5.e1" e2="miRNA-corp.d50.s5.e3" id="miRNA-corp.d50.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s6" origId="19501075.s2" text="MiRNA microarray has been found to be a high throughput global analysis tool for detecting miRNA expression profiling, and miRNA expression profiling will facilitate the study of the biological function of miRNAs. ">
            <entity charOffset="0-4" id="miRNA-corp.d50.s6.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-95" id="miRNA-corp.d50.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="123-127" id="miRNA-corp.d50.s6.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="206-211" id="miRNA-corp.d50.s6.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s7" origId="19501075.s3" text="In this report, we describe the miRNA expression level in rat cerebral cortex after traumatic brain injury using microarray method. ">
            <entity charOffset="32-36" id="miRNA-corp.d50.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-105" id="miRNA-corp.d50.s7.e1" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="58-60" id="miRNA-corp.d50.s7.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d50.s7.e0" e2="miRNA-corp.d50.s7.e1" id="miRNA-corp.d50.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s8" origId="19501075.s4" text="We choose several time points post brain injury: 6 h, 24 h, 48 h and 72 h, respectively, to reveal differential expression of miRNAs in rat brain cortex compared with control groups. ">
            <entity charOffset="126-131" id="miRNA-corp.d50.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-46" id="miRNA-corp.d50.s8.e1" text="brain injury" type="Diseases"/>
            <entity charOffset="99-121" id="miRNA-corp.d50.s8.e2" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="136-138" id="miRNA-corp.d50.s8.e3" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d50.s8.e0" e2="miRNA-corp.d50.s8.e1" id="miRNA-corp.d50.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d50.s9" origId="19501075.s0" text="Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury.  ">
            <entity charOffset="78-99" id="miRNA-corp.d50.s9.e0" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="29-36" id="miRNA-corp.d50.s9.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-54" id="miRNA-corp.d50.s9.e2" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d50.s9.e1" e2="miRNA-corp.d50.s9.e0" id="miRNA-corp.d50.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d51" origId="20413881">
        <sentence id="miRNA-corp.d51.s0" origId="20413881.s0" text="MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study.  ">
            <entity charOffset="0-6" id="miRNA-corp.d51.s0.e0" text="MiR-107" type="Specific_miRNAs"/>
            <entity charOffset="22-40" id="miRNA-corp.d51.s0.e1" text="Alzheimer's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d51.s0.e0" e2="miRNA-corp.d51.s0.e1" id="miRNA-corp.d51.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s1" origId="20413881.s1" text="MiR-107 is a microRNA (miRNA) that we reported previously to have decreased expression in the temporal cortical gray matter early in the progression of Alzheimer's disease (AD). ">
            <entity charOffset="13-20" id="miRNA-corp.d51.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-27" id="miRNA-corp.d51.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-85" id="miRNA-corp.d51.s1.e2" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="152-170" id="miRNA-corp.d51.s1.e3" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="173-174" id="miRNA-corp.d51.s1.e4" text="AD" type="Diseases"/>
            <entity charOffset="0-6" id="miRNA-corp.d51.s1.e5" text="MiR-107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d51.s1.e0" e2="miRNA-corp.d51.s1.e4" id="miRNA-corp.d51.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s1.e0" e2="miRNA-corp.d51.s1.e3" id="miRNA-corp.d51.s1.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s1.e5" e2="miRNA-corp.d51.s1.e4" id="miRNA-corp.d51.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s1.e5" e2="miRNA-corp.d51.s1.e3" id="miRNA-corp.d51.s1.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s1.e1" e2="miRNA-corp.d51.s1.e4" id="miRNA-corp.d51.s1.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s1.e1" e2="miRNA-corp.d51.s1.e3" id="miRNA-corp.d51.s1.p5" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s2" origId="20413881.s4" text="Correlation was observed between decreased miR-107 expression and increased neuritic plaque counts (P&lt; 0.05) and neurofibrillary tangle counts (P&lt; 0.02) in adjacent brain tissue. ">
            <entity charOffset="33-60" id="miRNA-corp.d51.s2.e0" text="decreased miR-107 expression" type="Relation_Trigger"/>
            <entity charOffset="43-49" id="miRNA-corp.d51.s2.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="0-10" id="miRNA-corp.d51.s2.e2" text="Correlation" type="Relation_Trigger"/>
            <entity charOffset="76-90" id="miRNA-corp.d51.s2.e3" text="neuritic plaque" type="Diseases"/>
            <pair e1="miRNA-corp.d51.s2.e1" e2="miRNA-corp.d51.s2.e3" id="miRNA-corp.d51.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s3" origId="20413881.s5" text="Adjusted miR-107 and BACE1 mRNA levels tended to correlate negatively (trend with regression P&lt; 0.07). ">
            <entity charOffset="49-68" id="miRNA-corp.d51.s3.e0" text="correlate negatively" type="Relation_Trigger"/>
            <entity charOffset="21-25" id="miRNA-corp.d51.s3.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="9-15" id="miRNA-corp.d51.s3.e2" text="miR-107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d51.s3.e2" e2="miRNA-corp.d51.s3.e1" id="miRNA-corp.d51.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s4" origId="20413881.s2" text="Here we study a new group of well-characterized human temporal cortex samples (N=19). ">
            <entity charOffset="48-52" id="miRNA-corp.d51.s4.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s5" origId="20413881.s3" text="MiR-107 expression was assessed, normalized to miR-124 and let-7a. ">
            <entity charOffset="0-6" id="miRNA-corp.d51.s5.e0" text="MiR-107" type="Specific_miRNAs"/>
            <entity charOffset="47-53" id="miRNA-corp.d51.s5.e1" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="59-64" id="miRNA-corp.d51.s5.e2" text="let-7a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d51.s6" origId="20413881.s6" text="In sum, miR-107 expression tends to be lower relative to other miRNAs as AD progresses.   ">
            <entity charOffset="63-68" id="miRNA-corp.d51.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-43" id="miRNA-corp.d51.s6.e1" text="expression tends to be lower" type="Relation_Trigger"/>
            <entity charOffset="73-74" id="miRNA-corp.d51.s6.e2" text="AD" type="Diseases"/>
            <entity charOffset="8-14" id="miRNA-corp.d51.s6.e3" text="miR-107" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d51.s6.e0" e2="miRNA-corp.d51.s6.e2" id="miRNA-corp.d51.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d51.s6.e3" e2="miRNA-corp.d51.s6.e2" id="miRNA-corp.d51.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d52" origId="20072941">
        <sentence id="miRNA-corp.d52.s0" origId="20072941.s1" text="Small RNAs are short (approximately 18 to 30 nucleotides), non-coding RNA molecules that can regulate gene expression in both the cytoplasm and the nucleus via post-transcriptional gene silencing (PTGS), chromatin-dependent gene silencing (CDGS) or RNA activation (RNAa). ">
            <entity charOffset="93-116" id="miRNA-corp.d52.s0.e0" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s1" origId="20072941.s0" text="Novel functions for small RNA molecules.  "/>
        <sentence id="miRNA-corp.d52.s2" origId="20072941.s3" text="Research has indicated that small RNAs play important roles in cellular processes such as cell differentiation, growth/proliferation, migration, apoptosis/death, metabolism and defense. "/>
        <sentence id="miRNA-corp.d52.s3" origId="20072941.s2" text="Three classes of small RNAs have been defined: microRNAs (miRNAs), siRNAs and Piwi-interacting RNAs (piRNAs). ">
            <entity charOffset="47-55" id="miRNA-corp.d52.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="58-63" id="miRNA-corp.d52.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s4" origId="20072941.s5" text="More interestingly, increasing evidence indicates that small RNAs are involved in the pathogenesis of diverse diseases including cancer, cardiovascular disease, stroke, neurodegenerative disease, diabetes, liver disease, kidney disease and infectious disease. ">
            <entity charOffset="137-158" id="miRNA-corp.d52.s4.e0" text="cardiovascular disease" type="Diseases"/>
            <entity charOffset="161-166" id="miRNA-corp.d52.s4.e1" text="stroke" type="Diseases"/>
            <entity charOffset="169-193" id="miRNA-corp.d52.s4.e2" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="196-203" id="miRNA-corp.d52.s4.e3" text="diabetes" type="Diseases"/>
            <entity charOffset="206-218" id="miRNA-corp.d52.s4.e4" text="liver disease" type="Diseases"/>
            <entity charOffset="221-234" id="miRNA-corp.d52.s4.e5" text="kidney disease" type="Diseases"/>
            <entity charOffset="240-257" id="miRNA-corp.d52.s4.e6" text="infectious disease" type="Diseases"/>
            <entity charOffset="129-134" id="miRNA-corp.d52.s4.e7" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s5" origId="20072941.s4" text="Accordingly, small RNAs are critical regulators of normal development and physiology. ">
            <entity charOffset="37-46" id="miRNA-corp.d52.s5.e0" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s6" origId="20072941.s7" text="Additionally, small RNAs may serve as novel biomarkers and therapeutic targets for the majority of diseases.   ">
            <entity charOffset="59-77" id="miRNA-corp.d52.s6.e0" text="therapeutic targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d52.s7" origId="20072941.s6" text="More than 20 clinical trials are ongoing to evaluate therapies based on small RNA. "/>
    </document>
    <document id="miRNA-corp.d53" origId="21422175">
        <sentence id="miRNA-corp.d53.s0" origId="21422175.s2" text="We studied the expression of selected miRNAs following infection of CBA mice with Plasmodium berghei ANKA (PbA), which causes cerebral malaria (CM), or Plasmodium berghei K173 (PbK), which causes severe malaria but without cerebral complications, termed non-CM. ">
            <entity charOffset="38-43" id="miRNA-corp.d53.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="126-141" id="miRNA-corp.d53.s0.e1" text="cerebral malaria" type="Diseases"/>
            <entity charOffset="203-209" id="miRNA-corp.d53.s0.e2" text="malaria" type="Diseases"/>
            <entity charOffset="144-145" id="miRNA-corp.d53.s0.e3" text="CM" type="Diseases"/>
            <entity charOffset="55-63" id="miRNA-corp.d53.s0.e4" text="infection" type="Diseases"/>
            <entity charOffset="72-75" id="miRNA-corp.d53.s0.e5" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d53.s0.e0" e2="miRNA-corp.d53.s0.e2" id="miRNA-corp.d53.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s0.e0" e2="miRNA-corp.d53.s0.e3" id="miRNA-corp.d53.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s0.e0" e2="miRNA-corp.d53.s0.e4" id="miRNA-corp.d53.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s0.e0" e2="miRNA-corp.d53.s0.e1" id="miRNA-corp.d53.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s1" origId="21422175.s1" text="MicroRNAs (miRNAs) are posttranscriptional regulatory molecules that have been implicated in the regulation of immune responses, but their role in the immune response to Plasmodium infection is unknown. ">
            <entity charOffset="0-8" id="miRNA-corp.d53.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d53.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-106" id="miRNA-corp.d53.s1.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="43-52" id="miRNA-corp.d53.s1.e3" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="170-189" id="miRNA-corp.d53.s1.e4" text="Plasmodium infection" type="Diseases"/>
            <pair e1="miRNA-corp.d53.s1.e0" e2="miRNA-corp.d53.s1.e4" id="miRNA-corp.d53.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s1.e1" e2="miRNA-corp.d53.s1.e4" id="miRNA-corp.d53.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s2" origId="21422175.s0" text="Differential MicroRNA Expression in Experimental Cerebral and Noncerebral Malaria.  ">
            <entity charOffset="13-20" id="miRNA-corp.d53.s2.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-80" id="miRNA-corp.d53.s2.e1" text="Malaria" type="Diseases"/>
            <entity charOffset="0-31" id="miRNA-corp.d53.s2.e2" text="Differential MicroRNA Expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d53.s2.e0" e2="miRNA-corp.d53.s2.e1" id="miRNA-corp.d53.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s3" origId="21422175.s6" text="To investigate the involvement of let-7i, miR-27a, and miR-150 in CM-resistant mice, we assessed the expression levels in gamma interferon knockout (IFN-γ(-/-)) mice on a C57BL/6 genetic background. ">
            <entity charOffset="66-67" id="miRNA-corp.d53.s3.e0" text="CM" type="Diseases"/>
            <entity charOffset="149-151" id="miRNA-corp.d53.s3.e1" text="IFN" type="Genes/Proteins"/>
            <entity charOffset="42-48" id="miRNA-corp.d53.s3.e2" text="miR-27a" type="Specific_miRNAs"/>
            <entity charOffset="55-61" id="miRNA-corp.d53.s3.e3" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="34-39" id="miRNA-corp.d53.s3.e4" text="let-7i" type="Specific_miRNAs"/>
            <entity charOffset="122-137" id="miRNA-corp.d53.s3.e5" text="gamma interferon" type="Genes/Proteins"/>
            <entity charOffset="79-82" id="miRNA-corp.d53.s3.e6" text="mice" type="Species"/>
            <entity charOffset="161-164" id="miRNA-corp.d53.s3.e7" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d53.s3.e2" e2="miRNA-corp.d53.s3.e0" id="miRNA-corp.d53.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s3.e2" e2="miRNA-corp.d53.s3.e1" id="miRNA-corp.d53.s3.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s3.e2" e2="miRNA-corp.d53.s3.e5" id="miRNA-corp.d53.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s3.e3" e2="miRNA-corp.d53.s3.e0" id="miRNA-corp.d53.s3.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s3.e3" e2="miRNA-corp.d53.s3.e1" id="miRNA-corp.d53.s3.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s3.e3" e2="miRNA-corp.d53.s3.e5" id="miRNA-corp.d53.s3.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s3.e4" e2="miRNA-corp.d53.s3.e0" id="miRNA-corp.d53.s3.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s3.e4" e2="miRNA-corp.d53.s3.e1" id="miRNA-corp.d53.s3.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s3.e4" e2="miRNA-corp.d53.s3.e5" id="miRNA-corp.d53.s3.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s4" origId="21422175.s5" text="In contrast, no miRNA changes were detected in the heart, an organ with no known pathology during acute malaria. ">
            <entity charOffset="16-20" id="miRNA-corp.d53.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-110" id="miRNA-corp.d53.s4.e1" text="acute malaria" type="Diseases"/>
            <pair e1="miRNA-corp.d53.s4.e0" e2="miRNA-corp.d53.s4.e1" id="miRNA-corp.d53.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s5" origId="21422175.s4" text="We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150. ">
            <entity charOffset="20-25" id="miRNA-corp.d53.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-60" id="miRNA-corp.d53.s5.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="101-105" id="miRNA-corp.d53.s5.e2" text="let7i" type="Specific_miRNAs"/>
            <entity charOffset="108-114" id="miRNA-corp.d53.s5.e3" text="miR-27a" type="Specific_miRNAs"/>
            <entity charOffset="121-127" id="miRNA-corp.d53.s5.e4" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="95-98" id="miRNA-corp.d53.s5.e5" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s6" origId="21422175.s3" text="The differential expression profiles of selected miRNAs (let-7i, miR-27a, miR-150, miR-126, miR-210, and miR-155) were analyzed in mouse brain and heart tissue by quantitative reverse transcription-PCR (qRT-PCR). ">
            <entity charOffset="49-54" id="miRNA-corp.d53.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-26" id="miRNA-corp.d53.s6.e1" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="57-62" id="miRNA-corp.d53.s6.e2" text="let-7i" type="Specific_miRNAs"/>
            <entity charOffset="65-71" id="miRNA-corp.d53.s6.e3" text="miR-27a" type="Specific_miRNAs"/>
            <entity charOffset="74-80" id="miRNA-corp.d53.s6.e4" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="83-89" id="miRNA-corp.d53.s6.e5" text="miR-126" type="Specific_miRNAs"/>
            <entity charOffset="92-98" id="miRNA-corp.d53.s6.e6" text="miR-210" type="Specific_miRNAs"/>
            <entity charOffset="105-111" id="miRNA-corp.d53.s6.e7" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="131-135" id="miRNA-corp.d53.s6.e8" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s7" origId="21422175.s9" text="Our data suggest that in the CBA mouse at least, miRNA may have a regulatory role in the pathogenesis of severe malaria.   ">
            <entity charOffset="49-53" id="miRNA-corp.d53.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-75" id="miRNA-corp.d53.s7.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="112-118" id="miRNA-corp.d53.s7.e2" text="malaria" type="Diseases"/>
            <entity charOffset="33-37" id="miRNA-corp.d53.s7.e3" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d53.s7.e0" e2="miRNA-corp.d53.s7.e2" id="miRNA-corp.d53.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s8" origId="21422175.s8" text="Overexpression of these three miRNAs during PbA, but not PbK, infection in WT mice may be critical for the triggering of the neurological syndrome via regulation of their potential downstream targets. ">
            <entity charOffset="30-35" id="miRNA-corp.d53.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="192-198" id="miRNA-corp.d53.s8.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="0-13" id="miRNA-corp.d53.s8.e2" text="Overexpression" type="Relation_Trigger"/>
            <entity charOffset="151-160" id="miRNA-corp.d53.s8.e3" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="62-70" id="miRNA-corp.d53.s8.e4" text="infection" type="Diseases"/>
            <entity charOffset="125-145" id="miRNA-corp.d53.s8.e5" text="neurological syndrome" type="Diseases"/>
            <entity charOffset="78-81" id="miRNA-corp.d53.s8.e6" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d53.s8.e0" e2="miRNA-corp.d53.s8.e4" id="miRNA-corp.d53.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s8.e0" e2="miRNA-corp.d53.s8.e5" id="miRNA-corp.d53.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d53.s9" origId="21422175.s7" text="The expression of let-7i, miR-27a, and miR-150 was unchanged in both wild-type (WT) and IFN-γ(-/-) mice following infection. ">
            <entity charOffset="88-90" id="miRNA-corp.d53.s9.e0" text="IFN" type="Genes/Proteins"/>
            <entity charOffset="18-23" id="miRNA-corp.d53.s9.e1" text="let-7i" type="Specific_miRNAs"/>
            <entity charOffset="26-32" id="miRNA-corp.d53.s9.e2" text="miR-27a" type="Specific_miRNAs"/>
            <entity charOffset="39-45" id="miRNA-corp.d53.s9.e3" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="114-122" id="miRNA-corp.d53.s9.e4" text="infection" type="Diseases"/>
            <entity charOffset="99-102" id="miRNA-corp.d53.s9.e5" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d53.s9.e1" e2="miRNA-corp.d53.s9.e0" id="miRNA-corp.d53.s9.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e1" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s9.e2" e2="miRNA-corp.d53.s9.e0" id="miRNA-corp.d53.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e2" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d53.s9.e3" e2="miRNA-corp.d53.s9.e0" id="miRNA-corp.d53.s9.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d53.s9.e3" e2="miRNA-corp.d53.s9.e4" id="miRNA-corp.d53.s9.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d54" origId="18541114">
        <sentence id="miRNA-corp.d54.s0" origId="18541114.s4" text="We also discuss the implications of these findings with respect to the involvement of miRNAs in the etiopathology of brain disorders and pinpoint the emerging therapeutic potential of miRNAs for the treatment of human diseases.   ">
            <entity charOffset="86-91" id="miRNA-corp.d54.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-189" id="miRNA-corp.d54.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-131" id="miRNA-corp.d54.s0.e2" text="brain disorders" type="Diseases"/>
            <entity charOffset="212-216" id="miRNA-corp.d54.s0.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d54.s0.e0" e2="miRNA-corp.d54.s0.e2" id="miRNA-corp.d54.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d54.s0.e1" e2="miRNA-corp.d54.s0.e2" id="miRNA-corp.d54.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s1" origId="18541114.s2" text="They are now thought to be involved in the control of about one third of all protein-coding genes and play a role in the majority of cellular processes that have been studied. "/>
        <sentence id="miRNA-corp.d54.s2" origId="18541114.s3" text="We focus on the role of the miRNA pathway in brain development, function, and disease by highlighting recent observations with respect to miRNA-mediated gene regulation in neuronal differentiation, synaptic plasticity, and the circadian clock. ">
            <entity charOffset="158-167" id="miRNA-corp.d54.s2.e0" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="138-142" id="miRNA-corp.d54.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-32" id="miRNA-corp.d54.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s3" origId="18541114.s0" text="MicroRNAs in brain function and disease.  ">
            <entity charOffset="0-8" id="miRNA-corp.d54.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d54.s4" origId="18541114.s1" text="MicroRNAs (miRNAs), a class of small, non-protein-coding transcripts about 21 nucleotides long, have recently entered center stage in the study of posttranscriptional gene regulation. ">
            <entity charOffset="0-8" id="miRNA-corp.d54.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d54.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="172-181" id="miRNA-corp.d54.s4.e2" text="regulation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d55" origId="12082608">
        <sentence id="miRNA-corp.d55.s0" origId="12082608.s3" text="In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the Tet-On system for p53 in the LN-Z308 glioblastoma cell line. ">
            <entity charOffset="140-151" id="miRNA-corp.d55.s0.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="55-57" id="miRNA-corp.d55.s0.e1" text="p53" type="Genes/Proteins"/>
            <entity charOffset="75-81" id="miRNA-corp.d55.s0.e2" text="gliomas" type="Diseases"/>
            <entity charOffset="121-123" id="miRNA-corp.d55.s0.e3" text="p53" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s1" origId="12082608.s2" text="p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis. ">
            <entity charOffset="7-15" id="miRNA-corp.d55.s1.e0" text="activated" type="Relation_Trigger"/>
            <entity charOffset="0-2" id="miRNA-corp.d55.s1.e1" text="p53" type="Genes/Proteins"/>
            <entity charOffset="161-170" id="miRNA-corp.d55.s1.e2" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s2" origId="12082608.s5" text="Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines. ">
            <entity charOffset="97-108" id="miRNA-corp.d55.s2.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="59-63" id="miRNA-corp.d55.s2.e1" text="MIC-1" type="Genes/Proteins"/>
            <entity charOffset="71-76" id="miRNA-corp.d55.s2.e2" text="anoxia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s3" origId="12082608.s4" text="The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling. ">
            <entity charOffset="89-94" id="miRNA-corp.d55.s3.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="4-35" id="miRNA-corp.d55.s3.e1" text="macrophage inhibitory cytokine-1" type="Genes/Proteins"/>
            <entity charOffset="38-42" id="miRNA-corp.d55.s3.e2" text="MIC-1" type="Genes/Proteins"/>
            <entity charOffset="85-87" id="miRNA-corp.d55.s3.e3" text="p53" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s4" origId="12082608.s7" text="Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected. ">
            <entity charOffset="35-39" id="miRNA-corp.d55.s4.e0" text="MIC-1" type="Genes/Proteins"/>
            <entity charOffset="13-30" id="miRNA-corp.d55.s4.e1" text="ectopic expression" type="Relation_Trigger"/>
            <entity charOffset="114-122" id="miRNA-corp.d55.s4.e2" text="nude mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s5" origId="12082608.s6" text="MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway. ">
            <entity charOffset="66-68" id="miRNA-corp.d55.s5.e0" text="p53" type="Genes/Proteins"/>
            <entity charOffset="0-4" id="miRNA-corp.d55.s5.e1" text="MIC-1" type="Genes/Proteins"/>
            <entity charOffset="23-28" id="miRNA-corp.d55.s5.e2" text="anoxia" type="Diseases"/>
            <entity charOffset="6-18" id="miRNA-corp.d55.s5.e3" text="up-regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s6" origId="12082608.s9" text="Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.   ">
            <entity charOffset="85-87" id="miRNA-corp.d55.s6.e0" text="p53" type="Genes/Proteins"/>
            <entity charOffset="40-44" id="miRNA-corp.d55.s6.e1" text="MIC-1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s7" origId="12082608.s8" text="In the present experimental model MIC-1 may exert its anti-tumorigenic properties via a paracrine mechanism mediated by host cells in vivo. ">
            <entity charOffset="34-38" id="miRNA-corp.d55.s7.e0" text="MIC-1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s8" origId="12082608.s1" text="Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression. ">
            <entity charOffset="62-77" id="miRNA-corp.d55.s8.e0" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="6-28" id="miRNA-corp.d55.s8.e1" text="astrocytic brain tumors" type="Diseases"/>
            <entity charOffset="58-60" id="miRNA-corp.d55.s8.e2" text="p53" type="Genes/Proteins"/>
            <entity charOffset="0-4" id="miRNA-corp.d55.s8.e3" text="Human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d55.s9" origId="12082608.s0" text="Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.  ">
            <entity charOffset="95-97" id="miRNA-corp.d55.s9.e0" text="p53" type="Genes/Proteins"/>
            <entity charOffset="15-46" id="miRNA-corp.d55.s9.e1" text="macrophage inhibitory cytokine-1" type="Genes/Proteins"/>
            <entity charOffset="49-53" id="miRNA-corp.d55.s9.e2" text="MIC-1" type="Genes/Proteins"/>
            <entity charOffset="0-5" id="miRNA-corp.d55.s9.e3" text="Anoxia" type="Diseases"/>
            <entity charOffset="59-70" id="miRNA-corp.d55.s9.e4" text="glioblastoma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d56" origId="21084719">
        <sentence id="miRNA-corp.d56.s0" origId="21084719.s7" text="This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse GLD model, providing a rationale to explore HSC-based gene therapy for GLD.   ">
            <entity charOffset="34-37" id="miRNA-corp.d56.s0.e0" text="GALC" type="Genes/Proteins"/>
            <entity charOffset="92-94" id="miRNA-corp.d56.s0.e1" text="GLD" type="Diseases"/>
            <entity charOffset="163-165" id="miRNA-corp.d56.s0.e2" text="GLD" type="Diseases"/>
            <entity charOffset="86-90" id="miRNA-corp.d56.s0.e3" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s1" origId="21084719.s1" text="Globoid cell leukodystrophy (GLD; also known as Krabbe disease) is an invariably fatal lysosomal storage disorder caused by mutations in the galactocerebrosidase (GALC) gene. ">
            <entity charOffset="0-26" id="miRNA-corp.d56.s1.e0" text="Globoid cell leukodystrophy" type="Diseases"/>
            <entity charOffset="29-31" id="miRNA-corp.d56.s1.e1" text="GLD" type="Diseases"/>
            <entity charOffset="48-61" id="miRNA-corp.d56.s1.e2" text="Krabbe disease" type="Diseases"/>
            <entity charOffset="141-160" id="miRNA-corp.d56.s1.e3" text="galactocerebrosidase" type="Genes/Proteins"/>
            <entity charOffset="163-166" id="miRNA-corp.d56.s1.e4" text="GALC" type="Genes/Proteins"/>
            <entity charOffset="81-112" id="miRNA-corp.d56.s1.e5" text="fatal lysosomal storage disorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s2" origId="21084719.s2" text="Hematopoietic stem cell (HSC)-based gene therapy is being explored for GLD; however, we found that forced GALC expression was toxic to HSCs and early progenitors, highlighting the need for improved regulation of vector expression. ">
            <entity charOffset="106-109" id="miRNA-corp.d56.s2.e0" text="GALC" type="Genes/Proteins"/>
            <entity charOffset="71-73" id="miRNA-corp.d56.s2.e1" text="GLD" type="Diseases"/>
            <entity charOffset="198-228" id="miRNA-corp.d56.s2.e2" text="regulation of vector expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s3" origId="21084719.s0" text="Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy.  ">
            <entity charOffset="51-56" id="miRNA-corp.d56.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-108" id="miRNA-corp.d56.s3.e1" text="globoid cell leukodystrophy" type="Diseases"/>
            <pair e1="miRNA-corp.d56.s3.e0" e2="miRNA-corp.d56.s3.e1" id="miRNA-corp.d56.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s4" origId="21084719.s5" text="Moreover, repopulating HSCs could be purified solely on the basis of miRNA expression, providing a new method relevant for human HSC isolation. ">
            <entity charOffset="69-73" id="miRNA-corp.d56.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="123-127" id="miRNA-corp.d56.s4.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s5" origId="21084719.s6" text="By incorporating miR-126 target sequences into a GALC-expressing vector, we suppressed GALC expression in HSCs while maintaining robust expression in mature hematopoietic cells. ">
            <entity charOffset="76-101" id="miRNA-corp.d56.s5.e0" text="suppressed GALC expression" type="Relation_Trigger"/>
            <entity charOffset="17-23" id="miRNA-corp.d56.s5.e1" text="miR-126" type="Specific_miRNAs"/>
            <entity charOffset="87-90" id="miRNA-corp.d56.s5.e2" text="GALC" type="Genes/Proteins"/>
            <entity charOffset="25-30" id="miRNA-corp.d56.s5.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="87-90" id="miRNA-corp.d56.s5.e4" text="GALC" type="Genes/Proteins"/>
            <entity charOffset="49-52" id="miRNA-corp.d56.s5.e5" text="GALC" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s5.e1" e2="miRNA-corp.d56.s5.e2" id="miRNA-corp.d56.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s5.e1" e2="miRNA-corp.d56.s5.e4" id="miRNA-corp.d56.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d56.s5.e1" e2="miRNA-corp.d56.s5.e5" id="miRNA-corp.d56.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s6" origId="21084719.s3" text="We used a genetic reporter strategy based on lentiviral vectors to detect microRNA activity in hematopoietic cells at single-cell resolution. ">
            <entity charOffset="74-81" id="miRNA-corp.d56.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d56.s7" origId="21084719.s4" text="We report that miR-126 and miR-130a were expressed in HSCs and early progenitors from both mice and humans, but not in differentiated progeny. ">
            <entity charOffset="15-21" id="miRNA-corp.d56.s7.e0" text="miR-126" type="Specific_miRNAs"/>
            <entity charOffset="27-34" id="miRNA-corp.d56.s7.e1" text="miR-130a" type="Specific_miRNAs"/>
            <entity charOffset="91-94" id="miRNA-corp.d56.s7.e2" text="mice" type="Species"/>
            <entity charOffset="100-105" id="miRNA-corp.d56.s7.e3" text="humans" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d57" origId="11914277">
        <sentence id="miRNA-corp.d57.s0" origId="11914277.s7" text="The genomic sequences predict that miRNAs are likely to be derived from larger precursors that have the capacity to form stem-loop structures.  ">
            <entity charOffset="35-40" id="miRNA-corp.d57.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s1" origId="11914277.s4" text="Here we report that Gemin3 and Gemin4 are also in a separate complex that contains eIF2C2, a member of the Argonaute protein family. ">
            <entity charOffset="20-25" id="miRNA-corp.d57.s1.e0" text="Gemin3" type="Genes/Proteins"/>
            <entity charOffset="31-36" id="miRNA-corp.d57.s1.e1" text="Gemin4" type="Genes/Proteins"/>
            <entity charOffset="83-88" id="miRNA-corp.d57.s1.e2" text="eIF2C2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s2" origId="11914277.s3" text="The SMN complex has critical functions in the assembly/restructuring of diverse ribonucleoprotein (RNP) complexes. "/>
        <sentence id="miRNA-corp.d57.s3" origId="11914277.s6" text="We describe 40 miRNAs, a few of which are identical to recently described human miRNAs, a class of small endogenous RNAs. ">
            <entity charOffset="15-20" id="miRNA-corp.d57.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-85" id="miRNA-corp.d57.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-78" id="miRNA-corp.d57.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s4" origId="11914277.s5" text="This novel complex is a large approximately 15S RNP that contains numerous microRNAs (miRNAs). ">
            <entity charOffset="75-83" id="miRNA-corp.d57.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-91" id="miRNA-corp.d57.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s5" origId="11914277.s0" text="miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs.  ">
            <entity charOffset="64-72" id="miRNA-corp.d57.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s6" origId="11914277.s2" text="Reduction in SMN protein results in Spinal muscular atrophy (SMA), a common neurodegenerative disease. ">
            <entity charOffset="36-58" id="miRNA-corp.d57.s6.e0" text="Spinal muscular atrophy" type="Diseases"/>
            <entity charOffset="61-63" id="miRNA-corp.d57.s6.e1" text="SMA" type="Diseases"/>
            <entity charOffset="76-100" id="miRNA-corp.d57.s6.e2" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="0-23" id="miRNA-corp.d57.s6.e3" text="Reduction in SMN protein" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d57.s7" origId="11914277.s1" text="Gemin3 is a DEAD-box RNA helicase that binds to the Survival of Motor Neurons (SMN) protein and is a component of the SMN complex, which also comprises SMN, Gemin2, Gemin4, Gemin5, and Gemin6. ">
            <entity charOffset="157-162" id="miRNA-corp.d57.s7.e0" text="Gemin2" type="Genes/Proteins"/>
            <entity charOffset="165-170" id="miRNA-corp.d57.s7.e1" text="Gemin4" type="Genes/Proteins"/>
            <entity charOffset="173-178" id="miRNA-corp.d57.s7.e2" text="Gemin5" type="Genes/Proteins"/>
            <entity charOffset="185-190" id="miRNA-corp.d57.s7.e3" text="Gemin6" type="Genes/Proteins"/>
            <entity charOffset="12-32" id="miRNA-corp.d57.s7.e4" text="DEAD-box RNA helicase" type="Genes/Proteins"/>
            <entity charOffset="0-5" id="miRNA-corp.d57.s7.e5" text="Gemin3" type="Genes/Proteins"/>
            <entity charOffset="39-43" id="miRNA-corp.d57.s7.e6" text="binds" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d58" origId="20616011">
        <sentence id="miRNA-corp.d58.s0" origId="20616011.s1" text="Defective RNA metabolism is an emerging mechanism involved in ALS pathogenesis and possibly in other neurodegenerative disorders. ">
            <entity charOffset="62-64" id="miRNA-corp.d58.s0.e0" text="ALS" type="Diseases"/>
            <entity charOffset="101-127" id="miRNA-corp.d58.s0.e1" text="neurodegenerative disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s1" origId="20616011.s0" text="miRNA malfunction causes spinal motor neuron disease.  ">
            <entity charOffset="0-4" id="miRNA-corp.d58.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="25-51" id="miRNA-corp.d58.s1.e1" text="spinal motor neuron disease" type="Diseases"/>
            <pair e1="miRNA-corp.d58.s1.e0" e2="miRNA-corp.d58.s1.e1" id="miRNA-corp.d58.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s2" origId="20616011.s3" text="Thus, mice that do not process miRNA in SMNs exhibit hallmarks of spinal muscular atrophy (SMA), including sclerosis of the spinal cord ventral horns, aberrant end plate architecture, and myofiber atrophy with signs of denervation. ">
            <entity charOffset="66-88" id="miRNA-corp.d58.s2.e0" text="spinal muscular atrophy" type="Diseases"/>
            <entity charOffset="91-93" id="miRNA-corp.d58.s2.e1" text="SMA" type="Diseases"/>
            <entity charOffset="31-35" id="miRNA-corp.d58.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-148" id="miRNA-corp.d58.s2.e3" text="sclerosis of the spinal cord ventral horns" type="Diseases"/>
            <entity charOffset="197-203" id="miRNA-corp.d58.s2.e4" text="atrophy" type="Diseases"/>
            <entity charOffset="6-9" id="miRNA-corp.d58.s2.e5" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d58.s2.e2" e2="miRNA-corp.d58.s2.e0" id="miRNA-corp.d58.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d58.s2.e2" e2="miRNA-corp.d58.s2.e1" id="miRNA-corp.d58.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d58.s2.e2" e2="miRNA-corp.d58.s2.e3" id="miRNA-corp.d58.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d58.s2.e2" e2="miRNA-corp.d58.s2.e4" id="miRNA-corp.d58.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s3" origId="20616011.s2" text="Here, we show that microRNA (miRNA) activity is essential for long-term survival of postmitotic spinal motor neurons (SMNs) in vivo. ">
            <entity charOffset="19-26" id="miRNA-corp.d58.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="29-33" id="miRNA-corp.d58.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s4" origId="20616011.s5" text="We demonstrate that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA. ">
            <entity charOffset="67-71" id="miRNA-corp.d58.s4.e0" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="140-142" id="miRNA-corp.d58.s4.e1" text="SMA" type="Diseases"/>
            <entity charOffset="76-80" id="miRNA-corp.d58.s4.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d58.s4.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="103-116" id="miRNA-corp.d58.s4.e4" text="down-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d58.s4.e0" e2="miRNA-corp.d58.s4.e1" id="miRNA-corp.d58.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d58.s4.e2" e2="miRNA-corp.d58.s4.e1" id="miRNA-corp.d58.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s5" origId="20616011.s4" text="Furthermore, a neurofilament heavy subunit previously implicated in motor neuron degeneration is specifically up-regulated in miRNA-deficient SMNs. ">
            <entity charOffset="126-130" id="miRNA-corp.d58.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-121" id="miRNA-corp.d58.s5.e1" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="68-92" id="miRNA-corp.d58.s5.e2" text="motor neuron degeneration" type="Diseases"/>
            <pair e1="miRNA-corp.d58.s5.e0" e2="miRNA-corp.d58.s5.e2" id="miRNA-corp.d58.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d58.s6" origId="20616011.s6" text="These data provide evidence for miRNA function in SMN diseases and emphasize the potential role of miR-9-based regulatory mechanisms in adult neurons and neurodegenerative states.   ">
            <entity charOffset="32-36" id="miRNA-corp.d58.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-103" id="miRNA-corp.d58.s6.e1" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="50-61" id="miRNA-corp.d58.s6.e2" text="SMN diseases" type="Diseases"/>
            <entity charOffset="111-120" id="miRNA-corp.d58.s6.e3" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d58.s6.e0" e2="miRNA-corp.d58.s6.e2" id="miRNA-corp.d58.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d58.s6.e1" e2="miRNA-corp.d58.s6.e2" id="miRNA-corp.d58.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d59" origId="20125089">
        <sentence id="miRNA-corp.d59.s0" origId="20125089.s0" text="Novel animal models for studying complex brain disorders: BAC-driven miRNA-mediated in vivo silencing of gene expression.  ">
            <entity charOffset="41-55" id="miRNA-corp.d59.s0.e0" text="brain disorders" type="Diseases"/>
            <entity charOffset="69-73" id="miRNA-corp.d59.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d59.s0.e1" e2="miRNA-corp.d59.s0.e0" id="miRNA-corp.d59.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s1" origId="20125089.s1" text="In schizophrenia, glutamic acid decarboxylase 1 (GAD1) disturbances are robust, consistently observed, cell-type specific and represent a core feature of the disease. ">
            <entity charOffset="3-15" id="miRNA-corp.d59.s1.e0" text="schizophrenia" type="Diseases"/>
            <entity charOffset="18-46" id="miRNA-corp.d59.s1.e1" text="glutamic acid decarboxylase 1" type="Genes/Proteins"/>
            <entity charOffset="49-52" id="miRNA-corp.d59.s1.e2" text="GAD1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s2" origId="20125089.s2" text="In addition, neuropeptide Y (NPY), which is a phenotypic marker of a sub-population of GAD1-containing interneurons, has shown reduced expression in the prefrontal cortex in subjects with schizophrenia, suggesting that dysfunction of the NPY+ cortical interneuronal sub-population might be a core feature of this devastating disorder. ">
            <entity charOffset="188-200" id="miRNA-corp.d59.s2.e0" text="schizophrenia" type="Diseases"/>
            <entity charOffset="87-90" id="miRNA-corp.d59.s2.e1" text="GAD1" type="Genes/Proteins"/>
            <entity charOffset="127-144" id="miRNA-corp.d59.s2.e2" text="reduced expression" type="Relation_Trigger"/>
            <entity charOffset="219-229" id="miRNA-corp.d59.s2.e3" text="dysfunction" type="Relation_Trigger"/>
            <entity charOffset="13-26" id="miRNA-corp.d59.s2.e4" text="neuropeptide Y" type="Genes/Proteins"/>
            <entity charOffset="29-31" id="miRNA-corp.d59.s2.e5" text="NPY" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s3" origId="20125089.s3" text="However, modeling gene expression disturbances in schizophrenia in a cell type-specific manner has been extremely challenging. ">
            <entity charOffset="50-62" id="miRNA-corp.d59.s3.e0" text="schizophrenia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s4" origId="20125089.s4" text="To more closely mimic these molecular and cellular human post-mortem findings, we generated a transgenic mouse in which we downregulated GAD1 mRNA expression specifically in NPY+ neurons. ">
            <entity charOffset="137-140" id="miRNA-corp.d59.s4.e0" text="GAD1" type="Genes/Proteins"/>
            <entity charOffset="123-156" id="miRNA-corp.d59.s4.e1" text="downregulated GAD1 mRNA expression" type="Relation_Trigger"/>
            <entity charOffset="174-176" id="miRNA-corp.d59.s4.e2" text="NPY" type="Genes/Proteins"/>
            <entity charOffset="51-55" id="miRNA-corp.d59.s4.e3" text="human" type="Species"/>
            <entity charOffset="94-109" id="miRNA-corp.d59.s4.e4" text="transgenic mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s5" origId="20125089.s5" text="This novel, cell type-specific in vivo system for reducing gene expression uses a bacterial artificial chromosome (BAC) containing the NPY promoter-enhancer elements, the reporter molecule (eGFP) and a modified intron containing a synthetic microRNA (miRNA) targeted to GAD1. ">
            <entity charOffset="241-248" id="miRNA-corp.d59.s5.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="251-255" id="miRNA-corp.d59.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="270-273" id="miRNA-corp.d59.s5.e2" text="GAD1" type="Genes/Proteins"/>
            <entity charOffset="50-73" id="miRNA-corp.d59.s5.e3" text="reducing gene expression" type="Relation_Trigger"/>
            <entity charOffset="135-137" id="miRNA-corp.d59.s5.e4" text="NPY" type="Genes/Proteins"/>
            <entity charOffset="258-265" id="miRNA-corp.d59.s5.e5" text="targeted" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d59.s5.e0" e2="miRNA-corp.d59.s5.e2" id="miRNA-corp.d59.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d59.s5.e0" e2="miRNA-corp.d59.s5.e4" id="miRNA-corp.d59.s5.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d59.s5.e1" e2="miRNA-corp.d59.s5.e2" id="miRNA-corp.d59.s5.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d59.s5.e1" e2="miRNA-corp.d59.s5.e4" id="miRNA-corp.d59.s5.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s6" origId="20125089.s6" text="The animals of isogenic strains are generated rapidly, providing a new tool for better understanding the molecular disturbances in the GABAergic system observed in complex neuropsychiatric disorders such as schizophrenia. ">
            <entity charOffset="172-197" id="miRNA-corp.d59.s6.e0" text="neuropsychiatric disorders" type="Diseases"/>
            <entity charOffset="207-219" id="miRNA-corp.d59.s6.e1" text="schizophrenia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d59.s7" origId="20125089.s7" text="In the future, because of the small size of the silencing miRNAs combined with our BAC strategy, this method may be modified to allow generation of mice with simultaneous silencing of multiple genes in the same cells with a single construct, and production of splice-variant-specific knockdown animals.   ">
            <entity charOffset="58-63" id="miRNA-corp.d59.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="148-151" id="miRNA-corp.d59.s7.e1" text="mice" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d60" origId="18986979">
        <sentence id="miRNA-corp.d60.s0" origId="18986979.s5" text="Through various experimental approaches, we validated computational predictions and demonstrated that miR-298 and miR-328 recognize specific binding sites in the 3'-UTR of BACE1 mRNA and exert regulatory effects on BACE1 protein expression in cultured neuronal cells. ">
            <entity charOffset="215-219" id="miRNA-corp.d60.s0.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="114-120" id="miRNA-corp.d60.s0.e1" text="miR-328" type="Specific_miRNAs"/>
            <entity charOffset="172-176" id="miRNA-corp.d60.s0.e2" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="102-108" id="miRNA-corp.d60.s0.e3" text="miR-298" type="Specific_miRNAs"/>
            <entity charOffset="193-238" id="miRNA-corp.d60.s0.e4" text="regulatory effects on BACE1 protein expression" type="Relation_Trigger"/>
            <entity charOffset="122-167" id="miRNA-corp.d60.s0.e5" text="recognize specific binding sites in the 3'-UTR" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d60.s0.e1" e2="miRNA-corp.d60.s0.e0" id="miRNA-corp.d60.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s0.e1" e2="miRNA-corp.d60.s0.e2" id="miRNA-corp.d60.s0.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s0.e3" e2="miRNA-corp.d60.s0.e0" id="miRNA-corp.d60.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s0.e3" e2="miRNA-corp.d60.s0.e2" id="miRNA-corp.d60.s0.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s1" origId="18986979.s4" text="Here we also observed a loss of correlation between BACE1 mRNA and protein levels in the hippocampus of a mouse model of AD. Consistent with an impairment of miRNA-mediated regulation of BACE1 expression, these findings prompted us to investigate the regulatory role of the BACE1 3'-UTR element and the possible involvement of specific miRNAs in cultured neuronal (N2a) and fibroblastic (NIH 3T3) cells. ">
            <entity charOffset="121-122" id="miRNA-corp.d60.s1.e0" text="AD" type="Diseases"/>
            <entity charOffset="274-278" id="miRNA-corp.d60.s1.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="158-162" id="miRNA-corp.d60.s1.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="336-341" id="miRNA-corp.d60.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-42" id="miRNA-corp.d60.s1.e4" text="loss of correlation" type="Relation_Trigger"/>
            <entity charOffset="173-202" id="miRNA-corp.d60.s1.e5" text="regulation of BACE1 expression" type="Relation_Trigger"/>
            <entity charOffset="251-260" id="miRNA-corp.d60.s1.e6" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="187-191" id="miRNA-corp.d60.s1.e7" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="52-56" id="miRNA-corp.d60.s1.e8" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="144-153" id="miRNA-corp.d60.s1.e9" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="106-110" id="miRNA-corp.d60.s1.e10" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d60.s1.e2" e2="miRNA-corp.d60.s1.e1" id="miRNA-corp.d60.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e2" e2="miRNA-corp.d60.s1.e7" id="miRNA-corp.d60.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e2" e2="miRNA-corp.d60.s1.e8" id="miRNA-corp.d60.s1.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e2" e2="miRNA-corp.d60.s1.e0" id="miRNA-corp.d60.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d60.s1.e3" e2="miRNA-corp.d60.s1.e1" id="miRNA-corp.d60.s1.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e3" e2="miRNA-corp.d60.s1.e7" id="miRNA-corp.d60.s1.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e3" e2="miRNA-corp.d60.s1.e8" id="miRNA-corp.d60.s1.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d60.s1.e3" e2="miRNA-corp.d60.s1.e0" id="miRNA-corp.d60.s1.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s2" origId="18986979.s6" text="Our results may provide the molecular basis underlying BACE1 deregulation in AD and offer new perspectives on the etiology of this neurological disorder.   ">
            <entity charOffset="77-78" id="miRNA-corp.d60.s2.e0" text="AD" type="Diseases"/>
            <entity charOffset="55-59" id="miRNA-corp.d60.s2.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="61-72" id="miRNA-corp.d60.s2.e2" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="131-151" id="miRNA-corp.d60.s2.e3" text="neurological disorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s3" origId="18986979.s1" text="MicroRNAs (miRNAs) are key regulatory RNAs known to repress mRNA translation through recognition of specific binding sites located mainly in their 3'-untranslated region (UTR). ">
            <entity charOffset="0-8" id="miRNA-corp.d60.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d60.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-75" id="miRNA-corp.d60.s3.e2" text="repress mRNA translation" type="Relation_Trigger"/>
            <entity charOffset="27-36" id="miRNA-corp.d60.s3.e3" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="109-121" id="miRNA-corp.d60.s3.e4" text="binding sites" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s4" origId="18986979.s0" text="MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1.  ">
            <entity charOffset="0-11" id="miRNA-corp.d60.s4.e0" text="MicroRNA-298" type="Specific_miRNAs"/>
            <entity charOffset="17-28" id="miRNA-corp.d60.s4.e1" text="microRNA-328" type="Specific_miRNAs"/>
            <entity charOffset="30-48" id="miRNA-corp.d60.s4.e2" text="regulate expression" type="Relation_Trigger"/>
            <entity charOffset="53-57" id="miRNA-corp.d60.s4.e3" text="mouse" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s5" origId="18986979.s3" text="Intriguingly, previous post-mortem analyses showed higher beta-amyloid precursor protein-converting enzyme (BACE) protein, but not mRNA, levels in the brain of patients that suffered from Alzheimer disease (AD). ">
            <entity charOffset="188-204" id="miRNA-corp.d60.s5.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="207-208" id="miRNA-corp.d60.s5.e1" text="AD" type="Diseases"/>
            <entity charOffset="51-120" id="miRNA-corp.d60.s5.e2" text="higher beta-amyloid precursor protein-converting enzyme (BACE) protein" type="Relation_Trigger"/>
            <entity charOffset="58-120" id="miRNA-corp.d60.s5.e3" text="beta-amyloid precursor protein-converting enzyme (BACE) protein" type="Genes/Proteins"/>
            <entity charOffset="108-111" id="miRNA-corp.d60.s5.e4" text="BACE" type="Genes/Proteins"/>
            <entity charOffset="160-167" id="miRNA-corp.d60.s5.e5" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d60.s6" origId="18986979.s2" text="Loss of specific miRNA control of gene expression is thus expected to underlie serious genetic diseases. ">
            <entity charOffset="17-21" id="miRNA-corp.d60.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-21" id="miRNA-corp.d60.s6.e1" text="Loss of specific miRNA" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d61" origId="21376023">
        <sentence id="miRNA-corp.d61.s0" origId="21376023.s2" text="MiRNAs microarray analysis results showed that 125 miRNAs were detected in the hippocampus of lithium-pilocarpine-induced TLE rats and normal rats. ">
            <entity charOffset="0-5" id="miRNA-corp.d61.s0.e0" text="MiRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-56" id="miRNA-corp.d61.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-124" id="miRNA-corp.d61.s0.e2" text="TLE" type="Diseases"/>
            <entity charOffset="126-129" id="miRNA-corp.d61.s0.e3" text="rats" type="Species"/>
            <entity charOffset="142-145" id="miRNA-corp.d61.s0.e4" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d61.s0.e0" e2="miRNA-corp.d61.s0.e2" id="miRNA-corp.d61.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s0.e1" e2="miRNA-corp.d61.s0.e2" id="miRNA-corp.d61.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s1" origId="21376023.s1" text="To understand the role of miRNAs in the molecular mechanisms of temporal lobe epilepsy (TLE), we investigated the changes in microRNA (miRNA) expression profiles of chronic TLE rat models. ">
            <entity charOffset="26-31" id="miRNA-corp.d61.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="125-132" id="miRNA-corp.d61.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-139" id="miRNA-corp.d61.s1.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-85" id="miRNA-corp.d61.s1.e3" text="temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="88-90" id="miRNA-corp.d61.s1.e4" text="TLE" type="Diseases"/>
            <entity charOffset="173-175" id="miRNA-corp.d61.s1.e5" text="TLE" type="Diseases"/>
            <entity charOffset="177-179" id="miRNA-corp.d61.s1.e6" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d61.s1.e2" e2="miRNA-corp.d61.s1.e3" id="miRNA-corp.d61.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e2" e2="miRNA-corp.d61.s1.e4" id="miRNA-corp.d61.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e2" e2="miRNA-corp.d61.s1.e5" id="miRNA-corp.d61.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e0" e2="miRNA-corp.d61.s1.e3" id="miRNA-corp.d61.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e0" e2="miRNA-corp.d61.s1.e4" id="miRNA-corp.d61.s1.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e0" e2="miRNA-corp.d61.s1.e5" id="miRNA-corp.d61.s1.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e1" e2="miRNA-corp.d61.s1.e3" id="miRNA-corp.d61.s1.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e1" e2="miRNA-corp.d61.s1.e4" id="miRNA-corp.d61.s1.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s1.e1" e2="miRNA-corp.d61.s1.e5" id="miRNA-corp.d61.s1.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s2" origId="21376023.s0" text="Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b.  ">
            <entity charOffset="98-106" id="miRNA-corp.d61.s2.e0" text="miR-23a/b" type="Specific_miRNAs"/>
            <entity charOffset="70-75" id="miRNA-corp.d61.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-21" id="miRNA-corp.d61.s2.e2" text="Temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="87-92" id="miRNA-corp.d61.s2.e3" text="let-7e" type="Specific_miRNAs"/>
            <entity charOffset="23-53" id="miRNA-corp.d61.s2.e4" text="induces differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d61.s2.e0" e2="miRNA-corp.d61.s2.e2" id="miRNA-corp.d61.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s2.e3" e2="miRNA-corp.d61.s2.e2" id="miRNA-corp.d61.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s2.e1" e2="miRNA-corp.d61.s2.e2" id="miRNA-corp.d61.s2.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s3" origId="21376023.s5" text="let-7e was detected down-regulated expression at 0h, 1h, 6h, 2days, 7days, 50days after SE and up-regulated expression at 12h, 24h, 10days, 30days after SE, which was significantly up-regulated expression at 24h after SE (10.49 folds, P&lt;0.01). ">
            <entity charOffset="0-5" id="miRNA-corp.d61.s3.e0" text="let-7e" type="Specific_miRNAs"/>
            <entity charOffset="20-44" id="miRNA-corp.d61.s3.e1" text="down-regulated expression" type="Relation_Trigger"/>
            <entity charOffset="95-117" id="miRNA-corp.d61.s3.e2" text="up-regulated expression" type="Relation_Trigger"/>
            <entity charOffset="218-219" id="miRNA-corp.d61.s3.e3" text="SE" type="Diseases"/>
            <entity charOffset="88-89" id="miRNA-corp.d61.s3.e4" text="SE" type="Diseases"/>
            <entity charOffset="153-154" id="miRNA-corp.d61.s3.e5" text="SE" type="Diseases"/>
            <entity charOffset="181-203" id="miRNA-corp.d61.s3.e6" text="up-regulated expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d61.s3.e0" e2="miRNA-corp.d61.s3.e3" id="miRNA-corp.d61.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e0" e2="miRNA-corp.d61.s3.e4" id="miRNA-corp.d61.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s3.e0" e2="miRNA-corp.d61.s3.e5" id="miRNA-corp.d61.s3.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s4" origId="21376023.s6" text="miR-23a/b was detected down-regulated at 0h, 1h, 6h, 12h, 2days, 7days, 10days, 30days after SE and significantly up-regulated at 24h (4.49 folds P&lt;0.01), 50d (2.4 folds, P&lt;0.01) after SE. TLE alters the expression levels of a subset of miRNAs in the hippocampus and these deregulated miRNAs may be involved in the pathogenesis of epilepsy directly or indirectly. ">
            <entity charOffset="0-8" id="miRNA-corp.d61.s4.e0" text="miR-23a/b" type="Specific_miRNAs"/>
            <entity charOffset="237-242" id="miRNA-corp.d61.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="285-290" id="miRNA-corp.d61.s4.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="331-338" id="miRNA-corp.d61.s4.e3" text="epilepsy" type="Diseases"/>
            <entity charOffset="23-36" id="miRNA-corp.d61.s4.e4" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="193-220" id="miRNA-corp.d61.s4.e5" text="alters the expression levels" type="Relation_Trigger"/>
            <entity charOffset="273-283" id="miRNA-corp.d61.s4.e6" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="189-191" id="miRNA-corp.d61.s4.e7" text="TLE" type="Diseases"/>
            <entity charOffset="185-186" id="miRNA-corp.d61.s4.e8" text="SE" type="Diseases"/>
            <entity charOffset="93-94" id="miRNA-corp.d61.s4.e9" text="SE" type="Diseases"/>
            <entity charOffset="114-125" id="miRNA-corp.d61.s4.e10" text="up-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d61.s4.e1" e2="miRNA-corp.d61.s4.e3" id="miRNA-corp.d61.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e1" e2="miRNA-corp.d61.s4.e7" id="miRNA-corp.d61.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e1" e2="miRNA-corp.d61.s4.e8" id="miRNA-corp.d61.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e1" e2="miRNA-corp.d61.s4.e9" id="miRNA-corp.d61.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e2" e2="miRNA-corp.d61.s4.e3" id="miRNA-corp.d61.s4.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e2" e2="miRNA-corp.d61.s4.e7" id="miRNA-corp.d61.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e2" e2="miRNA-corp.d61.s4.e8" id="miRNA-corp.d61.s4.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e2" e2="miRNA-corp.d61.s4.e9" id="miRNA-corp.d61.s4.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e0" e2="miRNA-corp.d61.s4.e3" id="miRNA-corp.d61.s4.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e0" e2="miRNA-corp.d61.s4.e7" id="miRNA-corp.d61.s4.p9" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e0" e2="miRNA-corp.d61.s4.e8" id="miRNA-corp.d61.s4.p10" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s4.e0" e2="miRNA-corp.d61.s4.e9" id="miRNA-corp.d61.s4.p11" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s5" origId="21376023.s3" text="Compared with normal rats (control group), 23 of the 125 miRNAs were expressed differentially in TLE rats including 5 down-regulated miRNAs (let-7e included) and 18 up-regulated miRNAs (miR-23a/b included). ">
            <entity charOffset="186-194" id="miRNA-corp.d61.s5.e0" text="miR-23a/b" type="Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d61.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-138" id="miRNA-corp.d61.s5.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="178-183" id="miRNA-corp.d61.s5.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-92" id="miRNA-corp.d61.s5.e4" text="expressed differentially" type="Relation_Trigger"/>
            <entity charOffset="118-131" id="miRNA-corp.d61.s5.e5" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="165-176" id="miRNA-corp.d61.s5.e6" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="141-146" id="miRNA-corp.d61.s5.e7" text="let-7e" type="Specific_miRNAs"/>
            <entity charOffset="97-99" id="miRNA-corp.d61.s5.e8" text="TLE" type="Diseases"/>
            <entity charOffset="21-24" id="miRNA-corp.d61.s5.e9" text="rats" type="Species"/>
            <entity charOffset="101-104" id="miRNA-corp.d61.s5.e10" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d61.s5.e1" e2="miRNA-corp.d61.s5.e8" id="miRNA-corp.d61.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e2" e2="miRNA-corp.d61.s5.e8" id="miRNA-corp.d61.s5.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e3" e2="miRNA-corp.d61.s5.e8" id="miRNA-corp.d61.s5.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e7" e2="miRNA-corp.d61.s5.e8" id="miRNA-corp.d61.s5.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s5.e0" e2="miRNA-corp.d61.s5.e8" id="miRNA-corp.d61.s5.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s6" origId="21376023.s4" text="Furthermore, let-7e and miR-23a/b analysis in rat hippocampus were performed by real-time quantitative polymerase chain reaction at 0h, 1h, 6h, 12h, 24h, 2days, 7days,10days, 30days,50days after induction of status epilepticus (SE). ">
            <entity charOffset="24-32" id="miRNA-corp.d61.s6.e0" text="miR-23a/b" type="Specific_miRNAs"/>
            <entity charOffset="208-225" id="miRNA-corp.d61.s6.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="228-229" id="miRNA-corp.d61.s6.e2" text="SE" type="Diseases"/>
            <entity charOffset="13-18" id="miRNA-corp.d61.s6.e3" text="let-7e" type="Specific_miRNAs"/>
            <entity charOffset="46-48" id="miRNA-corp.d61.s6.e4" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d61.s6.e0" e2="miRNA-corp.d61.s6.e1" id="miRNA-corp.d61.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e0" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e3" e2="miRNA-corp.d61.s6.e1" id="miRNA-corp.d61.s6.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s6.e3" e2="miRNA-corp.d61.s6.e2" id="miRNA-corp.d61.s6.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d61.s7" origId="21376023.s7" text="Also the temporal change of the let-7e and miR-23a/b expression in the epileptogenesis indicated their underlying functions on TLE.   ">
            <entity charOffset="32-37" id="miRNA-corp.d61.s7.e0" text="let-7e" type="Specific_miRNAs"/>
            <entity charOffset="43-51" id="miRNA-corp.d61.s7.e1" text="miR-23a/b" type="Specific_miRNAs"/>
            <entity charOffset="127-129" id="miRNA-corp.d61.s7.e2" text="TLE" type="Diseases"/>
            <entity charOffset="18-62" id="miRNA-corp.d61.s7.e3" text="change of the let-7e and miR-23a/b expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d61.s7.e0" e2="miRNA-corp.d61.s7.e2" id="miRNA-corp.d61.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d61.s7.e1" e2="miRNA-corp.d61.s7.e2" id="miRNA-corp.d61.s7.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d62" origId="19670632">
        <sentence id="miRNA-corp.d62.s0" origId="19670632.s2" text="However, prior to expression, it is necessary to convert the single-stranded DNA genome into double-stranded DNA, which hinders the efficiency of these vectors. "/>
        <sentence id="miRNA-corp.d62.s1" origId="19670632.s1" text="Numerous studies and clinical trials have demonstrated the efficacy of recombinant adeno-associated virus gene delivery vectors. "/>
        <sentence id="miRNA-corp.d62.s2" origId="19670632.s0" text="[Trends in development of self-complementary adeno-associated virus vector].  "/>
        <sentence id="miRNA-corp.d62.s3" origId="19670632.s3" text="We can entirely circumvent this step through the use of self-complementary recombinant adeno-associated virus vector (scrAAV). "/>
        <sentence id="miRNA-corp.d62.s4" origId="19670632.s4" text="ScrAAV packages an inverted repeat genome that can fold into double-stranded DNA without the requirement for DNA synthesis or base-pairing between multiple vector genomes. "/>
        <sentence id="miRNA-corp.d62.s5" origId="19670632.s5" text="By using scrAAV, we could increase expression efficiency and reduce immune response caused by vectors themselves. ">
            <entity charOffset="26-44" id="miRNA-corp.d62.s5.e0" text="increase expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s6" origId="19670632.s6" text="Therefore, it is a promising vector for gene therapy. "/>
        <sentence id="miRNA-corp.d62.s7" origId="19670632.s7" text="So far, it has been used in the treatment of hepatic diseases, central nervous system diseases, and eye diseases. ">
            <entity charOffset="63-93" id="miRNA-corp.d62.s7.e0" text="central nervous system diseases" type="Diseases"/>
            <entity charOffset="45-60" id="miRNA-corp.d62.s7.e1" text="hepatic diseases" type="Diseases"/>
            <entity charOffset="100-111" id="miRNA-corp.d62.s7.e2" text="eye diseases" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s8" origId="19670632.s8" text="It has also been used in the modifications of stem cells and as vectors for siRNA/miRNA and ribozymes. ">
            <entity charOffset="82-86" id="miRNA-corp.d62.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d62.s9" origId="19670632.s9" text="In this review, we focused on the preparation, expression and location of scrAAV both in vitro and in vivo. "/>
        <sentence id="miRNA-corp.d62.s10" origId="19670632.s10" text="We mainly introduced the recent progress of scrAAV based therapy of Hemophilia B, in order to elucidate the potential and prospects of scrAAV in gene therapy.   ">
            <entity charOffset="68-79" id="miRNA-corp.d62.s10.e0" text="Hemophilia B" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d63" origId="11992206">
        <sentence id="miRNA-corp.d63.s0" origId="11992206.s0" text="Learning, retention and generalization of a mirror tracing skill in Alzheimer's disease.  ">
            <entity charOffset="68-86" id="miRNA-corp.d63.s0.e0" text="Alzheimer's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s1" origId="11992206.s1" text="The present study examined the ability of 12 patients with probable Alzheimer's disease (AD) and 12 age- and education-matched normal control (NC) subjects to learn and retain the visuomotor skills necessary to efficiently trace a pattern (e.g., a 4- or 6-pointed star) seen only in mirror-reversed view. ">
            <entity charOffset="68-86" id="miRNA-corp.d63.s1.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="89-90" id="miRNA-corp.d63.s1.e1" text="AD" type="Diseases"/>
            <entity charOffset="45-52" id="miRNA-corp.d63.s1.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s2" origId="11992206.s2" text="Those AD (N=6) and NC (N=7) subjects who were able to initially perform the basic mirror tracing task did not differ significantly in initial level of performance, learning over trials, retention of the skill over a 30-min delay interval, and generalization of the skill to a new figure or to the opposite direction of tracing. ">
            <entity charOffset="6-7" id="miRNA-corp.d63.s2.e0" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s3" origId="11992206.s3" text="The AD patients who were unable to initially perform the mirror tracing task were significantly worse than those who could perform the task on several neuropsychological measures sensitive to deficits in problem solving and executive functions, but not on tests of global cognitive decline, memory, language, or visuoperceptual functioning. ">
            <entity charOffset="4-5" id="miRNA-corp.d63.s3.e0" text="AD" type="Diseases"/>
            <entity charOffset="7-14" id="miRNA-corp.d63.s3.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d63.s4" origId="11992206.s4" text="These results indicate that acquisition and retention of a complex visuomotor skill can proceed normally in the early stages of AD in those individuals who can initially perform the basic task, and that inability to perform the basic task may be related to the frontal lobe dysfunction that is often prominent in the disorder.   ">
            <entity charOffset="261-284" id="miRNA-corp.d63.s4.e0" text="frontal lobe dysfunction" type="Diseases"/>
            <entity charOffset="128-129" id="miRNA-corp.d63.s4.e1" text="AD" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d64" origId="18951327">
        <sentence id="miRNA-corp.d64.s0" origId="18951327.s1" text="This review reports the current knowledge of microRNA (miRNA) expression in pituitary adenomas, focusing on recent microarray data. ">
            <entity charOffset="45-52" id="miRNA-corp.d64.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="55-59" id="miRNA-corp.d64.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-93" id="miRNA-corp.d64.s0.e2" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d64.s0.e0" e2="miRNA-corp.d64.s0.e2" id="miRNA-corp.d64.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d64.s0.e1" e2="miRNA-corp.d64.s0.e2" id="miRNA-corp.d64.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s1" origId="18951327.s2" text="Moreover, a discussion is provided concerning the possible role of validated and putative targets of the most dysregulated miRNA in pituitary adenoma pathogenesis.   ">
            <entity charOffset="123-127" id="miRNA-corp.d64.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="132-148" id="miRNA-corp.d64.s1.e1" text="pituitary adenoma" type="Diseases"/>
            <entity charOffset="110-121" id="miRNA-corp.d64.s1.e2" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="81-96" id="miRNA-corp.d64.s1.e3" text="putative targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d64.s1.e0" e2="miRNA-corp.d64.s1.e1" id="miRNA-corp.d64.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d64.s2" origId="18951327.s0" text="MicroRNAs and possible role in pituitary adenoma.  ">
            <entity charOffset="0-8" id="miRNA-corp.d64.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-47" id="miRNA-corp.d64.s2.e1" text="pituitary adenoma" type="Diseases"/>
            <pair e1="miRNA-corp.d64.s2.e0" e2="miRNA-corp.d64.s2.e1" id="miRNA-corp.d64.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d65" origId="19888324">
        <sentence id="miRNA-corp.d65.s0" origId="19888324.s0" text="Expression profile of MicroRNAs in young stroke patients.  ">
            <entity charOffset="22-30" id="miRNA-corp.d65.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-46" id="miRNA-corp.d65.s0.e1" text="stroke" type="Diseases"/>
            <entity charOffset="48-55" id="miRNA-corp.d65.s0.e2" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d65.s0.e0" e2="miRNA-corp.d65.s0.e1" id="miRNA-corp.d65.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s1" origId="19888324.s1" text="BACKGROUND: The methods currently available for diagnosis and prognosis of cerebral ischaemia still require further improvements. ">
            <entity charOffset="75-92" id="miRNA-corp.d65.s1.e0" text="cerebral ischaemia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s2" origId="19888324.s6" text="Blood samples from normal (n=5) individuals were used as controls. "/>
        <sentence id="miRNA-corp.d65.s3" origId="19888324.s7" text="Total RNA extracted from whole blood was subjected to miroRNA profiling and real-time PCR analysis. ">
            <entity charOffset="54-60" id="miRNA-corp.d65.s3.e0" text="miroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s4" origId="19888324.s8" text="miRNAs that are implicated in the endothelial/vascular function, erythropoiesis, angiogenesis and neural function showed differential expression profile as compared to the normal control. ">
            <entity charOffset="0-5" id="miRNA-corp.d65.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-143" id="miRNA-corp.d65.s4.e1" text="differential expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s5" origId="19888324.s9" text="Interestingly, miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles. ">
            <entity charOffset="15-20" id="miRNA-corp.d65.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-94" id="miRNA-corp.d65.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-49" id="miRNA-corp.d65.s5.e2" text="hypoxic" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s5.e1" e2="miRNA-corp.d65.s5.e2" id="miRNA-corp.d65.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d65.s5.e0" e2="miRNA-corp.d65.s5.e2" id="miRNA-corp.d65.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s6" origId="19888324.s2" text="Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as cancer and diabetes. ">
            <entity charOffset="0-9" id="miRNA-corp.d65.s6.e0" text="Micro-RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="115-122" id="miRNA-corp.d65.s6.e1" text="diabetes" type="Diseases"/>
            <entity charOffset="104-109" id="miRNA-corp.d65.s6.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s6.e0" e2="miRNA-corp.d65.s6.e1" id="miRNA-corp.d65.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d65.s6.e0" e2="miRNA-corp.d65.s6.e2" id="miRNA-corp.d65.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s7" origId="19888324.s3" text="We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify characteristic patterns in ischaemic stroke. ">
            <entity charOffset="25-32" id="miRNA-corp.d65.s7.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="35-39" id="miRNA-corp.d65.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="124-139" id="miRNA-corp.d65.s7.e2" text="ischaemic stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s7.e0" e2="miRNA-corp.d65.s7.e2" id="miRNA-corp.d65.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d65.s7.e1" e2="miRNA-corp.d65.s7.e2" id="miRNA-corp.d65.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s8" origId="19888324.s4" text="METHODS/PRINCIPAL FINDINGS: The ischaemic stroke patients aged between 18-49 years, characterized based on World Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis [n=8] b) Small-vessel disease [n=3] c) Cardioembolism [n=5] d) Undetermined cause [n=3]. ">
            <entity charOffset="32-47" id="miRNA-corp.d65.s8.e0" text="ischaemic stroke" type="Diseases"/>
            <entity charOffset="226-240" id="miRNA-corp.d65.s8.e1" text="atherosclerosis" type="Diseases"/>
            <entity charOffset="49-56" id="miRNA-corp.d65.s8.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s9" origId="19888324.s5" text="The patients' functional status at the time of blood sampling (at the outpatient clinics) was evaluated with the modified Rankin Scale (mRS). ">
            <entity charOffset="4-11" id="miRNA-corp.d65.s9.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s10" origId="19888324.s10" text="CONCLUSION: We demonstrate that the peripheral blood miRNAs and their profiles can be developed as biomarkers in diagnosis and prognosis of cerebral ischaemic stroke. ">
            <entity charOffset="53-58" id="miRNA-corp.d65.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-164" id="miRNA-corp.d65.s10.e1" text="cerebral ischaemic stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d65.s10.e0" e2="miRNA-corp.d65.s10.e1" id="miRNA-corp.d65.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d65.s11" origId="19888324.s11" text="The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.   ">
            <entity charOffset="17-22" id="miRNA-corp.d65.s11.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-94" id="miRNA-corp.d65.s11.e1" text="stroke" type="Diseases"/>
            <entity charOffset="4-15" id="miRNA-corp.d65.s11.e2" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="149-156" id="miRNA-corp.d65.s11.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d65.s11.e0" e2="miRNA-corp.d65.s11.e1" id="miRNA-corp.d65.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d66" origId="21143783">
        <sentence id="miRNA-corp.d66.s0" origId="21143783.s4" text="We also indentified 97 differentially expressed microRNAs among 240 tumor and 10 normal samples. ">
            <entity charOffset="48-56" id="miRNA-corp.d66.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-46" id="miRNA-corp.d66.s0.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="68-72" id="miRNA-corp.d66.s0.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d66.s0.e0" e2="miRNA-corp.d66.s0.e2" id="miRNA-corp.d66.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s1" origId="21143783.s5" text="22 of which have been reported to affect glioblastoma and 50 of which were implicated in other cancers and brain diseases. ">
            <entity charOffset="41-52" id="miRNA-corp.d66.s1.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="107-120" id="miRNA-corp.d66.s1.e1" text="brain diseases" type="Diseases"/>
            <entity charOffset="95-101" id="miRNA-corp.d66.s1.e2" text="cancers" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s2" origId="21143783.s2" text="Though a lot of research has been focused on this disease, the causes and pathogenesis of glioblastoma have not been indentified clearly. ">
            <entity charOffset="90-101" id="miRNA-corp.d66.s2.e0" text="glioblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s3" origId="21143783.s3" text="RESULTS: We indentified 1,236 significantly differentially expressed genes, and 30 pathways enriched in the set of differentially expressed genes among 243 tumor and 11 normal samples. ">
            <entity charOffset="44-67" id="miRNA-corp.d66.s3.e0" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="115-138" id="miRNA-corp.d66.s3.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="156-160" id="miRNA-corp.d66.s3.e2" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s4" origId="21143783.s0" text="Investigation gene and microRNA expression in glioblastoma.  ">
            <entity charOffset="23-30" id="miRNA-corp.d66.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-57" id="miRNA-corp.d66.s4.e1" text="glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d66.s4.e0" e2="miRNA-corp.d66.s4.e1" id="miRNA-corp.d66.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s5" origId="21143783.s1" text="BACKGROUND: Glioblastoma is the most common primary brain tumor in adults. ">
            <entity charOffset="12-23" id="miRNA-corp.d66.s5.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="52-62" id="miRNA-corp.d66.s5.e1" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s6" origId="21143783.s9" text="CONCLUSION: We investigated gene and microRNA Expression in Glioblastoma and gave a comprehensive function study of differential expressed gene and microRNA in glioblastoma patients. ">
            <entity charOffset="37-44" id="miRNA-corp.d66.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="148-155" id="miRNA-corp.d66.s6.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="160-171" id="miRNA-corp.d66.s6.e2" text="glioblastoma" type="Diseases"/>
            <entity charOffset="116-137" id="miRNA-corp.d66.s6.e3" text="differential expressed" type="Relation_Trigger"/>
            <entity charOffset="60-71" id="miRNA-corp.d66.s6.e4" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="173-180" id="miRNA-corp.d66.s6.e5" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d66.s6.e0" e2="miRNA-corp.d66.s6.e2" id="miRNA-corp.d66.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s6.e0" e2="miRNA-corp.d66.s6.e4" id="miRNA-corp.d66.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s6.e1" e2="miRNA-corp.d66.s6.e2" id="miRNA-corp.d66.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d66.s6.e1" e2="miRNA-corp.d66.s6.e4" id="miRNA-corp.d66.s6.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s7" origId="21143783.s8" text="Further function analysis of target genes suggested that microRNAs most frequently targeted genes associated with Cell Signalling and Nervous System. ">
            <entity charOffset="57-65" id="miRNA-corp.d66.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="83-90" id="miRNA-corp.d66.s7.e1" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="98-107" id="miRNA-corp.d66.s7.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="29-34" id="miRNA-corp.d66.s7.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s8" origId="21143783.s7" text="We found two experimentally validated microRNA targets and 1,094 miRNA-target gene pairs in our datasets which were predicted by miRanda algorithm, 8 of the target genes were tumor suppressor genes and 3 were oncogenes. ">
            <entity charOffset="38-45" id="miRNA-corp.d66.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-69" id="miRNA-corp.d66.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-53" id="miRNA-corp.d66.s8.e2" text="targets" type="Relation_Trigger"/>
            <entity charOffset="175-190" id="miRNA-corp.d66.s8.e3" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="157-162" id="miRNA-corp.d66.s8.e4" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s9" origId="21143783.s6" text="We regressed gene expression on microRNA expression in 237 tumor tissues and 10 normal tissues comprehensively. ">
            <entity charOffset="32-39" id="miRNA-corp.d66.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-63" id="miRNA-corp.d66.s9.e1" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d66.s9.e0" e2="miRNA-corp.d66.s9.e1" id="miRNA-corp.d66.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d66.s10" origId="21143783.s10" text="These findings gave important clues to study of the carcinogenic process in glioblastomas.   ">
            <entity charOffset="76-88" id="miRNA-corp.d66.s10.e0" text="glioblastomas" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d67" origId="19621023">
        <sentence id="miRNA-corp.d67.s0" origId="19621023.s10" text="CONCLUSION: Our results indicate a time-dependent expression pattern of miR-223 and miR-124a in a mouse model of SCI. ">
            <entity charOffset="72-78" id="miRNA-corp.d67.s0.e0" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="84-91" id="miRNA-corp.d67.s0.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="113-115" id="miRNA-corp.d67.s0.e2" text="SCI" type="Diseases"/>
            <entity charOffset="98-102" id="miRNA-corp.d67.s0.e3" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d67.s0.e0" e2="miRNA-corp.d67.s0.e2" id="miRNA-corp.d67.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s0.e1" e2="miRNA-corp.d67.s0.e2" id="miRNA-corp.d67.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s1" origId="19621023.s11" text="In this study, the time course of miRNA-223 expression may be related to inflammatory responses after SCI, and the time course of decreased miR-124a expression may reflect cell death.   ">
            <entity charOffset="34-42" id="miRNA-corp.d67.s1.e0" text="miRNA-223" type="Specific_miRNAs"/>
            <entity charOffset="140-147" id="miRNA-corp.d67.s1.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="102-104" id="miRNA-corp.d67.s1.e2" text="SCI" type="Diseases"/>
            <entity charOffset="130-158" id="miRNA-corp.d67.s1.e3" text="decreased miR-124a expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d67.s1.e0" e2="miRNA-corp.d67.s1.e2" id="miRNA-corp.d67.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s1.e1" e2="miRNA-corp.d67.s1.e2" id="miRNA-corp.d67.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s2" origId="19621023.s9" text="However, miR-124a, which was present in the normal spinal cord, was not observed at the injured site. ">
            <entity charOffset="9-16" id="miRNA-corp.d67.s2.e0" text="miR-124a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s3" origId="19621023.s7" text="RESULTS: Quantitative PCR revealed two peaks of miR-223 expression at 6 and 12 h and 3 days after SCI. MiR-124a expression decreased significantly from 1 day to 7 days after SCI. ">
            <entity charOffset="48-54" id="miRNA-corp.d67.s3.e0" text="miR-223" type="Specific_miRNAs"/>
            <entity charOffset="103-110" id="miRNA-corp.d67.s3.e1" text="MiR-124a" type="Specific_miRNAs"/>
            <entity charOffset="98-100" id="miRNA-corp.d67.s3.e2" text="SCI" type="Diseases"/>
            <entity charOffset="174-176" id="miRNA-corp.d67.s3.e3" text="SCI" type="Diseases"/>
            <entity charOffset="112-131" id="miRNA-corp.d67.s3.e4" text="expression decreased" type="Relation_Trigger"/>
            <entity charOffset="123-145" id="miRNA-corp.d67.s3.e5" text="decreased significantly" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d67.s3.e0" e2="miRNA-corp.d67.s3.e2" id="miRNA-corp.d67.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s3.e0" e2="miRNA-corp.d67.s3.e3" id="miRNA-corp.d67.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s3.e1" e2="miRNA-corp.d67.s3.e2" id="miRNA-corp.d67.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s3.e1" e2="miRNA-corp.d67.s3.e3" id="miRNA-corp.d67.s3.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s4" origId="19621023.s8" text="In situ hybridization demonstrated the presence of miR-223 around the injured site. ">
            <entity charOffset="51-57" id="miRNA-corp.d67.s4.e0" text="miR-223" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s5" origId="19621023.s5" text="METHODS: We examined the expression of miRNA (miR)-223 and miR-124a in a mouse model at 6 h, 12 h, 1 day, 3 days and 7 days after SCI using quantitative PCR. ">
            <entity charOffset="39-53" id="miRNA-corp.d67.s5.e0" text="miRNA (miR)-223" type="Specific_miRNAs"/>
            <entity charOffset="59-66" id="miRNA-corp.d67.s5.e1" text="miR-124a" type="Specific_miRNAs"/>
            <entity charOffset="130-132" id="miRNA-corp.d67.s5.e2" text="SCI" type="Diseases"/>
            <entity charOffset="73-77" id="miRNA-corp.d67.s5.e3" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d67.s5.e0" e2="miRNA-corp.d67.s5.e2" id="miRNA-corp.d67.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s5.e1" e2="miRNA-corp.d67.s5.e2" id="miRNA-corp.d67.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s6" origId="19621023.s6" text="The miRNA expression was confirmed by in situ hybridization. ">
            <entity charOffset="4-8" id="miRNA-corp.d67.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s7" origId="19621023.s3" text="MiRNAs are short noncoding RNAs that suppress the translation of target genes by binding to their mRNAs, and play a central role in gene regulation in health and disease. ">
            <entity charOffset="0-5" id="miRNA-corp.d67.s7.e0" text="MiRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-70" id="miRNA-corp.d67.s7.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="81-87" id="miRNA-corp.d67.s7.e2" text="binding" type="Relation_Trigger"/>
            <entity charOffset="37-44" id="miRNA-corp.d67.s7.e3" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="137-146" id="miRNA-corp.d67.s7.e4" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s8" origId="19621023.s4" text="The purpose of this study was to examine miRNA expression after SCI. SETTING: Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University. ">
            <entity charOffset="64-66" id="miRNA-corp.d67.s8.e0" text="SCI" type="Diseases"/>
            <entity charOffset="41-45" id="miRNA-corp.d67.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d67.s8.e1" e2="miRNA-corp.d67.s8.e0" id="miRNA-corp.d67.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s9" origId="19621023.s1" text="STUDY DESIGN: We investigated microRNA (miRNA) expression after spinal cord injury (SCI) in mice. ">
            <entity charOffset="64-81" id="miRNA-corp.d67.s9.e0" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="84-86" id="miRNA-corp.d67.s9.e1" text="SCI" type="Diseases"/>
            <entity charOffset="30-37" id="miRNA-corp.d67.s9.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-44" id="miRNA-corp.d67.s9.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="92-95" id="miRNA-corp.d67.s9.e4" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d67.s9.e2" e2="miRNA-corp.d67.s9.e0" id="miRNA-corp.d67.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s9.e2" e2="miRNA-corp.d67.s9.e1" id="miRNA-corp.d67.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s9.e3" e2="miRNA-corp.d67.s9.e0" id="miRNA-corp.d67.s9.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d67.s9.e3" e2="miRNA-corp.d67.s9.e1" id="miRNA-corp.d67.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s10" origId="19621023.s2" text="OBJECTIVES: The recent discovery of miRNAs suggests a novel regulatory control over gene expression during plant and animal development. ">
            <entity charOffset="36-41" id="miRNA-corp.d67.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-69" id="miRNA-corp.d67.s10.e1" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d67.s11" origId="19621023.s0" text="Responses of microRNAs 124a and 223 following spinal cord injury in mice.  ">
            <entity charOffset="13-34" id="miRNA-corp.d67.s11.e0" text="microRNAs 124a and 223" type="Specific_miRNAs"/>
            <entity charOffset="46-63" id="miRNA-corp.d67.s11.e1" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="68-71" id="miRNA-corp.d67.s11.e2" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d67.s11.e0" e2="miRNA-corp.d67.s11.e1" id="miRNA-corp.d67.s11.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d68" origId="20202123">
        <sentence id="miRNA-corp.d68.s0" origId="20202123.s0" text="Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3.  AIMS: MicroRNAs (miRNAs) are small non-coding RNAs that regulate translational repression of target mRNAs. ">
            <entity charOffset="156-164" id="miRNA-corp.d68.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="167-172" id="miRNA-corp.d68.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-16" id="miRNA-corp.d68.s0.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-27" id="miRNA-corp.d68.s0.e3" text="Aberrant microRNA expression" type="Relation_Trigger"/>
            <entity charOffset="120-126" id="miRNA-corp.d68.s0.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="74-80" id="miRNA-corp.d68.s0.e5" text="miR-29a" type="Specific_miRNAs"/>
            <entity charOffset="95-111" id="miRNA-corp.d68.s0.e6" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="128-146" id="miRNA-corp.d68.s0.e7" text="neurone navigator 3" type="Genes/Proteins"/>
            <entity charOffset="243-248" id="miRNA-corp.d68.s0.e8" text="target" type="Relation_Trigger"/>
            <entity charOffset="215-238" id="miRNA-corp.d68.s0.e9" text="translational repression" type="Relation_Trigger"/>
            <entity charOffset="206-213" id="miRNA-corp.d68.s0.e10" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="46-71" id="miRNA-corp.d68.s0.e11" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e0" e2="miRNA-corp.d68.s0.e6" id="miRNA-corp.d68.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e0" e2="miRNA-corp.d68.s0.e7" id="miRNA-corp.d68.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s0.e0" e2="miRNA-corp.d68.s0.e11" id="miRNA-corp.d68.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e1" e2="miRNA-corp.d68.s0.e6" id="miRNA-corp.d68.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e1" e2="miRNA-corp.d68.s0.e7" id="miRNA-corp.d68.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s0.e1" e2="miRNA-corp.d68.s0.e11" id="miRNA-corp.d68.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e5" e2="miRNA-corp.d68.s0.e6" id="miRNA-corp.d68.s0.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e5" e2="miRNA-corp.d68.s0.e7" id="miRNA-corp.d68.s0.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s0.e5" e2="miRNA-corp.d68.s0.e11" id="miRNA-corp.d68.s0.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e2" e2="miRNA-corp.d68.s0.e6" id="miRNA-corp.d68.s0.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s0.e2" e2="miRNA-corp.d68.s0.e7" id="miRNA-corp.d68.s0.p10" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s0.e2" e2="miRNA-corp.d68.s0.e11" id="miRNA-corp.d68.s0.p11" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s1" origId="20202123.s9" text="MiR-29a-mediated down-regulation of NAV3 was verified by the luciferase reporter assay. ">
            <entity charOffset="0-6" id="miRNA-corp.d68.s1.e0" text="MiR-29a" type="Specific_miRNAs"/>
            <entity charOffset="17-31" id="miRNA-corp.d68.s1.e1" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="36-39" id="miRNA-corp.d68.s1.e2" text="NAV3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s1.e0" e2="miRNA-corp.d68.s1.e2" id="miRNA-corp.d68.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s2" origId="20202123.s7" text="However, we found significant down-regulation of miR-29a in Alzheimer disease (AD) brains. ">
            <entity charOffset="30-44" id="miRNA-corp.d68.s2.e0" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="49-55" id="miRNA-corp.d68.s2.e1" text="miR-29a" type="Specific_miRNAs"/>
            <entity charOffset="60-76" id="miRNA-corp.d68.s2.e2" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="79-80" id="miRNA-corp.d68.s2.e3" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d68.s2.e1" e2="miRNA-corp.d68.s2.e2" id="miRNA-corp.d68.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s2.e1" e2="miRNA-corp.d68.s2.e3" id="miRNA-corp.d68.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s3" origId="20202123.s8" text="The database search on TargetScan, PicTar and miRBase Target identified neurone navigator 3 (NAV3), a regulator of axon guidance, as a principal target of miR-29a, and actually NAV3 mRNA levels were elevated in AD brains. ">
            <entity charOffset="135-150" id="miRNA-corp.d68.s3.e0" text="principal target" type="Relation_Trigger"/>
            <entity charOffset="72-90" id="miRNA-corp.d68.s3.e1" text="neurone navigator 3" type="Genes/Proteins"/>
            <entity charOffset="93-96" id="miRNA-corp.d68.s3.e2" text="NAV3" type="Genes/Proteins"/>
            <entity charOffset="177-180" id="miRNA-corp.d68.s3.e3" text="NAV3" type="Genes/Proteins"/>
            <entity charOffset="155-161" id="miRNA-corp.d68.s3.e4" text="miR-29a" type="Specific_miRNAs"/>
            <entity charOffset="211-212" id="miRNA-corp.d68.s3.e5" text="AD" type="Diseases"/>
            <entity charOffset="54-59" id="miRNA-corp.d68.s3.e6" text="Target" type="Relation_Trigger"/>
            <entity charOffset="102-110" id="miRNA-corp.d68.s3.e7" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="187-206" id="miRNA-corp.d68.s3.e8" text="levels were elevated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d68.s3.e4" e2="miRNA-corp.d68.s3.e1" id="miRNA-corp.d68.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s3.e4" e2="miRNA-corp.d68.s3.e2" id="miRNA-corp.d68.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s3.e4" e2="miRNA-corp.d68.s3.e3" id="miRNA-corp.d68.s3.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s3.e4" e2="miRNA-corp.d68.s3.e5" id="miRNA-corp.d68.s3.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s4" origId="20202123.s5" text="This was followed by enlargement of study population with quantitative RT-PCR analysis (n = 21). "/>
        <sentence id="miRNA-corp.d68.s5" origId="20202123.s6" text="RESULTS: By microarray analysis, we identified up-regulation of miR-29a, miR-29b and miR-338-3p in amyotrophic lateral sclerosis brains, but due to a great interindividual variation, we could not validate these results by quantitative RT-PCR. ">
            <entity charOffset="99-127" id="miRNA-corp.d68.s5.e0" text="amyotrophic lateral sclerosis" type="Diseases"/>
            <entity charOffset="47-59" id="miRNA-corp.d68.s5.e1" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="64-70" id="miRNA-corp.d68.s5.e2" text="miR-29a" type="Specific_miRNAs"/>
            <entity charOffset="73-79" id="miRNA-corp.d68.s5.e3" text="miR-29b" type="Specific_miRNAs"/>
            <entity charOffset="85-94" id="miRNA-corp.d68.s5.e4" text="miR-338-3p" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d68.s5.e2" e2="miRNA-corp.d68.s5.e0" id="miRNA-corp.d68.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s5.e3" e2="miRNA-corp.d68.s5.e0" id="miRNA-corp.d68.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s5.e4" e2="miRNA-corp.d68.s5.e0" id="miRNA-corp.d68.s5.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s6" origId="20202123.s3" text="To identify miRNAs closely associated with neurodegeneration, we performed miRNA expression profiling of brain tissues of various neurodegenerative diseases. ">
            <entity charOffset="12-17" id="miRNA-corp.d68.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-79" id="miRNA-corp.d68.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-36" id="miRNA-corp.d68.s6.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="130-155" id="miRNA-corp.d68.s6.e3" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d68.s6.e0" e2="miRNA-corp.d68.s6.e3" id="miRNA-corp.d68.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s6.e1" e2="miRNA-corp.d68.s6.e3" id="miRNA-corp.d68.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s7" origId="20202123.s4" text="METHODS: We initially studied the frontal cortex derived from three amyotrophic lateral sclerosis patients by using a microarray of 723 human miRNAs. ">
            <entity charOffset="142-147" id="miRNA-corp.d68.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-105" id="miRNA-corp.d68.s7.e1" text="patients" type="Species"/>
            <entity charOffset="136-140" id="miRNA-corp.d68.s7.e2" text="human" type="Species"/>
            <entity charOffset="68-96" id="miRNA-corp.d68.s7.e3" text="amyotrophic lateral sclerosis" type="Diseases"/>
            <pair e1="miRNA-corp.d68.s7.e0" e2="miRNA-corp.d68.s7.e3" id="miRNA-corp.d68.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s8" origId="20202123.s1" text="Accumulating evidence indicates that various miRNAs, expressed in a spatially and temporally controlled that manner in the brain plays a key role in neuronal development. ">
            <entity charOffset="45-50" id="miRNA-corp.d68.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s9" origId="20202123.s2" text="However, at present, the pathological implication of aberrant miRNA expression in neurodegenerative events remains largely unknown. ">
            <entity charOffset="62-66" id="miRNA-corp.d68.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-77" id="miRNA-corp.d68.s9.e1" text="aberrant miRNA expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d68.s10" origId="20202123.s10" text="By immunohistochemistry, NAV3 expression was most evidently enhanced in degenerating pyramidal neurones in the cerebral cortex of AD. CONCLUSIONS: These observations suggest the hypothesis that underexpression of miR-29a affects neurodegenerative processes by enhancing neuronal NAV3 expression in AD brains.   ">
            <entity charOffset="194-208" id="miRNA-corp.d68.s10.e0" text="underexpression" type="Relation_Trigger"/>
            <entity charOffset="260-293" id="miRNA-corp.d68.s10.e1" text="enhancing neuronal NAV3 expression" type="Relation_Trigger"/>
            <entity charOffset="25-28" id="miRNA-corp.d68.s10.e2" text="NAV3" type="Genes/Proteins"/>
            <entity charOffset="298-299" id="miRNA-corp.d68.s10.e3" text="AD" type="Diseases"/>
            <entity charOffset="130-131" id="miRNA-corp.d68.s10.e4" text="AD" type="Diseases"/>
            <entity charOffset="213-219" id="miRNA-corp.d68.s10.e5" text="miR-29a" type="Specific_miRNAs"/>
            <entity charOffset="279-282" id="miRNA-corp.d68.s10.e6" text="NAV3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s10.e5" e2="miRNA-corp.d68.s10.e2" id="miRNA-corp.d68.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d68.s10.e5" e2="miRNA-corp.d68.s10.e3" id="miRNA-corp.d68.s10.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s10.e5" e2="miRNA-corp.d68.s10.e4" id="miRNA-corp.d68.s10.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d68.s10.e5" e2="miRNA-corp.d68.s10.e6" id="miRNA-corp.d68.s10.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d69" origId="21342132">
        <sentence id="miRNA-corp.d69.s0" origId="21342132.s6" text="Many miRNA targets have been computationally predicted but only a limited number of these were experimentally validated. ">
            <entity charOffset="5-9" id="miRNA-corp.d69.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-17" id="miRNA-corp.d69.s0.e1" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s1" origId="21342132.s5" text="However, interactions between miRNAs and their targets are complex and very often there are numerous putative miRNA recognition sites in mRNAs. ">
            <entity charOffset="30-35" id="miRNA-corp.d69.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-114" id="miRNA-corp.d69.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-53" id="miRNA-corp.d69.s1.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s2" origId="21342132.s4" text="Therefore, it is of particular interest to reliably predict potential miRNA targets which might be involved in these diseases. ">
            <entity charOffset="70-74" id="miRNA-corp.d69.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-82" id="miRNA-corp.d69.s2.e1" text="potential miRNA targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s3" origId="21342132.s3" text="Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases. ">
            <entity charOffset="45-50" id="miRNA-corp.d69.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-72" id="miRNA-corp.d69.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-83" id="miRNA-corp.d69.s3.e2" text="altered miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="131-136" id="miRNA-corp.d69.s3.e3" text="cancer" type="Diseases"/>
            <entity charOffset="169-194" id="miRNA-corp.d69.s3.e4" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="9-20" id="miRNA-corp.d69.s3.e5" text="deregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d69.s3.e0" e2="miRNA-corp.d69.s3.e3" id="miRNA-corp.d69.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s3.e0" e2="miRNA-corp.d69.s3.e4" id="miRNA-corp.d69.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s3.e1" e2="miRNA-corp.d69.s3.e3" id="miRNA-corp.d69.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s3.e1" e2="miRNA-corp.d69.s3.e4" id="miRNA-corp.d69.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s4" origId="21342132.s9" text="In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed. ">
            <entity charOffset="80-84" id="miRNA-corp.d69.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="215-219" id="miRNA-corp.d69.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-91" id="miRNA-corp.d69.s4.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="221-226" id="miRNA-corp.d69.s4.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s5" origId="21342132.s8" text="Hence, finding a functional miRNA target is still a challenging task. ">
            <entity charOffset="28-32" id="miRNA-corp.d69.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-39" id="miRNA-corp.d69.s5.e1" text="functional miRNA target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s6" origId="21342132.s7" text="Although a variety of miRNA target prediction algorithms are available, results of their application are often inconsistent. ">
            <entity charOffset="22-26" id="miRNA-corp.d69.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-33" id="miRNA-corp.d69.s6.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s7" origId="21342132.s1" text="microRNAs (miRNAs) are endogenous non-coding RNAs that control gene expression at the posttranscriptional level. ">
            <entity charOffset="0-8" id="miRNA-corp.d69.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d69.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s8" origId="21342132.s2" text="These small regulatory molecules play a key role in the majority of biological processes and their expression is also tightly regulated. ">
            <entity charOffset="99-134" id="miRNA-corp.d69.s8.e0" text="expression is also tightly regulated" type="Relation_Trigger"/>
            <entity charOffset="12-21" id="miRNA-corp.d69.s8.e1" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s9" origId="21342132.s0" text="Practical Aspects of microRNA Target Prediction.  ">
            <entity charOffset="21-28" id="miRNA-corp.d69.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="30-35" id="miRNA-corp.d69.s9.e1" text="Target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d69.s10" origId="21342132.s10" text="Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington's disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).   ">
            <entity charOffset="157-161" id="miRNA-corp.d69.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="260-298" id="miRNA-corp.d69.s10.e1" text="trinucleotide repeat expansion diseases" type="Diseases"/>
            <entity charOffset="301-305" id="miRNA-corp.d69.s10.e2" text="TREDs" type="Diseases"/>
            <entity charOffset="317-336" id="miRNA-corp.d69.s10.e3" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="339-340" id="miRNA-corp.d69.s10.e4" text="HD" type="Diseases"/>
            <entity charOffset="356-378" id="miRNA-corp.d69.s10.e5" text="spinocerebellar ataxias" type="Diseases"/>
            <entity charOffset="381-384" id="miRNA-corp.d69.s10.e6" text="SCAs" type="Diseases"/>
            <entity charOffset="392-416" id="miRNA-corp.d69.s10.e7" text="myotonic dystrophy type 1" type="Diseases"/>
            <entity charOffset="419-421" id="miRNA-corp.d69.s10.e8" text="DM1" type="Diseases"/>
            <entity charOffset="228-249" id="miRNA-corp.d69.s10.e9" text="neurological disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e1" id="miRNA-corp.d69.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e2" id="miRNA-corp.d69.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e3" id="miRNA-corp.d69.s10.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e4" id="miRNA-corp.d69.s10.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e5" id="miRNA-corp.d69.s10.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e6" id="miRNA-corp.d69.s10.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e7" id="miRNA-corp.d69.s10.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e8" id="miRNA-corp.d69.s10.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d69.s10.e0" e2="miRNA-corp.d69.s10.e9" id="miRNA-corp.d69.s10.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d70" origId="21138567">
        <sentence id="miRNA-corp.d70.s0" origId="21138567.s10" text="CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA. ">
            <entity charOffset="47-52" id="miRNA-corp.d70.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-63" id="miRNA-corp.d70.s0.e1" text="altered miRNAs expression" type="Relation_Trigger"/>
            <entity charOffset="189-198" id="miRNA-corp.d70.s0.e2" text="acromegaly" type="Diseases"/>
            <entity charOffset="93-110" id="miRNA-corp.d70.s0.e3" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s0.e0" e2="miRNA-corp.d70.s0.e2" id="miRNA-corp.d70.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s0.e0" e2="miRNA-corp.d70.s0.e3" id="miRNA-corp.d70.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s1" origId="21138567.s11" text="Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.   ">
            <entity charOffset="62-67" id="miRNA-corp.d70.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="142-158" id="miRNA-corp.d70.s1.e1" text="pituitary adenoma" type="Diseases"/>
            <entity charOffset="43-49" id="miRNA-corp.d70.s1.e2" text="targets" type="Relation_Trigger"/>
            <entity charOffset="152-158" id="miRNA-corp.d70.s1.e3" text="adenoma" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e1" id="miRNA-corp.d70.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s1.e0" e2="miRNA-corp.d70.s1.e3" id="miRNA-corp.d70.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s2" origId="21138567.s9" text="Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression. ">
            <entity charOffset="19-24" id="miRNA-corp.d70.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d70.s2.e1" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s2.e0" e2="miRNA-corp.d70.s2.e1" id="miRNA-corp.d70.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s3" origId="21138567.s8" text="Seven miRNAs were differentially expressed between SSA responders or GH nonresponders. ">
            <entity charOffset="6-11" id="miRNA-corp.d70.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="18-41" id="miRNA-corp.d70.s3.e1" text="differentially expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s4" origId="21138567.s5" text="RESULTS: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries. ">
            <entity charOffset="19-24" id="miRNA-corp.d70.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-54" id="miRNA-corp.d70.s4.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="77-94" id="miRNA-corp.d70.s4.e2" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s4.e0" e2="miRNA-corp.d70.s4.e2" id="miRNA-corp.d70.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s5" origId="21138567.s4" text="We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR. ">
            <entity charOffset="16-21" id="miRNA-corp.d70.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="142-147" id="miRNA-corp.d70.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-59" id="miRNA-corp.d70.s5.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="117-140" id="miRNA-corp.d70.s5.e3" text="differentially expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d70.s5.e0" e2="miRNA-corp.d70.s5.e2" id="miRNA-corp.d70.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s5.e1" e2="miRNA-corp.d70.s5.e2" id="miRNA-corp.d70.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s6" origId="21138567.s7" text="Thirteen miRNAs were differentially expressed between tumor samples from lanreotide-treated patients and those from lanreotide-untreated patients. ">
            <entity charOffset="9-14" id="miRNA-corp.d70.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="21-44" id="miRNA-corp.d70.s6.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="54-58" id="miRNA-corp.d70.s6.e2" text="tumor" type="Diseases"/>
            <entity charOffset="137-144" id="miRNA-corp.d70.s6.e3" text="patients" type="Species"/>
            <entity charOffset="92-99" id="miRNA-corp.d70.s6.e4" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d70.s6.e0" e2="miRNA-corp.d70.s6.e2" id="miRNA-corp.d70.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s7" origId="21138567.s6" text="Differential expression of 9 miRNAs was observed between micro- and macro-adenomas. ">
            <entity charOffset="29-34" id="miRNA-corp.d70.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-81" id="miRNA-corp.d70.s7.e1" text="macro-adenomas" type="Diseases"/>
            <entity charOffset="0-22" id="miRNA-corp.d70.s7.e2" text="Differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d70.s7.e0" e2="miRNA-corp.d70.s7.e1" id="miRNA-corp.d70.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s8" origId="21138567.s0" text="Differential expression of microRNAs in GH-secreting pituitary adenomas.  ">
            <entity charOffset="27-35" id="miRNA-corp.d70.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-70" id="miRNA-corp.d70.s8.e1" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="0-22" id="miRNA-corp.d70.s8.e2" text="Differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d70.s8.e0" e2="miRNA-corp.d70.s8.e1" id="miRNA-corp.d70.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s9" origId="21138567.s1" text="BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA). ">
            <entity charOffset="67-72" id="miRNA-corp.d70.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="191-196" id="miRNA-corp.d70.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-125" id="miRNA-corp.d70.s9.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="214-225" id="miRNA-corp.d70.s9.e3" text="somatostatin" type="Genes/Proteins"/>
            <entity charOffset="268-279" id="miRNA-corp.d70.s9.e4" text="somatostatin" type="Genes/Proteins"/>
            <entity charOffset="202-206" id="miRNA-corp.d70.s9.e5" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d70.s9.e0" e2="miRNA-corp.d70.s9.e2" id="miRNA-corp.d70.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s9.e0" e2="miRNA-corp.d70.s9.e3" id="miRNA-corp.d70.s9.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s9.e0" e2="miRNA-corp.d70.s9.e4" id="miRNA-corp.d70.s9.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s9.e0" e2="miRNA-corp.d70.s9.e5" id="miRNA-corp.d70.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s9.e1" e2="miRNA-corp.d70.s9.e2" id="miRNA-corp.d70.s9.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d70.s9.e1" e2="miRNA-corp.d70.s9.e3" id="miRNA-corp.d70.s9.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s9.e1" e2="miRNA-corp.d70.s9.e4" id="miRNA-corp.d70.s9.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d70.s9.e1" e2="miRNA-corp.d70.s9.e5" id="miRNA-corp.d70.s9.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s10" origId="21138567.s2" text="METHODS: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery. ">
            <entity charOffset="30-37" id="miRNA-corp.d70.s10.e0" text="adenomas" type="Diseases"/>
            <entity charOffset="39-46" id="miRNA-corp.d70.s10.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d70.s11" origId="21138567.s3" text="Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders. ">
            <entity charOffset="0-7" id="miRNA-corp.d70.s11.e0" text="Patients" type="Species"/>
            <entity charOffset="99-106" id="miRNA-corp.d70.s11.e1" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d71" origId="12554860">
        <sentence id="miRNA-corp.d71.s0" origId="12554860.s3" text="We recently showed in HeLa cells that two components of the SMN complex, Gemin3 and Gemin4, together with the argonaute protein eIF2C2, also associate with microRNAs (miRNAs) as part of a novel class of RNPs termed miRNPs. ">
            <entity charOffset="73-78" id="miRNA-corp.d71.s0.e0" text="Gemin3" type="Genes/Proteins"/>
            <entity charOffset="84-89" id="miRNA-corp.d71.s0.e1" text="Gemin4" type="Genes/Proteins"/>
            <entity charOffset="128-133" id="miRNA-corp.d71.s0.e2" text="eIF2C2" type="Genes/Proteins"/>
            <entity charOffset="141-149" id="miRNA-corp.d71.s0.e3" text="associate" type="Relation_Trigger"/>
            <entity charOffset="156-164" id="miRNA-corp.d71.s0.e4" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="167-172" id="miRNA-corp.d71.s0.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-62" id="miRNA-corp.d71.s0.e6" text="SMN" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e4" e2="miRNA-corp.d71.s0.e0" id="miRNA-corp.d71.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e4" e2="miRNA-corp.d71.s0.e1" id="miRNA-corp.d71.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e4" e2="miRNA-corp.d71.s0.e2" id="miRNA-corp.d71.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e4" e2="miRNA-corp.d71.s0.e6" id="miRNA-corp.d71.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e5" e2="miRNA-corp.d71.s0.e0" id="miRNA-corp.d71.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e5" e2="miRNA-corp.d71.s0.e1" id="miRNA-corp.d71.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e5" e2="miRNA-corp.d71.s0.e2" id="miRNA-corp.d71.s0.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s0.e5" e2="miRNA-corp.d71.s0.e6" id="miRNA-corp.d71.s0.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s1" origId="12554860.s2" text="SMN is part of a large complex that functions in the assembly/restructuring of ribonucleoprotein (RNP) complexes. ">
            <entity charOffset="0-2" id="miRNA-corp.d71.s1.e0" text="SMN" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s2" origId="12554860.s1" text="Spinal muscular atrophy (SMA) is a common neurodegenerative disease that is caused by deletions or loss-of-function mutations in the Survival of Motor Neuron (SMN) protein. ">
            <entity charOffset="0-22" id="miRNA-corp.d71.s2.e0" text="Spinal muscular atrophy" type="Diseases"/>
            <entity charOffset="25-27" id="miRNA-corp.d71.s2.e1" text="SMA" type="Diseases"/>
            <entity charOffset="42-66" id="miRNA-corp.d71.s2.e2" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="133-170" id="miRNA-corp.d71.s2.e3" text="Survival of Motor Neuron (SMN) protein" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s3" origId="12554860.s0" text="Numerous microRNPs in neuronal cells containing novel microRNAs.  ">
            <entity charOffset="54-62" id="miRNA-corp.d71.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s4" origId="12554860.s6" text="The chromosomal locations of most of the novel miRNAs were identified and indicate some phylogenetic conservation of the likely precursor structures. ">
            <entity charOffset="47-52" id="miRNA-corp.d71.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s5" origId="12554860.s7" text="Interestingly the gene locus of one miRNA, miR-175, is a candidate region for two neurologic diseases: early-onset parkinsonism (Waisman syndrome) and X-linked mental retardation (MRX3). ">
            <entity charOffset="57-72" id="miRNA-corp.d71.s5.e0" text="candidate region" type="Relation_Trigger"/>
            <entity charOffset="103-126" id="miRNA-corp.d71.s5.e1" text="early-onset parkinsonism" type="Diseases"/>
            <entity charOffset="151-177" id="miRNA-corp.d71.s5.e2" text="X-linked mental retardation" type="Diseases"/>
            <entity charOffset="43-49" id="miRNA-corp.d71.s5.e3" text="miR-175" type="Specific_miRNAs"/>
            <entity charOffset="36-40" id="miRNA-corp.d71.s5.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-144" id="miRNA-corp.d71.s5.e5" text="Waisman syndrome" type="Diseases"/>
            <entity charOffset="180-183" id="miRNA-corp.d71.s5.e6" text="MRX3" type="Diseases"/>
            <entity charOffset="129-144" id="miRNA-corp.d71.s5.e7" text="Waisman syndrome" type="Genes/Proteins"/>
            <entity charOffset="180-183" id="miRNA-corp.d71.s5.e8" text="MRX3" type="Genes/Proteins"/>
            <entity charOffset="82-100" id="miRNA-corp.d71.s5.e9" text="neurologic diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e5" id="miRNA-corp.d71.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e6" id="miRNA-corp.d71.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e7" id="miRNA-corp.d71.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e8" id="miRNA-corp.d71.s5.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e9" id="miRNA-corp.d71.s5.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e1" id="miRNA-corp.d71.s5.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e3" e2="miRNA-corp.d71.s5.e2" id="miRNA-corp.d71.s5.p6" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e5" id="miRNA-corp.d71.s5.p7" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e6" id="miRNA-corp.d71.s5.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e7" id="miRNA-corp.d71.s5.p9" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e8" id="miRNA-corp.d71.s5.p10" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e9" id="miRNA-corp.d71.s5.p11" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e1" id="miRNA-corp.d71.s5.p12" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d71.s5.e4" e2="miRNA-corp.d71.s5.e2" id="miRNA-corp.d71.s5.p13" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s6" origId="12554860.s4" text="Here we report on miRNPs isolated from neuronal cell lines of mouse and human, and describe 53 novel miRNAs. ">
            <entity charOffset="101-106" id="miRNA-corp.d71.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-66" id="miRNA-corp.d71.s6.e1" text="mouse" type="Species"/>
            <entity charOffset="72-76" id="miRNA-corp.d71.s6.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s7" origId="12554860.s5" text="Several of these miRNAs are conserved in divergent organisms, including rat, zebrafish, pufferfish, and the nematode Caenorhabditis elegans. ">
            <entity charOffset="17-22" id="miRNA-corp.d71.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-115" id="miRNA-corp.d71.s7.e1" text="nematode" type="Species"/>
            <entity charOffset="72-74" id="miRNA-corp.d71.s7.e2" text="rat" type="Species"/>
            <entity charOffset="77-85" id="miRNA-corp.d71.s7.e3" text="zebrafish" type="Species"/>
            <entity charOffset="117-138" id="miRNA-corp.d71.s7.e4" text="Caenorhabditis elegans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s8" origId="12554860.s8" text="Also, several miRNAs identified as part of miRNPs in these cells appear to constitute two distinct subfamilies. ">
            <entity charOffset="14-19" id="miRNA-corp.d71.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d71.s9" origId="12554860.s9" text="These subfamilies comprise multiple copies of miRNAs on different chromosomes, suggesting an important function in the regulation of gene expression.   ">
            <entity charOffset="46-51" id="miRNA-corp.d71.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="119-147" id="miRNA-corp.d71.s9.e1" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d72" origId="19668211">
        <sentence id="miRNA-corp.d72.s0" origId="19668211.s3" text="Here we show that human platelets harbor an abundant and diverse array of microRNAs (miRNAs), which are known as key regulators of mRNA translation in other cell types. ">
            <entity charOffset="74-82" id="miRNA-corp.d72.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-90" id="miRNA-corp.d72.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-146" id="miRNA-corp.d72.s0.e2" text="regulators of mRNA translation" type="Relation_Trigger"/>
            <entity charOffset="18-22" id="miRNA-corp.d72.s0.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s1" origId="19668211.s4" text="Further analyses revealed that platelets contain the Dicer and Argonaute 2 (Ago2) complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts, respectively. ">
            <entity charOffset="139-143" id="miRNA-corp.d72.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-57" id="miRNA-corp.d72.s1.e1" text="Dicer" type="Genes/Proteins"/>
            <entity charOffset="63-73" id="miRNA-corp.d72.s1.e2" text="Argonaute 2" type="Genes/Proteins"/>
            <entity charOffset="76-79" id="miRNA-corp.d72.s1.e3" text="Ago2" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d72.s1.e0" e2="miRNA-corp.d72.s1.e1" id="miRNA-corp.d72.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d72.s1.e0" e2="miRNA-corp.d72.s1.e2" id="miRNA-corp.d72.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d72.s1.e0" e2="miRNA-corp.d72.s1.e3" id="miRNA-corp.d72.s1.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s2" origId="19668211.s5" text="Detection of the receptor P2Y(12) mRNA in Ago2 immunoprecipitates suggests that P2Y(12) expression may be subjected to miRNA control in human platelets. ">
            <entity charOffset="119-123" id="miRNA-corp.d72.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-45" id="miRNA-corp.d72.s2.e1" text="Ago2" type="Genes/Proteins"/>
            <entity charOffset="136-140" id="miRNA-corp.d72.s2.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d72.s2.e0" e2="miRNA-corp.d72.s2.e1" id="miRNA-corp.d72.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s3" origId="19668211.s6" text="Our study lends an additional level of complexity to the control of gene expression in these anucleate elements of the cardiovascular system.   "/>
        <sentence id="miRNA-corp.d72.s4" origId="19668211.s0" text="Existence of a microRNA pathway in anucleate platelets.  ">
            <entity charOffset="15-22" id="miRNA-corp.d72.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s5" origId="19668211.s1" text="Platelets have a crucial role in the maintenance of hemostasis as well as in thrombosis and vessel occlusion, which underlie stroke and acute coronary syndromes. ">
            <entity charOffset="136-159" id="miRNA-corp.d72.s5.e0" text="acute coronary syndromes" type="Diseases"/>
            <entity charOffset="125-130" id="miRNA-corp.d72.s5.e1" text="stroke" type="Diseases"/>
            <entity charOffset="77-86" id="miRNA-corp.d72.s5.e2" text="thrombosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d72.s6" origId="19668211.s2" text="Anucleate platelets contain mRNAs and are capable of protein synthesis, raising the issue of how these mRNAs are regulated. ">
            <entity charOffset="113-121" id="miRNA-corp.d72.s6.e0" text="regulated" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d73" origId="19498445">
        <sentence id="miRNA-corp.d73.s0" origId="19498445.s0" text="miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.  ">
            <entity charOffset="12-19" id="miRNA-corp.d73.s0.e0" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="0-6" id="miRNA-corp.d73.s0.e1" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="24-29" id="miRNA-corp.d73.s0.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d73.s0.e0" e2="miRNA-corp.d73.s0.e2" id="miRNA-corp.d73.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s0.e1" e2="miRNA-corp.d73.s0.e2" id="miRNA-corp.d73.s0.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s1" origId="19498445.s2" text="Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, and suppresses tumorigenicity both in vitro and in vivo. ">
            <entity charOffset="20-25" id="miRNA-corp.d73.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="96-105" id="miRNA-corp.d73.s1.e1" text="suppresses" type="Relation_Trigger"/>
            <entity charOffset="27-34" id="miRNA-corp.d73.s1.e2" text="inhibits" type="Relation_Trigger"/>
            <entity charOffset="78-83" id="miRNA-corp.d73.s1.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d73.s1.e0" e2="miRNA-corp.d73.s1.e3" id="miRNA-corp.d73.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s2" origId="19498445.s1" text="MicroRNAs (miRNAs) encoded by the miR-15/16 cluster are known to act as tumor suppressors. ">
            <entity charOffset="34-42" id="miRNA-corp.d73.s2.e0" text="miR-15/16" type="Specific_miRNAs"/>
            <entity charOffset="0-8" id="miRNA-corp.d73.s2.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d73.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-88" id="miRNA-corp.d73.s2.e3" text="tumor suppressors" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s3" origId="19498445.s4" text="Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma. ">
            <entity charOffset="53-80" id="miRNA-corp.d73.s3.e0" text="chronic lymphocytic lymphoma" type="Diseases"/>
            <entity charOffset="83-85" id="miRNA-corp.d73.s3.e1" text="CLL" type="Diseases"/>
            <entity charOffset="25-30" id="miRNA-corp.d73.s3.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-106" id="miRNA-corp.d73.s3.e3" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="113-130" id="miRNA-corp.d73.s3.e4" text="prostate carcinoma" type="Diseases"/>
            <entity charOffset="0-14" id="miRNA-corp.d73.s3.e5" text="Down-regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d73.s3.e2" e2="miRNA-corp.d73.s3.e3" id="miRNA-corp.d73.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s3.e2" e2="miRNA-corp.d73.s3.e4" id="miRNA-corp.d73.s3.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s3.e2" e2="miRNA-corp.d73.s3.e0" id="miRNA-corp.d73.s3.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s3.e2" e2="miRNA-corp.d73.s3.e1" id="miRNA-corp.d73.s3.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s4" origId="19498445.s3" text="miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. ">
            <entity charOffset="0-6" id="miRNA-corp.d73.s4.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="12-19" id="miRNA-corp.d73.s4.e1" text="miR-16-1" type="Specific_miRNAs"/>
            <entity charOffset="73-76" id="miRNA-corp.d73.s4.e2" text="BCL2" type="Genes/Proteins"/>
            <entity charOffset="79-82" id="miRNA-corp.d73.s4.e3" text="MCL1" type="Genes/Proteins"/>
            <entity charOffset="85-89" id="miRNA-corp.d73.s4.e4" text="CCND1" type="Genes/Proteins"/>
            <entity charOffset="96-100" id="miRNA-corp.d73.s4.e5" text="WNT3A" type="Genes/Proteins"/>
            <entity charOffset="33-41" id="miRNA-corp.d73.s4.e6" text="targeting" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d73.s4.e0" e2="miRNA-corp.d73.s4.e2" id="miRNA-corp.d73.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e0" e2="miRNA-corp.d73.s4.e3" id="miRNA-corp.d73.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e0" e2="miRNA-corp.d73.s4.e4" id="miRNA-corp.d73.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e0" e2="miRNA-corp.d73.s4.e5" id="miRNA-corp.d73.s4.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e1" e2="miRNA-corp.d73.s4.e2" id="miRNA-corp.d73.s4.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e1" e2="miRNA-corp.d73.s4.e3" id="miRNA-corp.d73.s4.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e1" e2="miRNA-corp.d73.s4.e4" id="miRNA-corp.d73.s4.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d73.s4.e1" e2="miRNA-corp.d73.s4.e5" id="miRNA-corp.d73.s4.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d73.s5" origId="19498445.s5" text="This review summarizes the discovery, functions, and clinical relevance of these miRNAs in cancer, particularly CLL.   ">
            <entity charOffset="112-114" id="miRNA-corp.d73.s5.e0" text="CLL" type="Diseases"/>
            <entity charOffset="81-86" id="miRNA-corp.d73.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-96" id="miRNA-corp.d73.s5.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d73.s5.e1" e2="miRNA-corp.d73.s5.e0" id="miRNA-corp.d73.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d73.s5.e1" e2="miRNA-corp.d73.s5.e2" id="miRNA-corp.d73.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d74" origId="19707536">
        <sentence id="miRNA-corp.d74.s0" origId="19707536.s5" text="Molecular and cellular neurobiological studies of the miRNAs in neurodegeneration represent the exploration of a new Frontier of miRNAs biology and the potential development of new diagnostic tests and genetic therapies for neurodegenerative diseases.   ">
            <entity charOffset="54-59" id="miRNA-corp.d74.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-134" id="miRNA-corp.d74.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="224-249" id="miRNA-corp.d74.s0.e2" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d74.s0.e1" e2="miRNA-corp.d74.s0.e2" id="miRNA-corp.d74.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d74.s0.e0" e2="miRNA-corp.d74.s0.e2" id="miRNA-corp.d74.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s1" origId="19707536.s3" text="MiRNA studies in neurobiology showed their involvement in synaptic plasticity and brain diseases. ">
            <entity charOffset="0-4" id="miRNA-corp.d74.s1.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-95" id="miRNA-corp.d74.s1.e1" text="brain diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d74.s1.e0" e2="miRNA-corp.d74.s1.e1" id="miRNA-corp.d74.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s2" origId="19707536.s4" text="In this review ,correlations between miRNA-mediated gene silencing and Alzheimer's, Parkinson's, and other neurodegenerative diseases will be discussed. ">
            <entity charOffset="71-81" id="miRNA-corp.d74.s2.e0" text="Alzheimer's" type="Diseases"/>
            <entity charOffset="84-94" id="miRNA-corp.d74.s2.e1" text="Parkinson's" type="Diseases"/>
            <entity charOffset="16-27" id="miRNA-corp.d74.s2.e2" text="correlations" type="Relation_Trigger"/>
            <entity charOffset="37-41" id="miRNA-corp.d74.s2.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-132" id="miRNA-corp.d74.s2.e4" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d74.s2.e3" e2="miRNA-corp.d74.s2.e4" id="miRNA-corp.d74.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d74.s2.e3" e2="miRNA-corp.d74.s2.e0" id="miRNA-corp.d74.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d74.s2.e3" e2="miRNA-corp.d74.s2.e1" id="miRNA-corp.d74.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s3" origId="19707536.s1" text="In few years our understanding of microRNA (miRNA) biogenesis, molecular mechanisms by which miRNAs regulate gene expression, and the functional roles of miRNAs has been expanded. ">
            <entity charOffset="34-41" id="miRNA-corp.d74.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-48" id="miRNA-corp.d74.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-98" id="miRNA-corp.d74.s3.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="154-159" id="miRNA-corp.d74.s3.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-123" id="miRNA-corp.d74.s3.e4" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s4" origId="19707536.s2" text="Interestingly, numerous miRNAs are expressed in a spatially and temporally controlled manner in the nervous system, suggesting that their posttrascriptional regulation may be particularly relevant in neural development and function. ">
            <entity charOffset="24-29" id="miRNA-corp.d74.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="157-166" id="miRNA-corp.d74.s4.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d74.s5" origId="19707536.s0" text="Searching for MIND: microRNAs in neurodegenerative diseases.  ">
            <entity charOffset="20-28" id="miRNA-corp.d74.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-58" id="miRNA-corp.d74.s5.e1" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d74.s5.e0" e2="miRNA-corp.d74.s5.e1" id="miRNA-corp.d74.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d75" origId="20088716">
        <sentence id="miRNA-corp.d75.s0" origId="20088716.s7" text="TAKE HOME MESSAGE: Based on current data, although limited, the mesenchymal-epithelial transition is proposed to be one of the important ways for MSCs to participate tissue repair.   "/>
        <sentence id="miRNA-corp.d75.s1" origId="20088716.s2" text="AREAS COVERED IN THIS REVIEW: This review focuses on recent understanding on MSC's basic biological characteristics and the mechanisms underlying the therapeutic effects of MSCs in vivo. "/>
        <sentence id="miRNA-corp.d75.s2" origId="20088716.s1" text="IMPORTANCE OF THE FIELD: The pan-tissue existence and multipotency of differentiation make mesenchymal stem cells (MSCs) an attractive source of cells as tissue repair cells, seeds of engineered tissue, vehicles for gene therapy or in combination to promote tissue regeneration in wound healing and disease recovery. "/>
        <sentence id="miRNA-corp.d75.s3" origId="20088716.s0" text="More insight into mesenchymal stem cells and their effects inside the body.  "/>
        <sentence id="miRNA-corp.d75.s4" origId="20088716.s6" text="As examples, a detailed description is given on the regeneration of functional sweat glands on burned skin as well as neural cells in middle cerebral artery occlusion (MCAO) animals upon MSC transplantation. ">
            <entity charOffset="134-165" id="miRNA-corp.d75.s4.e0" text="middle cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="168-171" id="miRNA-corp.d75.s4.e1" text="MCAO" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s5" origId="20088716.s5" text="The mechanisms of therapeutic effects of MSCs are attributed to their ability to migrate along chemokine gradients, differentiate into tissue-specific cells, enhance angiogenesis of wound tissue and regulate immune response. ">
            <entity charOffset="199-206" id="miRNA-corp.d75.s5.e0" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="182-186" id="miRNA-corp.d75.s5.e1" text="wound" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s6" origId="20088716.s4" text="Special attention is given to miRNA expression and its relationship with the characteristics of MSCs. ">
            <entity charOffset="30-34" id="miRNA-corp.d75.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d75.s7" origId="20088716.s3" text="WHAT THE READER WILL GAIN: The gene expression profiles for mRNA, protein, microRNA and cell surface marker of MSCs are summarized. ">
            <entity charOffset="75-82" id="miRNA-corp.d75.s7.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d76" origId="18258830">
        <sentence id="miRNA-corp.d76.s0" origId="18258830.s0" text="MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion.  ">
            <entity charOffset="0-7" id="miRNA-corp.d76.s0.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-87" id="miRNA-corp.d76.s0.e1" text="ischemia" type="Diseases"/>
            <entity charOffset="92-123" id="miRNA-corp.d76.s0.e2" text="middle cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="46-49" id="miRNA-corp.d76.s0.e3" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d76.s0.e0" e2="miRNA-corp.d76.s0.e1" id="miRNA-corp.d76.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d76.s0.e0" e2="miRNA-corp.d76.s0.e2" id="miRNA-corp.d76.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s1" origId="18258830.s1" text="BACKGROUND AND PURPOSE: Several hundred small RNAs called microRNAs (miRNAs) have been identified and characterized from various organisms, including humans. ">
            <entity charOffset="58-66" id="miRNA-corp.d76.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-74" id="miRNA-corp.d76.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="150-155" id="miRNA-corp.d76.s1.e2" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s2" origId="18258830.s2" text="In humans, some of these miRNAs have been found to regulate (patho)physiologic conditions such as tumor progression/regression, cholesterol and glucose homeostasis, etc. ">
            <entity charOffset="25-30" id="miRNA-corp.d76.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-58" id="miRNA-corp.d76.s2.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="98-114" id="miRNA-corp.d76.s2.e2" text="tumor progression" type="Diseases"/>
            <entity charOffset="3-8" id="miRNA-corp.d76.s2.e3" text="humans" type="Species"/>
            <pair e1="miRNA-corp.d76.s2.e0" e2="miRNA-corp.d76.s2.e2" id="miRNA-corp.d76.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s3" origId="18258830.s3" text="In this report, we present data on the miRNAs expressed under ischemic conditions in both the brain and blood of rats subjected to middle cerebral artery occlusion (MCAo). ">
            <entity charOffset="39-44" id="miRNA-corp.d76.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="131-162" id="miRNA-corp.d76.s3.e1" text="middle cerebral artery occlusion" type="Diseases"/>
            <entity charOffset="165-168" id="miRNA-corp.d76.s3.e2" text="MCAo" type="Diseases"/>
            <entity charOffset="113-116" id="miRNA-corp.d76.s3.e3" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d76.s3.e0" e2="miRNA-corp.d76.s3.e1" id="miRNA-corp.d76.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d76.s3.e0" e2="miRNA-corp.d76.s3.e2" id="miRNA-corp.d76.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s4" origId="18258830.s4" text="METHODS: Sprague-Dawley rats subjected to MCAo were reperfused for either 24 or 48 hours, and both blood and brain samples were harvested. ">
            <entity charOffset="42-45" id="miRNA-corp.d76.s4.e0" text="MCAo" type="Diseases"/>
            <entity charOffset="24-27" id="miRNA-corp.d76.s4.e1" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s5" origId="18258830.s5" text="miRNA expression profiling and oligonucleotide microarray were carried out, and the data were validated by quantitative real-time polymerase chain reaction and correlated with published data on protein and gene expression in MCAo rats. ">
            <entity charOffset="0-4" id="miRNA-corp.d76.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="225-228" id="miRNA-corp.d76.s5.e1" text="MCAo" type="Diseases"/>
            <entity charOffset="230-233" id="miRNA-corp.d76.s5.e2" text="rats" type="Species"/>
            <entity charOffset="160-169" id="miRNA-corp.d76.s5.e3" text="correlated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d76.s5.e0" e2="miRNA-corp.d76.s5.e1" id="miRNA-corp.d76.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s6" origId="18258830.s6" text="RESULTS: We report here for the first time the involvement of miRNA regulation in brain pathogenesis associated with MCAo. ">
            <entity charOffset="62-66" id="miRNA-corp.d76.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-120" id="miRNA-corp.d76.s6.e1" text="MCAo" type="Diseases"/>
            <entity charOffset="68-77" id="miRNA-corp.d76.s6.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="101-110" id="miRNA-corp.d76.s6.e3" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d76.s6.e0" e2="miRNA-corp.d76.s6.e1" id="miRNA-corp.d76.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s7" origId="18258830.s7" text="Comparison with the corresponding DNA microarray data revealed that the target mRNA expression is correlated with the regulation of miRNA. ">
            <entity charOffset="132-136" id="miRNA-corp.d76.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-77" id="miRNA-corp.d76.s7.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="118-127" id="miRNA-corp.d76.s7.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="84-107" id="miRNA-corp.d76.s7.e3" text="expression is correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s8" origId="18258830.s8" text="We have also provided evidence that some of the miRNAs that are highly expressed in the ischemic brain can be detected in blood samples. ">
            <entity charOffset="48-53" id="miRNA-corp.d76.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-79" id="miRNA-corp.d76.s8.e1" text="highly expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d76.s9" origId="18258830.s9" text="CONCLUSIONS: Further studies are needed to evaluate the possible use of miRNAs as biomarkers in stroke and related pathologies.   ">
            <entity charOffset="72-77" id="miRNA-corp.d76.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="96-101" id="miRNA-corp.d76.s9.e1" text="stroke" type="Diseases"/>
            <pair e1="miRNA-corp.d76.s9.e0" e2="miRNA-corp.d76.s9.e1" id="miRNA-corp.d76.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d77" origId="18175567">
        <sentence id="miRNA-corp.d77.s0" origId="18175567.s0" text="[A study on miRNA alternation after H2O2-induced PC12 cell apoptosis using microarray technique].  ">
            <entity charOffset="12-16" id="miRNA-corp.d77.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s1" origId="18175567.s2" text="METHODS: PC12 cells were treated with different concentrations of H2O2 for 12 hours, and then the cell viabilities were evaluated by MTT assay and cell apoptosis rates were assessed by flow cytometry (FCM). "/>
        <sentence id="miRNA-corp.d77.s2" origId="18175567.s1" text="OBJECTIVE: To screen the differentially expressed microRNAs(miRNA) between H2O2-induced PC12 cell apoptosis and normal PC12 cells with microarray chips. ">
            <entity charOffset="50-58" id="miRNA-corp.d77.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-64" id="miRNA-corp.d77.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="25-48" id="miRNA-corp.d77.s2.e2" text="differentially expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s3" origId="18175567.s7" text="Of the 46 miRNAs in the H2O2 treated groups, 39 were similar to that of the control group and 6 were significantly down-regulated. ">
            <entity charOffset="10-15" id="miRNA-corp.d77.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="115-128" id="miRNA-corp.d77.s3.e1" text="down-regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s4" origId="18175567.s8" text="CONCLUSION: Our preliminary data may provide a new potential foundation for further study of pathogenesis and its treatment of nerve cell apoptosis caused by cerebral ischemia reperfusion.   ">
            <entity charOffset="158-186" id="miRNA-corp.d77.s4.e0" text="cerebral ischemia reperfusion" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s5" origId="18175567.s5" text="The apoptosis rates for them were 2.6%, 5.2%, 7.2%, 10.4%, 16.6%, and 72.2% accordingly. "/>
        <sentence id="miRNA-corp.d77.s6" origId="18175567.s6" text="Expression of 68 miRNAs and 46 miRNAs were detected in both control group and the H2O2 treated groups. ">
            <entity charOffset="17-22" id="miRNA-corp.d77.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-36" id="miRNA-corp.d77.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s7" origId="18175567.s3" text="miRNAs were isolated from control (0 nmol/L H2O2) and H2O2 treated (at concentrations of 50, 100, 200, and 400 nmol/L H2O2, respectively) groups of the PC12 cells, respectively, and were then detected and analyzed by microarray chips. ">
            <entity charOffset="0-5" id="miRNA-corp.d77.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d77.s8" origId="18175567.s4" text="RESULTS: The P12 cell viabilities in control and H2O2 treated group were (92 +/- 9.8)%, (90 +/- 14.70)%, (80 +/- 13.85)%, (54 +/- 12.23)%, and (22 +/- 7.35)%, respectively. "/>
    </document>
    <document id="miRNA-corp.d78" origId="17542255">
        <sentence id="miRNA-corp.d78.s0" origId="17542255.s10" text="CONCLUSIONS: The irregularity of prolactin secretion in patients with NPG is not dependant on the presence of a pituitary tumour which suggests that a hypothalamic dysfunction underlies this condition. ">
            <entity charOffset="151-174" id="miRNA-corp.d78.s0.e0" text="hypothalamic dysfunction" type="Diseases"/>
            <entity charOffset="33-41" id="miRNA-corp.d78.s0.e1" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="112-127" id="miRNA-corp.d78.s0.e2" text="pituitary tumour" type="Diseases"/>
            <entity charOffset="70-72" id="miRNA-corp.d78.s0.e3" text="NPG" type="Diseases"/>
            <entity charOffset="56-63" id="miRNA-corp.d78.s0.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s1" origId="17542255.s11" text="An irregular secretion and a higher daily mass production of prolactin in patients with NPG could explain both galactorrhea and infertility.   ">
            <entity charOffset="88-90" id="miRNA-corp.d78.s1.e0" text="NPG" type="Diseases"/>
            <entity charOffset="128-138" id="miRNA-corp.d78.s1.e1" text="infertility" type="Diseases"/>
            <entity charOffset="111-122" id="miRNA-corp.d78.s1.e2" text="galactorrhea" type="Diseases"/>
            <entity charOffset="61-69" id="miRNA-corp.d78.s1.e3" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="74-81" id="miRNA-corp.d78.s1.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s2" origId="17542255.s1" text="BACKGROUND: Abnormal frequency and pulse amplitud of prolactin secretion in micro and macroprolactinomas has been atributed to a dysfunctional tumoral lactotrope. ">
            <entity charOffset="53-61" id="miRNA-corp.d78.s2.e0" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="86-103" id="miRNA-corp.d78.s2.e1" text="macroprolactinomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s3" origId="17542255.s0" text="[Irregular secretion of prolactin in infertile women with normoprolactinemic galactorrhea].  ">
            <entity charOffset="24-32" id="miRNA-corp.d78.s3.e0" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="58-88" id="miRNA-corp.d78.s3.e1" text="normoprolactinemic galactorrhea" type="Diseases"/>
            <entity charOffset="47-51" id="miRNA-corp.d78.s3.e2" text="women" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s4" origId="17542255.s3" text="The regularity of prolactin secretion has not been studied with cuantitative methods in patients with normoprolactinemic galactorrhea (NPG) which could be considered an entity that precedes non tumoral and tumoral hyperprolactinemia. ">
            <entity charOffset="206-231" id="miRNA-corp.d78.s4.e0" text="tumoral hyperprolactinemia" type="Diseases"/>
            <entity charOffset="102-132" id="miRNA-corp.d78.s4.e1" text="normoprolactinemic galactorrhea" type="Diseases"/>
            <entity charOffset="135-137" id="miRNA-corp.d78.s4.e2" text="NPG" type="Diseases"/>
            <entity charOffset="18-26" id="miRNA-corp.d78.s4.e3" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="88-95" id="miRNA-corp.d78.s4.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s5" origId="17542255.s2" text="Previous evidence suggests that non tumoral hyperprolactinemia is caused by a hypothalamic dysfunction. ">
            <entity charOffset="78-101" id="miRNA-corp.d78.s5.e0" text="hypothalamic dysfunction" type="Diseases"/>
            <entity charOffset="32-61" id="miRNA-corp.d78.s5.e1" text="non tumoral hyperprolactinemia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s6" origId="17542255.s5" text="PATIENTS AND METHODS: A transversal-comparative study was carried out in 6 infertile women with normoprolactinemic galactorrhea and 4 healthy women as controls. ">
            <entity charOffset="96-126" id="miRNA-corp.d78.s6.e0" text="normoprolactinemic galactorrhea" type="Diseases"/>
            <entity charOffset="85-89" id="miRNA-corp.d78.s6.e1" text="women" type="Species"/>
            <entity charOffset="142-146" id="miRNA-corp.d78.s6.e2" text="women" type="Species"/>
            <entity charOffset="0-7" id="miRNA-corp.d78.s6.e3" text="PATIENTS" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s7" origId="17542255.s4" text="Objective: To analyze the 24-hour prolactin secretion pattern and its secretion regularity in a group of infertile women with normoprolactinemic galatorea. ">
            <entity charOffset="34-42" id="miRNA-corp.d78.s7.e0" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="115-119" id="miRNA-corp.d78.s7.e1" text="women" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s8" origId="17542255.s7" text="RESULTS: Blunting of the nyctohemeral rythm and nocturn hyperprolactinaemia occurred in patients with normoprolactinemic galactorrhea (NPG). ">
            <entity charOffset="48-74" id="miRNA-corp.d78.s8.e0" text="nocturn hyperprolactinaemia" type="Diseases"/>
            <entity charOffset="102-132" id="miRNA-corp.d78.s8.e1" text="normoprolactinemic galactorrhea" type="Diseases"/>
            <entity charOffset="135-137" id="miRNA-corp.d78.s8.e2" text="NPG" type="Diseases"/>
            <entity charOffset="88-95" id="miRNA-corp.d78.s8.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s9" origId="17542255.s6" text="The 24 hour prolactin profile, the ratio night time mean concentration/daytime mean concentrattion (NM/DM ratio) and apparent entropy (Ap En, Ap En ratio) were compared in the two groups. ">
            <entity charOffset="12-20" id="miRNA-corp.d78.s9.e0" text="prolactin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s10" origId="17542255.s9" text="Higher irregularity of prolactin secretion was found in patients with NPG (ApEn: 0.853 +/- 0.158 vs 0.608 +/- 0.171, p=0.04; Ap En ratio: 0.839 +/- 0.11 vs 0.661 +/- 0.14; p=0.04). ">
            <entity charOffset="70-72" id="miRNA-corp.d78.s10.e0" text="NPG" type="Diseases"/>
            <entity charOffset="23-31" id="miRNA-corp.d78.s10.e1" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="56-63" id="miRNA-corp.d78.s10.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d78.s11" origId="17542255.s8" text="NM/DM ratio was lower in patients with NPG than in controls (1.28 +/- 0.25 vs. 1.75 +/- 0.05; p= 0.01). ">
            <entity charOffset="39-41" id="miRNA-corp.d78.s11.e0" text="NPG" type="Diseases"/>
            <entity charOffset="25-32" id="miRNA-corp.d78.s11.e1" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d79" origId="19763905">
        <sentence id="miRNA-corp.d79.s0" origId="19763905.s7" text="Alteration of miRNA expression by disease and insult also holds the potential for improved diagnostic tools. ">
            <entity charOffset="14-18" id="miRNA-corp.d79.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-29" id="miRNA-corp.d79.s0.e1" text="Alteration of miRNA expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s1" origId="19763905.s8" text="Finally, miRNAs have been shown to control cellular proliferation and specification, suggesting that manipulation of miRNAs in cultured cells could result in more convenient generation of pure cell populations for transplantation.   ">
            <entity charOffset="9-14" id="miRNA-corp.d79.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-122" id="miRNA-corp.d79.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s2" origId="19763905.s2" text="miRNAs appear to be dysregulated in a number of neurodegenerative diseases, developmental disorders, and as a result of stroke. ">
            <entity charOffset="0-5" id="miRNA-corp.d79.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="120-125" id="miRNA-corp.d79.s2.e1" text="stroke" type="Diseases"/>
            <entity charOffset="76-98" id="miRNA-corp.d79.s2.e2" text="developmental disorders" type="Diseases"/>
            <entity charOffset="20-31" id="miRNA-corp.d79.s2.e3" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="48-73" id="miRNA-corp.d79.s2.e4" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d79.s2.e0" e2="miRNA-corp.d79.s2.e1" id="miRNA-corp.d79.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d79.s2.e0" e2="miRNA-corp.d79.s2.e2" id="miRNA-corp.d79.s2.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d79.s2.e0" e2="miRNA-corp.d79.s2.e4" id="miRNA-corp.d79.s2.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s3" origId="19763905.s1" text="MicroRNAS (miRNAs) have been suggested to play important roles in the central nervous system during development as well as disease. ">
            <entity charOffset="0-8" id="miRNA-corp.d79.s3.e0" text="MicroRNAS" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d79.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s4" origId="19763905.s0" text="The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair.  ">
            <entity charOffset="29-37" id="miRNA-corp.d79.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s5" origId="19763905.s6" text="Artificial miRNAs have also been generated for the repression of specific transcripts. ">
            <entity charOffset="11-16" id="miRNA-corp.d79.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-60" id="miRNA-corp.d79.s5.e1" text="repression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s6" origId="19763905.s5" text="Both viral delivery and administration of modified oligonucleotides mimicking or inhibiting specific miRNAs have been effective in model systems. ">
            <entity charOffset="101-106" id="miRNA-corp.d79.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-90" id="miRNA-corp.d79.s6.e1" text="inhibiting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s7" origId="19763905.s4" text="Recent findings suggest that it may eventually be possible to treat some neurological disorders by restoring or inhibiting miRNAs altered by disease pathology. ">
            <entity charOffset="123-128" id="miRNA-corp.d79.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="112-121" id="miRNA-corp.d79.s7.e1" text="inhibiting" type="Relation_Trigger"/>
            <entity charOffset="73-94" id="miRNA-corp.d79.s7.e2" text="neurological disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d79.s7.e0" e2="miRNA-corp.d79.s7.e2" id="miRNA-corp.d79.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d79.s8" origId="19763905.s3" text="Each miRNA has the ability to regulate hundreds of messenger RNA transcripts, both by causing degradation of the mRNA and by inhibition of protein translation. ">
            <entity charOffset="5-9" id="miRNA-corp.d79.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="30-37" id="miRNA-corp.d79.s8.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="125-157" id="miRNA-corp.d79.s8.e2" text="inhibition of protein translation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d80" origId="21487258">
        <sentence id="miRNA-corp.d80.s0" origId="21487258.s10" text="CONCLUSIONS: The study suggests that spatial orientation memory relies on the integrity of the right hippocampus. "/>
        <sentence id="miRNA-corp.d80.s1" origId="21487258.s11" text="Nevertheless, further studies are necessary to confirm this hypothesis.   "/>
        <sentence id="miRNA-corp.d80.s2" origId="21487258.s6" text="The subjects were submitted to a neuropsychologic evaluation through the Route Learning Test and the Childhood Home Test in the preoperative period. "/>
        <sentence id="miRNA-corp.d80.s3" origId="21487258.s7" text="The statistical analysis was performed using the Kruskal-Wallis, analysis of variance, χ, and Mann-Whitney U tests. "/>
        <sentence id="miRNA-corp.d80.s4" origId="21487258.s8" text="RESULTS: There was no significant difference in performance in the remote visuospatial memory (as measured by the Childhood Home Test) across the groups (LTLE, RTLE, and control). "/>
        <sentence id="miRNA-corp.d80.s5" origId="21487258.s9" text="Concerning the spatial orientation memory, however, there was a significant difference between the LTLE and controls as compared with the RTLE group (P&lt;0.001), the latter showing a poorer performance. "/>
        <sentence id="miRNA-corp.d80.s6" origId="21487258.s3" text="However, evaluations of the right hippocampal functions have not been consistent. "/>
        <sentence id="miRNA-corp.d80.s7" origId="21487258.s2" text="In ablative interventions, neuropsychologic testing of memory is a crucial step. "/>
        <sentence id="miRNA-corp.d80.s8" origId="21487258.s5" text="METHODS: A controlled study of patients with left (LTLE) or right (RTLE) TLE. ">
            <entity charOffset="73-75" id="miRNA-corp.d80.s8.e0" text="TLE" type="Diseases"/>
            <entity charOffset="31-38" id="miRNA-corp.d80.s8.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s9" origId="21487258.s4" text="AIM: To assess the hippocampal function in remote orientation and visuospatial memory in patients with refractory temporal epilepsy. ">
            <entity charOffset="103-130" id="miRNA-corp.d80.s9.e0" text="refractory temporal epilepsy" type="Diseases"/>
            <entity charOffset="89-96" id="miRNA-corp.d80.s9.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s10" origId="21487258.s1" text="INTRODUCTION: In temporal lobe epilepsy (TLE), about 30% of the patients do not achieve adequate pharmacologic control of refractory crises, and surgery becomes an alternative. ">
            <entity charOffset="17-38" id="miRNA-corp.d80.s10.e0" text="temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="41-43" id="miRNA-corp.d80.s10.e1" text="TLE" type="Diseases"/>
            <entity charOffset="64-71" id="miRNA-corp.d80.s10.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d80.s11" origId="21487258.s0" text="Route Learning Performance: Is it a Hippocampus Function?  "/>
    </document>
    <document id="miRNA-corp.d81" origId="16009764">
        <sentence id="miRNA-corp.d81.s0" origId="16009764.s12" text="Yet, genetic testing for CADASIL is associated with a nameable proportion of false-negative results. ">
            <entity charOffset="25-31" id="miRNA-corp.d81.s0.e0" text="CADASIL" type="Diseases"/>
            <entity charOffset="36-45" id="miRNA-corp.d81.s0.e1" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s1" origId="16009764.s11" text="Thus, genetic testing should initially be focused on these exons, with some variation depending on the population in whom it is being performed. "/>
        <sentence id="miRNA-corp.d81.s2" origId="16009764.s10" text="CONCLUSIONS: Almost 90% of mutations could be detected within a few exons (exons 2-6). "/>
        <sentence id="miRNA-corp.d81.s3" origId="16009764.s13" text="Cases with a high index of clinical suspicion should be investigated by skin biopsy if genetic testing is negative.   "/>
        <sentence id="miRNA-corp.d81.s4" origId="16009764.s8" text="Of the mutations, 58.3% were located in exon 4 and 85.8% in exons 2 through 6. "/>
        <sentence id="miRNA-corp.d81.s5" origId="16009764.s9" text="In 5 patients (4.0%), no mutation was identified. ">
            <entity charOffset="5-12" id="miRNA-corp.d81.s5.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s6" origId="16009764.s6" text="Results were compared with those of previously published studies. "/>
        <sentence id="miRNA-corp.d81.s7" origId="16009764.s7" text="RESULTS: We detected 54 distinct mutations (117 missense mutations and 3 in-frame deletions) in 120 (96.0%) of the 125 patients. ">
            <entity charOffset="119-126" id="miRNA-corp.d81.s7.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s8" origId="16009764.s1" text="BACKGROUND: Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is an important cause of stroke in young adults. ">
            <entity charOffset="58-147" id="miRNA-corp.d81.s8.e0" text="cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy" type="Diseases"/>
            <entity charOffset="150-156" id="miRNA-corp.d81.s8.e1" text="CADASIL" type="Diseases"/>
            <entity charOffset="191-196" id="miRNA-corp.d81.s8.e2" text="stroke" type="Diseases"/>
            <entity charOffset="29-34" id="miRNA-corp.d81.s8.e3" text="NOTCH3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s9" origId="16009764.s0" text="Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies.  ">
            <entity charOffset="39-45" id="miRNA-corp.d81.s9.e0" text="CADASIL" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s10" origId="16009764.s5" text="DESIGN: Screening for NOTCH3 mutations was performed in 125 unrelated German CADASIL patients with biopsy-proven disease by direct sequencing of exons coding for epidermal growth factor-like repeats. ">
            <entity charOffset="22-27" id="miRNA-corp.d81.s10.e0" text="NOTCH3" type="Genes/Proteins"/>
            <entity charOffset="77-83" id="miRNA-corp.d81.s10.e1" text="CADASIL" type="Diseases"/>
            <entity charOffset="85-92" id="miRNA-corp.d81.s10.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s11" origId="16009764.s4" text="OBJECTIVES: To identify the spectrum of NOTCH3 mutations in CADASIL and to discuss the implications for diagnostic strategies. ">
            <entity charOffset="40-45" id="miRNA-corp.d81.s11.e0" text="NOTCH3" type="Genes/Proteins"/>
            <entity charOffset="60-66" id="miRNA-corp.d81.s11.e1" text="CADASIL" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d81.s12" origId="16009764.s3" text="Identification of the mutation is critical for genetic counseling and testing of relatives at risk. "/>
        <sentence id="miRNA-corp.d81.s13" origId="16009764.s2" text="Mutations are typically located within epidermal growth factor-like repeat domains in the extracellular part of the Notch3 receptor. ">
            <entity charOffset="116-130" id="miRNA-corp.d81.s13.e0" text="Notch3 receptor" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d82" origId="20797687">
        <sentence id="miRNA-corp.d82.s0" origId="20797687.s0" text="Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.  ">
            <entity charOffset="13-18" id="miRNA-corp.d82.s0.e0" text="ABHD12" type="Genes/Proteins"/>
            <entity charOffset="56-60" id="miRNA-corp.d82.s0.e1" text="PHARC" type="Diseases"/>
            <entity charOffset="30-54" id="miRNA-corp.d82.s0.e2" text="neurodegenerative disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s1" origId="20797687.s2" text="Previously, we mapped this Refsum-like disorder to a 16 Mb region on chromosome 20. "/>
        <sentence id="miRNA-corp.d82.s2" origId="20797687.s1" text="Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a neurodegenerative disease marked by early-onset cataract and hearing loss, retinitis pigmentosa, and involvement of both the central and peripheral nervous systems, including demyelinating sensorimotor polyneuropathy and cerebellar ataxia. ">
            <entity charOffset="0-13" id="miRNA-corp.d82.s2.e0" text="Polyneuropathy" type="Diseases"/>
            <entity charOffset="16-27" id="miRNA-corp.d82.s2.e1" text="hearing loss" type="Diseases"/>
            <entity charOffset="30-35" id="miRNA-corp.d82.s2.e2" text="ataxia" type="Diseases"/>
            <entity charOffset="38-57" id="miRNA-corp.d82.s2.e3" text="retinitis pigmentosa" type="Diseases"/>
            <entity charOffset="64-71" id="miRNA-corp.d82.s2.e4" text="cataract" type="Diseases"/>
            <entity charOffset="74-78" id="miRNA-corp.d82.s2.e5" text="PHARC" type="Diseases"/>
            <entity charOffset="134-141" id="miRNA-corp.d82.s2.e6" text="cataract" type="Diseases"/>
            <entity charOffset="307-323" id="miRNA-corp.d82.s2.e7" text="cerebellar ataxia" type="Diseases"/>
            <entity charOffset="147-158" id="miRNA-corp.d82.s2.e8" text="hearing loss" type="Diseases"/>
            <entity charOffset="161-180" id="miRNA-corp.d82.s2.e9" text="retinitis pigmentosa" type="Diseases"/>
            <entity charOffset="288-301" id="miRNA-corp.d82.s2.e10" text="polyneuropathy" type="Diseases"/>
            <entity charOffset="86-110" id="miRNA-corp.d82.s2.e11" text="neurodegenerative disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s3" origId="20797687.s7" text="Our findings show that ABHD12 performs essential functions in both the central and peripheral nervous systems and the eye. ">
            <entity charOffset="23-28" id="miRNA-corp.d82.s3.e0" text="ABHD12" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s4" origId="20797687.s8" text="Any future drug-mediated interference with this enzyme should consider the potential risk of long-term adverse effects.   "/>
        <sentence id="miRNA-corp.d82.s5" origId="20797687.s3" text="Here we report that mutations in the ABHD12 gene cause PHARC disease and we describe the clinical manifestations in a total of 19 patients from four different countries. ">
            <entity charOffset="37-42" id="miRNA-corp.d82.s5.e0" text="ABHD12" type="Genes/Proteins"/>
            <entity charOffset="55-59" id="miRNA-corp.d82.s5.e1" text="PHARC" type="Diseases"/>
            <entity charOffset="130-137" id="miRNA-corp.d82.s5.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s6" origId="20797687.s4" text="The ABHD12 enzyme was recently shown to hydrolyze 2-arachidonoyl glycerol (2-AG), the main endocannabinoid lipid transmitter that acts on cannabinoid receptors CB1 and CB2. ">
            <entity charOffset="4-9" id="miRNA-corp.d82.s6.e0" text="ABHD12" type="Genes/Proteins"/>
            <entity charOffset="160-162" id="miRNA-corp.d82.s6.e1" text="CB1" type="Genes/Proteins"/>
            <entity charOffset="168-170" id="miRNA-corp.d82.s6.e2" text="CB2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d82.s7" origId="20797687.s5" text="Our data therefore represent an example of an inherited disorder related to endocannabinoid metabolism. "/>
        <sentence id="miRNA-corp.d82.s8" origId="20797687.s6" text="The endocannabinoid system is involved in a wide range of physiological processes including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation, and several potential drugs targeting these pathways are in development for clinical applications. ">
            <entity charOffset="212-220" id="miRNA-corp.d82.s8.e0" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="170-181" id="miRNA-corp.d82.s8.e1" text="inflammation" type="Diseases"/>
            <entity charOffset="127-130" id="miRNA-corp.d82.s8.e2" text="pain" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d83" origId="20564181">
        <sentence id="miRNA-corp.d83.s0" origId="20564181.s1" text="HIV-1-infected opiate abusers often exhibit an accelerated form of HIV-1-associated dementia and enhanced neurological dysfunction. ">
            <entity charOffset="84-91" id="miRNA-corp.d83.s0.e0" text="dementia" type="Diseases"/>
            <entity charOffset="67-71" id="miRNA-corp.d83.s0.e1" text="HIV-1" type="Species"/>
            <entity charOffset="0-4" id="miRNA-corp.d83.s0.e2" text="HIV-1" type="Species"/>
            <entity charOffset="106-129" id="miRNA-corp.d83.s0.e3" text="neurological dysfunction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s1" origId="20564181.s0" text="Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system.  ">
            <entity charOffset="78-82" id="miRNA-corp.d83.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="118-129" id="miRNA-corp.d83.s1.e1" text="inflammation" type="Diseases"/>
            <entity charOffset="22-26" id="miRNA-corp.d83.s1.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d83.s1.e0" e2="miRNA-corp.d83.s1.e1" id="miRNA-corp.d83.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s2" origId="20564181.s3" text="In order to understand the role of morphine in this process, we performed a genome-wide association study at the micro RNA (miRNA) and protein levels in human monocyte-derived macrophages (h-mdms). ">
            <entity charOffset="113-121" id="miRNA-corp.d83.s2.e0" text="micro RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="124-128" id="miRNA-corp.d83.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="153-157" id="miRNA-corp.d83.s2.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s3" origId="20564181.s2" text="Productive HIV-1 infection of microglia and perivascular macrophages and the resultant secretion of neurotoxic molecules by these cells contribute to this phenomenon. ">
            <entity charOffset="11-15" id="miRNA-corp.d83.s3.e0" text="HIV-1" type="Species"/>
            <entity charOffset="11-25" id="miRNA-corp.d83.s3.e1" text="HIV-1 infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s4" origId="20564181.s5" text="Computational analysis predicted fibroblast growth factor-2 (FGF-2) as the strongest target gene for hsa-miR15b. ">
            <entity charOffset="33-58" id="miRNA-corp.d83.s4.e0" text="fibroblast growth factor-2" type="Genes/Proteins"/>
            <entity charOffset="61-65" id="miRNA-corp.d83.s4.e1" text="FGF-2" type="Genes/Proteins"/>
            <entity charOffset="101-110" id="miRNA-corp.d83.s4.e2" text="hsa-miR15b" type="Specific_miRNAs"/>
            <entity charOffset="85-90" id="miRNA-corp.d83.s4.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d83.s4.e2" e2="miRNA-corp.d83.s4.e0" id="miRNA-corp.d83.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d83.s4.e2" e2="miRNA-corp.d83.s4.e1" id="miRNA-corp.d83.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s5" origId="20564181.s4" text="A total of 26 differentially expressed miRNA were identified (P &lt; 0.01), of which hsa-miR-15b and hsa-miR-181b had the greatest increase and decrease in expression levels, respectively. ">
            <entity charOffset="82-92" id="miRNA-corp.d83.s5.e0" text="hsa-miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="98-109" id="miRNA-corp.d83.s5.e1" text="hsa-miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="39-43" id="miRNA-corp.d83.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-37" id="miRNA-corp.d83.s5.e3" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="128-169" id="miRNA-corp.d83.s5.e4" text="increase and decrease in expression levels" type="Relation_Trigger"/>
            <entity charOffset="141-169" id="miRNA-corp.d83.s5.e5" text="decrease in expression levels" type="Relation_Trigger"/>
            <entity charOffset="141-169" id="miRNA-corp.d83.s5.e6" text="decrease in expression levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s6" origId="20564181.s7" text="Both hsa-miR-15b and hsa-miR-181b have several predicted gene targets involved in inflammation and T-cell activation pathways. ">
            <entity charOffset="5-15" id="miRNA-corp.d83.s6.e0" text="hsa-miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="21-32" id="miRNA-corp.d83.s6.e1" text="hsa-miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="47-68" id="miRNA-corp.d83.s6.e2" text="predicted gene targets" type="Relation_Trigger"/>
            <entity charOffset="106-115" id="miRNA-corp.d83.s6.e3" text="activation" type="Relation_Trigger"/>
            <entity charOffset="82-93" id="miRNA-corp.d83.s6.e4" text="inflammation" type="Diseases"/>
            <pair e1="miRNA-corp.d83.s6.e0" e2="miRNA-corp.d83.s6.e4" id="miRNA-corp.d83.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d83.s6.e1" e2="miRNA-corp.d83.s6.e4" id="miRNA-corp.d83.s6.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s7" origId="20564181.s6" text="Of note, we observed a decrease in FGF-2 protein expression in response to morphine. ">
            <entity charOffset="35-39" id="miRNA-corp.d83.s7.e0" text="FGF-2" type="Genes/Proteins"/>
            <entity charOffset="23-58" id="miRNA-corp.d83.s7.e1" text="decrease in FGF-2 protein expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s8" origId="20564181.s9" text="Moreover, proteomic analysis revealed the induction of mitochondrial superoxide dismutase in response to morphine treatment. "/>
        <sentence id="miRNA-corp.d83.s9" origId="20564181.s8" text="In this context, we observed induction of MCP-2 and IL-6 by morphine. ">
            <entity charOffset="42-46" id="miRNA-corp.d83.s9.e0" text="MCP-2" type="Genes/Proteins"/>
            <entity charOffset="52-55" id="miRNA-corp.d83.s9.e1" text="IL-6" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s10" origId="20564181.s12" text="Of note, differentially expressed miRNAs (hsa-miR-15b and 181-b) may have a potential role in regulating these processes.   ">
            <entity charOffset="34-39" id="miRNA-corp.d83.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-32" id="miRNA-corp.d83.s10.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="94-103" id="miRNA-corp.d83.s10.e2" text="regulating" type="Relation_Trigger"/>
            <entity charOffset="42-62" id="miRNA-corp.d83.s10.e3" text="hsa-miR-15b and 181-b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s11" origId="20564181.s11" text="Collectively, these observations demonstrate that morphine induces inflammation and oxidative stress in h-mdms thereby contributing to expansion of HIV-1 CNS reservoir expansion and disease progression. ">
            <entity charOffset="148-152" id="miRNA-corp.d83.s11.e0" text="HIV-1" type="Species"/>
            <entity charOffset="67-78" id="miRNA-corp.d83.s11.e1" text="inflammation" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d83.s12" origId="20564181.s10" text="HIV-1 infection did not induce mitochondrial superoxide dismutase. ">
            <entity charOffset="0-4" id="miRNA-corp.d83.s12.e0" text="HIV-1" type="Species"/>
            <entity charOffset="0-14" id="miRNA-corp.d83.s12.e1" text="HIV-1 infection" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d84" origId="19251578">
        <sentence id="miRNA-corp.d84.s0" origId="19251578.s9" text="MRI scan showed an area of encephalomalacia in the left temporal lobe, as well as post-surgical changes in the left frontal area. ">
            <entity charOffset="27-42" id="miRNA-corp.d84.s0.e0" text="encephalomalacia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s1" origId="19251578.s6" text="He presented with status epilepticus every two or three months, and required long periods of hospitalization on each occasion for post-ictal confusion and aphasia. ">
            <entity charOffset="18-35" id="miRNA-corp.d84.s1.e0" text="status epilepticus" type="Diseases"/>
            <entity charOffset="155-161" id="miRNA-corp.d84.s1.e1" text="aphasia" type="Diseases"/>
            <entity charOffset="130-149" id="miRNA-corp.d84.s1.e2" text="post-ictal confusion" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s2" origId="19251578.s5" text="He continued to have frequent seizures despite treatment with multiple combinations of antiepileptic medications. ">
            <entity charOffset="30-37" id="miRNA-corp.d84.s2.e0" text="seizures" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s3" origId="19251578.s8" text="EEG telemetry recorded multiple seizures, all with a clear focus in the left temporal area. ">
            <entity charOffset="23-39" id="miRNA-corp.d84.s3.e0" text="multiple seizures" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s4" origId="19251578.s7" text="Scalp EEG showed continuous spikes and polyspikes and persistent slowing in the left temporal area, as well as spikes in the left frontal area. "/>
        <sentence id="miRNA-corp.d84.s5" origId="19251578.s3" text="CASE REPORT: We report a case of a 75-year-old right-handed man who underwent a left fronto-temporal craniotomy for resection of a suprasellar meningioma in 2002. ">
            <entity charOffset="131-152" id="miRNA-corp.d84.s5.e0" text="suprasellar meningioma" type="Diseases"/>
            <entity charOffset="60-62" id="miRNA-corp.d84.s5.e1" text="man" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s6" origId="19251578.s4" text="Immediately following hospital discharge, he began to experience complex partial seizures. ">
            <entity charOffset="81-88" id="miRNA-corp.d84.s6.e0" text="seizures" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s7" origId="19251578.s1" text="BACKGROUND: Epilepsy surgery is increasingly well-supported as an effective treatment for patients with intractable epilepsy. ">
            <entity charOffset="12-19" id="miRNA-corp.d84.s7.e0" text="Epilepsy" type="Diseases"/>
            <entity charOffset="116-123" id="miRNA-corp.d84.s7.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="90-97" id="miRNA-corp.d84.s7.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s8" origId="19251578.s2" text="It is most often performed on younger patients and the safety and efficacy of epilepsy surgery in elderly patients are not frequently described. ">
            <entity charOffset="78-85" id="miRNA-corp.d84.s8.e0" text="epilepsy" type="Diseases"/>
            <entity charOffset="38-45" id="miRNA-corp.d84.s8.e1" text="patients" type="Species"/>
            <entity charOffset="106-113" id="miRNA-corp.d84.s8.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s9" origId="19251578.s0" text="Epilepsy surgery in the elderly: an unusual case of a 75-year-old man with recurrent status epilepticus.  ">
            <entity charOffset="85-102" id="miRNA-corp.d84.s9.e0" text="status epilepticus" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d84.s9.e1" text="Epilepsy" type="Diseases"/>
            <entity charOffset="66-68" id="miRNA-corp.d84.s9.e2" text="man" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s10" origId="19251578.s14" text="In addition, few cases with such a malignant evolution of temporal lobe epilepsy have been described in this age group.   ">
            <entity charOffset="58-79" id="miRNA-corp.d84.s10.e0" text="temporal lobe epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s11" origId="19251578.s11" text="A left anteromesial temporal lobectomy was performed with intraoperative electrocorticography. "/>
        <sentence id="miRNA-corp.d84.s12" origId="19251578.s10" text="Neuropsychological testing showed bilateral memory impairment with no significant cognitive decline expected after unilateral temporal lobe resection. ">
            <entity charOffset="34-60" id="miRNA-corp.d84.s12.e0" text="bilateral memory impairment" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s13" origId="19251578.s13" text="CONCLUSIONS: This is one of the oldest patients reported in the literature with epilepsy surgery and supports the possibility of epilepsy surgery in elderly patients for particular cases. ">
            <entity charOffset="80-87" id="miRNA-corp.d84.s13.e0" text="epilepsy" type="Diseases"/>
            <entity charOffset="129-136" id="miRNA-corp.d84.s13.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="39-46" id="miRNA-corp.d84.s13.e2" text="patients" type="Species"/>
            <entity charOffset="157-164" id="miRNA-corp.d84.s13.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d84.s14" origId="19251578.s12" text="Since surgery, the patient was not seizure-free (Engel class II-b), but had no further episodes of status epilepticus in one year and two months of follow-up. ">
            <entity charOffset="35-41" id="miRNA-corp.d84.s14.e0" text="seizure" type="Diseases"/>
            <entity charOffset="99-116" id="miRNA-corp.d84.s14.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="19-25" id="miRNA-corp.d84.s14.e2" text="patient" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d85" origId="18577221">
        <sentence id="miRNA-corp.d85.s0" origId="18577221.s2" text="Aberrant expression of miRNAs can lead to diseases, including cancer. ">
            <entity charOffset="23-28" id="miRNA-corp.d85.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-18" id="miRNA-corp.d85.s0.e1" text="Aberrant expression" type="Relation_Trigger"/>
            <entity charOffset="62-67" id="miRNA-corp.d85.s0.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d85.s0.e0" e2="miRNA-corp.d85.s0.e2" id="miRNA-corp.d85.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d85.s1" origId="18577221.s3" text="Expression of many miRNAs in the de-differentiated brain tumor cancer stem cells resembles that of neural stem cells. ">
            <entity charOffset="19-24" id="miRNA-corp.d85.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-61" id="miRNA-corp.d85.s1.e1" text="de-differentiated brain tumor" type="Diseases"/>
            <entity charOffset="63-68" id="miRNA-corp.d85.s1.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d85.s1.e0" e2="miRNA-corp.d85.s1.e1" id="miRNA-corp.d85.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s1.e0" e2="miRNA-corp.d85.s1.e2" id="miRNA-corp.d85.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d85.s2" origId="18577221.s0" text="MicroRNAs: regulators of oncogenesis and stemness.  ">
            <entity charOffset="0-8" id="miRNA-corp.d85.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-20" id="miRNA-corp.d85.s2.e1" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d85.s3" origId="18577221.s1" text="MicroRNAs (miRNAs) are essential post-transcriptional regulators that determine cell identity and fate. ">
            <entity charOffset="0-8" id="miRNA-corp.d85.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d85.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-63" id="miRNA-corp.d85.s3.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d85.s4" origId="18577221.s4" text="In this issue of BMC Medicine, Silber et al provide evidence of the expression of such miRNAs and their potential to mediate differentiation in both stem cell populations. ">
            <entity charOffset="87-92" id="miRNA-corp.d85.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d85.s5" origId="18577221.s5" text="In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.   ">
            <entity charOffset="185-191" id="miRNA-corp.d85.s5.e0" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="193-199" id="miRNA-corp.d85.s5.e1" text="miR-137" type="Specific_miRNAs"/>
            <entity charOffset="218-230" id="miRNA-corp.d85.s5.e2" text="glioblastomas" type="Diseases"/>
            <entity charOffset="201-213" id="miRNA-corp.d85.s5.e3" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="54-59" id="miRNA-corp.d85.s5.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="64-69" id="miRNA-corp.d85.s5.e5" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e0" e2="miRNA-corp.d85.s5.e5" id="miRNA-corp.d85.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e0" e2="miRNA-corp.d85.s5.e2" id="miRNA-corp.d85.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e1" e2="miRNA-corp.d85.s5.e5" id="miRNA-corp.d85.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e1" e2="miRNA-corp.d85.s5.e2" id="miRNA-corp.d85.s5.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e4" e2="miRNA-corp.d85.s5.e5" id="miRNA-corp.d85.s5.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d85.s5.e4" e2="miRNA-corp.d85.s5.e2" id="miRNA-corp.d85.s5.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d86" origId="17326821">
        <sentence id="miRNA-corp.d86.s0" origId="17326821.s3" text="RESULTS: We hypothesized that schizophrenia might be associated with altered miRNA profiles. ">
            <entity charOffset="77-81" id="miRNA-corp.d86.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-62" id="miRNA-corp.d86.s0.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="69-90" id="miRNA-corp.d86.s0.e2" text="altered miRNA profiles" type="Relation_Trigger"/>
            <entity charOffset="30-42" id="miRNA-corp.d86.s0.e3" text="schizophrenia" type="Diseases"/>
            <pair e1="miRNA-corp.d86.s0.e0" e2="miRNA-corp.d86.s0.e3" id="miRNA-corp.d86.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s1" origId="17326821.s4" text="To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray. ">
            <entity charOffset="72-77" id="miRNA-corp.d86.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="269-273" id="miRNA-corp.d86.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="166-189" id="miRNA-corp.d86.s1.e2" text="schizoaffective disorder" type="Diseases"/>
            <entity charOffset="140-152" id="miRNA-corp.d86.s1.e3" text="schizophrenia" type="Diseases"/>
            <entity charOffset="66-70" id="miRNA-corp.d86.s1.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d86.s1.e0" e2="miRNA-corp.d86.s1.e2" id="miRNA-corp.d86.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d86.s1.e0" e2="miRNA-corp.d86.s1.e3" id="miRNA-corp.d86.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d86.s1.e1" e2="miRNA-corp.d86.s1.e2" id="miRNA-corp.d86.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d86.s1.e1" e2="miRNA-corp.d86.s1.e3" id="miRNA-corp.d86.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s2" origId="17326821.s5" text="Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects. ">
            <entity charOffset="53-58" id="miRNA-corp.d86.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-88" id="miRNA-corp.d86.s2.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="204-215" id="miRNA-corp.d86.s2.e2" text="higher level" type="Relation_Trigger"/>
            <entity charOffset="140-164" id="miRNA-corp.d86.s2.e3" text="expressed at lower levels" type="Relation_Trigger"/>
            <entity charOffset="114-120" id="miRNA-corp.d86.s2.e4" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s3" origId="17326821.s6" text="The expression levels of 12 selected miRNAs were also determined by quantitative RT-PCR in our lab. ">
            <entity charOffset="37-42" id="miRNA-corp.d86.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s4" origId="17326821.s7" text="For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR. ">
            <entity charOffset="14-19" id="miRNA-corp.d86.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-173" id="miRNA-corp.d86.s4.e1" text="expressed at lower levels" type="Relation_Trigger"/>
            <entity charOffset="84-96" id="miRNA-corp.d86.s4.e2" text="schizophrenia" type="Diseases"/>
            <entity charOffset="44-79" id="miRNA-corp.d86.s4.e3" text="expressed at lower microarray levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d86.s4.e0" e2="miRNA-corp.d86.s4.e2" id="miRNA-corp.d86.s4.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s5" origId="17326821.s8" text="CONCLUSION: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.   ">
            <entity charOffset="52-56" id="miRNA-corp.d86.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-116" id="miRNA-corp.d86.s5.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="44-65" id="miRNA-corp.d86.s5.e2" text="altered miRNA profiles" type="Relation_Trigger"/>
            <entity charOffset="118-125" id="miRNA-corp.d86.s5.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d86.s5.e0" e2="miRNA-corp.d86.s5.e1" id="miRNA-corp.d86.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s6" origId="17326821.s0" text="microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.  ">
            <entity charOffset="0-7" id="miRNA-corp.d86.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-77" id="miRNA-corp.d86.s6.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="83-106" id="miRNA-corp.d86.s6.e2" text="schizoaffective disorder" type="Diseases"/>
            <pair e1="miRNA-corp.d86.s6.e0" e2="miRNA-corp.d86.s6.e1" id="miRNA-corp.d86.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d86.s6.e0" e2="miRNA-corp.d86.s6.e2" id="miRNA-corp.d86.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s7" origId="17326821.s1" text="BACKGROUND: microRNAs (miRNAs) are small, noncoding RNA molecules that are now thought to regulate the expression of many mRNAs. ">
            <entity charOffset="12-20" id="miRNA-corp.d86.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d86.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-112" id="miRNA-corp.d86.s7.e2" text="regulate the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d86.s8" origId="17326821.s2" text="They have been implicated in the etiology of a variety of complex diseases, including Tourette's syndrome, Fragile x syndrome, and several types of cancer. ">
            <entity charOffset="86-104" id="miRNA-corp.d86.s8.e0" text="Tourette's syndrome" type="Diseases"/>
            <entity charOffset="107-124" id="miRNA-corp.d86.s8.e1" text="Fragile x syndrome" type="Diseases"/>
            <entity charOffset="148-153" id="miRNA-corp.d86.s8.e2" text="cancer" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d87" origId="18405054">
        <sentence id="miRNA-corp.d87.s0" origId="18405054.s3" text="We explored to what extent abnormalities of echogenicity of the periventricular crossroads correlate with changes in size of the corpus callosum. ">
            <entity charOffset="91-99" id="miRNA-corp.d87.s0.e0" text="correlate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s1" origId="18405054.s2" text="These lesions damage the periventricular crossroads of commissural, projection and associative pathways, which are in a close topographical relationship with the lateral ventricles. "/>
        <sentence id="miRNA-corp.d87.s2" origId="18405054.s5" text="Periventricular areas, which topographically correspond to the frontal, main and occipital crossroad, were readily visualized by cranial ultrasound scans, performed during the first two weeks after birth. "/>
        <sentence id="miRNA-corp.d87.s3" origId="18405054.s4" text="Our study included nine infants (gestation from 26-41 weeks; birth weight between 938-4450 grams) with perinatal brain injury. ">
            <entity charOffset="103-124" id="miRNA-corp.d87.s3.e0" text="perinatal brain injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s4" origId="18405054.s7" text="We found a statistically significant correlation between the increased echogenicity in the crossroad areas and the decrease of the corpus callosum midsagittal area (p &lt; 0.05). ">
            <entity charOffset="37-47" id="miRNA-corp.d87.s4.e0" text="correlation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s5" origId="18405054.s6" text="Corpus callosum mediosagittal area measurements were performed using magnetic resonance images, acquired between the first and sixth postnatal month (postmenstrual age 40-49 weeks). "/>
        <sentence id="miRNA-corp.d87.s6" origId="18405054.s8" text="This supports the hypothesis that callosal fibers can be damaged, during growth through the periventricular crossroads of pathways.   "/>
        <sentence id="miRNA-corp.d87.s7" origId="18405054.s0" text="Changes of the corpus callosum in children who suffered perinatal injury of the periventricular crossroads of pathways.  ">
            <entity charOffset="34-41" id="miRNA-corp.d87.s7.e0" text="children" type="Species"/>
            <entity charOffset="56-71" id="miRNA-corp.d87.s7.e1" text="perinatal injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d87.s8" origId="18405054.s1" text="There is a high incidence of periventricular leukomalacia, caused by hypoxia-ischemia, in preterm infants. ">
            <entity charOffset="29-56" id="miRNA-corp.d87.s8.e0" text="periventricular leukomalacia" type="Diseases"/>
            <entity charOffset="69-84" id="miRNA-corp.d87.s8.e1" text="hypoxia-ischemia" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d88" origId="12684554">
        <sentence id="miRNA-corp.d88.s0" origId="12684554.s9" text="These results confirm those of other studies with animals and humans using novel imaging techniques, suggesting that the motor homunculus may not always be considered a definite and absolute representation of M1.   ">
            <entity charOffset="62-67" id="miRNA-corp.d88.s0.e0" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s1" origId="12684554.s8" text="The results of this study challenge the notion of orderly topographic relationships between the human sensorimotor functions and their representation in the primary motor cortex. ">
            <entity charOffset="96-100" id="miRNA-corp.d88.s1.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s2" origId="12684554.s4" text="Electrode position was represented graphically whenever a stimulus was delivered. "/>
        <sentence id="miRNA-corp.d88.s3" origId="12684554.s5" text="A total of 43 maps from 36 patients were analyzed. ">
            <entity charOffset="27-34" id="miRNA-corp.d88.s3.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s4" origId="12684554.s6" text="The authors found variations in the organization of M1 (primary motor cortex) in seven patients (19.4%). ">
            <entity charOffset="87-94" id="miRNA-corp.d88.s4.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s5" origId="12684554.s7" text="Four patients (11.1%) presented mosaicism (overlapping of functional areas), two (5.6%) presented variability (inverted disposition of M1 functional areas), and one (2.8%) had both. ">
            <entity charOffset="32-40" id="miRNA-corp.d88.s5.e0" text="mosaicism" type="Diseases"/>
            <entity charOffset="5-12" id="miRNA-corp.d88.s5.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s6" origId="12684554.s0" text="Functional variability of the human cortical motor map: electrical stimulation findings in perirolandic epilepsy surgery.  ">
            <entity charOffset="91-111" id="miRNA-corp.d88.s6.e0" text="perirolandic epilepsy" type="Diseases"/>
            <entity charOffset="30-34" id="miRNA-corp.d88.s6.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s7" origId="12684554.s1" text="The purpose of this study was to assess the cortical representation of sensorimotor functions in patients undergoing perirolandic epilepsy surgery, focusing on somatotopy, mosaicism, and variability of function in relation to the classic motor homunculus. ">
            <entity charOffset="117-137" id="miRNA-corp.d88.s7.e0" text="perirolandic epilepsy" type="Diseases"/>
            <entity charOffset="172-180" id="miRNA-corp.d88.s7.e1" text="mosaicism" type="Diseases"/>
            <entity charOffset="97-104" id="miRNA-corp.d88.s7.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s8" origId="12684554.s2" text="The authors studied 36 patients in whom intraoperative or extraoperative electrical cortical stimulation to map motor functions was performed. ">
            <entity charOffset="23-30" id="miRNA-corp.d88.s8.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d88.s9" origId="12684554.s3" text="A computer program was devised to register electrode number, stimulation parameters, and response to each stimulus. "/>
    </document>
    <document id="miRNA-corp.d89" origId="20091141">
        <sentence id="miRNA-corp.d89.s0" origId="20091141.s5" text="These results indicate that miRNAs are differentially expressed in C. elegans PD models and suggest a role for these molecules in disease pathogenesis.   ">
            <entity charOffset="28-33" id="miRNA-corp.d89.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-62" id="miRNA-corp.d89.s0.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="78-79" id="miRNA-corp.d89.s0.e2" text="PD" type="Diseases"/>
            <entity charOffset="67-76" id="miRNA-corp.d89.s0.e3" text="C. elegans" type="Species"/>
            <pair e1="miRNA-corp.d89.s0.e0" e2="miRNA-corp.d89.s0.e2" id="miRNA-corp.d89.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s1" origId="20091141.s3" text="Here, we show that 12 specific miRNAs are differentially regulated in the animals overexpressing alpha-synuclein, five in cat-1, and three in the pdr-1 mutants. ">
            <entity charOffset="97-111" id="miRNA-corp.d89.s1.e0" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="31-36" id="miRNA-corp.d89.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-65" id="miRNA-corp.d89.s1.e2" text="differentially regulated" type="Relation_Trigger"/>
            <entity charOffset="82-95" id="miRNA-corp.d89.s1.e3" text="overexpressing" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d89.s1.e1" e2="miRNA-corp.d89.s1.e0" id="miRNA-corp.d89.s1.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s2" origId="20091141.s4" text="The family of miR-64 and miR-65 are co-underexpressed in the alpha-synuclein transgenic and cat-1 strains, and members of let-7 family co-underexpressed in the alpha-synuclein and pdr-1 strains; mdl-1 and ptc-1 genes are target candidates for miR-64 and miR-65 and are overexpressed in alpha-synuclein transgenic as well as miR-64/65 (tm3711) knockout animals. ">
            <entity charOffset="14-19" id="miRNA-corp.d89.s2.e0" text="miR-64" type="Specific_miRNAs"/>
            <entity charOffset="25-30" id="miRNA-corp.d89.s2.e1" text="miR-65" type="Specific_miRNAs"/>
            <entity charOffset="195-199" id="miRNA-corp.d89.s2.e2" text="mdl-1" type="Genes/Proteins"/>
            <entity charOffset="160-174" id="miRNA-corp.d89.s2.e3" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="243-248" id="miRNA-corp.d89.s2.e4" text="miR-64" type="Specific_miRNAs"/>
            <entity charOffset="254-259" id="miRNA-corp.d89.s2.e5" text="miR-65" type="Specific_miRNAs"/>
            <entity charOffset="286-300" id="miRNA-corp.d89.s2.e6" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="205-209" id="miRNA-corp.d89.s2.e7" text="ptc-1" type="Genes/Proteins"/>
            <entity charOffset="61-75" id="miRNA-corp.d89.s2.e8" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="36-52" id="miRNA-corp.d89.s2.e9" text="co-underexpressed" type="Relation_Trigger"/>
            <entity charOffset="135-151" id="miRNA-corp.d89.s2.e10" text="co-underexpressed" type="Relation_Trigger"/>
            <entity charOffset="221-237" id="miRNA-corp.d89.s2.e11" text="target candidates" type="Relation_Trigger"/>
            <entity charOffset="269-281" id="miRNA-corp.d89.s2.e12" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="122-126" id="miRNA-corp.d89.s2.e13" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="25-27" id="miRNA-corp.d89.s2.e14" text="miR" type="Specific_miRNAs"/>
            <entity charOffset="324-332" id="miRNA-corp.d89.s2.e15" text="miR-64/65" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d89.s2.e5" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e5" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e5" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e5" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e5" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e13" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e13" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e13" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e13" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e13" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p9" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e14" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e14" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e14" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p12" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e14" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p13" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e14" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p14" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e15" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p15" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e15" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p16" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e15" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p17" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e15" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p18" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e15" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p19" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e0" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p20" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e0" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p21" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e0" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p22" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e0" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p23" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e0" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p24" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e1" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p25" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e1" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p26" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e1" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p27" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e1" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p28" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e1" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p29" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e4" e2="miRNA-corp.d89.s2.e6" id="miRNA-corp.d89.s2.p30" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e4" e2="miRNA-corp.d89.s2.e7" id="miRNA-corp.d89.s2.p31" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e4" e2="miRNA-corp.d89.s2.e8" id="miRNA-corp.d89.s2.p32" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e4" e2="miRNA-corp.d89.s2.e2" id="miRNA-corp.d89.s2.p33" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s2.e4" e2="miRNA-corp.d89.s2.e3" id="miRNA-corp.d89.s2.p34" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s3" origId="20091141.s1" text="MicroRNAs (miRNAs) play an important role in human brain development and maintenance. ">
            <entity charOffset="0-8" id="miRNA-corp.d89.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d89.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-49" id="miRNA-corp.d89.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s4" origId="20091141.s2" text="To search for miRNAs that may be involved in the pathogenesis of Parkinsons disease (PD), we utilized miRNA microarrays to identify potential gene expression changes in 115 annotated miRNAs in PD-associated Caenorhabditis elegans models that either overexpress human A53T alpha-synuclein or have mutations within the vesicular catecholamine transporter (cat-1) or parkin (pdr-1) ortholog. ">
            <entity charOffset="65-82" id="miRNA-corp.d89.s4.e0" text="Parkinsons disease" type="Diseases"/>
            <entity charOffset="85-86" id="miRNA-corp.d89.s4.e1" text="PD" type="Diseases"/>
            <entity charOffset="267-286" id="miRNA-corp.d89.s4.e2" text="A53T alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="14-19" id="miRNA-corp.d89.s4.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-106" id="miRNA-corp.d89.s4.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="183-188" id="miRNA-corp.d89.s4.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="193-194" id="miRNA-corp.d89.s4.e6" text="PD" type="Diseases"/>
            <entity charOffset="249-259" id="miRNA-corp.d89.s4.e7" text="overexpress" type="Relation_Trigger"/>
            <entity charOffset="147-164" id="miRNA-corp.d89.s4.e8" text="expression changes" type="Relation_Trigger"/>
            <entity charOffset="207-228" id="miRNA-corp.d89.s4.e9" text="Caenorhabditis elegans" type="Species"/>
            <entity charOffset="261-265" id="miRNA-corp.d89.s4.e10" text="human" type="Species"/>
            <pair e1="miRNA-corp.d89.s4.e3" e2="miRNA-corp.d89.s4.e0" id="miRNA-corp.d89.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e3" e2="miRNA-corp.d89.s4.e1" id="miRNA-corp.d89.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e3" e2="miRNA-corp.d89.s4.e6" id="miRNA-corp.d89.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e3" e2="miRNA-corp.d89.s4.e2" id="miRNA-corp.d89.s4.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s4.e4" e2="miRNA-corp.d89.s4.e0" id="miRNA-corp.d89.s4.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e4" e2="miRNA-corp.d89.s4.e1" id="miRNA-corp.d89.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e4" e2="miRNA-corp.d89.s4.e6" id="miRNA-corp.d89.s4.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e4" e2="miRNA-corp.d89.s4.e2" id="miRNA-corp.d89.s4.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d89.s4.e5" e2="miRNA-corp.d89.s4.e0" id="miRNA-corp.d89.s4.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e5" e2="miRNA-corp.d89.s4.e1" id="miRNA-corp.d89.s4.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e5" e2="miRNA-corp.d89.s4.e6" id="miRNA-corp.d89.s4.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d89.s4.e5" e2="miRNA-corp.d89.s4.e2" id="miRNA-corp.d89.s4.p11" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d89.s5" origId="20091141.s0" text="Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.  ">
            <entity charOffset="63-81" id="miRNA-corp.d89.s5.e0" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="7-14" id="miRNA-corp.d89.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-61" id="miRNA-corp.d89.s5.e2" text="Caenorhabditis elegans" type="Species"/>
            <pair e1="miRNA-corp.d89.s5.e1" e2="miRNA-corp.d89.s5.e0" id="miRNA-corp.d89.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d90" origId="19262177">
        <sentence id="miRNA-corp.d90.s0" origId="19262177.s0" text="Glioma angiogenesis: Towards novel RNA therapeutics.  ">
            <entity charOffset="0-5" id="miRNA-corp.d90.s0.e0" text="Glioma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s1" origId="19262177.s1" text="Brain tumors exhibit marked and aberrant blood vessel formation indicating angiogenic endothelial cells as a potential target for brain tumor treatment. ">
            <entity charOffset="0-11" id="miRNA-corp.d90.s1.e0" text="Brain tumors" type="Diseases"/>
            <entity charOffset="109-124" id="miRNA-corp.d90.s1.e1" text="potential target" type="Relation_Trigger"/>
            <entity charOffset="130-140" id="miRNA-corp.d90.s1.e2" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s2" origId="19262177.s2" text="The brain tumor blood vessels are used for nutrient delivery, and possibly for cancer cell migration. ">
            <entity charOffset="4-14" id="miRNA-corp.d90.s2.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="79-84" id="miRNA-corp.d90.s2.e1" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s3" origId="19262177.s3" text="The process of angiogenesis is complex and involves multiple players. "/>
        <sentence id="miRNA-corp.d90.s4" origId="19262177.s4" text="The current angiogenesis inhibitors used in clinical trials mostly target single angiogenic proteins and so far show limited effects on tumor growth. ">
            <entity charOffset="25-34" id="miRNA-corp.d90.s4.e0" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="67-72" id="miRNA-corp.d90.s4.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="136-140" id="miRNA-corp.d90.s4.e2" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s5" origId="19262177.s5" text="Besides the conventional angiogenesis inhibitors, RNA-based inhibitors such as small-interfering RNAs (siRNAs) are being analyzed for their capacity to silence the message of proteins involved in neovascularization. ">
            <entity charOffset="38-47" id="miRNA-corp.d90.s5.e0" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="60-69" id="miRNA-corp.d90.s5.e1" text="inhibitors" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s6" origId="19262177.s6" text="More recently, a new family of non-coding RNAs, named angiomirs [microRNAs (miRNAs) involved in angiogenesis] has emerged. ">
            <entity charOffset="65-73" id="miRNA-corp.d90.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d90.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-62" id="miRNA-corp.d90.s6.e2" text="angiomirs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s7" origId="19262177.s7" text="These small RNAs have the advantage over siRNAs in that they have the potential of silencing multiple messages at the same time and therefore they might become therapeutically relevant in a &quot;one-hit multiple-target&quot; context against brain tumor angiogenesis. ">
            <entity charOffset="232-242" id="miRNA-corp.d90.s7.e0" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d90.s8" origId="19262177.s8" text="In this review we will discuss the emerging technologies in anti-angiogenesis emphasizing on RNA-based therapeutics.   "/>
    </document>
    <document id="miRNA-corp.d91" origId="21122469">
        <sentence id="miRNA-corp.d91.s0" origId="21122469.s1" text="RNA editing by adenosine deamination is a posttranscriptional mechanism for the regulation of gene expression and is particularly widespread in mammals. ">
            <entity charOffset="80-108" id="miRNA-corp.d91.s0.e0" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s1" origId="21122469.s0" text="Gene regulation through RNA editing.  ">
            <entity charOffset="5-14" id="miRNA-corp.d91.s1.e0" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s2" origId="21122469.s6" text="Here, I am reviewing main features of this epigenetic phenomenon, its relevance for health and disease, as well as potential prospects for using RNA editing as a therapeutic tool.   "/>
        <sentence id="miRNA-corp.d91.s3" origId="21122469.s5" text="Widespread A-to-I modification of repeat sequences in the human transcriptome suggests additional roles for RNA editing and links it to other processes of gene regulation, such as RNA splicing as well as siRNA mediated gene silencing and miRNA function. ">
            <entity charOffset="238-242" id="miRNA-corp.d91.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="160-169" id="miRNA-corp.d91.s3.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="58-62" id="miRNA-corp.d91.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s4" origId="21122469.s4" text="The deficiency or misregulation of editing has been implicated in the etiology of neurological diseases, such as epilepsy, amyotrophic lateral sclerosis (ALS), depression and tumor progression. ">
            <entity charOffset="82-102" id="miRNA-corp.d91.s4.e0" text="neurological diseases" type="Diseases"/>
            <entity charOffset="113-120" id="miRNA-corp.d91.s4.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="123-151" id="miRNA-corp.d91.s4.e2" text="amyotrophic lateral sclerosis" type="Diseases"/>
            <entity charOffset="154-156" id="miRNA-corp.d91.s4.e3" text="ALS" type="Diseases"/>
            <entity charOffset="160-169" id="miRNA-corp.d91.s4.e4" text="depression" type="Diseases"/>
            <entity charOffset="175-179" id="miRNA-corp.d91.s4.e5" text="tumor" type="Diseases"/>
            <entity charOffset="18-30" id="miRNA-corp.d91.s4.e6" text="misregulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s5" origId="21122469.s3" text="Also, it regulates important functional properties of neurotransmitter receptor genes in the central nervous system by changing single codons in pre-mRNA. ">
            <entity charOffset="9-17" id="miRNA-corp.d91.s5.e0" text="regulates" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d91.s6" origId="21122469.s2" text="A-to-I RNA editing generates transcriptome and proteome diversity allowing organisms to produce many more gene products and functions than predicted based on the number of genes within their genome. "/>
    </document>
    <document id="miRNA-corp.d92" origId="21205279">
        <sentence id="miRNA-corp.d92.s0" origId="21205279.s0" text="New insights into the roles of microRNAs in drug addiction and neuroplasticity.  ">
            <entity charOffset="31-39" id="miRNA-corp.d92.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-57" id="miRNA-corp.d92.s0.e1" text="drug addiction" type="Diseases"/>
            <pair e1="miRNA-corp.d92.s0.e0" e2="miRNA-corp.d92.s0.e1" id="miRNA-corp.d92.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s1" origId="21205279.s9" text="In this review, the aim is to provide an overview of the emerging role of miRNAs in addiction.   ">
            <entity charOffset="74-79" id="miRNA-corp.d92.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s2" origId="21205279.s5" text="miRNAs are small non-coding RNAs, particularly abundant in the nervous system, that play key roles as regulatory molecules in processes such as neurogenesis, synapse development and plasticity in the brain. ">
            <entity charOffset="0-5" id="miRNA-corp.d92.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-121" id="miRNA-corp.d92.s2.e1" text="regulatory molecules" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s3" origId="21205279.s6" text="They also act as key spatiotemporal regulators during dendritic morphogenesis, controlling the expression of hundreds of genes involved in neuroplasticity and in the function of synapses. ">
            <entity charOffset="36-45" id="miRNA-corp.d92.s3.e0" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s4" origId="21205279.s7" text="Recent studies have identified changes of several specific miRNA expression profiles and polymorphisms affecting the interactions between miRNAs and their targets in various brain disorders, including addiction: miR-16 causes adaptive changes in production of the serotonin transporter; miR-133b is specifically expressed in midbrain dopaminergic neurons, and regulates the production of tyrosine hydroxylase and the dopamine transporter; miR-212 affects production of striatal brain-derived neurotrophic factor and synaptic plasticity upon cocaine. ">
            <entity charOffset="59-63" id="miRNA-corp.d92.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="138-143" id="miRNA-corp.d92.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="174-188" id="miRNA-corp.d92.s4.e2" text="brain disorders" type="Diseases"/>
            <entity charOffset="212-217" id="miRNA-corp.d92.s4.e3" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="439-445" id="miRNA-corp.d92.s4.e4" text="miR-212" type="Specific_miRNAs"/>
            <entity charOffset="287-294" id="miRNA-corp.d92.s4.e5" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="299-320" id="miRNA-corp.d92.s4.e6" text="specifically expressed" type="Relation_Trigger"/>
            <entity charOffset="360-368" id="miRNA-corp.d92.s4.e7" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="155-161" id="miRNA-corp.d92.s4.e8" text="targets" type="Relation_Trigger"/>
            <entity charOffset="478-510" id="miRNA-corp.d92.s4.e9" text="brain-derived neurotrophic factor" type="Genes/Proteins"/>
            <entity charOffset="388-407" id="miRNA-corp.d92.s4.e10" text="tyrosine hydroxylase" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e5" e2="miRNA-corp.d92.s4.e9" id="miRNA-corp.d92.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e5" e2="miRNA-corp.d92.s4.e10" id="miRNA-corp.d92.s4.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e5" e2="miRNA-corp.d92.s4.e2" id="miRNA-corp.d92.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s4.e0" e2="miRNA-corp.d92.s4.e9" id="miRNA-corp.d92.s4.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e0" e2="miRNA-corp.d92.s4.e10" id="miRNA-corp.d92.s4.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e0" e2="miRNA-corp.d92.s4.e2" id="miRNA-corp.d92.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s4.e1" e2="miRNA-corp.d92.s4.e9" id="miRNA-corp.d92.s4.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e1" e2="miRNA-corp.d92.s4.e10" id="miRNA-corp.d92.s4.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e1" e2="miRNA-corp.d92.s4.e2" id="miRNA-corp.d92.s4.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s4.e3" e2="miRNA-corp.d92.s4.e9" id="miRNA-corp.d92.s4.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e3" e2="miRNA-corp.d92.s4.e10" id="miRNA-corp.d92.s4.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e3" e2="miRNA-corp.d92.s4.e2" id="miRNA-corp.d92.s4.p11" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d92.s4.e4" e2="miRNA-corp.d92.s4.e9" id="miRNA-corp.d92.s4.p12" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e4" e2="miRNA-corp.d92.s4.e10" id="miRNA-corp.d92.s4.p13" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d92.s4.e4" e2="miRNA-corp.d92.s4.e2" id="miRNA-corp.d92.s4.p14" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s5" origId="21205279.s8" text="Clearly, specific miRNAs have emerged as key regulators leading to addiction, and could serve as valuable targets for more efficient therapies. ">
            <entity charOffset="18-23" id="miRNA-corp.d92.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-54" id="miRNA-corp.d92.s5.e1" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="106-112" id="miRNA-corp.d92.s5.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s6" origId="21205279.s1" text="ABSTRACT : Drug addiction is a major public health issue. ">
            <entity charOffset="11-24" id="miRNA-corp.d92.s6.e0" text="Drug addiction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s7" origId="21205279.s2" text="It is typically a multigenetic brain disorder, implying combined changes of expression of several hundred genes. ">
            <entity charOffset="31-44" id="miRNA-corp.d92.s7.e0" text="brain disorder" type="Diseases"/>
            <entity charOffset="65-85" id="miRNA-corp.d92.s7.e1" text="changes of expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s8" origId="21205279.s3" text="Psychostimulants (such as cocaine, heroin and amphetamines) induce strong and persistent neuroadaptive changes through a surfeit of gene regulatory mechanisms leading to addiction. ">
            <entity charOffset="137-146" id="miRNA-corp.d92.s8.e0" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d92.s9" origId="21205279.s4" text="Activity-dependent synaptic plasticity of the mesolimbic dopaminergic system, known as the 'reward pathway', plays a crucial role in the development of drug dependence. ">
            <entity charOffset="152-166" id="miRNA-corp.d92.s9.e0" text="drug dependence" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d93" origId="20043718">
        <sentence id="miRNA-corp.d93.s0" origId="20043718.s3" text="The authors review the literature on the role of miRNAs in the formation and propagation of gliomas and medulloblastomas, highlighting the potential of these molecules and their inhibitors as therapeutics.   ">
            <entity charOffset="49-54" id="miRNA-corp.d93.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-119" id="miRNA-corp.d93.s0.e1" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="92-98" id="miRNA-corp.d93.s0.e2" text="gliomas" type="Diseases"/>
            <entity charOffset="178-187" id="miRNA-corp.d93.s0.e3" text="inhibitors" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d93.s0.e0" e2="miRNA-corp.d93.s0.e1" id="miRNA-corp.d93.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d93.s0.e0" e2="miRNA-corp.d93.s0.e2" id="miRNA-corp.d93.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s1" origId="20043718.s2" text="In addition to the established role of miRNAs as developmental regulators of normal cellular function, they have recently been shown to be important players in pathological states such as cancer. ">
            <entity charOffset="39-44" id="miRNA-corp.d93.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="63-72" id="miRNA-corp.d93.s1.e1" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="188-193" id="miRNA-corp.d93.s1.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d93.s1.e0" e2="miRNA-corp.d93.s1.e2" id="miRNA-corp.d93.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s2" origId="20043718.s0" text="The many roles of microRNAs in brain tumor biology.  ">
            <entity charOffset="18-26" id="miRNA-corp.d93.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-41" id="miRNA-corp.d93.s2.e1" text="brain tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d93.s2.e0" e2="miRNA-corp.d93.s2.e1" id="miRNA-corp.d93.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d93.s3" origId="20043718.s1" text="MicroRNAs (miRNAs) are now recognized as the primary RNAs involved in the purposeful silencing of the cell's own message. ">
            <entity charOffset="0-8" id="miRNA-corp.d93.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d93.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d94" origId="20347935">
        <sentence id="miRNA-corp.d94.s0" origId="20347935.s1" text="Micro RNAs (miRNAs) are post-transcriptional modulators of gene expression that regulate the stability and translation of their target messenger RNAs (mRNAs). ">
            <entity charOffset="0-9" id="miRNA-corp.d94.s0.e0" text="Micro RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="12-17" id="miRNA-corp.d94.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-87" id="miRNA-corp.d94.s0.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="45-73" id="miRNA-corp.d94.s0.e3" text="modulators of gene expression" type="Relation_Trigger"/>
            <entity charOffset="128-133" id="miRNA-corp.d94.s0.e4" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s1" origId="20347935.s0" text="Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation.  ">
            <entity charOffset="0-13" id="miRNA-corp.d94.s1.e0" text="Micro RNA-125b" type="Specific_miRNAs"/>
            <entity charOffset="16-25" id="miRNA-corp.d94.s1.e1" text="miRNA-125b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s2" origId="20347935.s3" text="In vitro, anti-miRNA-125b added exogenously to IL-6-stressed NHA cultures attenuated both glial cell proliferation and increased the expression of the cyclin-dependent kinase inhibitor 2A (CDKN2A), a miRNA-125b target and negative regulator of cell growth. ">
            <entity charOffset="47-50" id="miRNA-corp.d94.s2.e0" text="IL-6" type="Genes/Proteins"/>
            <entity charOffset="211-216" id="miRNA-corp.d94.s2.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="119-142" id="miRNA-corp.d94.s2.e2" text="increased the expression" type="Relation_Trigger"/>
            <entity charOffset="200-209" id="miRNA-corp.d94.s2.e3" text="miRNA-125b" type="Specific_miRNAs"/>
            <entity charOffset="151-186" id="miRNA-corp.d94.s2.e4" text="cyclin-dependent kinase inhibitor 2A" type="Genes/Proteins"/>
            <entity charOffset="189-194" id="miRNA-corp.d94.s2.e5" text="CDKN2A" type="Genes/Proteins"/>
            <entity charOffset="74-83" id="miRNA-corp.d94.s2.e6" text="attenuated" type="Relation_Trigger"/>
            <entity charOffset="222-239" id="miRNA-corp.d94.s2.e7" text="negative regulator" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d94.s2.e3" e2="miRNA-corp.d94.s2.e0" id="miRNA-corp.d94.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s2.e3" e2="miRNA-corp.d94.s2.e4" id="miRNA-corp.d94.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s2.e3" e2="miRNA-corp.d94.s2.e5" id="miRNA-corp.d94.s2.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s3" origId="20347935.s2" text="Here we report that the levels of a human brain-enriched miRNA-125b are up-regulated in interleukin-6 (IL-6)-stressed normal human astrocytes (NHA), a treatment known to induce astrogliosis. ">
            <entity charOffset="72-83" id="miRNA-corp.d94.s3.e0" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="57-66" id="miRNA-corp.d94.s3.e1" text="miRNA-125b" type="Specific_miRNAs"/>
            <entity charOffset="88-100" id="miRNA-corp.d94.s3.e2" text="interleukin-6" type="Genes/Proteins"/>
            <entity charOffset="103-106" id="miRNA-corp.d94.s3.e3" text="IL-6" type="Genes/Proteins"/>
            <entity charOffset="36-40" id="miRNA-corp.d94.s3.e4" text="human" type="Species"/>
            <entity charOffset="125-129" id="miRNA-corp.d94.s3.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d94.s3.e1" e2="miRNA-corp.d94.s3.e2" id="miRNA-corp.d94.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s3.e1" e2="miRNA-corp.d94.s3.e3" id="miRNA-corp.d94.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s4" origId="20347935.s5" text="The results suggest that miRNA-125b up-regulation contributes to astrogliosis and to defects in the cell cycle that are characteristic of degenerating brain tissues.   ">
            <entity charOffset="36-48" id="miRNA-corp.d94.s4.e0" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="25-34" id="miRNA-corp.d94.s4.e1" text="miRNA-125b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d94.s5" origId="20347935.s4" text="A strong positive correlation between miRNA-125b abundance and the glial cell markers glial fibrillary acidic protein (GFAP) and vimentin, and CDKN2A down-regulation was noted in advanced Alzheimer's disease (AD) and in Down's syndrome (DS) brain, chronic neurological disorders associated with astrogliosis. ">
            <entity charOffset="129-136" id="miRNA-corp.d94.s5.e0" text="vimentin" type="Genes/Proteins"/>
            <entity charOffset="9-28" id="miRNA-corp.d94.s5.e1" text="positive correlation" type="Relation_Trigger"/>
            <entity charOffset="188-206" id="miRNA-corp.d94.s5.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="209-210" id="miRNA-corp.d94.s5.e3" text="AD" type="Diseases"/>
            <entity charOffset="220-234" id="miRNA-corp.d94.s5.e4" text="Down's syndrome" type="Diseases"/>
            <entity charOffset="237-238" id="miRNA-corp.d94.s5.e5" text="DS" type="Diseases"/>
            <entity charOffset="86-116" id="miRNA-corp.d94.s5.e6" text="glial fibrillary acidic protein" type="Genes/Proteins"/>
            <entity charOffset="119-122" id="miRNA-corp.d94.s5.e7" text="GFAP" type="Genes/Proteins"/>
            <entity charOffset="143-148" id="miRNA-corp.d94.s5.e8" text="CDKN2A" type="Genes/Proteins"/>
            <entity charOffset="38-47" id="miRNA-corp.d94.s5.e9" text="miRNA-125b" type="Specific_miRNAs"/>
            <entity charOffset="150-164" id="miRNA-corp.d94.s5.e10" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="279-288" id="miRNA-corp.d94.s5.e11" text="associated" type="Relation_Trigger"/>
            <entity charOffset="256-277" id="miRNA-corp.d94.s5.e12" text="neurological disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e2" id="miRNA-corp.d94.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e3" id="miRNA-corp.d94.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e4" id="miRNA-corp.d94.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e5" id="miRNA-corp.d94.s5.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e6" id="miRNA-corp.d94.s5.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e7" id="miRNA-corp.d94.s5.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e8" id="miRNA-corp.d94.s5.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e0" id="miRNA-corp.d94.s5.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d94.s5.e9" e2="miRNA-corp.d94.s5.e12" id="miRNA-corp.d94.s5.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d95" origId="21098324">
        <sentence id="miRNA-corp.d95.s0" origId="21098324.s1" text="PURPOSE Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children. ">
            <entity charOffset="104-114" id="miRNA-corp.d95.s0.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="8-23" id="miRNA-corp.d95.s0.e1" text="Medulloblastomas" type="Diseases"/>
            <entity charOffset="43-48" id="miRNA-corp.d95.s0.e2" text="tumors" type="Diseases"/>
            <entity charOffset="119-126" id="miRNA-corp.d95.s0.e3" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s1" origId="21098324.s0" text="Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.  ">
            <entity charOffset="32-46" id="miRNA-corp.d95.s1.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s2" origId="21098324.s7" text="We reveal the relative contribution of each subgroup to clinical outcome as a whole and show that a previously unidentified molecular subgroup, characterized genetically by c-MYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183∼96∼182 expression, is associated with significantly lower rates of event-free and overall survivals. ">
            <entity charOffset="175-177" id="miRNA-corp.d95.s2.e0" text="MYC" type="Genes/Proteins"/>
            <entity charOffset="273-286" id="miRNA-corp.d95.s2.e1" text="miR-183∼96∼182" type="Specific_miRNAs"/>
            <entity charOffset="303-312" id="miRNA-corp.d95.s2.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="263-297" id="miRNA-corp.d95.s2.e3" text="increased miR-183∼96∼182 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d95.s2.e1" e2="miRNA-corp.d95.s2.e0" id="miRNA-corp.d95.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s3" origId="21098324.s6" text="Results Identified are six molecular subgroups of medulloblastoma, each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression. ">
            <entity charOffset="183-187" id="miRNA-corp.d95.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-64" id="miRNA-corp.d95.s3.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="126-148" id="miRNA-corp.d95.s3.e2" text="chromosomal aberrations" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s3.e0" e2="miRNA-corp.d95.s3.e2" id="miRNA-corp.d95.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d95.s3.e0" e2="miRNA-corp.d95.s3.e1" id="miRNA-corp.d95.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s4" origId="21098324.s8" text="CONCLUSION Our results detail the complex genomic heterogeneity of medulloblastomas and identify a previously unrecognized molecular subgroup with poor clinical outcome for which more effective therapeutic strategies should be developed.   ">
            <entity charOffset="67-82" id="miRNA-corp.d95.s4.e0" text="medulloblastomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s5" origId="21098324.s3" text="PATIENTS AND METHODS We profiled the mRNA transcriptome of 194 medulloblastomas and performed high-density single nucleotide polymorphism array and miRNA analysis on 115 and 98 of these, respectively. ">
            <entity charOffset="148-152" id="miRNA-corp.d95.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="63-78" id="miRNA-corp.d95.s5.e1" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d95.s5.e2" text="PATIENTS" type="Species"/>
            <pair e1="miRNA-corp.d95.s5.e0" e2="miRNA-corp.d95.s5.e1" id="miRNA-corp.d95.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s6" origId="21098324.s2" text="To understand the molecular characteristics underlying their heterogeneity and to identify whether such characteristics represent risk factors for patients with this disease, we performed an integrated genomic analysis of a large series of primary tumors. ">
            <entity charOffset="248-253" id="miRNA-corp.d95.s6.e0" text="tumors" type="Diseases"/>
            <entity charOffset="147-154" id="miRNA-corp.d95.s6.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s7" origId="21098324.s5" text="We additionally validated our findings in three previously published independent medulloblastoma data sets. ">
            <entity charOffset="81-95" id="miRNA-corp.d95.s7.e0" text="medulloblastoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d95.s8" origId="21098324.s4" text="Non-negative matrix factorization-based clustering of mRNA expression data was used to identify molecular subgroups of medulloblastoma; DNA copy number, miRNA profiles, and clinical outcomes were analyzed for each. ">
            <entity charOffset="153-157" id="miRNA-corp.d95.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="119-133" id="miRNA-corp.d95.s8.e1" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d95.s8.e0" e2="miRNA-corp.d95.s8.e1" id="miRNA-corp.d95.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d96" origId="19566826">
        <sentence id="miRNA-corp.d96.s0" origId="19566826.s0" text="MicroRNAs and apoptosis: implications in the molecular therapy of human disease.  ">
            <entity charOffset="0-8" id="miRNA-corp.d96.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-70" id="miRNA-corp.d96.s0.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s1" origId="19566826.s1" text="1. MicroRNAs (miRNAs), the small non-coding RNAs of approximately 22 nucleotides, are now recognized as a very large family present throughout the genomes of plants and metazoans. ">
            <entity charOffset="3-11" id="miRNA-corp.d96.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-19" id="miRNA-corp.d96.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s2" origId="19566826.s2" text="These small transcripts modulate protein expression by binding to complementary or partially complementary target protein-coding mRNAs and targeting them for degradation or translational inhibition. ">
            <entity charOffset="107-112" id="miRNA-corp.d96.s2.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="139-147" id="miRNA-corp.d96.s2.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="173-196" id="miRNA-corp.d96.s2.e2" text="translational inhibition" type="Relation_Trigger"/>
            <entity charOffset="24-50" id="miRNA-corp.d96.s2.e3" text="modulate protein expression" type="Relation_Trigger"/>
            <entity charOffset="55-64" id="miRNA-corp.d96.s2.e4" text="binding to" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s3" origId="19566826.s3" text="2. The discovery of miRNAs has revolutionized our understanding of the mechanisms that regulate gene expression, with the addition of an entirely novel level of regulatory control. ">
            <entity charOffset="20-25" id="miRNA-corp.d96.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-110" id="miRNA-corp.d96.s3.e1" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="152-170" id="miRNA-corp.d96.s3.e2" text="level of regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s4" origId="19566826.s7" text="3. One of the most active fields of miRNA research is miRNA regulation of apoptosis, a programmed cell death implicated in many human diseases, such as cancer, Alzheimer's disease, hypertrophy and heart failure. ">
            <entity charOffset="36-40" id="miRNA-corp.d96.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-58" id="miRNA-corp.d96.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="160-178" id="miRNA-corp.d96.s4.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="181-191" id="miRNA-corp.d96.s4.e3" text="hypertrophy" type="Diseases"/>
            <entity charOffset="197-209" id="miRNA-corp.d96.s4.e4" text="heart failure" type="Diseases"/>
            <entity charOffset="60-69" id="miRNA-corp.d96.s4.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="152-157" id="miRNA-corp.d96.s4.e6" text="cancer" type="Diseases"/>
            <entity charOffset="128-132" id="miRNA-corp.d96.s4.e7" text="human" type="Species"/>
            <pair e1="miRNA-corp.d96.s4.e0" e2="miRNA-corp.d96.s4.e2" id="miRNA-corp.d96.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e0" e2="miRNA-corp.d96.s4.e3" id="miRNA-corp.d96.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e0" e2="miRNA-corp.d96.s4.e4" id="miRNA-corp.d96.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e0" e2="miRNA-corp.d96.s4.e6" id="miRNA-corp.d96.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e2" id="miRNA-corp.d96.s4.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e3" id="miRNA-corp.d96.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e4" id="miRNA-corp.d96.s4.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d96.s4.e1" e2="miRNA-corp.d96.s4.e6" id="miRNA-corp.d96.s4.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s5" origId="19566826.s6" text="Indeed, aberrant miRNA expression has been documented in human disease as well as in animal models, with evidence for a causative role in tumourigenesis. ">
            <entity charOffset="17-21" id="miRNA-corp.d96.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="8-32" id="miRNA-corp.d96.s5.e1" text="aberrant miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="57-61" id="miRNA-corp.d96.s5.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s6" origId="19566826.s5" text="We now know that miRNAs play pivotal roles in diverse processes, such as development and differentiation, control of cell proliferation and death, stress response and metabolism. ">
            <entity charOffset="17-22" id="miRNA-corp.d96.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s7" origId="19566826.s4" text="Considerable information on miRNAs has been accumulated in this rapidly evolving research field. ">
            <entity charOffset="28-33" id="miRNA-corp.d96.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s8" origId="19566826.s9" text="4. The present review provides a comprehensive summary and analysis of the currently available data, focusing on the transcriptional controls, target genes and signalling pathways linking the apoptosis-regulating miRNAs and apoptotic cell death.   ">
            <entity charOffset="213-218" id="miRNA-corp.d96.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="143-148" id="miRNA-corp.d96.s8.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d96.s9" origId="19566826.s8" text="Thus far, nearly 30 of 500 human miRNAs have been validated experimentally to regulate apoptosis; this number is likely to increase with future studies. ">
            <entity charOffset="33-38" id="miRNA-corp.d96.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-85" id="miRNA-corp.d96.s9.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="27-31" id="miRNA-corp.d96.s9.e2" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d97" origId="20886384">
        <sentence id="miRNA-corp.d97.s0" origId="20886384.s5" text="Additionally, several research groups have established that inserting microRNA (miRNA)-targeted sequences into the adenoviral genome can modulate adenoviral protein expression to confer tissue and tumor selectivity. ">
            <entity charOffset="70-77" id="miRNA-corp.d97.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-84" id="miRNA-corp.d97.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="137-174" id="miRNA-corp.d97.s0.e2" text="modulate adenoviral protein expression" type="Relation_Trigger"/>
            <entity charOffset="197-201" id="miRNA-corp.d97.s0.e3" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d97.s0.e0" e2="miRNA-corp.d97.s0.e3" id="miRNA-corp.d97.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s0.e1" e2="miRNA-corp.d97.s0.e3" id="miRNA-corp.d97.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s1" origId="20886384.s4" text="It has been suggested that the use of autophagy inducers, such as rapamycin, can enhance the oncolytic potency of recombinant adenoviruses. "/>
        <sentence id="miRNA-corp.d97.s2" origId="20886384.s7" text="This review discusses three aspects of the use of oncolytic adenoviruses to treat cancer: (i) the induction of autophagy and autophagic cell death during adenoviral replication; (ii) the opportunities and strategies involved in the exploitation of miRNA specificity to generate tissue- and tumor-selective oncolytic viruses; and (iii) the rationale for combining oncolytic adenoviruses with chemotherapeutic agents.   ">
            <entity charOffset="248-252" id="miRNA-corp.d97.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="290-294" id="miRNA-corp.d97.s2.e1" text="tumor" type="Diseases"/>
            <entity charOffset="82-87" id="miRNA-corp.d97.s2.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d97.s2.e0" e2="miRNA-corp.d97.s2.e1" id="miRNA-corp.d97.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d97.s2.e0" e2="miRNA-corp.d97.s2.e2" id="miRNA-corp.d97.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s3" origId="20886384.s6" text="Furthermore, the capability of adenoviruses to inhibit the expression of the DNA repair enzyme MGMT and to chemosensitize glioma cells to temozolomide has been demonstrated. ">
            <entity charOffset="47-68" id="miRNA-corp.d97.s3.e0" text="inhibit the expression" type="Relation_Trigger"/>
            <entity charOffset="122-127" id="miRNA-corp.d97.s3.e1" text="glioma" type="Diseases"/>
            <entity charOffset="95-98" id="miRNA-corp.d97.s3.e2" text="MGMT" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s4" origId="20886384.s1" text="In recent years, oncolytic viruses have been genetically engineered to target cancer cells selectively. ">
            <entity charOffset="71-76" id="miRNA-corp.d97.s4.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="78-83" id="miRNA-corp.d97.s4.e1" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s5" origId="20886384.s0" text="Oncolytic adenoviruses for the treatment of brain tumors.  ">
            <entity charOffset="44-55" id="miRNA-corp.d97.s5.e0" text="brain tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d97.s6" origId="20886384.s3" text="The observation that cells infected with replication-competent adenoviruses undergo autophagy has provided new options for investigating the mechanism of adenovirus-induced cell death. "/>
        <sentence id="miRNA-corp.d97.s7" origId="20886384.s2" text="Adenovirus is one such oncolytic virus that is being tested in clinical trials for the treatment of cancer. ">
            <entity charOffset="100-105" id="miRNA-corp.d97.s7.e0" text="cancer" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d98" origId="18234899">
        <sentence id="miRNA-corp.d98.s0" origId="18234899.s9" text="BACE1 mRNA levels tended to increase as miR-107 levels decreased in the progression of AD. Cell culture reporter assays performed with a subset of the predicted miR-107 binding sites indicate the presence of at least one physiological miR-107 miRNA recognition sequence in the 3'-UTR of BACE1 mRNA. ">
            <entity charOffset="161-167" id="miRNA-corp.d98.s0.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="40-46" id="miRNA-corp.d98.s0.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="235-241" id="miRNA-corp.d98.s0.e2" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="287-291" id="miRNA-corp.d98.s0.e3" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="0-4" id="miRNA-corp.d98.s0.e4" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="87-88" id="miRNA-corp.d98.s0.e5" text="AD" type="Diseases"/>
            <entity charOffset="11-35" id="miRNA-corp.d98.s0.e6" text="levels tended to increase" type="Relation_Trigger"/>
            <entity charOffset="48-63" id="miRNA-corp.d98.s0.e7" text="levels decreased" type="Relation_Trigger"/>
            <entity charOffset="169-181" id="miRNA-corp.d98.s0.e8" text="binding sites" type="Relation_Trigger"/>
            <entity charOffset="243-247" id="miRNA-corp.d98.s0.e9" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="243-282" id="miRNA-corp.d98.s0.e10" text="miRNA recognition sequence in the 3'-UTR" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d98.s0.e0" e2="miRNA-corp.d98.s0.e3" id="miRNA-corp.d98.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e0" e2="miRNA-corp.d98.s0.e4" id="miRNA-corp.d98.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e0" e2="miRNA-corp.d98.s0.e5" id="miRNA-corp.d98.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s0.e1" e2="miRNA-corp.d98.s0.e3" id="miRNA-corp.d98.s0.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e1" e2="miRNA-corp.d98.s0.e4" id="miRNA-corp.d98.s0.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e1" e2="miRNA-corp.d98.s0.e5" id="miRNA-corp.d98.s0.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s0.e2" e2="miRNA-corp.d98.s0.e3" id="miRNA-corp.d98.s0.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e2" e2="miRNA-corp.d98.s0.e4" id="miRNA-corp.d98.s0.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e2" e2="miRNA-corp.d98.s0.e5" id="miRNA-corp.d98.s0.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s0.e9" e2="miRNA-corp.d98.s0.e3" id="miRNA-corp.d98.s0.p9" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e9" e2="miRNA-corp.d98.s0.e4" id="miRNA-corp.d98.s0.p10" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s0.e9" e2="miRNA-corp.d98.s0.e5" id="miRNA-corp.d98.s0.p11" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s1" origId="18234899.s7" text="Computational analysis predicted that the 3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted multiply by miR-107. ">
            <entity charOffset="165-171" id="miRNA-corp.d98.s1.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="129-133" id="miRNA-corp.d98.s1.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="74-126" id="miRNA-corp.d98.s1.e2" text="beta-site amyloid precursor protein-cleaving enzyme 1" type="Genes/Proteins"/>
            <entity charOffset="42-151" id="miRNA-corp.d98.s1.e3" text="3'-untranslated region (UTR) of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA is targeted" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d98.s1.e0" e2="miRNA-corp.d98.s1.e1" id="miRNA-corp.d98.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s1.e0" e2="miRNA-corp.d98.s1.e2" id="miRNA-corp.d98.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s2" origId="18234899.s8" text="From the same RNA material analyzed on miRNA microarrays, mRNA expression profiling was performed using Affymetrix Exon Array microarrays on nondemented, MCI, and AD patients. ">
            <entity charOffset="163-164" id="miRNA-corp.d98.s2.e0" text="AD" type="Diseases"/>
            <entity charOffset="39-43" id="miRNA-corp.d98.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="154-156" id="miRNA-corp.d98.s2.e2" text="MCI" type="Diseases"/>
            <entity charOffset="166-173" id="miRNA-corp.d98.s2.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d98.s2.e1" e2="miRNA-corp.d98.s2.e0" id="miRNA-corp.d98.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s2.e1" e2="miRNA-corp.d98.s2.e2" id="miRNA-corp.d98.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s3" origId="18234899.s5" text="Among the AD-related miRNA expression changes, miR-107 was exceptional because miR-107 levels decreased significantly even in patients with the earliest stages of pathology. ">
            <entity charOffset="47-53" id="miRNA-corp.d98.s3.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="79-85" id="miRNA-corp.d98.s3.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="21-25" id="miRNA-corp.d98.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-11" id="miRNA-corp.d98.s3.e3" text="AD" type="Diseases"/>
            <entity charOffset="27-44" id="miRNA-corp.d98.s3.e4" text="expression changes" type="Relation_Trigger"/>
            <entity charOffset="87-102" id="miRNA-corp.d98.s3.e5" text="levels decreased" type="Relation_Trigger"/>
            <entity charOffset="94-116" id="miRNA-corp.d98.s3.e6" text="decreased significantly" type="Relation_Trigger"/>
            <entity charOffset="126-133" id="miRNA-corp.d98.s3.e7" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d98.s3.e2" e2="miRNA-corp.d98.s3.e3" id="miRNA-corp.d98.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s3.e0" e2="miRNA-corp.d98.s3.e3" id="miRNA-corp.d98.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s3.e1" e2="miRNA-corp.d98.s3.e3" id="miRNA-corp.d98.s3.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s4" origId="18234899.s6" text="In situ hybridization with cross-comparison to neuropathology demonstrated that particular cerebral cortical laminas involved by AD pathology exhibit diminished neuronal miR-107 expression. ">
            <entity charOffset="129-130" id="miRNA-corp.d98.s4.e0" text="AD" type="Diseases"/>
            <entity charOffset="170-176" id="miRNA-corp.d98.s4.e1" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="150-187" id="miRNA-corp.d98.s4.e2" text="diminished neuronal miR-107 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d98.s4.e1" e2="miRNA-corp.d98.s4.e0" id="miRNA-corp.d98.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s5" origId="18234899.s3" text="We used miRNA expression microarrays on RNA extracted from human brain tissue from the University of Kentucky Alzheimer's Disease Center Brain Bank with near-optimal clinicopathological correlation. ">
            <entity charOffset="8-12" id="miRNA-corp.d98.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-128" id="miRNA-corp.d98.s5.e1" text="Alzheimer's Disease" type="Diseases"/>
            <entity charOffset="186-196" id="miRNA-corp.d98.s5.e2" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="59-63" id="miRNA-corp.d98.s5.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d98.s5.e0" e2="miRNA-corp.d98.s5.e1" id="miRNA-corp.d98.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s6" origId="18234899.s4" text="Cases were separated into four groups: elderly nondemented with negligible AD-type pathology, nondemented with incipient AD pathology, mild cognitive impairment (MCI) with moderate AD pathology, and AD. ">
            <entity charOffset="121-122" id="miRNA-corp.d98.s6.e0" text="AD" type="Diseases"/>
            <entity charOffset="181-182" id="miRNA-corp.d98.s6.e1" text="AD" type="Diseases"/>
            <entity charOffset="199-200" id="miRNA-corp.d98.s6.e2" text="AD" type="Diseases"/>
            <entity charOffset="162-164" id="miRNA-corp.d98.s6.e3" text="MCI" type="Diseases"/>
            <entity charOffset="135-159" id="miRNA-corp.d98.s6.e4" text="mild cognitive impairment" type="Diseases"/>
            <entity charOffset="64-76" id="miRNA-corp.d98.s6.e5" text="negligible AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s7" origId="18234899.s1" text="MicroRNAs (miRNAs) are small regulatory RNAs that participate in posttranscriptional gene regulation in a sequence-specific manner. ">
            <entity charOffset="0-8" id="miRNA-corp.d98.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d98.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="29-38" id="miRNA-corp.d98.s7.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="90-99" id="miRNA-corp.d98.s7.e3" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s8" origId="18234899.s2" text="However, little is understood about the role(s) of miRNAs in Alzheimer's disease (AD). ">
            <entity charOffset="61-79" id="miRNA-corp.d98.s8.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="82-83" id="miRNA-corp.d98.s8.e1" text="AD" type="Diseases"/>
            <entity charOffset="51-56" id="miRNA-corp.d98.s8.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d98.s8.e2" e2="miRNA-corp.d98.s8.e0" id="miRNA-corp.d98.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s8.e2" e2="miRNA-corp.d98.s8.e1" id="miRNA-corp.d98.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s9" origId="18234899.s10" text="Together, the coordinated application of miRNA profiling, Affymetrix microarrays, new bioinformatics predictions, in situ hybridization, and biochemical validation indicate that miR-107 may be involved in accelerated disease progression through regulation of BACE1.   ">
            <entity charOffset="178-184" id="miRNA-corp.d98.s9.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="259-263" id="miRNA-corp.d98.s9.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="41-45" id="miRNA-corp.d98.s9.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="245-254" id="miRNA-corp.d98.s9.e3" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="205-215" id="miRNA-corp.d98.s9.e4" text="accelerated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d98.s9.e0" e2="miRNA-corp.d98.s9.e1" id="miRNA-corp.d98.s9.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s9.e2" e2="miRNA-corp.d98.s9.e1" id="miRNA-corp.d98.s9.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d98.s10" origId="18234899.s0" text="The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.  ">
            <entity charOffset="27-33" id="miRNA-corp.d98.s10.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="54-72" id="miRNA-corp.d98.s10.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="135-187" id="miRNA-corp.d98.s10.e2" text="beta-site amyloid precursor protein-cleaving enzyme 1" type="Genes/Proteins"/>
            <entity charOffset="18-25" id="miRNA-corp.d98.s10.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-43" id="miRNA-corp.d98.s10.e4" text="expression of microRNA miR-107 decreases" type="Relation_Trigger"/>
            <entity charOffset="121-130" id="miRNA-corp.d98.s10.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="82-91" id="miRNA-corp.d98.s10.e6" text="accelerate" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d98.s10.e0" e2="miRNA-corp.d98.s10.e1" id="miRNA-corp.d98.s10.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s10.e0" e2="miRNA-corp.d98.s10.e2" id="miRNA-corp.d98.s10.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d98.s10.e3" e2="miRNA-corp.d98.s10.e1" id="miRNA-corp.d98.s10.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d98.s10.e3" e2="miRNA-corp.d98.s10.e2" id="miRNA-corp.d98.s10.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d99" origId="18792561">
        <sentence id="miRNA-corp.d99.s0" origId="18792561.s11" text="This opportunistic mycosis infection presented with clinically totally nonspecific signs and symptoms of CNS affection. ">
            <entity charOffset="19-35" id="miRNA-corp.d99.s0.e0" text="mycosis infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s1" origId="18792561.s12" text="Therefore, we suspected affection of CNS with SLE. ">
            <entity charOffset="46-48" id="miRNA-corp.d99.s1.e0" text="SLE" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s2" origId="18792561.s13" text="Even though all diagnostic procedures were made on time and that adequate antifungal and supportive agents were applied very early after the infection onset, the outcome was fatal. ">
            <entity charOffset="141-149" id="miRNA-corp.d99.s2.e0" text="infection" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s3" origId="18792561.s14" text="Because of infective diathesis in patients with SLE, which present with common and opportunistic infections, and due to high mortality rates caused by these infections, we have tried to emphasise the importance of taking adequate specimens early after infection outcome for these rare infective agents like C. neophormans. ">
            <entity charOffset="83-106" id="miRNA-corp.d99.s3.e0" text="opportunistic infections" type="Diseases"/>
            <entity charOffset="157-166" id="miRNA-corp.d99.s3.e1" text="infections" type="Diseases"/>
            <entity charOffset="252-260" id="miRNA-corp.d99.s3.e2" text="infection" type="Diseases"/>
            <entity charOffset="48-50" id="miRNA-corp.d99.s3.e3" text="SLE" type="Diseases"/>
            <entity charOffset="34-41" id="miRNA-corp.d99.s3.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s4" origId="18792561.s10" text="It was meningitis caused by C. neoformans. ">
            <entity charOffset="7-16" id="miRNA-corp.d99.s4.e0" text="meningitis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s5" origId="18792561.s16" text="Reports from Europe are very rare, and this case is the one of that kind in Croatia.   "/>
        <sentence id="miRNA-corp.d99.s6" origId="18792561.s15" text="In recent medical literature are dominant cases reported in Asia. "/>
        <sentence id="miRNA-corp.d99.s7" origId="18792561.s1" text="Systemic erythematosus lupus (SLE) is a disease with wide range of clinical manifestations, signs and symptoms. ">
            <entity charOffset="0-27" id="miRNA-corp.d99.s7.e0" text="Systemic erythematosus lupus" type="Diseases"/>
            <entity charOffset="30-32" id="miRNA-corp.d99.s7.e1" text="SLE" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s8" origId="18792561.s0" text="[Cryptococcal meningitis as a diagnostic problem in a patient with SLE--case report].  ">
            <entity charOffset="67-69" id="miRNA-corp.d99.s8.e0" text="SLE" type="Diseases"/>
            <entity charOffset="1-23" id="miRNA-corp.d99.s8.e1" text="Cryptococcal meningitis" type="Diseases"/>
            <entity charOffset="54-60" id="miRNA-corp.d99.s8.e2" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s9" origId="18792561.s3" text="Very important cause of death in patients with SLE is infection. ">
            <entity charOffset="54-62" id="miRNA-corp.d99.s9.e0" text="infection" type="Diseases"/>
            <entity charOffset="47-49" id="miRNA-corp.d99.s9.e1" text="SLE" type="Diseases"/>
            <entity charOffset="33-40" id="miRNA-corp.d99.s9.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s10" origId="18792561.s2" text="Disease outcome depends mostly on the affection of kidneys and central nervous system by the disease. "/>
        <sentence id="miRNA-corp.d99.s11" origId="18792561.s9" text="During one of the disease flares the patient was hospitalized an opportunistic infection developed. ">
            <entity charOffset="79-87" id="miRNA-corp.d99.s11.e0" text="infection" type="Diseases"/>
            <entity charOffset="37-43" id="miRNA-corp.d99.s11.e1" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s12" origId="18792561.s8" text="As an outcome of the combined effect of disease and immunosuppressive agents used in the treatment of the disease, the patient had increased infective diathesis (repeated infections caused by S. enteritidis--urinary infections and sepsis). ">
            <entity charOffset="171-180" id="miRNA-corp.d99.s12.e0" text="infections" type="Diseases"/>
            <entity charOffset="231-236" id="miRNA-corp.d99.s12.e1" text="sepsis" type="Diseases"/>
            <entity charOffset="208-225" id="miRNA-corp.d99.s12.e2" text="urinary infections" type="Diseases"/>
            <entity charOffset="119-125" id="miRNA-corp.d99.s12.e3" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s13" origId="18792561.s5" text="In this case report we have presented a patient with SLE who initially had severe renal affection, but also complications of immunosuppressive therapy that was administered. ">
            <entity charOffset="53-55" id="miRNA-corp.d99.s13.e0" text="SLE" type="Diseases"/>
            <entity charOffset="40-46" id="miRNA-corp.d99.s13.e1" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s14" origId="18792561.s4" text="Infections are very common among these patients due to aggressive immunosuppressive treatment that is needed for the disease inflammatory activity control. ">
            <entity charOffset="0-9" id="miRNA-corp.d99.s14.e0" text="Infections" type="Diseases"/>
            <entity charOffset="39-46" id="miRNA-corp.d99.s14.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s15" origId="18792561.s7" text="Because of lupus nephropathy, in the early phase of the disease we administered aggressive immunosuppressive therapy (combined parenteral therapy of glucocorticoides and cyclophosphamide). ">
            <entity charOffset="11-27" id="miRNA-corp.d99.s15.e0" text="lupus nephropathy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d99.s16" origId="18792561.s6" text="Even though the disease was accidentally diagnosed, it had a severe clinical progress. "/>
    </document>
    <document id="miRNA-corp.d100" origId="18778868">
        <sentence id="miRNA-corp.d100.s0" origId="18778868.s6" text="Specifically, we highlight the importance of unbiased association studies and follow-up functional experiments for providing a clearer picture of the extent to which microRNA target site variations are relevant in various human diseases.   ">
            <entity charOffset="166-173" id="miRNA-corp.d100.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="175-180" id="miRNA-corp.d100.s0.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="54-64" id="miRNA-corp.d100.s0.e2" text="association" type="Relation_Trigger"/>
            <entity charOffset="222-226" id="miRNA-corp.d100.s0.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d100.s1" origId="18778868.s5" text="We therefore suggest a set of concrete recommendations to guide future investigations. "/>
        <sentence id="miRNA-corp.d100.s2" origId="18778868.s4" text="However, careful assessment of these studies indicates that very few provide a combination of rigorous genetic and functional evidence. "/>
        <sentence id="miRNA-corp.d100.s3" origId="18778868.s3" text="Several studies have identified genetic variants in miRNA target sites that are claimed to be associated with disorders ranging from Parkinson's disease to cancer. ">
            <entity charOffset="52-56" id="miRNA-corp.d100.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-151" id="miRNA-corp.d100.s3.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="94-103" id="miRNA-corp.d100.s3.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="58-63" id="miRNA-corp.d100.s3.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="156-161" id="miRNA-corp.d100.s3.e4" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d100.s3.e0" e2="miRNA-corp.d100.s3.e4" id="miRNA-corp.d100.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d100.s3.e0" e2="miRNA-corp.d100.s3.e1" id="miRNA-corp.d100.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d100.s4" origId="18778868.s2" text="They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie more human diseases than currently appreciated. ">
            <entity charOffset="72-76" id="miRNA-corp.d100.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-133" id="miRNA-corp.d100.s4.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d100.s5" origId="18778868.s1" text="MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression. ">
            <entity charOffset="0-8" id="miRNA-corp.d100.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d100.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-72" id="miRNA-corp.d100.s5.e2" text="regulators of eukaryotic gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d100.s6" origId="18778868.s0" text="MicroRNA target site polymorphisms and human disease.  ">
            <entity charOffset="0-7" id="miRNA-corp.d100.s6.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-14" id="miRNA-corp.d100.s6.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="39-43" id="miRNA-corp.d100.s6.e2" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d101" origId="20883153">
        <sentence id="miRNA-corp.d101.s0" origId="20883153.s0" text="Human traumatic brain injury alters plasma microRNA levels.  ">
            <entity charOffset="43-50" id="miRNA-corp.d101.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-27" id="miRNA-corp.d101.s0.e1" text="brain injury" type="Diseases"/>
            <entity charOffset="29-57" id="miRNA-corp.d101.s0.e2" text="alters plasma microRNA levels" type="Relation_Trigger"/>
            <entity charOffset="0-4" id="miRNA-corp.d101.s0.e3" text="Human" type="Species"/>
            <pair e1="miRNA-corp.d101.s0.e0" e2="miRNA-corp.d101.s0.e1" id="miRNA-corp.d101.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s1" origId="20883153.s1" text="Circulating microRNAs (miRNAs) present in the serum/plasma are characteristically altered in many pathological conditions, and have been employed as diagnostic markers for specific diseases. ">
            <entity charOffset="12-20" id="miRNA-corp.d101.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d101.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s2" origId="20883153.s2" text="We examined if plasma miRNA levels are altered in patients with traumatic brain injury (TBI) relative to matched healthy volunteers, and explored their potential for use as diagnostic TBI biomarkers. ">
            <entity charOffset="22-26" id="miRNA-corp.d101.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-45" id="miRNA-corp.d101.s2.e1" text="levels are altered" type="Relation_Trigger"/>
            <entity charOffset="88-90" id="miRNA-corp.d101.s2.e2" text="TBI" type="Diseases"/>
            <entity charOffset="64-85" id="miRNA-corp.d101.s2.e3" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="184-186" id="miRNA-corp.d101.s2.e4" text="TBI" type="Diseases"/>
            <entity charOffset="50-57" id="miRNA-corp.d101.s2.e5" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d101.s2.e0" e2="miRNA-corp.d101.s2.e2" id="miRNA-corp.d101.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s2.e0" e2="miRNA-corp.d101.s2.e3" id="miRNA-corp.d101.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s2.e0" e2="miRNA-corp.d101.s2.e4" id="miRNA-corp.d101.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s3" origId="20883153.s3" text="The plasma miRNA profiles from severe TBI patients (Glasgow Coma Scale [GCS] score ≤8) and age-, gender-, and race-matched healthy volunteers were compared by microarray analysis. ">
            <entity charOffset="11-15" id="miRNA-corp.d101.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-40" id="miRNA-corp.d101.s3.e1" text="TBI" type="Diseases"/>
            <entity charOffset="42-49" id="miRNA-corp.d101.s3.e2" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d101.s3.e0" e2="miRNA-corp.d101.s3.e1" id="miRNA-corp.d101.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s4" origId="20883153.s4" text="Of the 108 miRNAs identified in healthy volunteer plasma, 52 were altered after severe TBI, including 33 with decreased and 19 with increased relative abundance. ">
            <entity charOffset="11-16" id="miRNA-corp.d101.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-89" id="miRNA-corp.d101.s4.e1" text="TBI" type="Diseases"/>
            <pair e1="miRNA-corp.d101.s4.e0" e2="miRNA-corp.d101.s4.e1" id="miRNA-corp.d101.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s5" origId="20883153.s5" text="An additional 8 miRNAs were detected only in the TBI plasma. ">
            <entity charOffset="16-21" id="miRNA-corp.d101.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-51" id="miRNA-corp.d101.s5.e1" text="TBI" type="Diseases"/>
            <pair e1="miRNA-corp.d101.s5.e0" e2="miRNA-corp.d101.s5.e1" id="miRNA-corp.d101.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s6" origId="20883153.s6" text="We used quantitative RT-PCR to determine if plasma miRNAs could identify TBI patients within the first 24 h post-injury. ">
            <entity charOffset="51-56" id="miRNA-corp.d101.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-75" id="miRNA-corp.d101.s6.e1" text="TBI" type="Diseases"/>
            <entity charOffset="113-118" id="miRNA-corp.d101.s6.e2" text="injury" type="Diseases"/>
            <entity charOffset="77-84" id="miRNA-corp.d101.s6.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d101.s6.e0" e2="miRNA-corp.d101.s6.e1" id="miRNA-corp.d101.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s6.e0" e2="miRNA-corp.d101.s6.e2" id="miRNA-corp.d101.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s7" origId="20883153.s7" text="Receiver operating characteristic curve analysis indicated that miR-16, miR-92a, and miR-765 were good markers of severe TBI (0.89, 0.82, and 0.86 AUC values, respectively). ">
            <entity charOffset="121-123" id="miRNA-corp.d101.s7.e0" text="TBI" type="Diseases"/>
            <entity charOffset="85-91" id="miRNA-corp.d101.s7.e1" text="miR-765" type="Specific_miRNAs"/>
            <entity charOffset="72-78" id="miRNA-corp.d101.s7.e2" text="miR-92a" type="Specific_miRNAs"/>
            <entity charOffset="64-69" id="miRNA-corp.d101.s7.e3" text="miR-16" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d101.s7.e1" e2="miRNA-corp.d101.s7.e0" id="miRNA-corp.d101.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s7.e2" e2="miRNA-corp.d101.s7.e0" id="miRNA-corp.d101.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s7.e3" e2="miRNA-corp.d101.s7.e0" id="miRNA-corp.d101.s7.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s8" origId="20883153.s8" text="Multiple logistic regression analysis revealed that combining these miRNAs markedly increased diagnostic accuracy (100% specificity and 100% sensitivity), compared to either healthy volunteers or orthopedic injury patients. ">
            <entity charOffset="68-73" id="miRNA-corp.d101.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="196-212" id="miRNA-corp.d101.s8.e1" text="orthopedic injury" type="Diseases"/>
            <entity charOffset="214-221" id="miRNA-corp.d101.s8.e2" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d101.s8.e0" e2="miRNA-corp.d101.s8.e1" id="miRNA-corp.d101.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s9" origId="20883153.s9" text="In mild TBI patients (GCS score &gt; 12), miR-765 levels were unchanged, while the plasma levels of miR-92a and miR-16 were significantly increased within the first 24 h of injury compared to healthy volunteers, and had AUC values of 0.78 and 0.82, respectively. ">
            <entity charOffset="83-139" id="miRNA-corp.d101.s9.e0" text="sma levels of miR-92a and miR-16 were significantly incre" type="Relation_Trigger"/>
            <entity charOffset="8-10" id="miRNA-corp.d101.s9.e1" text="TBI" type="Diseases"/>
            <entity charOffset="109-114" id="miRNA-corp.d101.s9.e2" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="97-103" id="miRNA-corp.d101.s9.e3" text="miR-92a" type="Specific_miRNAs"/>
            <entity charOffset="39-45" id="miRNA-corp.d101.s9.e4" text="miR-765" type="Specific_miRNAs"/>
            <entity charOffset="170-175" id="miRNA-corp.d101.s9.e5" text="injury" type="Diseases"/>
            <entity charOffset="12-19" id="miRNA-corp.d101.s9.e6" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d101.s9.e2" e2="miRNA-corp.d101.s9.e1" id="miRNA-corp.d101.s9.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s9.e2" e2="miRNA-corp.d101.s9.e5" id="miRNA-corp.d101.s9.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s9.e3" e2="miRNA-corp.d101.s9.e1" id="miRNA-corp.d101.s9.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s9.e3" e2="miRNA-corp.d101.s9.e5" id="miRNA-corp.d101.s9.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s9.e4" e2="miRNA-corp.d101.s9.e1" id="miRNA-corp.d101.s9.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d101.s9.e4" e2="miRNA-corp.d101.s9.e5" id="miRNA-corp.d101.s9.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s10" origId="20883153.s11" text="Plasma-derived miRNA biomarkers, used in combination with established clinical practices such as imaging, neurocognitive, and motor examinations, have the potential to improve TBI patient classification and possibly management.   ">
            <entity charOffset="15-19" id="miRNA-corp.d101.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="176-178" id="miRNA-corp.d101.s10.e1" text="TBI" type="Diseases"/>
            <entity charOffset="180-186" id="miRNA-corp.d101.s10.e2" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d101.s10.e0" e2="miRNA-corp.d101.s10.e1" id="miRNA-corp.d101.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d101.s11" origId="20883153.s10" text="Our results demonstrate that circulating miRNA levels are altered after TBI, providing a rich new source of potential molecular biomarkers. ">
            <entity charOffset="41-45" id="miRNA-corp.d101.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-64" id="miRNA-corp.d101.s11.e1" text="levels are altered" type="Relation_Trigger"/>
            <entity charOffset="72-74" id="miRNA-corp.d101.s11.e2" text="TBI" type="Diseases"/>
            <pair e1="miRNA-corp.d101.s11.e0" e2="miRNA-corp.d101.s11.e2" id="miRNA-corp.d101.s11.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d102" origId="19665999">
        <sentence id="miRNA-corp.d102.s0" origId="19665999.s0" text="MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.  Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor that plays critical roles in the pathogenesis of several human diseases including tumor metastasis and Alzheimer's disease. ">
            <entity charOffset="0-11" id="miRNA-corp.d102.s0.e0" text="MicroRNA-205" type="Specific_miRNAs"/>
            <entity charOffset="122-171" id="miRNA-corp.d102.s0.e1" text="Low-density lipoprotein receptor-related protein 1" type="Genes/Proteins"/>
            <entity charOffset="174-177" id="miRNA-corp.d102.s0.e2" text="LRP1" type="Genes/Proteins"/>
            <entity charOffset="323-341" id="miRNA-corp.d102.s0.e3" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="89-118" id="miRNA-corp.d102.s0.e4" text="LDL receptor-related protein 1" type="Genes/Proteins"/>
            <entity charOffset="51-80" id="miRNA-corp.d102.s0.e5" text="down-regulating the expression" type="Relation_Trigger"/>
            <entity charOffset="13-20" id="miRNA-corp.d102.s0.e6" text="inhibits" type="Relation_Trigger"/>
            <entity charOffset="22-26" id="miRNA-corp.d102.s0.e7" text="tumor" type="Diseases"/>
            <entity charOffset="302-306" id="miRNA-corp.d102.s0.e8" text="tumor" type="Diseases"/>
            <entity charOffset="277-281" id="miRNA-corp.d102.s0.e9" text="human" type="Species"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e1" id="miRNA-corp.d102.s0.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e4" id="miRNA-corp.d102.s0.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e2" id="miRNA-corp.d102.s0.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e7" id="miRNA-corp.d102.s0.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e8" id="miRNA-corp.d102.s0.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d102.s0.e0" e2="miRNA-corp.d102.s0.e3" id="miRNA-corp.d102.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d102.s1" origId="19665999.s2" text="In human cell lines, we found that miR-205 down-regulates the expression of LRP1 by targeting sequences in the 3'UTR of LRP1 mRNA. ">
            <entity charOffset="35-41" id="miRNA-corp.d102.s1.e0" text="miR-205" type="Specific_miRNAs"/>
            <entity charOffset="76-79" id="miRNA-corp.d102.s1.e1" text="LRP1" type="Genes/Proteins"/>
            <entity charOffset="120-123" id="miRNA-corp.d102.s1.e2" text="LRP1" type="Genes/Proteins"/>
            <entity charOffset="43-71" id="miRNA-corp.d102.s1.e3" text="down-regulates the expression" type="Relation_Trigger"/>
            <entity charOffset="84-115" id="miRNA-corp.d102.s1.e4" text="targeting sequences in the 3'UTR" type="Relation_Trigger"/>
            <entity charOffset="3-7" id="miRNA-corp.d102.s1.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d102.s1.e0" e2="miRNA-corp.d102.s1.e1" id="miRNA-corp.d102.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s1.e0" e2="miRNA-corp.d102.s1.e2" id="miRNA-corp.d102.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d102.s2" origId="19665999.s1" text="However, mechanisms that regulate LRP1 expression under physiological and pathophysiological conditions are not unclear. ">
            <entity charOffset="34-37" id="miRNA-corp.d102.s2.e0" text="LRP1" type="Genes/Proteins"/>
            <entity charOffset="25-48" id="miRNA-corp.d102.s2.e1" text="regulate LRP1 expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d102.s3" origId="19665999.s4" text="The ectopic expression of miR-205 also significantly mitigated migration of both U87 and SK-LU-1 cells. ">
            <entity charOffset="26-32" id="miRNA-corp.d102.s3.e0" text="miR-205" type="Specific_miRNAs"/>
            <entity charOffset="4-21" id="miRNA-corp.d102.s3.e1" text="ectopic expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d102.s4" origId="19665999.s3" text="This effect was abolished by deleting the miR-205 seed site in the 3'UTR of LRP1. ">
            <entity charOffset="42-48" id="miRNA-corp.d102.s4.e0" text="miR-205" type="Specific_miRNAs"/>
            <entity charOffset="76-79" id="miRNA-corp.d102.s4.e1" text="LRP1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s4.e0" e2="miRNA-corp.d102.s4.e1" id="miRNA-corp.d102.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d102.s5" origId="19665999.s5" text="These results, for the first time, demonstrate that expression of human LRP1 is regulated in part by a specific miRNA, leading to decreased tumor cell migration.   ">
            <entity charOffset="72-75" id="miRNA-corp.d102.s5.e0" text="LRP1" type="Genes/Proteins"/>
            <entity charOffset="112-116" id="miRNA-corp.d102.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-88" id="miRNA-corp.d102.s5.e2" text="expression of human LRP1 is regulated" type="Relation_Trigger"/>
            <entity charOffset="140-144" id="miRNA-corp.d102.s5.e3" text="tumor" type="Diseases"/>
            <entity charOffset="66-70" id="miRNA-corp.d102.s5.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d102.s5.e1" e2="miRNA-corp.d102.s5.e0" id="miRNA-corp.d102.s5.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d102.s5.e1" e2="miRNA-corp.d102.s5.e3" id="miRNA-corp.d102.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d103" origId="20552018">
        <sentence id="miRNA-corp.d103.s0" origId="20552018.s3" text="In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease. ">
            <entity charOffset="71-75" id="miRNA-corp.d103.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-108" id="miRNA-corp.d103.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-57" id="miRNA-corp.d103.s0.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="60-61" id="miRNA-corp.d103.s0.e3" text="AD" type="Diseases"/>
            <entity charOffset="71-96" id="miRNA-corp.d103.s0.e4" text="miRNA profiles are altered" type="Relation_Trigger"/>
            <entity charOffset="110-120" id="miRNA-corp.d103.s0.e5" text="dysfunction" type="Relation_Trigger"/>
            <entity charOffset="3-29" id="miRNA-corp.d103.s0.e6" text="neurodegenerative disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e0" e2="miRNA-corp.d103.s0.e2" id="miRNA-corp.d103.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e0" e2="miRNA-corp.d103.s0.e3" id="miRNA-corp.d103.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e0" e2="miRNA-corp.d103.s0.e6" id="miRNA-corp.d103.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e1" e2="miRNA-corp.d103.s0.e2" id="miRNA-corp.d103.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e1" e2="miRNA-corp.d103.s0.e3" id="miRNA-corp.d103.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s0.e1" e2="miRNA-corp.d103.s0.e6" id="miRNA-corp.d103.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s1" origId="20552018.s2" text="These small non-coding RNA regulators are highly enriched in brain where they play key roles in neuronal development, plasticity and disease. ">
            <entity charOffset="27-36" id="miRNA-corp.d103.s1.e0" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s2" origId="20552018.s1" text="Normal brain development and function depends on microRNA (miRNA) networks to fine tune the balance between the transcriptome and proteome of the cell. ">
            <entity charOffset="49-56" id="miRNA-corp.d103.s2.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-63" id="miRNA-corp.d103.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s3" origId="20552018.s0" text="Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.  ">
            <entity charOffset="9-16" id="miRNA-corp.d103.s3.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-64" id="miRNA-corp.d103.s3.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="66-77" id="miRNA-corp.d103.s3.e2" text="amyloid-beta" type="Genes/Proteins"/>
            <entity charOffset="18-29" id="miRNA-corp.d103.s3.e3" text="deregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d103.s3.e0" e2="miRNA-corp.d103.s3.e1" id="miRNA-corp.d103.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s3.e0" e2="miRNA-corp.d103.s3.e2" id="miRNA-corp.d103.s3.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s4" origId="20552018.s7" text="Bioinformatic analysis predicts that the deregulated miRNAs are likely to affect target genes present in prominent neuronal pathways known to be disrupted in AD. Remarkably, we also found that the miRNA deregulation in hippocampal cultures was paralleled in vivo by a deregulation in the hippocampus of Abeta42-depositing APP23 mice, at the onset of Abeta plaque formation. ">
            <entity charOffset="53-58" id="miRNA-corp.d103.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="197-201" id="miRNA-corp.d103.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="158-159" id="miRNA-corp.d103.s4.e2" text="AD" type="Diseases"/>
            <entity charOffset="350-354" id="miRNA-corp.d103.s4.e3" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="41-51" id="miRNA-corp.d103.s4.e4" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="203-214" id="miRNA-corp.d103.s4.e5" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="268-279" id="miRNA-corp.d103.s4.e6" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="81-86" id="miRNA-corp.d103.s4.e7" text="target" type="Relation_Trigger"/>
            <entity charOffset="303-309" id="miRNA-corp.d103.s4.e8" text="Abeta42" type="Genes/Proteins"/>
            <entity charOffset="328-331" id="miRNA-corp.d103.s4.e9" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d103.s4.e1" e2="miRNA-corp.d103.s4.e2" id="miRNA-corp.d103.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s4.e1" e2="miRNA-corp.d103.s4.e3" id="miRNA-corp.d103.s4.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s4.e1" e2="miRNA-corp.d103.s4.e8" id="miRNA-corp.d103.s4.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s4.e0" e2="miRNA-corp.d103.s4.e2" id="miRNA-corp.d103.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s4.e0" e2="miRNA-corp.d103.s4.e3" id="miRNA-corp.d103.s4.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s4.e0" e2="miRNA-corp.d103.s4.e8" id="miRNA-corp.d103.s4.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s5" origId="20552018.s6" text="Time-course assays of neuronal Abeta treatments show that Abeta is in fact a powerful regulator of miRNA levels as the response of certain mature miRNAs is extremely rapid. ">
            <entity charOffset="99-103" id="miRNA-corp.d103.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="146-151" id="miRNA-corp.d103.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-35" id="miRNA-corp.d103.s5.e2" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="58-62" id="miRNA-corp.d103.s5.e3" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="86-110" id="miRNA-corp.d103.s5.e4" text="regulator of miRNA levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d103.s5.e0" e2="miRNA-corp.d103.s5.e2" id="miRNA-corp.d103.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s5.e0" e2="miRNA-corp.d103.s5.e3" id="miRNA-corp.d103.s5.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s5.e1" e2="miRNA-corp.d103.s5.e2" id="miRNA-corp.d103.s5.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s5.e1" e2="miRNA-corp.d103.s5.e3" id="miRNA-corp.d103.s5.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s6" origId="20552018.s5" text="We used sensitive TaqMan low density miRNA arrays (TLDA) on murine primary hippocampal cultures to show that about half of all miRNAs tested were down-regulated in response to Abeta peptides. ">
            <entity charOffset="127-132" id="miRNA-corp.d103.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="176-180" id="miRNA-corp.d103.s6.e1" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="146-159" id="miRNA-corp.d103.s6.e2" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="60-65" id="miRNA-corp.d103.s6.e3" text="murine" type="Species"/>
            <pair e1="miRNA-corp.d103.s6.e0" e2="miRNA-corp.d103.s6.e1" id="miRNA-corp.d103.s6.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s7" origId="20552018.s4" text="Our study dissects the complexity of human AD pathology, and addresses the hypothesis that amyloid-beta (Abeta) itself, a known causative factor of AD, causes neuronal miRNA deregulation, which could contribute to the pathomechanisms of AD. ">
            <entity charOffset="168-172" id="miRNA-corp.d103.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-44" id="miRNA-corp.d103.s7.e1" text="AD" type="Diseases"/>
            <entity charOffset="148-149" id="miRNA-corp.d103.s7.e2" text="AD" type="Diseases"/>
            <entity charOffset="237-238" id="miRNA-corp.d103.s7.e3" text="AD" type="Diseases"/>
            <entity charOffset="91-102" id="miRNA-corp.d103.s7.e4" text="amyloid-beta" type="Genes/Proteins"/>
            <entity charOffset="105-109" id="miRNA-corp.d103.s7.e5" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="174-185" id="miRNA-corp.d103.s7.e6" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="37-41" id="miRNA-corp.d103.s7.e7" text="human" type="Species"/>
            <pair e1="miRNA-corp.d103.s7.e0" e2="miRNA-corp.d103.s7.e1" id="miRNA-corp.d103.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s7.e0" e2="miRNA-corp.d103.s7.e2" id="miRNA-corp.d103.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s7.e0" e2="miRNA-corp.d103.s7.e3" id="miRNA-corp.d103.s7.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s7.e0" e2="miRNA-corp.d103.s7.e4" id="miRNA-corp.d103.s7.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d103.s7.e0" e2="miRNA-corp.d103.s7.e5" id="miRNA-corp.d103.s7.p4" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s8" origId="20552018.s8" text="In addition, the miRNA deregulation in hippocampal cultures and APP23 hippocampus overlaps with those obtained in human AD studies. ">
            <entity charOffset="17-21" id="miRNA-corp.d103.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="120-121" id="miRNA-corp.d103.s8.e1" text="AD" type="Diseases"/>
            <entity charOffset="23-34" id="miRNA-corp.d103.s8.e2" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="114-118" id="miRNA-corp.d103.s8.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d103.s8.e0" e2="miRNA-corp.d103.s8.e1" id="miRNA-corp.d103.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d103.s9" origId="20552018.s9" text="Taken together, our findings suggest that neuronal miRNA deregulation in response to an insult by Abeta may be an important factor contributing to the cascade of events leading to AD.   ">
            <entity charOffset="51-55" id="miRNA-corp.d103.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="180-181" id="miRNA-corp.d103.s9.e1" text="AD" type="Diseases"/>
            <entity charOffset="98-102" id="miRNA-corp.d103.s9.e2" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="57-68" id="miRNA-corp.d103.s9.e3" text="deregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d103.s9.e0" e2="miRNA-corp.d103.s9.e1" id="miRNA-corp.d103.s9.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d103.s9.e0" e2="miRNA-corp.d103.s9.e2" id="miRNA-corp.d103.s9.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d104" origId="19580667">
        <sentence id="miRNA-corp.d104.s0" origId="19580667.s3" text="We report here on a patient who was treated for an atypical brain meningioma with multiple surgeries and multiple sessions of stereotactic radiosurgery with good control of his brain disease. ">
            <entity charOffset="66-75" id="miRNA-corp.d104.s0.e0" text="meningioma" type="Diseases"/>
            <entity charOffset="177-189" id="miRNA-corp.d104.s0.e1" text="brain disease" type="Diseases"/>
            <entity charOffset="20-26" id="miRNA-corp.d104.s0.e2" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d104.s1" origId="19580667.s4" text="Thirteen years after diagnosis, he developed bilateral large sacroiliac and abdominal metastases.   "/>
        <sentence id="miRNA-corp.d104.s2" origId="19580667.s1" text="Extracranial metastases from brain meningiomas is a rare, but well-documented entity. ">
            <entity charOffset="35-45" id="miRNA-corp.d104.s2.e0" text="meningiomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d104.s3" origId="19580667.s2" text="Metastases occur mostly in the lungs, pleura and liver, but may also affect lymph nodes and bones. "/>
        <sentence id="miRNA-corp.d104.s4" origId="19580667.s0" text="Extraneural metastases from cranial meningioma: a case report.  ">
            <entity charOffset="28-45" id="miRNA-corp.d104.s4.e0" text="cranial meningioma" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d105" origId="21118127">
        <sentence id="miRNA-corp.d105.s0" origId="21118127.s8" text="The present review examines the various miRNAs that have been identified as being potentially involved in T2D, focusing on the insulin-sensitive organs: white adipose tissue, liver, skeletal muscle and the insulin-producing pancreatic β-cells.   ">
            <entity charOffset="40-45" id="miRNA-corp.d105.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="106-108" id="miRNA-corp.d105.s0.e1" text="T2D" type="Diseases"/>
            <entity charOffset="127-133" id="miRNA-corp.d105.s0.e2" text="insulin" type="Genes/Proteins"/>
            <entity charOffset="206-212" id="miRNA-corp.d105.s0.e3" text="insulin" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d105.s0.e0" e2="miRNA-corp.d105.s0.e1" id="miRNA-corp.d105.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d105.s0.e0" e2="miRNA-corp.d105.s0.e2" id="miRNA-corp.d105.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d105.s0.e0" e2="miRNA-corp.d105.s0.e3" id="miRNA-corp.d105.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s1" origId="21118127.s7" text="miRNAs are involved in a large number of biological functions such as development, metabolism, immunity and diseases such as cancer, cardiovascular diseases and diabetes. ">
            <entity charOffset="133-155" id="miRNA-corp.d105.s1.e0" text="cardiovascular diseases" type="Diseases"/>
            <entity charOffset="161-168" id="miRNA-corp.d105.s1.e1" text="diabetes" type="Diseases"/>
            <entity charOffset="125-130" id="miRNA-corp.d105.s1.e2" text="cancer" type="Diseases"/>
            <entity charOffset="0-5" id="miRNA-corp.d105.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d105.s1.e3" e2="miRNA-corp.d105.s1.e0" id="miRNA-corp.d105.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d105.s1.e3" e2="miRNA-corp.d105.s1.e1" id="miRNA-corp.d105.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d105.s1.e3" e2="miRNA-corp.d105.s1.e2" id="miRNA-corp.d105.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s2" origId="21118127.s6" text="miRNAs are small 22-25-nt-long untranslated RNAs that negatively regulate the translation of mRNAs. ">
            <entity charOffset="65-88" id="miRNA-corp.d105.s2.e0" text="regulate the translation" type="Relation_Trigger"/>
            <entity charOffset="0-5" id="miRNA-corp.d105.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s3" origId="21118127.s5" text="Although T2D seems to be strongly linked to environmental factors such as nutrition and lifestyle, studies have shown that genetic factors, such as polymorphisms associated with metabolic genes, imprinting, fetal programming and miRNA (microRNA) expression, could also contribute to the development of this disease. ">
            <entity charOffset="229-233" id="miRNA-corp.d105.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="236-243" id="miRNA-corp.d105.s3.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-11" id="miRNA-corp.d105.s3.e2" text="T2D" type="Diseases"/>
            <entity charOffset="162-171" id="miRNA-corp.d105.s3.e3" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d105.s3.e0" e2="miRNA-corp.d105.s3.e2" id="miRNA-corp.d105.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d105.s3.e1" e2="miRNA-corp.d105.s3.e2" id="miRNA-corp.d105.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s4" origId="21118127.s4" text="The aetiology and molecular mechanisms of T2D are not fully understood, but compelling evidence points to a link between T2D, obesity, dyslipidaemia and insulin resistance. ">
            <entity charOffset="42-44" id="miRNA-corp.d105.s4.e0" text="T2D" type="Diseases"/>
            <entity charOffset="121-123" id="miRNA-corp.d105.s4.e1" text="T2D" type="Diseases"/>
            <entity charOffset="126-132" id="miRNA-corp.d105.s4.e2" text="obesity" type="Diseases"/>
            <entity charOffset="135-147" id="miRNA-corp.d105.s4.e3" text="dyslipidaemia" type="Diseases"/>
            <entity charOffset="153-170" id="miRNA-corp.d105.s4.e4" text="insulin resistance" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s5" origId="21118127.s3" text="Improper treatment of TD2 can lead to severe complications such as heart disease, stroke, kidney failure, blindness and nerve damage. ">
            <entity charOffset="22-24" id="miRNA-corp.d105.s5.e0" text="TD2" type="Diseases"/>
            <entity charOffset="67-79" id="miRNA-corp.d105.s5.e1" text="heart disease" type="Diseases"/>
            <entity charOffset="82-87" id="miRNA-corp.d105.s5.e2" text="stroke" type="Diseases"/>
            <entity charOffset="90-103" id="miRNA-corp.d105.s5.e3" text="kidney failure" type="Diseases"/>
            <entity charOffset="106-114" id="miRNA-corp.d105.s5.e4" text="blindness" type="Diseases"/>
            <entity charOffset="120-131" id="miRNA-corp.d105.s5.e5" text="nerve damage" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s6" origId="21118127.s2" text="T2D is a progressive metabolic disorder characterized by reduced insulin sensitivity, insulin resistance and pancreatic β-cell dysfunction. ">
            <entity charOffset="0-2" id="miRNA-corp.d105.s6.e0" text="T2D" type="Diseases"/>
            <entity charOffset="65-71" id="miRNA-corp.d105.s6.e1" text="insulin" type="Genes/Proteins"/>
            <entity charOffset="86-103" id="miRNA-corp.d105.s6.e2" text="insulin resistance" type="Diseases"/>
            <entity charOffset="109-137" id="miRNA-corp.d105.s6.e3" text="pancreatic β-cell dysfunction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s7" origId="21118127.s0" text="The involvement of microRNAs in Type 2 diabetes.  ">
            <entity charOffset="19-27" id="miRNA-corp.d105.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-46" id="miRNA-corp.d105.s7.e1" text="Type 2 diabetes" type="Diseases"/>
            <pair e1="miRNA-corp.d105.s7.e0" e2="miRNA-corp.d105.s7.e1" id="miRNA-corp.d105.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d105.s8" origId="21118127.s1" text="T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide. ">
            <entity charOffset="0-2" id="miRNA-corp.d105.s8.e0" text="T2D" type="Diseases"/>
            <entity charOffset="5-28" id="miRNA-corp.d105.s8.e1" text="Type 2 diabetes mellitus" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d106" origId="15105437">
        <sentence id="miRNA-corp.d106.s0" origId="15105437.s0" text="Isolation and characterization of a novel pituitary tumor apoptosis gene.  ">
            <entity charOffset="42-71" id="miRNA-corp.d106.s0.e0" text="pituitary tumor apoptosis gene" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s1" origId="15105437.s2" text="We report the isolation of a novel differentially methylated chromosome 22 CpG island-associated gene (C22orf3). ">
            <entity charOffset="103-109" id="miRNA-corp.d106.s1.e0" text="C22orf3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s2" origId="15105437.s1" text="To determine mechanisms for pituitary neoplasia we used methylation-sensitive arbitrarily primed-PCR to isolate novel genes that are differentially methylated relative to normal pituitary. "/>
        <sentence id="miRNA-corp.d106.s3" origId="15105437.s4" text="Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene. ">
            <entity charOffset="82-98" id="miRNA-corp.d106.s3.e0" text="failed to express" type="Relation_Trigger"/>
            <entity charOffset="287-303" id="miRNA-corp.d106.s3.e1" text="failed to express" type="Relation_Trigger"/>
            <entity charOffset="100-129" id="miRNA-corp.d106.s3.e2" text="pituitary tumor apoptosis gene" type="Genes/Proteins"/>
            <entity charOffset="132-135" id="miRNA-corp.d106.s3.e3" text="PTAG" type="Genes/Proteins"/>
            <entity charOffset="275-280" id="miRNA-corp.d106.s3.e4" text="tumors" type="Diseases"/>
            <entity charOffset="42-49" id="miRNA-corp.d106.s3.e5" text="adenomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s4" origId="15105437.s3" text="Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary. ">
            <entity charOffset="38-42" id="miRNA-corp.d106.s4.e0" text="tumor" type="Diseases"/>
            <entity charOffset="303-319" id="miRNA-corp.d106.s4.e1" text="failed to express" type="Relation_Trigger"/>
            <entity charOffset="126-133" id="miRNA-corp.d106.s4.e2" text="adenomas" type="Diseases"/>
            <entity charOffset="235-241" id="miRNA-corp.d106.s4.e3" text="adenoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s5" origId="15105437.s6" text="Enforced expression of C22orf3 in AtT20 cells had no measurable effects on cell proliferation or viability; however, in response to bromocriptine challenge (10-40 microm) cells expressing this gene showed a significantly augmented apoptotic response as determined by both acridine orange staining and TUNEL labeling. ">
            <entity charOffset="23-29" id="miRNA-corp.d106.s5.e0" text="C22orf3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s6" origId="15105437.s5" text="In those cases where the CpG island of these genes was methylated it was invariably associated with loss of transcript expression. ">
            <entity charOffset="100-128" id="miRNA-corp.d106.s6.e0" text="loss of transcript expression" type="Relation_Trigger"/>
            <entity charOffset="84-93" id="miRNA-corp.d106.s6.e1" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s7" origId="15105437.s8" text="In addition, in time course experiments, direct measurement of active caspases by fluorochrome-labeled inhibition of caspases, showed an augmented increase (approximately 2.4 fold) in active caspases in response to bromocriptine challenge in cells expressing C22orf3 relative to those harboring an empty vector control. ">
            <entity charOffset="103-112" id="miRNA-corp.d106.s7.e0" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="259-265" id="miRNA-corp.d106.s7.e1" text="C22orf3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s8" origId="15105437.s7" text="The apoptotic response to bromocriptine challenge was inhibited in coincubation experiments with the general caspase inhibitor z-VAD-fmk. ">
            <entity charOffset="54-62" id="miRNA-corp.d106.s8.e0" text="inhibited" type="Relation_Trigger"/>
            <entity charOffset="117-125" id="miRNA-corp.d106.s8.e1" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s9" origId="15105437.s9" text="The pituitary tumor derivation and its role in apoptosis of this gene led us to assign the acronym PTAG to this gene and its protein product. ">
            <entity charOffset="99-102" id="miRNA-corp.d106.s9.e0" text="PTAG" type="Genes/Proteins"/>
            <entity charOffset="4-18" id="miRNA-corp.d106.s9.e1" text="pituitary tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d106.s10" origId="15105437.s10" text="The ability of cells, showing reduced expression of PTAG, to evade or show a blunted apoptotic response may underlie oncogenic transformation in both the pituitary and other tumor types.   ">
            <entity charOffset="52-55" id="miRNA-corp.d106.s10.e0" text="PTAG" type="Genes/Proteins"/>
            <entity charOffset="174-178" id="miRNA-corp.d106.s10.e1" text="tumor" type="Diseases"/>
            <entity charOffset="30-47" id="miRNA-corp.d106.s10.e2" text="reduced expression" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d107" origId="18434550">
        <sentence id="miRNA-corp.d107.s0" origId="18434550.s0" text="Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.  ">
            <entity charOffset="25-35" id="miRNA-corp.d107.s0.e0" text="miR-29a/b-1" type="Specific_miRNAs"/>
            <entity charOffset="95-99" id="miRNA-corp.d107.s0.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="8-15" id="miRNA-corp.d107.s0.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-23" id="miRNA-corp.d107.s0.e3" text="Loss of microRNA cluster" type="Relation_Trigger"/>
            <entity charOffset="85-125" id="miRNA-corp.d107.s0.e4" text="increased BACE1/beta-secretase expression" type="Relation_Trigger"/>
            <entity charOffset="40-67" id="miRNA-corp.d107.s0.e5" text="sporadic Alzheimer's disease" type="Diseases"/>
            <entity charOffset="101-114" id="miRNA-corp.d107.s0.e6" text="beta-secretase" type="Genes/Proteins"/>
            <entity charOffset="69-78" id="miRNA-corp.d107.s0.e7" text="correlates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d107.s0.e0" e2="miRNA-corp.d107.s0.e1" id="miRNA-corp.d107.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s0.e0" e2="miRNA-corp.d107.s0.e5" id="miRNA-corp.d107.s0.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s0.e0" e2="miRNA-corp.d107.s0.e6" id="miRNA-corp.d107.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s0.e2" e2="miRNA-corp.d107.s0.e1" id="miRNA-corp.d107.s0.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s0.e2" e2="miRNA-corp.d107.s0.e5" id="miRNA-corp.d107.s0.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s0.e2" e2="miRNA-corp.d107.s0.e6" id="miRNA-corp.d107.s0.p5" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s1" origId="18434550.s1" text="Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease. ">
            <entity charOffset="21-23" id="miRNA-corp.d107.s1.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="72-73" id="miRNA-corp.d107.s1.e1" text="AD" type="Diseases"/>
            <entity charOffset="167-171" id="miRNA-corp.d107.s1.e2" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="214-218" id="miRNA-corp.d107.s1.e3" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="300-302" id="miRNA-corp.d107.s1.e4" text="APP" type="Genes/Proteins"/>
            <entity charOffset="307-311" id="miRNA-corp.d107.s1.e5" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="187-197" id="miRNA-corp.d107.s1.e6" text="sporadic AD" type="Diseases"/>
            <entity charOffset="43-69" id="miRNA-corp.d107.s1.e7" text="genetic Alzheimer's disease" type="Diseases"/>
            <entity charOffset="262-281" id="miRNA-corp.d107.s1.e8" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="340-349" id="miRNA-corp.d107.s1.e9" text="associated" type="Relation_Trigger"/>
            <entity charOffset="313-326" id="miRNA-corp.d107.s1.e10" text="beta-secretase" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s2" origId="18434550.s2" text="We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain. ">
            <entity charOffset="170-172" id="miRNA-corp.d107.s2.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="178-182" id="miRNA-corp.d107.s2.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="37-44" id="miRNA-corp.d107.s2.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-51" id="miRNA-corp.d107.s2.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-126" id="miRNA-corp.d107.s2.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-87" id="miRNA-corp.d107.s2.e5" text="sporadic AD" type="Diseases"/>
            <entity charOffset="26-63" id="miRNA-corp.d107.s2.e6" text="changes in microRNA (miRNA) expression" type="Relation_Trigger"/>
            <entity charOffset="156-165" id="miRNA-corp.d107.s2.e7" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="184-218" id="miRNA-corp.d107.s2.e8" text="expression appeared to be decreased" type="Relation_Trigger"/>
            <entity charOffset="89-96" id="miRNA-corp.d107.s2.e9" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d107.s2.e2" e2="miRNA-corp.d107.s2.e5" id="miRNA-corp.d107.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s2.e2" e2="miRNA-corp.d107.s2.e0" id="miRNA-corp.d107.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s2.e2" e2="miRNA-corp.d107.s2.e1" id="miRNA-corp.d107.s2.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s2.e3" e2="miRNA-corp.d107.s2.e5" id="miRNA-corp.d107.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s2.e3" e2="miRNA-corp.d107.s2.e0" id="miRNA-corp.d107.s2.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s2.e3" e2="miRNA-corp.d107.s2.e1" id="miRNA-corp.d107.s2.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s2.e4" e2="miRNA-corp.d107.s2.e5" id="miRNA-corp.d107.s2.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s2.e4" e2="miRNA-corp.d107.s2.e0" id="miRNA-corp.d107.s2.p7" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s2.e4" e2="miRNA-corp.d107.s2.e1" id="miRNA-corp.d107.s2.p8" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s3" origId="18434550.s3" text="We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro. ">
            <entity charOffset="55-59" id="miRNA-corp.d107.s3.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="46-70" id="miRNA-corp.d107.s3.e1" text="regulate BACE1 expression" type="Relation_Trigger"/>
            <entity charOffset="18-40" id="miRNA-corp.d107.s3.e2" text="miR-29a, -29b-1, and -9" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d107.s3.e2" e2="miRNA-corp.d107.s3.e0" id="miRNA-corp.d107.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s4" origId="18434550.s4" text="The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. ">
            <entity charOffset="121-125" id="miRNA-corp.d107.s4.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="82-83" id="miRNA-corp.d107.s4.e1" text="AD" type="Diseases"/>
            <entity charOffset="4-14" id="miRNA-corp.d107.s4.e2" text="miR-29a/b-1" type="Specific_miRNAs"/>
            <entity charOffset="47-48" id="miRNA-corp.d107.s4.e3" text="AD" type="Diseases"/>
            <entity charOffset="50-57" id="miRNA-corp.d107.s4.e4" text="dementia" type="Diseases"/>
            <entity charOffset="28-77" id="miRNA-corp.d107.s4.e5" text="significantly (and AD-dementia-specific) decreased" type="Relation_Trigger"/>
            <entity charOffset="105-133" id="miRNA-corp.d107.s4.e6" text="abnormally high BACE1 protein" type="Relation_Trigger"/>
            <entity charOffset="85-92" id="miRNA-corp.d107.s4.e7" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d107.s4.e2" e2="miRNA-corp.d107.s4.e1" id="miRNA-corp.d107.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s4.e2" e2="miRNA-corp.d107.s4.e3" id="miRNA-corp.d107.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s4.e2" e2="miRNA-corp.d107.s4.e4" id="miRNA-corp.d107.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d107.s4.e2" e2="miRNA-corp.d107.s4.e0" id="miRNA-corp.d107.s4.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s5" origId="18434550.s5" text="Similar correlations between expression of this cluster and BACE1 were found during brain development and in primary neuronal cultures. ">
            <entity charOffset="60-64" id="miRNA-corp.d107.s5.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="8-38" id="miRNA-corp.d107.s5.e1" text="correlations between expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s6" origId="18434550.s6" text="Finally, we provide evidence for a potential causal relationship between miR-29a/b-1 expression and Abeta generation in a cell culture model. ">
            <entity charOffset="100-104" id="miRNA-corp.d107.s6.e0" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="73-83" id="miRNA-corp.d107.s6.e1" text="miR-29a/b-1" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d107.s6.e1" e2="miRNA-corp.d107.s6.e0" id="miRNA-corp.d107.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d107.s7" origId="18434550.s7" text="We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.   ">
            <entity charOffset="68-72" id="miRNA-corp.d107.s7.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="78-82" id="miRNA-corp.d107.s7.e1" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="33-38" id="miRNA-corp.d107.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-38" id="miRNA-corp.d107.s7.e3" text="loss of specific miRNAs" type="Relation_Trigger"/>
            <entity charOffset="58-89" id="miRNA-corp.d107.s7.e4" text="increased BACE1 and Abeta levels" type="Relation_Trigger"/>
            <entity charOffset="94-104" id="miRNA-corp.d107.s7.e5" text="sporadic AD" type="Diseases"/>
            <pair e1="miRNA-corp.d107.s7.e2" e2="miRNA-corp.d107.s7.e0" id="miRNA-corp.d107.s7.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s7.e2" e2="miRNA-corp.d107.s7.e1" id="miRNA-corp.d107.s7.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d107.s7.e2" e2="miRNA-corp.d107.s7.e5" id="miRNA-corp.d107.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d108" origId="18723524">
        <sentence id="miRNA-corp.d108.s0" origId="18723524.s2" text="Here we expand the role of GRN in FTLD-U and demonstrate that a common genetic variant (rs5848), located in the 3'-untranslated region (UTR) of GRN in a binding-site for miR-659, is a major susceptibility factor for FTLD-U. ">
            <entity charOffset="27-29" id="miRNA-corp.d108.s0.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="34-39" id="miRNA-corp.d108.s0.e1" text="FTLD-U" type="Diseases"/>
            <entity charOffset="144-146" id="miRNA-corp.d108.s0.e2" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="170-176" id="miRNA-corp.d108.s0.e3" text="miR-659" type="Specific_miRNAs"/>
            <entity charOffset="216-221" id="miRNA-corp.d108.s0.e4" text="FTLD-U" type="Diseases"/>
            <entity charOffset="153-164" id="miRNA-corp.d108.s0.e5" text="binding-site" type="Relation_Trigger"/>
            <entity charOffset="153-159" id="miRNA-corp.d108.s0.e6" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d108.s0.e3" e2="miRNA-corp.d108.s0.e4" id="miRNA-corp.d108.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d108.s0.e3" e2="miRNA-corp.d108.s0.e0" id="miRNA-corp.d108.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s0.e3" e2="miRNA-corp.d108.s0.e1" id="miRNA-corp.d108.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d108.s0.e3" e2="miRNA-corp.d108.s0.e2" id="miRNA-corp.d108.s0.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s1" origId="18723524.s1" text="Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting approximately 10% of early-onset dementia patients. ">
            <entity charOffset="43-45" id="miRNA-corp.d108.s1.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="114-136" id="miRNA-corp.d108.s1.e1" text="frontotemporal dementia" type="Diseases"/>
            <entity charOffset="139-144" id="miRNA-corp.d108.s1.e2" text="FTLD-U" type="Diseases"/>
            <entity charOffset="219-238" id="miRNA-corp.d108.s1.e3" text="early-onset dementia" type="Diseases"/>
            <entity charOffset="150-186" id="miRNA-corp.d108.s1.e4" text="progressive neurodegenerative disease" type="Diseases"/>
            <entity charOffset="30-40" id="miRNA-corp.d108.s1.e5" text="progranulin" type="Genes/Proteins"/>
            <entity charOffset="69-94" id="miRNA-corp.d108.s1.e6" text="TAR DNA-binding protein 43" type="Genes/Proteins"/>
            <entity charOffset="97-102" id="miRNA-corp.d108.s1.e7" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="54-62" id="miRNA-corp.d108.s1.e8" text="ubiquitin" type="Genes/Proteins"/>
            <entity charOffset="240-247" id="miRNA-corp.d108.s1.e9" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s2" origId="18723524.s0" text="Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.  ">
            <entity charOffset="24-30" id="miRNA-corp.d108.s2.e0" text="miR-659" type="Specific_miRNAs"/>
            <entity charOffset="48-50" id="miRNA-corp.d108.s2.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="94-116" id="miRNA-corp.d108.s2.e2" text="frontotemporal dementia" type="Diseases"/>
            <entity charOffset="79-83" id="miRNA-corp.d108.s2.e3" text="TDP43" type="Genes/Proteins"/>
            <entity charOffset="32-43" id="miRNA-corp.d108.s2.e4" text="binding-site" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d108.s2.e0" e2="miRNA-corp.d108.s2.e1" id="miRNA-corp.d108.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s2.e0" e2="miRNA-corp.d108.s2.e2" id="miRNA-corp.d108.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d108.s2.e0" e2="miRNA-corp.d108.s2.e3" id="miRNA-corp.d108.s2.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s3" origId="18723524.s6" text="In support of these findings, the neuropathology of homozygous rs5848 T-allele carriers frequently resembled the pathological FTLD-U subtype of GRN mutation carriers. ">
            <entity charOffset="126-131" id="miRNA-corp.d108.s3.e0" text="FTLD-U" type="Diseases"/>
            <entity charOffset="144-146" id="miRNA-corp.d108.s3.e1" text="GRN" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s4" origId="18723524.s5" text="A significant reduction in GRN protein was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical methods, mimicking the effect of heterozygous loss-of-function GRN mutations. ">
            <entity charOffset="27-29" id="miRNA-corp.d108.s4.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="200-202" id="miRNA-corp.d108.s4.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="14-37" id="miRNA-corp.d108.s4.e2" text="reduction in GRN protein" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s5" origId="18723524.s4" text="We further demonstrate that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efficiently to the high risk T-allele of rs5848 resulting in augmented translational inhibition of GRN. ">
            <entity charOffset="199-201" id="miRNA-corp.d108.s5.e0" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="49-51" id="miRNA-corp.d108.s5.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="79-85" id="miRNA-corp.d108.s5.e2" text="miR-659" type="Specific_miRNAs"/>
            <entity charOffset="28-34" id="miRNA-corp.d108.s5.e3" text="miR-659" type="Specific_miRNAs"/>
            <entity charOffset="171-194" id="miRNA-corp.d108.s5.e4" text="translational inhibition" type="Relation_Trigger"/>
            <entity charOffset="40-62" id="miRNA-corp.d108.s5.e5" text="regulate GRN expression" type="Relation_Trigger"/>
            <entity charOffset="87-93" id="miRNA-corp.d108.s5.e6" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d108.s5.e2" e2="miRNA-corp.d108.s5.e0" id="miRNA-corp.d108.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s5.e2" e2="miRNA-corp.d108.s5.e1" id="miRNA-corp.d108.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s5.e3" e2="miRNA-corp.d108.s5.e0" id="miRNA-corp.d108.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s5.e3" e2="miRNA-corp.d108.s5.e1" id="miRNA-corp.d108.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s6" origId="18723524.s3" text="In a series of pathologically confirmed FTLD-U patients without GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50-6.73). ">
            <entity charOffset="40-45" id="miRNA-corp.d108.s6.e0" text="FTLD-U" type="Diseases"/>
            <entity charOffset="181-186" id="miRNA-corp.d108.s6.e1" text="FTLD-U" type="Diseases"/>
            <entity charOffset="64-66" id="miRNA-corp.d108.s6.e2" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="47-54" id="miRNA-corp.d108.s6.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s7" origId="18723524.s8" text="Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegenerative disorders.   ">
            <entity charOffset="0-23" id="miRNA-corp.d108.s7.e0" text="Translational regulation" type="Relation_Trigger"/>
            <entity charOffset="28-33" id="miRNA-corp.d108.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-113" id="miRNA-corp.d108.s7.e2" text="neurodegenerative disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d108.s7.e1" e2="miRNA-corp.d108.s7.e2" id="miRNA-corp.d108.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d108.s8" origId="18723524.s7" text="We suggest that the expression of GRN is regulated by miRNAs and that common genetic variability in a miRNA binding-site can significantly increase the risk for FTLD-U. ">
            <entity charOffset="161-166" id="miRNA-corp.d108.s8.e0" text="FTLD-U" type="Diseases"/>
            <entity charOffset="34-36" id="miRNA-corp.d108.s8.e1" text="GRN" type="Genes/Proteins"/>
            <entity charOffset="102-106" id="miRNA-corp.d108.s8.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-59" id="miRNA-corp.d108.s8.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-49" id="miRNA-corp.d108.s8.e4" text="expression of GRN is regulated" type="Relation_Trigger"/>
            <entity charOffset="125-146" id="miRNA-corp.d108.s8.e5" text="significantly increase" type="Relation_Trigger"/>
            <entity charOffset="108-119" id="miRNA-corp.d108.s8.e6" text="binding-site" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d108.s8.e2" e2="miRNA-corp.d108.s8.e0" id="miRNA-corp.d108.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d108.s8.e2" e2="miRNA-corp.d108.s8.e1" id="miRNA-corp.d108.s8.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d108.s8.e3" e2="miRNA-corp.d108.s8.e0" id="miRNA-corp.d108.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d108.s8.e3" e2="miRNA-corp.d108.s8.e1" id="miRNA-corp.d108.s8.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d109" origId="19135980">
        <sentence id="miRNA-corp.d109.s0" origId="19135980.s7" text="Taken together, our findings indicate that miR-15b regulates cell cycle progression in glioma cells by targeting cell cycle-related molecules.   ">
            <entity charOffset="43-49" id="miRNA-corp.d109.s0.e0" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="51-59" id="miRNA-corp.d109.s0.e1" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="103-111" id="miRNA-corp.d109.s0.e2" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="87-92" id="miRNA-corp.d109.s0.e3" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d109.s0.e0" e2="miRNA-corp.d109.s0.e3" id="miRNA-corp.d109.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s1" origId="19135980.s5" text="Over-expression of miR-15b resulted in cell cycle arrest at G0/G1 phase while suppression of miR-15b expression resulted in a decrease of cell populations in G0/G1 and a corresponding increase of cell populations in S phase. ">
            <entity charOffset="19-25" id="miRNA-corp.d109.s1.e0" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="93-99" id="miRNA-corp.d109.s1.e1" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="0-14" id="miRNA-corp.d109.s1.e2" text="Over-expression" type="Relation_Trigger"/>
            <entity charOffset="78-110" id="miRNA-corp.d109.s1.e3" text="suppression of miR-15b expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s2" origId="19135980.s6" text="We further showed that CCNE1 (encoding cyclin E1) is one of the downstream targets of miR-15b. ">
            <entity charOffset="86-92" id="miRNA-corp.d109.s2.e0" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="23-27" id="miRNA-corp.d109.s2.e1" text="CCNE1" type="Genes/Proteins"/>
            <entity charOffset="39-47" id="miRNA-corp.d109.s2.e2" text="cyclin E1" type="Genes/Proteins"/>
            <entity charOffset="75-81" id="miRNA-corp.d109.s2.e3" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d109.s2.e0" e2="miRNA-corp.d109.s2.e2" id="miRNA-corp.d109.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d109.s2.e0" e2="miRNA-corp.d109.s2.e1" id="miRNA-corp.d109.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s3" origId="19135980.s3" text="We have recently compared the miRNA expression profiles between normal brain and glioma tissues from Chinese patients by miRNA microarray and identified a panel of differentially expressed miRNAs. ">
            <entity charOffset="30-34" id="miRNA-corp.d109.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-125" id="miRNA-corp.d109.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="189-194" id="miRNA-corp.d109.s3.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="164-187" id="miRNA-corp.d109.s3.e3" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="81-86" id="miRNA-corp.d109.s3.e4" text="glioma" type="Diseases"/>
            <entity charOffset="109-116" id="miRNA-corp.d109.s3.e5" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d109.s3.e0" e2="miRNA-corp.d109.s3.e4" id="miRNA-corp.d109.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d109.s3.e1" e2="miRNA-corp.d109.s3.e4" id="miRNA-corp.d109.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d109.s3.e2" e2="miRNA-corp.d109.s3.e4" id="miRNA-corp.d109.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s4" origId="19135980.s4" text="Here, we studied the function of one miRNA, miR-15b, in glioma carcinogenesis and elucidated its downstream targets. ">
            <entity charOffset="44-50" id="miRNA-corp.d109.s4.e0" text="miR-15b" type="Specific_miRNAs"/>
            <entity charOffset="56-61" id="miRNA-corp.d109.s4.e1" text="glioma" type="Diseases"/>
            <entity charOffset="37-41" id="miRNA-corp.d109.s4.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-114" id="miRNA-corp.d109.s4.e3" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d109.s4.e2" e2="miRNA-corp.d109.s4.e1" id="miRNA-corp.d109.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d109.s4.e0" e2="miRNA-corp.d109.s4.e1" id="miRNA-corp.d109.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s5" origId="19135980.s1" text="MicroRNAs (miRNAs) are non-protein-coding RNAs that function as post-transcriptional gene regulators. ">
            <entity charOffset="0-8" id="miRNA-corp.d109.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d109.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-99" id="miRNA-corp.d109.s5.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s6" origId="19135980.s2" text="Recent evidence has shown that miRNA plays a pivotal role in the development of many cancers including glioma, a lethal brain cancer. ">
            <entity charOffset="103-108" id="miRNA-corp.d109.s6.e0" text="glioma" type="Diseases"/>
            <entity charOffset="120-131" id="miRNA-corp.d109.s6.e1" text="brain cancer" type="Diseases"/>
            <entity charOffset="31-35" id="miRNA-corp.d109.s6.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-91" id="miRNA-corp.d109.s6.e3" text="cancers" type="Diseases"/>
            <pair e1="miRNA-corp.d109.s6.e2" e2="miRNA-corp.d109.s6.e0" id="miRNA-corp.d109.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d109.s6.e2" e2="miRNA-corp.d109.s6.e1" id="miRNA-corp.d109.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d109.s6.e2" e2="miRNA-corp.d109.s6.e3" id="miRNA-corp.d109.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d109.s7" origId="19135980.s0" text="MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.  ">
            <entity charOffset="0-11" id="miRNA-corp.d109.s7.e0" text="MicroRNA-15b" type="Specific_miRNAs"/>
            <entity charOffset="13-21" id="miRNA-corp.d109.s7.e1" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="49-57" id="miRNA-corp.d109.s7.e2" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="70-75" id="miRNA-corp.d109.s7.e3" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d109.s7.e0" e2="miRNA-corp.d109.s7.e3" id="miRNA-corp.d109.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d110" origId="21408164">
        <sentence id="miRNA-corp.d110.s0" origId="21408164.s2" text="It has been recently demonstrated that herpesviruses encode miRNAs to control the post-transcriptional regulation of expression from their own genomes and possibly that of their host, thus adding an additional layer of complexity to the physiological cross-talk between host and pathogen. ">
            <entity charOffset="60-65" id="miRNA-corp.d110.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-126" id="miRNA-corp.d110.s0.e1" text="regulation of expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s1" origId="21408164.s1" text="MicroRNAs are small non-coding RNAs approximately 22 nt long that modulate gene expression in animals and plants. ">
            <entity charOffset="0-8" id="miRNA-corp.d110.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-89" id="miRNA-corp.d110.s1.e1" text="modulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s2" origId="21408164.s0" text="Co-expression of host and viral microRNAs in porcine dendritic cells infected by the pseudorabies virus.  ">
            <entity charOffset="32-40" id="miRNA-corp.d110.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-12" id="miRNA-corp.d110.s2.e1" text="Co-expression" type="Relation_Trigger"/>
            <entity charOffset="45-51" id="miRNA-corp.d110.s2.e2" text="porcine" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s3" origId="21408164.s6" text="Almost 95% of reads mapped to the draft pig genome sequence and pig miRNAs previously annotated in dedicated databases were detected by sequence alignment. ">
            <entity charOffset="68-73" id="miRNA-corp.d110.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-42" id="miRNA-corp.d110.s3.e1" text="pig" type="Species"/>
            <entity charOffset="64-66" id="miRNA-corp.d110.s3.e2" text="pig" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s4" origId="21408164.s5" text="An average of 2 million reads per sample with a size of 21-24 nucleotides was obtained from six libraries representing three biological replicates of infected and mock-infected DCs. "/>
        <sentence id="miRNA-corp.d110.s5" origId="21408164.s4" text="A catalogue of porcine and viral miRNAs, expressed eight hours post-infection, was established by deep sequencing. ">
            <entity charOffset="33-38" id="miRNA-corp.d110.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-76" id="miRNA-corp.d110.s5.e1" text="infection" type="Diseases"/>
            <entity charOffset="15-21" id="miRNA-corp.d110.s5.e2" text="porcine" type="Species"/>
            <pair e1="miRNA-corp.d110.s5.e0" e2="miRNA-corp.d110.s5.e1" id="miRNA-corp.d110.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s6" origId="21408164.s3" text="The present study focussed on the interactions between porcine dendritic cells (DCs) and the Pseudorabies virus (PRV), an alpha-herpesvirus causing Aujeszky's disease in pigs. ">
            <entity charOffset="148-165" id="miRNA-corp.d110.s6.e0" text="Aujeszky's disease" type="Diseases"/>
            <entity charOffset="170-173" id="miRNA-corp.d110.s6.e1" text="pigs" type="Species"/>
            <entity charOffset="55-61" id="miRNA-corp.d110.s6.e2" text="porcine" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s7" origId="21408164.s7" text="In silico prediction allowed the identification of unknown porcine as well as of five miRNAs transcribed by the Large Latency Transcript (LLT) of PRV. ">
            <entity charOffset="86-91" id="miRNA-corp.d110.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-65" id="miRNA-corp.d110.s7.e1" text="porcine" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s8" origId="21408164.s8" text="The gene target prediction of the viral miRNAs and the Ingenuity Pathway Analysis of differentially expressed pig miRNAs were conducted to contextualize the identified small RNA molecules and functionally characterize their involvement in the post-transcriptional regulation of gene expression. ">
            <entity charOffset="40-45" id="miRNA-corp.d110.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="114-119" id="miRNA-corp.d110.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-14" id="miRNA-corp.d110.s8.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="85-108" id="miRNA-corp.d110.s8.e3" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="264-292" id="miRNA-corp.d110.s8.e4" text="regulation of gene expression" type="Relation_Trigger"/>
            <entity charOffset="110-112" id="miRNA-corp.d110.s8.e5" text="pig" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s9" origId="21408164.s9" text="The results support a role for PRV miRNAs in the maintenance of the host cell latency state through the down-regulation of immediate-early viral genes which is similar to other herpesviruses. ">
            <entity charOffset="35-40" id="miRNA-corp.d110.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-118" id="miRNA-corp.d110.s9.e1" text="down-regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d110.s10" origId="21408164.s10" text="The differentially expressed swine miRNAs identified a unique network of target genes with highly significant functions in the development and function of the nervous system and in infectious mechanisms, suggesting that the modulation of both host and viral miRNAs is necessary for the establishment of PRV latency.   ">
            <entity charOffset="35-40" id="miRNA-corp.d110.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="258-263" id="miRNA-corp.d110.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-78" id="miRNA-corp.d110.s10.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="4-27" id="miRNA-corp.d110.s10.e3" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="224-233" id="miRNA-corp.d110.s10.e4" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="29-33" id="miRNA-corp.d110.s10.e5" text="swine" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d111" origId="18619557">
        <sentence id="miRNA-corp.d111.s0" origId="18619557.s5" text="An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy.   ">
            <entity charOffset="24-32" id="miRNA-corp.d111.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="120-128" id="miRNA-corp.d111.s0.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="95-115" id="miRNA-corp.d111.s0.e2" text="affect the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d111.s1" origId="18619557.s1" text="MicroRNAs (miRNAs) are short non-coding RNAs involved in post-transcriptional regulation of gene expression. ">
            <entity charOffset="0-8" id="miRNA-corp.d111.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d111.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-106" id="miRNA-corp.d111.s1.e2" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d111.s2" origId="18619557.s2" text="Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing. ">
            <entity charOffset="44-48" id="miRNA-corp.d111.s2.e0" text="lin-4" type="Specific_miRNAs"/>
            <entity charOffset="33-37" id="miRNA-corp.d111.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-79" id="miRNA-corp.d111.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-62" id="miRNA-corp.d111.s2.e3" text="C. elegans" type="Species"/>
            <entity charOffset="105-110" id="miRNA-corp.d111.s2.e4" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d111.s3" origId="18619557.s3" text="Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies. ">
            <entity charOffset="128-146" id="miRNA-corp.d111.s3.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="149-167" id="miRNA-corp.d111.s3.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="170-185" id="miRNA-corp.d111.s3.e2" text="viral infections" type="Diseases"/>
            <entity charOffset="188-195" id="miRNA-corp.d111.s3.e3" text="diabetes" type="Diseases"/>
            <entity charOffset="202-211" id="miRNA-corp.d111.s3.e4" text="myopathies" type="Diseases"/>
            <entity charOffset="55-60" id="miRNA-corp.d111.s3.e5" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d111.s4" origId="18619557.s4" text="In the present review we will summarize miRNA profiling studies in human diseases and discuss the newly discovered link between microRNAs and drug response. ">
            <entity charOffset="40-44" id="miRNA-corp.d111.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-136" id="miRNA-corp.d111.s4.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-71" id="miRNA-corp.d111.s4.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d111.s5" origId="18619557.s0" text="MicroRNAs in diseases and drug response.  ">
            <entity charOffset="0-8" id="miRNA-corp.d111.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d112" origId="17347136">
        <sentence id="miRNA-corp.d112.s0" origId="17347136.s0" text="Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo.  "/>
        <sentence id="miRNA-corp.d112.s1" origId="17347136.s2" text="These cancers are thought to be linked to indirect radiation-induced bystander effect. ">
            <entity charOffset="6-12" id="miRNA-corp.d112.s1.e0" text="cancers" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d112.s2" origId="17347136.s1" text="Radiation therapy is a primary treatment modality for brain tumors, yet it has been linked to the increased incidence of secondary, post-radiation therapy cancers. ">
            <entity charOffset="54-65" id="miRNA-corp.d112.s2.e0" text="brain tumors" type="Diseases"/>
            <entity charOffset="155-161" id="miRNA-corp.d112.s2.e1" text="cancers" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d112.s3" origId="17347136.s4" text="Recent evidence suggests that bystander effect may be epigenetic in nature; however, characterization of epigenetic mechanisms involved in bystander effect generation and its long-term persistence has yet to be defined. "/>
        <sentence id="miRNA-corp.d112.s4" origId="17347136.s3" text="Bystander effect occurs when irradiated cells communicate damage to nearby, non-irradiated 'bystander' cells, ultimately contributing to genome destabilization in the non-exposed cells. "/>
        <sentence id="miRNA-corp.d112.s5" origId="17347136.s6" text="We found that localized cranial radiation exposure led to the induction of bystander effect in lead-shielded, distant spleen tissue. "/>
        <sentence id="miRNA-corp.d112.s6" origId="17347136.s5" text="To investigate the possibility that localized X-ray irradiation induces persistent bystander effects in distant tissue, we monitored the induction of epigenetic changes (i.e. alterations in DNA methylation, histone methylation and microRNA (miRNA) expression) in the rat spleen tissue 24 h and 7 months after localized cranial exposure to 20 Gy of X-rays. ">
            <entity charOffset="231-238" id="miRNA-corp.d112.s6.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="241-245" id="miRNA-corp.d112.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="267-269" id="miRNA-corp.d112.s6.e2" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d112.s7" origId="17347136.s8" text="Further, irradiation significantly altered expression of miR-194, a miRNA putatively targeting both DNA methyltransferase-3a and MeCP2. ">
            <entity charOffset="57-63" id="miRNA-corp.d112.s7.e0" text="miR-194" type="Specific_miRNAs"/>
            <entity charOffset="129-133" id="miRNA-corp.d112.s7.e1" text="MeCP2" type="Genes/Proteins"/>
            <entity charOffset="68-72" id="miRNA-corp.d112.s7.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-93" id="miRNA-corp.d112.s7.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="35-52" id="miRNA-corp.d112.s7.e4" text="altered expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d112.s7.e0" e2="miRNA-corp.d112.s7.e1" id="miRNA-corp.d112.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d112.s7.e2" e2="miRNA-corp.d112.s7.e1" id="miRNA-corp.d112.s7.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d112.s8" origId="17347136.s7" text="Specifically, this exposure caused the profound epigenetic dysregulation in the bystander spleen tissue that manifested as a significant loss of global DNA methylation, alterations in methylation of long interspersed nucleotide element-1 (LINE-1) retrotransposable elements and down-regulation of DNA methyltransferases and methyl-binding protein methyl CpG binding protein 2 (MeCP2). ">
            <entity charOffset="377-381" id="miRNA-corp.d112.s8.e0" text="MeCP2" type="Genes/Proteins"/>
            <entity charOffset="59-71" id="miRNA-corp.d112.s8.e1" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="278-292" id="miRNA-corp.d112.s8.e2" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="347-374" id="miRNA-corp.d112.s8.e3" text="methyl CpG binding protein 2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d112.s9" origId="17347136.s9" text="This study is the first to report conclusive evidence of the long-term persistence of bystander effects in radiation carcinogenesis target organ (spleen) upon localized distant exposure using the doses comparable with those used for clinical brain tumor treatments.   ">
            <entity charOffset="242-252" id="miRNA-corp.d112.s9.e0" text="brain tumor" type="Diseases"/>
            <entity charOffset="132-137" id="miRNA-corp.d112.s9.e1" text="target" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d113" origId="15782179">
        <sentence id="miRNA-corp.d113.s0" origId="15782179.s8" text="The RAKE assay is theoretically versatile and may be used for other applications, such as viral gene profiling.   "/>
        <sentence id="miRNA-corp.d113.s1" origId="15782179.s7" text="Furthermore, we demonstrate that miRNAs can be isolated and profiled from formalin-fixed paraffin-embedded tissue, which opens up new opportunities for analyses of small RNAs from archival human tissue. ">
            <entity charOffset="33-38" id="miRNA-corp.d113.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="189-193" id="miRNA-corp.d113.s1.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s2" origId="15782179.s6" text="RAKE offers unique advantages for specificity over northern blots or other microarray-based expression profiling platforms. "/>
        <sentence id="miRNA-corp.d113.s3" origId="15782179.s5" text="We show that the RAKE assay is sensitive and specific for miRNAs and is ideally suited for rapid expression profiling of all known miRNAs. ">
            <entity charOffset="58-63" id="miRNA-corp.d113.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="131-136" id="miRNA-corp.d113.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s4" origId="15782179.s4" text="We used RAKE to study human cell lines and brain tumors. ">
            <entity charOffset="43-54" id="miRNA-corp.d113.s4.e0" text="brain tumors" type="Diseases"/>
            <entity charOffset="22-26" id="miRNA-corp.d113.s4.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s5" origId="15782179.s3" text="The technique is termed the RNA-primed, array-based Klenow enzyme (RAKE) assay, because it involves on-slide application of the Klenow fragment of DNA polymerase I to extend unmodified miRNAs hybridized to immobilized DNA probes. ">
            <entity charOffset="185-190" id="miRNA-corp.d113.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s6" origId="15782179.s2" text="We describe a new method for high-throughput miRNA detection. ">
            <entity charOffset="45-49" id="miRNA-corp.d113.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s7" origId="15782179.s1" text="MicroRNAs (miRNAs) are small regulatory RNAs that serve fundamental biological roles across eukaryotic species. ">
            <entity charOffset="0-8" id="miRNA-corp.d113.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d113.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="29-38" id="miRNA-corp.d113.s7.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d113.s8" origId="15782179.s0" text="Microarray-based, high-throughput gene expression profiling of microRNAs.  ">
            <entity charOffset="63-71" id="miRNA-corp.d113.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d114" origId="19540598">
        <sentence id="miRNA-corp.d114.s0" origId="19540598.s2" text="Brain cells maintain distinct populations of miRNAs that support physiologically normal patterns of expression, however, certain miRNA abundances are significantly altered in neurodegenerative disorders such as Alzheimer's disease (AD). ">
            <entity charOffset="211-229" id="miRNA-corp.d114.s0.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="232-233" id="miRNA-corp.d114.s0.e1" text="AD" type="Diseases"/>
            <entity charOffset="45-50" id="miRNA-corp.d114.s0.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-133" id="miRNA-corp.d114.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="150-170" id="miRNA-corp.d114.s0.e4" text="significantly altered" type="Relation_Trigger"/>
            <entity charOffset="175-201" id="miRNA-corp.d114.s0.e5" text="neurodegenerative disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e2" e2="miRNA-corp.d114.s0.e0" id="miRNA-corp.d114.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e2" e2="miRNA-corp.d114.s0.e1" id="miRNA-corp.d114.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e2" e2="miRNA-corp.d114.s0.e5" id="miRNA-corp.d114.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e3" e2="miRNA-corp.d114.s0.e0" id="miRNA-corp.d114.s0.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e3" e2="miRNA-corp.d114.s0.e1" id="miRNA-corp.d114.s0.p4" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s0.e3" e2="miRNA-corp.d114.s0.e5" id="miRNA-corp.d114.s0.p5" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s1" origId="19540598.s3" text="Here we provide evidence in human neural (HN) cells of an aluminum-sulfate- and reactive oxygen species (ROS)-mediated up-regulation of an NF-kappaB-sensitive miRNA-146a that down-regulates the expression of complement factor H (CFH), an important repressor of inflammation. ">
            <entity charOffset="159-168" id="miRNA-corp.d114.s1.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="208-226" id="miRNA-corp.d114.s1.e1" text="complement factor H" type="Genes/Proteins"/>
            <entity charOffset="229-231" id="miRNA-corp.d114.s1.e2" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="119-131" id="miRNA-corp.d114.s1.e3" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="248-256" id="miRNA-corp.d114.s1.e4" text="repressor" type="Relation_Trigger"/>
            <entity charOffset="175-203" id="miRNA-corp.d114.s1.e5" text="down-regulates the expression" type="Relation_Trigger"/>
            <entity charOffset="28-32" id="miRNA-corp.d114.s1.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d114.s1.e0" e2="miRNA-corp.d114.s1.e1" id="miRNA-corp.d114.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s1.e0" e2="miRNA-corp.d114.s1.e2" id="miRNA-corp.d114.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s2" origId="19540598.s0" text="Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.  ">
            <entity charOffset="83-101" id="miRNA-corp.d114.s2.e0" text="complement factor H" type="Genes/Proteins"/>
            <entity charOffset="104-106" id="miRNA-corp.d114.s2.e1" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="44-53" id="miRNA-corp.d114.s2.e2" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="64-78" id="miRNA-corp.d114.s2.e3" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="135-139" id="miRNA-corp.d114.s2.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d114.s2.e2" e2="miRNA-corp.d114.s2.e0" id="miRNA-corp.d114.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s2.e2" e2="miRNA-corp.d114.s2.e1" id="miRNA-corp.d114.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s3" origId="19540598.s1" text="Micro RNAs (miRNAs) represent a family of small ribonucleic acids (RNAs) that are post-transcriptional regulators of messenger RNA (mRNA) complexity. ">
            <entity charOffset="0-9" id="miRNA-corp.d114.s3.e0" text="Micro RNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="12-17" id="miRNA-corp.d114.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-112" id="miRNA-corp.d114.s3.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s4" origId="19540598.s6" text="An NF-kappaB-containing miRNA-146a-promoter-luciferase reporter construct transfected into HN cells showed significant up-regulation of miRNA-146a after aluminum-sulfate treatment that corresponded to decreased CFH gene expression. ">
            <entity charOffset="136-145" id="miRNA-corp.d114.s4.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="211-213" id="miRNA-corp.d114.s4.e1" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="24-33" id="miRNA-corp.d114.s4.e2" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="119-131" id="miRNA-corp.d114.s4.e3" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="201-229" id="miRNA-corp.d114.s4.e4" text="decreased CFH gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d114.s4.e2" e2="miRNA-corp.d114.s4.e1" id="miRNA-corp.d114.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s4.e0" e2="miRNA-corp.d114.s4.e1" id="miRNA-corp.d114.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s5" origId="19540598.s7" text="These data suggest that (1) as in AD brain, NF-kappaB-sensitive, miRNA-146a-mediated, modulation of CFH gene expression may contribute to inflammatory responses in aluminum-stressed HN cells, and (2) underscores the potential of nanomolar aluminum to drive genotoxic mechanisms characteristic of neurodegenerative disease processes.   ">
            <entity charOffset="100-102" id="miRNA-corp.d114.s5.e0" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="34-35" id="miRNA-corp.d114.s5.e1" text="AD" type="Diseases"/>
            <entity charOffset="65-74" id="miRNA-corp.d114.s5.e2" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="86-118" id="miRNA-corp.d114.s5.e3" text="modulation of CFH gene expression" type="Relation_Trigger"/>
            <entity charOffset="296-320" id="miRNA-corp.d114.s5.e4" text="neurodegenerative disease" type="Diseases"/>
            <pair e1="miRNA-corp.d114.s5.e2" e2="miRNA-corp.d114.s5.e4" id="miRNA-corp.d114.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d114.s5.e2" e2="miRNA-corp.d114.s5.e0" id="miRNA-corp.d114.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s5.e2" e2="miRNA-corp.d114.s5.e1" id="miRNA-corp.d114.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s6" origId="19540598.s4" text="This NF-kappaB-miRNA-146a-CFH signaling circuit is known to be similarly affected by Abeta42 peptides and in AD brain. ">
            <entity charOffset="109-110" id="miRNA-corp.d114.s6.e0" text="AD" type="Diseases"/>
            <entity charOffset="85-91" id="miRNA-corp.d114.s6.e1" text="Abeta42" type="Genes/Proteins"/>
            <entity charOffset="26-28" id="miRNA-corp.d114.s6.e2" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="15-24" id="miRNA-corp.d114.s6.e3" text="miRNA-146a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d114.s6.e3" e2="miRNA-corp.d114.s6.e1" id="miRNA-corp.d114.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s6.e3" e2="miRNA-corp.d114.s6.e2" id="miRNA-corp.d114.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d114.s6.e3" e2="miRNA-corp.d114.s6.e0" id="miRNA-corp.d114.s6.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d114.s7" origId="19540598.s5" text="These aluminum-sulfate-inducible events were not observed in parallel experiments using iron-, magnesium-, or zinc-sulfate-stressed HN cells. "/>
    </document>
    <document id="miRNA-corp.d115" origId="16039986">
        <sentence id="miRNA-corp.d115.s0" origId="16039986.s0" text="Extensive modulation of a set of microRNAs in primary glioblastoma.  ">
            <entity charOffset="10-19" id="miRNA-corp.d115.s0.e0" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="33-41" id="miRNA-corp.d115.s0.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-65" id="miRNA-corp.d115.s0.e2" text="primary glioblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d115.s0.e1" e2="miRNA-corp.d115.s0.e2" id="miRNA-corp.d115.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d115.s1" origId="16039986.s1" text="MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles in animals and plants by repressing translation or cleaving RNA transcripts. ">
            <entity charOffset="0-8" id="miRNA-corp.d115.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d115.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-125" id="miRNA-corp.d115.s1.e2" text="repressing translation" type="Relation_Trigger"/>
            <entity charOffset="62-71" id="miRNA-corp.d115.s1.e3" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d115.s2" origId="16039986.s2" text="The specific modulation of several microRNAs has been recently associated to some forms of human cancer, suggesting that these short molecules may represent a new class of genes involved in oncogenesis. ">
            <entity charOffset="35-43" id="miRNA-corp.d115.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-22" id="miRNA-corp.d115.s2.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="63-72" id="miRNA-corp.d115.s2.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="97-102" id="miRNA-corp.d115.s2.e3" text="cancer" type="Diseases"/>
            <entity charOffset="91-95" id="miRNA-corp.d115.s2.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d115.s2.e0" e2="miRNA-corp.d115.s2.e3" id="miRNA-corp.d115.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d115.s3" origId="16039986.s3" text="In our study, we examined by microarray the global expression levels of 245 microRNAs in glioblastoma multiforme, the most frequent and malignant of primary brain tumors. ">
            <entity charOffset="89-100" id="miRNA-corp.d115.s3.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="157-168" id="miRNA-corp.d115.s3.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="76-84" id="miRNA-corp.d115.s3.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d115.s3.e2" e2="miRNA-corp.d115.s3.e0" id="miRNA-corp.d115.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s3.e2" e2="miRNA-corp.d115.s3.e1" id="miRNA-corp.d115.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d115.s4" origId="16039986.s4" text="The analysis of both glioblastoma tissues and glioblastoma cell lines allowed us to identify a group of microRNAs whose expression is significantly altered in this tumor. ">
            <entity charOffset="21-32" id="miRNA-corp.d115.s4.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="104-112" id="miRNA-corp.d115.s4.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="120-154" id="miRNA-corp.d115.s4.e2" text="expression is significantly altered" type="Relation_Trigger"/>
            <entity charOffset="46-57" id="miRNA-corp.d115.s4.e3" text="glioblastoma" type="Diseases"/>
            <entity charOffset="164-168" id="miRNA-corp.d115.s4.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d115.s4.e1" e2="miRNA-corp.d115.s4.e3" id="miRNA-corp.d115.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s4.e1" e2="miRNA-corp.d115.s4.e4" id="miRNA-corp.d115.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s4.e1" e2="miRNA-corp.d115.s4.e0" id="miRNA-corp.d115.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d115.s5" origId="16039986.s5" text="The most interesting results came from miR-221, strongly up-regulated in glioblastoma and from a set of brain-enriched miRNAs, miR-128, miR-181a, miR-181b, and miR-181c, which are down-regulated in glioblastoma.   ">
            <entity charOffset="39-45" id="miRNA-corp.d115.s5.e0" text="miR-221" type="Specific_miRNAs"/>
            <entity charOffset="127-133" id="miRNA-corp.d115.s5.e1" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="136-143" id="miRNA-corp.d115.s5.e2" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="146-153" id="miRNA-corp.d115.s5.e3" text="miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="160-167" id="miRNA-corp.d115.s5.e4" text="miR-181c" type="Specific_miRNAs"/>
            <entity charOffset="73-84" id="miRNA-corp.d115.s5.e5" text="glioblastoma" type="Diseases"/>
            <entity charOffset="198-209" id="miRNA-corp.d115.s5.e6" text="glioblastoma" type="Diseases"/>
            <entity charOffset="119-124" id="miRNA-corp.d115.s5.e7" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="180-193" id="miRNA-corp.d115.s5.e8" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="57-68" id="miRNA-corp.d115.s5.e9" text="up-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d115.s5.e0" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e0" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e1" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e1" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e7" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e7" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p5" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e2" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e2" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p7" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e3" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e3" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p9" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e4" e2="miRNA-corp.d115.s5.e5" id="miRNA-corp.d115.s5.p10" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d115.s5.e4" e2="miRNA-corp.d115.s5.e6" id="miRNA-corp.d115.s5.p11" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d116" origId="20145152">
        <sentence id="miRNA-corp.d116.s0" origId="20145152.s7" text="Pharmacologic and genetic inhibition of p53 corroborated the hypothesis that pre-miR-630 (but not pre-miR-181a) blocks the upstream signaling pathways that are ignited by DNA damage and converge on p53 activation. ">
            <entity charOffset="102-109" id="miRNA-corp.d116.s0.e0" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="81-87" id="miRNA-corp.d116.s0.e1" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="198-200" id="miRNA-corp.d116.s0.e2" text="p53" type="Genes/Proteins"/>
            <entity charOffset="40-42" id="miRNA-corp.d116.s0.e3" text="p53" type="Genes/Proteins"/>
            <entity charOffset="26-35" id="miRNA-corp.d116.s0.e4" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="202-211" id="miRNA-corp.d116.s0.e5" text="activation" type="Relation_Trigger"/>
            <entity charOffset="112-117" id="miRNA-corp.d116.s0.e6" text="blocks" type="Relation_Trigger"/>
            <entity charOffset="171-180" id="miRNA-corp.d116.s0.e7" text="DNA damage" type="Diseases"/>
            <pair e1="miRNA-corp.d116.s0.e1" e2="miRNA-corp.d116.s0.e2" id="miRNA-corp.d116.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s0.e1" e2="miRNA-corp.d116.s0.e3" id="miRNA-corp.d116.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s0.e1" e2="miRNA-corp.d116.s0.e7" id="miRNA-corp.d116.s0.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d116.s0.e0" e2="miRNA-corp.d116.s0.e2" id="miRNA-corp.d116.s0.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s0.e0" e2="miRNA-corp.d116.s0.e3" id="miRNA-corp.d116.s0.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s0.e0" e2="miRNA-corp.d116.s0.e7" id="miRNA-corp.d116.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s1" origId="20145152.s8" text="Pre-miR-630 arrested A549 cells in the G0-G1 phase of the cell cycle, correlating with increased levels of the cell cycle inhibitor p27(Kip1) as well as with reduced proliferation rates and resulting in greatly diminished sensitivity of A549 cells to the late S-G2-M cell cycle arrest mediated by CDDP. ">
            <entity charOffset="4-10" id="miRNA-corp.d116.s1.e0" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="132-134" id="miRNA-corp.d116.s1.e1" text="p27" type="Genes/Proteins"/>
            <entity charOffset="136-139" id="miRNA-corp.d116.s1.e2" text="Kip1" type="Genes/Proteins"/>
            <entity charOffset="70-80" id="miRNA-corp.d116.s1.e3" text="correlating" type="Relation_Trigger"/>
            <entity charOffset="122-130" id="miRNA-corp.d116.s1.e4" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="87-102" id="miRNA-corp.d116.s1.e5" text="increased levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d116.s1.e0" e2="miRNA-corp.d116.s1.e1" id="miRNA-corp.d116.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s1.e0" e2="miRNA-corp.d116.s1.e2" id="miRNA-corp.d116.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s2" origId="20145152.s9" text="Altogether, these results identify miR-181a and miR-630 as novel modulators of the CDDP response in NSCLC.   ">
            <entity charOffset="35-42" id="miRNA-corp.d116.s2.e0" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="48-54" id="miRNA-corp.d116.s2.e1" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="100-104" id="miRNA-corp.d116.s2.e2" text="NSCLC" type="Diseases"/>
            <entity charOffset="65-74" id="miRNA-corp.d116.s2.e3" text="modulators" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d116.s2.e1" e2="miRNA-corp.d116.s2.e2" id="miRNA-corp.d116.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d116.s2.e0" e2="miRNA-corp.d116.s2.e2" id="miRNA-corp.d116.s2.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s3" origId="20145152.s3" text="The corresponding synthetic miRNA precursors (pre-miRNAs) per se were not lethal when transfected into A549 cells yet affected cell death induction by CDDP, C2-ceramide, cadmium, etoposide, and mitoxantrone in an inducer-specific fashion. ">
            <entity charOffset="28-32" id="miRNA-corp.d116.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-55" id="miRNA-corp.d116.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s4" origId="20145152.s4" text="Whereas synthetic miRNA inhibitors (anti-miRNAs) targeting miR-181a and miR-630 failed to modulate the response of A549 to CDDP, pre-miR-181a and pre-miR-630 enhanced and reduced CDDP-triggered cell death, respectively. ">
            <entity charOffset="133-140" id="miRNA-corp.d116.s4.e0" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="150-156" id="miRNA-corp.d116.s4.e1" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="59-66" id="miRNA-corp.d116.s4.e2" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="72-78" id="miRNA-corp.d116.s4.e3" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="24-33" id="miRNA-corp.d116.s4.e4" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="49-57" id="miRNA-corp.d116.s4.e5" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="90-97" id="miRNA-corp.d116.s4.e6" text="modulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s5" origId="20145152.s5" text="Pre-miR-181a and pre-miR-630 consistently modulated mitochondrial/postmitochondrial steps of the intrinsic pathway of apoptosis, including Bax oligomerization, mitochondrial transmembrane potential dissipation, and the proteolytic maturation of caspase-9 and caspase-3. ">
            <entity charOffset="4-11" id="miRNA-corp.d116.s5.e0" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="21-27" id="miRNA-corp.d116.s5.e1" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="245-253" id="miRNA-corp.d116.s5.e2" text="caspase-9" type="Genes/Proteins"/>
            <entity charOffset="259-267" id="miRNA-corp.d116.s5.e3" text="caspase-3" type="Genes/Proteins"/>
            <entity charOffset="139-141" id="miRNA-corp.d116.s5.e4" text="Bax" type="Genes/Proteins"/>
            <entity charOffset="42-50" id="miRNA-corp.d116.s5.e5" text="modulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d116.s5.e0" e2="miRNA-corp.d116.s5.e2" id="miRNA-corp.d116.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s5.e0" e2="miRNA-corp.d116.s5.e3" id="miRNA-corp.d116.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s5.e0" e2="miRNA-corp.d116.s5.e4" id="miRNA-corp.d116.s5.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s5.e1" e2="miRNA-corp.d116.s5.e2" id="miRNA-corp.d116.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s5.e1" e2="miRNA-corp.d116.s5.e3" id="miRNA-corp.d116.s5.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s5.e1" e2="miRNA-corp.d116.s5.e4" id="miRNA-corp.d116.s5.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s6" origId="20145152.s6" text="In addition, pre-miR-630 blocked early manifestations of the DNA damage response, including the phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase and of two ATM substrates, histone H2AX and p53. ">
            <entity charOffset="17-23" id="miRNA-corp.d116.s6.e0" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="119-147" id="miRNA-corp.d116.s6.e1" text="ataxia-telangiectasia mutated" type="Genes/Proteins"/>
            <entity charOffset="150-152" id="miRNA-corp.d116.s6.e2" text="ATM" type="Genes/Proteins"/>
            <entity charOffset="173-175" id="miRNA-corp.d116.s6.e3" text="ATM" type="Genes/Proteins"/>
            <entity charOffset="197-200" id="miRNA-corp.d116.s6.e4" text="H2AX" type="Genes/Proteins"/>
            <entity charOffset="206-208" id="miRNA-corp.d116.s6.e5" text="p53" type="Genes/Proteins"/>
            <entity charOffset="25-31" id="miRNA-corp.d116.s6.e6" text="blocked" type="Relation_Trigger"/>
            <entity charOffset="61-70" id="miRNA-corp.d116.s6.e7" text="DNA damage" type="Diseases"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e1" id="miRNA-corp.d116.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e2" id="miRNA-corp.d116.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e3" id="miRNA-corp.d116.s6.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e4" id="miRNA-corp.d116.s6.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e5" id="miRNA-corp.d116.s6.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d116.s6.e0" e2="miRNA-corp.d116.s6.e7" id="miRNA-corp.d116.s6.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s7" origId="20145152.s0" text="miR-181a and miR-630 regulate cisplatin-induced cancer cell death.  ">
            <entity charOffset="0-7" id="miRNA-corp.d116.s7.e0" text="miR-181a" type="Specific_miRNAs"/>
            <entity charOffset="13-19" id="miRNA-corp.d116.s7.e1" text="miR-630" type="Specific_miRNAs"/>
            <entity charOffset="21-28" id="miRNA-corp.d116.s7.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="48-53" id="miRNA-corp.d116.s7.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d116.s7.e0" e2="miRNA-corp.d116.s7.e3" id="miRNA-corp.d116.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d116.s7.e1" e2="miRNA-corp.d116.s7.e3" id="miRNA-corp.d116.s7.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s8" origId="20145152.s1" text="MicroRNAs (miRNA) are noncoding RNAs that regulate multiple cellular processes, including proliferation and apoptosis. ">
            <entity charOffset="0-8" id="miRNA-corp.d116.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d116.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-49" id="miRNA-corp.d116.s8.e2" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d116.s9" origId="20145152.s2" text="We used microarray technology to identify miRNAs that were upregulated by non-small cell lung cancer (NSCLC) A549 cells in response to cisplatin (CDDP). ">
            <entity charOffset="42-47" id="miRNA-corp.d116.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-99" id="miRNA-corp.d116.s9.e1" text="non-small cell lung cancer" type="Diseases"/>
            <entity charOffset="102-106" id="miRNA-corp.d116.s9.e2" text="NSCLC" type="Diseases"/>
            <entity charOffset="59-69" id="miRNA-corp.d116.s9.e3" text="upregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d116.s9.e0" e2="miRNA-corp.d116.s9.e1" id="miRNA-corp.d116.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d116.s9.e0" e2="miRNA-corp.d116.s9.e2" id="miRNA-corp.d116.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d117" origId="20630759">
        <sentence id="miRNA-corp.d117.s0" origId="20630759.s3" text="Here, we discuss recent data that support a view that endolysosomal positioning of RNA might facilitate intercellular transmission of RNA and host defence against viruses and retrotransposons. "/>
        <sentence id="miRNA-corp.d117.s1" origId="20630759.s4" text="Positioning of RNA regulatory mechanisms on endolysosomal membranes might permit rapid and localized control of microRNA (miRNA) gene regulatory programs and mRNA translation in response to environmental signals, such as activated plasma membrane receptors transported on endosomes. ">
            <entity charOffset="112-119" id="miRNA-corp.d117.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-126" id="miRNA-corp.d117.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="134-143" id="miRNA-corp.d117.s1.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="221-229" id="miRNA-corp.d117.s1.e3" text="activated" type="Relation_Trigger"/>
            <entity charOffset="19-28" id="miRNA-corp.d117.s1.e4" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d117.s2" origId="20630759.s5" text="Finally, we suggest that the pathology of several conditions, including Huntington's disease, might be a consequence of the disruption of the control of RNA via endolysosomal membranes.   ">
            <entity charOffset="72-91" id="miRNA-corp.d117.s2.e0" text="Huntington's disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d117.s3" origId="20630759.s0" text="Control of RNA silencing and localization by endolysosomes.  "/>
        <sentence id="miRNA-corp.d117.s4" origId="20630759.s1" text="Recent advances in the cell biology of RNA silencing have unraveled an intriguing association of post-transcriptionally regulated RNA with endolysosomal membranes in several circumstances of mRNA localization, microRNA activity and viral RNA transport and packaging. ">
            <entity charOffset="210-217" id="miRNA-corp.d117.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-92" id="miRNA-corp.d117.s4.e1" text="association" type="Relation_Trigger"/>
            <entity charOffset="120-128" id="miRNA-corp.d117.s4.e2" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d117.s5" origId="20630759.s2" text="Endolysosomal membranes are a nexus of communication and transport between cells and their exterior environment for signaling receptors, pathogens and nutrients. "/>
    </document>
    <document id="miRNA-corp.d118" origId="20668041">
        <sentence id="miRNA-corp.d118.s0" origId="20668041.s9" text="A specific subset of five miRNAs revealed by in silico target prediction was significantly overexpressed in NFA samples; three miRs (miR-128a, miR-155, and miR-516a-3p) targeted the 3'-untranslated region of the Wee1 transcript, and exogenous overexpression of these miRs inhibited Wee1 protein expression and HeLa cell proliferation. ">
            <entity charOffset="143-149" id="miRNA-corp.d118.s0.e0" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="156-166" id="miRNA-corp.d118.s0.e1" text="miR-516a-3p" type="Specific_miRNAs"/>
            <entity charOffset="133-140" id="miRNA-corp.d118.s0.e2" text="miR-128a" type="Specific_miRNAs"/>
            <entity charOffset="26-31" id="miRNA-corp.d118.s0.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="127-130" id="miRNA-corp.d118.s0.e4" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="267-270" id="miRNA-corp.d118.s0.e5" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="212-215" id="miRNA-corp.d118.s0.e6" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="282-285" id="miRNA-corp.d118.s0.e7" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="243-256" id="miRNA-corp.d118.s0.e8" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="55-60" id="miRNA-corp.d118.s0.e9" text="target" type="Relation_Trigger"/>
            <entity charOffset="91-103" id="miRNA-corp.d118.s0.e10" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="272-304" id="miRNA-corp.d118.s0.e11" text="inhibited Wee1 protein expression" type="Relation_Trigger"/>
            <entity charOffset="169-203" id="miRNA-corp.d118.s0.e12" text="targeted the 3'-untranslated region" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d118.s0.e0" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e0" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e3" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e3" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e4" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e4" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e5" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e5" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p7" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e1" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p8" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e1" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e2" e2="miRNA-corp.d118.s0.e6" id="miRNA-corp.d118.s0.p10" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s0.e2" e2="miRNA-corp.d118.s0.e7" id="miRNA-corp.d118.s0.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s1" origId="20668041.s8" text="RESULTS: Wee1 protein expression was decreased in NFAs and GH-producing tumors with or without prolactin production, but no change in mRNA expression was observed with qRT-PCR. ">
            <entity charOffset="9-12" id="miRNA-corp.d118.s1.e0" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="124-148" id="miRNA-corp.d118.s1.e1" text="change in mRNA expression" type="Relation_Trigger"/>
            <entity charOffset="14-45" id="miRNA-corp.d118.s1.e2" text="protein expression was decreased" type="Relation_Trigger"/>
            <entity charOffset="95-103" id="miRNA-corp.d118.s1.e3" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="72-77" id="miRNA-corp.d118.s1.e4" text="tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s2" origId="20668041.s10" text="CONCLUSIONS: To our knowledge, this is the first report suggesting that regulation of Wee1 kinase by miRs may be linked to pituitary tumorigenesis.   ">
            <entity charOffset="101-104" id="miRNA-corp.d118.s2.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-81" id="miRNA-corp.d118.s2.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="86-89" id="miRNA-corp.d118.s2.e2" text="Wee1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s2.e0" e2="miRNA-corp.d118.s2.e2" id="miRNA-corp.d118.s2.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s3" origId="20668041.s1" text="CONTEXT: The tumorigenic mechanisms involved in pituitary adenomas, especially of nonfunctional pituitary adenomas (NFAs), remains unclear. ">
            <entity charOffset="48-65" id="miRNA-corp.d118.s3.e0" text="pituitary adenomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s4" origId="20668041.s0" text="Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas.  ">
            <entity charOffset="55-62" id="miRNA-corp.d118.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-99" id="miRNA-corp.d118.s4.e1" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="0-14" id="miRNA-corp.d118.s4.e2" text="Down-regulation" type="Relation_Trigger"/>
            <entity charOffset="19-22" id="miRNA-corp.d118.s4.e3" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="67-71" id="miRNA-corp.d118.s4.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d118.s4.e0" e2="miRNA-corp.d118.s4.e1" id="miRNA-corp.d118.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d118.s4.e0" e2="miRNA-corp.d118.s4.e3" id="miRNA-corp.d118.s4.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s5" origId="20668041.s3" text="OBJECTIVE: Our objective was to examine the expression of Wee1 in pituitary tumors and to identify microRNAs (miRs) that can regulate its expression. ">
            <entity charOffset="58-61" id="miRNA-corp.d118.s5.e0" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="99-107" id="miRNA-corp.d118.s5.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-113" id="miRNA-corp.d118.s5.e2" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-81" id="miRNA-corp.d118.s5.e3" text="pituitary tumors" type="Diseases"/>
            <entity charOffset="125-147" id="miRNA-corp.d118.s5.e4" text="regulate its expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d118.s5.e1" e2="miRNA-corp.d118.s5.e0" id="miRNA-corp.d118.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s5.e1" e2="miRNA-corp.d118.s5.e3" id="miRNA-corp.d118.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d118.s5.e2" e2="miRNA-corp.d118.s5.e0" id="miRNA-corp.d118.s5.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s5.e2" e2="miRNA-corp.d118.s5.e3" id="miRNA-corp.d118.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s6" origId="20668041.s2" text="Various cell cycle inhibitors have been found to be underexpressed in pituitary tumors; however, Wee1 kinase, a nuclear protein that delays mitosis and was recently recognized as a tumor suppressor gene, has not been previously investigated in pituitary tumors. ">
            <entity charOffset="70-85" id="miRNA-corp.d118.s6.e0" text="pituitary tumors" type="Diseases"/>
            <entity charOffset="244-259" id="miRNA-corp.d118.s6.e1" text="pituitary tumors" type="Diseases"/>
            <entity charOffset="52-65" id="miRNA-corp.d118.s6.e2" text="underexpressed" type="Relation_Trigger"/>
            <entity charOffset="19-28" id="miRNA-corp.d118.s6.e3" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="181-196" id="miRNA-corp.d118.s6.e4" text="tumor suppressor" type="Relation_Trigger"/>
            <entity charOffset="97-100" id="miRNA-corp.d118.s6.e5" text="Wee1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s7" origId="20668041.s5" text="Identification of miRs targeting the Wee1 3'-untranslated region was performed by miR array followed by expression analysis of identified miRs using qRT-PCR. ">
            <entity charOffset="18-21" id="miRNA-corp.d118.s7.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-84" id="miRNA-corp.d118.s7.e1" text="miR" type="Non-Specific_miRNAs"/>
            <entity charOffset="138-141" id="miRNA-corp.d118.s7.e2" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-40" id="miRNA-corp.d118.s7.e3" text="Wee1" type="Genes/Proteins"/>
            <entity charOffset="23-63" id="miRNA-corp.d118.s7.e4" text="targeting the Wee1 3'-untranslated region" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d118.s7.e2" e2="miRNA-corp.d118.s7.e3" id="miRNA-corp.d118.s7.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s7.e0" e2="miRNA-corp.d118.s7.e3" id="miRNA-corp.d118.s7.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s7.e1" e2="miRNA-corp.d118.s7.e3" id="miRNA-corp.d118.s7.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s8" origId="20668041.s4" text="DESIGN: Expression of Wee1 was examined by immunohistochemistry and quantitative real-time PCR (qRT-PCR). ">
            <entity charOffset="22-25" id="miRNA-corp.d118.s8.e0" text="Wee1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s9" origId="20668041.s7" text="PATIENTS: A total of 57 pituitary tissue samples including 27 NFAs, 15 GH-producing adenomas with or without prolactin overproduction, and 15 normal pituitary glands were analyzed. ">
            <entity charOffset="84-91" id="miRNA-corp.d118.s9.e0" text="adenomas" type="Diseases"/>
            <entity charOffset="109-117" id="miRNA-corp.d118.s9.e1" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="0-7" id="miRNA-corp.d118.s9.e2" text="PATIENTS" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d118.s10" origId="20668041.s6" text="Dual-luciferase assay and transient transfection of miRs into Hela cells followed by immunoblot analysis of Wee1 protein and cell proliferation analysis were carried out. ">
            <entity charOffset="52-55" id="miRNA-corp.d118.s10.e0" text="miRs" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-111" id="miRNA-corp.d118.s10.e1" text="Wee1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d118.s10.e0" e2="miRNA-corp.d118.s10.e1" id="miRNA-corp.d118.s10.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d119" origId="20126538">
        <sentence id="miRNA-corp.d119.s0" origId="20126538.s1" text="Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about their roles in Alzheimer's disease (AD). ">
            <entity charOffset="9-17" id="miRNA-corp.d119.s0.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-153" id="miRNA-corp.d119.s0.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="156-157" id="miRNA-corp.d119.s0.e2" text="AD" type="Diseases"/>
            <entity charOffset="74-79" id="miRNA-corp.d119.s0.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d119.s0.e0" e2="miRNA-corp.d119.s0.e1" id="miRNA-corp.d119.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s0.e0" e2="miRNA-corp.d119.s0.e2" id="miRNA-corp.d119.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s0.e0" e2="miRNA-corp.d119.s0.e3" id="miRNA-corp.d119.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s1" origId="20126538.s0" text="Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation.  ">
            <entity charOffset="31-35" id="miRNA-corp.d119.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-107" id="miRNA-corp.d119.s1.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-78" id="miRNA-corp.d119.s1.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="95-118" id="miRNA-corp.d119.s1.e3" text="altered miRNA regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d119.s1.e0" e2="miRNA-corp.d119.s1.e2" id="miRNA-corp.d119.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s1.e1" e2="miRNA-corp.d119.s1.e2" id="miRNA-corp.d119.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s2" origId="20126538.s3" text="These data provided the unique opportunity to study the relationship between miRNA and mRNA expression in normal and AD brains. ">
            <entity charOffset="77-81" id="miRNA-corp.d119.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-118" id="miRNA-corp.d119.s2.e1" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d119.s2.e0" e2="miRNA-corp.d119.s2.e1" id="miRNA-corp.d119.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s3" origId="20126538.s2" text="In this study, we used microarrays for the first joint profiling and analysis of miRNAs and mRNAs expression in brain cortex from AD and age-matched control subjects. ">
            <entity charOffset="81-86" id="miRNA-corp.d119.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="130-131" id="miRNA-corp.d119.s3.e1" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d119.s3.e0" e2="miRNA-corp.d119.s3.e1" id="miRNA-corp.d119.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s4" origId="20126538.s5" text="Comparative analysis with independent cancer datasets showed that such miRNA-mRNA expression correlations are not static, but rather context-dependent. ">
            <entity charOffset="71-75" id="miRNA-corp.d119.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-104" id="miRNA-corp.d119.s4.e1" text="expression correlations" type="Relation_Trigger"/>
            <entity charOffset="38-43" id="miRNA-corp.d119.s4.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d119.s4.e0" e2="miRNA-corp.d119.s4.e2" id="miRNA-corp.d119.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s5" origId="20126538.s4" text="Using a non-parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those of their target mRNAs. ">
            <entity charOffset="67-72" id="miRNA-corp.d119.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="144-149" id="miRNA-corp.d119.s5.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="52-97" id="miRNA-corp.d119.s5.e2" text="levels of many miRNAs can be either positively" type="Relation_Trigger"/>
            <entity charOffset="102-122" id="miRNA-corp.d119.s5.e3" text="negatively correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s6" origId="20126538.s7" text="Our results demonstrate a robust relationship between the levels of miRNAs and those of their targets in the brain. ">
            <entity charOffset="68-73" id="miRNA-corp.d119.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-100" id="miRNA-corp.d119.s6.e1" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s7" origId="20126538.s6" text="Subsequently, we identified a large set of miRNA-mRNA associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system. ">
            <entity charOffset="146-150" id="miRNA-corp.d119.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-88" id="miRNA-corp.d119.s7.e1" text="AD" type="Diseases"/>
            <entity charOffset="43-47" id="miRNA-corp.d119.s7.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-65" id="miRNA-corp.d119.s7.e3" text="associations" type="Relation_Trigger"/>
            <entity charOffset="119-120" id="miRNA-corp.d119.s7.e4" text="AD" type="Diseases"/>
            <entity charOffset="152-161" id="miRNA-corp.d119.s7.e5" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d119.s7.e2" e2="miRNA-corp.d119.s7.e1" id="miRNA-corp.d119.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s7.e2" e2="miRNA-corp.d119.s7.e4" id="miRNA-corp.d119.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s7.e0" e2="miRNA-corp.d119.s7.e1" id="miRNA-corp.d119.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d119.s7.e0" e2="miRNA-corp.d119.s7.e4" id="miRNA-corp.d119.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d119.s8" origId="20126538.s8" text="This has implications in the study of the molecular pathology of AD, as well as miRNA biology in general.   ">
            <entity charOffset="80-84" id="miRNA-corp.d119.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-66" id="miRNA-corp.d119.s8.e1" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d119.s8.e0" e2="miRNA-corp.d119.s8.e1" id="miRNA-corp.d119.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d120" origId="20347722">
        <sentence id="miRNA-corp.d120.s0" origId="20347722.s5" text="In this review article, the molecular mechanisms underlying the role and function of miRNAs in the regulation of genes involved in neurological and neurodegenerative diseases will be discussed, with a focus on the fragile X syndrome, Alzheimer's disease (AD) and prion disease.   ">
            <entity charOffset="85-90" id="miRNA-corp.d120.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="234-252" id="miRNA-corp.d120.s0.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="255-256" id="miRNA-corp.d120.s0.e2" text="AD" type="Diseases"/>
            <entity charOffset="263-275" id="miRNA-corp.d120.s0.e3" text="prion disease" type="Diseases"/>
            <entity charOffset="214-231" id="miRNA-corp.d120.s0.e4" text="fragile X syndrome" type="Diseases"/>
            <entity charOffset="99-108" id="miRNA-corp.d120.s0.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="148-173" id="miRNA-corp.d120.s0.e6" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d120.s0.e0" e2="miRNA-corp.d120.s0.e3" id="miRNA-corp.d120.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s0.e0" e2="miRNA-corp.d120.s0.e4" id="miRNA-corp.d120.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s0.e0" e2="miRNA-corp.d120.s0.e6" id="miRNA-corp.d120.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s0.e0" e2="miRNA-corp.d120.s0.e1" id="miRNA-corp.d120.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s0.e0" e2="miRNA-corp.d120.s0.e2" id="miRNA-corp.d120.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d120.s1" origId="20347722.s4" text="Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying diseases affecting major organs, such as the brain. ">
            <entity charOffset="69-73" id="miRNA-corp.d120.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-109" id="miRNA-corp.d120.s1.e1" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d120.s2" origId="20347722.s0" text="MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.  ">
            <entity charOffset="0-8" id="miRNA-corp.d120.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-84" id="miRNA-corp.d120.s2.e1" text="prion diseases" type="Diseases"/>
            <entity charOffset="55-65" id="miRNA-corp.d120.s2.e2" text="Alzheimer's" type="Diseases"/>
            <entity charOffset="35-52" id="miRNA-corp.d120.s2.e3" text="mental retardation" type="Diseases"/>
            <pair e1="miRNA-corp.d120.s2.e0" e2="miRNA-corp.d120.s2.e2" id="miRNA-corp.d120.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s2.e0" e2="miRNA-corp.d120.s2.e3" id="miRNA-corp.d120.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d120.s2.e0" e2="miRNA-corp.d120.s2.e1" id="miRNA-corp.d120.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d120.s3" origId="20347722.s1" text="MicroRNAs (miRNAs) are small, approximately 21- to 23-nucleotide (nt) non-coding RNA species that act as key regulators of gene expression along a central and well-defined cellular process known as RNA silencing, and involving the recognition and translational control of specific messenger RNA (mRNAs). ">
            <entity charOffset="0-8" id="miRNA-corp.d120.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d120.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-137" id="miRNA-corp.d120.s3.e2" text="regulators of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d120.s4" origId="20347722.s2" text="Generated through the well-orchestrated and sequential processing of miRNA precursor molecules, mature miRNAs are subsequently incorporated into miRNA-containing ribonucleoprotein effector complexes to regulate mRNA translation through the recognition of specific binding sites of imperfect complementarity located mainly in the 3' untranslated region. ">
            <entity charOffset="69-73" id="miRNA-corp.d120.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-108" id="miRNA-corp.d120.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="145-149" id="miRNA-corp.d120.s4.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="202-226" id="miRNA-corp.d120.s4.e3" text="regulate mRNA translation" type="Relation_Trigger"/>
            <entity charOffset="264-276" id="miRNA-corp.d120.s4.e4" text="binding sites" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d120.s5" origId="20347722.s3" text="Predicted to regulate up to 90% of the genes in humans, miRNAs may thus control cellular processes in all cells and tissues of the human body. ">
            <entity charOffset="56-61" id="miRNA-corp.d120.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-20" id="miRNA-corp.d120.s5.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="48-53" id="miRNA-corp.d120.s5.e2" text="humans" type="Species"/>
            <entity charOffset="131-135" id="miRNA-corp.d120.s5.e3" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d121" origId="21209202">
        <sentence id="miRNA-corp.d121.s0" origId="21209202.s0" text="Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.  ">
            <entity charOffset="0-19" id="miRNA-corp.d121.s0.e0" text="Phosphodiesterase-4D" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s1" origId="21209202.s1" text="Phosphodiesterase-4 (PDE4) plays an important role in mediating memory via the control of intracellular cAMP signaling; inhibition of PDE4 enhances memory. ">
            <entity charOffset="21-24" id="miRNA-corp.d121.s1.e0" text="PDE4" type="Genes/Proteins"/>
            <entity charOffset="134-137" id="miRNA-corp.d121.s1.e1" text="PDE4" type="Genes/Proteins"/>
            <entity charOffset="120-129" id="miRNA-corp.d121.s1.e2" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="0-18" id="miRNA-corp.d121.s1.e3" text="Phosphodiesterase-4" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s2" origId="21209202.s2" text="However, development of PDE4 inhibitors as memory enhancers has been hampered by their major side effect of emesis. ">
            <entity charOffset="29-38" id="miRNA-corp.d121.s2.e0" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="108-113" id="miRNA-corp.d121.s2.e1" text="emesis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s3" origId="21209202.s3" text="PDE4 has four subtypes (PDE4A-D) consisting of 25 splice variants. ">
            <entity charOffset="0-3" id="miRNA-corp.d121.s3.e0" text="PDE4" type="Genes/Proteins"/>
            <entity charOffset="24-30" id="miRNA-corp.d121.s3.e1" text="PDE4A-D" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s4" origId="21209202.s4" text="Mice deficient in PDE4D displayed memory enhancement in radial arm maze, water maze, and object recognition tests. ">
            <entity charOffset="18-22" id="miRNA-corp.d121.s4.e0" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="0-3" id="miRNA-corp.d121.s4.e1" text="Mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s5" origId="21209202.s5" text="These effects were mimicked by repeated treatment with rolipram in wild-type mice. ">
            <entity charOffset="77-80" id="miRNA-corp.d121.s5.e0" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s6" origId="21209202.s6" text="In addition, similarly as rolipram-treated wild-type mice, PDE4D-deficient mice also displayed increased hippocampal neurogenesis and phosphorylated cAMP response element-binding protein (pCREB). ">
            <entity charOffset="134-185" id="miRNA-corp.d121.s6.e0" text="phosphorylated cAMP response element-binding protein" type="Genes/Proteins"/>
            <entity charOffset="188-192" id="miRNA-corp.d121.s6.e1" text="pCREB" type="Genes/Proteins"/>
            <entity charOffset="59-63" id="miRNA-corp.d121.s6.e2" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="53-56" id="miRNA-corp.d121.s6.e3" text="mice" type="Species"/>
            <entity charOffset="75-78" id="miRNA-corp.d121.s6.e4" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s7" origId="21209202.s7" text="Furthermore, microinfusion of lentiviral vectors that contained microRNAs (miRNAs) targeting long-form PDE4D isoforms into bilateral dentate gyri of the mouse hippocampus downregulated PDE4D4 and PDE4D5, enhanced memory, and increased hippocampal neurogenesis and pCREB. ">
            <entity charOffset="64-72" id="miRNA-corp.d121.s7.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-80" id="miRNA-corp.d121.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-107" id="miRNA-corp.d121.s7.e2" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="196-201" id="miRNA-corp.d121.s7.e3" text="PDE4D5" type="Genes/Proteins"/>
            <entity charOffset="264-268" id="miRNA-corp.d121.s7.e4" text="pCREB" type="Genes/Proteins"/>
            <entity charOffset="83-91" id="miRNA-corp.d121.s7.e5" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="171-183" id="miRNA-corp.d121.s7.e6" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="185-190" id="miRNA-corp.d121.s7.e7" text="PDE4D4" type="Genes/Proteins"/>
            <entity charOffset="153-157" id="miRNA-corp.d121.s7.e8" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d121.s7.e0" e2="miRNA-corp.d121.s7.e4" id="miRNA-corp.d121.s7.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e0" e2="miRNA-corp.d121.s7.e7" id="miRNA-corp.d121.s7.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e0" e2="miRNA-corp.d121.s7.e2" id="miRNA-corp.d121.s7.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e0" e2="miRNA-corp.d121.s7.e3" id="miRNA-corp.d121.s7.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e1" e2="miRNA-corp.d121.s7.e4" id="miRNA-corp.d121.s7.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e1" e2="miRNA-corp.d121.s7.e7" id="miRNA-corp.d121.s7.p5" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e1" e2="miRNA-corp.d121.s7.e2" id="miRNA-corp.d121.s7.p6" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s7.e1" e2="miRNA-corp.d121.s7.e3" id="miRNA-corp.d121.s7.p7" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s8" origId="21209202.s8" text="Finally, while rolipram and PDE4D deficiency shortened α2 adrenergic receptor-mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocampus did not. ">
            <entity charOffset="28-32" id="miRNA-corp.d121.s8.e0" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="145-149" id="miRNA-corp.d121.s8.e1" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="130-134" id="miRNA-corp.d121.s8.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-127" id="miRNA-corp.d121.s8.e3" text="emesis" type="Diseases"/>
            <pair e1="miRNA-corp.d121.s8.e2" e2="miRNA-corp.d121.s8.e0" id="miRNA-corp.d121.s8.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s8.e2" e2="miRNA-corp.d121.s8.e1" id="miRNA-corp.d121.s8.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d121.s8.e2" e2="miRNA-corp.d121.s8.e3" id="miRNA-corp.d121.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s9" origId="21209202.s9" text="The present results suggest that PDE4D, in particular long-form PDE4D, plays a critical role in the mediation of memory and hippocampal neurogenesis, which are mediated by cAMP/CREB signaling; reduced expression of PDE4D, or at least PDE4D4 and PDE4D5, in the hippocampus enhances memory but appears not to cause emesis. ">
            <entity charOffset="33-37" id="miRNA-corp.d121.s9.e0" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="64-68" id="miRNA-corp.d121.s9.e1" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="172-175" id="miRNA-corp.d121.s9.e2" text="cAMP" type="Genes/Proteins"/>
            <entity charOffset="177-180" id="miRNA-corp.d121.s9.e3" text="CREB" type="Genes/Proteins"/>
            <entity charOffset="215-219" id="miRNA-corp.d121.s9.e4" text="PDE4D" type="Genes/Proteins"/>
            <entity charOffset="245-250" id="miRNA-corp.d121.s9.e5" text="PDE4D5" type="Genes/Proteins"/>
            <entity charOffset="193-210" id="miRNA-corp.d121.s9.e6" text="reduced expression" type="Relation_Trigger"/>
            <entity charOffset="313-318" id="miRNA-corp.d121.s9.e7" text="emesis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d121.s10" origId="21209202.s10" text="These novel findings will aid in the development of PDE4 subtype- or variant-selective inhibitors for treatment of disorders involving impaired cognition, including Alzheimer's disease.   ">
            <entity charOffset="52-55" id="miRNA-corp.d121.s10.e0" text="PDE4" type="Genes/Proteins"/>
            <entity charOffset="165-183" id="miRNA-corp.d121.s10.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="87-96" id="miRNA-corp.d121.s10.e2" text="inhibitors" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d122" origId="19136928">
        <sentence id="miRNA-corp.d122.s0" origId="19136928.s9" text="High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P&lt;0.0001). ">
            <entity charOffset="15-36" id="miRNA-corp.d122.s0.e0" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="0-47" id="miRNA-corp.d122.s0.e1" text="High levels of high-mobility group A2 expression" type="Relation_Trigger"/>
            <entity charOffset="68-77" id="miRNA-corp.d122.s0.e2" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="88-113" id="miRNA-corp.d122.s0.e3" text="proliferation marker Ki-67" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s1" origId="19136928.s8" text="High levels of high-mobility group A2 expression were more frequently observed in macroadenomas than in microadenomas (P&lt;0.05). ">
            <entity charOffset="15-36" id="miRNA-corp.d122.s1.e0" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="0-47" id="miRNA-corp.d122.s1.e1" text="High levels of high-mobility group A2 expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s2" origId="19136928.s6" text="Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas. ">
            <entity charOffset="365-367" id="miRNA-corp.d122.s2.e0" text="PRL" type="Genes/Proteins"/>
            <entity charOffset="183-191" id="miRNA-corp.d122.s2.e1" text="prolactin" type="Genes/Proteins"/>
            <entity charOffset="194-196" id="miRNA-corp.d122.s2.e2" text="PRL" type="Genes/Proteins"/>
            <entity charOffset="72-89" id="miRNA-corp.d122.s2.e3" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="18-39" id="miRNA-corp.d122.s2.e4" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="200-227" id="miRNA-corp.d122.s2.e5" text="adrenocorticotrophic hormone" type="Genes/Proteins"/>
            <entity charOffset="233-260" id="miRNA-corp.d122.s2.e6" text="follicle-stimulating hormone" type="Genes/Proteins"/>
            <entity charOffset="262-280" id="miRNA-corp.d122.s2.e7" text="luteinizing hormone" type="Genes/Proteins"/>
            <entity charOffset="332-345" id="miRNA-corp.d122.s2.e8" text="growth hormone" type="Genes/Proteins"/>
            <entity charOffset="0-13" id="miRNA-corp.d122.s2.e9" text="Overexpression" type="Relation_Trigger"/>
            <entity charOffset="164-171" id="miRNA-corp.d122.s2.e10" text="adenomas" type="Diseases"/>
            <entity charOffset="369-376" id="miRNA-corp.d122.s2.e11" text="adenomas" type="Diseases"/>
            <entity charOffset="299-306" id="miRNA-corp.d122.s2.e12" text="adenomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s3" origId="19136928.s7" text="High-mobility group A2 expression was significantly associated with tumor invasion (P&lt;0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P&lt;0.05). ">
            <entity charOffset="0-21" id="miRNA-corp.d122.s3.e0" text="High-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="52-61" id="miRNA-corp.d122.s3.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="68-72" id="miRNA-corp.d122.s3.e2" text="tumor" type="Diseases"/>
            <entity charOffset="163-170" id="miRNA-corp.d122.s3.e3" text="adenomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s4" origId="19136928.s4" text="However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas. ">
            <entity charOffset="118-122" id="miRNA-corp.d122.s4.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="124-128" id="miRNA-corp.d122.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="146-163" id="miRNA-corp.d122.s4.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="67-88" id="miRNA-corp.d122.s4.e3" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="140-144" id="miRNA-corp.d122.s4.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d122.s4.e1" e2="miRNA-corp.d122.s4.e2" id="miRNA-corp.d122.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d122.s4.e1" e2="miRNA-corp.d122.s4.e3" id="miRNA-corp.d122.s4.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s4.e0" e2="miRNA-corp.d122.s4.e2" id="miRNA-corp.d122.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d122.s4.e0" e2="miRNA-corp.d122.s4.e3" id="miRNA-corp.d122.s4.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s5" origId="19136928.s5" text="Using immunohistochemistry, we analyzed high-mobility group A2 expression with respect to various clinicopathologic factors in 98 pituitary adenomas. ">
            <entity charOffset="130-147" id="miRNA-corp.d122.s5.e0" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="40-61" id="miRNA-corp.d122.s5.e1" text="high-mobility group A2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s6" origId="19136928.s2" text="Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro. ">
            <entity charOffset="81-85" id="miRNA-corp.d122.s6.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="27-48" id="miRNA-corp.d122.s6.e1" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="87-95" id="miRNA-corp.d122.s6.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-103" id="miRNA-corp.d122.s6.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-72" id="miRNA-corp.d122.s6.e4" text="negatively regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d122.s6.e0" e2="miRNA-corp.d122.s6.e1" id="miRNA-corp.d122.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s6.e2" e2="miRNA-corp.d122.s6.e1" id="miRNA-corp.d122.s6.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s6.e3" e2="miRNA-corp.d122.s6.e1" id="miRNA-corp.d122.s6.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s7" origId="19136928.s3" text="The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis. ">
            <entity charOffset="19-36" id="miRNA-corp.d122.s7.e0" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="41-62" id="miRNA-corp.d122.s7.e1" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="92-113" id="miRNA-corp.d122.s7.e2" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="64-78" id="miRNA-corp.d122.s7.e3" text="transgenic mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s8" origId="19136928.s0" text="Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.  ">
            <entity charOffset="18-22" id="miRNA-corp.d122.s8.e0" text="HMGA2" type="Genes/Proteins"/>
            <entity charOffset="52-56" id="miRNA-corp.d122.s8.e1" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="114-131" id="miRNA-corp.d122.s8.e2" text="pituitary adenomas" type="Diseases"/>
            <entity charOffset="0-13" id="miRNA-corp.d122.s8.e3" text="Overexpression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d122.s8.e1" e2="miRNA-corp.d122.s8.e0" id="miRNA-corp.d122.s8.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s8.e1" e2="miRNA-corp.d122.s8.e2" id="miRNA-corp.d122.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s9" origId="19136928.s1" text="High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors. ">
            <entity charOffset="0-21" id="miRNA-corp.d122.s9.e0" text="High-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="90-105" id="miRNA-corp.d122.s9.e1" text="malignant tumors" type="Diseases"/>
            <entity charOffset="26-41" id="miRNA-corp.d122.s9.e2" text="highly expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s10" origId="19136928.s10" text="Real-time quantitative RT-PCR analysis was carried out to evaluate the expression of let-7 in 55 pituitary adenomas. ">
            <entity charOffset="85-89" id="miRNA-corp.d122.s10.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="97-114" id="miRNA-corp.d122.s10.e1" text="pituitary adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d122.s10.e0" e2="miRNA-corp.d122.s10.e1" id="miRNA-corp.d122.s10.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s11" origId="19136928.s11" text="Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P&lt;0.05). ">
            <entity charOffset="38-42" id="miRNA-corp.d122.s11.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="14-33" id="miRNA-corp.d122.s11.e1" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="109-125" id="miRNA-corp.d122.s11.e2" text="high-grade tumors" type="Diseases"/>
            <entity charOffset="93-102" id="miRNA-corp.d122.s11.e3" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="76-83" id="miRNA-corp.d122.s11.e4" text="adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d122.s11.e0" e2="miRNA-corp.d122.s11.e2" id="miRNA-corp.d122.s11.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d122.s11.e0" e2="miRNA-corp.d122.s11.e4" id="miRNA-corp.d122.s11.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s12" origId="19136928.s12" text="An inverse correlation between let-7 and high-mobility group A2 expression was evident (R=-0.33, P&lt;0.05). ">
            <entity charOffset="31-35" id="miRNA-corp.d122.s12.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="41-62" id="miRNA-corp.d122.s12.e1" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="3-21" id="miRNA-corp.d122.s12.e2" text="inverse correlation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d122.s12.e0" e2="miRNA-corp.d122.s12.e1" id="miRNA-corp.d122.s12.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d122.s13" origId="19136928.s13" text="These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.   ">
            <entity charOffset="45-49" id="miRNA-corp.d122.s13.e0" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="94-98" id="miRNA-corp.d122.s13.e1" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="119-140" id="miRNA-corp.d122.s13.e2" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="55-76" id="miRNA-corp.d122.s13.e3" text="high-mobility group A2" type="Genes/Proteins"/>
            <entity charOffset="86-109" id="miRNA-corp.d122.s13.e4" text="loss of let-7 expression" type="Relation_Trigger"/>
            <entity charOffset="142-153" id="miRNA-corp.d122.s13.e5" text="upregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d122.s13.e0" e2="miRNA-corp.d122.s13.e2" id="miRNA-corp.d122.s13.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s13.e0" e2="miRNA-corp.d122.s13.e3" id="miRNA-corp.d122.s13.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s13.e1" e2="miRNA-corp.d122.s13.e2" id="miRNA-corp.d122.s13.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d122.s13.e1" e2="miRNA-corp.d122.s13.e3" id="miRNA-corp.d122.s13.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d123" origId="19021292">
        <sentence id="miRNA-corp.d123.s0" origId="19021292.s2" text="MicroRNAs (miRNAs) are known to influence many important cellular processes, including proliferation, apoptosis, neurogenesis, angiogenesis, and morphogenesis, all processes that are involved in TBI pathophysiology. ">
            <entity charOffset="195-197" id="miRNA-corp.d123.s0.e0" text="TBI" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d123.s0.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d123.s0.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d123.s0.e1" e2="miRNA-corp.d123.s0.e0" id="miRNA-corp.d123.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d123.s0.e2" e2="miRNA-corp.d123.s0.e0" id="miRNA-corp.d123.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s1" origId="19021292.s1" text="Multiple cellular, molecular, and biochemical changes contribute to outcome after traumatic brain injury (TBI). ">
            <entity charOffset="82-103" id="miRNA-corp.d123.s1.e0" text="traumatic brain injury" type="Diseases"/>
            <entity charOffset="106-108" id="miRNA-corp.d123.s1.e1" text="TBI" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s2" origId="19021292.s4" text="In the present study, we used a microarray platform to examine changes in the hippocampal expression levels of 444 verified rodent miRNAs at 3 and 24 hr after controlled cortical impact injury. ">
            <entity charOffset="131-136" id="miRNA-corp.d123.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="63-99" id="miRNA-corp.d123.s2.e1" text="changes in the hippocampal expression" type="Relation_Trigger"/>
            <entity charOffset="186-191" id="miRNA-corp.d123.s2.e2" text="injury" type="Diseases"/>
            <pair e1="miRNA-corp.d123.s2.e0" e2="miRNA-corp.d123.s2.e2" id="miRNA-corp.d123.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s3" origId="19021292.s3" text="However, it has not yet been determined whether miRNA expression is altered after TBI. ">
            <entity charOffset="82-84" id="miRNA-corp.d123.s3.e0" text="TBI" type="Diseases"/>
            <entity charOffset="54-74" id="miRNA-corp.d123.s3.e1" text="expression is altered" type="Relation_Trigger"/>
            <entity charOffset="48-52" id="miRNA-corp.d123.s3.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d123.s3.e2" e2="miRNA-corp.d123.s3.e0" id="miRNA-corp.d123.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s4" origId="19021292.s6" text="We extended the microarray findings using quantitative polymerase chain reaction analysis for a subset of the miRNAs with altered expression levels (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711). ">
            <entity charOffset="122-146" id="miRNA-corp.d123.s4.e0" text="altered expression levels" type="Relation_Trigger"/>
            <entity charOffset="110-115" id="miRNA-corp.d123.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="149-208" id="miRNA-corp.d123.s4.e2" text="miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s5" origId="19021292.s5" text="Our analysis found 50 miRNAs exhibited decreased expression levels and 35 miRNAs exhibited increased expression levels in the hippocampus after injury. ">
            <entity charOffset="39-65" id="miRNA-corp.d123.s5.e0" text="decreased expression levels" type="Relation_Trigger"/>
            <entity charOffset="91-117" id="miRNA-corp.d123.s5.e1" text="increased expression levels" type="Relation_Trigger"/>
            <entity charOffset="22-27" id="miRNA-corp.d123.s5.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-79" id="miRNA-corp.d123.s5.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="144-149" id="miRNA-corp.d123.s5.e4" text="injury" type="Diseases"/>
            <pair e1="miRNA-corp.d123.s5.e2" e2="miRNA-corp.d123.s5.e4" id="miRNA-corp.d123.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d123.s5.e3" e2="miRNA-corp.d123.s5.e4" id="miRNA-corp.d123.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s6" origId="19021292.s8" text="Our results indicate that multiple protein targets and biological processes involved in TBI pathophysiology may be regulated by miRNAs.   ">
            <entity charOffset="88-90" id="miRNA-corp.d123.s6.e0" text="TBI" type="Diseases"/>
            <entity charOffset="115-123" id="miRNA-corp.d123.s6.e1" text="regulated" type="Relation_Trigger"/>
            <entity charOffset="128-133" id="miRNA-corp.d123.s6.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-49" id="miRNA-corp.d123.s6.e3" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d123.s6.e2" e2="miRNA-corp.d123.s6.e0" id="miRNA-corp.d123.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s7" origId="19021292.s7" text="Bioinformatic analysis of the predicted targets for this panel of miRNAs revealed an overrepresentation of proteins involved in several biological processes and functions known to be initiated after injury, including signal transduction, transcriptional regulation, proliferation, and differentiation. ">
            <entity charOffset="66-71" id="miRNA-corp.d123.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="238-263" id="miRNA-corp.d123.s7.e1" text="transcriptional regulation" type="Relation_Trigger"/>
            <entity charOffset="30-46" id="miRNA-corp.d123.s7.e2" text="predicted targets" type="Relation_Trigger"/>
            <entity charOffset="199-204" id="miRNA-corp.d123.s7.e3" text="injury" type="Diseases"/>
            <pair e1="miRNA-corp.d123.s7.e0" e2="miRNA-corp.d123.s7.e3" id="miRNA-corp.d123.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d123.s8" origId="19021292.s0" text="Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes.  ">
            <entity charOffset="0-21" id="miRNA-corp.d123.s8.e0" text="Traumatic brain injury" type="Diseases"/>
            <entity charOffset="23-39" id="miRNA-corp.d123.s8.e1" text="alters expression" type="Relation_Trigger"/>
            <entity charOffset="56-64" id="miRNA-corp.d123.s8.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-86" id="miRNA-corp.d123.s8.e3" text="potential regulators" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d123.s8.e2" e2="miRNA-corp.d123.s8.e0" id="miRNA-corp.d123.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d124" origId="21095568">
        <sentence id="miRNA-corp.d124.s0" origId="21095568.s5" text="Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.   ">
            <entity charOffset="39-41" id="miRNA-corp.d124.s0.e0" text="HTT" type="Genes/Proteins"/>
            <entity charOffset="99-100" id="miRNA-corp.d124.s0.e1" text="HD" type="Diseases"/>
            <entity charOffset="25-34" id="miRNA-corp.d124.s0.e2" text="inhibition" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d124.s1" origId="21095568.s4" text="Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (&lt;10 nM) and highly selective (&gt;30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. ">
            <entity charOffset="49-54" id="miRNA-corp.d124.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="206-240" id="miRNA-corp.d124.s1.e1" text="inhibition of mutant HTT expression" type="Relation_Trigger"/>
            <entity charOffset="245-251" id="miRNA-corp.d124.s1.e2" text="patient" type="Species"/>
            <entity charOffset="201-203" id="miRNA-corp.d124.s1.e3" text="HTT" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d124.s1.e0" e2="miRNA-corp.d124.s1.e3" id="miRNA-corp.d124.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d124.s2" origId="21095568.s3" text="We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. ">
            <entity charOffset="89-91" id="miRNA-corp.d124.s2.e0" text="HTT" type="Genes/Proteins"/>
            <entity charOffset="48-56" id="miRNA-corp.d124.s2.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="98-113" id="miRNA-corp.d124.s2.e2" text="block expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d124.s3" origId="21095568.s2" text="An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. ">
            <entity charOffset="100-102" id="miRNA-corp.d124.s3.e0" text="HTT" type="Genes/Proteins"/>
            <entity charOffset="31-46" id="miRNA-corp.d124.s3.e1" text="block expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d124.s4" origId="21095568.s1" text="Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. ">
            <entity charOffset="37-39" id="miRNA-corp.d124.s4.e0" text="HTT" type="Genes/Proteins"/>
            <entity charOffset="25-34" id="miRNA-corp.d124.s4.e1" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="87-106" id="miRNA-corp.d124.s4.e2" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="109-110" id="miRNA-corp.d124.s4.e3" text="HD" type="Diseases"/>
            <entity charOffset="133-142" id="miRNA-corp.d124.s4.e4" text="inhibition" type="Relation_Trigger"/>
            <entity charOffset="0-20" id="miRNA-corp.d124.s4.e5" text="Inhibiting expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d124.s5" origId="21095568.s0" text="Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.  ">
            <entity charOffset="31-40" id="miRNA-corp.d124.s5.e0" text="huntingtin" type="Genes/Proteins"/>
            <entity charOffset="72-76" id="miRNA-corp.d124.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-51" id="miRNA-corp.d124.s5.e2" text="inhibition of huntingtin expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d124.s5.e1" e2="miRNA-corp.d124.s5.e0" id="miRNA-corp.d124.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d125" origId="21483847">
        <sentence id="miRNA-corp.d125.s0" origId="21483847.s12" text="Thus we have identified a miRNA expression signature that can predict GBM patient survival. ">
            <entity charOffset="70-72" id="miRNA-corp.d125.s0.e0" text="GBM" type="Diseases"/>
            <entity charOffset="74-80" id="miRNA-corp.d125.s0.e1" text="patient" type="Species"/>
            <entity charOffset="26-30" id="miRNA-corp.d125.s0.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d125.s0.e0" e2="miRNA-corp.d125.s0.e2" id="miRNA-corp.d125.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s1" origId="21483847.s11" text="Cox multivariate analysis with patient age as a covariate on the entire patient set identified risk score based on the 10 miRNA expression signature to be an independent predictor of patient survival (HR = 1.120; 95% CI = 1.04-1.20; p = 0.003). ">
            <entity charOffset="122-126" id="miRNA-corp.d125.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-37" id="miRNA-corp.d125.s1.e1" text="patient" type="Species"/>
            <entity charOffset="72-78" id="miRNA-corp.d125.s1.e2" text="patient" type="Species"/>
            <entity charOffset="183-189" id="miRNA-corp.d125.s1.e3" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s2" origId="21483847.s12" text="These findings may have implications in the understanding of gliomagenesis, development of targeted therapy and selection of high risk cancer patients for adjuvant therapy.   ">
            <entity charOffset="91-98" id="miRNA-corp.d125.s2.e0" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="135-140" id="miRNA-corp.d125.s2.e1" text="cancer" type="Diseases"/>
            <entity charOffset="142-149" id="miRNA-corp.d125.s2.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s3" origId="21483847.s8" text="GBM patients with high risk scores had overall poor survival compared to the patients with low risk scores. ">
            <entity charOffset="77-84" id="miRNA-corp.d125.s3.e0" text="patients" type="Species"/>
            <entity charOffset="0-2" id="miRNA-corp.d125.s3.e1" text="GBM" type="Diseases"/>
            <entity charOffset="4-11" id="miRNA-corp.d125.s3.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s4" origId="21483847.s9" text="Overall survival among the entire patient set was 35.0% at 2 years, 21.5% at 3 years, 18.5% at 4 years and 11.8% at 5 years in the low risk group, versus 11.0%, 5.5%, 0.0 and 0.0% respectively in the high risk group (HR = 2.0; 95% CI = 1.4-2.8; p&lt;0.0001). ">
            <entity charOffset="34-40" id="miRNA-corp.d125.s4.e0" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s5" origId="21483847.s2" text="To identify a microRNA (miRNA) expression signature that can predict GBM patient survival, we analyzed the miRNA expression data of GBM patients (n = 222) derived from The Cancer Genome Atlas (TCGA) dataset. ">
            <entity charOffset="14-21" id="miRNA-corp.d125.s5.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-28" id="miRNA-corp.d125.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-111" id="miRNA-corp.d125.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-71" id="miRNA-corp.d125.s5.e3" text="GBM" type="Diseases"/>
            <entity charOffset="132-134" id="miRNA-corp.d125.s5.e4" text="GBM" type="Diseases"/>
            <entity charOffset="73-79" id="miRNA-corp.d125.s5.e5" text="patient" type="Species"/>
            <entity charOffset="136-143" id="miRNA-corp.d125.s5.e6" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d125.s5.e0" e2="miRNA-corp.d125.s5.e3" id="miRNA-corp.d125.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d125.s5.e0" e2="miRNA-corp.d125.s5.e4" id="miRNA-corp.d125.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d125.s5.e1" e2="miRNA-corp.d125.s5.e3" id="miRNA-corp.d125.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d125.s5.e1" e2="miRNA-corp.d125.s5.e4" id="miRNA-corp.d125.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d125.s5.e2" e2="miRNA-corp.d125.s5.e3" id="miRNA-corp.d125.s5.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d125.s5.e2" e2="miRNA-corp.d125.s5.e4" id="miRNA-corp.d125.s5.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s6" origId="21483847.s3" text="We divided the patients randomly into training and testing sets with equal number in each group. ">
            <entity charOffset="15-22" id="miRNA-corp.d125.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s7" origId="21483847.s0" text="A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma.  ">
            <entity charOffset="57-68" id="miRNA-corp.d125.s7.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="6-13" id="miRNA-corp.d125.s7.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d125.s7.e1" e2="miRNA-corp.d125.s7.e0" id="miRNA-corp.d125.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s8" origId="21483847.s1" text="Glioblastoma (GBM) is the most common and aggressive primary brain tumor with very poor patient median survival. ">
            <entity charOffset="0-11" id="miRNA-corp.d125.s8.e0" text="Glioblastoma" type="Diseases"/>
            <entity charOffset="14-16" id="miRNA-corp.d125.s8.e1" text="GBM" type="Diseases"/>
            <entity charOffset="61-71" id="miRNA-corp.d125.s8.e2" text="brain tumor" type="Diseases"/>
            <entity charOffset="88-94" id="miRNA-corp.d125.s8.e3" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s9" origId="21483847.s6" text="Of these 10 miRNAs, 7 were found to be risky miRNAs and 3 were found to be protective. ">
            <entity charOffset="12-17" id="miRNA-corp.d125.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-50" id="miRNA-corp.d125.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d125.s10" origId="21483847.s7" text="This signature was independently validated in the testing set (HR = 1.7; 95% CI = 1.1-2.8; p = 0.002). ">
        </sentence>
        <sentence id="miRNA-corp.d125.s11" origId="21483847.s4" text="We identified 10 significant miRNAs using Cox regression analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated the patients into high and low risk groups with significantly different survival times (hazard ratio [HR] = 2.4; 95% CI = 1.4-3.8; p&lt;0.0001). ">
            <entity charOffset="29-34" id="miRNA-corp.d125.s11.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="157-162" id="miRNA-corp.d125.s11.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-191" id="miRNA-corp.d125.s11.e2" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d126" origId="20097875">
        <sentence id="miRNA-corp.d126.s0" origId="20097875.s3" text="Microarray analysis showed differential expression of multiple miRNAs in HIVE compared to control brains. ">
            <entity charOffset="63-68" id="miRNA-corp.d126.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-76" id="miRNA-corp.d126.s0.e1" text="HIVE" type="Diseases"/>
            <entity charOffset="27-49" id="miRNA-corp.d126.s0.e2" text="differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d126.s0.e0" e2="miRNA-corp.d126.s0.e1" id="miRNA-corp.d126.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s1" origId="20097875.s4" text="Target prediction and gene ontology enrichment analysis disclosed targeting of several gene families/biological processes by differentially expressed miRNAs (DEMs), with cell death-related genes, including caspase-6, showing a bias toward down-regulated DEMs. ">
            <entity charOffset="150-155" id="miRNA-corp.d126.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="206-214" id="miRNA-corp.d126.s1.e1" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="125-148" id="miRNA-corp.d126.s1.e2" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="66-74" id="miRNA-corp.d126.s1.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="239-252" id="miRNA-corp.d126.s1.e4" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="0-5" id="miRNA-corp.d126.s1.e5" text="Target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d126.s1.e0" e2="miRNA-corp.d126.s1.e1" id="miRNA-corp.d126.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s2" origId="20097875.s5" text="Consistent with the miRNA data, HIVE brains exhibited higher levels of caspase-6 transcripts compared with control patients. ">
            <entity charOffset="20-24" id="miRNA-corp.d126.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-35" id="miRNA-corp.d126.s2.e1" text="HIVE" type="Diseases"/>
            <entity charOffset="71-79" id="miRNA-corp.d126.s2.e2" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="54-66" id="miRNA-corp.d126.s2.e3" text="higher levels" type="Relation_Trigger"/>
            <entity charOffset="115-122" id="miRNA-corp.d126.s2.e4" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d126.s2.e0" e2="miRNA-corp.d126.s2.e1" id="miRNA-corp.d126.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d126.s2.e0" e2="miRNA-corp.d126.s2.e2" id="miRNA-corp.d126.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s3" origId="20097875.s6" text="Immunohistochemical analysis showed localization of the cleaved form of caspase-6 in astrocytes in HIVE brain sections. ">
            <entity charOffset="72-80" id="miRNA-corp.d126.s3.e0" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="99-102" id="miRNA-corp.d126.s3.e1" text="HIVE" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s4" origId="20097875.s7" text="Exposure of cultured human primary astrocytes to HIV viral protein R (Vpr) induced p53 up-regulation, loss of mitochondrial membrane potential, and caspase-6 activation followed by cell injury. ">
            <entity charOffset="83-85" id="miRNA-corp.d126.s4.e0" text="p53" type="Genes/Proteins"/>
            <entity charOffset="148-156" id="miRNA-corp.d126.s4.e1" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="87-99" id="miRNA-corp.d126.s4.e2" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="158-167" id="miRNA-corp.d126.s4.e3" text="activation" type="Relation_Trigger"/>
            <entity charOffset="181-191" id="miRNA-corp.d126.s4.e4" text="cell injury" type="Diseases"/>
            <entity charOffset="21-25" id="miRNA-corp.d126.s4.e5" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s5" origId="20097875.s8" text="Transgenic mice, expressing Vpr in microglial cells, demonstrated astrocyte apoptosis in brain, which was associated with caspase-6 activation and neurobehavioral abnormalities. ">
            <entity charOffset="122-130" id="miRNA-corp.d126.s5.e0" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="106-115" id="miRNA-corp.d126.s5.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="132-141" id="miRNA-corp.d126.s5.e2" text="activation" type="Relation_Trigger"/>
            <entity charOffset="147-175" id="miRNA-corp.d126.s5.e3" text="neurobehavioral abnormalities" type="Diseases"/>
            <entity charOffset="0-14" id="miRNA-corp.d126.s5.e4" text="Transgenic mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s6" origId="20097875.s9" text="Overall, these data point to previously unrecognized alterations in miRNA profile in the brain during HIV infection, which contribute to cell death through dysregulation of cell death machinery.   ">
            <entity charOffset="68-72" id="miRNA-corp.d126.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-114" id="miRNA-corp.d126.s6.e1" text="HIV infection" type="Diseases"/>
            <entity charOffset="53-80" id="miRNA-corp.d126.s6.e2" text="alterations in miRNA profile" type="Relation_Trigger"/>
            <entity charOffset="156-168" id="miRNA-corp.d126.s6.e3" text="dysregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d126.s6.e0" e2="miRNA-corp.d126.s6.e1" id="miRNA-corp.d126.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s7" origId="20097875.s0" text="MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival.  ">
            <entity charOffset="0-7" id="miRNA-corp.d126.s7.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="65-73" id="miRNA-corp.d126.s7.e1" text="caspase-6" type="Genes/Proteins"/>
            <entity charOffset="75-83" id="miRNA-corp.d126.s7.e2" text="regulates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d126.s7.e0" e2="miRNA-corp.d126.s7.e1" id="miRNA-corp.d126.s7.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s8" origId="20097875.s1" text="MicroRNAs (miRNAs) are small noncoding RNA molecules, which are known to regulate gene expression in physiological and pathological conditions. ">
            <entity charOffset="0-8" id="miRNA-corp.d126.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d126.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-96" id="miRNA-corp.d126.s8.e2" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d126.s9" origId="20097875.s2" text="miRNA profiling was performed using brain tissue from patients with HIV encephalitis (HIVE), a neuroinflammatory/degenerative disorder caused by HIV infection of the brain. ">
            <entity charOffset="0-4" id="miRNA-corp.d126.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="145-157" id="miRNA-corp.d126.s9.e1" text="HIV infection" type="Diseases"/>
            <entity charOffset="68-83" id="miRNA-corp.d126.s9.e2" text="HIV encephalitis" type="Diseases"/>
            <entity charOffset="86-89" id="miRNA-corp.d126.s9.e3" text="HIVE" type="Diseases"/>
            <entity charOffset="95-133" id="miRNA-corp.d126.s9.e4" text="neuroinflammatory/degenerative disorder" type="Diseases"/>
            <entity charOffset="54-61" id="miRNA-corp.d126.s9.e5" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d126.s9.e0" e2="miRNA-corp.d126.s9.e1" id="miRNA-corp.d126.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d126.s9.e0" e2="miRNA-corp.d126.s9.e2" id="miRNA-corp.d126.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d126.s9.e0" e2="miRNA-corp.d126.s9.e3" id="miRNA-corp.d126.s9.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d126.s9.e0" e2="miRNA-corp.d126.s9.e4" id="miRNA-corp.d126.s9.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d127" origId="20423304">
        <sentence id="miRNA-corp.d127.s0" origId="20423304.s10" text="The method by which MSCs could be applied for future therapies might require trans-disciplinary approaches for personalized treatments.   "/>
        <sentence id="miRNA-corp.d127.s1" origId="20423304.s1" text="Implantation of adult human mesenchymal stem cells (MSCs) to treat neural disorders shows promise. ">
            <entity charOffset="67-82" id="miRNA-corp.d127.s1.e0" text="neural disorders" type="Diseases"/>
            <entity charOffset="22-26" id="miRNA-corp.d127.s1.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s2" origId="20423304.s2" text="Depending on their microenvironment, MSCs could potentially be used for the repair and/or replacement of neurons in traumatic brain injury or the treatment of Parkinson's disease. ">
            <entity charOffset="159-177" id="miRNA-corp.d127.s2.e0" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="126-137" id="miRNA-corp.d127.s2.e1" text="brain injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s3" origId="20423304.s3" text="This cross-disciplinary review incorporates aspects of neuroscience, stem cell biology, cancer biology and immunology to discuss interactions between inflammatory mediators and MSCs. ">
            <entity charOffset="88-93" id="miRNA-corp.d127.s3.e0" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s4" origId="20423304.s4" text="We first discuss the role of microRNAs (miRNAs) in neurological development. ">
            <entity charOffset="29-37" id="miRNA-corp.d127.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-45" id="miRNA-corp.d127.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s5" origId="20423304.s0" text="Neurogenesis: role for microRNAs and mesenchymal stem cells in pathological states.  ">
            <entity charOffset="23-31" id="miRNA-corp.d127.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s6" origId="20423304.s9" text="Exploring the predisposition of MSCs to oncogenesis is critical for translational science since the implementation of safeguarding measures prior to therapy can lead to the successful delivery of stem cells to patients. ">
            <entity charOffset="210-217" id="miRNA-corp.d127.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s7" origId="20423304.s6" text="The administration of effective and safe MSC therapy must acknowledge immune mediators that may predispose the early differentiating MSCs to oncogenic insults. "/>
        <sentence id="miRNA-corp.d127.s8" origId="20423304.s5" text="Secondly, we discuss the ability of MSCs to transdifferentiate into functional neurons, which are regulated by miRNAs, and the implications of these cells for the therapy of neuropathological states. ">
            <entity charOffset="111-116" id="miRNA-corp.d127.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="98-106" id="miRNA-corp.d127.s8.e1" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s9" origId="20423304.s8" text="Immune mediators could be central to MSC responses within a region of tissue injury and are also discussed in detail. ">
            <entity charOffset="70-82" id="miRNA-corp.d127.s9.e0" text="tissue injury" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d127.s10" origId="20423304.s7" text="Thus, we discuss a key gene, RE-1 silencing transcription factor (REST), based on its dual role in neurogenesis and cancer development. ">
            <entity charOffset="29-63" id="miRNA-corp.d127.s10.e0" text="RE-1 silencing transcription factor" type="Genes/Proteins"/>
            <entity charOffset="66-69" id="miRNA-corp.d127.s10.e1" text="REST" type="Genes/Proteins"/>
            <entity charOffset="116-121" id="miRNA-corp.d127.s10.e2" text="cancer" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d128" origId="18392411">
        <sentence id="miRNA-corp.d128.s0" origId="18392411.s0" text="Language brain dominance in patients with refractory temporal lobe epilepsy: a comparative study between functional magnetic resonance imaging and dichotic listening test.  ">
            <entity charOffset="42-74" id="miRNA-corp.d128.s0.e0" text="refractory temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="28-35" id="miRNA-corp.d128.s0.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s1" origId="18392411.s1" text="PURPOSE: To identify brain dominance for language functions with DLT and correlate these results with those obtained from fMRI in patients suffering from intractable temporal lobe epilepsy. ">
            <entity charOffset="154-187" id="miRNA-corp.d128.s1.e0" text="intractable temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="73-81" id="miRNA-corp.d128.s1.e1" text="correlate" type="Relation_Trigger"/>
            <entity charOffset="130-137" id="miRNA-corp.d128.s1.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s2" origId="18392411.s2" text="METHOD: This study reports on 13 patients who underwent pre-surgical epileptic evaluation between April and October 2004 at the Epilepsy Surgery Program, Hospital Sao Lucas, PUCRS. ">
            <entity charOffset="33-40" id="miRNA-corp.d128.s2.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s3" origId="18392411.s3" text="In DLT, dominance was assessed through a consonant-vowel task, whereas in fMRI patients performed a verb generation task. ">
            <entity charOffset="79-86" id="miRNA-corp.d128.s3.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s4" origId="18392411.s6" text="These findings indicate that DLT (a non-invasive procedure) could be a useful tool to evaluate language brain dominance in pre-surgical epileptic patients as it is cheaper to perform than fMRI.   ">
            <entity charOffset="146-153" id="miRNA-corp.d128.s4.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s5" origId="18392411.s5" text="CONCLUSION: DLT was found to significantly correlate with fMRI. ">
            <entity charOffset="43-51" id="miRNA-corp.d128.s5.e0" text="correlate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d128.s6" origId="18392411.s4" text="RESULTS: Our results identified a correlation between the fMRI lateralization index and the DLT ear predominance index and reply difference index (r=0.6, p=0.02; Pearson Correlation Coefficient), showing positive correlation between results obtained from fMRI and DLT. ">
            <entity charOffset="204-223" id="miRNA-corp.d128.s6.e0" text="positive correlation" type="Relation_Trigger"/>
            <entity charOffset="34-44" id="miRNA-corp.d128.s6.e1" text="correlation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d129" origId="18319074">
        <sentence id="miRNA-corp.d129.s0" origId="18319074.s10" text="Finally, a phylogenetic analysis shows that ADCK3 belongs to the family of atypical kinases, which includes phosphoinositide and choline kinases, suggesting that ADCK3 plays an indirect regulatory role in ubiquinone biosynthesis possibly as part of a feedback loop that regulates ATP production.   ">
            <entity charOffset="186-195" id="miRNA-corp.d129.s0.e0" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="44-56" id="miRNA-corp.d129.s0.e1" text="ADCK3 belongs" type="Genes/Proteins"/>
            <entity charOffset="162-166" id="miRNA-corp.d129.s0.e2" text="ADCK3" type="Genes/Proteins"/>
            <entity charOffset="270-278" id="miRNA-corp.d129.s0.e3" text="regulates" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s1" origId="18319074.s0" text="ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency.  ">
            <entity charOffset="52-67" id="miRNA-corp.d129.s1.e0" text="recessive ataxia" type="Diseases"/>
            <entity charOffset="0-4" id="miRNA-corp.d129.s1.e1" text="ADCK3" type="Genes/Proteins"/>
            <entity charOffset="69-78" id="miRNA-corp.d129.s1.e2" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s2" origId="18319074.s1" text="Muscle coenzyme Q(10) (CoQ(10) or ubiquinone) deficiency has been identified in more than 20 patients with presumed autosomal-recessive ataxia. ">
            <entity charOffset="116-141" id="miRNA-corp.d129.s2.e0" text="autosomal-recessive ataxia" type="Diseases"/>
            <entity charOffset="93-100" id="miRNA-corp.d129.s2.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s3" origId="18319074.s2" text="However, mutations in genes required for CoQ(10) biosynthetic pathway have been identified only in patients with infantile-onset multisystemic diseases or isolated nephropathy. ">
            <entity charOffset="155-174" id="miRNA-corp.d129.s3.e0" text="isolated nephropathy" type="Diseases"/>
            <entity charOffset="99-106" id="miRNA-corp.d129.s3.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s4" origId="18319074.s3" text="Our SNP-based genome-wide scan in a large consanguineous family revealed a locus for autosomal-recessive ataxia at chromosome 1q41. ">
            <entity charOffset="85-110" id="miRNA-corp.d129.s4.e0" text="autosomal-recessive ataxia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s5" origId="18319074.s4" text="The causative mutation is a homozygous splice-site mutation in the aarF-domain-containing kinase 3 gene (ADCK3). ">
            <entity charOffset="67-102" id="miRNA-corp.d129.s5.e0" text="aarF-domain-containing kinase 3 gene" type="Genes/Proteins"/>
            <entity charOffset="105-109" id="miRNA-corp.d129.s5.e1" text="ADCK3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s6" origId="18319074.s5" text="Five additional mutations in ADCK3 were found in three patients with sporadic ataxia, including one known to have CoQ(10) deficiency in muscle. ">
            <entity charOffset="69-83" id="miRNA-corp.d129.s6.e0" text="sporadic ataxia" type="Diseases"/>
            <entity charOffset="29-33" id="miRNA-corp.d129.s6.e1" text="ADCK3" type="Genes/Proteins"/>
            <entity charOffset="55-62" id="miRNA-corp.d129.s6.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s7" origId="18319074.s6" text="All of the patients have childhood-onset cerebellar ataxia with slow progression, and three of six have mildly elevated lactate levels. ">
            <entity charOffset="111-133" id="miRNA-corp.d129.s7.e0" text="elevated lactate levels" type="Relation_Trigger"/>
            <entity charOffset="41-57" id="miRNA-corp.d129.s7.e1" text="cerebellar ataxia" type="Diseases"/>
            <entity charOffset="11-18" id="miRNA-corp.d129.s7.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s8" origId="18319074.s7" text="ADCK3 is a mitochondrial protein homologous to the yeast COQ8 and the bacterial UbiB proteins, which are required for CoQ biosynthesis. ">
            <entity charOffset="0-4" id="miRNA-corp.d129.s8.e0" text="ADCK3" type="Genes/Proteins"/>
            <entity charOffset="57-60" id="miRNA-corp.d129.s8.e1" text="COQ8" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s9" origId="18319074.s8" text="Three out of four patients tested showed a low endogenous pool of CoQ(10) in their fibroblasts or lymphoblasts, and two out of three patients showed impaired ubiquinone synthesis, strongly suggesting that ADCK3 is also involved in CoQ(10) biosynthesis. ">
            <entity charOffset="149-156" id="miRNA-corp.d129.s9.e0" text="impaired" type="Relation_Trigger"/>
            <entity charOffset="205-209" id="miRNA-corp.d129.s9.e1" text="ADCK3" type="Genes/Proteins"/>
            <entity charOffset="18-25" id="miRNA-corp.d129.s9.e2" text="patients" type="Species"/>
            <entity charOffset="133-140" id="miRNA-corp.d129.s9.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d129.s10" origId="18319074.s9" text="The deleterious nature of the three identified missense changes was confirmed by the introduction of them at the corresponding positions of the yeast COQ8 gene. ">
            <entity charOffset="150-153" id="miRNA-corp.d129.s10.e0" text="COQ8" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d130" origId="19831127">
        <sentence id="miRNA-corp.d130.s0" origId="19831127.s10" text="Our method significantly decreased the duration of hospital admission for monitoring and minimal complications occurred only in 8% of patients. ">
            <entity charOffset="11-33" id="miRNA-corp.d130.s0.e0" text="significantly decreased" type="Relation_Trigger"/>
            <entity charOffset="134-141" id="miRNA-corp.d130.s0.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s1" origId="19831127.s11" text="CONCLUSIONS: In conclusion, our method for short VEEG monitoring has a high yield for diagnosis, minimal complications and is cost effective. "/>
        <sentence id="miRNA-corp.d130.s2" origId="19831127.s12" text="These qualities, together with good surgery results validate our method for the investigation and treatment of refractory seizure cases.   ">
            <entity charOffset="111-128" id="miRNA-corp.d130.s2.e0" text="refractory seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s3" origId="19831127.s6" text="RESULTS: Our monitoring answered the study question in 88% of the patients. ">
            <entity charOffset="66-73" id="miRNA-corp.d130.s3.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s4" origId="19831127.s5" text="We prospectively assessed the yield and safety of the telemetry investigation as well as epilepsy surgery outcomes. ">
            <entity charOffset="89-96" id="miRNA-corp.d130.s4.e0" text="epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s5" origId="19831127.s8" text="Our results changed the management in 74% of cases and potentially improved quality of life by decreasing the AEDs consumption and number of seizures per month. ">
            <entity charOffset="141-148" id="miRNA-corp.d130.s5.e0" text="seizures" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s6" origId="19831127.s7" text="The question was not answered in 12% of cases due to the lack of recorded events. "/>
        <sentence id="miRNA-corp.d130.s7" origId="19831127.s9" text="Over all, 22% received epilepsy surgery and became either seizure free or their seizures became non-disabling. ">
            <entity charOffset="58-64" id="miRNA-corp.d130.s7.e0" text="seizure" type="Diseases"/>
            <entity charOffset="80-87" id="miRNA-corp.d130.s7.e1" text="seizures" type="Diseases"/>
            <entity charOffset="23-30" id="miRNA-corp.d130.s7.e2" text="epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d130.s8" origId="19831127.s0" text="Safety and yield of early cessation of AEDs in video-EEG telemetry and outcomes.  "/>
        <sentence id="miRNA-corp.d130.s9" origId="19831127.s2" text="METHODS: This is a prospective study performed to asses the safety and yield of early discontinuation of antiepileptic drugs (AEDs) in the telemetry unit. "/>
        <sentence id="miRNA-corp.d130.s10" origId="19831127.s1" text="BACKGROUND: Video-electroencephalography (VEEG) telemetry is the simultaneous recording of ictal and interictal EEG pattern and paroxysmal behavior to investigate the nature of paroxysmal events. "/>
        <sentence id="miRNA-corp.d130.s11" origId="19831127.s4" text="In most cases AEDs (except Phenobarbital) were discontinued in 24h. "/>
        <sentence id="miRNA-corp.d130.s12" origId="19831127.s3" text="Over a 2.5-year period, 50 patients that met the indications for VEEG monitoring were admitted by an epileptologist to neuro-observation units with continuous monitoring, nursing coverage and EEG technicians support during working hours and on-call thereafter. ">
            <entity charOffset="27-34" id="miRNA-corp.d130.s12.e0" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d131" origId="19731102">
        <sentence id="miRNA-corp.d131.s0" origId="19731102.s2" text="The molecular mechanisms that contribute to gliomagenesis have become increasingly clear in recent years, yet much remains to be learned. "/>
        <sentence id="miRNA-corp.d131.s1" origId="19731102.s1" text="Gliomas are the most common form of primary brain tumors and are associated with a poor clinical outcome. ">
            <entity charOffset="0-6" id="miRNA-corp.d131.s1.e0" text="Gliomas" type="Diseases"/>
            <entity charOffset="44-55" id="miRNA-corp.d131.s1.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="65-74" id="miRNA-corp.d131.s1.e2" text="associated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d131.s2" origId="19731102.s0" text="microRNAs in gliomas: small regulators of a big problem.  ">
            <entity charOffset="0-8" id="miRNA-corp.d131.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-19" id="miRNA-corp.d131.s2.e1" text="gliomas" type="Diseases"/>
            <entity charOffset="28-37" id="miRNA-corp.d131.s2.e2" text="regulators" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d131.s2.e0" e2="miRNA-corp.d131.s2.e1" id="miRNA-corp.d131.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d131.s3" origId="19731102.s6" text="This is a rapidly evolving field and it is likely that we have only begun to appreciate the involvement of microRNAs in relation to glioma formation, and the therapeutic potential of microRNAs to improve outcome for glioma patients.   ">
            <entity charOffset="107-115" id="miRNA-corp.d131.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="183-191" id="miRNA-corp.d131.s3.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="132-137" id="miRNA-corp.d131.s3.e2" text="glioma" type="Diseases"/>
            <entity charOffset="216-221" id="miRNA-corp.d131.s3.e3" text="glioma" type="Diseases"/>
            <entity charOffset="223-230" id="miRNA-corp.d131.s3.e4" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d131.s3.e0" e2="miRNA-corp.d131.s3.e2" id="miRNA-corp.d131.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d131.s3.e0" e2="miRNA-corp.d131.s3.e3" id="miRNA-corp.d131.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d131.s3.e1" e2="miRNA-corp.d131.s3.e2" id="miRNA-corp.d131.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d131.s3.e1" e2="miRNA-corp.d131.s3.e3" id="miRNA-corp.d131.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d131.s4" origId="19731102.s5" text="Here we review the current state of knowledge related to the role of microRNAs in glial tumor development. ">
            <entity charOffset="69-77" id="miRNA-corp.d131.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="82-92" id="miRNA-corp.d131.s4.e1" text="glial tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d131.s4.e0" e2="miRNA-corp.d131.s4.e1" id="miRNA-corp.d131.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d131.s5" origId="19731102.s4" text="It is now evident that microRNAs regulate a wide variety of tumorigenic processes including cellular proliferation, differentiation, angiogenesis, invasion, and apoptosis. ">
            <entity charOffset="23-31" id="miRNA-corp.d131.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-40" id="miRNA-corp.d131.s5.e1" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d131.s6" origId="19731102.s3" text="This is particularly true for the role of microRNAs in gliomagenesis, as an appreciation for the significance of aberrant miRNA expression in human cancer has only emerged in the last 5 years. ">
            <entity charOffset="42-50" id="miRNA-corp.d131.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-126" id="miRNA-corp.d131.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="113-137" id="miRNA-corp.d131.s6.e2" text="aberrant miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="148-153" id="miRNA-corp.d131.s6.e3" text="cancer" type="Diseases"/>
            <entity charOffset="142-146" id="miRNA-corp.d131.s6.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d131.s6.e0" e2="miRNA-corp.d131.s6.e3" id="miRNA-corp.d131.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d131.s6.e1" e2="miRNA-corp.d131.s6.e3" id="miRNA-corp.d131.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d132" origId="20488792">
        <sentence id="miRNA-corp.d132.s0" origId="20488792.s8" text="Moreover, LPS stimulation decreased expression of microRNAs (miRNA)--miR-17-5, miR-20a, and miR-93--which target MICA, implicating a novel role for miRNAs in NKG2D ligand expression. ">
            <entity charOffset="92-97" id="miRNA-corp.d132.s0.e0" text="miR-93" type="Specific_miRNAs"/>
            <entity charOffset="113-116" id="miRNA-corp.d132.s0.e1" text="MICA" type="Genes/Proteins"/>
            <entity charOffset="50-58" id="miRNA-corp.d132.s0.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="61-65" id="miRNA-corp.d132.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="148-153" id="miRNA-corp.d132.s0.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-45" id="miRNA-corp.d132.s0.e5" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="106-111" id="miRNA-corp.d132.s0.e6" text="target" type="Relation_Trigger"/>
            <entity charOffset="69-76" id="miRNA-corp.d132.s0.e7" text="miR-17-5" type="Specific_miRNAs"/>
            <entity charOffset="79-85" id="miRNA-corp.d132.s0.e8" text="miR-20a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d132.s0.e0" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d132.s0.e2" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d132.s0.e3" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d132.s0.e4" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d132.s0.e7" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d132.s0.e8" e2="miRNA-corp.d132.s0.e1" id="miRNA-corp.d132.s0.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s1" origId="20488792.s7" text="However, it was not sufficient for surface protein expression, which was controlled posttranscriptionally via a separate pathway involving the ataxia telangiectasia mutated/ataxia telangiectasia and Rad3 related kinases. ">
            <entity charOffset="143-171" id="miRNA-corp.d132.s1.e0" text="ataxia telangiectasia mutated" type="Genes/Proteins"/>
            <entity charOffset="173-210" id="miRNA-corp.d132.s1.e1" text="ataxia telangiectasia and Rad3 related" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s2" origId="20488792.s9" text="Thus, TLR stimulation allows expression of NKG2D ligands through multiple pathways, including downmodulation of specific miRNAs.   ">
            <entity charOffset="121-126" id="miRNA-corp.d132.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-107" id="miRNA-corp.d132.s2.e1" text="downmodulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s3" origId="20488792.s4" text="In this paper, we clarify that LPS, which ligates TLR-4, preferentially upregulated MICA and not MICB; CL097, which ligates TLR-7/8, upregulated both MICA and MICB; and polyinosinic-polycytidylic acid, which ligates TLR-3, upregulated neither. ">
            <entity charOffset="50-54" id="miRNA-corp.d132.s3.e0" text="TLR-4" type="Genes/Proteins"/>
            <entity charOffset="216-220" id="miRNA-corp.d132.s3.e1" text="TLR-3" type="Genes/Proteins"/>
            <entity charOffset="150-153" id="miRNA-corp.d132.s3.e2" text="MICA" type="Genes/Proteins"/>
            <entity charOffset="159-162" id="miRNA-corp.d132.s3.e3" text="MICB" type="Genes/Proteins"/>
            <entity charOffset="124-130" id="miRNA-corp.d132.s3.e4" text="TLR-7/8" type="Genes/Proteins"/>
            <entity charOffset="103-107" id="miRNA-corp.d132.s3.e5" text="CL097" type="Genes/Proteins"/>
            <entity charOffset="97-100" id="miRNA-corp.d132.s3.e6" text="MICB" type="Genes/Proteins"/>
            <entity charOffset="84-87" id="miRNA-corp.d132.s3.e7" text="MICA" type="Genes/Proteins"/>
            <entity charOffset="72-82" id="miRNA-corp.d132.s3.e8" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="133-143" id="miRNA-corp.d132.s3.e9" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="223-233" id="miRNA-corp.d132.s3.e10" text="upregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s4" origId="20488792.s3" text="However, NKG2D ligands can also be induced on human macrophages by TLR stimulation, which has been far less studied. ">
            <entity charOffset="46-50" id="miRNA-corp.d132.s4.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s5" origId="20488792.s6" text="This finding suggests that increased levels of MICA mRNA following LPS stimulation resulted from increased transcription. ">
            <entity charOffset="47-50" id="miRNA-corp.d132.s5.e0" text="MICA" type="Genes/Proteins"/>
            <entity charOffset="27-42" id="miRNA-corp.d132.s5.e1" text="increased levels" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s6" origId="20488792.s5" text="To probe how LPS stimulation triggers MICA expression, we determined that the stability of MICA mRNA was much longer than that of MICB mRNA, but neither was changed by LPS stimulation. ">
            <entity charOffset="91-94" id="miRNA-corp.d132.s6.e0" text="MICA" type="Genes/Proteins"/>
            <entity charOffset="130-133" id="miRNA-corp.d132.s6.e1" text="MICB" type="Genes/Proteins"/>
            <entity charOffset="38-41" id="miRNA-corp.d132.s6.e2" text="MICA" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s7" origId="20488792.s0" text="Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk.  ">
            <entity charOffset="34-38" id="miRNA-corp.d132.s7.e0" text="TLR-4" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s8" origId="20488792.s2" text="This establishes recognition of &quot;induced self&quot; as an important strategy for surveillance of infections or tumor transformation. ">
            <entity charOffset="92-101" id="miRNA-corp.d132.s8.e0" text="infections" type="Diseases"/>
            <entity charOffset="106-110" id="miRNA-corp.d132.s8.e1" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d132.s9" origId="20488792.s1" text="The activating receptor NKG2D recognizes proteins that are not normally expressed at the surface of most cells but are expressed during a cellular &quot;stress&quot; response (e.g., upon induction of the DNA damage pathway). ">
            <entity charOffset="24-28" id="miRNA-corp.d132.s9.e0" text="NKG2D" type="Genes/Proteins"/>
            <entity charOffset="4-13" id="miRNA-corp.d132.s9.e1" text="activating" type="Relation_Trigger"/>
            <entity charOffset="194-203" id="miRNA-corp.d132.s9.e2" text="DNA damage" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d133" origId="20204141">
        <sentence id="miRNA-corp.d133.s0" origId="20204141.s0" text="MicroRNA in Situ Hybridization in the Human Entorhinal and Transentorhinal Cortex.  ">
            <entity charOffset="0-7" id="miRNA-corp.d133.s0.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-42" id="miRNA-corp.d133.s0.e1" text="Human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s1" origId="20204141.s1" text="MicroRNAs (miRNAs) play key roles in gene expression regulation in both healthy and disease brains. ">
            <entity charOffset="0-8" id="miRNA-corp.d133.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d133.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-62" id="miRNA-corp.d133.s1.e2" text="expression regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s2" origId="20204141.s2" text="To better understand those roles, it is necessary to characterize the miRNAs that are expressed in particular cell types under a range of conditions. ">
            <entity charOffset="70-75" id="miRNA-corp.d133.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s3" origId="20204141.s3" text="In situ hybridization (ISH) can demonstrate cell- and lamina-specific patterns of miRNA expression that would be lost in tissue-level expression profiling. ">
            <entity charOffset="82-86" id="miRNA-corp.d133.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s4" origId="20204141.s4" text="In the present study, ISH was performed with special focus on the human entorhinal cortex (EC) and transentorhinal cortex (TEC). ">
            <entity charOffset="66-70" id="miRNA-corp.d133.s4.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s5" origId="20204141.s5" text="The TEC is the area of the cerebral cortex that first develops neurofibrillary tangles in Alzheimer's disease (AD). ">
            <entity charOffset="90-108" id="miRNA-corp.d133.s5.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="111-112" id="miRNA-corp.d133.s5.e1" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s6" origId="20204141.s6" text="However, the reason for TEC's special vulnerability to AD-type pathology is unknown. ">
            <entity charOffset="55-56" id="miRNA-corp.d133.s6.e0" text="AD" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s7" origId="20204141.s7" text="MiRNA ISH was performed on three human brains with well-characterized clinical and pathological parameters. ">
            <entity charOffset="0-4" id="miRNA-corp.d133.s7.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-37" id="miRNA-corp.d133.s7.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s8" origId="20204141.s8" text="Locked nucleic acid ISH probes were used referent to miR-107, miR-124, miR-125b, and miR-320. ">
            <entity charOffset="53-59" id="miRNA-corp.d133.s8.e0" text="miR-107" type="Specific_miRNAs"/>
            <entity charOffset="62-68" id="miRNA-corp.d133.s8.e1" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="71-78" id="miRNA-corp.d133.s8.e2" text="miR-125b" type="Specific_miRNAs"/>
            <entity charOffset="85-91" id="miRNA-corp.d133.s8.e3" text="miR-320" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s9" origId="20204141.s9" text="In order to correlate the ISH data with AD pathology, the ISH staining was compared with near-adjacent slides processed using Thioflavine stains. ">
            <entity charOffset="40-41" id="miRNA-corp.d133.s9.e0" text="AD" type="Diseases"/>
            <entity charOffset="12-20" id="miRNA-corp.d133.s9.e1" text="correlate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s10" origId="20204141.s12" text="MiRNA ISH is among the first methods to show special staining characteristics of cells and laminae of the human TEC.   ">
            <entity charOffset="0-4" id="miRNA-corp.d133.s10.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="106-110" id="miRNA-corp.d133.s10.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s11" origId="20204141.s11" text="As with other areas of brain, the TEC and EC have characteristic miRNA expression patterns. ">
            <entity charOffset="65-69" id="miRNA-corp.d133.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d133.s12" origId="20204141.s10" text="Not all neurons or cortical lamina stain with equal intensity for individual miRNAs. ">
            <entity charOffset="77-82" id="miRNA-corp.d133.s12.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d134" origId="20709030">
        <sentence id="miRNA-corp.d134.s0" origId="20709030.s10" text="Our in vitro results suggested that Aβ42 oligomer-induced miR-106b leads to impairment in TGF-β signaling through TβR II, concomitant with retinoic acid-induced neurodegeneration in SH-SY5Y cells. ">
            <entity charOffset="114-119" id="miRNA-corp.d134.s0.e0" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="58-65" id="miRNA-corp.d134.s0.e1" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="76-85" id="miRNA-corp.d134.s0.e2" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="90-94" id="miRNA-corp.d134.s0.e3" text="TGF-β" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s0.e1" e2="miRNA-corp.d134.s0.e0" id="miRNA-corp.d134.s0.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s0.e1" e2="miRNA-corp.d134.s0.e3" id="miRNA-corp.d134.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s1" origId="20709030.s11" text="These results show that TβR II is a functional target of miR-106b and that miR-106b may influence TGF-β signaling, thereby contributing to the pathogenesis of AD.   ">
            <entity charOffset="24-29" id="miRNA-corp.d134.s1.e0" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="75-82" id="miRNA-corp.d134.s1.e1" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="57-64" id="miRNA-corp.d134.s1.e2" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="159-160" id="miRNA-corp.d134.s1.e3" text="AD" type="Diseases"/>
            <entity charOffset="36-52" id="miRNA-corp.d134.s1.e4" text="functional target" type="Relation_Trigger"/>
            <entity charOffset="98-102" id="miRNA-corp.d134.s1.e5" text="TGF-β" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s1.e1" e2="miRNA-corp.d134.s1.e0" id="miRNA-corp.d134.s1.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s1.e1" e2="miRNA-corp.d134.s1.e3" id="miRNA-corp.d134.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s1.e1" e2="miRNA-corp.d134.s1.e5" id="miRNA-corp.d134.s1.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s1.e2" e2="miRNA-corp.d134.s1.e0" id="miRNA-corp.d134.s1.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s1.e2" e2="miRNA-corp.d134.s1.e3" id="miRNA-corp.d134.s1.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s1.e2" e2="miRNA-corp.d134.s1.e5" id="miRNA-corp.d134.s1.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s2" origId="20709030.s1" text="MicroRNAs (miRNAs) are abundantly expressed in the brain and play an important role in disorders of the brain, including Alzheimer's diseases (AD). ">
            <entity charOffset="121-140" id="miRNA-corp.d134.s2.e0" text="Alzheimer's diseases" type="Diseases"/>
            <entity charOffset="143-144" id="miRNA-corp.d134.s2.e1" text="AD" type="Diseases"/>
            <entity charOffset="11-16" id="miRNA-corp.d134.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-8" id="miRNA-corp.d134.s2.e3" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-42" id="miRNA-corp.d134.s2.e3" text="abundantly expressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d134.s2.e2" e2="miRNA-corp.d134.s2.e0" id="miRNA-corp.d134.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s2.e2" e2="miRNA-corp.d134.s2.e1" id="miRNA-corp.d134.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s2.e3" e2="miRNA-corp.d134.s2.e0" id="miRNA-corp.d134.s2.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s2.e3" e2="miRNA-corp.d134.s2.e1" id="miRNA-corp.d134.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s3" origId="20709030.s0" text="miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.  ">
            <entity charOffset="0-7" id="miRNA-corp.d134.s3.e0" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="69-87" id="miRNA-corp.d134.s3.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="97-118" id="miRNA-corp.d134.s3.e2" text="TGF-β type II receptor" type="Genes/Proteins"/>
            <entity charOffset="9-28" id="miRNA-corp.d134.s3.e3" text="aberrantly expressed" type="Relation_Trigger"/>
            <entity charOffset="89-95" id="miRNA-corp.d134.s3.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="42-57" id="miRNA-corp.d134.s3.e5" text="transgenic mouse" type="Species"/>
            <pair e1="miRNA-corp.d134.s3.e0" e2="miRNA-corp.d134.s3.e1" id="miRNA-corp.d134.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s3.e0" e2="miRNA-corp.d134.s3.e2" id="miRNA-corp.d134.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s4" origId="20709030.s3" text="However, it is unclear whether miRNAs involved in AD pathogenesis by regulating TGF-β signaling. ">
            <entity charOffset="50-51" id="miRNA-corp.d134.s4.e0" text="AD" type="Diseases"/>
            <entity charOffset="31-36" id="miRNA-corp.d134.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-78" id="miRNA-corp.d134.s4.e2" text="regulating" type="Relation_Trigger"/>
            <entity charOffset="80-84" id="miRNA-corp.d134.s4.e3" text="TGF-β" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s4.e1" e2="miRNA-corp.d134.s4.e0" id="miRNA-corp.d134.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s4.e1" e2="miRNA-corp.d134.s4.e3" id="miRNA-corp.d134.s4.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s5" origId="20709030.s2" text="Growing body of evidence suggests that the TGF-β signaling pathway plays a key role in the pathogenesis of AD. ">
            <entity charOffset="107-108" id="miRNA-corp.d134.s5.e0" text="AD" type="Diseases"/>
            <entity charOffset="43-47" id="miRNA-corp.d134.s5.e1" text="TGF-β" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s6" origId="20709030.s5" text="Sequence analysis revealed two putative binding sites for miR-106b in the 3' UTR of the TβR II mRNA. ">
            <entity charOffset="88-93" id="miRNA-corp.d134.s6.e0" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="58-65" id="miRNA-corp.d134.s6.e1" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="40-52" id="miRNA-corp.d134.s6.e2" text="binding sites" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d134.s6.e1" e2="miRNA-corp.d134.s6.e0" id="miRNA-corp.d134.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s7" origId="20709030.s4" text="Here we found that miR-106b and TGF-β type II receptor (TβR II) were aberrantly expressed in APPswe/PS∆E9 mice (a double transgenic mouse model for AD). ">
            <entity charOffset="32-53" id="miRNA-corp.d134.s7.e0" text="TGF-β type II receptor" type="Genes/Proteins"/>
            <entity charOffset="56-61" id="miRNA-corp.d134.s7.e1" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="19-26" id="miRNA-corp.d134.s7.e2" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="148-149" id="miRNA-corp.d134.s7.e3" text="AD" type="Diseases"/>
            <entity charOffset="69-88" id="miRNA-corp.d134.s7.e4" text="aberrantly expressed" type="Relation_Trigger"/>
            <entity charOffset="121-136" id="miRNA-corp.d134.s7.e5" text="transgenic mouse" type="Species"/>
            <entity charOffset="106-109" id="miRNA-corp.d134.s7.e6" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d134.s7.e2" e2="miRNA-corp.d134.s7.e3" id="miRNA-corp.d134.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d134.s7.e2" e2="miRNA-corp.d134.s7.e0" id="miRNA-corp.d134.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s7.e2" e2="miRNA-corp.d134.s7.e1" id="miRNA-corp.d134.s7.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s8" origId="20709030.s7" text="After induced neurodifferentiation with all-trans retinoic acid, we observed significant neurodegeneration in SH-SY5Y cells stably transfected with miR-106b. ">
            <entity charOffset="148-155" id="miRNA-corp.d134.s8.e0" text="miR-106b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s9" origId="20709030.s6" text="Our results showed that the expression of miR-106b was inversely correlated with TβR II protein levels and miR-106b can directly inhibit the TβR II translation in vitro. ">
            <entity charOffset="81-86" id="miRNA-corp.d134.s9.e0" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="141-146" id="miRNA-corp.d134.s9.e1" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="42-49" id="miRNA-corp.d134.s9.e2" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="107-114" id="miRNA-corp.d134.s9.e3" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="55-74" id="miRNA-corp.d134.s9.e4" text="inversely correlated" type="Relation_Trigger"/>
            <entity charOffset="129-158" id="miRNA-corp.d134.s9.e5" text="inhibit the TβR II translation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d134.s9.e2" e2="miRNA-corp.d134.s9.e0" id="miRNA-corp.d134.s9.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s9.e2" e2="miRNA-corp.d134.s9.e1" id="miRNA-corp.d134.s9.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s9.e3" e2="miRNA-corp.d134.s9.e0" id="miRNA-corp.d134.s9.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s9.e3" e2="miRNA-corp.d134.s9.e1" id="miRNA-corp.d134.s9.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s10" origId="20709030.s9" text="Exposure of SH-SY5Y cells to Aβ42 oligomers led to the expression of miR-106b was first increased and then decreased and TβR II levels reduced. ">
            <entity charOffset="69-76" id="miRNA-corp.d134.s10.e0" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="121-126" id="miRNA-corp.d134.s10.e1" text="TβR II" type="Genes/Proteins"/>
            <entity charOffset="128-141" id="miRNA-corp.d134.s10.e2" text="levels reduced" type="Relation_Trigger"/>
            <entity charOffset="55-96" id="miRNA-corp.d134.s10.e3" text="expression of miR-106b was first increased" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d134.s10.e0" e2="miRNA-corp.d134.s10.e1" id="miRNA-corp.d134.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d134.s11" origId="20709030.s8" text="Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line. ">
            <entity charOffset="83-97" id="miRNA-corp.d134.s11.e0" text="phospho-Smad2/3" type="Genes/Proteins"/>
            <entity charOffset="100-108" id="miRNA-corp.d134.s11.e1" text="p-Smad2/3" type="Genes/Proteins"/>
            <entity charOffset="47-53" id="miRNA-corp.d134.s11.e2" text="Smad2/3" type="Genes/Proteins"/>
            <entity charOffset="125-131" id="miRNA-corp.d134.s11.e3" text="Smad6/7" type="Genes/Proteins"/>
            <entity charOffset="155-162" id="miRNA-corp.d134.s11.e4" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="115-146" id="miRNA-corp.d134.s11.e5" text="increased Smad6/7 protein levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d134.s11.e4" e2="miRNA-corp.d134.s11.e0" id="miRNA-corp.d134.s11.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s11.e4" e2="miRNA-corp.d134.s11.e1" id="miRNA-corp.d134.s11.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s11.e4" e2="miRNA-corp.d134.s11.e2" id="miRNA-corp.d134.s11.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d134.s11.e4" e2="miRNA-corp.d134.s11.e3" id="miRNA-corp.d134.s11.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d135" origId="20423455">
        <sentence id="miRNA-corp.d135.s0" origId="20423455.s0" text="Nuclear factor TDP-43 can affect selected microRNA levels.  ">
            <entity charOffset="15-20" id="miRNA-corp.d135.s0.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="42-49" id="miRNA-corp.d135.s0.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="26-56" id="miRNA-corp.d135.s0.e2" text="affect selected microRNA levels" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d135.s0.e1" e2="miRNA-corp.d135.s0.e0" id="miRNA-corp.d135.s0.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s1" origId="20423455.s1" text="TDP-43 has recently been described as the major component of the inclusions found in the brain of patients with a variety of neurodegenerative diseases, such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis. ">
            <entity charOffset="0-5" id="miRNA-corp.d135.s1.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="199-227" id="miRNA-corp.d135.s1.e1" text="amyotrophic lateral sclerosis" type="Diseases"/>
            <entity charOffset="161-193" id="miRNA-corp.d135.s1.e2" text="frontotemporal lobar degeneration" type="Diseases"/>
            <entity charOffset="125-150" id="miRNA-corp.d135.s1.e3" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="98-105" id="miRNA-corp.d135.s1.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s2" origId="20423455.s3" text="Apart from its involvement in transcription, splicing and mRNA stability, TDP-43 has also been described as a Drosha-associated protein. ">
            <entity charOffset="74-79" id="miRNA-corp.d135.s2.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="110-115" id="miRNA-corp.d135.s2.e1" text="Drosha" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s3" origId="20423455.s2" text="TDP-43 is a ubiquitous protein whose specific functions are probably crucial to establishing its pathogenic role. ">
            <entity charOffset="0-5" id="miRNA-corp.d135.s3.e0" text="TDP-43" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s4" origId="20423455.s5" text="Here we report for the first time which changes occur in the total miRNA population following TDP-43 knockdown in culture cells. ">
            <entity charOffset="94-99" id="miRNA-corp.d135.s4.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="67-71" id="miRNA-corp.d135.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d135.s4.e1" e2="miRNA-corp.d135.s4.e0" id="miRNA-corp.d135.s4.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s5" origId="20423455.s4" text="However, our knowledge of the role of TDP-43 in the microRNA (miRNA) synthesis pathway is limited to the association mentioned above. ">
            <entity charOffset="38-43" id="miRNA-corp.d135.s5.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="105-115" id="miRNA-corp.d135.s5.e1" text="association" type="Relation_Trigger"/>
            <entity charOffset="52-59" id="miRNA-corp.d135.s5.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-66" id="miRNA-corp.d135.s5.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d135.s5.e2" e2="miRNA-corp.d135.s5.e0" id="miRNA-corp.d135.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d135.s5.e3" e2="miRNA-corp.d135.s5.e0" id="miRNA-corp.d135.s5.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s6" origId="20423455.s7" text="Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663). ">
            <entity charOffset="164-170" id="miRNA-corp.d135.s6.e0" text="miR-663" type="Specific_miRNAs"/>
            <entity charOffset="62-67" id="miRNA-corp.d135.s6.e1" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="20-25" id="miRNA-corp.d135.s6.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-108" id="miRNA-corp.d135.s6.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="127-132" id="miRNA-corp.d135.s6.e4" text="let-7b" type="Specific_miRNAs"/>
            <entity charOffset="42-48" id="miRNA-corp.d135.s6.e5" text="binding" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d135.s6.e2" e2="miRNA-corp.d135.s6.e1" id="miRNA-corp.d135.s6.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d135.s6.e3" e2="miRNA-corp.d135.s6.e1" id="miRNA-corp.d135.s6.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d135.s6.e4" e2="miRNA-corp.d135.s6.e1" id="miRNA-corp.d135.s6.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d135.s6.e0" e2="miRNA-corp.d135.s6.e1" id="miRNA-corp.d135.s6.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s7" origId="20423455.s6" text="In particular, we have observed that let-7b and miR-663 expression levels are down- and upregulated, respectively. ">
            <entity charOffset="37-42" id="miRNA-corp.d135.s7.e0" text="let-7b" type="Specific_miRNAs"/>
            <entity charOffset="48-54" id="miRNA-corp.d135.s7.e1" text="miR-663" type="Specific_miRNAs"/>
            <entity charOffset="67-98" id="miRNA-corp.d135.s7.e2" text="levels are down- and upregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d135.s8" origId="20423455.s8" text="Using microarray data and real-time PCR we have also identified several candidate transcripts whose expression levels are selectively affected by these TDP-43-miRNA interactions.   ">
            <entity charOffset="152-157" id="miRNA-corp.d135.s8.e0" text="TDP-43" type="Genes/Proteins"/>
            <entity charOffset="159-163" id="miRNA-corp.d135.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-141" id="miRNA-corp.d135.s8.e2" text="expression levels are selectively affected" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d135.s8.e1" e2="miRNA-corp.d135.s8.e0" id="miRNA-corp.d135.s8.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d136" origId="19576215">
        <sentence id="miRNA-corp.d136.s0" origId="19576215.s0" text="Altered microRNA expression following traumatic spinal cord injury.  ">
            <entity charOffset="8-15" id="miRNA-corp.d136.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-65" id="miRNA-corp.d136.s0.e1" text="traumatic spinal cord injury" type="Diseases"/>
            <entity charOffset="0-26" id="miRNA-corp.d136.s0.e2" text="Altered microRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d136.s0.e0" e2="miRNA-corp.d136.s0.e1" id="miRNA-corp.d136.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d136.s1" origId="19576215.s1" text="MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation. ">
            <entity charOffset="11-16" id="miRNA-corp.d136.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="0-8" id="miRNA-corp.d136.s1.e1" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="180-185" id="miRNA-corp.d136.s1.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="210-233" id="miRNA-corp.d136.s1.e3" text="translational inhibition" type="Relation_Trigger"/>
            <entity charOffset="78-101" id="miRNA-corp.d136.s1.e4" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="139-145" id="miRNA-corp.d136.s1.e5" text="binding" type="Relation_Trigger"/>
            <entity charOffset="67-85" id="miRNA-corp.d136.s1.e6" text="negatively regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d136.s2" origId="19576215.s2" text="We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis. ">
            <entity charOffset="86-91" id="miRNA-corp.d136.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="115-132" id="miRNA-corp.d136.s2.e1" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="135-137" id="miRNA-corp.d136.s2.e2" text="SCI" type="Diseases"/>
            <entity charOffset="34-66" id="miRNA-corp.d136.s2.e3" text="alteration in temporal expression" type="Relation_Trigger"/>
            <entity charOffset="149-152" id="miRNA-corp.d136.s2.e4" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d136.s2.e0" e2="miRNA-corp.d136.s2.e1" id="miRNA-corp.d136.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d136.s2.e0" e2="miRNA-corp.d136.s2.e2" id="miRNA-corp.d136.s2.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d136.s3" origId="19576215.s3" text="These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) down-regulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI. ">
            <entity charOffset="14-19" id="miRNA-corp.d136.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-186" id="miRNA-corp.d136.s3.e1" text="SCI" type="Diseases"/>
            <entity charOffset="62-74" id="miRNA-corp.d136.s3.e2" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="81-95" id="miRNA-corp.d136.s3.e3" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="114-126" id="miRNA-corp.d136.s3.e4" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="147-161" id="miRNA-corp.d136.s3.e5" text="down-regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d136.s3.e0" e2="miRNA-corp.d136.s3.e1" id="miRNA-corp.d136.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d136.s4" origId="19576215.s4" text="The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI. ">
            <entity charOffset="69-74" id="miRNA-corp.d136.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-92" id="miRNA-corp.d136.s4.e1" text="SCI" type="Diseases"/>
            <entity charOffset="254-256" id="miRNA-corp.d136.s4.e2" text="SCI" type="Diseases"/>
            <entity charOffset="47-63" id="miRNA-corp.d136.s4.e3" text="potential targets" type="Relation_Trigger"/>
            <entity charOffset="153-164" id="miRNA-corp.d136.s4.e4" text="inflammation" type="Diseases"/>
            <pair e1="miRNA-corp.d136.s4.e0" e2="miRNA-corp.d136.s4.e1" id="miRNA-corp.d136.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d136.s4.e0" e2="miRNA-corp.d136.s4.e2" id="miRNA-corp.d136.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d136.s4.e0" e2="miRNA-corp.d136.s4.e4" id="miRNA-corp.d136.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d136.s5" origId="19576215.s5" text="These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI.   ">
            <entity charOffset="51-56" id="miRNA-corp.d136.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="96-98" id="miRNA-corp.d136.s5.e1" text="SCI" type="Diseases"/>
            <entity charOffset="166-168" id="miRNA-corp.d136.s5.e2" text="SCI" type="Diseases"/>
            <entity charOffset="28-46" id="miRNA-corp.d136.s5.e3" text="abnormal expression" type="Relation_Trigger"/>
            <entity charOffset="108-124" id="miRNA-corp.d136.s5.e4" text="potential targets" type="Relation_Trigger"/>
            <entity charOffset="118-140" id="miRNA-corp.d136.s5.e5" text="targets for therapeutic" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d136.s5.e0" e2="miRNA-corp.d136.s5.e1" id="miRNA-corp.d136.s5.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d136.s5.e0" e2="miRNA-corp.d136.s5.e2" id="miRNA-corp.d136.s5.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d137" origId="18928881">
        <sentence id="miRNA-corp.d137.s0" origId="18928881.s2" text="Demyelinating process may be the feature of nervous impairment in systemic lupus erythematosus, Behcet's disease (BD), Sjoegren's syndrome (SS), systemic sclerosis (SSc) or very rarely other systemic autoimmune diseases. ">
            <entity charOffset="191-218" id="miRNA-corp.d137.s0.e0" text="systemic autoimmune diseases" type="Diseases"/>
            <entity charOffset="96-111" id="miRNA-corp.d137.s0.e1" text="Behcet's disease" type="Diseases"/>
            <entity charOffset="114-115" id="miRNA-corp.d137.s0.e2" text="BD" type="Diseases"/>
            <entity charOffset="119-137" id="miRNA-corp.d137.s0.e3" text="Sjoegren's syndrome" type="Diseases"/>
            <entity charOffset="140-141" id="miRNA-corp.d137.s0.e4" text="SS" type="Diseases"/>
            <entity charOffset="145-162" id="miRNA-corp.d137.s0.e5" text="systemic sclerosis" type="Diseases"/>
            <entity charOffset="165-167" id="miRNA-corp.d137.s0.e6" text="SSc" type="Diseases"/>
            <entity charOffset="52-61" id="miRNA-corp.d137.s0.e7" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="66-93" id="miRNA-corp.d137.s0.e8" text="systemic lupus erythematosus" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d137.s1" origId="18928881.s3" text="An acute isolated neurological syndrome, as the most common symptom of MS can sometimes be the only feature or even first manifestation of nervous impairment in connective tissue disease, hence presenting the diagnostic problem. ">
            <entity charOffset="139-156" id="miRNA-corp.d137.s1.e0" text="nervous impairment" type="Diseases"/>
            <entity charOffset="71-72" id="miRNA-corp.d137.s1.e1" text="MS" type="Diseases"/>
            <entity charOffset="147-156" id="miRNA-corp.d137.s1.e2" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="161-185" id="miRNA-corp.d137.s1.e3" text="connective tissue disease" type="Diseases"/>
            <entity charOffset="18-38" id="miRNA-corp.d137.s1.e4" text="neurological syndrome" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d137.s2" origId="18928881.s4" text="Although the white matter abnormalities seen by magnetic resonance imaging may be similar in non-MS autoimmune demyelination and MS, it is the most important diagnostic tool in the differential diagnosis of the mentioned conditions. ">
            <entity charOffset="129-130" id="miRNA-corp.d137.s2.e0" text="MS" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d137.s3" origId="18928881.s5" text="Investigating the presence of various autoantibodies potentially involved in the pathogenesis of demyelinating lesions as well as cerebrospinal fluid (CSF) analysis can be helpful.   ">
            <entity charOffset="97-117" id="miRNA-corp.d137.s3.e0" text="demyelinating lesions" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d137.s4" origId="18928881.s0" text="Non-MS autoimmune demyelination.  "/>
        <sentence id="miRNA-corp.d137.s5" origId="18928881.s1" text="Connective tissue diseases can be characterised by central nervous system (CNS) involvement, in some patients manifested by demyelination areas in the white matter of the brain and spinal cord, which are difficult to differentiate from multiple sclerosis (MS) and other demyelinating processes, such as transverse myelitis and optic neuritis. ">
            <entity charOffset="236-253" id="miRNA-corp.d137.s5.e0" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="256-257" id="miRNA-corp.d137.s5.e1" text="MS" type="Diseases"/>
            <entity charOffset="124-136" id="miRNA-corp.d137.s5.e2" text="demyelination" type="Diseases"/>
            <entity charOffset="0-25" id="miRNA-corp.d137.s5.e3" text="Connective tissue diseases" type="Diseases"/>
            <entity charOffset="327-340" id="miRNA-corp.d137.s5.e4" text="optic neuritis" type="Diseases"/>
            <entity charOffset="303-321" id="miRNA-corp.d137.s5.e5" text="transverse myelitis" type="Diseases"/>
            <entity charOffset="101-108" id="miRNA-corp.d137.s5.e6" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d138" origId="18986230">
        <sentence id="miRNA-corp.d138.s0" origId="18986230.s0" text="Targeting miRNAs in Alzheimer's disease.     ">
            <entity charOffset="10-15" id="miRNA-corp.d138.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-38" id="miRNA-corp.d138.s0.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d138.s0.e2" text="Targeting" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d138.s0.e0" e2="miRNA-corp.d138.s0.e1" id="miRNA-corp.d138.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d139" origId="19745058">
        <sentence id="miRNA-corp.d139.s0" origId="19745058.s10" text="CONCLUSIONS: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.   ">
            <entity charOffset="60-65" id="miRNA-corp.d139.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="126-138" id="miRNA-corp.d139.s0.e1" text="tissue injury" type="Diseases"/>
            <pair e1="miRNA-corp.d139.s0.e0" e2="miRNA-corp.d139.s0.e1" id="miRNA-corp.d139.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s1" origId="19745058.s9" text="The miR-124 concentration increased in the plasma of rats 8 h after surgery to produce brain injury and peaked at 24 h, while the miR-122 and miR-133a concentrations remained at baseline values. ">
            <entity charOffset="4-10" id="miRNA-corp.d139.s1.e0" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="142-149" id="miRNA-corp.d139.s1.e1" text="miR-133a" type="Specific_miRNAs"/>
            <entity charOffset="130-136" id="miRNA-corp.d139.s1.e2" text="miR-122" type="Specific_miRNAs"/>
            <entity charOffset="87-98" id="miRNA-corp.d139.s1.e3" text="brain injury" type="Diseases"/>
            <entity charOffset="151-192" id="miRNA-corp.d139.s1.e4" text="concentrations remained at baseline values" type="Relation_Trigger"/>
            <entity charOffset="12-34" id="miRNA-corp.d139.s1.e5" text="concentration increased" type="Relation_Trigger"/>
            <entity charOffset="53-56" id="miRNA-corp.d139.s1.e6" text="rats" type="Species"/>
            <pair e1="miRNA-corp.d139.s1.e1" e2="miRNA-corp.d139.s1.e3" id="miRNA-corp.d139.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s1.e2" e2="miRNA-corp.d139.s1.e3" id="miRNA-corp.d139.s1.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s1.e0" e2="miRNA-corp.d139.s1.e3" id="miRNA-corp.d139.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s2" origId="19745058.s8" text="Furthermore, miR-122 exhibited a diagnostic sensitivity superior to that of ALT when the results were correlated to the liver histopathologic results. ">
            <entity charOffset="13-19" id="miRNA-corp.d139.s2.e0" text="miR-122" type="Specific_miRNAs"/>
            <entity charOffset="102-111" id="miRNA-corp.d139.s2.e1" text="correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s3" origId="19745058.s0" text="Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.  ">
            <entity charOffset="7-15" id="miRNA-corp.d139.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-69" id="miRNA-corp.d139.s3.e1" text="tissue injury" type="Diseases"/>
            <pair e1="miRNA-corp.d139.s3.e0" e2="miRNA-corp.d139.s3.e1" id="miRNA-corp.d139.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s4" origId="19745058.s1" text="BACKGROUND: MicroRNAs (miRNAs) are endogenous, small noncoding RNAs. ">
            <entity charOffset="12-20" id="miRNA-corp.d139.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d139.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s5" origId="19745058.s2" text="Because of their size, abundance, tissue specificity, and relative stability in plasma, miRNAs hold promise as unique accessible biomarkers to monitor tissue injury. ">
            <entity charOffset="88-93" id="miRNA-corp.d139.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="151-163" id="miRNA-corp.d139.s5.e1" text="tissue injury" type="Diseases"/>
            <pair e1="miRNA-corp.d139.s5.e0" e2="miRNA-corp.d139.s5.e1" id="miRNA-corp.d139.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s6" origId="19745058.s3" text="METHODS: We investigated the use of liver-, muscle- and brain-specific miRNAs as circulating biomarkers of tissue injury. ">
            <entity charOffset="71-76" id="miRNA-corp.d139.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-119" id="miRNA-corp.d139.s6.e1" text="tissue injury" type="Diseases"/>
            <pair e1="miRNA-corp.d139.s6.e0" e2="miRNA-corp.d139.s6.e1" id="miRNA-corp.d139.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s7" origId="19745058.s4" text="We used a highly sensitive quantitative PCR assay to measure specific miRNAs (miR-122, miR-133a, and miR-124) in plasma samples from rats treated with liver or muscle toxicants and from a rat surgical model of stroke. ">
            <entity charOffset="78-84" id="miRNA-corp.d139.s7.e0" text="miR-122" type="Specific_miRNAs"/>
            <entity charOffset="87-94" id="miRNA-corp.d139.s7.e1" text="miR-133a" type="Specific_miRNAs"/>
            <entity charOffset="101-107" id="miRNA-corp.d139.s7.e2" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="210-215" id="miRNA-corp.d139.s7.e3" text="stroke" type="Diseases"/>
            <entity charOffset="70-75" id="miRNA-corp.d139.s7.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-136" id="miRNA-corp.d139.s7.e5" text="rats" type="Species"/>
            <entity charOffset="188-190" id="miRNA-corp.d139.s7.e6" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d139.s7.e0" e2="miRNA-corp.d139.s7.e3" id="miRNA-corp.d139.s7.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s7.e1" e2="miRNA-corp.d139.s7.e3" id="miRNA-corp.d139.s7.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s7.e4" e2="miRNA-corp.d139.s7.e3" id="miRNA-corp.d139.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s7.e2" e2="miRNA-corp.d139.s7.e3" id="miRNA-corp.d139.s7.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s8" origId="19745058.s5" text="RESULTS: We observed increases in plasma concentrations of miR-122, miR-133a, and miR-124 corresponding to injuries in liver, muscle, and brain, respectively. ">
            <entity charOffset="59-65" id="miRNA-corp.d139.s8.e0" text="miR-122" type="Specific_miRNAs"/>
            <entity charOffset="68-75" id="miRNA-corp.d139.s8.e1" text="miR-133a" type="Specific_miRNAs"/>
            <entity charOffset="82-88" id="miRNA-corp.d139.s8.e2" text="miR-124" type="Specific_miRNAs"/>
            <entity charOffset="107-123" id="miRNA-corp.d139.s8.e3" text="injuries in liver" type="Diseases"/>
            <entity charOffset="21-54" id="miRNA-corp.d139.s8.e4" text="increases in plasma concentrations" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d139.s8.e0" e2="miRNA-corp.d139.s8.e3" id="miRNA-corp.d139.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s8.e1" e2="miRNA-corp.d139.s8.e3" id="miRNA-corp.d139.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d139.s8.e2" e2="miRNA-corp.d139.s8.e3" id="miRNA-corp.d139.s8.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s9" origId="19745058.s6" text="miR-122 and miR-133a illustrated specificity for liver and muscle toxicity, respectively, because they were not detectable in the plasma of animals with toxicity to the other organ. ">
            <entity charOffset="0-6" id="miRNA-corp.d139.s9.e0" text="miR-122" type="Specific_miRNAs"/>
            <entity charOffset="12-19" id="miRNA-corp.d139.s9.e1" text="miR-133a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d139.s10" origId="19745058.s7" text="This result contrasted with the results for alanine aminotransferase (ALT) and aspartate aminotransferase, which were both increased with either organ toxicity. ">
            <entity charOffset="44-67" id="miRNA-corp.d139.s10.e0" text="alanine aminotransferase" type="Genes/Proteins"/>
            <entity charOffset="79-104" id="miRNA-corp.d139.s10.e1" text="aspartate aminotransferase" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d140" origId="21126225">
        <sentence id="miRNA-corp.d140.s0" origId="21126225.s1" text="Atrial fibrillation (AF) is an emerging clinical problem with multifaceted issues: current and expected prevalence, significant morbidity, potentially fatal outcome (e.g., stroke) and gaps in therapeutic approaches. ">
            <entity charOffset="0-18" id="miRNA-corp.d140.s0.e0" text="Atrial fibrillation" type="Diseases"/>
            <entity charOffset="21-22" id="miRNA-corp.d140.s0.e1" text="AF" type="Diseases"/>
            <entity charOffset="172-177" id="miRNA-corp.d140.s0.e2" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s1" origId="21126225.s0" text="Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.  ">
            <entity charOffset="0-8" id="miRNA-corp.d140.s1.e0" text="Targeting" type="Relation_Trigger"/>
            <entity charOffset="42-60" id="miRNA-corp.d140.s1.e1" text="atrial fibrillation" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s2" origId="21126225.s3" text="Although a number of drugs have just come out of the pipeline with promising results (e.g., dronedarone), the question arises whether channel-targeted drugs represent the only viable approach. "/>
        <sentence id="miRNA-corp.d140.s3" origId="21126225.s2" text="Current anti-arrhythmic strategies not only fail to guarantee effective rhythm control, but also cause &quot;on target&quot; (i.e., pro-arrhythmia, namely torsade de pointes) and &quot;off target&quot; (i.e., extra-cardiac toxicities) side effects. ">
            <entity charOffset="126-135" id="miRNA-corp.d140.s3.e0" text="arrhythmia" type="Diseases"/>
            <entity charOffset="107-112" id="miRNA-corp.d140.s3.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="174-179" id="miRNA-corp.d140.s3.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="145-162" id="miRNA-corp.d140.s3.e3" text="torsade de pointes" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s4" origId="21126225.s8" text="Fascinating and innovative strategies have been proposed (e.g., miRNAs modulation), but the actual benefit is debated. ">
            <entity charOffset="64-69" id="miRNA-corp.d140.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-80" id="miRNA-corp.d140.s4.e1" text="modulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s5" origId="21126225.s9" text="This review will provide mechanistic insights into structural remodeling and highlight emerging upstream strategies in AF management.   ">
            <entity charOffset="119-120" id="miRNA-corp.d140.s5.e0" text="AF" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s6" origId="21126225.s4" text="A body of evidence has emerged supporting structural remodeling as the main arrhythmogenic substrate perpetuating AF. Fibrosis, inflammation and oxidative stress appear strongly interconnected in the pathogenesis of remodeling-induced abnormalities. ">
            <entity charOffset="114-115" id="miRNA-corp.d140.s6.e0" text="AF" type="Diseases"/>
            <entity charOffset="118-125" id="miRNA-corp.d140.s6.e1" text="Fibrosis" type="Diseases"/>
            <entity charOffset="128-139" id="miRNA-corp.d140.s6.e2" text="inflammation" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s7" origId="21126225.s5" text="Moreover, insights into extracellular matrix network strongly suggested an active cross-talk within the cardiac microenvironment, which should be further investigated as promising &quot;anti-remodeling&quot; approach. "/>
        <sentence id="miRNA-corp.d140.s8" origId="21126225.s6" text="Therefore, pharmacological modulation of non-ionic targets (the so called &quot;upstream&quot; therapy) has gained interest as a preventive strategy in AF. ">
            <entity charOffset="142-143" id="miRNA-corp.d140.s8.e0" text="AF" type="Diseases"/>
            <entity charOffset="27-36" id="miRNA-corp.d140.s8.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="51-57" id="miRNA-corp.d140.s8.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d140.s9" origId="21126225.s7" text="At the present state of knowledge, renin-angiotensin-aldosterone system blockers and statins offer evidence for potential clinical exploitation, while several remodeling-targeted therapies have been tested only experimentally or failed when studied for human validation. ">
            <entity charOffset="41-51" id="miRNA-corp.d140.s9.e0" text="angiotensin" type="Genes/Proteins"/>
            <entity charOffset="35-39" id="miRNA-corp.d140.s9.e1" text="renin" type="Genes/Proteins"/>
            <entity charOffset="253-257" id="miRNA-corp.d140.s9.e2" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d141" origId="18836290">
        <sentence id="miRNA-corp.d141.s0" origId="18836290.s1" text="Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence. ">
            <entity charOffset="44-73" id="miRNA-corp.d141.s0.e0" text="alterations in gene expression" type="Relation_Trigger"/>
            <entity charOffset="64-89" id="miRNA-corp.d141.s0.e1" text="expression without changes" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d141.s1" origId="18836290.s0" text="Epigenetic changes in gliomas.  ">
            <entity charOffset="22-28" id="miRNA-corp.d141.s1.e0" text="gliomas" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d141.s2" origId="18836290.s3" text="In this review, we will first describe briefly histone modifications, DNA methylation and miRNAs and the functions of these epigenetic marks during different cellular processes involving DNA metabolism. ">
            <entity charOffset="90-95" id="miRNA-corp.d141.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d141.s3" origId="18836290.s2" text="While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells. ">
            <entity charOffset="101-105" id="miRNA-corp.d141.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-98" id="miRNA-corp.d141.s3.e1" text="regulate gene expression" type="Relation_Trigger"/>
            <entity charOffset="188-193" id="miRNA-corp.d141.s3.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d141.s3.e0" e2="miRNA-corp.d141.s3.e2" id="miRNA-corp.d141.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d141.s4" origId="18836290.s5" text="We expect that novel therapies will be developed to counter epigenetic changes in this deadly disease.   "/>
        <sentence id="miRNA-corp.d141.s5" origId="18836290.s4" text="We will then highlight some epigenetic changes in glioblastomas, a malignant form of brain tumor, and potential application of epigenetic means for diagnosis, prognosis, and treatment of gliomas. ">
            <entity charOffset="187-193" id="miRNA-corp.d141.s5.e0" text="gliomas" type="Diseases"/>
            <entity charOffset="50-62" id="miRNA-corp.d141.s5.e1" text="glioblastomas" type="Diseases"/>
            <entity charOffset="85-95" id="miRNA-corp.d141.s5.e2" text="brain tumor" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d142" origId="20375468">
        <sentence id="miRNA-corp.d142.s0" origId="20375468.s0" text="Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases.  ">
            <entity charOffset="36-43" id="miRNA-corp.d142.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-78" id="miRNA-corp.d142.s0.e1" text="Alzheimer's" type="Diseases"/>
            <pair e1="miRNA-corp.d142.s0.e0" e2="miRNA-corp.d142.s0.e1" id="miRNA-corp.d142.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d142.s1" origId="20375468.s1" text="Generated by the ribonuclease III Dicer, microRNAs (miRNAs) are predicted to regulate up to 90% of the genes in humans, suggesting that they may control every cellular processes in all cells and tissues of the human body! ">
            <entity charOffset="41-49" id="miRNA-corp.d142.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-57" id="miRNA-corp.d142.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-38" id="miRNA-corp.d142.s1.e2" text="ribonuclease III Dicer" type="Genes/Proteins"/>
            <entity charOffset="77-87" id="miRNA-corp.d142.s1.e3" text="regulate up" type="Relation_Trigger"/>
            <entity charOffset="112-117" id="miRNA-corp.d142.s1.e4" text="humans" type="Species"/>
            <entity charOffset="210-214" id="miRNA-corp.d142.s1.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d142.s1.e0" e2="miRNA-corp.d142.s1.e2" id="miRNA-corp.d142.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s1.e1" e2="miRNA-corp.d142.s1.e2" id="miRNA-corp.d142.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d142.s2" origId="20375468.s2" text="Likely to play a central role in health and disease, a dysfunctional miRNA-based regulation of gene expression may represent the main etiologic factor underlying age-related diseases affecting major organs, such as the brain. ">
            <entity charOffset="69-73" id="miRNA-corp.d142.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-109" id="miRNA-corp.d142.s2.e1" text="regulation of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d142.s3" origId="20375468.s3" text="Here, we discuss some of the limitations associated to the interpretation and applicability of miRNA data, based on our recent study on the etiology of Alzheimer's disease (AD). ">
            <entity charOffset="95-99" id="miRNA-corp.d142.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-50" id="miRNA-corp.d142.s3.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="152-170" id="miRNA-corp.d142.s3.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="173-174" id="miRNA-corp.d142.s3.e3" text="AD" type="Diseases"/>
            <pair e1="miRNA-corp.d142.s3.e0" e2="miRNA-corp.d142.s3.e2" id="miRNA-corp.d142.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s3.e0" e2="miRNA-corp.d142.s3.e3" id="miRNA-corp.d142.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d142.s4" origId="20375468.s4" text="Using transiently transfected murine neuronal N2a cells in culture, in parallel to a mouse model of AD, we were able to demonstrate a role for two miRNAs (miR-298 and miR-328) in the regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation, thereby providing key insights into the molecular basis underlying BACE deregulation in AD. ">
            <entity charOffset="237-239" id="miRNA-corp.d142.s4.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="147-152" id="miRNA-corp.d142.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="197-258" id="miRNA-corp.d142.s4.e2" text="beta-amyloid (Abeta) precursor protein (APP)-converting enzyme" type="Genes/Proteins"/>
            <entity charOffset="373-384" id="miRNA-corp.d142.s4.e3" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="155-161" id="miRNA-corp.d142.s4.e4" text="miR-298" type="Specific_miRNAs"/>
            <entity charOffset="167-173" id="miRNA-corp.d142.s4.e5" text="miR-328" type="Specific_miRNAs"/>
            <entity charOffset="100-101" id="miRNA-corp.d142.s4.e6" text="AD" type="Diseases"/>
            <entity charOffset="389-390" id="miRNA-corp.d142.s4.e7" text="AD" type="Diseases"/>
            <entity charOffset="368-371" id="miRNA-corp.d142.s4.e8" text="BACE" type="Genes/Proteins"/>
            <entity charOffset="261-264" id="miRNA-corp.d142.s4.e9" text="BACE" type="Genes/Proteins"/>
            <entity charOffset="183-298" id="miRNA-corp.d142.s4.e10" text="regulation of beta-amyloid (Abeta) precursor protein (APP)-converting enzyme (BACE) messenger RNA (mRNA) translation" type="Relation_Trigger"/>
            <entity charOffset="85-89" id="miRNA-corp.d142.s4.e11" text="mouse" type="Species"/>
            <entity charOffset="30-35" id="miRNA-corp.d142.s4.e12" text="murine" type="Species"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e0" id="miRNA-corp.d142.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e6" id="miRNA-corp.d142.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e7" id="miRNA-corp.d142.s4.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e8" id="miRNA-corp.d142.s4.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e9" id="miRNA-corp.d142.s4.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e4" e2="miRNA-corp.d142.s4.e2" id="miRNA-corp.d142.s4.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e0" id="miRNA-corp.d142.s4.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e6" id="miRNA-corp.d142.s4.p7" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e7" id="miRNA-corp.d142.s4.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e8" id="miRNA-corp.d142.s4.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e9" id="miRNA-corp.d142.s4.p10" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e5" e2="miRNA-corp.d142.s4.e2" id="miRNA-corp.d142.s4.p11" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e0" id="miRNA-corp.d142.s4.p12" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e6" id="miRNA-corp.d142.s4.p13" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e7" id="miRNA-corp.d142.s4.p14" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e8" id="miRNA-corp.d142.s4.p15" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e9" id="miRNA-corp.d142.s4.p16" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d142.s4.e1" e2="miRNA-corp.d142.s4.e2" id="miRNA-corp.d142.s4.p17" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d142.s5" origId="20375468.s5" text="However, whether miRNA data can be extrapolated and transposed to the human context of age-related diseases, such as AD, not only requires caution, but also warrants several considerations.   ">
            <entity charOffset="117-118" id="miRNA-corp.d142.s5.e0" text="AD" type="Diseases"/>
            <entity charOffset="17-21" id="miRNA-corp.d142.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-74" id="miRNA-corp.d142.s5.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d142.s5.e1" e2="miRNA-corp.d142.s5.e0" id="miRNA-corp.d142.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d143" origId="15054117">
        <sentence id="miRNA-corp.d143.s0" origId="15054117.s5" text="Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis. ">
            <entity charOffset="64-73" id="miRNA-corp.d143.s0.e0" text="caveolin-1" type="Genes/Proteins"/>
            <entity charOffset="80-89" id="miRNA-corp.d143.s0.e1" text="calmodulin" type="Genes/Proteins"/>
            <entity charOffset="57-60" id="miRNA-corp.d143.s0.e2" text="eNOS" type="Genes/Proteins"/>
            <entity charOffset="32-54" id="miRNA-corp.d143.s0.e3" text="endothelial NO synthase" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s1" origId="15054117.s6" text="Plasma NO levels were doubled by daidzein or 17beta-estradiol. "/>
        <sentence id="miRNA-corp.d143.s2" origId="15054117.s7" text="NO production and endothelium-dependent contraction in response to the NOS inhibitor NG-nitro-L-arginine (L-NNA; 100 microM) was enhanced by 50 to 100% in carotid arteries from rats treated with daidzein or 17beta-estradiol. ">
            <entity charOffset="75-83" id="miRNA-corp.d143.s2.e0" text="inhibitor" type="Relation_Trigger"/>
            <entity charOffset="177-180" id="miRNA-corp.d143.s2.e1" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s3" origId="15054117.s8" text="Acetylcholine-induced relaxation was selectively enhanced in carotid arteries from rats treated with daidzein. ">
            <entity charOffset="83-86" id="miRNA-corp.d143.s3.e0" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s4" origId="15054117.s1" text="The use of estrogen for protection against vascular dysfunction is limited due to its effects on the reproductive system, particularly in males. ">
            <entity charOffset="43-62" id="miRNA-corp.d143.s4.e0" text="vascular dysfunction" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s5" origId="15054117.s2" text="We postulated that daidzein, an isoflavone with estrogen-like effects on the systemic vasculature but not the reproductive system, might enhance nitric oxide (NO)-mediated cerebral vasodilatation. "/>
        <sentence id="miRNA-corp.d143.s6" origId="15054117.s3" text="Male rats were administered vehicle, 17beta-estradiol (0.1 mg/kg s.c.), or daidzein (0.2 mg/kg s.c.) daily for 7 days. ">
            <entity charOffset="5-8" id="miRNA-corp.d143.s6.e0" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s7" origId="15054117.s4" text="Basal and acetylcholine-stimulated NO release was assessed in vitro via carotid arterial rings or in vivo by measuring changes in basilar artery diameter. "/>
        <sentence id="miRNA-corp.d143.s8" origId="15054117.s9" text="Similarly, constrictor responses of the basilar artery to L-NNA in vivo were selectively augmented by approximately 100% by 17beta-estradiol treatment and tended to be approximately 50% greater in daidzein-treated rats. ">
            <entity charOffset="214-217" id="miRNA-corp.d143.s8.e0" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s9" origId="15054117.s0" text="Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol.  ">
            <entity charOffset="53-56" id="miRNA-corp.d143.s9.e0" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s10" origId="15054117.s12" text="These data suggest that short-term administration of daidzein or 17beta-estradiol modulates cerebral artery reactivity in males by enhancing synthesis and release of endothelium-derived NO. Isoflavone therapy may therefore be a feasible approach to protect against cerebrovascular disease and stroke.   ">
            <entity charOffset="82-90" id="miRNA-corp.d143.s10.e0" text="modulates" type="Relation_Trigger"/>
            <entity charOffset="265-287" id="miRNA-corp.d143.s10.e1" text="cerebrovascular disease" type="Diseases"/>
            <entity charOffset="293-298" id="miRNA-corp.d143.s10.e2" text="stroke" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s11" origId="15054117.s10" text="Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats. ">
            <entity charOffset="14-23" id="miRNA-corp.d143.s11.e0" text="caveolin-1" type="Genes/Proteins"/>
            <entity charOffset="44-53" id="miRNA-corp.d143.s11.e1" text="calmodulin" type="Genes/Proteins"/>
            <entity charOffset="0-37" id="miRNA-corp.d143.s11.e2" text="Expression of caveolin-1 was decreased" type="Relation_Trigger"/>
            <entity charOffset="124-127" id="miRNA-corp.d143.s11.e3" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d143.s12" origId="15054117.s11" text="eNOS expression was unaffected by the treatments. ">
            <entity charOffset="0-3" id="miRNA-corp.d143.s12.e0" text="eNOS" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d144" origId="18801740">
        <sentence id="miRNA-corp.d144.s0" origId="18801740.s1" text="Human brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions; however, specific miRNA abundance is significantly altered in neurological disorders such as Alzheimer disease (AD) when compared with age-matched controls. ">
            <entity charOffset="221-237" id="miRNA-corp.d144.s0.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="240-241" id="miRNA-corp.d144.s0.e1" text="AD" type="Diseases"/>
            <entity charOffset="44-52" id="miRNA-corp.d144.s0.e2" text="micro RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="55-59" id="miRNA-corp.d144.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="146-150" id="miRNA-corp.d144.s0.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="165-185" id="miRNA-corp.d144.s0.e5" text="significantly altered" type="Relation_Trigger"/>
            <entity charOffset="190-211" id="miRNA-corp.d144.s0.e6" text="neurological disorders" type="Diseases"/>
            <entity charOffset="0-4" id="miRNA-corp.d144.s0.e7" text="Human" type="Species"/>
            <pair e1="miRNA-corp.d144.s0.e2" e2="miRNA-corp.d144.s0.e0" id="miRNA-corp.d144.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e2" e2="miRNA-corp.d144.s0.e1" id="miRNA-corp.d144.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e2" e2="miRNA-corp.d144.s0.e6" id="miRNA-corp.d144.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e3" e2="miRNA-corp.d144.s0.e0" id="miRNA-corp.d144.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e3" e2="miRNA-corp.d144.s0.e1" id="miRNA-corp.d144.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e3" e2="miRNA-corp.d144.s0.e6" id="miRNA-corp.d144.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e4" e2="miRNA-corp.d144.s0.e0" id="miRNA-corp.d144.s0.p6" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e4" e2="miRNA-corp.d144.s0.e1" id="miRNA-corp.d144.s0.p7" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s0.e4" e2="miRNA-corp.d144.s0.e6" id="miRNA-corp.d144.s0.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s1" origId="18801740.s0" text="An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells.  ">
            <entity charOffset="71-87" id="miRNA-corp.d144.s1.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="23-36" id="miRNA-corp.d144.s1.e1" text="micro RNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="105-109" id="miRNA-corp.d144.s1.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d144.s1.e1" e2="miRNA-corp.d144.s1.e0" id="miRNA-corp.d144.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s2" origId="18801740.s3" text="Up-regulation of miRNA-146a coupled to down-regulation of CFH was observed in AD brain and in interleukin-1beta, Abeta42, and/or oxidatively stressed human neural (HN) cells in primary culture. ">
            <entity charOffset="17-26" id="miRNA-corp.d144.s2.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="58-60" id="miRNA-corp.d144.s2.e1" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="78-79" id="miRNA-corp.d144.s2.e2" text="AD" type="Diseases"/>
            <entity charOffset="94-110" id="miRNA-corp.d144.s2.e3" text="interleukin-1beta" type="Genes/Proteins"/>
            <entity charOffset="0-12" id="miRNA-corp.d144.s2.e4" text="Up-regulation" type="Relation_Trigger"/>
            <entity charOffset="39-53" id="miRNA-corp.d144.s2.e5" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="113-119" id="miRNA-corp.d144.s2.e6" text="Abeta42" type="Genes/Proteins"/>
            <entity charOffset="150-154" id="miRNA-corp.d144.s2.e7" text="human" type="Species"/>
            <pair e1="miRNA-corp.d144.s2.e0" e2="miRNA-corp.d144.s2.e3" id="miRNA-corp.d144.s2.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s2.e0" e2="miRNA-corp.d144.s2.e6" id="miRNA-corp.d144.s2.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s2.e0" e2="miRNA-corp.d144.s2.e1" id="miRNA-corp.d144.s2.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s2.e0" e2="miRNA-corp.d144.s2.e2" id="miRNA-corp.d144.s2.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s3" origId="18801740.s2" text="Here we provide evidence in AD brains of a specific up-regulation of an NF-kappaB-sensitive miRNA-146a highly complementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the inflammatory response of the brain. ">
            <entity charOffset="92-101" id="miRNA-corp.d144.s3.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="157-176" id="miRNA-corp.d144.s3.e1" text="complement factor H " type="Genes/Proteins"/>
            <entity charOffset="178-180" id="miRNA-corp.d144.s3.e2" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="28-29" id="miRNA-corp.d144.s3.e3" text="AD" type="Diseases"/>
            <entity charOffset="52-64" id="miRNA-corp.d144.s3.e4" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="103-152" id="miRNA-corp.d144.s3.e5" text="highly complementary to the 3'-untranslated region" type="Relation_Trigger"/>
            <entity charOffset="197-205" id="miRNA-corp.d144.s3.e6" text="repressor" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d144.s3.e0" e2="miRNA-corp.d144.s3.e1" id="miRNA-corp.d144.s3.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s3.e0" e2="miRNA-corp.d144.s3.e2" id="miRNA-corp.d144.s3.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s3.e0" e2="miRNA-corp.d144.s3.e3" id="miRNA-corp.d144.s3.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s4" origId="18801740.s5" text="Treatment of stressed HN cells with the NF-kappaB inhibitor pyrollidine dithiocarbamate or the resveratrol analog CAY10512 abrogated this response. ">
            <entity charOffset="50-58" id="miRNA-corp.d144.s4.e0" text="inhibitor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s5" origId="18801740.s4" text="Transfection of HN cells using an NF-kappaB-containing pre-miRNA-146a promoter-luciferase reporter construct in stressed HN cells showed significant up-regulation of luciferase activity that paralleled decreases in CFH gene expression. ">
            <entity charOffset="215-217" id="miRNA-corp.d144.s5.e0" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="59-68" id="miRNA-corp.d144.s5.e1" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="202-233" id="miRNA-corp.d144.s5.e2" text="decreases in CFH gene expression" type="Relation_Trigger"/>
            <entity charOffset="149-161" id="miRNA-corp.d144.s5.e3" text="up-regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d144.s5.e1" e2="miRNA-corp.d144.s5.e0" id="miRNA-corp.d144.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s6" origId="18801740.s6" text="Incubation of an antisense oligonucleotide to miRNA-146a (anti-miRNA-146a; AM-146a) was found to restore CFH expression levels. ">
            <entity charOffset="105-107" id="miRNA-corp.d144.s6.e0" text="CFH" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d144.s7" origId="18801740.s7" text="These data indicate that NF-kappaB-sensitive miRNA-146a-mediated modulation of CFH gene expression may in part regulate an inflammatory response in AD brain and in stressed HN cell models of AD and illustrate the potential for anti-miRNAs as an effective therapeutic strategy against pathogenic inflammatory signaling.   ">
            <entity charOffset="79-81" id="miRNA-corp.d144.s7.e0" text="CFH" type="Genes/Proteins"/>
            <entity charOffset="191-192" id="miRNA-corp.d144.s7.e1" text="AD" type="Diseases"/>
            <entity charOffset="148-149" id="miRNA-corp.d144.s7.e2" text="AD" type="Diseases"/>
            <entity charOffset="45-54" id="miRNA-corp.d144.s7.e3" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="111-118" id="miRNA-corp.d144.s7.e4" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="65-97" id="miRNA-corp.d144.s7.e5" text="modulation of CFH gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d144.s7.e3" e2="miRNA-corp.d144.s7.e0" id="miRNA-corp.d144.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d144.s7.e3" e2="miRNA-corp.d144.s7.e1" id="miRNA-corp.d144.s7.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d144.s7.e3" e2="miRNA-corp.d144.s7.e2" id="miRNA-corp.d144.s7.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d145" origId="21035445">
        <sentence id="miRNA-corp.d145.s0" origId="21035445.s9" text="Meanwhile, 3NP rats showed dynamic changes in the miRNA profiles during disease development and a few miRNAs with altered expression. ">
            <entity charOffset="50-54" id="miRNA-corp.d145.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-107" id="miRNA-corp.d145.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="114-131" id="miRNA-corp.d145.s0.e2" text="altered expression" type="Relation_Trigger"/>
            <entity charOffset="15-18" id="miRNA-corp.d145.s0.e3" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s1" origId="21035445.s7" text="In 10-week-old R6/2 mice, downregulation was dominant in the miRNA expressions and the level of Drosha decreased concomitantly. ">
            <entity charOffset="61-65" id="miRNA-corp.d145.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="96-101" id="miRNA-corp.d145.s1.e1" text="Drosha" type="Genes/Proteins"/>
            <entity charOffset="26-39" id="miRNA-corp.d145.s1.e2" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="87-111" id="miRNA-corp.d145.s1.e3" text="level of Drosha decreased" type="Relation_Trigger"/>
            <entity charOffset="20-23" id="miRNA-corp.d145.s1.e4" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d145.s1.e0" e2="miRNA-corp.d145.s1.e1" id="miRNA-corp.d145.s1.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s2" origId="21035445.s8" text="Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice. ">
            <entity charOffset="5-10" id="miRNA-corp.d145.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-18" id="miRNA-corp.d145.s2.e1" text="miR-22" type="Specific_miRNAs"/>
            <entity charOffset="21-27" id="miRNA-corp.d145.s2.e2" text="miR-29c" type="Specific_miRNAs"/>
            <entity charOffset="30-36" id="miRNA-corp.d145.s2.e3" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="39-45" id="miRNA-corp.d145.s2.e4" text="miR-132" type="Specific_miRNAs"/>
            <entity charOffset="48-54" id="miRNA-corp.d145.s2.e5" text="miR-138" type="Specific_miRNAs"/>
            <entity charOffset="57-63" id="miRNA-corp.d145.s2.e6" text="miR-218" type="Specific_miRNAs"/>
            <entity charOffset="66-72" id="miRNA-corp.d145.s2.e7" text="miR-222" type="Specific_miRNAs"/>
            <entity charOffset="75-81" id="miRNA-corp.d145.s2.e8" text="miR-344" type="Specific_miRNAs"/>
            <entity charOffset="88-94" id="miRNA-corp.d145.s2.e9" text="miR-674" type="Specific_miRNAs"/>
            <entity charOffset="112-125" id="miRNA-corp.d145.s2.e10" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="180-183" id="miRNA-corp.d145.s2.e11" text="mice" type="Species"/>
            <entity charOffset="180-183" id="miRNA-corp.d145.s2.e12" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s3" origId="21035445.s6" text="Concomitantly, the expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased at 5months, and the expression of Dicer was decreased at 12 months. ">
            <entity charOffset="48-57" id="miRNA-corp.d145.s3.e0" text="Exportin-5" type="Genes/Proteins"/>
            <entity charOffset="118-122" id="miRNA-corp.d145.s3.e1" text="Dicer" type="Genes/Proteins"/>
            <entity charOffset="19-82" id="miRNA-corp.d145.s3.e2" text="expressions of Drosha-DGCR8, Exportin-5, and Dcp1 were increased" type="Relation_Trigger"/>
            <entity charOffset="104-136" id="miRNA-corp.d145.s3.e3" text="expression of Dicer was decreased" type="Relation_Trigger"/>
            <entity charOffset="34-39" id="miRNA-corp.d145.s3.e4" text="Drosha" type="Genes/Proteins"/>
            <entity charOffset="41-45" id="miRNA-corp.d145.s3.e5" text="DGCR8" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s4" origId="21035445.s5" text="YAC128 mice showed upregulation-dominant miRNA expressions at 5 months and downregulation-dominant expressions at 12 months. ">
            <entity charOffset="41-45" id="miRNA-corp.d145.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="7-10" id="miRNA-corp.d145.s4.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s5" origId="21035445.s4" text="After characterizing the phenotypes by behavioral tests and histological analyses, we profiled striatal miRNAs using a miRNA microarray and we measured the key molecules involved in miRNA biogenesis and function. ">
            <entity charOffset="104-109" id="miRNA-corp.d145.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="119-123" id="miRNA-corp.d145.s5.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="182-186" id="miRNA-corp.d145.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s6" origId="21035445.s3" text="Here, we analyzed the miRNA expression and miRNA regulators in two transgenic models of HD, YAC128 and R6/2 mice, and in a 3-nitropropionic acid (3NP)-induced striatal degeneration rat model. ">
            <entity charOffset="22-26" id="miRNA-corp.d145.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-47" id="miRNA-corp.d145.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-89" id="miRNA-corp.d145.s6.e2" text="HD" type="Diseases"/>
            <entity charOffset="49-58" id="miRNA-corp.d145.s6.e3" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="108-111" id="miRNA-corp.d145.s6.e4" text="mice" type="Species"/>
            <entity charOffset="181-183" id="miRNA-corp.d145.s6.e5" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d145.s6.e0" e2="miRNA-corp.d145.s6.e2" id="miRNA-corp.d145.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s6.e1" e2="miRNA-corp.d145.s6.e2" id="miRNA-corp.d145.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s7" origId="21035445.s2" text="MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD. However, the profiles and regulation of miRNAs in HD are not fully understood. ">
            <entity charOffset="0-8" id="miRNA-corp.d145.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d145.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="169-174" id="miRNA-corp.d145.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="125-126" id="miRNA-corp.d145.s7.e3" text="HD" type="Diseases"/>
            <entity charOffset="179-180" id="miRNA-corp.d145.s7.e4" text="HD" type="Diseases"/>
            <entity charOffset="43-68" id="miRNA-corp.d145.s7.e5" text="regulating gene expression" type="Relation_Trigger"/>
            <entity charOffset="155-164" id="miRNA-corp.d145.s7.e6" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d145.s7.e0" e2="miRNA-corp.d145.s7.e3" id="miRNA-corp.d145.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s7.e0" e2="miRNA-corp.d145.s7.e4" id="miRNA-corp.d145.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s7.e1" e2="miRNA-corp.d145.s7.e3" id="miRNA-corp.d145.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s7.e1" e2="miRNA-corp.d145.s7.e4" id="miRNA-corp.d145.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s7.e2" e2="miRNA-corp.d145.s7.e3" id="miRNA-corp.d145.s7.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d145.s7.e2" e2="miRNA-corp.d145.s7.e4" id="miRNA-corp.d145.s7.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s8" origId="21035445.s1" text="Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion. ">
            <entity charOffset="0-19" id="miRNA-corp.d145.s8.e0" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="22-23" id="miRNA-corp.d145.s8.e1" text="HD" type="Diseases"/>
            <entity charOffset="39-63" id="miRNA-corp.d145.s8.e2" text="neurodegenerative disease" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s9" origId="21035445.s0" text="Altered microRNA regulation in Huntington's disease models.  ">
            <entity charOffset="8-15" id="miRNA-corp.d145.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-50" id="miRNA-corp.d145.s9.e1" text="Huntington's disease" type="Diseases"/>
            <entity charOffset="0-26" id="miRNA-corp.d145.s9.e2" text="Altered microRNA regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d145.s9.e0" e2="miRNA-corp.d145.s9.e1" id="miRNA-corp.d145.s9.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s10" origId="21035445.s11" text="This information should aid in future studies on therapeutic application of miRNAs in HD.   ">
            <entity charOffset="76-81" id="miRNA-corp.d145.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="86-87" id="miRNA-corp.d145.s10.e1" text="HD" type="Diseases"/>
            <pair e1="miRNA-corp.d145.s10.e0" e2="miRNA-corp.d145.s10.e1" id="miRNA-corp.d145.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d145.s11" origId="21035445.s10" text="Our results show that transgenic HD mice have abnormal miRNA biogenesis. ">
            <entity charOffset="55-59" id="miRNA-corp.d145.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-34" id="miRNA-corp.d145.s11.e1" text="HD" type="Diseases"/>
            <entity charOffset="36-39" id="miRNA-corp.d145.s11.e2" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d145.s11.e0" e2="miRNA-corp.d145.s11.e1" id="miRNA-corp.d145.s11.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d146" origId="19822222">
        <sentence id="miRNA-corp.d146.s0" origId="19822222.s1" text="The prevalence of neurodegenerative disorders is rising steadily as human life expectancy increases. ">
            <entity charOffset="18-44" id="miRNA-corp.d146.s0.e0" text="neurodegenerative disorders" type="Diseases"/>
            <entity charOffset="68-72" id="miRNA-corp.d146.s0.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s1" origId="19822222.s2" text="However, limited knowledge of the molecular basis of disease pathogenesis is a major hurdle in the identification of drug targets and development of therapeutic strategies for these largely incurable disorders. ">
            <entity charOffset="122-128" id="miRNA-corp.d146.s1.e0" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s2" origId="19822222.s0" text="MicroRNAs: novel therapeutic targets in neurodegenerative diseases.  ">
            <entity charOffset="0-8" id="miRNA-corp.d146.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-35" id="miRNA-corp.d146.s2.e1" text="therapeutic targets" type="Relation_Trigger"/>
            <entity charOffset="40-65" id="miRNA-corp.d146.s2.e2" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d146.s2.e0" e2="miRNA-corp.d146.s2.e2" id="miRNA-corp.d146.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s3" origId="19822222.s5" text="Our bioinformatic analysis suggests novel miRNA-target interactions that could potentially influence neurodegeneration. ">
            <entity charOffset="42-46" id="miRNA-corp.d146.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s4" origId="19822222.s6" text="The recent development of molecules that alter miRNA expression promises valuable tools that will enhance the therapeutic potential of miRNAs.   ">
            <entity charOffset="47-51" id="miRNA-corp.d146.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-140" id="miRNA-corp.d146.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-62" id="miRNA-corp.d146.s4.e2" text="alter miRNA expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s5" origId="19822222.s3" text="Recently, differential expression of endogenous regulatory small RNAs, known as 'microRNAs' (miRNAs), in patients of Alzheimer's disease, Parkinson's disease and models of ataxia suggest that they might have key regulatory roles in neurodegeneration. ">
            <entity charOffset="81-89" id="miRNA-corp.d146.s5.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="93-98" id="miRNA-corp.d146.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-135" id="miRNA-corp.d146.s5.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="138-156" id="miRNA-corp.d146.s5.e3" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="48-57" id="miRNA-corp.d146.s5.e4" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="212-221" id="miRNA-corp.d146.s5.e5" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="10-32" id="miRNA-corp.d146.s5.e6" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="172-177" id="miRNA-corp.d146.s5.e7" text="ataxia" type="Diseases"/>
            <entity charOffset="105-112" id="miRNA-corp.d146.s5.e8" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d146.s5.e0" e2="miRNA-corp.d146.s5.e7" id="miRNA-corp.d146.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d146.s5.e0" e2="miRNA-corp.d146.s5.e2" id="miRNA-corp.d146.s5.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d146.s5.e0" e2="miRNA-corp.d146.s5.e3" id="miRNA-corp.d146.s5.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d146.s5.e1" e2="miRNA-corp.d146.s5.e7" id="miRNA-corp.d146.s5.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d146.s5.e1" e2="miRNA-corp.d146.s5.e2" id="miRNA-corp.d146.s5.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d146.s5.e1" e2="miRNA-corp.d146.s5.e3" id="miRNA-corp.d146.s5.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d146.s6" origId="19822222.s4" text="miRNAs that can target known mediators of neurodegeneration offer potential therapeutic targets. ">
            <entity charOffset="0-5" id="miRNA-corp.d146.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="16-21" id="miRNA-corp.d146.s6.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="76-94" id="miRNA-corp.d146.s6.e2" text="therapeutic targets" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d147" origId="21356210">
        <sentence id="miRNA-corp.d147.s0" origId="21356210.s8" text="To our knowledge, this is the first report of miRNA profiles in A. cantonensis, which may represent a new platform for studying regulation of genes and their networks in A. cantonensis.   ">
            <entity charOffset="46-50" id="miRNA-corp.d147.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-137" id="miRNA-corp.d147.s0.e1" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s1" origId="21356210.s7" text="Nucleotide bias analysis showed that uracil was the prominent nucleotide, particularly at positions of 1, 10, 14, 17 and 22, approximately at the beginning, middle and the end of the conserved miRNAs. ">
            <entity charOffset="193-198" id="miRNA-corp.d147.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s2" origId="21356210.s6" text="No new miRNA sequence was found. ">
            <entity charOffset="7-11" id="miRNA-corp.d147.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s3" origId="21356210.s5" text="A total of 8861,260 and 10,957,957 high quality reads with 20 and 23 conserved miRNAs were obtained in females and males, respectively. ">
            <entity charOffset="79-84" id="miRNA-corp.d147.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s4" origId="21356210.s4" text="The objective of this study was to determine and characterize miRNAs of female and male adults of A. cantonensis by Solexa deep sequencing. ">
            <entity charOffset="62-67" id="miRNA-corp.d147.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s5" origId="21356210.s3" text="They have been identified in a diverse range of organisms. "/>
        <sentence id="miRNA-corp.d147.s6" origId="21356210.s2" text="microRNAs (miRNAs) are endogenous small non-coding RNAs that play crucial roles in gene expression regulation, cellular function and defense, homeostasis and pathogenesis. ">
            <entity charOffset="0-8" id="miRNA-corp.d147.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d147.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-108" id="miRNA-corp.d147.s6.e2" text="expression regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s7" origId="21356210.s1" text="Angiostrongylus cantonensis causes eosinophilic meningitis and eosinophilic pleocytosis in humans and is of significant socio-economic importance globally. ">
            <entity charOffset="35-57" id="miRNA-corp.d147.s7.e0" text="eosinophilic meningitis" type="Diseases"/>
            <entity charOffset="63-86" id="miRNA-corp.d147.s7.e1" text="eosinophilic pleocytosis" type="Diseases"/>
            <entity charOffset="91-96" id="miRNA-corp.d147.s7.e2" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d147.s8" origId="21356210.s0" text="Angiostrongylus cantonensis: Identification and characterization of microRNAs in male and female adults.  ">
            <entity charOffset="68-76" id="miRNA-corp.d147.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d148" origId="20214679">
        <sentence id="miRNA-corp.d148.s0" origId="20214679.s6" text="The miR-146a expression was confirmed to be present in reactive astrocytes. ">
            <entity charOffset="4-11" id="miRNA-corp.d148.s0.e0" text="miR-146a" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s1" origId="20214679.s7" text="In human TLE with hippocampal sclerosis, increased astroglial expression of miR-146a was observed mainly in regions where neuronal cell loss and reactive gliosis occurred. ">
            <entity charOffset="41-71" id="miRNA-corp.d148.s1.e0" text="increased astroglial expression" type="Relation_Trigger"/>
            <entity charOffset="9-11" id="miRNA-corp.d148.s1.e1" text="TLE" type="Diseases"/>
            <entity charOffset="76-83" id="miRNA-corp.d148.s1.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="18-38" id="miRNA-corp.d148.s1.e3" text="hippocampal sclerosis" type="Diseases"/>
            <entity charOffset="154-160" id="miRNA-corp.d148.s1.e4" text="gliosis" type="Diseases"/>
            <entity charOffset="3-7" id="miRNA-corp.d148.s1.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d148.s1.e2" e2="miRNA-corp.d148.s1.e1" id="miRNA-corp.d148.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s1.e2" e2="miRNA-corp.d148.s1.e3" id="miRNA-corp.d148.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s1.e2" e2="miRNA-corp.d148.s1.e4" id="miRNA-corp.d148.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s2" origId="20214679.s8" text="The increased and persistent expression of miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response occurring in TLE and provides a target for future studies aimed at developing strategies against pro-epileptogenic inflammatory signalling.   ">
            <entity charOffset="112-117" id="miRNA-corp.d148.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-38" id="miRNA-corp.d148.s2.e1" text="increased and persistent expression" type="Relation_Trigger"/>
            <entity charOffset="126-135" id="miRNA-corp.d148.s2.e2" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="190-192" id="miRNA-corp.d148.s2.e3" text="TLE" type="Diseases"/>
            <entity charOffset="43-50" id="miRNA-corp.d148.s2.e4" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="209-214" id="miRNA-corp.d148.s2.e5" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d148.s2.e4" e2="miRNA-corp.d148.s2.e3" id="miRNA-corp.d148.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s2.e0" e2="miRNA-corp.d148.s2.e3" id="miRNA-corp.d148.s2.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s3" origId="20214679.s1" text="Increasing evidence supports the involvement of inflammatory and immune processes in temporal lobe epilepsy (TLE). ">
            <entity charOffset="85-106" id="miRNA-corp.d148.s3.e0" text="temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="109-111" id="miRNA-corp.d148.s3.e1" text="TLE" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s4" origId="20214679.s0" text="Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy.  ">
            <entity charOffset="95-116" id="miRNA-corp.d148.s4.e0" text="temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="59-66" id="miRNA-corp.d148.s4.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-29" id="miRNA-corp.d148.s4.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="35-46" id="miRNA-corp.d148.s4.e3" text="inflammation" type="Diseases"/>
            <entity charOffset="89-93" id="miRNA-corp.d148.s4.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d148.s4.e2" e2="miRNA-corp.d148.s4.e0" id="miRNA-corp.d148.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s4.e2" e2="miRNA-corp.d148.s4.e3" id="miRNA-corp.d148.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s4.e1" e2="miRNA-corp.d148.s4.e0" id="miRNA-corp.d148.s4.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s4.e1" e2="miRNA-corp.d148.s4.e3" id="miRNA-corp.d148.s4.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s5" origId="20214679.s3" text="We investigated the expression and cellular distribution of miRNA-146a (miR-146a) in a rat model of TLE as well as in human TLE. ">
            <entity charOffset="124-126" id="miRNA-corp.d148.s5.e0" text="TLE" type="Diseases"/>
            <entity charOffset="60-69" id="miRNA-corp.d148.s5.e1" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="72-79" id="miRNA-corp.d148.s5.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="100-102" id="miRNA-corp.d148.s5.e3" text="TLE" type="Diseases"/>
            <entity charOffset="87-89" id="miRNA-corp.d148.s5.e4" text="rat" type="Species"/>
            <entity charOffset="118-122" id="miRNA-corp.d148.s5.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d148.s5.e1" e2="miRNA-corp.d148.s5.e0" id="miRNA-corp.d148.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s5.e1" e2="miRNA-corp.d148.s5.e3" id="miRNA-corp.d148.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s5.e2" e2="miRNA-corp.d148.s5.e0" id="miRNA-corp.d148.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s5.e2" e2="miRNA-corp.d148.s5.e3" id="miRNA-corp.d148.s5.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s6" origId="20214679.s2" text="MicroRNAs (miRNA) represent small regulatory RNA molecules that have been shown to act as negative regulators of gene expression controlling different biological processes, including immune-system homeostasis and function. ">
            <entity charOffset="0-8" id="miRNA-corp.d148.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-15" id="miRNA-corp.d148.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="34-43" id="miRNA-corp.d148.s6.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="90-108" id="miRNA-corp.d148.s6.e3" text="negative regulators" type="Relation_Trigger"/>
            <entity charOffset="99-127" id="miRNA-corp.d148.s6.e4" text="regulators of gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s7" origId="20214679.s5" text="Prominent upregulation of miR-146a activation was evident at 1 week after SE and persisted in the chronic phase. ">
            <entity charOffset="74-75" id="miRNA-corp.d148.s7.e0" text="SE" type="Diseases"/>
            <entity charOffset="10-21" id="miRNA-corp.d148.s7.e1" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="35-44" id="miRNA-corp.d148.s7.e2" text="activation" type="Relation_Trigger"/>
            <entity charOffset="26-33" id="miRNA-corp.d148.s7.e3" text="miR-146a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d148.s7.e3" e2="miRNA-corp.d148.s7.e0" id="miRNA-corp.d148.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d148.s8" origId="20214679.s4" text="miR-146a analysis in rat hippocampus was performed by polymerase chain reaction and immunocytochemistry at 1 week and 3-4 months after induction of status epilepticus (SE). ">
            <entity charOffset="148-165" id="miRNA-corp.d148.s8.e0" text="status epilepticus" type="Diseases"/>
            <entity charOffset="168-169" id="miRNA-corp.d148.s8.e1" text="SE" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d148.s8.e2" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="21-23" id="miRNA-corp.d148.s8.e3" text="rat" type="Species"/>
            <pair e1="miRNA-corp.d148.s8.e2" e2="miRNA-corp.d148.s8.e0" id="miRNA-corp.d148.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d148.s8.e2" e2="miRNA-corp.d148.s8.e1" id="miRNA-corp.d148.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d149" origId="18805830">
        <sentence id="miRNA-corp.d149.s0" origId="18805830.s8" text="However, none of these individuals reported here have epilepsy, although two have an abnormal EEG. ">
            <entity charOffset="54-61" id="miRNA-corp.d149.s0.e0" text="epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s1" origId="18805830.s9" text="CONCLUSIONS: The phenotype of chromosome 15q13.2q13.3 BP4-BP5 microdeletion/duplication syndrome may include features of autism spectrum disorder, a variety of neuropsychiatric disorders, and cognitive impairment. ">
            <entity charOffset="121-144" id="miRNA-corp.d149.s1.e0" text="autism spectrum disorder" type="Diseases"/>
            <entity charOffset="160-185" id="miRNA-corp.d149.s1.e1" text="neuropsychiatric disorders" type="Diseases"/>
            <entity charOffset="192-211" id="miRNA-corp.d149.s1.e2" text="cognitive impairment" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s2" origId="18805830.s10" text="Recognition of this broader phenotype has implications for clinical diagnostic testing and efforts to understand the underlying aetiology of this syndrome.   "/>
        <sentence id="miRNA-corp.d149.s3" origId="18805830.s2" text="PATIENTS: DNA samples from 1445 unrelated patients submitted consecutively for clinical array comparative genomic hybridisation (CGH) testing at Children's Hospital Boston and DNA samples from 1441 individuals with autism from 751 families in the Autism Genetic Resource Exchange (AGRE) repository. ">
            <entity charOffset="215-220" id="miRNA-corp.d149.s3.e0" text="autism" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d149.s3.e1" text="PATIENTS" type="Species"/>
            <entity charOffset="247-252" id="miRNA-corp.d149.s3.e2" text="Autism" type="Diseases"/>
            <entity charOffset="42-49" id="miRNA-corp.d149.s3.e3" text="patients" type="Species"/>
            <entity charOffset="145-154" id="miRNA-corp.d149.s3.e4" text="Children's" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s4" origId="18805830.s3" text="RESULTS: We report the clinical features of five patients with a BP4-BP5 deletion, three with a BP4-BP5 duplication, and two with an overlapping but smaller duplication identified by whole genome high resolution oligonucleotide array CGH. ">
            <entity charOffset="49-56" id="miRNA-corp.d149.s4.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s5" origId="18805830.s0" text="Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders.  ">
            <entity charOffset="77-82" id="miRNA-corp.d149.s5.e0" text="autism" type="Diseases"/>
            <entity charOffset="94-119" id="miRNA-corp.d149.s5.e1" text="neuropsychiatric disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s6" origId="18805830.s1" text="BACKGROUND: Segmental duplications at breakpoints (BP4-BP5) of chromosome 15q13.2q13.3 mediate a recurrent genomic imbalance syndrome associated with mental retardation, epilepsy, and/or electroencephalogram (EEG) abnormalities. ">
            <entity charOffset="170-177" id="miRNA-corp.d149.s6.e0" text="epilepsy" type="Diseases"/>
            <entity charOffset="134-143" id="miRNA-corp.d149.s6.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="150-167" id="miRNA-corp.d149.s6.e2" text="mental retardation" type="Diseases"/>
            <entity charOffset="187-226" id="miRNA-corp.d149.s6.e3" text="electroencephalogram (EEG) abnormalities" type="Diseases"/>
        </sentence>  
        <sentence id="miRNA-corp.d149.s7" origId="18805830.s6" text="BP4-BP5 covers approximately 1.5 Mb (chr15:28.719-30.298 Mb) and includes six reference genes and 1 miRNA gene, while the smaller duplications cover approximately 500 kb (chr15:28.902-29.404 Mb) and contain three reference genes and one miRNA gene. ">
        	<entity charOffset="100-104" id="miRNA-corp.d149.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
		<entity charOffset="237-241" id="miRNA-corp.d149.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
		<sentence id="miRNA-corp.d149.s8" origId="18805830.s5" text="Cognitive impairment varied from moderate mental retardation to normal IQ with learning disability. ">
            <entity charOffset="42-59" id="miRNA-corp.d149.s8.e0" text="mental retardation" type="Diseases"/>
            <entity charOffset="0-19" id="miRNA-corp.d149.s8.e1" text="Cognitive impairment" type="Diseases"/>
            <entity charOffset="79-97" id="miRNA-corp.d149.s8.e2" text="learning disability" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s9" origId="18805830.s4" text="These BP4-BP5 deletion cases exhibit minor dysmorphic features, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder, and mood disorder. ">
            <entity charOffset="166-189" id="miRNA-corp.d149.s9.e0" text="autism spectrum disorder" type="Diseases"/>
            <entity charOffset="192-231" id="miRNA-corp.d149.s9.e1" text="attention deficit hyperactivity disorder" type="Diseases"/>
            <entity charOffset="234-249" id="miRNA-corp.d149.s9.e2" text="anxiety disorder" type="Diseases"/>
            <entity charOffset="256-268" id="miRNA-corp.d149.s9.e3" text="mood disorder" type="Diseases"/>
            <entity charOffset="124-151" id="miRNA-corp.d149.s9.e4" text="neuropsychiatric impairments" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d149.s10" origId="18805830.s7" text="The BP4-BP5 deletion and duplication events span CHRNA7, a candidate gene for seizures. ">
            <entity charOffset="78-85" id="miRNA-corp.d149.s10.e0" text="seizures" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d150" origId="20826435">
        <sentence id="miRNA-corp.d150.s0" origId="20826435.s6" text="The KIAA0226 gene encodes a protein that we named rundataxin, with two conserved domains: an N-terminal RUN domain and a C-terminal domain containing a diacylglycerol binding-like motif. ">
            <entity charOffset="50-59" id="miRNA-corp.d150.s0.e0" text="rundataxin" type="Genes/Proteins"/>
            <entity charOffset="4-11" id="miRNA-corp.d150.s0.e1" text="KIAA0226" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s1" origId="20826435.s5" text="Mutation screening of all coding sequences revealed a single nucleotide deletion, 2927delC, in exon 19 of the KIAA0226 gene, which results in a frame shift of the C-terminal domain (p.Ala943ValfsX146). ">
            <entity charOffset="110-117" id="miRNA-corp.d150.s1.e0" text="KIAA0226" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s2" origId="20826435.s8" text="The rundataxin pathway appears therefore distinct from the ataxia pathways involving deficiency in mitochondrial or nuclear proteins and broadens the range of mechanisms leading to recessive ataxias.   ">
            <entity charOffset="59-64" id="miRNA-corp.d150.s2.e0" text="ataxia" type="Diseases"/>
            <entity charOffset="191-197" id="miRNA-corp.d150.s2.e1" text="ataxias" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s3" origId="20826435.s7" text="The closest paralogue of rundataxin, the plekstrin homology domain family member M1, has been shown to colocalize with Rab7, a small GTPase associated with late endosomes/lysosomes, suggesting that rundataxin may also be associated with vesicular trafficking and signalling pathways through its RUN and diacylglycerol binding-like domains. ">
            <entity charOffset="140-149" id="miRNA-corp.d150.s3.e0" text="associated" type="Relation_Trigger"/>
            <entity charOffset="221-230" id="miRNA-corp.d150.s3.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="25-34" id="miRNA-corp.d150.s3.e2" text="rundataxin" type="Genes/Proteins"/>
            <entity charOffset="198-207" id="miRNA-corp.d150.s3.e3" text="rundataxin" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s4" origId="20826435.s2" text="The three patients presented with childhood onset gait and limb ataxia, dysarthria and had limited walking without aid into their teenage years. ">
            <entity charOffset="64-69" id="miRNA-corp.d150.s4.e0" text="ataxia" type="Diseases"/>
            <entity charOffset="72-81" id="miRNA-corp.d150.s4.e1" text="dysarthria" type="Diseases"/>
            <entity charOffset="10-17" id="miRNA-corp.d150.s4.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s5" origId="20826435.s1" text="We have identified a novel form of recessive ataxia that segregates in three children of a large consanguineous Saudi Arabian family. ">
            <entity charOffset="45-50" id="miRNA-corp.d150.s5.e0" text="ataxia" type="Diseases"/>
            <entity charOffset="77-84" id="miRNA-corp.d150.s5.e1" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s6" origId="20826435.s4" text="Linkage studies allowed us to identify a single locus that segregated with the disease on chromosome 3q28-qter. "/>
        <sentence id="miRNA-corp.d150.s7" origId="20826435.s3" text="Two patients developed epilepsy at 7 months without relapse after treatment, and mental retardation. ">
            <entity charOffset="81-98" id="miRNA-corp.d150.s7.e0" text="mental retardation" type="Diseases"/>
            <entity charOffset="23-30" id="miRNA-corp.d150.s7.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="4-21" id="miRNA-corp.d150.s7.e2" text="patients developed" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d150.s8" origId="20826435.s0" text="Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia.  ">
            <entity charOffset="56-62" id="miRNA-corp.d150.s8.e0" text="binding" type="Relation_Trigger"/>
            <entity charOffset="0-9" id="miRNA-corp.d150.s8.e1" text="Rundataxin" type="Genes/Proteins"/>
            <entity charOffset="102-107" id="miRNA-corp.d150.s8.e2" text="ataxia" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d151" origId="19901543">
        <sentence id="miRNA-corp.d151.s0" origId="19901543.s4" text="These tumors arise in the cerebellum and may attribute their origins to deregulated proliferation of neural progenitor cells during development. ">
            <entity charOffset="6-11" id="miRNA-corp.d151.s0.e0" text="tumors" type="Diseases"/>
            <entity charOffset="72-82" id="miRNA-corp.d151.s0.e1" text="deregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s1" origId="19901543.s3" text="However, only a few studies to date have focused on the role of miRNAs in medulloblastoma, the most common malignant pediatric brain tumor. ">
            <entity charOffset="64-69" id="miRNA-corp.d151.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-88" id="miRNA-corp.d151.s1.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="127-137" id="miRNA-corp.d151.s1.e2" text="brain tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d151.s1.e0" e2="miRNA-corp.d151.s1.e1" id="miRNA-corp.d151.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d151.s1.e0" e2="miRNA-corp.d151.s1.e2" id="miRNA-corp.d151.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s2" origId="19901543.s6" text="MiRNA expression profiling of both mouse and human medulloblastomas has led to the identification of signatures correlating with the molecular subgroups of medulloblastoma, tumor diagnosis and response to treatment, as well as novel targets of potential clinical relevance. ">
            <entity charOffset="0-4" id="miRNA-corp.d151.s2.e0" text="MiRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="156-170" id="miRNA-corp.d151.s2.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="227-239" id="miRNA-corp.d151.s2.e2" text="novel targets" type="Relation_Trigger"/>
            <entity charOffset="51-66" id="miRNA-corp.d151.s2.e3" text="medulloblastomas" type="Diseases"/>
            <entity charOffset="233-252" id="miRNA-corp.d151.s2.e4" text="targets of potential" type="Relation_Trigger"/>
            <entity charOffset="112-122" id="miRNA-corp.d151.s2.e5" text="correlating" type="Relation_Trigger"/>
            <entity charOffset="173-177" id="miRNA-corp.d151.s2.e6" text="tumor" type="Diseases"/>
            <entity charOffset="35-39" id="miRNA-corp.d151.s2.e7" text="mouse" type="Species"/>
            <entity charOffset="45-49" id="miRNA-corp.d151.s2.e8" text="human" type="Species"/>
            <pair e1="miRNA-corp.d151.s2.e0" e2="miRNA-corp.d151.s2.e1" id="miRNA-corp.d151.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d151.s2.e0" e2="miRNA-corp.d151.s2.e3" id="miRNA-corp.d151.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d151.s2.e0" e2="miRNA-corp.d151.s2.e6" id="miRNA-corp.d151.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s3" origId="19901543.s5" text="Understanding the interplay between normal brain development and medulloblastoma pathogenesis is necessary in order for more efficient, less toxic targeted therapies to be developed and implemented. ">
            <entity charOffset="65-79" id="miRNA-corp.d151.s3.e0" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="147-154" id="miRNA-corp.d151.s3.e1" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s4" origId="19901543.s0" text="Normal and oncogenic roles for microRNAs in the developing brain.  ">
            <entity charOffset="31-39" id="miRNA-corp.d151.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s5" origId="19901543.s2" text="Emerging evidence indicates that miRNAs are key players in mammalian development that, when altered, contribute to tumorigenesis. ">
            <entity charOffset="33-38" id="miRNA-corp.d151.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s6" origId="19901543.s1" text="MicroRNAS (miRNAs) are small endogenous non-coding RNAs that play important roles in many different biological processes including proliferation, differentiation and apoptosis through silencing of target genes. ">
            <entity charOffset="0-8" id="miRNA-corp.d151.s6.e0" text="MicroRNAS" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d151.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="197-202" id="miRNA-corp.d151.s6.e2" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d151.s7" origId="19901543.s7" text="This review summarizes the recent miRNA literature in both medulloblastoma and normal brain development.   ">
            <entity charOffset="34-38" id="miRNA-corp.d151.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-73" id="miRNA-corp.d151.s7.e1" text="medulloblastoma" type="Diseases"/>
            <pair e1="miRNA-corp.d151.s7.e0" e2="miRNA-corp.d151.s7.e1" id="miRNA-corp.d151.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d152" origId="18987751">
        <sentence id="miRNA-corp.d152.s0" origId="18987751.s0" text="A miRNA signature of prion induced neurodegeneration.  ">
            <entity charOffset="2-6" id="miRNA-corp.d152.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="21-25" id="miRNA-corp.d152.s0.e1" text="prion" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d152.s0.e0" e2="miRNA-corp.d152.s0.e1" id="miRNA-corp.d152.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s1" origId="18987751.s2" text="Compelling evidence links miRNAs to the control of neuronal development and differentiation, however, little is known about their role in neurodegeneration. ">
            <entity charOffset="26-31" id="miRNA-corp.d152.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s2" origId="18987751.s1" text="MicroRNAs (miRNAs) are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular processes. ">
            <entity charOffset="0-8" id="miRNA-corp.d152.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d152.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-90" id="miRNA-corp.d152.s2.e2" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s3" origId="18987751.s4" text="We determined 15 miRNAs were de-regulated during the disease processes; miR-342-3p, miR-320, let-7b, miR-328, miR-128, miR-139-5p and miR-146a were over 2.5 fold up-regulated and miR-338-3p and miR-337-3p over 2.5 fold down-regulated. ">
            <entity charOffset="72-81" id="miRNA-corp.d152.s3.e0" text="miR-342-3p" type="Specific_miRNAs"/>
            <entity charOffset="84-90" id="miRNA-corp.d152.s3.e1" text="miR-320" type="Specific_miRNAs"/>
            <entity charOffset="93-98" id="miRNA-corp.d152.s3.e2" text="let-7b" type="Specific_miRNAs"/>
            <entity charOffset="101-107" id="miRNA-corp.d152.s3.e3" text="miR-328" type="Specific_miRNAs"/>
            <entity charOffset="110-116" id="miRNA-corp.d152.s3.e4" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="119-128" id="miRNA-corp.d152.s3.e5" text="miR-139-5p" type="Specific_miRNAs"/>
            <entity charOffset="134-141" id="miRNA-corp.d152.s3.e6" text="miR-146a" type="Specific_miRNAs"/>
            <entity charOffset="179-188" id="miRNA-corp.d152.s3.e7" text="miR-338-3p" type="Specific_miRNAs"/>
            <entity charOffset="194-203" id="miRNA-corp.d152.s3.e8" text="miR-337-3p" type="Specific_miRNAs"/>
            <entity charOffset="29-40" id="miRNA-corp.d152.s3.e9" text="de-regulated" type="Relation_Trigger"/>
            <entity charOffset="162-173" id="miRNA-corp.d152.s3.e10" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="219-232" id="miRNA-corp.d152.s3.e11" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="17-22" id="miRNA-corp.d152.s3.e12" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s4" origId="18987751.s3" text="We used microarrays and RT-PCR to profile miRNA expression changes in the brains of mice infected with mouse-adapted scrapie. ">
            <entity charOffset="117-123" id="miRNA-corp.d152.s4.e0" text="scrapie" type="Diseases"/>
            <entity charOffset="42-46" id="miRNA-corp.d152.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="48-65" id="miRNA-corp.d152.s4.e2" text="expression changes" type="Relation_Trigger"/>
            <entity charOffset="103-107" id="miRNA-corp.d152.s4.e3" text="mouse" type="Species"/>
            <entity charOffset="84-87" id="miRNA-corp.d152.s4.e4" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d152.s4.e1" e2="miRNA-corp.d152.s4.e0" id="miRNA-corp.d152.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s5" origId="18987751.s6" text="De-regulation of a unique subset of miRNAs suggests a conserved, disease-specific pattern of differentially expressed miRNAs is associated with prion-induced neurodegeneration. ">
            <entity charOffset="0-12" id="miRNA-corp.d152.s5.e0" text="De-regulation" type="Relation_Trigger"/>
            <entity charOffset="93-116" id="miRNA-corp.d152.s5.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="36-41" id="miRNA-corp.d152.s5.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="118-123" id="miRNA-corp.d152.s5.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="144-148" id="miRNA-corp.d152.s5.e4" text="prion" type="Genes/Proteins"/>
            <entity charOffset="128-137" id="miRNA-corp.d152.s5.e5" text="associated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d152.s5.e2" e2="miRNA-corp.d152.s5.e4" id="miRNA-corp.d152.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d152.s5.e3" e2="miRNA-corp.d152.s5.e4" id="miRNA-corp.d152.s5.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s6" origId="18987751.s5" text="Only one of these miRNAs, miR-128, has previously been shown to be de-regulated in neurodegenerative disease. ">
            <entity charOffset="26-32" id="miRNA-corp.d152.s6.e0" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="67-78" id="miRNA-corp.d152.s6.e1" text="de-regulated" type="Relation_Trigger"/>
            <entity charOffset="18-23" id="miRNA-corp.d152.s6.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="83-107" id="miRNA-corp.d152.s6.e3" text="neurodegenerative disease" type="Diseases"/>
            <pair e1="miRNA-corp.d152.s6.e2" e2="miRNA-corp.d152.s6.e3" id="miRNA-corp.d152.s6.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d152.s6.e0" e2="miRNA-corp.d152.s6.e3" id="miRNA-corp.d152.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s7" origId="18987751.s7" text="Computational analysis predicted numerous potential gene targets of these miRNAs, including 119 genes previously determined to be also de-regulated in mouse scrapie. ">
            <entity charOffset="74-79" id="miRNA-corp.d152.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="57-63" id="miRNA-corp.d152.s7.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="157-163" id="miRNA-corp.d152.s7.e2" text="scrapie" type="Diseases"/>
            <entity charOffset="135-146" id="miRNA-corp.d152.s7.e3" text="de-regulated" type="Relation_Trigger"/>
            <entity charOffset="151-155" id="miRNA-corp.d152.s7.e4" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d152.s7.e0" e2="miRNA-corp.d152.s7.e2" id="miRNA-corp.d152.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s8" origId="18987751.s8" text="We used a co-ordinated approach to integrate miRNA and mRNA profiling, bioinformatic predictions and biochemical validation to determine miRNA regulated processes and genes potentially involved in disease progression. ">
            <entity charOffset="45-49" id="miRNA-corp.d152.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="137-141" id="miRNA-corp.d152.s8.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="143-151" id="miRNA-corp.d152.s8.e2" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d152.s9" origId="18987751.s9" text="In particular, a correlation between miRNA expression and putative gene targets involved in intracellular protein-degradation pathways and signaling pathways related to cell death, synapse function and neurogenesis was identified.   ">
            <entity charOffset="37-41" id="miRNA-corp.d152.s9.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-52" id="miRNA-corp.d152.s9.e1" text="correlation between miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="72-78" id="miRNA-corp.d152.s9.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d153" origId="20660113">
        <sentence id="miRNA-corp.d153.s0" origId="20660113.s1" text="Type III RNase Dicer is responsible for the maturation and function of microRNA (miRNA) molecules in the cell. ">
            <entity charOffset="0-19" id="miRNA-corp.d153.s0.e0" text="Type III RNase Dicer" type="Genes/Proteins"/>
            <entity charOffset="71-78" id="miRNA-corp.d153.s0.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="81-85" id="miRNA-corp.d153.s0.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d153.s0.e2" e2="miRNA-corp.d153.s0.e0" id="miRNA-corp.d153.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d153.s0.e1" e2="miRNA-corp.d153.s0.e0" id="miRNA-corp.d153.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s1" origId="20660113.s0" text="Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration.  ">
            <entity charOffset="20-24" id="miRNA-corp.d153.s1.e0" text="Dicer" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s2" origId="20660113.s5" text="Although neuronal loss is observed in the hippocampus, cellular shrinkage is predominant in the cortex. "/>
        <sentence id="miRNA-corp.d153.s3" origId="20660113.s4" text="Here we show that the absence of Dicer in the adult forebrain is accompanied by a mixed neurodegenerative phenotype. ">
            <entity charOffset="33-37" id="miRNA-corp.d153.s3.e0" text="Dicer" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s4" origId="20660113.s3" text="However, the underlying mechanisms involved in neuronal death, particularly in the adult brain, remain poorly defined. "/>
        <sentence id="miRNA-corp.d153.s5" origId="20660113.s2" text="It is now well-documented that Dicer and the fine-tuning of the miRNA gene network are important for neuronal integrity. ">
            <entity charOffset="64-68" id="miRNA-corp.d153.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-35" id="miRNA-corp.d153.s5.e1" text="Dicer" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d153.s5.e0" e2="miRNA-corp.d153.s5.e1" id="miRNA-corp.d153.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s6" origId="20660113.s8" text="We further demonstrate that miRNAs belonging to the miR-15 family are potent regulators of ERK1 expression in mouse neuronal cells and co-expressed with ERK1/2 in vivo. ">
            <entity charOffset="153-158" id="miRNA-corp.d153.s6.e0" text="ERK1/2" type="Genes/Proteins"/>
            <entity charOffset="91-94" id="miRNA-corp.d153.s6.e1" text="ERK1" type="Genes/Proteins"/>
            <entity charOffset="52-57" id="miRNA-corp.d153.s6.e2" text="miR-15" type="Specific_miRNAs"/>
            <entity charOffset="28-33" id="miRNA-corp.d153.s6.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-86" id="miRNA-corp.d153.s6.e4" text="potent regulators" type="Relation_Trigger"/>
            <entity charOffset="135-146" id="miRNA-corp.d153.s6.e5" text="co-expressed" type="Relation_Trigger"/>
            <entity charOffset="77-105" id="miRNA-corp.d153.s6.e6" text="regulators of ERK1 expression" type="Relation_Trigger"/>
            <entity charOffset="110-114" id="miRNA-corp.d153.s6.e7" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d153.s6.e3" e2="miRNA-corp.d153.s6.e0" id="miRNA-corp.d153.s6.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d153.s6.e3" e2="miRNA-corp.d153.s6.e1" id="miRNA-corp.d153.s6.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d153.s6.e2" e2="miRNA-corp.d153.s6.e0" id="miRNA-corp.d153.s6.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d153.s6.e2" e2="miRNA-corp.d153.s6.e1" id="miRNA-corp.d153.s6.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s7" origId="20660113.s9" text="Finally, we show that miR-15a is specifically downregulated in Alzheimer's disease brain. ">
            <entity charOffset="22-28" id="miRNA-corp.d153.s7.e0" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="63-81" id="miRNA-corp.d153.s7.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="46-58" id="miRNA-corp.d153.s7.e2" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d153.s7.e0" e2="miRNA-corp.d153.s7.e1" id="miRNA-corp.d153.s7.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s8" origId="20660113.s6" text="Interestingly, neuronal degeneration coincides with the hyperphosphorylation of endogenous tau at several epitopes previously associated with neurofibrillary pathology. ">
            <entity charOffset="126-135" id="miRNA-corp.d153.s8.e0" text="associated" type="Relation_Trigger"/>
            <entity charOffset="15-35" id="miRNA-corp.d153.s8.e1" text="neuronal degeneration" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s9" origId="20660113.s7" text="Transcriptome analysis of enzymes involved in tau phosphorylation identified ERK1 as one of the candidate kinases responsible for this event in vivo. ">
            <entity charOffset="77-80" id="miRNA-corp.d153.s9.e0" text="ERK1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d153.s10" origId="20660113.s10" text="In summary, these results support the hypothesis that changes in the miRNA network may contribute to a neurodegenerative phenotype by affecting tau phosphorylation.   ">
            <entity charOffset="69-73" id="miRNA-corp.d153.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d154" origId="21170291">
        <sentence id="miRNA-corp.d154.s0" origId="21170291.s4" text="MiR-21 can be induced in neurons by prolonged N-methyl-D-aspartic acid receptor stimulation, an excitotoxic process active in HIV and other neurodegenerative diseases. ">
            <entity charOffset="0-5" id="miRNA-corp.d154.s0.e0" text="MiR-21" type="Specific_miRNAs"/>
            <entity charOffset="140-165" id="miRNA-corp.d154.s0.e1" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d154.s0.e0" e2="miRNA-corp.d154.s0.e1" id="miRNA-corp.d154.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s1" origId="21170291.s5" text="Introduction of miR-21 into human neurons leads to pathological functional defects. ">
            <entity charOffset="16-21" id="miRNA-corp.d154.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="28-32" id="miRNA-corp.d154.s1.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s2" origId="21170291.s6" text="Furthermore, we show that miR-21 specifically targets the mRNA of myocyte enhancer factor 2C (MEF2C), a transcription factor crucial for neuronal function, and reduces its expression. ">
            <entity charOffset="33-52" id="miRNA-corp.d154.s2.e0" text="specifically targets" type="Relation_Trigger"/>
            <entity charOffset="160-181" id="miRNA-corp.d154.s2.e1" text="reduces its expression" type="Relation_Trigger"/>
            <entity charOffset="66-91" id="miRNA-corp.d154.s2.e2" text="myocyte enhancer factor 2C" type="Genes/Proteins"/>
            <entity charOffset="94-98" id="miRNA-corp.d154.s2.e3" text="MEF2C" type="Genes/Proteins"/>
            <entity charOffset="26-31" id="miRNA-corp.d154.s2.e4" text="miR-21" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d154.s2.e4" e2="miRNA-corp.d154.s2.e2" id="miRNA-corp.d154.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d154.s2.e4" e2="miRNA-corp.d154.s2.e3" id="miRNA-corp.d154.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s3" origId="21170291.s7" text="MEF2C is dramatically downregulated in neurons of HIV-associated dementia patients as well as monkeys with SIVE. ">
            <entity charOffset="65-72" id="miRNA-corp.d154.s3.e0" text="dementia" type="Diseases"/>
            <entity charOffset="22-34" id="miRNA-corp.d154.s3.e1" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="0-4" id="miRNA-corp.d154.s3.e2" text="MEF2C" type="Genes/Proteins"/>
            <entity charOffset="74-81" id="miRNA-corp.d154.s3.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s4" origId="21170291.s8" text="Together, this study elucidates a novel role for miR-21 in the brain, not only as a potential signature of neurological disease but also as a crucial effector of HIV induced neuronal dysfunction and neurodegeneration.   ">
            <entity charOffset="49-54" id="miRNA-corp.d154.s4.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="107-126" id="miRNA-corp.d154.s4.e1" text="neurological disease" type="Diseases"/>
            <entity charOffset="162-193" id="miRNA-corp.d154.s4.e2" text="HIV induced neuronal dysfunction" type="Diseases"/>
            <pair e1="miRNA-corp.d154.s4.e0" e2="miRNA-corp.d154.s4.e1" id="miRNA-corp.d154.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d154.s4.e0" e2="miRNA-corp.d154.s4.e2" id="miRNA-corp.d154.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s5" origId="21170291.s1" text="MicroRNAs (miRNAs) play important roles in regulating a plethora of physiological and pathophysiogical processes including neurodegeneration. ">
            <entity charOffset="0-8" id="miRNA-corp.d154.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d154.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="43-52" id="miRNA-corp.d154.s5.e2" text="regulating" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s6" origId="21170291.s0" text="MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.  ">
            <entity charOffset="12-38" id="miRNA-corp.d154.s6.e0" text="dysregulates the expression" type="Relation_Trigger"/>
            <entity charOffset="0-10" id="miRNA-corp.d154.s6.e1" text="MicroRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="43-47" id="miRNA-corp.d154.s6.e2" text="MEF2C" type="Genes/Proteins"/>
            <entity charOffset="80-107" id="miRNA-corp.d154.s6.e3" text="SIV/HIV neurological disease" type="Diseases"/>
            <entity charOffset="74-78" id="miRNA-corp.d154.s6.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d154.s6.e1" e2="miRNA-corp.d154.s6.e2" id="miRNA-corp.d154.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d154.s6.e1" e2="miRNA-corp.d154.s6.e3" id="miRNA-corp.d154.s6.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s7" origId="21170291.s3" text="In situ hybridization of the diseased brain sections revealed induction of miR-21 in neurons. ">
            <entity charOffset="75-80" id="miRNA-corp.d154.s7.e0" text="miR-21" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d154.s8" origId="21170291.s2" text="In both HIV associated dementia in humans and its monkey model SIV encephalitis we find miR-21, a miRNA largely known for its link to oncogenesis, to be significantly upregulated in the brain. ">
            <entity charOffset="98-102" id="miRNA-corp.d154.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-30" id="miRNA-corp.d154.s8.e1" text="dementia" type="Diseases"/>
            <entity charOffset="67-78" id="miRNA-corp.d154.s8.e2" text="encephalitis" type="Diseases"/>
            <entity charOffset="88-93" id="miRNA-corp.d154.s8.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="167-177" id="miRNA-corp.d154.s8.e4" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="12-21" id="miRNA-corp.d154.s8.e5" text="associated" type="Relation_Trigger"/>
            <entity charOffset="35-40" id="miRNA-corp.d154.s8.e6" text="humans" type="Species"/>
            <pair e1="miRNA-corp.d154.s8.e3" e2="miRNA-corp.d154.s8.e1" id="miRNA-corp.d154.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d154.s8.e3" e2="miRNA-corp.d154.s8.e2" id="miRNA-corp.d154.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d154.s8.e0" e2="miRNA-corp.d154.s8.e1" id="miRNA-corp.d154.s8.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d154.s8.e0" e2="miRNA-corp.d154.s8.e2" id="miRNA-corp.d154.s8.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d155" origId="17726534">
        <sentence id="miRNA-corp.d155.s0" origId="17726534.s11" text="However, by examining pairs in which the significance of the correlation coefficients is modestly relaxed, negative correlations do tend to predict targets and positive correlations tend to predict physically proximate pairs. ">
            <entity charOffset="148-154" id="miRNA-corp.d155.s0.e0" text="targets" type="Relation_Trigger"/>
            <entity charOffset="61-71" id="miRNA-corp.d155.s0.e1" text="correlation" type="Relation_Trigger"/>
            <entity charOffset="107-127" id="miRNA-corp.d155.s0.e2" text="negative correlations" type="Relation_Trigger"/>
            <entity charOffset="160-180" id="miRNA-corp.d155.s0.e3" text="positive correlations" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s1" origId="17726534.s12" text="A subset of high correlation pairs were experimentally validated by over-expressing or suppressing a miRNA and measuring the correlated mRNAs. ">
            <entity charOffset="101-105" id="miRNA-corp.d155.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="12-27" id="miRNA-corp.d155.s1.e1" text="high correlation" type="Relation_Trigger"/>
            <entity charOffset="68-82" id="miRNA-corp.d155.s1.e2" text="over-expressing" type="Relation_Trigger"/>
            <entity charOffset="87-97" id="miRNA-corp.d155.s1.e3" text="suppressing" type="Relation_Trigger"/>
            <entity charOffset="125-134" id="miRNA-corp.d155.s1.e4" text="correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s2" origId="17726534.s10" text="Most of these highest correlation pairs do not contain sufficiently complementary sequences to predict a target relationship; nor do they lie in physical proximity to each other. ">
            <entity charOffset="14-32" id="miRNA-corp.d155.s2.e0" text="highest correlation" type="Relation_Trigger"/>
            <entity charOffset="105-110" id="miRNA-corp.d155.s2.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s3" origId="17726534.s15" text="From these data sets, we inferred and validated a tumor suppression pathway linked to miR-181c.   ">
            <entity charOffset="86-93" id="miRNA-corp.d155.s3.e0" text="miR-181c" type="Specific_miRNAs"/>
            <entity charOffset="56-66" id="miRNA-corp.d155.s3.e1" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="50-54" id="miRNA-corp.d155.s3.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d155.s3.e0" e2="miRNA-corp.d155.s3.e2" id="miRNA-corp.d155.s3.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s4" origId="17726534.s13" text="CONCLUSIONS/SIGNIFICANCE: Sufficient information exists within a set of tumor samples to detect endogenous correlations between miRNA and mRNA levels. ">
            <entity charOffset="128-132" id="miRNA-corp.d155.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-118" id="miRNA-corp.d155.s4.e1" text="correlations" type="Relation_Trigger"/>
            <entity charOffset="72-76" id="miRNA-corp.d155.s4.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d155.s4.e0" e2="miRNA-corp.d155.s4.e2" id="miRNA-corp.d155.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s5" origId="17726534.s14" text="Based on the validations the causal arrow for these correlations is likely to be directed from the miRNAs to the mRNAs. ">
            <entity charOffset="99-104" id="miRNA-corp.d155.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-63" id="miRNA-corp.d155.s5.e1" text="correlations" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s6" origId="17726534.s6" text="METHODOLOGY/PRINCIPAL FINDINGS: RNA was extracted from 12 human primary brain tumor biopsies. ">
            <entity charOffset="64-82" id="miRNA-corp.d155.s6.e0" text="primary brain tumor" type="Diseases"/>
            <entity charOffset="58-62" id="miRNA-corp.d155.s6.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s7" origId="17726534.s7" text="These samples were used to determine genome-wide mRNA expression levels by microarray analysis and a miRNA profile by real-time reverse transcription PCR. ">
            <entity charOffset="101-105" id="miRNA-corp.d155.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s8" origId="17726534.s8" text="Correlation coefficients were determined for all possible mRNA-miRNA pairs and the distribution of these correlations compared to the random distribution. ">
            <entity charOffset="0-10" id="miRNA-corp.d155.s8.e0" text="Correlation" type="Relation_Trigger"/>
            <entity charOffset="105-116" id="miRNA-corp.d155.s8.e1" text="correlations" type="Relation_Trigger"/>
            <entity charOffset="63-67" id="miRNA-corp.d155.s8.e2" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s9" origId="17726534.s9" text="An excess of high positive and negative correlation pairs were observed at the tails of these distributions. ">
            <entity charOffset="31-50" id="miRNA-corp.d155.s9.e0" text="negative correlation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s10" origId="17726534.s1" text="BACKGROUND: microRNAs (miRNAs) are approximately 21 nucleotide non-coding transcripts capable of regulating gene expression. ">
            <entity charOffset="12-20" id="miRNA-corp.d155.s10.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d155.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-122" id="miRNA-corp.d155.s10.e2" text="regulating gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s11" origId="17726534.s0" text="Detection of a microRNA signal in an in vivo expression set of mRNAs.  ">
            <entity charOffset="15-22" id="miRNA-corp.d155.s11.e0" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s12" origId="17726534.s3" text="As a result, translation of the target mRNA is inhibited and the mRNA may be destabilized. ">
            <entity charOffset="32-37" id="miRNA-corp.d155.s12.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="47-55" id="miRNA-corp.d155.s12.e1" text="inhibited" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s13" origId="17726534.s2" text="The most widely studied mechanism of regulation involves binding of a miRNA to the target mRNA. ">
            <entity charOffset="70-74" id="miRNA-corp.d155.s13.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="83-88" id="miRNA-corp.d155.s13.e1" text="target" type="Relation_Trigger"/>
            <entity charOffset="37-46" id="miRNA-corp.d155.s13.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="57-63" id="miRNA-corp.d155.s13.e3" text="binding" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s14" origId="17726534.s5" text="We asked whether endogenous fluctuations in a set of mRNA and miRNA profiles contain correlated changes that are statistically distinguishable from the many other fluctuations in the data set. ">
            <entity charOffset="62-66" id="miRNA-corp.d155.s14.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="85-94" id="miRNA-corp.d155.s14.e1" text="correlated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d155.s15" origId="17726534.s4" text="The inhibitory effects of miRNAs have been linked to diverse cellular processes including malignant proliferation, apoptosis, development, differentiation, and metabolic processes. ">
            <entity charOffset="26-31" id="miRNA-corp.d155.s15.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-21" id="miRNA-corp.d155.s15.e1" text="inhibitory effects" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d156" origId="20156358">
        <sentence id="miRNA-corp.d156.s0" origId="20156358.s0" text="A novel microRNA and transcription factor mediated regulatory network in schizophrenia.  ">
            <entity charOffset="8-15" id="miRNA-corp.d156.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="73-85" id="miRNA-corp.d156.s0.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="51-60" id="miRNA-corp.d156.s0.e2" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s0.e0" e2="miRNA-corp.d156.s0.e1" id="miRNA-corp.d156.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s1" origId="20156358.s2" text="Previous studies have suggested that changes in gene expression may play an important role in the etiology of schizophrenia, and that microRNAs (miRNAs) and transcription factors (TFs) are primary regulators of this gene expression. ">
            <entity charOffset="134-142" id="miRNA-corp.d156.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="145-150" id="miRNA-corp.d156.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-122" id="miRNA-corp.d156.s1.e2" text="schizophrenia" type="Diseases"/>
            <entity charOffset="197-230" id="miRNA-corp.d156.s1.e3" text="regulators of this gene expression" type="Relation_Trigger"/>
            <entity charOffset="37-62" id="miRNA-corp.d156.s1.e4" text="changes in gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s1.e0" e2="miRNA-corp.d156.s1.e2" id="miRNA-corp.d156.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d156.s1.e1" e2="miRNA-corp.d156.s1.e2" id="miRNA-corp.d156.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s2" origId="20156358.s1" text="BACKGROUND: Schizophrenia is a complex brain disorder with molecular mechanisms that have yet to be elucidated. ">
            <entity charOffset="12-24" id="miRNA-corp.d156.s2.e0" text="Schizophrenia" type="Diseases"/>
            <entity charOffset="39-52" id="miRNA-corp.d156.s2.e1" text="brain disorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s3" origId="20156358.s4" text="We hypothesized that miRNAs and TFs might play combinatory regulatory roles for schizophrenia genes and, thus, explored miRNA-TF regulatory networks in schizophrenia. ">
            <entity charOffset="21-26" id="miRNA-corp.d156.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-92" id="miRNA-corp.d156.s3.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="152-164" id="miRNA-corp.d156.s3.e2" text="schizophrenia" type="Diseases"/>
            <entity charOffset="129-138" id="miRNA-corp.d156.s3.e3" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="59-68" id="miRNA-corp.d156.s3.e4" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="120-124" id="miRNA-corp.d156.s3.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d156.s3.e0" e2="miRNA-corp.d156.s3.e1" id="miRNA-corp.d156.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d156.s3.e0" e2="miRNA-corp.d156.s3.e2" id="miRNA-corp.d156.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d156.s3.e5" e2="miRNA-corp.d156.s3.e1" id="miRNA-corp.d156.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d156.s3.e5" e2="miRNA-corp.d156.s3.e2" id="miRNA-corp.d156.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s4" origId="20156358.s3" text="So far, several miRNA-TF mediated regulatory modules have been verified. ">
            <entity charOffset="34-43" id="miRNA-corp.d156.s4.e0" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="16-20" id="miRNA-corp.d156.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s5" origId="20156358.s6" text="Our evaluation revealed that these observed FFLs were significantly enriched in schizophrenia genes. ">
            <entity charOffset="80-92" id="miRNA-corp.d156.s5.e0" text="schizophrenia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s6" origId="20156358.s5" text="RESULTS: We identified 32 feed-forward loops (FFLs) among our compiled schizophrenia-related miRNAs, TFs and genes. ">
            <entity charOffset="93-98" id="miRNA-corp.d156.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-83" id="miRNA-corp.d156.s6.e1" text="schizophrenia" type="Diseases"/>
            <pair e1="miRNA-corp.d156.s6.e0" e2="miRNA-corp.d156.s6.e1" id="miRNA-corp.d156.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s7" origId="20156358.s7" text="By converging the FFLs and mutual feedback loops, we constructed a novel miRNA-TF regulatory network for schizophrenia. ">
            <entity charOffset="73-77" id="miRNA-corp.d156.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="105-117" id="miRNA-corp.d156.s7.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="82-91" id="miRNA-corp.d156.s7.e2" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s7.e0" e2="miRNA-corp.d156.s7.e1" id="miRNA-corp.d156.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s8" origId="20156358.s8" text="Our analysis revealed EGR3 and hsa-miR-195 were core regulators in this regulatory network. ">
            <entity charOffset="31-41" id="miRNA-corp.d156.s8.e0" text="hsa-miR-195" type="Specific_miRNAs"/>
            <entity charOffset="22-25" id="miRNA-corp.d156.s8.e1" text="EGR3" type="Genes/Proteins"/>
            <entity charOffset="48-62" id="miRNA-corp.d156.s8.e2" text="core regulators" type="Relation_Trigger"/>
            <entity charOffset="72-81" id="miRNA-corp.d156.s8.e3" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s8.e0" e2="miRNA-corp.d156.s8.e1" id="miRNA-corp.d156.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s9" origId="20156358.s9" text="We next proposed a model highlighting EGR3 and miRNAs involved in signaling pathways and regulatory networks in the nervous system. ">
            <entity charOffset="47-52" id="miRNA-corp.d156.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-41" id="miRNA-corp.d156.s9.e1" text="EGR3" type="Genes/Proteins"/>
            <entity charOffset="89-98" id="miRNA-corp.d156.s9.e2" text="regulatory" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s9.e0" e2="miRNA-corp.d156.s9.e1" id="miRNA-corp.d156.s9.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s10" origId="20156358.s12" text="It represents the first investigation of a miRNA-TF regulatory network for a complex disease, as demonstrated in schizophrenia.   ">
            <entity charOffset="113-125" id="miRNA-corp.d156.s10.e0" text="schizophrenia" type="Diseases"/>
            <entity charOffset="52-61" id="miRNA-corp.d156.s10.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="43-47" id="miRNA-corp.d156.s10.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d156.s10.e2" e2="miRNA-corp.d156.s10.e0" id="miRNA-corp.d156.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s11" origId="20156358.s11" text="CONCLUSIONS: This study provides many insights on the regulatory mechanisms of genes involved in schizophrenia. ">
            <entity charOffset="97-109" id="miRNA-corp.d156.s11.e0" text="schizophrenia" type="Diseases"/>
            <entity charOffset="54-63" id="miRNA-corp.d156.s11.e1" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d156.s12" origId="20156358.s10" text="Finally, we suggested several single nucleotide polymorphisms (SNPs) located on miRNAs, their target sites, and TFBSs, which may have an effect in schizophrenia gene regulation. ">
            <entity charOffset="80-85" id="miRNA-corp.d156.s12.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="147-159" id="miRNA-corp.d156.s12.e1" text="schizophrenia" type="Diseases"/>
            <entity charOffset="166-175" id="miRNA-corp.d156.s12.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="94-99" id="miRNA-corp.d156.s12.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d156.s12.e0" e2="miRNA-corp.d156.s12.e1" id="miRNA-corp.d156.s12.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d157" origId="19308264">
        <sentence id="miRNA-corp.d157.s0" origId="19308264.s6" text="METHODOLOGY/PRINCIPAL FINDINGS: In a screening of MB cell lines, the miRNA miR-199b-5p was seen to be a regulator of the Notch pathway through its targeting of the transcription factor HES1. Down-regulation of HES1 expression by miR-199b-5p negatively regulates the proliferation rate and anchorage-independent growth of MB cells. ">
            <entity charOffset="185-188" id="miRNA-corp.d157.s0.e0" text="HES1" type="Genes/Proteins"/>
            <entity charOffset="75-85" id="miRNA-corp.d157.s0.e1" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="210-213" id="miRNA-corp.d157.s0.e2" text="HES1" type="Genes/Proteins"/>
            <entity charOffset="229-239" id="miRNA-corp.d157.s0.e3" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="321-322" id="miRNA-corp.d157.s0.e4" text="MB" type="Diseases"/>
            <entity charOffset="147-155" id="miRNA-corp.d157.s0.e5" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="241-260" id="miRNA-corp.d157.s0.e6" text="negatively regulates" type="Relation_Trigger"/>
            <entity charOffset="69-73" id="miRNA-corp.d157.s0.e7" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-112" id="miRNA-corp.d157.s0.e8" text="regulator" type="Relation_Trigger"/>
            <entity charOffset="191-224" id="miRNA-corp.d157.s0.e9" text="Down-regulation of HES1 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d157.s0.e3" e2="miRNA-corp.d157.s0.e4" id="miRNA-corp.d157.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s0.e3" e2="miRNA-corp.d157.s0.e0" id="miRNA-corp.d157.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s0.e3" e2="miRNA-corp.d157.s0.e2" id="miRNA-corp.d157.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s0.e7" e2="miRNA-corp.d157.s0.e4" id="miRNA-corp.d157.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s0.e7" e2="miRNA-corp.d157.s0.e0" id="miRNA-corp.d157.s0.p4" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s0.e7" e2="miRNA-corp.d157.s0.e2" id="miRNA-corp.d157.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s0.e1" e2="miRNA-corp.d157.s0.e4" id="miRNA-corp.d157.s0.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s0.e1" e2="miRNA-corp.d157.s0.e0" id="miRNA-corp.d157.s0.p7" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s0.e1" e2="miRNA-corp.d157.s0.e2" id="miRNA-corp.d157.s0.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s1" origId="19308264.s7" text="MiR-199b-5p over-expression blocks expression of several cancer stem-cell genes, impairs the engrafting potential of MB cells in the cerebellum of athymic/nude mice, and of particular interest, decreases the MB stem-cell-like (CD133+) subpopulation of cells. ">
            <entity charOffset="0-10" id="miRNA-corp.d157.s1.e0" text="MiR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="28-44" id="miRNA-corp.d157.s1.e1" text="blocks expression" type="Relation_Trigger"/>
            <entity charOffset="117-118" id="miRNA-corp.d157.s1.e2" text="MB" type="Diseases"/>
            <entity charOffset="12-26" id="miRNA-corp.d157.s1.e3" text="over-expression" type="Relation_Trigger"/>
            <entity charOffset="81-87" id="miRNA-corp.d157.s1.e4" text="impairs" type="Relation_Trigger"/>
            <entity charOffset="208-209" id="miRNA-corp.d157.s1.e5" text="MB" type="Diseases"/>
            <entity charOffset="57-62" id="miRNA-corp.d157.s1.e6" text="cancer" type="Diseases"/>
            <entity charOffset="155-163" id="miRNA-corp.d157.s1.e7" text="nude mice" type="Species"/>
            <pair e1="miRNA-corp.d157.s1.e0" e2="miRNA-corp.d157.s1.e2" id="miRNA-corp.d157.s1.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s1.e0" e2="miRNA-corp.d157.s1.e5" id="miRNA-corp.d157.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s1.e0" e2="miRNA-corp.d157.s1.e6" id="miRNA-corp.d157.s1.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s2" origId="19308264.s8" text="In our analysis of 61 patients with MB, the expression of miR-199b-5p in the non-metastatic cases was significantly higher than in the metastatic cases (P = 0.001). ">
            <entity charOffset="36-37" id="miRNA-corp.d157.s2.e0" text="MB" type="Diseases"/>
            <entity charOffset="58-68" id="miRNA-corp.d157.s2.e1" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="44-121" id="miRNA-corp.d157.s2.e2" text="expression of miR-199b-5p in the non-metastatic cases was significantly higher" type="Relation_Trigger"/>
            <entity charOffset="22-29" id="miRNA-corp.d157.s2.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d157.s2.e1" e2="miRNA-corp.d157.s2.e0" id="miRNA-corp.d157.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s3" origId="19308264.s9" text="Correlation with survival for these patients with high levels of miR-199b expression showed a positive trend to better overall survival than for the low-expressing patients. ">
            <entity charOffset="65-72" id="miRNA-corp.d157.s3.e0" text="miR-199b" type="Specific_miRNAs"/>
            <entity charOffset="0-10" id="miRNA-corp.d157.s3.e1" text="Correlation" type="Relation_Trigger"/>
            <entity charOffset="50-83" id="miRNA-corp.d157.s3.e2" text="high levels of miR-199b expression" type="Relation_Trigger"/>
            <entity charOffset="36-43" id="miRNA-corp.d157.s3.e3" text="patients" type="Species"/>
            <entity charOffset="164-171" id="miRNA-corp.d157.s3.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s4" origId="19308264.s2" text="Here we have investigated medulloblastoma tumors (MBs), which arise from an early impairment of developmental processes in the cerebellum, where Notch signaling is involved in many cell-fate-determining stages. ">
            <entity charOffset="26-47" id="miRNA-corp.d157.s4.e0" text="medulloblastoma tumors" type="Diseases"/>
            <entity charOffset="50-52" id="miRNA-corp.d157.s4.e1" text="MBs" type="Diseases"/>
            <entity charOffset="82-91" id="miRNA-corp.d157.s4.e2" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="42-47" id="miRNA-corp.d157.s4.e3" text="tumors" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s5" origId="19308264.s3" text="MBs occur bimodally, with the peak incidence seen between 3-4 years and 8-9 years of age, although it can also occur in adults. ">
            <entity charOffset="0-2" id="miRNA-corp.d157.s5.e0" text="MBs" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s6" origId="19308264.s4" text="Notch regulates a subset of the MB cells that have stem-cell-like properties and can promote tumor growth. ">
            <entity charOffset="32-33" id="miRNA-corp.d157.s6.e0" text="MB" type="Diseases"/>
            <entity charOffset="6-14" id="miRNA-corp.d157.s6.e1" text="regulates" type="Relation_Trigger"/>
            <entity charOffset="93-97" id="miRNA-corp.d157.s6.e2" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s7" origId="19308264.s5" text="On the basis of this evidence, we hypothesized that miRNAs targeting the Notch pathway can regulated these phenomena, and can be used in anti-cancer therapies. ">
            <entity charOffset="52-57" id="miRNA-corp.d157.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-67" id="miRNA-corp.d157.s7.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="91-99" id="miRNA-corp.d157.s7.e2" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s8" origId="19308264.s1" text="BACKGROUND: Through negative regulation of gene expression, microRNAs (miRNAs) can function in cancers as oncosuppressors, and they can show altered expression in various tumor types. ">
            <entity charOffset="60-68" id="miRNA-corp.d157.s8.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-76" id="miRNA-corp.d157.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="29-57" id="miRNA-corp.d157.s8.e2" text="regulation of gene expression" type="Relation_Trigger"/>
            <entity charOffset="20-38" id="miRNA-corp.d157.s8.e3" text="negative regulation" type="Relation_Trigger"/>
            <entity charOffset="106-120" id="miRNA-corp.d157.s8.e4" text="oncosuppressors" type="Relation_Trigger"/>
            <entity charOffset="141-158" id="miRNA-corp.d157.s8.e5" text="altered expression" type="Relation_Trigger"/>
            <entity charOffset="95-101" id="miRNA-corp.d157.s8.e6" text="cancers" type="Diseases"/>
            <entity charOffset="171-175" id="miRNA-corp.d157.s8.e7" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d157.s8.e0" e2="miRNA-corp.d157.s8.e6" id="miRNA-corp.d157.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s8.e0" e2="miRNA-corp.d157.s8.e7" id="miRNA-corp.d157.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s8.e1" e2="miRNA-corp.d157.s8.e6" id="miRNA-corp.d157.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s8.e1" e2="miRNA-corp.d157.s8.e7" id="miRNA-corp.d157.s8.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s9" origId="19308264.s0" text="MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.  ">
            <entity charOffset="0-15" id="miRNA-corp.d157.s9.e0" text="MicroRNA-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="74-77" id="miRNA-corp.d157.s9.e1" text="HES1" type="Genes/Proteins"/>
            <entity charOffset="82-96" id="miRNA-corp.d157.s9.e2" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="17-23" id="miRNA-corp.d157.s9.e3" text="impairs" type="Relation_Trigger"/>
            <entity charOffset="51-69" id="miRNA-corp.d157.s9.e4" text="negative regulation" type="Relation_Trigger"/>
            <entity charOffset="25-30" id="miRNA-corp.d157.s9.e5" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d157.s9.e0" e2="miRNA-corp.d157.s9.e1" id="miRNA-corp.d157.s9.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d157.s9.e0" e2="miRNA-corp.d157.s9.e2" id="miRNA-corp.d157.s9.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s9.e0" e2="miRNA-corp.d157.s9.e5" id="miRNA-corp.d157.s9.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s10" origId="19308264.s17" text="To date, this is the first report that expression of a miRNA can deplete the tumor stem cells, indicating an interesting therapeutic approach for the targeting of these cells in brain tumors.   ">
            <entity charOffset="55-59" id="miRNA-corp.d157.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="178-189" id="miRNA-corp.d157.s10.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="77-81" id="miRNA-corp.d157.s10.e2" text="tumor" type="Diseases"/>
            <entity charOffset="150-158" id="miRNA-corp.d157.s10.e3" text="targeting" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d157.s10.e0" e2="miRNA-corp.d157.s10.e1" id="miRNA-corp.d157.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s10.e0" e2="miRNA-corp.d157.s10.e2" id="miRNA-corp.d157.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s11" origId="19308264.s14" text="CONCLUSIONS/SIGNIFICANCE: Despite advances in our understanding of the pathogenesis of MB, one-third of these patients remain incurable and current treatments can significantly damage long-term survivors. ">
            <entity charOffset="87-88" id="miRNA-corp.d157.s11.e0" text="MB" type="Diseases"/>
            <entity charOffset="110-117" id="miRNA-corp.d157.s11.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s12" origId="19308264.s13" text="Infection with MB cells in an induced xenograft model in the mouse cerebellum and the use of an adenovirus carrying miR-199b-5p indicate a clinical benefit through this negative influence of miR-199b-5p on tumor growth and on the subset of MB stem-cell-like cells, providing further proof of concept. ">
            <entity charOffset="116-126" id="miRNA-corp.d157.s12.e0" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="191-201" id="miRNA-corp.d157.s12.e1" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="240-241" id="miRNA-corp.d157.s12.e2" text="MB" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d157.s12.e3" text="Infection" type="Diseases"/>
            <entity charOffset="15-16" id="miRNA-corp.d157.s12.e4" text="MB" type="Diseases"/>
            <entity charOffset="206-210" id="miRNA-corp.d157.s12.e5" text="tumor" type="Diseases"/>
            <entity charOffset="61-65" id="miRNA-corp.d157.s12.e6" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d157.s12.e0" e2="miRNA-corp.d157.s12.e2" id="miRNA-corp.d157.s12.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e0" e2="miRNA-corp.d157.s12.e3" id="miRNA-corp.d157.s12.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e0" e2="miRNA-corp.d157.s12.e4" id="miRNA-corp.d157.s12.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e0" e2="miRNA-corp.d157.s12.e5" id="miRNA-corp.d157.s12.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e1" e2="miRNA-corp.d157.s12.e2" id="miRNA-corp.d157.s12.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e1" e2="miRNA-corp.d157.s12.e3" id="miRNA-corp.d157.s12.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e1" e2="miRNA-corp.d157.s12.e4" id="miRNA-corp.d157.s12.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s12.e1" e2="miRNA-corp.d157.s12.e5" id="miRNA-corp.d157.s12.p7" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s13" origId="19308264.s16" text="We further show that in a xenograft model, MB tumor burden can be reduced, indicating the use of miR199b-5p as an adjuvant therapy after surgery, in combination with radiation and chemotherapy, for the improvement of anti-cancer MB therapies and patient quality of life. ">
            <entity charOffset="97-106" id="miRNA-corp.d157.s13.e0" text="miR199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="229-230" id="miRNA-corp.d157.s13.e1" text="MB" type="Diseases"/>
            <entity charOffset="43-50" id="miRNA-corp.d157.s13.e2" text="MB tumor" type="Diseases"/>
            <entity charOffset="46-50" id="miRNA-corp.d157.s13.e3" text="tumor" type="Diseases"/>
            <entity charOffset="246-252" id="miRNA-corp.d157.s13.e4" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d157.s13.e0" e2="miRNA-corp.d157.s13.e1" id="miRNA-corp.d157.s13.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s13.e0" e2="miRNA-corp.d157.s13.e2" id="miRNA-corp.d157.s13.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d157.s13.e0" e2="miRNA-corp.d157.s13.e3" id="miRNA-corp.d157.s13.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s14" origId="19308264.s15" text="Here we show that miR-199b-5p expression correlates with metastasis spread, identifying a new molecular marker for a poor-risk class in patients with MB. ">
            <entity charOffset="18-28" id="miRNA-corp.d157.s14.e0" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="150-151" id="miRNA-corp.d157.s14.e1" text="MB" type="Diseases"/>
            <entity charOffset="30-50" id="miRNA-corp.d157.s14.e2" text="expression correlates" type="Relation_Trigger"/>
            <entity charOffset="136-143" id="miRNA-corp.d157.s14.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d157.s14.e0" e2="miRNA-corp.d157.s14.e1" id="miRNA-corp.d157.s14.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s15" origId="19308264.s10" text="These data showing the down-regulation of miR-199b-5p in metastatic MBs suggest a potential silencing mechanism through epigenetic or genetic alterations. ">
            <entity charOffset="42-52" id="miRNA-corp.d157.s15.e0" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="68-70" id="miRNA-corp.d157.s15.e1" text="MBs" type="Diseases"/>
            <entity charOffset="23-37" id="miRNA-corp.d157.s15.e2" text="down-regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d157.s15.e0" e2="miRNA-corp.d157.s15.e1" id="miRNA-corp.d157.s15.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s16" origId="19308264.s12" text="Furthermore, two cell lines (Med8a and UW228) showed significant up-regulation of miR-199b-5p upon treatment. ">
            <entity charOffset="82-92" id="miRNA-corp.d157.s16.e0" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="65-77" id="miRNA-corp.d157.s16.e1" text="up-regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d157.s17" origId="19308264.s11" text="Upon induction of de-methylation using 5-aza-deoxycytidine, lower miR-199b-5p expression was seen in a panel of MB cell lines, supported an epigenetic mechanism of regulation. ">
            <entity charOffset="66-76" id="miRNA-corp.d157.s17.e0" text="miR-199b-5p" type="Specific_miRNAs"/>
            <entity charOffset="60-87" id="miRNA-corp.d157.s17.e1" text="lower miR-199b-5p expression" type="Relation_Trigger"/>
            <entity charOffset="164-173" id="miRNA-corp.d157.s17.e2" text="regulation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d158" origId="19393719">
        <sentence id="miRNA-corp.d158.s0" origId="19393719.s4" text="Many tools have been developed to help describe the repertoire of miRNAs present at the tissue level in a given sample. ">
            <entity charOffset="66-71" id="miRNA-corp.d158.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s1" origId="19393719.s3" text="To understand how miRNAs contribute to normal biologic functions and disease states, it is critical to understand the miRNAs that are expressed in particular cell types under a range of conditions. ">
            <entity charOffset="18-23" id="miRNA-corp.d158.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="118-123" id="miRNA-corp.d158.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s2" origId="19393719.s6" text="Such knowledge is especially important in the nervous system with its many cell types, microscopic heterogeneity with regard to functionally distinct cell groups, and extreme geometrical complexity in cellular shapes. "/>
        <sentence id="miRNA-corp.d158.s3" origId="19393719.s5" text="However, tissue level miRNA profiling is inadequate to pinpoint the cellular and sub-cellular distribution of individual miRNAs. ">
            <entity charOffset="22-26" id="miRNA-corp.d158.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-126" id="miRNA-corp.d158.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s4" origId="19393719.s0" text="In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain.  ">
            <entity charOffset="64-71" id="miRNA-corp.d158.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-78" id="miRNA-corp.d158.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-113" id="miRNA-corp.d158.s4.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s5" origId="19393719.s2" text="However, much remains to be learned in this fast-paced field. "/>
        <sentence id="miRNA-corp.d158.s6" origId="19393719.s1" text="MicroRNAs (miRNAs) play fundamental roles in human brain neurochemistry. ">
            <entity charOffset="0-8" id="miRNA-corp.d158.s6.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d158.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-49" id="miRNA-corp.d158.s6.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s7" origId="19393719.s8" text="Thus, in situ hybridization is an important experimental complement to tissue level miRNA expression profiling. ">
            <entity charOffset="84-88" id="miRNA-corp.d158.s7.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s8" origId="19393719.s7" text="We have found that in situ hybridization shows important cerebral cortical lamina-specific patterns of miRNA expression that would be lost on most tissue level expression studies, and these lamina-specific patterns can be directly relevant to human brain disease. ">
            <entity charOffset="103-107" id="miRNA-corp.d158.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="109-137" id="miRNA-corp.d158.s8.e1" text="expression that would be lost" type="Relation_Trigger"/>
            <entity charOffset="134-169" id="miRNA-corp.d158.s8.e2" text="lost on most tissue level expression" type="Relation_Trigger"/>
            <entity charOffset="243-261" id="miRNA-corp.d158.s8.e3" text="human brain disease" type="Diseases"/>
            <entity charOffset="243-247" id="miRNA-corp.d158.s8.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d158.s8.e0" e2="miRNA-corp.d158.s8.e3" id="miRNA-corp.d158.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d158.s9" origId="19393719.s9" text="Technical and theoretical aspects of this important technique are described, especially those pertinent to studying the human brain.   ">
            <entity charOffset="120-124" id="miRNA-corp.d158.s9.e0" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d159" origId="20536606">
        <sentence id="miRNA-corp.d159.s0" origId="20536606.s2" text="However, we report the experience of a patient who inadvertently received live polio vaccine whilst receiving anti-TNF therapy. ">
            <entity charOffset="79-83" id="miRNA-corp.d159.s0.e0" text="polio" type="Diseases"/>
            <entity charOffset="39-45" id="miRNA-corp.d159.s0.e1" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s1" origId="20536606.s1" text="International guidelines state that live vaccines are contraindicated in patients on anti-TNF therapy. ">
            <entity charOffset="73-80" id="miRNA-corp.d159.s1.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s2" origId="20536606.s0" text="Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis.  ">
            <entity charOffset="5-9" id="miRNA-corp.d159.s2.e0" text="polio" type="Diseases"/>
            <entity charOffset="74-82" id="miRNA-corp.d159.s2.e1" text="arthritis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s3" origId="20536606.s6" text="Patients should be counseled regarding the risks of live vaccines prior to treatment with anti-TNF therapy.   ">
            <entity charOffset="0-7" id="miRNA-corp.d159.s3.e0" text="Patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s4" origId="20536606.s5" text="However, if we consider adult patients with rheumatic diseases to have altered immunocompetence, it is recommended that they receive the usual inactivated vaccines according to standard schedules, and live vaccines should be avoided in those who are treated with more potent forms of immune suppression. ">
            <entity charOffset="291-301" id="miRNA-corp.d159.s4.e0" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="44-61" id="miRNA-corp.d159.s4.e1" text="rheumatic diseases" type="Diseases"/>
            <entity charOffset="30-37" id="miRNA-corp.d159.s4.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s5" origId="20536606.s4" text="No clear guidelines are available for all vaccines in patients with specific rheumatic diseases. ">
            <entity charOffset="77-94" id="miRNA-corp.d159.s5.e0" text="rheumatic diseases" type="Diseases"/>
            <entity charOffset="54-61" id="miRNA-corp.d159.s5.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d159.s6" origId="20536606.s3" text="Patient did not suffer from any infectious sequel as a result. ">
            <entity charOffset="0-6" id="miRNA-corp.d159.s6.e0" text="Patient" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d160" origId="20711171">
        <sentence id="miRNA-corp.d160.s0" origId="20711171.s8" text="Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.   ">
            <entity charOffset="69-79" id="miRNA-corp.d160.s0.e0" text="astrocytoma" type="Diseases"/>
            <entity charOffset="96-107" id="miRNA-corp.d160.s0.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="167-177" id="miRNA-corp.d160.s0.e2" text="astrocytoma" type="Diseases"/>
            <entity charOffset="28-32" id="miRNA-corp.d160.s0.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="125-129" id="miRNA-corp.d160.s0.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d160.s0.e3" e2="miRNA-corp.d160.s0.e0" id="miRNA-corp.d160.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s0.e3" e2="miRNA-corp.d160.s0.e1" id="miRNA-corp.d160.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s0.e3" e2="miRNA-corp.d160.s0.e2" id="miRNA-corp.d160.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s0.e4" e2="miRNA-corp.d160.s0.e0" id="miRNA-corp.d160.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s0.e4" e2="miRNA-corp.d160.s0.e1" id="miRNA-corp.d160.s0.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s0.e4" e2="miRNA-corp.d160.s0.e2" id="miRNA-corp.d160.s0.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s1" origId="20711171.s7" text="Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity. ">
            <entity charOffset="51-56" id="miRNA-corp.d160.s1.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="62-68" id="miRNA-corp.d160.s1.e1" text="miR-23a" type="Specific_miRNAs"/>
            <entity charOffset="154-163" id="miRNA-corp.d160.s1.e2" text="miR-219-5p" type="Specific_miRNAs"/>
            <entity charOffset="142-148" id="miRNA-corp.d160.s1.e3" text="miR-218" type="Specific_miRNAs"/>
            <entity charOffset="43-48" id="miRNA-corp.d160.s1.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="134-139" id="miRNA-corp.d160.s1.e5" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="18-29" id="miRNA-corp.d160.s1.e6" text="glioblastoma" type="Diseases"/>
            <entity charOffset="107-118" id="miRNA-corp.d160.s1.e7" text="glioblastoma" type="Diseases"/>
            <entity charOffset="85-98" id="miRNA-corp.d160.s1.e8" text="overexpression" type="Relation_Trigger"/>
            <entity charOffset="0-9" id="miRNA-corp.d160.s1.e9" text="Inhibition" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d160.s1.e0" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e0" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e1" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e1" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e2" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e2" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e3" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e3" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p7" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e4" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p8" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e4" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e5" e2="miRNA-corp.d160.s1.e6" id="miRNA-corp.d160.s1.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s1.e5" e2="miRNA-corp.d160.s1.e7" id="miRNA-corp.d160.s1.p11" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s2" origId="20711171.s2" text="Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities. ">
            <entity charOffset="12-23" id="miRNA-corp.d160.s2.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="52-62" id="miRNA-corp.d160.s2.e1" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s3" origId="20711171.s1" text="Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV). ">
            <entity charOffset="31-52" id="miRNA-corp.d160.s3.e0" text="anaplastic astrocytoma" type="Diseases"/>
            <entity charOffset="70-81" id="miRNA-corp.d160.s3.e1" text="glioblastoma" type="Diseases"/>
            <entity charOffset="10-20" id="miRNA-corp.d160.s3.e2" text="astrocytoma" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s4" origId="20711171.s0" text="Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.  ">
            <entity charOffset="76-86" id="miRNA-corp.d160.s4.e0" text="astrocytoma" type="Diseases"/>
            <entity charOffset="56-61" id="miRNA-corp.d160.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-54" id="miRNA-corp.d160.s4.e2" text="deregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d160.s4.e1" e2="miRNA-corp.d160.s4.e0" id="miRNA-corp.d160.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s5" origId="20711171.s6" text="The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7). ">
            <entity charOffset="44-49" id="miRNA-corp.d160.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-139" id="miRNA-corp.d160.s5.e1" text="astrocytomas" type="Diseases"/>
            <entity charOffset="4-26" id="miRNA-corp.d160.s5.e2" text="differential expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d160.s5.e0" e2="miRNA-corp.d160.s5.e1" id="miRNA-corp.d160.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s6" origId="20711171.s5" text="More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%. ">
            <entity charOffset="129-140" id="miRNA-corp.d160.s6.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="158-168" id="miRNA-corp.d160.s6.e1" text="astrocytoma" type="Diseases"/>
            <entity charOffset="57-61" id="miRNA-corp.d160.s6.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d160.s6.e2" e2="miRNA-corp.d160.s6.e0" id="miRNA-corp.d160.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s6.e2" e2="miRNA-corp.d160.s6.e1" id="miRNA-corp.d160.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s7" origId="20711171.s4" text="We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA. ">
            <entity charOffset="47-52" id="miRNA-corp.d160.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-45" id="miRNA-corp.d160.s7.e1" text="differentially regulated" type="Relation_Trigger"/>
            <entity charOffset="102-107" id="miRNA-corp.d160.s7.e2" text="glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d160.s7.e0" e2="miRNA-corp.d160.s7.e2" id="miRNA-corp.d160.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d160.s8" origId="20711171.s3" text="We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma. ">
            <entity charOffset="92-103" id="miRNA-corp.d160.s8.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="109-130" id="miRNA-corp.d160.s8.e1" text="anaplastic astrocytoma" type="Diseases"/>
            <entity charOffset="210-220" id="miRNA-corp.d160.s8.e2" text="astrocytoma" type="Diseases"/>
            <entity charOffset="40-47" id="miRNA-corp.d160.s8.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-54" id="miRNA-corp.d160.s8.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="191-195" id="miRNA-corp.d160.s8.e5" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="179-189" id="miRNA-corp.d160.s8.e6" text="deregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d160.s8.e3" e2="miRNA-corp.d160.s8.e0" id="miRNA-corp.d160.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e3" e2="miRNA-corp.d160.s8.e1" id="miRNA-corp.d160.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e3" e2="miRNA-corp.d160.s8.e2" id="miRNA-corp.d160.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e4" e2="miRNA-corp.d160.s8.e0" id="miRNA-corp.d160.s8.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e4" e2="miRNA-corp.d160.s8.e1" id="miRNA-corp.d160.s8.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e4" e2="miRNA-corp.d160.s8.e2" id="miRNA-corp.d160.s8.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e5" e2="miRNA-corp.d160.s8.e0" id="miRNA-corp.d160.s8.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e5" e2="miRNA-corp.d160.s8.e1" id="miRNA-corp.d160.s8.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d160.s8.e5" e2="miRNA-corp.d160.s8.e2" id="miRNA-corp.d160.s8.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d161" origId="19196975">
        <sentence id="miRNA-corp.d161.s0" origId="19196975.s10" text="Our findings suggest a functional collaboration between the miR-17 approximately 92 cluster and the SHH signaling pathway in the development of MBs in mouse and man.   ">
            <entity charOffset="60-65" id="miRNA-corp.d161.s0.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="144-146" id="miRNA-corp.d161.s0.e1" text="MBs" type="Diseases"/>
            <entity charOffset="151-155" id="miRNA-corp.d161.s0.e2" text="mouse" type="Species"/>
            <entity charOffset="161-163" id="miRNA-corp.d161.s0.e3" text="man" type="Species"/>
            <entity charOffset="100-102" id="miRNA-corp.d161.s0.e4" text="SHH" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s0.e0" e2="miRNA-corp.d161.s0.e1" id="miRNA-corp.d161.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s0.e0" e2="miRNA-corp.d161.s0.e4" id="miRNA-corp.d161.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s1" origId="19196975.s6" text="Analysis of human MBs demonstrated that 3 miR-17 approximately 92 cluster miRNAs (miR-92, miR-19a, and miR-20) were also overexpressed in human MBs with a constitutively activated Sonic Hedgehog (SHH) signaling pathway, but not in other forms of the disease. ">
            <entity charOffset="42-47" id="miRNA-corp.d161.s1.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="82-87" id="miRNA-corp.d161.s1.e1" text="miR-92" type="Specific_miRNAs"/>
            <entity charOffset="90-96" id="miRNA-corp.d161.s1.e2" text="miR-19a" type="Specific_miRNAs"/>
            <entity charOffset="103-108" id="miRNA-corp.d161.s1.e3" text="miR-20" type="Specific_miRNAs"/>
            <entity charOffset="144-146" id="miRNA-corp.d161.s1.e4" text="MBs" type="Diseases"/>
            <entity charOffset="121-133" id="miRNA-corp.d161.s1.e5" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="170-178" id="miRNA-corp.d161.s1.e6" text="activated" type="Relation_Trigger"/>
            <entity charOffset="12-20" id="miRNA-corp.d161.s1.e7" text="human MBs" type="Diseases"/>
            <entity charOffset="74-79" id="miRNA-corp.d161.s1.e8" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="180-193" id="miRNA-corp.d161.s1.e9" text="Sonic Hedgehog" type="Genes/Proteins"/>
            <entity charOffset="196-198" id="miRNA-corp.d161.s1.e10" text="SHH" type="Genes/Proteins"/>
            <entity charOffset="12-16" id="miRNA-corp.d161.s1.e11" text="human" type="Species"/>
            <entity charOffset="138-142" id="miRNA-corp.d161.s1.e12" text="human" type="Species"/>
            <pair e1="miRNA-corp.d161.s1.e0" e2="miRNA-corp.d161.s1.e4" id="miRNA-corp.d161.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e0" e2="miRNA-corp.d161.s1.e7" id="miRNA-corp.d161.s1.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e0" e2="miRNA-corp.d161.s1.e9" id="miRNA-corp.d161.s1.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e0" e2="miRNA-corp.d161.s1.e10" id="miRNA-corp.d161.s1.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e1" e2="miRNA-corp.d161.s1.e4" id="miRNA-corp.d161.s1.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e1" e2="miRNA-corp.d161.s1.e7" id="miRNA-corp.d161.s1.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e1" e2="miRNA-corp.d161.s1.e9" id="miRNA-corp.d161.s1.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e1" e2="miRNA-corp.d161.s1.e10" id="miRNA-corp.d161.s1.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e2" e2="miRNA-corp.d161.s1.e4" id="miRNA-corp.d161.s1.p8" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e2" e2="miRNA-corp.d161.s1.e7" id="miRNA-corp.d161.s1.p9" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e2" e2="miRNA-corp.d161.s1.e9" id="miRNA-corp.d161.s1.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e2" e2="miRNA-corp.d161.s1.e10" id="miRNA-corp.d161.s1.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e8" e2="miRNA-corp.d161.s1.e4" id="miRNA-corp.d161.s1.p12" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e8" e2="miRNA-corp.d161.s1.e7" id="miRNA-corp.d161.s1.p13" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e8" e2="miRNA-corp.d161.s1.e9" id="miRNA-corp.d161.s1.p14" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e8" e2="miRNA-corp.d161.s1.e10" id="miRNA-corp.d161.s1.p15" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e3" e2="miRNA-corp.d161.s1.e4" id="miRNA-corp.d161.s1.p16" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e3" e2="miRNA-corp.d161.s1.e7" id="miRNA-corp.d161.s1.p17" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s1.e3" e2="miRNA-corp.d161.s1.e9" id="miRNA-corp.d161.s1.p18" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s1.e3" e2="miRNA-corp.d161.s1.e10" id="miRNA-corp.d161.s1.p19" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s2" origId="19196975.s7" text="To test whether the miR-17 approximately 92 cluster could promote MB formation, we enforced expression of these miRNAs in GNPs isolated from cerebella of postnatal (P) day P6 Ink4c-/-; Ptch1+/- mice. ">
            <entity charOffset="20-25" id="miRNA-corp.d161.s2.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="66-67" id="miRNA-corp.d161.s2.e1" text="MB" type="Diseases"/>
            <entity charOffset="112-117" id="miRNA-corp.d161.s2.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="194-197" id="miRNA-corp.d161.s2.e3" text="mice" type="Species"/>
            <entity charOffset="175-179" id="miRNA-corp.d161.s2.e4" text="Ink4c" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s2.e2" e2="miRNA-corp.d161.s2.e1" id="miRNA-corp.d161.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s2.e2" e2="miRNA-corp.d161.s2.e4" id="miRNA-corp.d161.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s2.e0" e2="miRNA-corp.d161.s2.e1" id="miRNA-corp.d161.s2.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s2.e0" e2="miRNA-corp.d161.s2.e4" id="miRNA-corp.d161.s2.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s3" origId="19196975.s8" text="These, but not similarly engineered cells from Ink4c-/-; p53-/- mice, formed MBs in orthotopic transplants with complete penetrance. ">
            <entity charOffset="77-79" id="miRNA-corp.d161.s3.e0" text="MBs" type="Diseases"/>
            <entity charOffset="57-59" id="miRNA-corp.d161.s3.e1" text="p53" type="Genes/Proteins"/>
            <entity charOffset="47-51" id="miRNA-corp.d161.s3.e2" text="Ink4c" type="Genes/Proteins"/>
            <entity charOffset="64-67" id="miRNA-corp.d161.s3.e3" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s4" origId="19196975.s9" text="Interestingly, orthotopic mouse tumors ectopically expressing miR-17 approximately 92 lost expression of the wild-type Ptch1 allele. ">
            <entity charOffset="62-67" id="miRNA-corp.d161.s4.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="119-123" id="miRNA-corp.d161.s4.e1" text="Ptch1" type="Genes/Proteins"/>
            <entity charOffset="39-60" id="miRNA-corp.d161.s4.e2" text="ectopically expressing" type="Relation_Trigger"/>
            <entity charOffset="86-100" id="miRNA-corp.d161.s4.e3" text="lost expression" type="Relation_Trigger"/>
            <entity charOffset="26-30" id="miRNA-corp.d161.s4.e4" text="mouse" type="Species"/>
            <entity charOffset="32-37" id="miRNA-corp.d161.s4.e5" text="tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d161.s4.e0" e2="miRNA-corp.d161.s4.e1" id="miRNA-corp.d161.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s4.e0" e2="miRNA-corp.d161.s4.e5" id="miRNA-corp.d161.s4.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s5" origId="19196975.s2" text="Some are thought to originate from cerebellar granule neuron progenitors (GNPs) that fail to undergo normal cell cycle exit and differentiation. "/>
        <sentence id="miRNA-corp.d161.s6" origId="19196975.s3" text="Because microRNAs regulate numerous aspects of cellular physiology and development, we reasoned that alterations in miRNA expression might contribute to MB. We tested this hypothesis using 2 spontaneous mouse MB models with specific initiating mutations, Ink4c-/-; Ptch1+/- and Ink4c-/-; p53-/-. ">
            <entity charOffset="153-154" id="miRNA-corp.d161.s6.e0" text="MB" type="Diseases"/>
            <entity charOffset="209-210" id="miRNA-corp.d161.s6.e1" text="MB" type="Diseases"/>
            <entity charOffset="8-16" id="miRNA-corp.d161.s6.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-120" id="miRNA-corp.d161.s6.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="255-259" id="miRNA-corp.d161.s6.e4" text="Ink4c" type="Genes/Proteins"/>
            <entity charOffset="288-290" id="miRNA-corp.d161.s6.e5" text="p53" type="Genes/Proteins"/>
            <entity charOffset="278-282" id="miRNA-corp.d161.s6.e6" text="Ink4c" type="Genes/Proteins"/>
            <entity charOffset="18-25" id="miRNA-corp.d161.s6.e7" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="101-131" id="miRNA-corp.d161.s6.e8" text="alterations in miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="203-207" id="miRNA-corp.d161.s6.e9" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d161.s6.e2" e2="miRNA-corp.d161.s6.e0" id="miRNA-corp.d161.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s6.e2" e2="miRNA-corp.d161.s6.e1" id="miRNA-corp.d161.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s6.e2" e2="miRNA-corp.d161.s6.e4" id="miRNA-corp.d161.s6.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s6.e2" e2="miRNA-corp.d161.s6.e5" id="miRNA-corp.d161.s6.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s6.e2" e2="miRNA-corp.d161.s6.e6" id="miRNA-corp.d161.s6.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s6.e3" e2="miRNA-corp.d161.s6.e0" id="miRNA-corp.d161.s6.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s6.e3" e2="miRNA-corp.d161.s6.e1" id="miRNA-corp.d161.s6.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s6.e3" e2="miRNA-corp.d161.s6.e4" id="miRNA-corp.d161.s6.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s6.e3" e2="miRNA-corp.d161.s6.e5" id="miRNA-corp.d161.s6.p8" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s6.e3" e2="miRNA-corp.d161.s6.e6" id="miRNA-corp.d161.s6.p9" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s7" origId="19196975.s4" text="We found that 26 miRNAs showed increased expression and 24 miRNAs showed decreased expression in proliferating mouse GNPs and MBs relative to mature mouse cerebellum, regardless of genotype. ">
            <entity charOffset="17-22" id="miRNA-corp.d161.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-64" id="miRNA-corp.d161.s7.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="126-128" id="miRNA-corp.d161.s7.e2" text="MBs" type="Diseases"/>
            <entity charOffset="31-50" id="miRNA-corp.d161.s7.e3" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="73-92" id="miRNA-corp.d161.s7.e4" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="111-115" id="miRNA-corp.d161.s7.e5" text="mouse" type="Species"/>
            <entity charOffset="149-153" id="miRNA-corp.d161.s7.e6" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d161.s7.e0" e2="miRNA-corp.d161.s7.e2" id="miRNA-corp.d161.s7.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s7.e1" e2="miRNA-corp.d161.s7.e2" id="miRNA-corp.d161.s7.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s8" origId="19196975.s5" text="Among the 26 overexpressed miRNAs, 9 were encoded by the miR-17 approximately 92 cluster family, a group of microRNAs implicated as oncogenes in several tumor types. ">
            <entity charOffset="57-62" id="miRNA-corp.d161.s8.e0" text="miR-17" type="Specific_miRNAs"/>
            <entity charOffset="27-32" id="miRNA-corp.d161.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-116" id="miRNA-corp.d161.s8.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-25" id="miRNA-corp.d161.s8.e3" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="153-157" id="miRNA-corp.d161.s8.e4" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d161.s8.e0" e2="miRNA-corp.d161.s8.e4" id="miRNA-corp.d161.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s8.e1" e2="miRNA-corp.d161.s8.e4" id="miRNA-corp.d161.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s8.e2" e2="miRNA-corp.d161.s8.e4" id="miRNA-corp.d161.s8.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s9" origId="19196975.s0" text="The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.  ">
            <entity charOffset="4-12" id="miRNA-corp.d161.s9.e0" text="miR-17~92" type="Specific_miRNAs"/>
            <entity charOffset="70-84" id="miRNA-corp.d161.s9.e1" text="medulloblastoma" type="Diseases"/>
            <entity charOffset="44-57" id="miRNA-corp.d161.s9.e2" text="Sonic Hedgehog" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d161.s9.e0" e2="miRNA-corp.d161.s9.e1" id="miRNA-corp.d161.s9.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d161.s9.e0" e2="miRNA-corp.d161.s9.e2" id="miRNA-corp.d161.s9.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d161.s10" origId="19196975.s1" text="Medulloblastomas (MBs) are the most common brain tumors in children. ">
            <entity charOffset="43-54" id="miRNA-corp.d161.s10.e0" text="brain tumors" type="Diseases"/>
            <entity charOffset="0-15" id="miRNA-corp.d161.s10.e1" text="Medulloblastomas" type="Diseases"/>
            <entity charOffset="18-20" id="miRNA-corp.d161.s10.e2" text="MBs" type="Diseases"/>
            <entity charOffset="49-54" id="miRNA-corp.d161.s10.e3" text="tumors" type="Diseases"/>
            <entity charOffset="59-66" id="miRNA-corp.d161.s10.e4" text="children" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d162" origId="21092923">
        <sentence id="miRNA-corp.d162.s0" origId="21092923.s1" text="Autosomal-recessive cerebellar ataxias comprise a clinically and genetically heterogeneous group of neurodegenerative disorders. ">
            <entity charOffset="0-37" id="miRNA-corp.d162.s0.e0" text="Autosomal-recessive cerebellar ataxias" type="Diseases"/>
            <entity charOffset="100-126" id="miRNA-corp.d162.s0.e1" text="neurodegenerative disorders" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s1" origId="21092923.s2" text="In contrast to their dominant counterparts, unraveling the molecular background of these ataxias has proven to be more complicated and the currently known mutations provide incomplete coverage for genotyping of patients. ">
            <entity charOffset="89-95" id="miRNA-corp.d162.s1.e0" text="ataxias" type="Diseases"/>
            <entity charOffset="211-218" id="miRNA-corp.d162.s1.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s2" origId="21092923.s3" text="By combining SNP array-based linkage analysis and targeted resequencing of relevant sequences in the linkage interval with the use of next-generation sequencing technology, we identified a mutation in a gene and have shown its association with autosomal-recessive cerebellar ataxia. ">
            <entity charOffset="50-57" id="miRNA-corp.d162.s2.e0" text="targeted" type="Relation_Trigger"/>
            <entity charOffset="227-237" id="miRNA-corp.d162.s2.e1" text="association" type="Relation_Trigger"/>
            <entity charOffset="244-280" id="miRNA-corp.d162.s2.e2" text="autosomal-recessive cerebellar ataxia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s3" origId="21092923.s4" text="In a Dutch consanguineous family with three affected siblings a homozygous 12.5 Mb region on chromosome 3 was targeted by array-based sequence capture. ">
            <entity charOffset="110-117" id="miRNA-corp.d162.s3.e0" text="targeted" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s4" origId="21092923.s0" text="Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia.  ">
            <entity charOffset="0-7" id="miRNA-corp.d162.s4.e0" text="Targeted" type="Relation_Trigger"/>
            <entity charOffset="108-144" id="miRNA-corp.d162.s4.e1" text="autosomal-recessive cerebellar ataxia" type="Diseases"/>
            <entity charOffset="75-79" id="miRNA-corp.d162.s4.e2" text="ANO10" type="Genes/Proteins"/>
            <entity charOffset="94-101" id="miRNA-corp.d162.s4.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s5" origId="21092923.s7" text="The analysis of ANO10 by Sanger sequencing revealed three additional mutations: a homozygous mutation (c.1150_1151del [p.Leu384fs]) in a Serbian family and a compound-heterozygous splice-site mutation (c.1476+1G&gt;T) and a frameshift mutation (c.1604del [p.Leu535X]) in a French family. ">
            <entity charOffset="16-20" id="miRNA-corp.d162.s5.e0" text="ANO10" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s6" origId="21092923.s8" text="This illustrates the power of using initial homozygosity mapping with next-generation sequencing technology to identify genes involved in autosomal-recessive diseases. "/>
        <sentence id="miRNA-corp.d162.s7" origId="21092923.s5" text="Prioritization of all detected sequence variants led to four candidate genes, one of which contained a variant with a high base pair conservation score (phyloP score: 5.26). "/>
        <sentence id="miRNA-corp.d162.s8" origId="21092923.s6" text="This variant was a leucine-to-arginine substitution in the DUF 590 domain of a 16K transmembrane protein, a putative calcium-activated chloride channel encoded by anoctamin 10 (ANO10). ">
            <entity charOffset="177-181" id="miRNA-corp.d162.s8.e0" text="ANO10" type="Genes/Proteins"/>
            <entity charOffset="163-174" id="miRNA-corp.d162.s8.e1" text="anoctamin 10" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d162.s9" origId="21092923.s9" text="Moreover, identifying a putative calcium-dependent chloride channel involved in cerebellar ataxia adds another pathway to the list of pathophysiological mechanisms that may cause cerebellar ataxia.   ">
            <entity charOffset="80-96" id="miRNA-corp.d162.s9.e0" text="cerebellar ataxia" type="Diseases"/>
            <entity charOffset="179-195" id="miRNA-corp.d162.s9.e1" text="cerebellar ataxia" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d163" origId="21338582">
        <sentence id="miRNA-corp.d163.s0" origId="21338582.s2" text="Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD. ">
            <entity charOffset="31-34" id="miRNA-corp.d163.s0.e0" text="SNCA" type="Genes/Proteins"/>
            <entity charOffset="177-180" id="miRNA-corp.d163.s0.e1" text="SNCA" type="Genes/Proteins"/>
            <entity charOffset="227-228" id="miRNA-corp.d163.s0.e2" text="PD" type="Diseases"/>
            <entity charOffset="6-20" id="miRNA-corp.d163.s0.e3" text="over-expression" type="Relation_Trigger"/>
            <entity charOffset="145-157" id="miRNA-corp.d163.s0.e4" text="reduce levels" type="Relation_Trigger"/>
            <entity charOffset="25-29" id="miRNA-corp.d163.s0.e5" text="human" type="Species"/>
            <entity charOffset="91-95" id="miRNA-corp.d163.s0.e6" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s1" origId="21338582.s1" text="Alpha-synuclein (SNCA), an abundantly expressed presynaptic protein, is implicated in Parkinson's disease (PD). ">
            <entity charOffset="0-14" id="miRNA-corp.d163.s1.e0" text="Alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="17-20" id="miRNA-corp.d163.s1.e1" text="SNCA" type="Genes/Proteins"/>
            <entity charOffset="86-104" id="miRNA-corp.d163.s1.e2" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="107-108" id="miRNA-corp.d163.s1.e3" text="PD" type="Diseases"/>
            <entity charOffset="27-46" id="miRNA-corp.d163.s1.e4" text="abundantly expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s2" origId="21338582.s0" text="A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons.  ">
            <entity charOffset="2-9" id="miRNA-corp.d163.s2.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="24-38" id="miRNA-corp.d163.s2.e1" text="alpha-synuclein" type="Genes/Proteins"/>
            <entity charOffset="20-22" id="miRNA-corp.d163.s2.e2" text="AAV" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d163.s2.e0" e2="miRNA-corp.d163.s2.e1" id="miRNA-corp.d163.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d163.s2.e0" e2="miRNA-corp.d163.s2.e2" id="miRNA-corp.d163.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s3" origId="21338582.s8" text="Our in vitro data suggest that this miRNA-embedded silencing vector may be ideal for chronic in vivo SNCA gene silencing in DA neurons.   ">
            <entity charOffset="101-104" id="miRNA-corp.d163.s3.e0" text="SNCA" type="Genes/Proteins"/>
            <entity charOffset="36-40" id="miRNA-corp.d163.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d163.s3.e1" e2="miRNA-corp.d163.s3.e0" id="miRNA-corp.d163.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s4" origId="21338582.s7" text="However, the mir30 embedded vector was significantly less toxic to both PC12 and SH-SY5Y cells. ">
            <entity charOffset="13-17" id="miRNA-corp.d163.s4.e0" text="mir30" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s5" origId="21338582.s6" text="In DA PC12 cells, neither vector decreased expression of rat SNCA, tyrosine hydroxylase (TH), dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT). ">
            <entity charOffset="61-64" id="miRNA-corp.d163.s5.e0" text="SNCA" type="Genes/Proteins"/>
            <entity charOffset="67-86" id="miRNA-corp.d163.s5.e1" text="tyrosine hydroxylase" type="Genes/Proteins"/>
            <entity charOffset="33-52" id="miRNA-corp.d163.s5.e2" text="decreased expression" type="Relation_Trigger"/>
            <entity charOffset="128-158" id="miRNA-corp.d163.s5.e3" text="vesicular monoamine transporter" type="Genes/Proteins"/>
            <entity charOffset="94-113" id="miRNA-corp.d163.s5.e4" text="dopamine transporter" type="Genes/Proteins"/>
            <entity charOffset="57-59" id="miRNA-corp.d163.s5.e5" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s6" origId="21338582.s5" text="Both vectors silenced hSNCA to the same extent in 293T cells transfected with hSNCA. "/>
        <sentence id="miRNA-corp.d163.s7" origId="21338582.s4" text="The same hSNCA silencing sequence (shRNA) was used in both vectors, but in one vector, the shRNA was embedded in a microRNA backbone and driven by a pol II promoter, and in the other the shRNA was not embedded in a microRNA and was driven by a pol III promoter. ">
            <entity charOffset="115-122" id="miRNA-corp.d163.s7.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="215-222" id="miRNA-corp.d163.s7.e1" text="microRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d163.s8" origId="21338582.s3" text="To begin to develop a gene therapy for PD based on hSNCA gene silencing, two AAV gene silencing vectors were designed, and tested for efficiency and specificity of silencing, as well as toxicity in vitro. ">
            <entity charOffset="39-40" id="miRNA-corp.d163.s8.e0" text="PD" type="Diseases"/>
            <entity charOffset="77-79" id="miRNA-corp.d163.s8.e1" text="AAV" type="Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d164" origId="19936094">
        <sentence id="miRNA-corp.d164.s0" origId="19936094.s10" text="Taken together, induction of microRNA expression in BMC may contribute to the aberrant systemic decline in mRNA levels in sporadic AD.   ">
            <entity charOffset="29-36" id="miRNA-corp.d164.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-132" id="miRNA-corp.d164.s0.e1" text="sporadic AD" type="Diseases"/>
            <pair e1="miRNA-corp.d164.s0.e0" e2="miRNA-corp.d164.s0.e1" id="miRNA-corp.d164.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s1" origId="19936094.s0" text="MicroRNA expression in Alzheimer blood mononuclear cells.  ">
            <entity charOffset="23-31" id="miRNA-corp.d164.s1.e0" text="Alzheimer" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d164.s1.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d164.s1.e1" e2="miRNA-corp.d164.s1.e0" id="miRNA-corp.d164.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s2" origId="19936094.s1" text="Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD). ">
            <entity charOffset="142-158" id="miRNA-corp.d164.s2.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="161-162" id="miRNA-corp.d164.s2.e1" text="AD" type="Diseases"/>
            <entity charOffset="69-81" id="miRNA-corp.d164.s2.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="119-126" id="miRNA-corp.d164.s2.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s3" origId="19936094.s2" text="Noncoding microRNAs (miRNA) regulate gene expression by degrading messages or inhibiting translation. ">
            <entity charOffset="10-18" id="miRNA-corp.d164.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="21-25" id="miRNA-corp.d164.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-99" id="miRNA-corp.d164.s3.e2" text="inhibiting translation" type="Relation_Trigger"/>
            <entity charOffset="28-51" id="miRNA-corp.d164.s3.e3" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s4" origId="19936094.s3" text="Using BMC as a paradigm for the study of systemic alterations in AD, we investigated whether peripheral miRNA expression is altered in this condition. ">
            <entity charOffset="65-66" id="miRNA-corp.d164.s4.e0" text="AD" type="Diseases"/>
            <entity charOffset="104-108" id="miRNA-corp.d164.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-130" id="miRNA-corp.d164.s4.e2" text="expression is altered" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d164.s4.e1" e2="miRNA-corp.d164.s4.e0" id="miRNA-corp.d164.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s5" origId="19936094.s4" text="MicroRNA levels were assessed using the microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR. ">
            <entity charOffset="0-7" id="miRNA-corp.d164.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-47" id="miRNA-corp.d164.s5.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-94" id="miRNA-corp.d164.s5.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-88" id="miRNA-corp.d164.s5.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s6" origId="19936094.s5" text="Sixteen AD patients and sixteen normal elderly controls (NEC) were matched for ethnicity, age, gender and education. ">
            <entity charOffset="8-9" id="miRNA-corp.d164.s6.e0" text="AD" type="Diseases"/>
            <entity charOffset="11-18" id="miRNA-corp.d164.s6.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s7" origId="19936094.s6" text="The expression of several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one or two APOE4 alleles. ">
            <entity charOffset="112-113" id="miRNA-corp.d164.s7.e0" text="AD" type="Diseases"/>
            <entity charOffset="62-63" id="miRNA-corp.d164.s7.e1" text="AD" type="Diseases"/>
            <entity charOffset="30-35" id="miRNA-corp.d164.s7.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-57" id="miRNA-corp.d164.s7.e3" text="expression of several BMC miRNAs was found to increase" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d164.s7.e2" e2="miRNA-corp.d164.s7.e0" id="miRNA-corp.d164.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d164.s7.e2" e2="miRNA-corp.d164.s7.e1" id="miRNA-corp.d164.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s8" origId="19936094.s7" text="As compared to NEC, miRNAs significantly upregulated in AD subjects and confirmed by qPCR were miR-34a and 181b. ">
            <entity charOffset="95-110" id="miRNA-corp.d164.s8.e0" text="miR-34a and 181b" type="Specific_miRNAs"/>
            <entity charOffset="56-57" id="miRNA-corp.d164.s8.e1" text="AD" type="Diseases"/>
            <entity charOffset="20-25" id="miRNA-corp.d164.s8.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-51" id="miRNA-corp.d164.s8.e3" text="upregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d164.s8.e2" e2="miRNA-corp.d164.s8.e1" id="miRNA-corp.d164.s8.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d164.s8.e0" e2="miRNA-corp.d164.s8.e1" id="miRNA-corp.d164.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s9" origId="19936094.s8" text="Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the functional categories of Transcription/Translation and Synaptic Activity. ">
            <entity charOffset="40-48" id="miRNA-corp.d164.s9.e0" text="Alzheimer" type="Diseases"/>
            <entity charOffset="91-96" id="miRNA-corp.d164.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-35" id="miRNA-corp.d164.s9.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="59-68" id="miRNA-corp.d164.s9.e3" text="correlated" type="Relation_Trigger"/>
            <entity charOffset="79-89" id="miRNA-corp.d164.s9.e4" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="0-15" id="miRNA-corp.d164.s9.e5" text="Predicted target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d164.s9.e1" e2="miRNA-corp.d164.s9.e0" id="miRNA-corp.d164.s9.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d164.s10" origId="19936094.s9" text="Several miRNAs targeting the same genes were within the functional category of Injury response/Redox homeostasis. ">
            <entity charOffset="8-13" id="miRNA-corp.d164.s10.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="15-23" id="miRNA-corp.d164.s10.e1" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="79-84" id="miRNA-corp.d164.s10.e2" text="Injury" type="Diseases"/>
            <pair e1="miRNA-corp.d164.s10.e0" e2="miRNA-corp.d164.s10.e2" id="miRNA-corp.d164.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d165" origId="21450054">
        <sentence id="miRNA-corp.d165.s0" origId="21450054.s7" text="Despite the small sample available, we can show that this approach permits identification of meaningful structures, in particular two polycistronic miRNA genes related to transcriptional activity and likely to be relevant in the discrimination between gliosarcomas and other brain tumors. ">
            <entity charOffset="148-152" id="miRNA-corp.d165.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="252-263" id="miRNA-corp.d165.s0.e1" text="gliosarcomas" type="Diseases"/>
            <entity charOffset="275-286" id="miRNA-corp.d165.s0.e2" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d165.s0.e0" e2="miRNA-corp.d165.s0.e1" id="miRNA-corp.d165.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d165.s0.e0" e2="miRNA-corp.d165.s0.e2" id="miRNA-corp.d165.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d165.s1" origId="21450054.s6" text="Our intention is to identify structures that contain information from both mRNAs and miRNAs, and that can explain the complexity of the data. ">
            <entity charOffset="85-90" id="miRNA-corp.d165.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d165.s2" origId="21450054.s5" text="RESULTS: We use Factor Analysis coupled with pre-established knowledge as a theoretical base to achieve this goal. "/>
        <sentence id="miRNA-corp.d165.s3" origId="21450054.s4" text="We analyzed one of the (currently) few datasets that provide both transcriptional and post-transcriptional data of the same samples to investigate the possibility to extract more information, using a joint analysis approach. "/>
        <sentence id="miRNA-corp.d165.s4" origId="21450054.s8" text="CONCLUSIONS: This suggests the need to develop methodologies to simultaneously mine information from different levels of biological organization, rather than linking separate analyses performed in parallel.   "/>
        <sentence id="miRNA-corp.d165.s5" origId="21450054.s2" text="However, to date, most computational and algorithmic efforts have been directed at mining data from each of these molecular levels (genomic, transcriptional, etc.) separately. "/>
        <sentence id="miRNA-corp.d165.s6" origId="21450054.s3" text="In view of the rapid advances in technology (new generation sequencing, high-throughput proteomics) it is important to address the problem of analyzing these data as a whole, i.e. preserving the emergent properties that appear in the cellular system when all molecular levels are interacting. "/>
        <sentence id="miRNA-corp.d165.s7" origId="21450054.s0" text="Joint analysis of transcriptional and post- transcriptional brain tumor data: searching for emergent properties of cellular systems.  ">
            <entity charOffset="60-70" id="miRNA-corp.d165.s7.e0" text="brain tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d165.s8" origId="21450054.s1" text="UNLABELLED: ABSTRACT: BACKGROUND: Advances in biotechnology offer a fast growing variety of high-throughput data for screening molecular activities of genomic, transcriptional, post-transcriptional and translational observations. "/>
    </document>
    <document id="miRNA-corp.d166" origId="19911064">
        <sentence id="miRNA-corp.d166.s0" origId="19911064.s2" text="To investigate noncoding tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29 genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in 3'UTR using TargetScan (version 5.1). ">
            <entity charOffset="30-37" id="miRNA-corp.d166.s0.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="114-118" id="miRNA-corp.d166.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="252-259" id="miRNA-corp.d166.s0.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="165-166" id="miRNA-corp.d166.s0.e3" text="PD" type="Diseases"/>
            <entity charOffset="53-62" id="miRNA-corp.d166.s0.e4" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="120-125" id="miRNA-corp.d166.s0.e5" text="target" type="Relation_Trigger"/>
            <entity charOffset="261-266" id="miRNA-corp.d166.s0.e6" text="target" type="Relation_Trigger"/>
            <entity charOffset="108-112" id="miRNA-corp.d166.s0.e7" text="human" type="Species"/>
            <pair e1="miRNA-corp.d166.s0.e0" e2="miRNA-corp.d166.s0.e3" id="miRNA-corp.d166.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d166.s0.e1" e2="miRNA-corp.d166.s0.e3" id="miRNA-corp.d166.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d166.s0.e2" e2="miRNA-corp.d166.s0.e3" id="miRNA-corp.d166.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s1" origId="19911064.s3" text="Data extracted by miRanda elucidates the mode of microRNA action based on the location of target sites in the Parkinson genes. ">
            <entity charOffset="49-56" id="miRNA-corp.d166.s1.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-95" id="miRNA-corp.d166.s1.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s2" origId="19911064.s4" text="Sites prone to action of multiple miRNAs were identified as &quot;hot spots.&quot; ">
            <entity charOffset="34-39" id="miRNA-corp.d166.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s3" origId="19911064.s5" text="Important properties of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and their targets. ">
            <entity charOffset="29-33" id="miRNA-corp.d166.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="133-138" id="miRNA-corp.d166.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="150-156" id="miRNA-corp.d166.s3.e2" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s4" origId="19911064.s6" text="Two sets of predicted results were explored for the occurrence of target sites of 112 miRNAs expressed in midbrain. ">
            <entity charOffset="86-91" id="miRNA-corp.d166.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-71" id="miRNA-corp.d166.s4.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s5" origId="19911064.s7" text="Overall, convergence of results predicted by two algorithms revealed that 48 target sites for midbrain-specific miRNA occur in close proximity in 9 genes. ">
            <entity charOffset="112-116" id="miRNA-corp.d166.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-82" id="miRNA-corp.d166.s5.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s6" origId="19911064.s8" text="This study will pave a way for selection of potential miRNA candidates for Parkinson's disease-related genes for quick therapeutic applications and diagnosis.   ">
            <entity charOffset="54-58" id="miRNA-corp.d166.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="75-93" id="miRNA-corp.d166.s6.e1" text="Parkinson's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d166.s6.e0" e2="miRNA-corp.d166.s6.e1" id="miRNA-corp.d166.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s7" origId="19911064.s1" text="Parkinson's disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons. ">
            <entity charOffset="0-18" id="miRNA-corp.d166.s7.e0" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="21-22" id="miRNA-corp.d166.s7.e1" text="PD" type="Diseases"/>
            <entity charOffset="49-61" id="miRNA-corp.d166.s7.e2" text="neurodisorder" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d166.s8" origId="19911064.s0" text="Interaction map and selection of microRNA targets in Parkinson's disease-related genes.  ">
            <entity charOffset="33-40" id="miRNA-corp.d166.s8.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-48" id="miRNA-corp.d166.s8.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="53-71" id="miRNA-corp.d166.s8.e2" text="Parkinson's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d166.s8.e0" e2="miRNA-corp.d166.s8.e2" id="miRNA-corp.d166.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d167" origId="17172864">
        <sentence id="miRNA-corp.d167.s0" origId="17172864.s7" text="These studies suggest that miRNAs may be important for neuronal survival in the context of human neurodegenerative disease. ">
            <entity charOffset="27-32" id="miRNA-corp.d167.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="97-121" id="miRNA-corp.d167.s0.e1" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="91-95" id="miRNA-corp.d167.s0.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d167.s0.e0" e2="miRNA-corp.d167.s0.e1" id="miRNA-corp.d167.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s1" origId="17172864.s8" text="These studies provide the foundation to define the miRNAs involved in neurodegenerative disease, and the biological pathways affected.   ">
            <entity charOffset="51-56" id="miRNA-corp.d167.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-94" id="miRNA-corp.d167.s1.e1" text="neurodegenerative disease" type="Diseases"/>
            <pair e1="miRNA-corp.d167.s1.e0" e2="miRNA-corp.d167.s1.e1" id="miRNA-corp.d167.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s2" origId="17172864.s5" text="These studies showed that upregulation of ban mitigates degeneration induced by the pathogenic polyglutamine (polyQ) protein Ataxin-3, which is mutated in the human polyglutamine disease spinocerebellar ataxia type 3 (SCA3). ">
            <entity charOffset="125-132" id="miRNA-corp.d167.s2.e0" text="Ataxin-3" type="Genes/Proteins"/>
            <entity charOffset="26-37" id="miRNA-corp.d167.s2.e1" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="179-215" id="miRNA-corp.d167.s2.e2" text="disease spinocerebellar ataxia type 3" type="Diseases"/>
            <entity charOffset="218-221" id="miRNA-corp.d167.s2.e3" text="SCA3" type="Diseases"/>
            <entity charOffset="159-163" id="miRNA-corp.d167.s2.e4" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s3" origId="17172864.s6" text="To address the broader role for miRNAs in neuroprotection, we also showed that loss of all miRNAs, by dicer mutation, dramatically enhances pathogenic polyQ protein toxicity in flies and in human HeLa cells. ">
            <entity charOffset="32-37" id="miRNA-corp.d167.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="91-96" id="miRNA-corp.d167.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-106" id="miRNA-corp.d167.s3.e2" text="dicer" type="Genes/Proteins"/>
            <entity charOffset="79-96" id="miRNA-corp.d167.s3.e3" text="loss of all miRNAs" type="Relation_Trigger"/>
            <entity charOffset="190-194" id="miRNA-corp.d167.s3.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d167.s3.e0" e2="miRNA-corp.d167.s3.e2" id="miRNA-corp.d167.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d167.s3.e1" e2="miRNA-corp.d167.s3.e2" id="miRNA-corp.d167.s3.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s4" origId="17172864.s0" text="A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins.  ">
            <entity charOffset="15-22" id="miRNA-corp.d167.s4.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="34-43" id="miRNA-corp.d167.s4.e1" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="83-87" id="miRNA-corp.d167.s4.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s5" origId="17172864.s1" text="MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of target transcript mRNAs. ">
            <entity charOffset="0-8" id="miRNA-corp.d167.s5.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d167.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d167.s5.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="49-71" id="miRNA-corp.d167.s5.e3" text="regulate the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s6" origId="17172864.s2" text="Many miRNAs have been defined, however their roles and the processes influenced by miRNA pathways are still being elucidated. ">
            <entity charOffset="5-10" id="miRNA-corp.d167.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="83-87" id="miRNA-corp.d167.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s7" origId="17172864.s3" text="A role for miRNAs in development and cancer has been described. ">
            <entity charOffset="11-16" id="miRNA-corp.d167.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="37-42" id="miRNA-corp.d167.s7.e1" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d167.s7.e0" e2="miRNA-corp.d167.s7.e1" id="miRNA-corp.d167.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d167.s8" origId="17172864.s4" text="We recently isolated the miRNA bantam (ban) in a genetic screen for modulators of pathogenicity of a human neurodegenerative disease model in Drosophila. ">
            <entity charOffset="25-29" id="miRNA-corp.d167.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="68-77" id="miRNA-corp.d167.s8.e1" text="modulators" type="Relation_Trigger"/>
            <entity charOffset="107-131" id="miRNA-corp.d167.s8.e2" text="neurodegenerative disease" type="Diseases"/>
            <entity charOffset="101-105" id="miRNA-corp.d167.s8.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d167.s8.e0" e2="miRNA-corp.d167.s8.e2" id="miRNA-corp.d167.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d168" origId="17989771">
        <sentence id="miRNA-corp.d168.s0" origId="17989771.s8" text="CONCLUSIONS/SIGNIFICANCE: We provide a list of ten miRNA loci potentially involved in the development of blood cancer or brain tumors. ">
            <entity charOffset="51-55" id="miRNA-corp.d168.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="121-132" id="miRNA-corp.d168.s0.e1" text="brain tumors" type="Diseases"/>
            <entity charOffset="111-116" id="miRNA-corp.d168.s0.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d168.s0.e0" e2="miRNA-corp.d168.s0.e1" id="miRNA-corp.d168.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d168.s0.e0" e2="miRNA-corp.d168.s0.e2" id="miRNA-corp.d168.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s1" origId="17989771.s9" text="There is independent experimental support from other studies for the involvement of miRNAs from at least three CIS-associated miRNA loci in cancer development.   ">
            <entity charOffset="126-130" id="miRNA-corp.d168.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d168.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="140-145" id="miRNA-corp.d168.s1.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d168.s1.e0" e2="miRNA-corp.d168.s1.e2" id="miRNA-corp.d168.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d168.s1.e1" e2="miRNA-corp.d168.s1.e2" id="miRNA-corp.d168.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s2" origId="17989771.s6" text="CIS-associated miRNAs on average are more conserved in vertebrates than miRNAs associated with non-CIS inserts and their human homologs are also located in regions perturbed in cancer. ">
            <entity charOffset="15-20" id="miRNA-corp.d168.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="72-77" id="miRNA-corp.d168.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-88" id="miRNA-corp.d168.s2.e2" text="associated" type="Relation_Trigger"/>
            <entity charOffset="177-182" id="miRNA-corp.d168.s2.e3" text="cancer" type="Diseases"/>
            <entity charOffset="121-125" id="miRNA-corp.d168.s2.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d168.s2.e0" e2="miRNA-corp.d168.s2.e3" id="miRNA-corp.d168.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d168.s2.e1" e2="miRNA-corp.d168.s2.e3" id="miRNA-corp.d168.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s3" origId="17989771.s7" text="In addition we show that miRNA genes are enriched around promoter and/or terminator regions of RefSeq genes in both mouse and human. ">
            <entity charOffset="25-29" id="miRNA-corp.d168.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="116-120" id="miRNA-corp.d168.s3.e1" text="mouse" type="Species"/>
            <entity charOffset="126-130" id="miRNA-corp.d168.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s4" origId="17989771.s4" text="Ten CIS-associated miRNA loci containing 22 miRNAs are located within 10 kb of known CIS insertions. ">
            <entity charOffset="19-23" id="miRNA-corp.d168.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-49" id="miRNA-corp.d168.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s5" origId="17989771.s5" text="Only one CIS-associated miRNA locus overlaps a RefSeq protein-coding gene and six loci are located more than 10 kb from any RefSeq gene. ">
            <entity charOffset="24-28" id="miRNA-corp.d168.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s6" origId="17989771.s2" text="METHODOLOGY/PRINCIPAL FINDINGS: Using a public database of mapped retroviral insertion sites from various mouse models of cancer we demonstrate that MLV-derived retroviral inserts are enriched in close proximity to mouse miRNA loci. ">
            <entity charOffset="221-225" id="miRNA-corp.d168.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-127" id="miRNA-corp.d168.s6.e1" text="cancer" type="Diseases"/>
            <entity charOffset="106-110" id="miRNA-corp.d168.s6.e2" text="mouse" type="Species"/>
            <entity charOffset="215-219" id="miRNA-corp.d168.s6.e3" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d168.s6.e0" e2="miRNA-corp.d168.s6.e1" id="miRNA-corp.d168.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s7" origId="17989771.s3" text="Clustered inserts from cancer-associated regions (Common Integration Sites, CIS) have a higher association with miRNAs than non-clustered inserts. ">
            <entity charOffset="112-117" id="miRNA-corp.d168.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-105" id="miRNA-corp.d168.s7.e1" text="higher association" type="Relation_Trigger"/>
            <entity charOffset="23-28" id="miRNA-corp.d168.s7.e2" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d168.s7.e0" e2="miRNA-corp.d168.s7.e2" id="miRNA-corp.d168.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s8" origId="17989771.s1" text="BACKGROUND: MicroRNAs (miRNAs) are short non-coding RNAs that regulate differentiation and development in many organisms and play an important role in cancer. ">
            <entity charOffset="12-20" id="miRNA-corp.d168.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-28" id="miRNA-corp.d168.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="62-69" id="miRNA-corp.d168.s8.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="151-156" id="miRNA-corp.d168.s8.e3" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d168.s8.e0" e2="miRNA-corp.d168.s8.e3" id="miRNA-corp.d168.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d168.s8.e1" e2="miRNA-corp.d168.s8.e3" id="miRNA-corp.d168.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d168.s9" origId="17989771.s0" text="Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse.  ">
            <entity charOffset="12-19" id="miRNA-corp.d168.s9.e0" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="42-47" id="miRNA-corp.d168.s9.e1" text="cancer" type="Diseases"/>
            <entity charOffset="79-83" id="miRNA-corp.d168.s9.e2" text="human" type="Species"/>
            <entity charOffset="89-93" id="miRNA-corp.d168.s9.e3" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d168.s9.e0" e2="miRNA-corp.d168.s9.e1" id="miRNA-corp.d168.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d169" origId="20960104">
        <sentence id="miRNA-corp.d169.s0" origId="20960104.s0" text="MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.  ">
            <entity charOffset="0-7" id="miRNA-corp.d169.s0.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-53" id="miRNA-corp.d169.s0.e1" text="pituitary tumors" type="Diseases"/>
            <entity charOffset="98-117" id="miRNA-corp.d169.s0.e2" text="pituitary carcinomas" type="Diseases"/>
            <entity charOffset="73-93" id="miRNA-corp.d169.s0.e3" text="microRNA-122 and -493" type="Specific_miRNAs"/>
            <entity charOffset="56-68" id="miRNA-corp.d169.s0.e4" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="23-26" id="miRNA-corp.d169.s0.e5" text="ACTH" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s0.e0" e2="miRNA-corp.d169.s0.e2" id="miRNA-corp.d169.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s0.e0" e2="miRNA-corp.d169.s0.e5" id="miRNA-corp.d169.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s0.e0" e2="miRNA-corp.d169.s0.e1" id="miRNA-corp.d169.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s0.e3" e2="miRNA-corp.d169.s0.e2" id="miRNA-corp.d169.s0.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s0.e3" e2="miRNA-corp.d169.s0.e5" id="miRNA-corp.d169.s0.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s0.e3" e2="miRNA-corp.d169.s0.e1" id="miRNA-corp.d169.s0.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s1" origId="20960104.s4" text="Real-time RT-PCR and in situ hybridization were used to confirm and independently validate miRNAs that were significantly up-regulated or down-regulated between the pituitary tissues. ">
            <entity charOffset="91-96" id="miRNA-corp.d169.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="138-151" id="miRNA-corp.d169.s1.e1" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="122-133" id="miRNA-corp.d169.s1.e2" text="up-regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s2" origId="20960104.s3" text="We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases). ">
            <entity charOffset="8-12" id="miRNA-corp.d169.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="51-55" id="miRNA-corp.d169.s2.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="184-203" id="miRNA-corp.d169.s2.e2" text="pituitary carcinomas" type="Diseases"/>
            <entity charOffset="145-152" id="miRNA-corp.d169.s2.e3" text="adenomas" type="Diseases"/>
            <entity charOffset="129-132" id="miRNA-corp.d169.s2.e4" text="ACTH" type="Genes/Proteins"/>
            <entity charOffset="108-126" id="miRNA-corp.d169.s2.e5" text="adrenocorticotropin" type="Genes/Proteins"/>
            <entity charOffset="169-172" id="miRNA-corp.d169.s2.e6" text="ACTH" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e0" e2="miRNA-corp.d169.s2.e2" id="miRNA-corp.d169.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s2.e0" e2="miRNA-corp.d169.s2.e3" id="miRNA-corp.d169.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s2.e0" e2="miRNA-corp.d169.s2.e4" id="miRNA-corp.d169.s2.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e0" e2="miRNA-corp.d169.s2.e5" id="miRNA-corp.d169.s2.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e0" e2="miRNA-corp.d169.s2.e6" id="miRNA-corp.d169.s2.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e1" e2="miRNA-corp.d169.s2.e2" id="miRNA-corp.d169.s2.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s2.e1" e2="miRNA-corp.d169.s2.e3" id="miRNA-corp.d169.s2.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s2.e1" e2="miRNA-corp.d169.s2.e4" id="miRNA-corp.d169.s2.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e1" e2="miRNA-corp.d169.s2.e5" id="miRNA-corp.d169.s2.p8" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s2.e1" e2="miRNA-corp.d169.s2.e6" id="miRNA-corp.d169.s2.p9" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s3" origId="20960104.s2" text="The expression of miRNAs in pituitary carcinomas has not been previously examined. ">
            <entity charOffset="18-23" id="miRNA-corp.d169.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-47" id="miRNA-corp.d169.s3.e1" text="pituitary carcinomas" type="Diseases"/>
            <pair e1="miRNA-corp.d169.s3.e0" e2="miRNA-corp.d169.s3.e1" id="miRNA-corp.d169.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s4" origId="20960104.s1" text="MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and can function as tumor suppressor genes or oncogenes. ">
            <entity charOffset="0-8" id="miRNA-corp.d169.s4.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d169.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="107-122" id="miRNA-corp.d169.s4.e2" text="tumor suppressor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s5" origId="20960104.s7" text="MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas. ">
            <entity charOffset="19-30" id="miRNA-corp.d169.s5.e0" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="0-8" id="miRNA-corp.d169.s5.e1" text="MiRNA-493" type="Specific_miRNAs"/>
            <entity charOffset="58-61" id="miRNA-corp.d169.s5.e2" text="ACTH" type="Genes/Proteins"/>
            <entity charOffset="63-70" id="miRNA-corp.d169.s5.e3" text="adenomas" type="Diseases"/>
            <entity charOffset="35-44" id="miRNA-corp.d169.s5.e4" text="carcinomas" type="Diseases"/>
            <pair e1="miRNA-corp.d169.s5.e1" e2="miRNA-corp.d169.s5.e2" id="miRNA-corp.d169.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s5.e1" e2="miRNA-corp.d169.s5.e3" id="miRNA-corp.d169.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s5.e1" e2="miRNA-corp.d169.s5.e4" id="miRNA-corp.d169.s5.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s6" origId="20960104.s8" text="Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth. ">
            <entity charOffset="154-168" id="miRNA-corp.d169.s6.e0" text="pituitary tumor" type="Diseases"/>
            <entity charOffset="23-31" id="miRNA-corp.d169.s6.e1" text="miRNA-493" type="Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d169.s6.e2" text="LGALS3" type="Genes/Proteins"/>
            <entity charOffset="68-72" id="miRNA-corp.d169.s6.e3" text="RUNX2" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s6.e1" e2="miRNA-corp.d169.s6.e0" id="miRNA-corp.d169.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s6.e1" e2="miRNA-corp.d169.s6.e2" id="miRNA-corp.d169.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d169.s6.e1" e2="miRNA-corp.d169.s6.e3" id="miRNA-corp.d169.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s7" origId="20960104.s5" text="There were more miRNAs up- (188) or down-regulated (160) between adenomas and normal pituitaries compared to carcinomas and normal pituitaries (92 up- and 91 down-regulated) or between carcinomas and adenomas (46 up- and 52 down-regulated). ">
            <entity charOffset="16-21" id="miRNA-corp.d169.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="36-49" id="miRNA-corp.d169.s7.e1" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="158-171" id="miRNA-corp.d169.s7.e2" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="224-237" id="miRNA-corp.d169.s7.e3" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="65-72" id="miRNA-corp.d169.s7.e4" text="adenomas" type="Diseases"/>
            <entity charOffset="200-207" id="miRNA-corp.d169.s7.e5" text="adenomas" type="Diseases"/>
            <entity charOffset="109-118" id="miRNA-corp.d169.s7.e6" text="carcinomas" type="Diseases"/>
            <entity charOffset="185-194" id="miRNA-corp.d169.s7.e7" text="carcinomas" type="Diseases"/>
            <pair e1="miRNA-corp.d169.s7.e0" e2="miRNA-corp.d169.s7.e4" id="miRNA-corp.d169.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s7.e0" e2="miRNA-corp.d169.s7.e5" id="miRNA-corp.d169.s7.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s7.e0" e2="miRNA-corp.d169.s7.e6" id="miRNA-corp.d169.s7.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s7.e0" e2="miRNA-corp.d169.s7.e7" id="miRNA-corp.d169.s7.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s8" origId="20960104.s6" text="Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas. ">
            <entity charOffset="102-121" id="miRNA-corp.d169.s8.e0" text="pituitary carcinomas" type="Diseases"/>
            <entity charOffset="67-79" id="miRNA-corp.d169.s8.e1" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="84-92" id="miRNA-corp.d169.s8.e2" text="miRNA-122" type="Specific_miRNAs"/>
            <entity charOffset="127-134" id="miRNA-corp.d169.s8.e3" text="adenomas" type="Diseases"/>
            <pair e1="miRNA-corp.d169.s8.e2" e2="miRNA-corp.d169.s8.e0" id="miRNA-corp.d169.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d169.s8.e2" e2="miRNA-corp.d169.s8.e3" id="miRNA-corp.d169.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d169.s9" origId="20960104.s9" text="These results provide information about marker miRNAs that may lead to further insights into the regulation of pituitary tumor growth and development.   ">
            <entity charOffset="47-52" id="miRNA-corp.d169.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="111-125" id="miRNA-corp.d169.s9.e1" text="pituitary tumor" type="Diseases"/>
            <entity charOffset="97-106" id="miRNA-corp.d169.s9.e2" text="regulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d169.s9.e0" e2="miRNA-corp.d169.s9.e1" id="miRNA-corp.d169.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d170" origId="16509149">
        <sentence id="miRNA-corp.d170.s0" origId="16509149.s2" text="METHODS: Surgical outcome data were prospectively collected for 2 to 11 years in 161 consecutive patients with MTLE/ HS. Eighty patients underwent an ATL and 81 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme. ">
            <entity charOffset="111-114" id="miRNA-corp.d170.s0.e0" text="MTLE" type="Diseases"/>
            <entity charOffset="117-118" id="miRNA-corp.d170.s0.e1" text="HS" type="Diseases"/>
            <entity charOffset="168-174" id="miRNA-corp.d170.s0.e2" text="Seizure" type="Diseases"/>
            <entity charOffset="128-135" id="miRNA-corp.d170.s0.e3" text="patients" type="Species"/>
            <entity charOffset="97-104" id="miRNA-corp.d170.s0.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s1" origId="16509149.s3" text="Postoperative memory testing was performed in 86 patients (53%). ">
            <entity charOffset="49-56" id="miRNA-corp.d170.s1.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s2" origId="16509149.s4" text="At the last follow up, 72% of the patients who had undergone an ATL (mean follow up 6.7 years) and 71% of those who had undergone an SA (mean follow up 4.5 years) were seizure free (Engle Class IA). ">
            <entity charOffset="168-174" id="miRNA-corp.d170.s2.e0" text="seizure" type="Diseases"/>
            <entity charOffset="34-41" id="miRNA-corp.d170.s2.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s3" origId="16509149.s5" text="Estimated survival in patients in Engel Classes I, IA, and I and II combined did not differ between the two surgical techniques. ">
            <entity charOffset="22-29" id="miRNA-corp.d170.s3.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s4" origId="16509149.s6" text="Preoperatively, 58% of the patients had verbal memory scores one standard deviation (SD) below the normal mean. ">
            <entity charOffset="27-34" id="miRNA-corp.d170.s4.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s5" origId="16509149.s7" text="One third of the patients with preoperative scores in the normal range worsened after surgery, although this outcome was not related to the surgical technique. ">
            <entity charOffset="17-24" id="miRNA-corp.d170.s5.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s6" origId="16509149.s8" text="In contrast, one third of those whose preoperative scores were less than -1 SD experienced improvement after surgery. "/>
        <sentence id="miRNA-corp.d170.s7" origId="16509149.s9" text="Nine (18%) of the 50 patients whose left side had been surgically treated improved their verbal memory scores by more than one SD. Seven (78%) of these nine underwent an SA (p = 0.05). ">
            <entity charOffset="21-28" id="miRNA-corp.d170.s7.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s8" origId="16509149.s1" text="OBJECT: The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA). ">
            <entity charOffset="45-51" id="miRNA-corp.d170.s8.e0" text="seizure" type="Diseases"/>
            <entity charOffset="110-138" id="miRNA-corp.d170.s8.e1" text="mesial temporal lobe epilepsy" type="Diseases"/>
            <entity charOffset="147-167" id="miRNA-corp.d170.s8.e2" text="hippocampal sclerosis" type="Diseases"/>
            <entity charOffset="170-173" id="miRNA-corp.d170.s8.e3" text="MTLE" type="Diseases"/>
            <entity charOffset="175-176" id="miRNA-corp.d170.s8.e4" text="HS" type="Diseases"/>
            <entity charOffset="75-82" id="miRNA-corp.d170.s8.e5" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s9" origId="16509149.s0" text="Seizure and memory outcome following temporal lobe surgery: selective compared with nonselective approaches for hippocampal sclerosis.  ">
            <entity charOffset="0-6" id="miRNA-corp.d170.s9.e0" text="Seizure" type="Diseases"/>
            <entity charOffset="112-132" id="miRNA-corp.d170.s9.e1" text="hippocampal sclerosis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s10" origId="16509149.s11" text="Preliminary data suggest that postoperative verbal memory scores may improve in patients who undergo selective resection of a sclerotic hippocampus in the dominant temporal lobe.   ">
            <entity charOffset="80-87" id="miRNA-corp.d170.s10.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d170.s11" origId="16509149.s10" text="CONCLUSIONS: Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS. ">
            <entity charOffset="59-65" id="miRNA-corp.d170.s11.e0" text="seizure" type="Diseases"/>
            <entity charOffset="92-95" id="miRNA-corp.d170.s11.e1" text="MTLE" type="Diseases"/>
            <entity charOffset="97-98" id="miRNA-corp.d170.s11.e2" text="HS" type="Diseases"/>
            <entity charOffset="78-85" id="miRNA-corp.d170.s11.e3" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d171" origId="21049191">
        <sentence id="miRNA-corp.d171.s0" origId="21049191.s9" text="Paired Student's &quot;t&quot; test was applied to the scores and no significant difference was found (p = 0.315). "/>
        <sentence id="miRNA-corp.d171.s1" origId="21049191.s8" text="In the postoperative period the mean MMSE score was 28.40 (SD, 1.46). "/>
        <sentence id="miRNA-corp.d171.s2" origId="21049191.s4" text="METHOD: A consecutive series of 40 patients who underwent microsurgical clipping for UIA were studied. ">
            <entity charOffset="35-42" id="miRNA-corp.d171.s2.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s3" origId="21049191.s5" text="The cognitive assessment (Mini Mental State Examination, MMSE) was performed immediately before and at least one month after surgery. "/>
        <sentence id="miRNA-corp.d171.s4" origId="21049191.s6" text="Paired Student's &quot;t&quot; test and analysis of variance (ANOVA) were used for statistical purposes. "/>
        <sentence id="miRNA-corp.d171.s5" origId="21049191.s7" text="RESULTS: The mean MMSE score in the preoperative analysis was 28.12 (SD, 1.34). "/>
        <sentence id="miRNA-corp.d171.s6" origId="21049191.s0" text="Microsurgical clipping in forty patients with unruptured anterior cerebral circulation aneurysms: an investigation into cognitive outcome.  ">
            <entity charOffset="87-95" id="miRNA-corp.d171.s6.e0" text="aneurysms" type="Diseases"/>
            <entity charOffset="32-39" id="miRNA-corp.d171.s6.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s7" origId="21049191.s1" text="OBJECTIVE: It is a consensus that most unruptured intracranial aneurysms (UIA) can be treated with acceptably low morbidity. ">
            <entity charOffset="50-71" id="miRNA-corp.d171.s7.e0" text="intracranial aneurysms" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s8" origId="21049191.s2" text="However, some studies recently reported postoperative cognitive impairment, suggesting that it could be attributable to surgical damage. ">
            <entity charOffset="54-73" id="miRNA-corp.d171.s8.e0" text="cognitive impairment" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s9" origId="21049191.s3" text="Our goal is to evaluate cognitive function before and after microsurgical clipping in patients with UIA. ">
            <entity charOffset="86-93" id="miRNA-corp.d171.s9.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s10" origId="21049191.s10" text="ANOVA did not find independent associations between MMSE scores and age, hypertension, smoking, dyslipidemia, education, aneurysm location, number, laterality or size. ">
            <entity charOffset="31-42" id="miRNA-corp.d171.s10.e0" text="associations" type="Relation_Trigger"/>
            <entity charOffset="121-128" id="miRNA-corp.d171.s10.e1" text="aneurysm" type="Diseases"/>
            <entity charOffset="96-107" id="miRNA-corp.d171.s10.e2" text="dyslipidemia" type="Diseases"/>
            <entity charOffset="73-84" id="miRNA-corp.d171.s10.e3" text="hypertension" type="Diseases"/>
            <entity charOffset="73-84" id="miRNA-corp.d171.s10.e4" text="hypertension" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d171.s11" origId="21049191.s11" text="CONCLUSION: The present study suggests that microsurgical clipping for UIA does not result in major cognitive dysfunction as determined by the MMSE.   ">
            <entity charOffset="100-120" id="miRNA-corp.d171.s11.e0" text="cognitive dysfunction" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d172" origId="21447094">
        <sentence id="miRNA-corp.d172.s0" origId="21447094.s0" text="MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish.  ">
            <entity charOffset="61-78" id="miRNA-corp.d172.s0.e0" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d172.s0.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-16" id="miRNA-corp.d172.s0.e2" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="89-97" id="miRNA-corp.d172.s0.e3" text="zebrafish" type="Species"/>
            <pair e1="miRNA-corp.d172.s0.e2" e2="miRNA-corp.d172.s0.e0" id="miRNA-corp.d172.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d172.s0.e1" e2="miRNA-corp.d172.s0.e0" id="miRNA-corp.d172.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s1" origId="21447094.s1" text="MicroRNAs (miRNAs) play important roles during development and also in adult organisms by regulating the expression of multiple target genes. ">
            <entity charOffset="0-8" id="miRNA-corp.d172.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d172.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-114" id="miRNA-corp.d172.s1.e2" text="regulating the expression" type="Relation_Trigger"/>
            <entity charOffset="128-133" id="miRNA-corp.d172.s1.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s2" origId="21447094.s2" text="Here, we studied the function of miR-133b during zebrafish spinal cord regeneration and show upregulation of miR-133b expression in regenerating neurons of the brainstem after transection of the spinal cord. ">
            <entity charOffset="93-127" id="miRNA-corp.d172.s2.e0" text="upregulation of miR-133b expression" type="Relation_Trigger"/>
            <entity charOffset="33-40" id="miRNA-corp.d172.s2.e1" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="109-116" id="miRNA-corp.d172.s2.e2" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="49-57" id="miRNA-corp.d172.s2.e3" text="zebrafish" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s3" origId="21447094.s3" text="miR-133b has been shown to promote tissue regeneration in other tissue, but its ability to do so in the nervous system has yet to be tested. ">
            <entity charOffset="0-7" id="miRNA-corp.d172.s3.e0" text="miR-133b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s4" origId="21447094.s4" text="Inhibition of miR-133b expression by antisense morpholino (MO) application resulted in impaired locomotor recovery and reduced regeneration of axons from neurons in the nucleus of the medial longitudinal fascicle, superior reticular formation and intermediate reticular formation. ">
            <entity charOffset="0-32" id="miRNA-corp.d172.s4.e0" text="Inhibition of miR-133b expression" type="Relation_Trigger"/>
            <entity charOffset="14-21" id="miRNA-corp.d172.s4.e1" text="miR-133b" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s5" origId="21447094.s5" text="miR-133b targets the small GTPase RhoA, which is an inhibitor of axonal growth, as well as other neurite outgrowth-related molecules. ">
            <entity charOffset="34-37" id="miRNA-corp.d172.s5.e0" text="RhoA" type="Genes/Proteins"/>
            <entity charOffset="9-15" id="miRNA-corp.d172.s5.e1" text="targets" type="Relation_Trigger"/>
            <entity charOffset="0-7" id="miRNA-corp.d172.s5.e2" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="52-60" id="miRNA-corp.d172.s5.e3" text="inhibitor" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d172.s5.e2" e2="miRNA-corp.d172.s5.e0" id="miRNA-corp.d172.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s6" origId="21447094.s6" text="Our results indicate that miR-133b is an important determinant in spinal cord regeneration of adult zebrafish through reduction in RhoA protein levels by direct interaction with its mRNA. ">
            <entity charOffset="131-134" id="miRNA-corp.d172.s6.e0" text="RhoA" type="Genes/Proteins"/>
            <entity charOffset="118-149" id="miRNA-corp.d172.s6.e1" text="reduction in RhoA protein levels" type="Relation_Trigger"/>
            <entity charOffset="26-33" id="miRNA-corp.d172.s6.e2" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="100-108" id="miRNA-corp.d172.s6.e3" text="zebrafish" type="Species"/>
            <pair e1="miRNA-corp.d172.s6.e2" e2="miRNA-corp.d172.s6.e0" id="miRNA-corp.d172.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s7" origId="21447094.s7" text="While RhoA has been studied as a therapeutic target in spinal cord injury, this is the first demonstration of endogenous regulation of RhoA by a microRNA that is required for spinal cord regeneration in zebrafish. ">
            <entity charOffset="55-72" id="miRNA-corp.d172.s7.e0" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="6-9" id="miRNA-corp.d172.s7.e1" text="RhoA" type="Genes/Proteins"/>
            <entity charOffset="135-138" id="miRNA-corp.d172.s7.e2" text="RhoA" type="Genes/Proteins"/>
            <entity charOffset="145-152" id="miRNA-corp.d172.s7.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-50" id="miRNA-corp.d172.s7.e4" text="therapeutic target" type="Relation_Trigger"/>
            <entity charOffset="121-130" id="miRNA-corp.d172.s7.e5" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="203-211" id="miRNA-corp.d172.s7.e6" text="zebrafish" type="Species"/>
            <pair e1="miRNA-corp.d172.s7.e3" e2="miRNA-corp.d172.s7.e0" id="miRNA-corp.d172.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d172.s7.e3" e2="miRNA-corp.d172.s7.e1" id="miRNA-corp.d172.s7.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d172.s7.e3" e2="miRNA-corp.d172.s7.e2" id="miRNA-corp.d172.s7.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d172.s8" origId="21447094.s8" text="The ability of miR-133b to suppress molecules that inhibit axon regrowth may underlie the capacity for adult zebrafish to recover locomotor function after spinal cord injury.   ">
            <entity charOffset="155-172" id="miRNA-corp.d172.s8.e0" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="15-22" id="miRNA-corp.d172.s8.e1" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="51-57" id="miRNA-corp.d172.s8.e2" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="27-34" id="miRNA-corp.d172.s8.e3" text="suppress" type="Relation_Trigger"/>
            <entity charOffset="109-117" id="miRNA-corp.d172.s8.e4" text="zebrafish" type="Species"/>
            <pair e1="miRNA-corp.d172.s8.e1" e2="miRNA-corp.d172.s8.e0" id="miRNA-corp.d172.s8.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d173" origId="17629564">
        <sentence id="miRNA-corp.d173.s0" origId="17629564.s7" text="These findings further support the idea that iron- and aluminum-sulfates induce genotoxicity via a ROS-mediated up-regulation of specific regulatory elements and pathogenic genes that redirect brain cell fate towards progressive dysfunction and apoptotic cell death.   ">
            <entity charOffset="229-239" id="miRNA-corp.d173.s0.e0" text="dysfunction" type="Relation_Trigger"/>
            <entity charOffset="138-147" id="miRNA-corp.d173.s0.e1" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="112-124" id="miRNA-corp.d173.s0.e2" text="up-regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s1" origId="17629564.s6" text="Notably, these same miRNAs are up-regulated in AD brain. ">
            <entity charOffset="47-48" id="miRNA-corp.d173.s1.e0" text="AD" type="Diseases"/>
            <entity charOffset="20-25" id="miRNA-corp.d173.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="31-42" id="miRNA-corp.d173.s1.e2" text="up-regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d173.s1.e1" e2="miRNA-corp.d173.s1.e0" id="miRNA-corp.d173.s1.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s2" origId="17629564.s5" text="The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128. ">
            <entity charOffset="129-133" id="miRNA-corp.d173.s2.e0" text="miR-9" type="Specific_miRNAs"/>
            <entity charOffset="136-143" id="miRNA-corp.d173.s2.e1" text="miR-125b" type="Specific_miRNAs"/>
            <entity charOffset="149-155" id="miRNA-corp.d173.s2.e2" text="miR-128" type="Specific_miRNAs"/>
            <entity charOffset="108-113" id="miRNA-corp.d173.s2.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-88" id="miRNA-corp.d173.s2.e4" text="up-regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s3" origId="17629564.s4" text="In this study we have extended our investigations to analyze the expression of micro RNA (miRNA) populations in iron- and aluminum-sulfate treated human neural cells in primary culture. ">
            <entity charOffset="79-87" id="miRNA-corp.d173.s3.e0" text="micro RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-94" id="miRNA-corp.d173.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="147-151" id="miRNA-corp.d173.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s4" origId="17629564.s3" text="Notably, iron- and aluminum-sulfate induce genes in cultured human brain cells that exhibit expression patterns similar to those observed to be up-regulated in moderate- to late-stage Alzheimer's disease (AD). ">
            <entity charOffset="184-202" id="miRNA-corp.d173.s4.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="205-206" id="miRNA-corp.d173.s4.e1" text="AD" type="Diseases"/>
            <entity charOffset="144-155" id="miRNA-corp.d173.s4.e2" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="61-65" id="miRNA-corp.d173.s4.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s5" origId="17629564.s2" text="Previous studies have shown that following ROS induction, a family of pathogenic brain genes that promote inflammatory signalling, cellular apoptosis and brain cell death is significantly over-expressed. ">
            <entity charOffset="188-201" id="miRNA-corp.d173.s5.e0" text="over-expressed" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s6" origId="17629564.s1" text="Iron- and aluminum-sulfate together, at nanomolar concentrations, trigger the production of reactive oxygen species (ROS) in cultures of human brain cells. ">
            <entity charOffset="137-141" id="miRNA-corp.d173.s6.e0" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d173.s7" origId="17629564.s0" text="Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells.  ">
            <entity charOffset="22-30" id="miRNA-corp.d173.s7.e0" text="micro RNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="33-37" id="miRNA-corp.d173.s7.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="92-96" id="miRNA-corp.d173.s7.e2" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d174" origId="18563458">
        <sentence id="miRNA-corp.d174.s0" origId="18563458.s3" text="As a genetically complex disease, dysregulation of miRNA expression might be a feature of autism spectrum disorders (ASDs). ">
            <entity charOffset="51-55" id="miRNA-corp.d174.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="90-114" id="miRNA-corp.d174.s0.e1" text="autism spectrum disorders" type="Diseases"/>
            <entity charOffset="117-120" id="miRNA-corp.d174.s0.e2" text="ASDs" type="Diseases"/>
            <entity charOffset="34-66" id="miRNA-corp.d174.s0.e3" text="dysregulation of miRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d174.s0.e0" e2="miRNA-corp.d174.s0.e1" id="miRNA-corp.d174.s0.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s0.e0" e2="miRNA-corp.d174.s0.e2" id="miRNA-corp.d174.s0.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s1" origId="18563458.s4" text="Using multiplex quantitative polymerase chain reaction (PCR), we compared the expression of 466 human miRNAs from postmortem cerebellar cortex tissue of individuals with ASD (n = 13) and a control set of non-autistic cerebellar samples (n = 13). ">
            <entity charOffset="102-107" id="miRNA-corp.d174.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="170-172" id="miRNA-corp.d174.s1.e1" text="ASD" type="Diseases"/>
            <entity charOffset="96-100" id="miRNA-corp.d174.s1.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d174.s1.e0" e2="miRNA-corp.d174.s1.e1" id="miRNA-corp.d174.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s2" origId="18563458.s1" text="microRNAs (miRNAs) are approximately 21 nt transcripts capable of regulating the expression of many mRNAs and are abundant in the brain. ">
            <entity charOffset="0-8" id="miRNA-corp.d174.s2.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d174.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-90" id="miRNA-corp.d174.s2.e2" text="regulating the expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s3" origId="18563458.s2" text="miRNAs have a role in several complex diseases including cancer as well as some neurological diseases such as Tourette's syndrome and Fragile x syndrome. ">
            <entity charOffset="0-5" id="miRNA-corp.d174.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="110-128" id="miRNA-corp.d174.s3.e1" text="Tourette's syndrome" type="Diseases"/>
            <entity charOffset="134-151" id="miRNA-corp.d174.s3.e2" text="Fragile x syndrome" type="Diseases"/>
            <entity charOffset="57-62" id="miRNA-corp.d174.s3.e3" text="cancer" type="Diseases"/>
            <entity charOffset="80-100" id="miRNA-corp.d174.s3.e4" text="neurological diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d174.s3.e0" e2="miRNA-corp.d174.s3.e1" id="miRNA-corp.d174.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s3.e0" e2="miRNA-corp.d174.s3.e2" id="miRNA-corp.d174.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s3.e0" e2="miRNA-corp.d174.s3.e3" id="miRNA-corp.d174.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s3.e0" e2="miRNA-corp.d174.s3.e4" id="miRNA-corp.d174.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s4" origId="18563458.s7" text="To validate the finding, we reversed the analysis and compared each non-autism control to a single mean value for each miRNA across all autism cases. ">
            <entity charOffset="119-123" id="miRNA-corp.d174.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="136-141" id="miRNA-corp.d174.s4.e1" text="autism" type="Diseases"/>
            <pair e1="miRNA-corp.d174.s4.e0" e2="miRNA-corp.d174.s4.e1" id="miRNA-corp.d174.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s5" origId="18563458.s8" text="In this analysis, the number of dysregulated miRNAs fell from 28 to 9 miRNAs. ">
            <entity charOffset="70-75" id="miRNA-corp.d174.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-50" id="miRNA-corp.d174.s5.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-43" id="miRNA-corp.d174.s5.e2" text="dysregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s6" origId="18563458.s5" text="While most miRNAs levels showed little variation across all samples suggesting that autism does not induce global dysfunction of miRNA expression, some miRNAs among the autistic samples were expressed at significantly different levels compared to the mean control value. ">
            <entity charOffset="129-133" id="miRNA-corp.d174.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="152-157" id="miRNA-corp.d174.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d174.s6.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d174.s6.e3" text="autism" type="Diseases"/>
            <entity charOffset="18-47" id="miRNA-corp.d174.s6.e4" text="levels showed little variation" type="Relation_Trigger"/>
            <entity charOffset="114-144" id="miRNA-corp.d174.s6.e5" text="dysfunction of miRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d174.s6.e2" e2="miRNA-corp.d174.s6.e3" id="miRNA-corp.d174.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s6.e0" e2="miRNA-corp.d174.s6.e3" id="miRNA-corp.d174.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s6.e1" e2="miRNA-corp.d174.s6.e3" id="miRNA-corp.d174.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s7" origId="18563458.s6" text="Twenty-eight miRNAs were expressed at significantly different levels compared to the non-autism control set in at least one of the autism samples. ">
            <entity charOffset="13-18" id="miRNA-corp.d174.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="131-136" id="miRNA-corp.d174.s7.e1" text="autism" type="Diseases"/>
            <pair e1="miRNA-corp.d174.s7.e0" e2="miRNA-corp.d174.s7.e1" id="miRNA-corp.d174.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s8" origId="18563458.s9" text="Among the predicted targets of dysregulated miRNAs are genes that are known genetic causes of autism such Neurexin and SHANK3. ">
            <entity charOffset="44-49" id="miRNA-corp.d174.s8.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="119-124" id="miRNA-corp.d174.s8.e1" text="SHANK3" type="Genes/Proteins"/>
            <entity charOffset="31-42" id="miRNA-corp.d174.s8.e2" text="dysregulated" type="Relation_Trigger"/>
            <entity charOffset="10-26" id="miRNA-corp.d174.s8.e3" text="predicted targets" type="Relation_Trigger"/>
            <entity charOffset="94-99" id="miRNA-corp.d174.s8.e4" text="autism" type="Diseases"/>
            <pair e1="miRNA-corp.d174.s8.e0" e2="miRNA-corp.d174.s8.e1" id="miRNA-corp.d174.s8.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d174.s8.e0" e2="miRNA-corp.d174.s8.e4" id="miRNA-corp.d174.s8.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s9" origId="18563458.s0" text="Heterogeneous dysregulation of microRNAs across the autism spectrum.  ">
            <entity charOffset="31-39" id="miRNA-corp.d174.s9.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="52-57" id="miRNA-corp.d174.s9.e1" text="autism" type="Diseases"/>
            <entity charOffset="14-26" id="miRNA-corp.d174.s9.e2" text="dysregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d174.s9.e0" e2="miRNA-corp.d174.s9.e1" id="miRNA-corp.d174.s9.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d174.s10" origId="18563458.s10" text="This study finds that altered miRNA expression levels are observed in postmortem cerebellar cortex from autism patients, a finding which suggests that dysregulation of miRNAs may contribute to autism spectrum phenotype.   ">
            <entity charOffset="30-34" id="miRNA-corp.d174.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="168-173" id="miRNA-corp.d174.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="104-109" id="miRNA-corp.d174.s10.e2" text="autism" type="Diseases"/>
            <entity charOffset="193-198" id="miRNA-corp.d174.s10.e3" text="autism" type="Diseases"/>
            <entity charOffset="151-163" id="miRNA-corp.d174.s10.e4" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="22-52" id="miRNA-corp.d174.s10.e5" text="altered miRNA expression levels" type="Relation_Trigger"/>
            <entity charOffset="111-118" id="miRNA-corp.d174.s10.e6" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d174.s10.e0" e2="miRNA-corp.d174.s10.e2" id="miRNA-corp.d174.s10.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s10.e0" e2="miRNA-corp.d174.s10.e3" id="miRNA-corp.d174.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s10.e1" e2="miRNA-corp.d174.s10.e2" id="miRNA-corp.d174.s10.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d174.s10.e1" e2="miRNA-corp.d174.s10.e3" id="miRNA-corp.d174.s10.p3" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d175" origId="19110058">
        <sentence id="miRNA-corp.d175.s0" origId="19110058.s4" text="A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons. ">
            <entity charOffset="34-39" id="miRNA-corp.d175.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="45-47" id="miRNA-corp.d175.s0.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="8-18" id="miRNA-corp.d175.s0.e2" text="correlation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d175.s0.e0" e2="miRNA-corp.d175.s0.e1" id="miRNA-corp.d175.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s1" origId="19110058.s5" text="We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease. ">
            <entity charOffset="17-22" id="miRNA-corp.d175.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="58-60" id="miRNA-corp.d175.s1.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="152-154" id="miRNA-corp.d175.s1.e2" text="APP" type="Genes/Proteins"/>
            <entity charOffset="104-108" id="miRNA-corp.d175.s1.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-71" id="miRNA-corp.d175.s1.e4" text="regulators of APP expression" type="Relation_Trigger"/>
            <entity charOffset="90-119" id="miRNA-corp.d175.s1.e5" text="variations in miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="141-165" id="miRNA-corp.d175.s1.e6" text="changes in APP expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d175.s1.e3" e2="miRNA-corp.d175.s1.e1" id="miRNA-corp.d175.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s1.e3" e2="miRNA-corp.d175.s1.e2" id="miRNA-corp.d175.s1.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s1.e0" e2="miRNA-corp.d175.s1.e1" id="miRNA-corp.d175.s1.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s1.e0" e2="miRNA-corp.d175.s1.e2" id="miRNA-corp.d175.s1.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s2" origId="19110058.s6" text="This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.   ">
            <entity charOffset="105-112" id="miRNA-corp.d175.s2.e0" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="138-148" id="miRNA-corp.d175.s2.e1" text="sporadic AD" type="Diseases"/>
            <entity charOffset="81-123" id="miRNA-corp.d175.s2.e2" text="significant decrease in miR-106b expression" type="Relation_Trigger"/>
            <entity charOffset="150-157" id="miRNA-corp.d175.s2.e3" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d175.s2.e0" e2="miRNA-corp.d175.s2.e1" id="miRNA-corp.d175.s2.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s3" origId="19110058.s0" text="MicroRNA regulation of Alzheimer's Amyloid precursor protein expression.  ">
            <entity charOffset="35-59" id="miRNA-corp.d175.s3.e0" text="Amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="23-33" id="miRNA-corp.d175.s3.e1" text="Alzheimer's" type="Diseases"/>
            <entity charOffset="0-7" id="miRNA-corp.d175.s3.e2" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="9-70" id="miRNA-corp.d175.s3.e3" text="regulation of Alzheimer's Amyloid precursor protein expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d175.s3.e2" e2="miRNA-corp.d175.s3.e1" id="miRNA-corp.d175.s3.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s3.e2" e2="miRNA-corp.d175.s3.e0" id="miRNA-corp.d175.s3.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s4" origId="19110058.s1" text="Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD). ">
            <entity charOffset="117-121" id="miRNA-corp.d175.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="74-75" id="miRNA-corp.d175.s4.e1" text="AD" type="Diseases"/>
            <entity charOffset="23-47" id="miRNA-corp.d175.s4.e2" text="Amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="50-52" id="miRNA-corp.d175.s4.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="248-249" id="miRNA-corp.d175.s4.e4" text="AD" type="Diseases"/>
            <entity charOffset="107-114" id="miRNA-corp.d175.s4.e5" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="218-245" id="miRNA-corp.d175.s4.e6" text="sporadic Alzheimer's disease" type="Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e0" e2="miRNA-corp.d175.s4.e6" id="miRNA-corp.d175.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e0" e2="miRNA-corp.d175.s4.e1" id="miRNA-corp.d175.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e0" e2="miRNA-corp.d175.s4.e2" id="miRNA-corp.d175.s4.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s4.e0" e2="miRNA-corp.d175.s4.e3" id="miRNA-corp.d175.s4.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s4.e0" e2="miRNA-corp.d175.s4.e4" id="miRNA-corp.d175.s4.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e5" e2="miRNA-corp.d175.s4.e6" id="miRNA-corp.d175.s4.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e5" e2="miRNA-corp.d175.s4.e1" id="miRNA-corp.d175.s4.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d175.s4.e5" e2="miRNA-corp.d175.s4.e2" id="miRNA-corp.d175.s4.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s4.e5" e2="miRNA-corp.d175.s4.e3" id="miRNA-corp.d175.s4.p8" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s4.e5" e2="miRNA-corp.d175.s4.e4" id="miRNA-corp.d175.s4.p9" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s5" origId="19110058.s2" text="We therefore investigated whether miRNAs could participate in the regulation of APP gene expression. ">
            <entity charOffset="34-39" id="miRNA-corp.d175.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="80-82" id="miRNA-corp.d175.s5.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="66-98" id="miRNA-corp.d175.s5.e2" text="regulation of APP gene expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d175.s5.e0" e2="miRNA-corp.d175.s5.e1" id="miRNA-corp.d175.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d175.s6" origId="19110058.s3" text="We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines. ">
            <entity charOffset="62-68" id="miRNA-corp.d175.s6.e0" text="miR-20a" type="Specific_miRNAs"/>
            <entity charOffset="71-79" id="miRNA-corp.d175.s6.e1" text="miR-17-5p" type="Specific_miRNAs"/>
            <entity charOffset="85-92" id="miRNA-corp.d175.s6.e2" text="miR-106b" type="Specific_miRNAs"/>
            <entity charOffset="110-112" id="miRNA-corp.d175.s6.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="13-18" id="miRNA-corp.d175.s6.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="101-123" id="miRNA-corp.d175.s6.e5" text="regulate APP expression" type="Relation_Trigger"/>
            <entity charOffset="37-43" id="miRNA-corp.d175.s6.e6" text="miR-20a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d175.s6.e0" e2="miRNA-corp.d175.s6.e3" id="miRNA-corp.d175.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s6.e1" e2="miRNA-corp.d175.s6.e3" id="miRNA-corp.d175.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s6.e2" e2="miRNA-corp.d175.s6.e3" id="miRNA-corp.d175.s6.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s6.e4" e2="miRNA-corp.d175.s6.e3" id="miRNA-corp.d175.s6.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d175.s6.e6" e2="miRNA-corp.d175.s6.e3" id="miRNA-corp.d175.s6.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d176" origId="19801956">
        <sentence id="miRNA-corp.d176.s0" origId="19801956.s5" text="These data suggest a role for HSV-1-induced miRNA-146a in the evasion of HSV-1 from the complement system, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change.   ">
            <entity charOffset="44-53" id="miRNA-corp.d176.s0.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="115-124" id="miRNA-corp.d176.s0.e1" text="activation" type="Relation_Trigger"/>
            <entity charOffset="73-77" id="miRNA-corp.d176.s0.e2" text="HSV-1" type="Species"/>
            <entity charOffset="30-34" id="miRNA-corp.d176.s0.e3" text="HSV-1" type="Species"/>
            <entity charOffset="197-205" id="miRNA-corp.d176.s0.e4" text="Alzheimer" type="Diseases"/>
            <pair e1="miRNA-corp.d176.s0.e0" e2="miRNA-corp.d176.s0.e4" id="miRNA-corp.d176.s0.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d176.s1" origId="19801956.s4" text="A known miRNA-146a target in the brain, complement factor H, was downregulated. ">
            <entity charOffset="8-17" id="miRNA-corp.d176.s1.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="40-58" id="miRNA-corp.d176.s1.e1" text="complement factor H" type="Genes/Proteins"/>
            <entity charOffset="65-77" id="miRNA-corp.d176.s1.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="19-24" id="miRNA-corp.d176.s1.e3" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d176.s1.e0" e2="miRNA-corp.d176.s1.e1" id="miRNA-corp.d176.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d176.s2" origId="19801956.s3" text="Expression of cytoplasmic phospholipase A2, the inducible prostaglandin synthase cyclooxygenase-2, and the neuroinflammatory cytokine interleukin-1beta were each upregulated. ">
            <entity charOffset="134-150" id="miRNA-corp.d176.s2.e0" text="interleukin-1beta" type="Genes/Proteins"/>
            <entity charOffset="58-96" id="miRNA-corp.d176.s2.e1" text="prostaglandin synthase cyclooxygenase-2" type="Genes/Proteins"/>
            <entity charOffset="162-172" id="miRNA-corp.d176.s2.e2" text="upregulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d176.s3" origId="19801956.s2" text="We report that infection of human primary neural cells with a high phenotypic reactivator HSV-1 (17syn+) induces upregulation of a brain-enriched microRNA (miRNA)-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease. ">
            <entity charOffset="146-166" id="miRNA-corp.d176.s3.e0" text="microRNA (miRNA)-146a" type="Specific_miRNAs"/>
            <entity charOffset="246-264" id="miRNA-corp.d176.s3.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="113-124" id="miRNA-corp.d176.s3.e2" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="176-185" id="miRNA-corp.d176.s3.e3" text="associated" type="Relation_Trigger"/>
            <entity charOffset="90-94" id="miRNA-corp.d176.s3.e4" text="HSV-1" type="Species"/>
            <entity charOffset="15-23" id="miRNA-corp.d176.s3.e5" text="infection" type="Diseases"/>
            <entity charOffset="28-32" id="miRNA-corp.d176.s3.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d176.s3.e0" e2="miRNA-corp.d176.s3.e5" id="miRNA-corp.d176.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d176.s3.e0" e2="miRNA-corp.d176.s3.e1" id="miRNA-corp.d176.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d176.s4" origId="19801956.s1" text="Herpes simplex virus type-1 (HSV-1) infection of human brain cells induces changes in gene expression favorable to the propagation of the infecting agent and detrimental to the function of the host cells. ">
            <entity charOffset="75-100" id="miRNA-corp.d176.s4.e0" text="changes in gene expression" type="Relation_Trigger"/>
            <entity charOffset="0-33" id="miRNA-corp.d176.s4.e1" text="Herpes simplex virus type-1 (HSV-1" type="Species"/>
            <entity charOffset="0-44" id="miRNA-corp.d176.s4.e2" text="Herpes simplex virus type-1 (HSV-1) infection" type="Diseases"/>
            <entity charOffset="49-53" id="miRNA-corp.d176.s4.e3" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d176.s5" origId="19801956.s0" text="HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling.  ">
            <entity charOffset="45-54" id="miRNA-corp.d176.s5.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="0-4" id="miRNA-corp.d176.s5.e1" text="HSV-1" type="Species"/>
            <entity charOffset="0-14" id="miRNA-corp.d176.s5.e2" text="HSV-1 infection" type="Diseases"/>
            <entity charOffset="60-68" id="miRNA-corp.d176.s5.e3" text="Alzheimer" type="Diseases"/>
            <entity charOffset="19-23" id="miRNA-corp.d176.s5.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d176.s5.e0" e2="miRNA-corp.d176.s5.e2" id="miRNA-corp.d176.s5.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d176.s5.e0" e2="miRNA-corp.d176.s5.e3" id="miRNA-corp.d176.s5.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d177" origId="20004148">
        <sentence id="miRNA-corp.d177.s0" origId="20004148.s8" text="We concluded that patients with partial recurrent seizures of temporal origin have poor subjective sleep quality that improves significantly after epilepsy surgery.   ">
            <entity charOffset="32-57" id="miRNA-corp.d177.s0.e0" text="partial recurrent seizures" type="Diseases"/>
            <entity charOffset="147-154" id="miRNA-corp.d177.s0.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="18-25" id="miRNA-corp.d177.s0.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s1" origId="20004148.s7" text="ESS and PSQI scores were also analyzed by gender, antiepileptic drug class, age, and seizure frequency, with no significant differences. ">
            <entity charOffset="85-91" id="miRNA-corp.d177.s1.e0" text="seizure" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s2" origId="20004148.s5" text="Global PSQI was high (mean=5.65 SD=3.71) before the surgical procedure (P&lt;0.001). "/>
        <sentence id="miRNA-corp.d177.s3" origId="20004148.s4" text="Two questionnaires were used to assess daytime sleepiness (Epworth Sleepiness Scale [ESS]) and sleep quality (Pittsburgh Sleep Quality Index [PSQI]). ">
            <entity charOffset="39-56" id="miRNA-corp.d177.s3.e0" text="daytime sleepiness" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s4" origId="20004148.s6" text="PSQI evaluation revealed higher and statistically significant scores in three components as well as in the global score, when analyzed by predominance of daytime or nocturnal seizures. ">
            <entity charOffset="165-182" id="miRNA-corp.d177.s4.e0" text="nocturnal seizures" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s5" origId="20004148.s0" text="Evaluation of sleep quality in patients with refractory seizures who undergo epilepsy surgery.  ">
            <entity charOffset="77-84" id="miRNA-corp.d177.s5.e0" text="epilepsy" type="Diseases"/>
            <entity charOffset="56-63" id="miRNA-corp.d177.s5.e1" text="seizures" type="Diseases"/>
            <entity charOffset="31-38" id="miRNA-corp.d177.s5.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s6" origId="20004148.s1" text="The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures. ">
            <entity charOffset="37-64" id="miRNA-corp.d177.s6.e0" text="excessive daytime sleepiness" type="Diseases"/>
            <entity charOffset="172-179" id="miRNA-corp.d177.s6.e1" text="seizures" type="Diseases"/>
            <entity charOffset="119-126" id="miRNA-corp.d177.s6.e2" text="epilepsy" type="Diseases"/>
            <entity charOffset="98-105" id="miRNA-corp.d177.s6.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s7" origId="20004148.s2" text="Forty-eight patients were enrolled in this research study. ">
            <entity charOffset="12-19" id="miRNA-corp.d177.s7.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d177.s8" origId="20004148.s3" text="All of them were evaluated 2 days before and 3 months after the surgery. "/>
    </document>
    <document id="miRNA-corp.d178" origId="19934272">
        <sentence id="miRNA-corp.d178.s0" origId="19934272.s2" text="Here, we investigated the possibility that IFN-beta may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effects. ">
            <entity charOffset="43-50" id="miRNA-corp.d178.s0.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="88-96" id="miRNA-corp.d178.s0.e1" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="99-103" id="miRNA-corp.d178.s0.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-77" id="miRNA-corp.d178.s0.e3" text="downregulate" type="Relation_Trigger"/>
            <entity charOffset="115-123" id="miRNA-corp.d178.s0.e4" text="neoplasms" type="Diseases"/>
            <entity charOffset="109-113" id="miRNA-corp.d178.s0.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d178.s0.e1" e2="miRNA-corp.d178.s0.e0" id="miRNA-corp.d178.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s0.e1" e2="miRNA-corp.d178.s0.e4" id="miRNA-corp.d178.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s0.e2" e2="miRNA-corp.d178.s0.e0" id="miRNA-corp.d178.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s0.e2" e2="miRNA-corp.d178.s0.e4" id="miRNA-corp.d178.s0.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s1" origId="19934272.s3" text="Because of its known connection to glioma biology, we focused on miR-21 among seven miRNAs influenced by IFN-beta. ">
            <entity charOffset="105-112" id="miRNA-corp.d178.s1.e0" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="35-40" id="miRNA-corp.d178.s1.e1" text="glioma" type="Diseases"/>
            <entity charOffset="65-70" id="miRNA-corp.d178.s1.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d178.s1.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="84-89" id="miRNA-corp.d178.s1.e4" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d178.s1.e3" e2="miRNA-corp.d178.s1.e0" id="miRNA-corp.d178.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s1.e3" e2="miRNA-corp.d178.s1.e1" id="miRNA-corp.d178.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s1.e4" e2="miRNA-corp.d178.s1.e0" id="miRNA-corp.d178.s1.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s1.e4" e2="miRNA-corp.d178.s1.e1" id="miRNA-corp.d178.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s1.e2" e2="miRNA-corp.d178.s1.e0" id="miRNA-corp.d178.s1.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s1.e2" e2="miRNA-corp.d178.s1.e1" id="miRNA-corp.d178.s1.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s2" origId="19934272.s0" text="The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.  ">
            <entity charOffset="130-135" id="miRNA-corp.d178.s2.e0" text="glioma" type="Diseases"/>
            <entity charOffset="68-119" id="miRNA-corp.d178.s2.e1" text="signal transducers and activators of transcription 3" type="Genes/Proteins"/>
            <entity charOffset="18-26" id="miRNA-corp.d178.s2.e2" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="4-13" id="miRNA-corp.d178.s2.e3" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="54-63" id="miRNA-corp.d178.s2.e4" text="activation" type="Relation_Trigger"/>
            <entity charOffset="31-40" id="miRNA-corp.d178.s2.e5" text="type I IFN" type="Genes/Proteins"/>
            <entity charOffset="124-128" id="miRNA-corp.d178.s2.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d178.s2.e2" e2="miRNA-corp.d178.s2.e0" id="miRNA-corp.d178.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s2.e2" e2="miRNA-corp.d178.s2.e1" id="miRNA-corp.d178.s2.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s2.e2" e2="miRNA-corp.d178.s2.e5" id="miRNA-corp.d178.s2.p2" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s3" origId="19934272.s1" text="Type I IFNs are involved in double-stranded RNA responses. ">
            <entity charOffset="0-10" id="miRNA-corp.d178.s3.e0" text="Type I IFNs" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s4" origId="19934272.s6" text="The levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased 6 hours after the addition of IFN-beta, indicating that the reduction in miR-21 levels was due to transcriptional suppression. ">
            <entity charOffset="22-27" id="miRNA-corp.d178.s4.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="57-62" id="miRNA-corp.d178.s4.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="166-171" id="miRNA-corp.d178.s4.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d178.s4.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="123-130" id="miRNA-corp.d178.s4.e4" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="4-91" id="miRNA-corp.d178.s4.e5" text="levels of primary miR-21 gene transcripts, precursor miR-21, and mature miR-21 decreased" type="Relation_Trigger"/>
            <entity charOffset="153-178" id="miRNA-corp.d178.s4.e6" text="reduction in miR-21 levels" type="Relation_Trigger"/>
            <entity charOffset="207-217" id="miRNA-corp.d178.s4.e7" text="suppression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d178.s4.e2" e2="miRNA-corp.d178.s4.e4" id="miRNA-corp.d178.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s4.e3" e2="miRNA-corp.d178.s4.e4" id="miRNA-corp.d178.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s4.e0" e2="miRNA-corp.d178.s4.e4" id="miRNA-corp.d178.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s4.e1" e2="miRNA-corp.d178.s4.e4" id="miRNA-corp.d178.s4.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s5" origId="19934272.s7" text="We did reporter assays to elucidate the IFN-beta-mediated suppression of miR-21; the addition of signal transducers and activators of transcription 3 (STAT3)-expressing vectors induced the IFN-beta-mediated suppression of miR-21, whereas STAT3-inhibiting agents inhibited the miR-21 suppression. ">
            <entity charOffset="276-281" id="miRNA-corp.d178.s5.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="222-227" id="miRNA-corp.d178.s5.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="73-78" id="miRNA-corp.d178.s5.e2" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="189-196" id="miRNA-corp.d178.s5.e3" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="58-68" id="miRNA-corp.d178.s5.e4" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="207-217" id="miRNA-corp.d178.s5.e5" text="suppression" type="Relation_Trigger"/>
            <entity charOffset="262-270" id="miRNA-corp.d178.s5.e6" text="inhibited" type="Relation_Trigger"/>
            <entity charOffset="40-47" id="miRNA-corp.d178.s5.e7" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="120-129" id="miRNA-corp.d178.s5.e8" text="activators" type="Relation_Trigger"/>
            <entity charOffset="151-155" id="miRNA-corp.d178.s5.e9" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="97-148" id="miRNA-corp.d178.s5.e10" text="signal transducers and activators of transcription 3" type="Genes/Proteins"/>
            <entity charOffset="283-293" id="miRNA-corp.d178.s5.e11" text="suppression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d178.s5.e0" e2="miRNA-corp.d178.s5.e3" id="miRNA-corp.d178.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e0" e2="miRNA-corp.d178.s5.e7" id="miRNA-corp.d178.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e0" e2="miRNA-corp.d178.s5.e9" id="miRNA-corp.d178.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e0" e2="miRNA-corp.d178.s5.e10" id="miRNA-corp.d178.s5.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e1" e2="miRNA-corp.d178.s5.e3" id="miRNA-corp.d178.s5.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e1" e2="miRNA-corp.d178.s5.e7" id="miRNA-corp.d178.s5.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e1" e2="miRNA-corp.d178.s5.e9" id="miRNA-corp.d178.s5.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e1" e2="miRNA-corp.d178.s5.e10" id="miRNA-corp.d178.s5.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e2" e2="miRNA-corp.d178.s5.e3" id="miRNA-corp.d178.s5.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e2" e2="miRNA-corp.d178.s5.e7" id="miRNA-corp.d178.s5.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e2" e2="miRNA-corp.d178.s5.e9" id="miRNA-corp.d178.s5.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s5.e2" e2="miRNA-corp.d178.s5.e10" id="miRNA-corp.d178.s5.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s6" origId="19934272.s4" text="We analyzed the effect of IFN-beta treatment on miR-21 expression in glioma cells and intracranial glioma xenografts. ">
            <entity charOffset="48-53" id="miRNA-corp.d178.s6.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="69-74" id="miRNA-corp.d178.s6.e1" text="glioma" type="Diseases"/>
            <entity charOffset="26-33" id="miRNA-corp.d178.s6.e2" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="86-104" id="miRNA-corp.d178.s6.e3" text="intracranial glioma" type="Diseases"/>
            <pair e1="miRNA-corp.d178.s6.e0" e2="miRNA-corp.d178.s6.e1" id="miRNA-corp.d178.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s6.e0" e2="miRNA-corp.d178.s6.e2" id="miRNA-corp.d178.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s6.e0" e2="miRNA-corp.d178.s6.e3" id="miRNA-corp.d178.s6.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s7" origId="19934272.s5" text="IFN-beta treatment reduced miR-21 expression in glioma cells markedly, and IFN-beta administration suppressed the growth of glioma-initiating cell-derived intracranial tumors. ">
            <entity charOffset="27-32" id="miRNA-corp.d178.s7.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="0-7" id="miRNA-corp.d178.s7.e1" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="75-82" id="miRNA-corp.d178.s7.e2" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="48-53" id="miRNA-corp.d178.s7.e3" text="glioma" type="Diseases"/>
            <entity charOffset="124-129" id="miRNA-corp.d178.s7.e4" text="glioma" type="Diseases"/>
            <entity charOffset="99-108" id="miRNA-corp.d178.s7.e5" text="suppressed" type="Relation_Trigger"/>
            <entity charOffset="19-43" id="miRNA-corp.d178.s7.e6" text="reduced miR-21 expression" type="Relation_Trigger"/>
            <entity charOffset="155-173" id="miRNA-corp.d178.s7.e7" text="intracranial tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d178.s7.e0" e2="miRNA-corp.d178.s7.e1" id="miRNA-corp.d178.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s7.e0" e2="miRNA-corp.d178.s7.e2" id="miRNA-corp.d178.s7.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s7.e0" e2="miRNA-corp.d178.s7.e3" id="miRNA-corp.d178.s7.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s7.e0" e2="miRNA-corp.d178.s7.e4" id="miRNA-corp.d178.s7.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d178.s7.e0" e2="miRNA-corp.d178.s7.e7" id="miRNA-corp.d178.s7.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s8" origId="19934272.s8" text="Thus, the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation. ">
            <entity charOffset="63-68" id="miRNA-corp.d178.s8.e0" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="128-133" id="miRNA-corp.d178.s8.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="110-117" id="miRNA-corp.d178.s8.e2" text="IFN-beta" type="Genes/Proteins"/>
            <entity charOffset="173-177" id="miRNA-corp.d178.s8.e3" text="STAT3" type="Genes/Proteins"/>
            <entity charOffset="45-58" id="miRNA-corp.d178.s8.e4" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="149-168" id="miRNA-corp.d178.s8.e5" text="negatively regulated" type="Relation_Trigger"/>
            <entity charOffset="179-188" id="miRNA-corp.d178.s8.e6" text="activation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d178.s8.e0" e2="miRNA-corp.d178.s8.e2" id="miRNA-corp.d178.s8.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s8.e0" e2="miRNA-corp.d178.s8.e3" id="miRNA-corp.d178.s8.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s8.e1" e2="miRNA-corp.d178.s8.e2" id="miRNA-corp.d178.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d178.s8.e1" e2="miRNA-corp.d178.s8.e3" id="miRNA-corp.d178.s8.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d178.s9" origId="19934272.s9" text="These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis.   ">
            <entity charOffset="94-99" id="miRNA-corp.d178.s9.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="60-85" id="miRNA-corp.d178.s9.e1" text="transcriptional regulation" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d179" origId="20585616">
        <sentence id="miRNA-corp.d179.s0" origId="20585616.s8" text="This study reveals the occurrence of novel mechanisms of HIF regulation, which might contribute to developing novel strategies for therapeutic intervention of HIF-related pathologies, including heart attack, cancer, and stroke.   ">
            <entity charOffset="194-205" id="miRNA-corp.d179.s0.e0" text="heart attack" type="Diseases"/>
            <entity charOffset="208-213" id="miRNA-corp.d179.s0.e1" text="cancer" type="Diseases"/>
            <entity charOffset="220-225" id="miRNA-corp.d179.s0.e2" text="stroke" type="Diseases"/>
            <entity charOffset="61-70" id="miRNA-corp.d179.s0.e3" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s1" origId="20585616.s6" text="One remarkable hit was the argonaute 1 (ago1) gene, a central element of the microRNA (miRNA) translational silencing machinery. ">
            <entity charOffset="40-43" id="miRNA-corp.d179.s1.e0" text="ago1" type="Genes/Proteins"/>
            <entity charOffset="77-84" id="miRNA-corp.d179.s1.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="87-91" id="miRNA-corp.d179.s1.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-37" id="miRNA-corp.d179.s1.e3" text="argonaute 1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d179.s1.e1" e2="miRNA-corp.d179.s1.e0" id="miRNA-corp.d179.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d179.s1.e1" e2="miRNA-corp.d179.s1.e3" id="miRNA-corp.d179.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d179.s1.e2" e2="miRNA-corp.d179.s1.e0" id="miRNA-corp.d179.s1.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d179.s1.e2" e2="miRNA-corp.d179.s1.e3" id="miRNA-corp.d179.s1.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s2" origId="20585616.s7" text="Further studies confirmed the physiological role of the miRNA machinery in HIF-dependent transcription. ">
            <entity charOffset="56-60" id="miRNA-corp.d179.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s3" origId="20585616.s4" text="After 3 rounds of selection, 30 genes emerged as critical HIF regulators in hypoxia, most of which had not been previously associated with HIF biology. ">
            <entity charOffset="62-71" id="miRNA-corp.d179.s3.e0" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="123-132" id="miRNA-corp.d179.s3.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="76-82" id="miRNA-corp.d179.s3.e2" text="hypoxia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s4" origId="20585616.s5" text="The list of genes includes components of chromatin remodeling complexes, transcription elongation factors, and translational regulators. ">
            <entity charOffset="111-134" id="miRNA-corp.d179.s4.e0" text="translational regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s5" origId="20585616.s2" text="Molecular mechanisms that mediate oxygen-dependent HIF regulation operate at the level of the alpha subunit, controlling protein stability, subcellular localization, and transcriptional coactivator recruitment. ">
            <entity charOffset="55-64" id="miRNA-corp.d179.s5.e0" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s6" origId="20585616.s3" text="We have conducted an unbiased genome-wide RNA interference (RNAi) screen in Drosophila cells aimed to the identification of genes required for HIF activity. "/>
        <sentence id="miRNA-corp.d179.s7" origId="20585616.s0" text="Drosophila genome-wide RNAi screen identifies multiple regulators of HIF-dependent transcription in hypoxia.  ">
            <entity charOffset="55-95" id="miRNA-corp.d179.s7.e0" text="regulators of HIF-dependent transcription" type="Relation_Trigger"/>
            <entity charOffset="100-106" id="miRNA-corp.d179.s7.e1" text="hypoxia" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d179.s8" origId="20585616.s1" text="Hypoxia-inducible factors (HIFs) are a family of evolutionary conserved alpha-beta heterodimeric transcription factors that induce a wide range of genes in response to low oxygen tension. "/>
    </document>
    <document id="miRNA-corp.d180" origId="19462468">
        <sentence id="miRNA-corp.d180.s0" origId="19462468.s2" text="In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified six variants in the 3' untranslated region (UTR) of APP and 29 variants in the 3' UTR of BACE1, of which few variants were restricted to patients: in APP; 4 variants in 6 patients ( approximately 2%) and in BACE1; 7 variants in 11 patients ( approximately 3.5%). ">
            <entity charOffset="450-454" id="miRNA-corp.d180.s0.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="332-336" id="miRNA-corp.d180.s0.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="160-164" id="miRNA-corp.d180.s0.e2" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="45-46" id="miRNA-corp.d180.s0.e3" text="AD" type="Diseases"/>
            <entity charOffset="152-154" id="miRNA-corp.d180.s0.e4" text="APP" type="Genes/Proteins"/>
            <entity charOffset="210-211" id="miRNA-corp.d180.s0.e5" text="AD" type="Diseases"/>
            <entity charOffset="295-297" id="miRNA-corp.d180.s0.e6" text="APP" type="Genes/Proteins"/>
            <entity charOffset="393-395" id="miRNA-corp.d180.s0.e7" text="APP" type="Genes/Proteins"/>
            <entity charOffset="118-125" id="miRNA-corp.d180.s0.e8" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-132" id="miRNA-corp.d180.s0.e9" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="183-188" id="miRNA-corp.d180.s0.e10" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-147" id="miRNA-corp.d180.s0.e11" text="binding sites" type="Relation_Trigger"/>
            <entity charOffset="172-181" id="miRNA-corp.d180.s0.e12" text="associated" type="Relation_Trigger"/>
            <entity charOffset="414-421" id="miRNA-corp.d180.s0.e13" text="patients" type="Species"/>
            <entity charOffset="474-481" id="miRNA-corp.d180.s0.e14" text="patients" type="Species"/>
            <entity charOffset="48-55" id="miRNA-corp.d180.s0.e15" text="patients" type="Species"/>
            <entity charOffset="380-387" id="miRNA-corp.d180.s0.e16" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e3" id="miRNA-corp.d180.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e4" id="miRNA-corp.d180.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e5" id="miRNA-corp.d180.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e6" id="miRNA-corp.d180.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e7" id="miRNA-corp.d180.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e0" id="miRNA-corp.d180.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e1" id="miRNA-corp.d180.s0.p6" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e8" e2="miRNA-corp.d180.s0.e2" id="miRNA-corp.d180.s0.p7" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e3" id="miRNA-corp.d180.s0.p8" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e4" id="miRNA-corp.d180.s0.p9" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e5" id="miRNA-corp.d180.s0.p10" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e6" id="miRNA-corp.d180.s0.p11" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e7" id="miRNA-corp.d180.s0.p12" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e0" id="miRNA-corp.d180.s0.p13" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e1" id="miRNA-corp.d180.s0.p14" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e9" e2="miRNA-corp.d180.s0.e2" id="miRNA-corp.d180.s0.p15" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e3" id="miRNA-corp.d180.s0.p16" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e4" id="miRNA-corp.d180.s0.p17" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e5" id="miRNA-corp.d180.s0.p18" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e6" id="miRNA-corp.d180.s0.p19" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e7" id="miRNA-corp.d180.s0.p20" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e0" id="miRNA-corp.d180.s0.p21" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e1" id="miRNA-corp.d180.s0.p22" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s0.e10" e2="miRNA-corp.d180.s0.e2" id="miRNA-corp.d180.s0.p23" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s1" origId="19462468.s1" text="Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression. ">
            <entity charOffset="137-153" id="miRNA-corp.d180.s1.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="156-157" id="miRNA-corp.d180.s1.e1" text="AD" type="Diseases"/>
            <entity charOffset="25-49" id="miRNA-corp.d180.s1.e2" text="amyloid precursor protein" type="Genes/Proteins"/>
            <entity charOffset="52-54" id="miRNA-corp.d180.s1.e3" text="APP" type="Genes/Proteins"/>
            <entity charOffset="80-84" id="miRNA-corp.d180.s1.e4" text="Abeta" type="Genes/Proteins"/>
            <entity charOffset="106-110" id="miRNA-corp.d180.s1.e5" text="BACE1" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s2" origId="19462468.s0" text="APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.  ">
            <entity charOffset="0-2" id="miRNA-corp.d180.s2.e0" text="APP" type="Genes/Proteins"/>
            <entity charOffset="8-12" id="miRNA-corp.d180.s2.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="70-86" id="miRNA-corp.d180.s2.e2" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="14-18" id="miRNA-corp.d180.s2.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d180.s2.e3" e2="miRNA-corp.d180.s2.e0" id="miRNA-corp.d180.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s2.e3" e2="miRNA-corp.d180.s2.e1" id="miRNA-corp.d180.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s2.e3" e2="miRNA-corp.d180.s2.e2" id="miRNA-corp.d180.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s3" origId="19462468.s3" text="Further genetic screening of the miR-29 cluster encoding the miR-29a/b-1 genes showed 10 variants in close proximity of this cluster. ">
            <entity charOffset="33-38" id="miRNA-corp.d180.s3.e0" text="miR-29" type="Specific_miRNAs"/>
            <entity charOffset="61-71" id="miRNA-corp.d180.s3.e1" text="miR-29a/b-1" type="Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s4" origId="19462468.s4" text="Association studies using all common variants detected in the 3' UTR of BACE1 and the miR-29 gene cluster did not identify an association with AD risk. ">
            <entity charOffset="86-91" id="miRNA-corp.d180.s4.e0" text="miR-29" type="Specific_miRNAs"/>
            <entity charOffset="72-76" id="miRNA-corp.d180.s4.e1" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="143-144" id="miRNA-corp.d180.s4.e2" text="AD" type="Diseases"/>
            <entity charOffset="126-136" id="miRNA-corp.d180.s4.e3" text="association" type="Relation_Trigger"/>
            <entity charOffset="0-10" id="miRNA-corp.d180.s4.e4" text="Association" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d180.s4.e0" e2="miRNA-corp.d180.s4.e1" id="miRNA-corp.d180.s4.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s4.e0" e2="miRNA-corp.d180.s4.e2" id="miRNA-corp.d180.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s5" origId="19462468.s5" text="However, we did observe statistical interaction between rs535860 (BACE1 3' UTR) and rs34772568 (near miR29a; odds ratio [OR](interaction), 0.4; 95% confidence interval [CI], 0.17-0.96; P=0.033). ">
            <entity charOffset="101-106" id="miRNA-corp.d180.s5.e0" text="miR29a" type="Specific_miRNAs"/>
            <entity charOffset="66-70" id="miRNA-corp.d180.s5.e1" text="BACE1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s5.e0" e2="miRNA-corp.d180.s5.e1" id="miRNA-corp.d180.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d180.s6" origId="19462468.s6" text="While the exact role of the patient-specific miRNA variants within the 3' UTR region of APP and BACE1 demands further analyses, this study does not support a major contribution of miRNA genetic variability to AD pathogenesis.   ">
            <entity charOffset="96-100" id="miRNA-corp.d180.s6.e0" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="88-90" id="miRNA-corp.d180.s6.e1" text="APP" type="Genes/Proteins"/>
            <entity charOffset="209-210" id="miRNA-corp.d180.s6.e2" text="AD" type="Diseases"/>
            <entity charOffset="45-49" id="miRNA-corp.d180.s6.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="180-184" id="miRNA-corp.d180.s6.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-34" id="miRNA-corp.d180.s6.e5" text="patient" type="Species"/>
            <pair e1="miRNA-corp.d180.s6.e3" e2="miRNA-corp.d180.s6.e2" id="miRNA-corp.d180.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s6.e3" e2="miRNA-corp.d180.s6.e0" id="miRNA-corp.d180.s6.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s6.e3" e2="miRNA-corp.d180.s6.e1" id="miRNA-corp.d180.s6.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s6.e4" e2="miRNA-corp.d180.s6.e2" id="miRNA-corp.d180.s6.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d180.s6.e4" e2="miRNA-corp.d180.s6.e0" id="miRNA-corp.d180.s6.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d180.s6.e4" e2="miRNA-corp.d180.s6.e1" id="miRNA-corp.d180.s6.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d181" origId="20937840">
        <sentence id="miRNA-corp.d181.s0" origId="20937840.s0" text="Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease.  ">
            <entity charOffset="0-22" id="miRNA-corp.d181.s0.e0" text="Differential regulation" type="Relation_Trigger"/>
            <entity charOffset="27-68" id="miRNA-corp.d181.s0.e1" text="interleukin-1 receptor-associated kinase-1" type="Genes/Proteins"/>
            <entity charOffset="71-76" id="miRNA-corp.d181.s0.e2" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="83-88" id="miRNA-corp.d181.s0.e3" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="93-105" id="miRNA-corp.d181.s0.e4" text="microRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="163-179" id="miRNA-corp.d181.s0.e5" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="133-137" id="miRNA-corp.d181.s0.e6" text="human" type="Species"/>
            <pair e1="miRNA-corp.d181.s0.e4" e2="miRNA-corp.d181.s0.e1" id="miRNA-corp.d181.s0.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s0.e4" e2="miRNA-corp.d181.s0.e2" id="miRNA-corp.d181.s0.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s0.e4" e2="miRNA-corp.d181.s0.e3" id="miRNA-corp.d181.s0.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s0.e4" e2="miRNA-corp.d181.s0.e5" id="miRNA-corp.d181.s0.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s1" origId="20937840.s1" text="Specific microRNAs (miRNAs), small non-coding RNAs that support homeostatic gene expression, are significantly altered in abundance in human neurological disorders. ">
            <entity charOffset="9-17" id="miRNA-corp.d181.s1.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-25" id="miRNA-corp.d181.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="141-162" id="miRNA-corp.d181.s1.e2" text="neurological disorders" type="Diseases"/>
            <entity charOffset="135-139" id="miRNA-corp.d181.s1.e3" text="human" type="Species"/>
            <pair e1="miRNA-corp.d181.s1.e0" e2="miRNA-corp.d181.s1.e2" id="miRNA-corp.d181.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d181.s1.e1" e2="miRNA-corp.d181.s1.e2" id="miRNA-corp.d181.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s2" origId="20937840.s2" text="In monocytes, increased expression of an NF-κB-regulated miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an essential component of Toll-like/IL-1 receptor signaling. ">
            <entity charOffset="14-33" id="miRNA-corp.d181.s2.e0" text="increased expression" type="Relation_Trigger"/>
            <entity charOffset="68-92" id="miRNA-corp.d181.s2.e1" text="down-regulates expression" type="Relation_Trigger"/>
            <entity charOffset="57-66" id="miRNA-corp.d181.s2.e2" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="101-142" id="miRNA-corp.d181.s2.e3" text="interleukin-1 receptor-associated kinase-1" type="Genes/Proteins"/>
            <entity charOffset="145-150" id="miRNA-corp.d181.s2.e4" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="190-193" id="miRNA-corp.d181.s2.e5" text="IL-1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s2.e2" e2="miRNA-corp.d181.s2.e3" id="miRNA-corp.d181.s2.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s2.e2" e2="miRNA-corp.d181.s2.e4" id="miRNA-corp.d181.s2.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s2.e2" e2="miRNA-corp.d181.s2.e5" id="miRNA-corp.d181.s2.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s3" origId="20937840.s3" text="Here we extend those observations to the hippocampus and neocortex of Alzheimer disease (AD) brain and to stressed human astroglial (HAG) cells in primary culture. ">
            <entity charOffset="70-86" id="miRNA-corp.d181.s3.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="89-90" id="miRNA-corp.d181.s3.e1" text="AD" type="Diseases"/>
            <entity charOffset="115-119" id="miRNA-corp.d181.s3.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s4" origId="20937840.s4" text="In 66 control and AD samples we note a significant up-regulation of miRNA-146a coupled to down-regulation of IRAK-1 and a compensatory up-regulation of IRAK-2. ">
            <entity charOffset="51-63" id="miRNA-corp.d181.s4.e0" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="90-104" id="miRNA-corp.d181.s4.e1" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="135-147" id="miRNA-corp.d181.s4.e2" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="18-19" id="miRNA-corp.d181.s4.e3" text="AD" type="Diseases"/>
            <entity charOffset="152-157" id="miRNA-corp.d181.s4.e4" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="109-114" id="miRNA-corp.d181.s4.e5" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="68-77" id="miRNA-corp.d181.s4.e6" text="miRNA-146a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d181.s4.e6" e2="miRNA-corp.d181.s4.e3" id="miRNA-corp.d181.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d181.s4.e6" e2="miRNA-corp.d181.s4.e4" id="miRNA-corp.d181.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s4.e6" e2="miRNA-corp.d181.s4.e5" id="miRNA-corp.d181.s4.p2" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s5" origId="20937840.s5" text="Using miRNA-146a-, IRAK-1-, or IRAK-2 promoter-luciferase reporter constructs, we observe decreases in IRAK-1 and increases in miRNA-146a and IRAK-2 expression in interleukin-1β (IL-1β) and amyloid-β-42 (Aβ42) peptide-stressed HAG cells. ">
            <entity charOffset="163-176" id="miRNA-corp.d181.s5.e0" text="interleukin-1β" type="Genes/Proteins"/>
            <entity charOffset="179-183" id="miRNA-corp.d181.s5.e1" text="IL-1β" type="Genes/Proteins"/>
            <entity charOffset="190-201" id="miRNA-corp.d181.s5.e2" text="amyloid-β-42" type="Genes/Proteins"/>
            <entity charOffset="204-207" id="miRNA-corp.d181.s5.e3" text="Aβ42" type="Genes/Proteins"/>
            <entity charOffset="19-24" id="miRNA-corp.d181.s5.e4" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="31-36" id="miRNA-corp.d181.s5.e5" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="142-147" id="miRNA-corp.d181.s5.e6" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="103-108" id="miRNA-corp.d181.s5.e7" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="127-136" id="miRNA-corp.d181.s5.e8" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="6-15" id="miRNA-corp.d181.s5.e9" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="114-158" id="miRNA-corp.d181.s5.e10" text="increases in miRNA-146a and IRAK-2 expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e0" id="miRNA-corp.d181.s5.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e1" id="miRNA-corp.d181.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e2" id="miRNA-corp.d181.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e4" id="miRNA-corp.d181.s5.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e3" id="miRNA-corp.d181.s5.p4" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e5" id="miRNA-corp.d181.s5.p5" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e6" id="miRNA-corp.d181.s5.p6" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e8" e2="miRNA-corp.d181.s5.e7" id="miRNA-corp.d181.s5.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e0" id="miRNA-corp.d181.s5.p8" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e1" id="miRNA-corp.d181.s5.p9" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e2" id="miRNA-corp.d181.s5.p10" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e4" id="miRNA-corp.d181.s5.p11" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e3" id="miRNA-corp.d181.s5.p12" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e5" id="miRNA-corp.d181.s5.p13" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e6" id="miRNA-corp.d181.s5.p14" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s5.e9" e2="miRNA-corp.d181.s5.e7" id="miRNA-corp.d181.s5.p15" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s6" origId="20937840.s6" text="NF-κB-mediated transcriptional control of human IRAK-2 was localized to between -119 and +12 bp of the immediate IRAK-2 promoter. ">
            <entity charOffset="48-53" id="miRNA-corp.d181.s6.e0" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="113-118" id="miRNA-corp.d181.s6.e1" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="42-46" id="miRNA-corp.d181.s6.e2" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s7" origId="20937840.s7" text="The NF-κB inhibitors curcumin, pyrrolidine dithiocarbamate or CAY10512 abrogated both IRAK-2 and miRNA-146a expression, whereas IRAK-1 was up-regulated. ">
            <entity charOffset="139-150" id="miRNA-corp.d181.s7.e0" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="86-91" id="miRNA-corp.d181.s7.e1" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="128-133" id="miRNA-corp.d181.s7.e2" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="97-106" id="miRNA-corp.d181.s7.e3" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="10-19" id="miRNA-corp.d181.s7.e4" text="inhibitors" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d181.s7.e3" e2="miRNA-corp.d181.s7.e1" id="miRNA-corp.d181.s7.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s7.e3" e2="miRNA-corp.d181.s7.e2" id="miRNA-corp.d181.s7.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s8" origId="20937840.s8" text="Incubation of a protected antisense miRNA-146a was found to inhibit miRNA-146a and restore IRAK-1, whereas IRAK-2 remained unaffected. ">
            <entity charOffset="60-66" id="miRNA-corp.d181.s8.e0" text="inhibit" type="Relation_Trigger"/>
            <entity charOffset="91-96" id="miRNA-corp.d181.s8.e1" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="107-112" id="miRNA-corp.d181.s8.e2" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="68-77" id="miRNA-corp.d181.s8.e3" text="miRNA-146a" type="Specific_miRNAs"/>
            <pair e1="miRNA-corp.d181.s8.e3" e2="miRNA-corp.d181.s8.e1" id="miRNA-corp.d181.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s8.e3" e2="miRNA-corp.d181.s8.e2" id="miRNA-corp.d181.s8.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s9" origId="20937840.s9" text="These data suggest a significantly independent regulation of IRAK-1 and IRAK-2 in AD and in IL-1β+Aβ42 peptide-stressed HAG cells and that an inducible, NF-κB-sensitive, miRNA-146a-mediated down-regulation of IRAK-1 coupled to an NF-κB-induced up-regulation of IRAK-2 expression drives an extensively sustained inflammatory response. ">
            <entity charOffset="170-179" id="miRNA-corp.d181.s9.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="153-157" id="miRNA-corp.d181.s9.e1" text="NF-κB" type="Genes/Proteins"/>
            <entity charOffset="47-56" id="miRNA-corp.d181.s9.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="190-204" id="miRNA-corp.d181.s9.e3" text="down-regulation" type="Relation_Trigger"/>
            <entity charOffset="244-256" id="miRNA-corp.d181.s9.e4" text="up-regulation" type="Relation_Trigger"/>
            <entity charOffset="72-77" id="miRNA-corp.d181.s9.e5" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="61-66" id="miRNA-corp.d181.s9.e6" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="82-83" id="miRNA-corp.d181.s9.e7" text="AD" type="Diseases"/>
            <entity charOffset="209-214" id="miRNA-corp.d181.s9.e8" text="IRAK-1" type="Genes/Proteins"/>
            <entity charOffset="261-266" id="miRNA-corp.d181.s9.e9" text="IRAK-2" type="Genes/Proteins"/>
            <entity charOffset="98-101" id="miRNA-corp.d181.s9.e10" text="Aβ42" type="Genes/Proteins"/>
            <entity charOffset="92-95" id="miRNA-corp.d181.s9.e11" text="IL-1" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e5" id="miRNA-corp.d181.s9.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e6" id="miRNA-corp.d181.s9.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e7" id="miRNA-corp.d181.s9.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e1" id="miRNA-corp.d181.s9.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e8" id="miRNA-corp.d181.s9.p4" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e9" id="miRNA-corp.d181.s9.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e10" id="miRNA-corp.d181.s9.p6" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s9.e0" e2="miRNA-corp.d181.s9.e11" id="miRNA-corp.d181.s9.p7" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s10" origId="20937840.s11" text="The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling.   ">
            <entity charOffset="47-56" id="miRNA-corp.d181.s10.e0" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="31-40" id="miRNA-corp.d181.s10.e1" text="inhibitors" type="Relation_Trigger"/>
            <entity charOffset="155-160" id="miRNA-corp.d181.s10.e2" text="IRAK-2" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s10.e0" e2="miRNA-corp.d181.s10.e2" id="miRNA-corp.d181.s10.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d181.s11" origId="20937840.s10" text="The interactive signaling of NF-κB and miRNA-146a further illustrate interplay between inducible transcription factors and pro-inflammatory miRNAs that regulate brain IRAK expression. ">
            <entity charOffset="140-145" id="miRNA-corp.d181.s11.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-48" id="miRNA-corp.d181.s11.e1" text="miRNA-146a" type="Specific_miRNAs"/>
            <entity charOffset="167-170" id="miRNA-corp.d181.s11.e2" text="IRAK" type="Genes/Proteins"/>
            <entity charOffset="152-181" id="miRNA-corp.d181.s11.e3" text="regulate brain IRAK expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d181.s11.e1" e2="miRNA-corp.d181.s11.e2" id="miRNA-corp.d181.s11.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d181.s11.e0" e2="miRNA-corp.d181.s11.e2" id="miRNA-corp.d181.s11.p1" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d182" origId="19683563">
        <sentence id="miRNA-corp.d182.s0" origId="19683563.s1" text="MicroRNAs (miRNAs) are short noncoding regulatory RNA molecules that modulate protein expression by inhibiting mRNA translation or promoting mRNA degradation. ">
            <entity charOffset="0-8" id="miRNA-corp.d182.s0.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d182.s0.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-126" id="miRNA-corp.d182.s0.e2" text="inhibiting mRNA translation" type="Relation_Trigger"/>
            <entity charOffset="39-95" id="miRNA-corp.d182.s0.e3" text="regulatory RNA molecules that modulate protein expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s1" origId="19683563.s0" text="miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation.  ">
            <entity charOffset="0-6" id="miRNA-corp.d182.s1.e0" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="71-89" id="miRNA-corp.d182.s1.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="101-104" id="miRNA-corp.d182.s1.e2" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="11-18" id="miRNA-corp.d182.s1.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-31" id="miRNA-corp.d182.s1.e4" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="92-116" id="miRNA-corp.d182.s1.e5" text="inhibits bcl2 translation" type="Relation_Trigger"/>
            <entity charOffset="56-60" id="miRNA-corp.d182.s1.e6" text="mouse" type="Species"/>
            <pair e1="miRNA-corp.d182.s1.e0" e2="miRNA-corp.d182.s1.e1" id="miRNA-corp.d182.s1.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s1.e0" e2="miRNA-corp.d182.s1.e2" id="miRNA-corp.d182.s1.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s1.e3" e2="miRNA-corp.d182.s1.e1" id="miRNA-corp.d182.s1.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s1.e3" e2="miRNA-corp.d182.s1.e2" id="miRNA-corp.d182.s1.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s2" origId="19683563.s3" text="During a research for miRNAs that are differentially expressed in cerebral cortex of APPswe/PSDeltaE9 mice (a model for Alzheimer's disease) and age-matched controls, one candidate miRNA that is relatively highly expressed, miR-34a, was studied further because sequence analysis suggested a likely interaction with the 3'-untranslated region of bcl2 mRNA. ">
            <entity charOffset="120-138" id="miRNA-corp.d182.s2.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="224-230" id="miRNA-corp.d182.s2.e1" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="345-348" id="miRNA-corp.d182.s2.e2" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="22-27" id="miRNA-corp.d182.s2.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="181-185" id="miRNA-corp.d182.s2.e4" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="206-221" id="miRNA-corp.d182.s2.e5" text="highly expressed" type="Relation_Trigger"/>
            <entity charOffset="38-61" id="miRNA-corp.d182.s2.e6" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="298-340" id="miRNA-corp.d182.s2.e7" text="interaction with the 3'-untranslated region" type="Relation_Trigger"/>
            <entity charOffset="102-105" id="miRNA-corp.d182.s2.e8" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d182.s2.e3" e2="miRNA-corp.d182.s2.e0" id="miRNA-corp.d182.s2.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s2.e3" e2="miRNA-corp.d182.s2.e2" id="miRNA-corp.d182.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s2.e4" e2="miRNA-corp.d182.s2.e0" id="miRNA-corp.d182.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s2.e4" e2="miRNA-corp.d182.s2.e2" id="miRNA-corp.d182.s2.p3" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s2.e1" e2="miRNA-corp.d182.s2.e0" id="miRNA-corp.d182.s2.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s2.e1" e2="miRNA-corp.d182.s2.e2" id="miRNA-corp.d182.s2.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s3" origId="19683563.s2" text="However, little is understood about the roles of miRNAs in Alzheimer's disease. ">
            <entity charOffset="59-77" id="miRNA-corp.d182.s3.e0" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="49-54" id="miRNA-corp.d182.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d182.s3.e1" e2="miRNA-corp.d182.s3.e0" id="miRNA-corp.d182.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s4" origId="19683563.s5" text="No effect on bcl2 mRNA level was observed. ">
            <entity charOffset="13-16" id="miRNA-corp.d182.s4.e0" text="bcl2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s5" origId="19683563.s4" text="We show that the expression of miR-34a is inversely correlated with the protein level of bcl2 in APPswe/PSDeltaE9 mice and age-matched controls, and miR-34a expression directly inhibits bcl2 translation in SH-SY5Y cells. ">
            <entity charOffset="31-37" id="miRNA-corp.d182.s5.e0" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="149-155" id="miRNA-corp.d182.s5.e1" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="89-92" id="miRNA-corp.d182.s5.e2" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="186-189" id="miRNA-corp.d182.s5.e3" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="42-61" id="miRNA-corp.d182.s5.e4" text="inversely correlated" type="Relation_Trigger"/>
            <entity charOffset="157-184" id="miRNA-corp.d182.s5.e5" text="expression directly inhibits" type="Relation_Trigger"/>
            <entity charOffset="177-201" id="miRNA-corp.d182.s5.e6" text="inhibits bcl2 translation" type="Relation_Trigger"/>
            <entity charOffset="114-117" id="miRNA-corp.d182.s5.e7" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d182.s5.e0" e2="miRNA-corp.d182.s5.e2" id="miRNA-corp.d182.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s5.e0" e2="miRNA-corp.d182.s5.e3" id="miRNA-corp.d182.s5.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s5.e1" e2="miRNA-corp.d182.s5.e2" id="miRNA-corp.d182.s5.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s5.e1" e2="miRNA-corp.d182.s5.e3" id="miRNA-corp.d182.s5.p3" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s6" origId="19683563.s7" text="Consistently, miR-34a knockdown through antisense LNA oligonucleotides increased the level of bcl2 protein in SH-SY5Y cells, which was accompanied by a decrease of active caspase-3. ">
            <entity charOffset="94-97" id="miRNA-corp.d182.s6.e0" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="14-20" id="miRNA-corp.d182.s6.e1" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="171-179" id="miRNA-corp.d182.s6.e2" text="caspase-3" type="Genes/Proteins"/>
            <entity charOffset="152-169" id="miRNA-corp.d182.s6.e3" text="decrease of active" type="Relation_Trigger"/>
            <entity charOffset="71-105" id="miRNA-corp.d182.s6.e4" text="increased the level of bcl2 protein" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d182.s6.e1" e2="miRNA-corp.d182.s6.e0" id="miRNA-corp.d182.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s6.e1" e2="miRNA-corp.d182.s6.e2" id="miRNA-corp.d182.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s7" origId="19683563.s6" text="Western blot analysis of active caspase-3 showed higher levels in APPswe/PSDeltaE9 mice and stable transfecant cell line of miR-34a than in controls. ">
            <entity charOffset="124-130" id="miRNA-corp.d182.s7.e0" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="32-40" id="miRNA-corp.d182.s7.e1" text="caspase-3" type="Genes/Proteins"/>
            <entity charOffset="49-61" id="miRNA-corp.d182.s7.e2" text="higher levels" type="Relation_Trigger"/>
            <entity charOffset="83-86" id="miRNA-corp.d182.s7.e3" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d182.s7.e0" e2="miRNA-corp.d182.s7.e1" id="miRNA-corp.d182.s7.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d182.s8" origId="19683563.s8" text="These findings suggested that bcl2 is an important functional target for miR-34a, and the abnormal expression of miR-34a may contribute to the pathogenesis of Alzheimer's disease, at least in part by affecting the expression of bcl2.   ">
            <entity charOffset="73-79" id="miRNA-corp.d182.s8.e0" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="113-119" id="miRNA-corp.d182.s8.e1" text="miR-34a" type="Specific_miRNAs"/>
            <entity charOffset="30-33" id="miRNA-corp.d182.s8.e2" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="159-177" id="miRNA-corp.d182.s8.e3" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="228-231" id="miRNA-corp.d182.s8.e4" text="bcl2" type="Genes/Proteins"/>
            <entity charOffset="51-67" id="miRNA-corp.d182.s8.e5" text="functional target" type="Relation_Trigger"/>
            <entity charOffset="90-108" id="miRNA-corp.d182.s8.e6" text="abnormal expression" type="Relation_Trigger"/>
            <entity charOffset="200-223" id="miRNA-corp.d182.s8.e7" text="affecting the expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d182.s8.e0" e2="miRNA-corp.d182.s8.e2" id="miRNA-corp.d182.s8.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s8.e0" e2="miRNA-corp.d182.s8.e3" id="miRNA-corp.d182.s8.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s8.e0" e2="miRNA-corp.d182.s8.e4" id="miRNA-corp.d182.s8.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s8.e1" e2="miRNA-corp.d182.s8.e2" id="miRNA-corp.d182.s8.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d182.s8.e1" e2="miRNA-corp.d182.s8.e3" id="miRNA-corp.d182.s8.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d182.s8.e1" e2="miRNA-corp.d182.s8.e4" id="miRNA-corp.d182.s8.p5" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d183" origId="17504026">
        <sentence id="miRNA-corp.d183.s0" origId="17504026.s8" text="Therein lies the therapeutic potential of miRNA, as it may now be possible to induce or inhibit RNAi in a given diseased cell population by controlling the cells' miRNA expression profile. ">
            <entity charOffset="42-46" id="miRNA-corp.d183.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="163-167" id="miRNA-corp.d183.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="88-94" id="miRNA-corp.d183.s0.e2" text="inhibit" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s1" origId="17504026.s9" text="This review outlines the potential of miRNA as a therapeutic strategy against high-grade gliomas, and also the technological hurdles that need to be addressed before this promising technique can be administered in a clinical setting.   ">
            <entity charOffset="38-42" id="miRNA-corp.d183.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-95" id="miRNA-corp.d183.s1.e1" text="high-grade gliomas" type="Diseases"/>
            <pair e1="miRNA-corp.d183.s1.e0" e2="miRNA-corp.d183.s1.e1" id="miRNA-corp.d183.s1.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s2" origId="17504026.s6" text="Thus, miRNA can be considered the cells' answer to siRNA. ">
            <entity charOffset="6-10" id="miRNA-corp.d183.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s3" origId="17504026.s7" text="Discovered over a decade ago, miRNA is fast becoming recognized as crucial in regulating gene expression in cancers. ">
            <entity charOffset="30-34" id="miRNA-corp.d183.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-103" id="miRNA-corp.d183.s3.e1" text="regulating gene expression" type="Relation_Trigger"/>
            <entity charOffset="108-114" id="miRNA-corp.d183.s3.e2" text="cancers" type="Diseases"/>
            <pair e1="miRNA-corp.d183.s3.e0" e2="miRNA-corp.d183.s3.e2" id="miRNA-corp.d183.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s4" origId="17504026.s1" text="Malignant brain tumors, including high-grade gliomas, are among the most lethal of all cancers. ">
            <entity charOffset="10-21" id="miRNA-corp.d183.s4.e0" text="brain tumors" type="Diseases"/>
            <entity charOffset="34-51" id="miRNA-corp.d183.s4.e1" text="high-grade gliomas" type="Diseases"/>
            <entity charOffset="87-93" id="miRNA-corp.d183.s4.e2" text="cancers" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s5" origId="17504026.s0" text="MicroRNA and brain tumors: a cause and a cure?  ">
            <entity charOffset="0-7" id="miRNA-corp.d183.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-24" id="miRNA-corp.d183.s5.e1" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d183.s5.e0" e2="miRNA-corp.d183.s5.e1" id="miRNA-corp.d183.s5.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s6" origId="17504026.s5" text="MicroRNA (miRNA), an endogenously expressed form of siRNA, not only presents an alternate method to induce RNAi in a given diseased tissue or organ, but also exposes a unique set of diagnostic markers that can be used to identify, and then differentiate between tumor grades. ">
            <entity charOffset="0-7" id="miRNA-corp.d183.s6.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-14" id="miRNA-corp.d183.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="262-266" id="miRNA-corp.d183.s6.e2" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d183.s6.e0" e2="miRNA-corp.d183.s6.e2" id="miRNA-corp.d183.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d183.s6.e1" e2="miRNA-corp.d183.s6.e2" id="miRNA-corp.d183.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s7" origId="17504026.s4" text="However, practical difficulties in tissue- or organ-specific targeting of therapeutic quantities of siRNA still preclude its applicability in a clinical setting. ">
            <entity charOffset="61-69" id="miRNA-corp.d183.s7.e0" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s8" origId="17504026.s3" text="With the discovery of RNA interference (RNAi) for target-specific gene silencing via small interfering RNA (siRNA), a novel method to target malignant gliomas has been exposed, an endeavor that is aggressively being carried out in numerous laboratories. ">
            <entity charOffset="141-157" id="miRNA-corp.d183.s8.e0" text="malignant gliomas" type="Diseases"/>
            <entity charOffset="134-139" id="miRNA-corp.d183.s8.e1" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d183.s9" origId="17504026.s2" text="Despite considerable advances, including multi-modal treatments with surgery, radiotherapy, and chemotherapy, the overall prognosis remains dismal for patients diagnosed with these tumors. ">
            <entity charOffset="181-186" id="miRNA-corp.d183.s9.e0" text="tumors" type="Diseases"/>
            <entity charOffset="151-158" id="miRNA-corp.d183.s9.e1" text="patients" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d184" origId="18840638">
        <sentence id="miRNA-corp.d184.s0" origId="18840638.s5" text="The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. ">
            <entity charOffset="27-32" id="miRNA-corp.d184.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-74" id="miRNA-corp.d184.s0.e1" text="RNU44" type="Genes/Proteins"/>
            <entity charOffset="80-84" id="miRNA-corp.d184.s0.e2" text="RNU49" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d184.s0.e0" e2="miRNA-corp.d184.s0.e1" id="miRNA-corp.d184.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d184.s0.e0" e2="miRNA-corp.d184.s0.e2" id="miRNA-corp.d184.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s1" origId="18840638.s6" text="Relative quantification of miRNA expression was calculated using the 2(-DeltaDeltaCt) method. ">
            <entity charOffset="27-31" id="miRNA-corp.d184.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s2" origId="18840638.s3" text="Objective: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment. ">
            <entity charOffset="78-83" id="miRNA-corp.d184.s2.e0" text="let-7a" type="Specific_miRNAs"/>
            <entity charOffset="86-92" id="miRNA-corp.d184.s2.e1" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="95-100" id="miRNA-corp.d184.s2.e2" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="103-108" id="miRNA-corp.d184.s2.e3" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="111-117" id="miRNA-corp.d184.s2.e4" text="miR-141" type="Specific_miRNAs"/>
            <entity charOffset="120-126" id="miRNA-corp.d184.s2.e5" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="129-135" id="miRNA-corp.d184.s2.e6" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="142-148" id="miRNA-corp.d184.s2.e7" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="153-169" id="miRNA-corp.d184.s2.e8" text="corticotropinomas" type="Diseases"/>
            <entity charOffset="51-73" id="miRNA-corp.d184.s2.e9" text="differential expression" type="Relation_Trigger"/>
            <entity charOffset="235-255" id="miRNA-corp.d184.s2.e10" text="expression correlates" type="Relation_Trigger"/>
            <entity charOffset="262-266" id="miRNA-corp.d184.s2.e11" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e0" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e0" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e1" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e1" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e2" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p4" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e2" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p5" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e7" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p6" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e7" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p7" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e3" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p8" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e3" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p9" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e4" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p10" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e4" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p11" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e5" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p12" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e5" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p13" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e6" e2="miRNA-corp.d184.s2.e8" id="miRNA-corp.d184.s2.p14" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s2.e6" e2="miRNA-corp.d184.s2.e11" id="miRNA-corp.d184.s2.p15" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s3" origId="18840638.s4" text="MATERIAL AND METHODS: ACTH-secreting pituitary tumor samples were obtained during transphenoidal surgery from patients with Cushing disease and normal pituitary tissues from autopsies. ">
            <entity charOffset="124-138" id="miRNA-corp.d184.s3.e0" text="Cushing disease" type="Diseases"/>
            <entity charOffset="22-51" id="miRNA-corp.d184.s3.e1" text="ACTH-secreting pituitary tumor" type="Diseases"/>
            <entity charOffset="110-117" id="miRNA-corp.d184.s3.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s4" origId="18840638.s9" text="CONCLUSION: Our results support the possibility that altered miRNA expression profile might be involved in corticotrophic tumorigenesis. ">
            <entity charOffset="61-65" id="miRNA-corp.d184.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-84" id="miRNA-corp.d184.s4.e1" text="altered miRNA expression profile" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s5" origId="18840638.s7" text="RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues. ">
            <entity charOffset="37-43" id="miRNA-corp.d184.s5.e0" text="miR-145" type="Specific_miRNAs"/>
            <entity charOffset="67-72" id="miRNA-corp.d184.s5.e1" text="miR-21" type="Specific_miRNAs"/>
            <entity charOffset="157-163" id="miRNA-corp.d184.s5.e2" text="miR-150" type="Specific_miRNAs"/>
            <entity charOffset="127-132" id="miRNA-corp.d184.s5.e3" text="let-7a" type="Specific_miRNAs"/>
            <entity charOffset="217-222" id="miRNA-corp.d184.s5.e4" text="miR-16" type="Specific_miRNAs"/>
            <entity charOffset="187-193" id="miRNA-corp.d184.s5.e5" text="miR-15a" type="Specific_miRNAs"/>
            <entity charOffset="97-103" id="miRNA-corp.d184.s5.e6" text="miR-141" type="Specific_miRNAs"/>
            <entity charOffset="251-257" id="miRNA-corp.d184.s5.e7" text="miR-143" type="Specific_miRNAs"/>
            <entity charOffset="18-32" id="miRNA-corp.d184.s5.e8" text="underexpression" type="Relation_Trigger"/>
            <entity charOffset="284-314" id="miRNA-corp.d184.s5.e9" text="ACTH-secreting pituitary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e3" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e4" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e5" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e6" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p3" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e7" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p4" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e0" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p5" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e1" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p6" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s5.e2" e2="miRNA-corp.d184.s5.e9" id="miRNA-corp.d184.s5.p7" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s6" origId="18840638.s8" text="There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission. ">
            <entity charOffset="168-174" id="miRNA-corp.d184.s6.e0" text="miR-141" type="Specific_miRNAs"/>
            <entity charOffset="34-38" id="miRNA-corp.d184.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-81" id="miRNA-corp.d184.s6.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="162-185" id="miRNA-corp.d184.s6.e3" text="lower miR-141 expression" type="Relation_Trigger"/>
            <entity charOffset="55-59" id="miRNA-corp.d184.s6.e4" text="tumor" type="Diseases"/>
            <entity charOffset="142-149" id="miRNA-corp.d184.s6.e5" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d184.s6.e0" e2="miRNA-corp.d184.s6.e4" id="miRNA-corp.d184.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s6.e1" e2="miRNA-corp.d184.s6.e4" id="miRNA-corp.d184.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s6.e2" e2="miRNA-corp.d184.s6.e4" id="miRNA-corp.d184.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s7" origId="18840638.s0" text="MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.  ">
            <entity charOffset="0-8" id="miRNA-corp.d184.s7.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="10-33" id="miRNA-corp.d184.s7.e1" text="differentially expressed" type="Relation_Trigger"/>
            <entity charOffset="38-68" id="miRNA-corp.d184.s7.e2" text="ACTH-secreting pituitary tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d184.s7.e0" e2="miRNA-corp.d184.s7.e2" id="miRNA-corp.d184.s7.p0" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s8" origId="18840638.s2" text="More than 50% of miRNA genes are located in cancer-associated genomic regions or in fragile sites of the genome. ">
            <entity charOffset="17-21" id="miRNA-corp.d184.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="44-49" id="miRNA-corp.d184.s8.e1" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d184.s8.e0" e2="miRNA-corp.d184.s8.e1" id="miRNA-corp.d184.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s9" origId="18840638.s1" text="CONTEXT: MicroRNAs (miRNAs) are small noncoding RNAs, functioning as antisense regulators of gene expression by targeting mRNA and contributing to cancer development and progression. ">
            <entity charOffset="9-17" id="miRNA-corp.d184.s9.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="20-25" id="miRNA-corp.d184.s9.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="79-107" id="miRNA-corp.d184.s9.e2" text="regulators of gene expression" type="Relation_Trigger"/>
            <entity charOffset="112-120" id="miRNA-corp.d184.s9.e3" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="147-152" id="miRNA-corp.d184.s9.e4" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d184.s9.e0" e2="miRNA-corp.d184.s9.e4" id="miRNA-corp.d184.s9.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s9.e1" e2="miRNA-corp.d184.s9.e4" id="miRNA-corp.d184.s9.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d184.s10" origId="18840638.s10" text="However, the lack of knowledge about miRNA target genes postpones full understanding of the biological functions of down-regulated or up-regulated miRNAs in corticotropinomas.   ">
            <entity charOffset="37-41" id="miRNA-corp.d184.s10.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="147-152" id="miRNA-corp.d184.s10.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="157-173" id="miRNA-corp.d184.s10.e2" text="corticotropinomas" type="Diseases"/>
            <entity charOffset="116-129" id="miRNA-corp.d184.s10.e3" text="down-regulated" type="Relation_Trigger"/>
            <entity charOffset="134-145" id="miRNA-corp.d184.s10.e4" text="up-regulated" type="Relation_Trigger"/>
            <entity charOffset="43-48" id="miRNA-corp.d184.s10.e5" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d184.s10.e0" e2="miRNA-corp.d184.s10.e2" id="miRNA-corp.d184.s10.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d184.s10.e1" e2="miRNA-corp.d184.s10.e2" id="miRNA-corp.d184.s10.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d185" origId="19724284">
        <sentence id="miRNA-corp.d185.s0" origId="19724284.s0" text="Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures.  ">
            <entity charOffset="66-89" id="miRNA-corp.d185.s0.e0" text="intracerebral hemorrhage" type="Diseases"/>
            <entity charOffset="16-23" id="miRNA-corp.d185.s0.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-63" id="miRNA-corp.d185.s0.e2" text="ischemic stroke" type="Diseases"/>
            <entity charOffset="96-111" id="miRNA-corp.d185.s0.e3" text="kainate seizures" type="Diseases"/>
            <pair e1="miRNA-corp.d185.s0.e1" e2="miRNA-corp.d185.s0.e0" id="miRNA-corp.d185.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s0.e1" e2="miRNA-corp.d185.s0.e2" id="miRNA-corp.d185.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s0.e1" e2="miRNA-corp.d185.s0.e3" id="miRNA-corp.d185.s0.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s1" origId="19724284.s1" text="MicroRNAs (miRNAs) regulate gene expression and have a critical role in many biologic and pathologic processes. ">
            <entity charOffset="0-8" id="miRNA-corp.d185.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d185.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="19-42" id="miRNA-corp.d185.s1.e2" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s2" origId="19724284.s8" text="The results show the possible use of blood miRNAs as biomarkers for brain injury; that selected blood miRNAs may correlate with miRNA changes in the brain; and that many of the mRNAs, previously shown to be regulated in brain and blood after brain injury, are likely accounted for by changes in miRNA expression.   ">
            <entity charOffset="43-48" id="miRNA-corp.d185.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-107" id="miRNA-corp.d185.s2.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="128-132" id="miRNA-corp.d185.s2.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="295-299" id="miRNA-corp.d185.s2.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="242-253" id="miRNA-corp.d185.s2.e4" text="brain injury" type="Diseases"/>
            <entity charOffset="68-79" id="miRNA-corp.d185.s2.e5" text="brain injury" type="Diseases"/>
            <entity charOffset="284-310" id="miRNA-corp.d185.s2.e6" text="changes in miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="113-121" id="miRNA-corp.d185.s2.e7" text="correlate" type="Relation_Trigger"/>
            <entity charOffset="207-215" id="miRNA-corp.d185.s2.e8" text="regulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d185.s2.e0" e2="miRNA-corp.d185.s2.e4" id="miRNA-corp.d185.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e0" e2="miRNA-corp.d185.s2.e5" id="miRNA-corp.d185.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e1" e2="miRNA-corp.d185.s2.e4" id="miRNA-corp.d185.s2.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e1" e2="miRNA-corp.d185.s2.e5" id="miRNA-corp.d185.s2.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e2" e2="miRNA-corp.d185.s2.e4" id="miRNA-corp.d185.s2.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e2" e2="miRNA-corp.d185.s2.e5" id="miRNA-corp.d185.s2.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e3" e2="miRNA-corp.d185.s2.e4" id="miRNA-corp.d185.s2.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s2.e3" e2="miRNA-corp.d185.s2.e5" id="miRNA-corp.d185.s2.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s3" origId="19724284.s7" text="A few miRNAs (e.g., miR-298, miR-155, and miR-362-3p) were upregulated or downregulated more than twofold in both brain and blood after several different injuries. ">
            <entity charOffset="20-26" id="miRNA-corp.d185.s3.e0" text="miR-298" type="Specific_miRNAs"/>
            <entity charOffset="29-35" id="miRNA-corp.d185.s3.e1" text="miR-155" type="Specific_miRNAs"/>
            <entity charOffset="42-51" id="miRNA-corp.d185.s3.e2" text="miR-362-3p" type="Specific_miRNAs"/>
            <entity charOffset="6-11" id="miRNA-corp.d185.s3.e3" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="154-161" id="miRNA-corp.d185.s3.e4" text="injuries" type="Diseases"/>
            <entity charOffset="59-69" id="miRNA-corp.d185.s3.e5" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="74-86" id="miRNA-corp.d185.s3.e6" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d185.s3.e3" e2="miRNA-corp.d185.s3.e4" id="miRNA-corp.d185.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s3.e0" e2="miRNA-corp.d185.s3.e4" id="miRNA-corp.d185.s3.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s3.e1" e2="miRNA-corp.d185.s3.e4" id="miRNA-corp.d185.s3.p2" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s3.e2" e2="miRNA-corp.d185.s3.e4" id="miRNA-corp.d185.s3.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s4" origId="19724284.s6" text="Many miRNAs changed more than 1.5-fold in brain and blood after each experimental manipulation, and several miRNAs were upregulated or downregulated in both brain and blood after a given injury. ">
            <entity charOffset="5-10" id="miRNA-corp.d185.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="108-113" id="miRNA-corp.d185.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="135-147" id="miRNA-corp.d185.s4.e2" text="downregulated" type="Relation_Trigger"/>
            <entity charOffset="187-192" id="miRNA-corp.d185.s4.e3" text="injury" type="Diseases"/>
            <entity charOffset="120-130" id="miRNA-corp.d185.s4.e4" text="upregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d185.s4.e0" e2="miRNA-corp.d185.s4.e3" id="miRNA-corp.d185.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d185.s4.e1" e2="miRNA-corp.d185.s4.e3" id="miRNA-corp.d185.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s5" origId="19724284.s5" text="MicroRNA response profiles were different for each condition. ">
            <entity charOffset="0-7" id="miRNA-corp.d185.s5.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s6" origId="19724284.s4" text="Brain and whole-blood miRNA expression profiles were assessed 24 h later using TaqMan rodent miRNA arrays. ">
            <entity charOffset="93-97" id="miRNA-corp.d185.s6.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-26" id="miRNA-corp.d185.s6.e1" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s7" origId="19724284.s3" text="Adult, untouched, control rats were compared with rats with sham surgeries, ischemic strokes, brain hemorrhage (lysed blood, fresh blood, or thrombin), and kainate-induced seizures. ">
            <entity charOffset="94-109" id="miRNA-corp.d185.s7.e0" text="brain hemorrhage" type="Diseases"/>
            <entity charOffset="76-91" id="miRNA-corp.d185.s7.e1" text="ischemic strokes" type="Diseases"/>
            <entity charOffset="156-179" id="miRNA-corp.d185.s7.e2" text="kainate-induced seizures" type="Diseases"/>
            <entity charOffset="141-148" id="miRNA-corp.d185.s7.e3" text="thrombin" type="Genes/Proteins"/>
            <entity charOffset="26-29" id="miRNA-corp.d185.s7.e4" text="rats" type="Species"/>
            <entity charOffset="50-53" id="miRNA-corp.d185.s7.e5" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d185.s8" origId="19724284.s2" text="We hypothesized that miRNA expression profiles in injured brain (hippocampus) would show common as well as unique profiles when compared with those of blood. ">
            <entity charOffset="21-25" id="miRNA-corp.d185.s8.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="50-62" id="miRNA-corp.d185.s8.e1" text="injured brain" type="Diseases"/>
            <pair e1="miRNA-corp.d185.s8.e0" e2="miRNA-corp.d185.s8.e1" id="miRNA-corp.d185.s8.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d186" origId="17761882">
        <sentence id="miRNA-corp.d186.s0" origId="17761882.s0" text="A MicroRNA feedback circuit in midbrain dopamine neurons.  ">
            <entity charOffset="2-9" id="miRNA-corp.d186.s0.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s1" origId="17761882.s1" text="MicroRNAs (miRNAs) are evolutionarily conserved, 18- to 25-nucleotide, non-protein coding transcripts that posttranscriptionally regulate gene expression during development. ">
            <entity charOffset="0-8" id="miRNA-corp.d186.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d186.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="129-152" id="miRNA-corp.d186.s1.e2" text="regulate gene expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s2" origId="17761882.s2" text="miRNAs also occur in postmitotic cells, such as neurons in the mammalian central nervous system, but their function is less well characterized. ">
            <entity charOffset="0-5" id="miRNA-corp.d186.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s3" origId="17761882.s3" text="We investigated the role of miRNAs in mammalian midbrain dopaminergic neurons (DNs). ">
            <entity charOffset="28-33" id="miRNA-corp.d186.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s4" origId="17761882.s4" text="We identified a miRNA, miR-133b, that is specifically expressed in midbrain DNs and is deficient in midbrain tissue from patients with Parkinson's disease. ">
            <entity charOffset="23-30" id="miRNA-corp.d186.s4.e0" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="135-153" id="miRNA-corp.d186.s4.e1" text="Parkinson's disease" type="Diseases"/>
            <entity charOffset="16-20" id="miRNA-corp.d186.s4.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="41-62" id="miRNA-corp.d186.s4.e3" text="specifically expressed" type="Relation_Trigger"/>
            <entity charOffset="121-128" id="miRNA-corp.d186.s4.e4" text="patients" type="Species"/>
            <pair e1="miRNA-corp.d186.s4.e0" e2="miRNA-corp.d186.s4.e1" id="miRNA-corp.d186.s4.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d186.s4.e2" e2="miRNA-corp.d186.s4.e1" id="miRNA-corp.d186.s4.p1" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s5" origId="17761882.s5" text="miR-133b regulates the maturation and function of midbrain DNs within a negative feedback circuit that includes the paired-like homeodomain transcription factor Pitx3. ">
            <entity charOffset="0-7" id="miRNA-corp.d186.s5.e0" text="miR-133b" type="Specific_miRNAs"/>
            <entity charOffset="161-165" id="miRNA-corp.d186.s5.e1" text="Pitx3" type="Genes/Proteins"/>
            <entity charOffset="9-17" id="miRNA-corp.d186.s5.e2" text="regulates" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d186.s5.e0" e2="miRNA-corp.d186.s5.e1" id="miRNA-corp.d186.s5.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d186.s6" origId="17761882.s6" text="We propose a role for this feedback circuit in the fine-tuning of dopaminergic behaviors such as locomotion.   "/>
    </document>
    <document id="miRNA-corp.d187" origId="20671708">
        <sentence id="miRNA-corp.d187.s0" origId="20671708.s11" text="Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies.   ">
            <entity charOffset="112-116" id="miRNA-corp.d187.s0.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="149-153" id="miRNA-corp.d187.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="22-32" id="miRNA-corp.d187.s0.e2" text="deregulated" type="Relation_Trigger"/>
            <entity charOffset="83-92" id="miRNA-corp.d187.s0.e3" text="impairment" type="Relation_Trigger"/>
            <entity charOffset="47-50" id="miRNA-corp.d187.s0.e4" text="E2F1" type="Genes/Proteins"/>
            <entity charOffset="52-53" id="miRNA-corp.d187.s0.e5" text="DP" type="Genes/Proteins"/>
            <entity charOffset="69-73" id="miRNA-corp.d187.s0.e6" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d187.s0.e1" e2="miRNA-corp.d187.s0.e0" id="miRNA-corp.d187.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s0.e1" e2="miRNA-corp.d187.s0.e4" id="miRNA-corp.d187.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s0.e1" e2="miRNA-corp.d187.s0.e5" id="miRNA-corp.d187.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s0.e6" e2="miRNA-corp.d187.s0.e0" id="miRNA-corp.d187.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s0.e6" e2="miRNA-corp.d187.s0.e4" id="miRNA-corp.d187.s0.p4" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s0.e6" e2="miRNA-corp.d187.s0.e5" id="miRNA-corp.d187.s0.p5" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s1" origId="20671708.s10" text="Further, pathogenic LRRK2 promoted the association of phospho-4E-BP1 with hAgo2. ">
            <entity charOffset="20-24" id="miRNA-corp.d187.s1.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="74-78" id="miRNA-corp.d187.s1.e1" text="hAgo2" type="Genes/Proteins"/>
            <entity charOffset="39-49" id="miRNA-corp.d187.s1.e2" text="association" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s2" origId="20671708.s2" text="The molecular mechanism of LRRK2 action is not known. ">
            <entity charOffset="27-31" id="miRNA-corp.d187.s2.e0" text="LRRK2" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s3" origId="20671708.s3" text="Here we show that LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis. ">
            <entity charOffset="18-22" id="miRNA-corp.d187.s3.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="71-78" id="miRNA-corp.d187.s3.e1" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="43-50" id="miRNA-corp.d187.s3.e2" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="53-57" id="miRNA-corp.d187.s3.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d187.s3.e2" e2="miRNA-corp.d187.s3.e0" id="miRNA-corp.d187.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s3.e3" e2="miRNA-corp.d187.s3.e0" id="miRNA-corp.d187.s3.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s4" origId="20671708.s4" text="Drosophila e2f1 and dp messenger RNAs are translationally repressed by let-7 and miR-184*, respectively. ">
            <entity charOffset="11-14" id="miRNA-corp.d187.s4.e0" text="e2f1" type="Genes/Proteins"/>
            <entity charOffset="71-75" id="miRNA-corp.d187.s4.e1" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="81-87" id="miRNA-corp.d187.s4.e2" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="42-66" id="miRNA-corp.d187.s4.e3" text="translationally repressed" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d187.s4.e1" e2="miRNA-corp.d187.s4.e0" id="miRNA-corp.d187.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s4.e2" e2="miRNA-corp.d187.s4.e0" id="miRNA-corp.d187.s4.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s5" origId="20671708.s5" text="Pathogenic LRRK2 antagonizes these miRNAs, leading to the overproduction of E2F1/DP, previously implicated in cell cycle and survival control and shown here to be critical for LRRK2 pathogenesis. ">
            <entity charOffset="11-15" id="miRNA-corp.d187.s5.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="176-180" id="miRNA-corp.d187.s5.e1" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="35-40" id="miRNA-corp.d187.s5.e2" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="76-79" id="miRNA-corp.d187.s5.e3" text="E2F1" type="Genes/Proteins"/>
            <entity charOffset="81-82" id="miRNA-corp.d187.s5.e4" text="DP" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s5.e2" e2="miRNA-corp.d187.s5.e1" id="miRNA-corp.d187.s5.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s5.e2" e2="miRNA-corp.d187.s5.e3" id="miRNA-corp.d187.s5.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s5.e2" e2="miRNA-corp.d187.s5.e4" id="miRNA-corp.d187.s5.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s5.e2" e2="miRNA-corp.d187.s5.e0" id="miRNA-corp.d187.s5.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s6" origId="20671708.s6" text="Genetic deletion of let-7, antagomir-mediated blockage of let-7 and miR-184* action, transgenic expression of dp target protector, or replacement of endogenous dp with a dp transgene non-responsive to let-7 each had toxic effects similar to those of pathogenic LRRK2. ">
            <entity charOffset="261-265" id="miRNA-corp.d187.s6.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="20-24" id="miRNA-corp.d187.s6.e1" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="58-62" id="miRNA-corp.d187.s6.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="68-74" id="miRNA-corp.d187.s6.e3" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="201-205" id="miRNA-corp.d187.s6.e4" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="113-118" id="miRNA-corp.d187.s6.e5" text="target" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d187.s6.e1" e2="miRNA-corp.d187.s6.e0" id="miRNA-corp.d187.s6.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s6.e2" e2="miRNA-corp.d187.s6.e0" id="miRNA-corp.d187.s6.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s6.e3" e2="miRNA-corp.d187.s6.e0" id="miRNA-corp.d187.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s6.e4" e2="miRNA-corp.d187.s6.e0" id="miRNA-corp.d187.s6.p3" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s7" origId="20671708.s7" text="Conversely, increasing the level of let-7 or miR-184* attenuated pathogenic LRRK2 effects. ">
            <entity charOffset="76-80" id="miRNA-corp.d187.s7.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="45-51" id="miRNA-corp.d187.s7.e1" text="miR-184" type="Specific_miRNAs"/>
            <entity charOffset="36-40" id="miRNA-corp.d187.s7.e2" text="let-7" type="Specific_miRNAs"/>
            <entity charOffset="54-63" id="miRNA-corp.d187.s7.e3" text="attenuated" type="Relation_Trigger"/>
            <entity charOffset="12-31" id="miRNA-corp.d187.s7.e4" text="increasing the level" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d187.s7.e1" e2="miRNA-corp.d187.s7.e0" id="miRNA-corp.d187.s7.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d187.s7.e2" e2="miRNA-corp.d187.s7.e0" id="miRNA-corp.d187.s7.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s8" origId="20671708.s8" text="LRRK2 associated with Drosophila Argonaute-1 (dAgo1) or human Argonaute-2 (hAgo2) of the RNA-induced silencing complex (RISC). ">
            <entity charOffset="0-4" id="miRNA-corp.d187.s8.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="6-15" id="miRNA-corp.d187.s8.e1" text="associated" type="Relation_Trigger"/>
            <entity charOffset="56-72" id="miRNA-corp.d187.s8.e2" text="human Argonaute-2" type="Genes/Proteins"/>
            <entity charOffset="75-79" id="miRNA-corp.d187.s8.e3" text="hAgo2" type="Genes/Proteins"/>
            <entity charOffset="56-60" id="miRNA-corp.d187.s8.e4" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s9" origId="20671708.s9" text="In aged fly brain, dAgo1 protein level was negatively regulated by LRRK2. ">
            <entity charOffset="67-71" id="miRNA-corp.d187.s9.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="33-62" id="miRNA-corp.d187.s9.e1" text="level was negatively regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s10" origId="20671708.s0" text="Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.  ">
            <entity charOffset="11-15" id="miRNA-corp.d187.s10.e0" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="38-45" id="miRNA-corp.d187.s10.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="17-36" id="miRNA-corp.d187.s10.e2" text="negatively regulates" type="Relation_Trigger"/>
            <entity charOffset="28-68" id="miRNA-corp.d187.s10.e3" text="regulates microRNA-mediated translational" type="Relation_Trigger"/>
            <entity charOffset="56-79" id="miRNA-corp.d187.s10.e4" text="translational repression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d187.s10.e1" e2="miRNA-corp.d187.s10.e0" id="miRNA-corp.d187.s10.p0" interaction="True" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d187.s11" origId="20671708.s1" text="Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease characterized by age-dependent degeneration of dopaminergic neurons. ">
            <entity charOffset="30-57" id="miRNA-corp.d187.s11.e0" text="leucine-rich repeat kinase 2" type="Genes/Proteins"/>
            <entity charOffset="60-64" id="miRNA-corp.d187.s11.e1" text="LRRK2" type="Genes/Proteins"/>
            <entity charOffset="102-120" id="miRNA-corp.d187.s11.e2" text="Parkinson's disease" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d188" origId="20463920">
        <sentence id="miRNA-corp.d188.s0" origId="20463920.s12" text="The predicted targets of these miRNAs include those with known or suspected roles in oligodendrocyte development and myelination including C11Orf9, CLDN11, MYTL1, MBOP, MPZL2, and DDR1. ">
            <entity charOffset="31-36" id="miRNA-corp.d188.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="139-145" id="miRNA-corp.d188.s0.e1" text="C11Orf9" type="Genes/Proteins"/>
            <entity charOffset="148-153" id="miRNA-corp.d188.s0.e2" text="CLDN11" type="Genes/Proteins"/>
            <entity charOffset="169-173" id="miRNA-corp.d188.s0.e3" text="MPZL2" type="Genes/Proteins"/>
            <entity charOffset="180-183" id="miRNA-corp.d188.s0.e4" text="DDR1" type="Genes/Proteins"/>
            <entity charOffset="4-20" id="miRNA-corp.d188.s0.e5" text="predicted targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d188.s0.e0" e2="miRNA-corp.d188.s0.e1" id="miRNA-corp.d188.s0.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d188.s0.e0" e2="miRNA-corp.d188.s0.e2" id="miRNA-corp.d188.s0.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d188.s0.e0" e2="miRNA-corp.d188.s0.e3" id="miRNA-corp.d188.s0.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d188.s0.e0" e2="miRNA-corp.d188.s0.e4" id="miRNA-corp.d188.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s1" origId="20463920.s13" text="CONCLUSIONS/SIGNIFICANCE: We demonstrate miRNA profiles during distinct stages in oligodendroglial differentiation that may provide key markers of OL maturation. ">
            <entity charOffset="41-45" id="miRNA-corp.d188.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s2" origId="20463920.s10" text="Principal component analysis revealed four main clusters of miRNA expression corresponding to early, mid, and late progenitors, and mature OLs. These results were supported by correlation analyses between adjacent stages. ">
            <entity charOffset="60-64" id="miRNA-corp.d188.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="176-186" id="miRNA-corp.d188.s2.e1" text="correlation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s3" origId="20463920.s11" text="Interestingly, the highest differentially-expressed miRNAs demonstrated a similar pattern of expression throughout all stages of differentiation, suggesting that they potentially regulate a common target or set of targets in this process. ">
            <entity charOffset="52-57" id="miRNA-corp.d188.s3.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-50" id="miRNA-corp.d188.s3.e1" text="differentially-expressed" type="Relation_Trigger"/>
            <entity charOffset="179-186" id="miRNA-corp.d188.s3.e2" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="197-202" id="miRNA-corp.d188.s3.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="214-220" id="miRNA-corp.d188.s3.e4" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s4" origId="20463920.s14" text="Our results reveal pronounced trends in miRNA expression and their potential mRNA target interactions that could provide valuable insight into the molecular mechanisms of differentiation.   ">
            <entity charOffset="40-44" id="miRNA-corp.d188.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="67-87" id="miRNA-corp.d188.s4.e1" text="potential mRNA target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s5" origId="20463920.s9" text="A comparison of miRNAs from our cultured OLs and OL progenitors showed significant similarities with published results from equivalent cells found in the rat and mouse central nervous system. ">
            <entity charOffset="16-21" id="miRNA-corp.d188.s5.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="162-166" id="miRNA-corp.d188.s5.e1" text="mouse" type="Species"/>
            <entity charOffset="154-156" id="miRNA-corp.d188.s5.e2" text="rat" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s6" origId="20463920.s0" text="MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells.  ">
            <entity charOffset="0-7" id="miRNA-corp.d188.s6.e0" text="MicroRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="70-74" id="miRNA-corp.d188.s6.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s7" origId="20463920.s3" text="However, the molecular mechanisms controlling OL differentiation are largely unknown. "/>
        <sentence id="miRNA-corp.d188.s8" origId="20463920.s4" text="MicroRNAs (miRNAs) are considered the &quot;micromanagers&quot; of gene expression with suggestive roles in cellular differentiation and maintenance. ">
            <entity charOffset="0-8" id="miRNA-corp.d188.s8.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d188.s8.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s9" origId="20463920.s1" text="BACKGROUND: Cells of the oligodendrocyte (OL) lineage play a vital role in the production and maintenance of myelin, a multilamellar membrane which allows for saltatory conduction along axons. "/>
        <sentence id="miRNA-corp.d188.s10" origId="20463920.s2" text="These cells may provide immense therapeutic potential for lost sensory and motor function in demyelinating conditions, such as spinal cord injury, multiple sclerosis, and transverse myelitis. ">
            <entity charOffset="127-144" id="miRNA-corp.d188.s10.e0" text="spinal cord injury" type="Diseases"/>
            <entity charOffset="147-164" id="miRNA-corp.d188.s10.e1" text="multiple sclerosis" type="Diseases"/>
            <entity charOffset="171-189" id="miRNA-corp.d188.s10.e2" text="transverse myelitis" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s11" origId="20463920.s7" text="METHODOLOGY/PRINCIPAL FINDINGS: We isolated cells from 8 stages of OL differentiation. "/>
        <sentence id="miRNA-corp.d188.s12" origId="20463920.s8" text="Total RNA was subjected to miRNA profiling and validations preformed using real-time qRT-PCR. ">
            <entity charOffset="27-31" id="miRNA-corp.d188.s12.e0" text="miRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s13" origId="20463920.s5" text="Although unique patterns of miRNA expression in various cell lineages have been characterized, this is the first report documenting their expression during oligodendrocyte maturation from human embryonic stem (hES) cells. ">
            <entity charOffset="28-32" id="miRNA-corp.d188.s13.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="188-192" id="miRNA-corp.d188.s13.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d188.s14" origId="20463920.s6" text="Here, we performed a global miRNA analysis to reveal and identify characteristic patterns in the multiple stages leading to OL maturation from hES cells including those targeting factors involved in myelin production. ">
            <entity charOffset="28-32" id="miRNA-corp.d188.s14.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="169-177" id="miRNA-corp.d188.s14.e1" text="targeting" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d189" origId="19159078">
        <sentence id="miRNA-corp.d189.s0" origId="19159078.s2" text="Recent evidence indicates that miRNAs can function both as tumor suppressors and as oncogenes. ">
            <entity charOffset="31-36" id="miRNA-corp.d189.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="59-75" id="miRNA-corp.d189.s0.e1" text="tumor suppressors" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s1" origId="19159078.s1" text="MicroRNAs (miRNAs) are small noncoding regulatory RNAs that reduce stability and/or translation of fully or partially sequence-complementary target mRNAs. ">
            <entity charOffset="0-8" id="miRNA-corp.d189.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d189.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="39-48" id="miRNA-corp.d189.s1.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="141-146" id="miRNA-corp.d189.s1.e3" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s2" origId="19159078.s4" text="Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy. ">
            <entity charOffset="183-199" id="miRNA-corp.d189.s2.e0" text="astrocytic tumors" type="Diseases"/>
            <entity charOffset="14-60" id="miRNA-corp.d189.s2.e1" text="miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c" type="Specific_miRNAs"/>
            <entity charOffset="177-181" id="miRNA-corp.d189.s2.e2" text="human" type="Species"/>
            <pair e1="miRNA-corp.d189.s2.e1" e2="miRNA-corp.d189.s2.e0" id="miRNA-corp.d189.s2.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s3" origId="19159078.s3" text="It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated. ">
            <entity charOffset="33-44" id="miRNA-corp.d189.s3.e0" text="glioblastoma" type="Diseases"/>
            <entity charOffset="57-70" id="miRNA-corp.d189.s3.e1" text="miR-21 and 221" type="Specific_miRNAs"/>
            <entity charOffset="96-110" id="miRNA-corp.d189.s3.e2" text="miR-128 and 181" type="Specific_miRNAs"/>
            <entity charOffset="76-86" id="miRNA-corp.d189.s3.e3" text="upregulated" type="Relation_Trigger"/>
            <entity charOffset="116-128" id="miRNA-corp.d189.s3.e4" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d189.s3.e1" e2="miRNA-corp.d189.s3.e0" id="miRNA-corp.d189.s3.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s3.e2" e2="miRNA-corp.d189.s3.e0" id="miRNA-corp.d189.s3.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s4" origId="19159078.s6" text="miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas. ">
            <entity charOffset="0-7" id="miRNA-corp.d189.s4.e0" text="miRNA-21" type="Specific_miRNAs"/>
            <entity charOffset="74-82" id="miRNA-corp.d189.s4.e1" text="miRNA-221" type="Specific_miRNAs"/>
            <entity charOffset="13-26" id="miRNA-corp.d189.s4.e2" text="hyperexpressed" type="Relation_Trigger"/>
            <entity charOffset="57-69" id="miRNA-corp.d189.s4.e3" text="higher levels" type="Relation_Trigger"/>
            <entity charOffset="98-115" id="miRNA-corp.d189.s4.e4" text="high-grade gliomas" type="Diseases"/>
            <entity charOffset="35-39" id="miRNA-corp.d189.s4.e5" text="tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d189.s4.e0" e2="miRNA-corp.d189.s4.e4" id="miRNA-corp.d189.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s4.e0" e2="miRNA-corp.d189.s4.e5" id="miRNA-corp.d189.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s4.e1" e2="miRNA-corp.d189.s4.e4" id="miRNA-corp.d189.s4.p2" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s4.e1" e2="miRNA-corp.d189.s4.e5" id="miRNA-corp.d189.s4.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s5" origId="19159078.s5" text="miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue. ">
            <entity charOffset="0-13" id="miRNA-corp.d189.s5.e0" text="miR-21 and 221" type="Specific_miRNAs"/>
            <entity charOffset="61-70" id="miRNA-corp.d189.s5.e1" text="miRNA 181b" type="Specific_miRNAs"/>
            <entity charOffset="37-42" id="miRNA-corp.d189.s5.e2" text="glioma" type="Diseases"/>
            <entity charOffset="20-32" id="miRNA-corp.d189.s5.e3" text="overexpressed" type="Relation_Trigger"/>
            <entity charOffset="76-88" id="miRNA-corp.d189.s5.e4" text="downregulated" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d189.s5.e0" e2="miRNA-corp.d189.s5.e2" id="miRNA-corp.d189.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s5.e1" e2="miRNA-corp.d189.s5.e2" id="miRNA-corp.d189.s5.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s6" origId="19159078.s8" text="The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.   ">
            <entity charOffset="282-293" id="miRNA-corp.d189.s6.e0" text="brain tumors" type="Diseases"/>
            <entity charOffset="225-230" id="miRNA-corp.d189.s6.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="143-148" id="miRNA-corp.d189.s6.e2" text="target" type="Relation_Trigger"/>
            <entity charOffset="45-50" id="miRNA-corp.d189.s6.e3" text="tumors" type="Diseases"/>
            <entity charOffset="159-164" id="miRNA-corp.d189.s6.e4" text="tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d189.s6.e1" e2="miRNA-corp.d189.s6.e0" id="miRNA-corp.d189.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s6.e1" e2="miRNA-corp.d189.s6.e3" id="miRNA-corp.d189.s6.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s6.e1" e2="miRNA-corp.d189.s6.e4" id="miRNA-corp.d189.s6.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s7" origId="19159078.s7" text="This study is the first analysis of miRNAs in astrocytic tumor at different stages of malignancy. ">
            <entity charOffset="36-41" id="miRNA-corp.d189.s7.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="46-61" id="miRNA-corp.d189.s7.e1" text="astrocytic tumor" type="Diseases"/>
            <pair e1="miRNA-corp.d189.s7.e0" e2="miRNA-corp.d189.s7.e1" id="miRNA-corp.d189.s7.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d189.s8" origId="19159078.s0" text="miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.  ">
            <entity charOffset="0-13" id="miRNA-corp.d189.s8.e0" text="miR-21 and 221" type="Specific_miRNAs"/>
            <entity charOffset="32-39" id="miRNA-corp.d189.s8.e1" text="miR-181b" type="Specific_miRNAs"/>
            <entity charOffset="15-26" id="miRNA-corp.d189.s8.e2" text="upregulation" type="Relation_Trigger"/>
            <entity charOffset="41-54" id="miRNA-corp.d189.s8.e3" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="65-93" id="miRNA-corp.d189.s8.e4" text="grade II-IV astrocytic tumors" type="Diseases"/>
            <entity charOffset="59-63" id="miRNA-corp.d189.s8.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d189.s8.e0" e2="miRNA-corp.d189.s8.e4" id="miRNA-corp.d189.s8.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d189.s8.e1" e2="miRNA-corp.d189.s8.e4" id="miRNA-corp.d189.s8.p1" interaction="True" type="Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d190" origId="19679163">
        <sentence id="miRNA-corp.d190.s0" origId="19679163.s7" text="Not surprisingly, deregulation of REST and ncRNAs are both implicated in the molecular pathophysiology underlying diverse disorders that range from brain cancer and stroke to neurodevelopmental and neurodegenerative diseases. ">
            <entity charOffset="34-37" id="miRNA-corp.d190.s0.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="18-29" id="miRNA-corp.d190.s0.e1" text="deregulation" type="Relation_Trigger"/>
            <entity charOffset="148-159" id="miRNA-corp.d190.s0.e2" text="brain cancer" type="Diseases"/>
            <entity charOffset="165-170" id="miRNA-corp.d190.s0.e3" text="stroke" type="Diseases"/>
            <entity charOffset="198-223" id="miRNA-corp.d190.s0.e4" text="neurodegenerative diseases" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s1" origId="19679163.s8" text="This review summarizes emerging aspects of the complex mechanistic relationships between these intricately interlaced control systems for neural gene expression and function.   "/>
        <sentence id="miRNA-corp.d190.s2" origId="19679163.s3" text="REST and its primary cofactor, CoREST, dynamically recruit highly malleable macromolecular complexes to widely distributed genomic regulatory sequences, including the repressor element-1/neuron restrictive silencer element (RE1/NRSE). ">
            <entity charOffset="0-3" id="miRNA-corp.d190.s2.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="31-36" id="miRNA-corp.d190.s2.e1" text="CoREST" type="Genes/Proteins"/>
            <entity charOffset="131-140" id="miRNA-corp.d190.s2.e2" text="regulatory" type="Relation_Trigger"/>
            <entity charOffset="167-175" id="miRNA-corp.d190.s2.e3" text="repressor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s3" origId="19679163.s4" text="Through epigenetic mechanisms, such as site-specific targeting and higher-order chromatin remodeling, REST and CoREST can mediate cell type- and developmental stage-specific gene repression, gene activation, and long-term gene silencing for protein-coding genes and for several classes of ncRNAs (e.g. microRNAs [miRNAs] and long ncRNAs). ">
            <entity charOffset="302-310" id="miRNA-corp.d190.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="313-318" id="miRNA-corp.d190.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="102-105" id="miRNA-corp.d190.s3.e2" text="REST" type="Genes/Proteins"/>
            <entity charOffset="111-116" id="miRNA-corp.d190.s3.e3" text="CoREST" type="Genes/Proteins"/>
            <entity charOffset="53-61" id="miRNA-corp.d190.s3.e4" text="targeting" type="Relation_Trigger"/>
            <entity charOffset="179-188" id="miRNA-corp.d190.s3.e5" text="repression" type="Relation_Trigger"/>
            <entity charOffset="196-205" id="miRNA-corp.d190.s3.e6" text="activation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d190.s3.e0" e2="miRNA-corp.d190.s3.e2" id="miRNA-corp.d190.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d190.s3.e0" e2="miRNA-corp.d190.s3.e3" id="miRNA-corp.d190.s3.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d190.s3.e1" e2="miRNA-corp.d190.s3.e2" id="miRNA-corp.d190.s3.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d190.s3.e1" e2="miRNA-corp.d190.s3.e3" id="miRNA-corp.d190.s3.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s4" origId="19679163.s5" text="In turn, these ncRNAs have similarly been implicated in the regulation of chromatin architecture and dynamics, transcription, post-transcriptional processing, and RNA editing and trafficking. ">
            <entity charOffset="60-69" id="miRNA-corp.d190.s4.e0" text="regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s5" origId="19679163.s6" text="In addition, REST and CoREST expression and function are tightly regulated by context-specific transcriptional and post-transcriptional mechanisms including bidirectional feedback loops with various ncRNAs. ">
            <entity charOffset="13-16" id="miRNA-corp.d190.s5.e0" text="REST" type="Genes/Proteins"/>
            <entity charOffset="22-27" id="miRNA-corp.d190.s5.e1" text="CoREST" type="Genes/Proteins"/>
            <entity charOffset="65-73" id="miRNA-corp.d190.s5.e2" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s6" origId="19679163.s0" text="Regulation of non-coding RNA networks in the nervous system--what's the REST of the story?  ">
            <entity charOffset="0-9" id="miRNA-corp.d190.s6.e0" text="Regulation" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s7" origId="19679163.s2" text="The repressor element-1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) and non-coding RNAs (ncRNAs) are emerging as key regulators that seem to orchestrate almost every aspect of nervous system development, homeostasis, and plasticity. ">
            <entity charOffset="4-53" id="miRNA-corp.d190.s7.e0" text="repressor element-1 silencing transcription factor" type="Genes/Proteins"/>
            <entity charOffset="55-89" id="miRNA-corp.d190.s7.e1" text="neuron-restrictive silencing factor" type="Genes/Proteins"/>
            <entity charOffset="92-95" id="miRNA-corp.d190.s7.e2" text="REST" type="Genes/Proteins"/>
            <entity charOffset="97-100" id="miRNA-corp.d190.s7.e3" text="NRSF" type="Genes/Proteins"/>
            <entity charOffset="152-161" id="miRNA-corp.d190.s7.e4" text="regulators" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d190.s8" origId="19679163.s1" text="Recent advances are now providing novel insights into the mechanisms that underlie how cellular complexity, diversity, and connectivity are encoded within the genome. "/>
    </document>
    <document id="miRNA-corp.d191" origId="20953120">
        <sentence id="miRNA-corp.d191.s0" origId="20953120.s2" text="The miRNAs in a whole cell regulate greater than 30% of all protein-coding genes. ">
            <entity charOffset="4-9" id="miRNA-corp.d191.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="27-34" id="miRNA-corp.d191.s0.e1" text="regulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d191.s1" origId="20953120.s1" text="MicroRNAs (miRNAs) are a group of small noncoding RNAs that regulate translational repression of multiple target mRNAs. ">
            <entity charOffset="0-8" id="miRNA-corp.d191.s1.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d191.s1.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="69-92" id="miRNA-corp.d191.s1.e2" text="translational repression" type="Relation_Trigger"/>
            <entity charOffset="60-67" id="miRNA-corp.d191.s1.e3" text="regulate" type="Relation_Trigger"/>
            <entity charOffset="106-111" id="miRNA-corp.d191.s1.e4" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d191.s2" origId="20953120.s0" text="MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains.  ">
            <entity charOffset="0-8" id="miRNA-corp.d191.s2.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="71-78" id="miRNA-corp.d191.s2.e1" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="94-112" id="miRNA-corp.d191.s2.e2" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="62-89" id="miRNA-corp.d191.s2.e3" text="aberrant microRNA expression" type="Relation_Trigger"/>
            <entity charOffset="46-50" id="miRNA-corp.d191.s2.e4" text="human" type="Species"/>
            <pair e1="miRNA-corp.d191.s2.e0" e2="miRNA-corp.d191.s2.e2" id="miRNA-corp.d191.s2.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d191.s2.e1" e2="miRNA-corp.d191.s2.e2" id="miRNA-corp.d191.s2.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d191.s3" origId="20953120.s6" text="This review will briefly summarize recent studies that focus attention on aberrant miRNA expression in Alzheimer's disease brains.   ">
            <entity charOffset="83-87" id="miRNA-corp.d191.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="103-121" id="miRNA-corp.d191.s3.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="74-98" id="miRNA-corp.d191.s3.e2" text="aberrant miRNA expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d191.s3.e0" e2="miRNA-corp.d191.s3.e1" id="miRNA-corp.d191.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d191.s4" origId="20953120.s5" text="However, at present, the pathological implications of deregulated miRNA expression in neurodegenerative diseases remain largely unknown. ">
            <entity charOffset="66-70" id="miRNA-corp.d191.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-81" id="miRNA-corp.d191.s4.e1" text="deregulated miRNA expression" type="Relation_Trigger"/>
            <entity charOffset="86-111" id="miRNA-corp.d191.s4.e2" text="neurodegenerative diseases" type="Diseases"/>
            <pair e1="miRNA-corp.d191.s4.e0" e2="miRNA-corp.d191.s4.e2" id="miRNA-corp.d191.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d191.s5" origId="20953120.s4" text="They play a key role in neuronal development, differentiation, and synaptic plasticity. "/>
        <sentence id="miRNA-corp.d191.s6" origId="20953120.s3" text="The vast majority of presently identified miRNAs are expressed in the brain in a spatially and temporally controlled manner. ">
            <entity charOffset="42-47" id="miRNA-corp.d191.s6.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d192" origId="17018300">
        <sentence id="miRNA-corp.d192.s0" origId="17018300.s7" text="Our studies suggest that ban functions downstream of toxicity of the SCA3 protein, to prevent degeneration. ">
            <entity charOffset="69-72" id="miRNA-corp.d192.s0.e0" text="SCA3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s1" origId="17018300.s8" text="These findings indicate that miRNA pathways dramatically modulate polyQ- and tau-induced neurodegeneration, providing the foundation for new insight into therapeutics.   ">
            <entity charOffset="57-64" id="miRNA-corp.d192.s1.e0" text="modulate" type="Relation_Trigger"/>
            <entity charOffset="77-79" id="miRNA-corp.d192.s1.e1" text="tau" type="Genes/Proteins"/>
            <entity charOffset="29-33" id="miRNA-corp.d192.s1.e2" text="miRNA" type="Non-Specific_miRNAs"/>
            <pair e1="miRNA-corp.d192.s1.e2" e2="miRNA-corp.d192.s1.e1" id="miRNA-corp.d192.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s2" origId="17018300.s4" text="To address whether miRNA pathways play a role in neurodegeneration, we tested whether genes critical for miRNA processing modulated toxicity induced by the spinocerebellar ataxia type 3 (SCA3) protein. ">
            <entity charOffset="105-109" id="miRNA-corp.d192.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="122-130" id="miRNA-corp.d192.s2.e1" text="modulated" type="Relation_Trigger"/>
            <entity charOffset="187-190" id="miRNA-corp.d192.s2.e2" text="SCA3" type="Genes/Proteins"/>
            <entity charOffset="19-23" id="miRNA-corp.d192.s2.e3" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="156-199" id="miRNA-corp.d192.s2.e4" text="spinocerebellar ataxia type 3 (SCA3) protein" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d192.s2.e3" e2="miRNA-corp.d192.s2.e2" id="miRNA-corp.d192.s2.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d192.s2.e3" e2="miRNA-corp.d192.s2.e4" id="miRNA-corp.d192.s2.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d192.s2.e0" e2="miRNA-corp.d192.s2.e2" id="miRNA-corp.d192.s2.p2" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d192.s2.e0" e2="miRNA-corp.d192.s2.e4" id="miRNA-corp.d192.s2.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s3" origId="17018300.s3" text="MicroRNAs (miRNAs) have been shown to modulate programmed cell death during development. ">
            <entity charOffset="0-8" id="miRNA-corp.d192.s3.e0" text="MicroRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="11-16" id="miRNA-corp.d192.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="38-45" id="miRNA-corp.d192.s3.e2" text="modulate" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s4" origId="17018300.s6" text="In parallel genetic screens, we identified the miRNA bantam (ban) as a potent modulator of both polyQ and tau toxicity in flies. ">
            <entity charOffset="47-51" id="miRNA-corp.d192.s4.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-86" id="miRNA-corp.d192.s4.e1" text="modulator" type="Relation_Trigger"/>
            <entity charOffset="106-108" id="miRNA-corp.d192.s4.e2" text="tau" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d192.s4.e0" e2="miRNA-corp.d192.s4.e2" id="miRNA-corp.d192.s4.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s5" origId="17018300.s5" text="These studies revealed a striking enhancement of polyQ toxicity upon reduction of miRNA processing in Drosophila and human cells. ">
            <entity charOffset="82-86" id="miRNA-corp.d192.s5.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="117-121" id="miRNA-corp.d192.s5.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s6" origId="17018300.s0" text="MicroRNA pathways modulate polyglutamine-induced neurodegeneration.  ">
            <entity charOffset="18-25" id="miRNA-corp.d192.s6.e0" text="modulate" type="Relation_Trigger"/>
            <entity charOffset="0-7" id="miRNA-corp.d192.s6.e1" text="MicroRNA" type="Non-Specific_miRNAs"/>
        </sentence>
        <sentence id="miRNA-corp.d192.s7" origId="17018300.s2" text="Polyglutamine (polyQ) expansion confers dominant toxicity, resulting in neuronal degeneration. "/>
        <sentence id="miRNA-corp.d192.s8" origId="17018300.s1" text="Nine human neurodegenerative diseases are due to expansion of a CAG repeat- encoding glutamine within the open reading frame of the respective genes. ">
            <entity charOffset="11-36" id="miRNA-corp.d192.s8.e0" text="neurodegenerative diseases" type="Diseases"/>
            <entity charOffset="5-9" id="miRNA-corp.d192.s8.e1" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d193" origId="21166051">
        <sentence id="miRNA-corp.d193.s0" origId="21166051.s5" text="Western blot was applied to analyze the expression of eiF4E3 in both experimental group and control group. ">
            <entity charOffset="54-59" id="miRNA-corp.d193.s0.e0" text="eiF4E3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s1" origId="21166051.s6" text="RESULT: EiF4E3 was the most likely potential targeting protein of microRNA-338. ">
            <entity charOffset="35-61" id="miRNA-corp.d193.s1.e0" text="potential targeting protein" type="Relation_Trigger"/>
            <entity charOffset="66-77" id="miRNA-corp.d193.s1.e1" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="8-13" id="miRNA-corp.d193.s1.e2" text="EiF4E3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d193.s1.e1" e2="miRNA-corp.d193.s1.e2" id="miRNA-corp.d193.s1.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s2" origId="21166051.s3" text="The potential targeting proteins were then selected according to their secondary structures using RNA structure 4.6 software and their involvement in cerebral ischemia and reperfusion injury was studied. ">
            <entity charOffset="150-166" id="miRNA-corp.d193.s2.e0" text="cerebral ischemia" type="Diseases"/>
            <entity charOffset="172-189" id="miRNA-corp.d193.s2.e1" text="reperfusion injury" type="Diseases"/>
            <entity charOffset="14-22" id="miRNA-corp.d193.s2.e2" text="targeting" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s3" origId="21166051.s4" text="Dual-luciferase reporter assay was used to testify whether microRNA-338 can recognize the 3'UTR of target protein. ">
            <entity charOffset="59-70" id="miRNA-corp.d193.s3.e0" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="76-94" id="miRNA-corp.d193.s3.e1" text="recognize the 3'UTR" type="Relation_Trigger"/>
            <entity charOffset="99-104" id="miRNA-corp.d193.s3.e2" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s4" origId="21166051.s1" text="OBJECTIVE: To analyze the interaction between the microRNA-338 and its targeting proteins during the cerebral ischemia and reperfusion injury. ">
            <entity charOffset="50-61" id="miRNA-corp.d193.s4.e0" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="101-117" id="miRNA-corp.d193.s4.e1" text="cerebral ischemia" type="Diseases"/>
            <entity charOffset="123-140" id="miRNA-corp.d193.s4.e2" text="reperfusion injury" type="Diseases"/>
            <entity charOffset="71-79" id="miRNA-corp.d193.s4.e3" text="targeting" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d193.s4.e0" e2="miRNA-corp.d193.s4.e1" id="miRNA-corp.d193.s4.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d193.s4.e0" e2="miRNA-corp.d193.s4.e2" id="miRNA-corp.d193.s4.p1" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s5" origId="21166051.s2" text="METHODS: TargetScan was used to predict the targets of microRNA-338. ">
            <entity charOffset="55-66" id="miRNA-corp.d193.s5.e0" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="44-50" id="miRNA-corp.d193.s5.e1" text="targets" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s6" origId="21166051.s0" text="[Interaction of microRNA-338 and its potential targeting protein eiF4E3].  ">
            <entity charOffset="37-63" id="miRNA-corp.d193.s6.e0" text="potential targeting protein" type="Relation_Trigger"/>
            <entity charOffset="16-27" id="miRNA-corp.d193.s6.e1" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="65-70" id="miRNA-corp.d193.s6.e2" text="eiF4E3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d193.s6.e1" e2="miRNA-corp.d193.s6.e2" id="miRNA-corp.d193.s6.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s7" origId="21166051.s9" text="However, there was no significant difference in the expression of eiF4E3 between these two groups. ">
            <entity charOffset="66-71" id="miRNA-corp.d193.s7.e0" text="eiF4E3" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s8" origId="21166051.s7" text="The secondary structure of local region of eiF4E3 recognizing microRNA-338 was conservative. ">
            <entity charOffset="62-73" id="miRNA-corp.d193.s8.e0" text="microRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="43-48" id="miRNA-corp.d193.s8.e1" text="eiF4E3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d193.s8.e0" e2="miRNA-corp.d193.s8.e1" id="miRNA-corp.d193.s8.p0" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s9" origId="21166051.s8" text="The ratio of firefly to renilla luciferase activity in the experimental group was much higher than that of control group. "/>
        <sentence id="miRNA-corp.d193.s10" origId="21166051.s10" text="CONCLUSION: MicroRNA-338 can recognize the 3'UTR of eiF4E3 while it has no significant effect on the expression of eiF4E3. ">
            <entity charOffset="29-47" id="miRNA-corp.d193.s10.e0" text="recognize the 3'UTR" type="Relation_Trigger"/>
            <entity charOffset="12-23" id="miRNA-corp.d193.s10.e1" text="MicroRNA-338" type="Specific_miRNAs"/>
            <entity charOffset="52-57" id="miRNA-corp.d193.s10.e2" text="eiF4E3" type="Genes/Proteins"/>
            <entity charOffset="115-120" id="miRNA-corp.d193.s10.e3" text="eiF4E3" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d193.s10.e1" e2="miRNA-corp.d193.s10.e2" id="miRNA-corp.d193.s10.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d193.s10.e1" e2="miRNA-corp.d193.s10.e3" id="miRNA-corp.d193.s10.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d193.s11" origId="21166051.s11" text="The post-target-recognizing regulation for miRNA do exist and this mechanism is possibly related to the tertiary structure of target mRNA.   ">
            <entity charOffset="43-47" id="miRNA-corp.d193.s11.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="28-37" id="miRNA-corp.d193.s11.e1" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="126-131" id="miRNA-corp.d193.s11.e2" text="target" type="Relation_Trigger"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d194" origId="17716659">
        <sentence id="miRNA-corp.d194.s0" origId="17716659.s8" text="We conclude that lentiviral expression of anti-ADK miRNA constitutes a versatile tool to generate therapeutically effective adenosine releasing hMSCs, thus representing a model system to generate patient identical autologous adult stem cell grafts.   ">
            <entity charOffset="51-55" id="miRNA-corp.d194.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="196-202" id="miRNA-corp.d194.s0.e1" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s1" origId="17716659.s7" text="While mice with control implants expressing a scrambled miRNA sequence or sham treated control animals were characterized by KA-induced status epilepticus and subsequent CA3 neuronal cell loss, animals with therapeutic ADK knockdown implants displayed a 35% reduction in seizure duration and 65% reduction in CA3 neuronal cell loss, when analyzed 24 h after KA-injection. ">
            <entity charOffset="56-60" id="miRNA-corp.d194.s1.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="136-153" id="miRNA-corp.d194.s1.e1" text="status epilepticus" type="Diseases"/>
            <entity charOffset="219-221" id="miRNA-corp.d194.s1.e2" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="271-277" id="miRNA-corp.d194.s1.e3" text="seizure" type="Diseases"/>
            <entity charOffset="6-9" id="miRNA-corp.d194.s1.e4" text="mice" type="Species"/>
            <pair e1="miRNA-corp.d194.s1.e0" e2="miRNA-corp.d194.s1.e2" id="miRNA-corp.d194.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d194.s1.e0" e2="miRNA-corp.d194.s1.e3" id="miRNA-corp.d194.s1.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d194.s1.e0" e2="miRNA-corp.d194.s1.e1" id="miRNA-corp.d194.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s2" origId="17716659.s6" text="hMSCs with a knockdown of ADK or cells expressing a scrambled control sequence were transplanted into hippocampi of mice 1 week prior to the intraamygdaloid injection of kainic acid (KA). ">
            <entity charOffset="26-28" id="miRNA-corp.d194.s2.e0" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="116-119" id="miRNA-corp.d194.s2.e1" text="mice" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s3" origId="17716659.s5" text="Following lentiviral transduction of hMSCs with anti-ADK miRNA expression cassettes we demonstrate up to 80% downregulation of ADK and a concentration of 8.5 ng adenosine per ml of medium after incubating 10(5) cells for 8 h. ">
            <entity charOffset="57-61" id="miRNA-corp.d194.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="127-129" id="miRNA-corp.d194.s3.e1" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="109-122" id="miRNA-corp.d194.s3.e2" text="downregulation" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d194.s3.e0" e2="miRNA-corp.d194.s3.e1" id="miRNA-corp.d194.s3.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s4" origId="17716659.s4" text="Here we describe a novel approach based on lentiviral RNAi mediated downregulation of adenosine kinase (ADK), the major adenosine-removing enzyme, in human mesenchymal stem cells (hMSCs), which would be compatible with autologous cell grafting in patients. ">
            <entity charOffset="68-81" id="miRNA-corp.d194.s4.e0" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="86-101" id="miRNA-corp.d194.s4.e1" text="adenosine kinase" type="Genes/Proteins"/>
            <entity charOffset="104-106" id="miRNA-corp.d194.s4.e2" text="ADK" type="Genes/Proteins"/>
            <entity charOffset="150-154" id="miRNA-corp.d194.s4.e3" text="human" type="Species"/>
            <entity charOffset="247-254" id="miRNA-corp.d194.s4.e4" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s5" origId="17716659.s3" text="Autologous patient-derived adenosine-releasing cell implants would constitute a major therapeutic advance to avoid both xenotransplantation and immunosuppression. ">
            <entity charOffset="11-17" id="miRNA-corp.d194.s5.e0" text="patient" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s6" origId="17716659.s2" text="However, hitherto used therapeutic cells were derived from rodents and thus not suitable for clinical applications. "/>
        <sentence id="miRNA-corp.d194.s7" origId="17716659.s1" text="Cell therapies based on focal delivery of the inhibitory neuromodulator adenosine were previously shown to provide potent seizure suppression in animal models of epilepsy. ">
            <entity charOffset="122-128" id="miRNA-corp.d194.s7.e0" text="seizure" type="Diseases"/>
            <entity charOffset="162-169" id="miRNA-corp.d194.s7.e1" text="epilepsy" type="Diseases"/>
            <entity charOffset="46-55" id="miRNA-corp.d194.s7.e2" text="inhibitory" type="Relation_Trigger"/>
            <entity charOffset="130-140" id="miRNA-corp.d194.s7.e3" text="suppression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d194.s8" origId="17716659.s0" text="Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.  ">
            <entity charOffset="122-128" id="miRNA-corp.d194.s8.e0" text="seizure" type="Diseases"/>
            <entity charOffset="24-37" id="miRNA-corp.d194.s8.e1" text="downregulation" type="Relation_Trigger"/>
            <entity charOffset="42-57" id="miRNA-corp.d194.s8.e2" text="adenosine kinase" type="Genes/Proteins"/>
            <entity charOffset="62-66" id="miRNA-corp.d194.s8.e3" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d195" origId="19487573">
        <sentence id="miRNA-corp.d195.s0" origId="19487573.s0" text="The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.  ">
            <entity charOffset="64-69" id="miRNA-corp.d195.s0.e0" text="glioma" type="Diseases"/>
            <entity charOffset="29-35" id="miRNA-corp.d195.s0.e1" text="miR-26a" type="Specific_miRNAs"/>
            <entity charOffset="4-7" id="miRNA-corp.d195.s0.e2" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="20-27" id="miRNA-corp.d195.s0.e3" text="microRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="40-48" id="miRNA-corp.d195.s0.e4" text="amplified" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d195.s0.e1" e2="miRNA-corp.d195.s0.e0" id="miRNA-corp.d195.s0.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s0.e1" e2="miRNA-corp.d195.s0.e2" id="miRNA-corp.d195.s0.p1" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d195.s0.e3" e2="miRNA-corp.d195.s0.e0" id="miRNA-corp.d195.s0.p2" interaction="True" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s0.e3" e2="miRNA-corp.d195.s0.e2" id="miRNA-corp.d195.s0.p3" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s1" origId="19487573.s1" text="Activated oncogenic signaling is central to the development of nearly all forms of cancer, including the most common class of primary brain tumor, glioma. ">
            <entity charOffset="147-152" id="miRNA-corp.d195.s1.e0" text="glioma" type="Diseases"/>
            <entity charOffset="134-144" id="miRNA-corp.d195.s1.e1" text="brain tumor" type="Diseases"/>
            <entity charOffset="0-8" id="miRNA-corp.d195.s1.e2" text="Activated" type="Relation_Trigger"/>
            <entity charOffset="83-88" id="miRNA-corp.d195.s1.e3" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s2" origId="19487573.s2" text="Research over the last two decades has revealed the particular importance of the Akt pathway, and its molecular antagonist PTEN (phosphatase and tensin homolog), in the process of gliomagenesis. "/>
        <sentence id="miRNA-corp.d195.s3" origId="19487573.s3" text="Recent studies have also demonstrated that microRNAs (miRNAs) may be responsible for the modulation of cancer-implicated genes in tumors. ">
            <entity charOffset="43-51" id="miRNA-corp.d195.s3.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="54-59" id="miRNA-corp.d195.s3.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="89-98" id="miRNA-corp.d195.s3.e2" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="130-135" id="miRNA-corp.d195.s3.e3" text="tumors" type="Diseases"/>
            <entity charOffset="103-108" id="miRNA-corp.d195.s3.e4" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d195.s3.e0" e2="miRNA-corp.d195.s3.e3" id="miRNA-corp.d195.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s3.e0" e2="miRNA-corp.d195.s3.e4" id="miRNA-corp.d195.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s3.e1" e2="miRNA-corp.d195.s3.e3" id="miRNA-corp.d195.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s3.e1" e2="miRNA-corp.d195.s3.e4" id="miRNA-corp.d195.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s4" origId="19487573.s4" text="Here we report the identification miR-26a as a direct regulator of PTEN expression. ">
            <entity charOffset="67-70" id="miRNA-corp.d195.s4.e0" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="34-40" id="miRNA-corp.d195.s4.e1" text="miR-26a" type="Specific_miRNAs"/>
            <entity charOffset="54-81" id="miRNA-corp.d195.s4.e2" text="regulator of PTEN expression" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d195.s4.e1" e2="miRNA-corp.d195.s4.e0" id="miRNA-corp.d195.s4.p0" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s5" origId="19487573.s5" text="We also show that miR-26a is frequently amplified at the DNA level in human glioma, most often in association with monoallelic PTEN loss. ">
            <entity charOffset="127-130" id="miRNA-corp.d195.s5.e0" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="18-24" id="miRNA-corp.d195.s5.e1" text="miR-26a" type="Specific_miRNAs"/>
            <entity charOffset="76-81" id="miRNA-corp.d195.s5.e2" text="glioma" type="Diseases"/>
            <entity charOffset="40-48" id="miRNA-corp.d195.s5.e3" text="amplified" type="Relation_Trigger"/>
            <entity charOffset="98-135" id="miRNA-corp.d195.s5.e4" text="association with monoallelic PTEN loss" type="Relation_Trigger"/>
            <entity charOffset="70-74" id="miRNA-corp.d195.s5.e5" text="human" type="Species"/>
            <pair e1="miRNA-corp.d195.s5.e1" e2="miRNA-corp.d195.s5.e2" id="miRNA-corp.d195.s5.p0" interaction="True" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s5.e1" e2="miRNA-corp.d195.s5.e0" id="miRNA-corp.d195.s5.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s6" origId="19487573.s6" text="Finally, we demonstrate that miR-26a-mediated PTEN repression in a murine glioma model both enhances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus. ">
            <entity charOffset="46-49" id="miRNA-corp.d195.s6.e0" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="170-173" id="miRNA-corp.d195.s6.e1" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="74-79" id="miRNA-corp.d195.s6.e2" text="glioma" type="Diseases"/>
            <entity charOffset="29-35" id="miRNA-corp.d195.s6.e3" text="miR-26a" type="Specific_miRNAs"/>
            <entity charOffset="51-60" id="miRNA-corp.d195.s6.e4" text="repression" type="Relation_Trigger"/>
            <entity charOffset="109-113" id="miRNA-corp.d195.s6.e5" text="tumor" type="Diseases"/>
            <entity charOffset="67-72" id="miRNA-corp.d195.s6.e6" text="murine" type="Species"/>
            <pair e1="miRNA-corp.d195.s6.e3" e2="miRNA-corp.d195.s6.e5" id="miRNA-corp.d195.s6.p0" interaction="False" type="Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d195.s6.e3" e2="miRNA-corp.d195.s6.e0" id="miRNA-corp.d195.s6.p1" interaction="True" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d195.s6.e3" e2="miRNA-corp.d195.s6.e1" id="miRNA-corp.d195.s6.p2" interaction="False" type="Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d195.s6.e3" e2="miRNA-corp.d195.s6.e2" id="miRNA-corp.d195.s6.p3" interaction="False" type="Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d195.s7" origId="19487573.s7" text="Our results document a new epigenetic mechanism for PTEN regulation in glioma and further highlight dysregulation of Akt signaling as crucial to the development of these tumors.   ">
            <entity charOffset="52-55" id="miRNA-corp.d195.s7.e0" text="PTEN" type="Genes/Proteins"/>
            <entity charOffset="71-76" id="miRNA-corp.d195.s7.e1" text="glioma" type="Diseases"/>
            <entity charOffset="57-66" id="miRNA-corp.d195.s7.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="100-112" id="miRNA-corp.d195.s7.e3" text="dysregulation" type="Relation_Trigger"/>
            <entity charOffset="170-175" id="miRNA-corp.d195.s7.e4" text="tumors" type="Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d196" origId="16917625">
        <sentence id="miRNA-corp.d196.s0" origId="16917625.s3" text="The research was divided into two studies: the first one the test was adapted, and in order to check its capacity to investigate the deficits of SOM, it has applied in groups of 10 (ten) subjects, one group with patients that have Alzheimer disease and the other one with healthy elderly (p&lt;0.001). ">
            <entity charOffset="231-247" id="miRNA-corp.d196.s0.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="212-219" id="miRNA-corp.d196.s0.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d196.s1" origId="16917625.s2" text="This study had the purpose to adapt a test based in these experiments in order to check the performance of SOM and the participation of hippocampus into SOM in patients with mesial temporal sclerosis (MTS). ">
            <entity charOffset="174-198" id="miRNA-corp.d196.s1.e0" text="mesial temporal sclerosis" type="Diseases"/>
            <entity charOffset="201-203" id="miRNA-corp.d196.s1.e1" text="MTS" type="Diseases"/>
            <entity charOffset="160-167" id="miRNA-corp.d196.s1.e2" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d196.s2" origId="16917625.s1" text="Experimental studies have identified pyramidal cells in hippocampus in rats with participation in the spatial orientation memory (SOM), which are named location cells. ">
            <entity charOffset="71-74" id="miRNA-corp.d196.s2.e0" text="rats" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d196.s3" origId="16917625.s0" text="[Spatial orientation memory: evaluation in patents with Alzheimer disease and temporal lobe epilepsy].  ">
            <entity charOffset="56-72" id="miRNA-corp.d196.s3.e0" text="Alzheimer disease" type="Diseases"/>
            <entity charOffset="78-99" id="miRNA-corp.d196.s3.e1" text="temporal lobe epilepsy" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d196.s4" origId="16917625.s4" text="The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p&lt;0,05 between MTS and SAH and between controlled and SAH. ">
            <entity charOffset="97-121" id="miRNA-corp.d196.s4.e0" text="mesial temporal sclerosis" type="Diseases"/>
            <entity charOffset="124-126" id="miRNA-corp.d196.s4.e1" text="MTS" type="Diseases"/>
            <entity charOffset="237-239" id="miRNA-corp.d196.s4.e2" text="MTS" type="Diseases"/>
            <entity charOffset="79-86" id="miRNA-corp.d196.s4.e3" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d196.s5" origId="16917625.s5" text="It was shown that the test of SOM is suitable to evaluate deficits, but it seems the SOM is not a specific function of human hippocampus.   ">
            <entity charOffset="119-123" id="miRNA-corp.d196.s5.e0" text="human" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d197" origId="21080802">
        <sentence id="miRNA-corp.d197.s0" origId="21080802.s0" text="Potential role of miRNAs and their inhibitors in glioma treatment.  ">
            <entity charOffset="18-23" id="miRNA-corp.d197.s0.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="49-54" id="miRNA-corp.d197.s0.e1" text="glioma" type="Diseases"/>
            <entity charOffset="35-44" id="miRNA-corp.d197.s0.e2" text="inhibitors" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d197.s0.e0" e2="miRNA-corp.d197.s0.e1" id="miRNA-corp.d197.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d197.s1" origId="21080802.s1" text="Recent years have seen an intense period of research on the functions of miRNAs, recently discovered key regulators of gene expression that act through suppression of translation of target mRNAs. ">
            <entity charOffset="73-78" id="miRNA-corp.d197.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="105-114" id="miRNA-corp.d197.s1.e1" text="regulators" type="Relation_Trigger"/>
            <entity charOffset="152-177" id="miRNA-corp.d197.s1.e2" text="suppression of translation" type="Relation_Trigger"/>
            <entity charOffset="182-187" id="miRNA-corp.d197.s1.e3" text="target" type="Relation_Trigger"/>
            <entity charOffset="124-162" id="miRNA-corp.d197.s1.e4" text="expression that act through suppression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d197.s2" origId="21080802.s2" text="Several hundred miRNAs have been identified in humans, and these show characteristic expression patterns, depending on tissue type, cell type or environmental stimuli. ">
            <entity charOffset="16-21" id="miRNA-corp.d197.s2.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-52" id="miRNA-corp.d197.s2.e1" text="humans" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d197.s3" origId="21080802.s3" text="Like other types of cancer, the brain tumor glioblastoma shows a distinct miRNA expression signature, and a number of recent studies have linked these miRNA alterations to key hallmarks of glioblastoma including proliferation, survival, invasion, angiogenesis and stem cell-like behavior. ">
            <entity charOffset="74-78" id="miRNA-corp.d197.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="151-155" id="miRNA-corp.d197.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="32-42" id="miRNA-corp.d197.s3.e2" text="brain tumor" type="Diseases"/>
            <entity charOffset="44-55" id="miRNA-corp.d197.s3.e3" text="glioblastoma" type="Diseases"/>
            <entity charOffset="189-200" id="miRNA-corp.d197.s3.e4" text="glioblastoma" type="Diseases"/>
            <entity charOffset="20-25" id="miRNA-corp.d197.s3.e5" text="cancer" type="Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e0" e2="miRNA-corp.d197.s3.e4" id="miRNA-corp.d197.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e0" e2="miRNA-corp.d197.s3.e5" id="miRNA-corp.d197.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e0" e2="miRNA-corp.d197.s3.e2" id="miRNA-corp.d197.s3.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e0" e2="miRNA-corp.d197.s3.e3" id="miRNA-corp.d197.s3.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e1" e2="miRNA-corp.d197.s3.e4" id="miRNA-corp.d197.s3.p4" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e1" e2="miRNA-corp.d197.s3.e5" id="miRNA-corp.d197.s3.p5" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e1" e2="miRNA-corp.d197.s3.e2" id="miRNA-corp.d197.s3.p6" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s3.e1" e2="miRNA-corp.d197.s3.e3" id="miRNA-corp.d197.s3.p7" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d197.s4" origId="21080802.s4" text="These studies have opened the door to the possibility of utilizing miRNAs or miRNA antagonists as therapeutic agents for the treatment of brain tumors.   ">
            <entity charOffset="67-72" id="miRNA-corp.d197.s4.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="77-81" id="miRNA-corp.d197.s4.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="138-149" id="miRNA-corp.d197.s4.e2" text="brain tumors" type="Diseases"/>
            <pair e1="miRNA-corp.d197.s4.e0" e2="miRNA-corp.d197.s4.e2" id="miRNA-corp.d197.s4.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d197.s4.e1" e2="miRNA-corp.d197.s4.e2" id="miRNA-corp.d197.s4.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d198" origId="17897455">
        <sentence id="miRNA-corp.d198.s0" origId="17897455.s0" text="pHUSH: a single vector system for conditional gene expression.  "/>
        <sentence id="miRNA-corp.d198.s1" origId="17897455.s4" text="RESULTS: Both Pol II and Pol III promoters have been successfully combined with a second expression cassette containing a codon-optimized tetracycline repressor and selectable marker. ">
            <entity charOffset="151-159" id="miRNA-corp.d198.s1.e0" text="repressor" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d198.s2" origId="17897455.s3" text="We have therefore developed pHUSH, an inducible expression system that allows regulated expression of shRNA, miRNA or cDNA cassettes on a single viral vector. ">
            <entity charOffset="109-113" id="miRNA-corp.d198.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="78-97" id="miRNA-corp.d198.s2.e1" text="regulated expression" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d198.s3" origId="17897455.s2" text="However, most systems require multiple plasmids that must be independently engineered into the target system, resulting in experimental delay and an increased potential for selection of a cell subpopulation that differs significantly from the parental line. ">
            <entity charOffset="95-100" id="miRNA-corp.d198.s3.e0" text="target" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d198.s4" origId="17897455.s1" text="BACKGROUND: Conditional expression vectors have become a valuable research tool to avoid artefacts that may result from traditional gene expression studies. "/>
        <sentence id="miRNA-corp.d198.s5" origId="17897455.s7" text="These studies demonstrate the broad application potential of pHUSH for conditional genetic engineering in mammalian cells.   "/>
        <sentence id="miRNA-corp.d198.s6" origId="17897455.s6" text="CONCLUSION: We have successfully developed and employed a single vector system that enables Doxycycline regulated RNAi or transgene expression in a variety of in vitro and in vivo model systems. ">
            <entity charOffset="104-112" id="miRNA-corp.d198.s6.e0" text="regulated" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d198.s7" origId="17897455.s5" text="We provide examples of how pHUSH has been successfully employed to study the function of target genes in a number of cell types within in vitro and in vivo assays, including conditional gene knockdown in a murine model of brain cancer. ">
            <entity charOffset="89-94" id="miRNA-corp.d198.s7.e0" text="target" type="Relation_Trigger"/>
            <entity charOffset="222-233" id="miRNA-corp.d198.s7.e1" text="brain cancer" type="Diseases"/>
            <entity charOffset="206-211" id="miRNA-corp.d198.s7.e2" text="murine" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d199" origId="21445348">
        <sentence id="miRNA-corp.d199.s0" origId="21445348.s13" text="SIGNIFICANCE: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in children, suggesting a higher incidence of CPC in southern Brazil.   ">
            <entity charOffset="65-68" id="miRNA-corp.d199.s0.e0" text="TP53" type="Genes/Proteins"/>
            <entity charOffset="109-111" id="miRNA-corp.d199.s0.e1" text="CPC" type="Diseases"/>
            <entity charOffset="165-167" id="miRNA-corp.d199.s0.e2" text="CPC" type="Diseases"/>
            <entity charOffset="122-129" id="miRNA-corp.d199.s0.e3" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s1" origId="21445348.s12" text="Family history of cancer (with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/14) of them were compatible with Li-Fraumeni-like syndrome. ">
            <entity charOffset="18-23" id="miRNA-corp.d199.s1.e0" text="cancer" type="Diseases"/>
            <entity charOffset="179-203" id="miRNA-corp.d199.s1.e1" text="Li-Fraumeni-like syndrome" type="Diseases"/>
            <entity charOffset="41-46" id="miRNA-corp.d199.s1.e2" text="cancer" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s2" origId="21445348.s11" text="Cure (&gt;5 years survival free of disease) was observed in 18.1% of the CPC cases with the R337H mutation (2/11), 71.4% of the Pp (5/7), and 25% of CPC cases negative for the R337H mutation (2/8). ">
            <entity charOffset="70-72" id="miRNA-corp.d199.s2.e0" text="CPC" type="Diseases"/>
            <entity charOffset="146-148" id="miRNA-corp.d199.s2.e1" text="CPC" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s3" origId="21445348.s10" text="All Pp cases (7/7, 100%) were negative for R337H. "/>
        <sentence id="miRNA-corp.d199.s4" origId="21445348.s8" text="We found 63.3% (14/22) of the CPC patients positive for the germline R337H mutation; CPC samples were either heterozygous (n = 7), lost only the wild-type (n = 4), or only the R337H copy (n = 2). ">
            <entity charOffset="85-87" id="miRNA-corp.d199.s4.e0" text="CPC" type="Diseases"/>
            <entity charOffset="34-41" id="miRNA-corp.d199.s4.e1" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s5" origId="21445348.s9" text="One CPC sample was not available. "/>
	    <entity charOffset="4-6" id="miRNA-corp.d199.s5.e0" text="CPC" type="Diseases"/>
        <sentence id="miRNA-corp.d199.s6" origId="21445348.s6" text="The patients, all parents, and some relatives submitted samples for blood DNA analysis. ">
            <entity charOffset="4-11" id="miRNA-corp.d199.s6.e0" text="patients" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s7" origId="21445348.s7" text="In addition, we have also examined the presence of the mutation in DNA from paraffin-embedded tumor samples to evaluate loss of heterozygosity. ">
            <entity charOffset="94-98" id="miRNA-corp.d199.s7.e0" text="tumor" type="Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s8" origId="21445348.s1" text="BACKGROUND: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children. ">
            <entity charOffset="12-36" id="miRNA-corp.d199.s8.e0" text="Choroid plexus carcinomas" type="Diseases"/>
            <entity charOffset="39-41" id="miRNA-corp.d199.s8.e1" text="CPC" type="Diseases"/>
            <entity charOffset="53-58" id="miRNA-corp.d199.s8.e2" text="tumors" type="Diseases"/>
            <entity charOffset="83-90" id="miRNA-corp.d199.s8.e3" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s9" origId="21445348.s0" text="Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil.  ">
            <entity charOffset="38-46" id="miRNA-corp.d199.s9.e0" text="carcinoma" type="Diseases"/>
            <entity charOffset="68-71" id="miRNA-corp.d199.s9.e1" text="TP53" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s10" origId="21445348.s5" text="Blood and/or tumor DNA was extracted and analyzed using PCR-RFLP and results were confirmed by sequencing 240 bp of the TP53 exon 10. ">
            <entity charOffset="13-17" id="miRNA-corp.d199.s10.e0" text="tumor" type="Diseases"/>
            <entity charOffset="120-123" id="miRNA-corp.d199.s10.e1" text="TP53" type="Genes/Proteins"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s11" origId="21445348.s4" text="Surgical resection was possible in 28 children. ">
            <entity charOffset="38-45" id="miRNA-corp.d199.s11.e0" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s12" origId="21445348.s3" text="METHODOLOGY/PRINCIPAL FINDINGS: The present series included 29 patients that were admitted to the same institution from 1992 to 2010, including 22 children with CPC (0.08-13.6 years of age at diagnosis) and 7 children with papilloma of the choroid plexus (Pp; 0.5-9.8 years of age). ">
            <entity charOffset="223-231" id="miRNA-corp.d199.s12.e0" text="papilloma" type="Diseases"/>
            <entity charOffset="63-70" id="miRNA-corp.d199.s12.e1" text="patients" type="Species"/>
            <entity charOffset="147-154" id="miRNA-corp.d199.s12.e2" text="children" type="Species"/>
            <entity charOffset="209-216" id="miRNA-corp.d199.s12.e3" text="children" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d199.s13" origId="21445348.s2" text="Given the high frequency of the germline R337H mutation in the TP53 gene in southern Brazil, we have evaluated the frequency of the R337H mutation in families with CPC in children. ">
            <entity charOffset="63-66" id="miRNA-corp.d199.s13.e0" text="TP53" type="Genes/Proteins"/>
            <entity charOffset="164-166" id="miRNA-corp.d199.s13.e1" text="CPC" type="Diseases"/>
            <entity charOffset="171-178" id="miRNA-corp.d199.s13.e2" text="children" type="Species"/>
        </sentence>
    </document>
    <document id="miRNA-corp.d200" origId="19536656">
        <sentence id="miRNA-corp.d200.s0" origId="19536656.s6" text="Here, we present an overview of the current progress in miRNA research related to CNS disorders and also highlight the utility of LNA (locked nucleic acid)-modified oligonucleotides in the detection and modulation of miRNA activity.   ">
            <entity charOffset="56-60" id="miRNA-corp.d200.s0.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="217-221" id="miRNA-corp.d200.s0.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="203-212" id="miRNA-corp.d200.s0.e2" text="modulation" type="Relation_Trigger"/>
            <entity charOffset="82-94" id="miRNA-corp.d200.s0.e3" text="CNS disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d200.s0.e0" e2="miRNA-corp.d200.s0.e3" id="miRNA-corp.d200.s0.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d200.s0.e1" e2="miRNA-corp.d200.s0.e3" id="miRNA-corp.d200.s0.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s1" origId="19536656.s5" text="Recent studies have identified a molecular and ultimately pathogenic role for a subset of miRNAs in Alzheimer's disease and schizophrenia, including the characterization of their downstream CNS mRNA targets, such as beta-secretase (BACE1) and calmodulin-dependent protein kinase II (CaMKII). ">
            <entity charOffset="90-95" id="miRNA-corp.d200.s1.e0" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="100-118" id="miRNA-corp.d200.s1.e1" text="Alzheimer's disease" type="Diseases"/>
            <entity charOffset="124-136" id="miRNA-corp.d200.s1.e2" text="schizophrenia" type="Diseases"/>
            <entity charOffset="232-236" id="miRNA-corp.d200.s1.e3" text="BACE1" type="Genes/Proteins"/>
            <entity charOffset="199-205" id="miRNA-corp.d200.s1.e4" text="targets" type="Relation_Trigger"/>
            <entity charOffset="216-229" id="miRNA-corp.d200.s1.e5" text="beta-secretase" type="Genes/Proteins"/>
            <pair e1="miRNA-corp.d200.s1.e0" e2="miRNA-corp.d200.s1.e3" id="miRNA-corp.d200.s1.p0" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d200.s1.e0" e2="miRNA-corp.d200.s1.e5" id="miRNA-corp.d200.s1.p1" interaction="False" type="Non-Specific_miRNAs-Genes/Proteins"/>
            <pair e1="miRNA-corp.d200.s1.e0" e2="miRNA-corp.d200.s1.e1" id="miRNA-corp.d200.s1.p2" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d200.s1.e0" e2="miRNA-corp.d200.s1.e2" id="miRNA-corp.d200.s1.p3" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s2" origId="19536656.s4" text="The intricate molecular networks mediated by an miRNA form a robust mechanism for rapid and potent responses to cellular events throughout the development of the human brain. ">
            <entity charOffset="48-52" id="miRNA-corp.d200.s2.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="162-166" id="miRNA-corp.d200.s2.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s3" origId="19536656.s3" text="Disruption of miRNA-based post-transcriptional regulation has been implicated in a range of CNS disorders as one miRNA is predicted to impact the expression of numerous downstream mRNA targets. ">
            <entity charOffset="113-117" id="miRNA-corp.d200.s3.e0" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="14-18" id="miRNA-corp.d200.s3.e1" text="miRNA" type="Non-Specific_miRNAs"/>
            <entity charOffset="47-56" id="miRNA-corp.d200.s3.e2" text="regulation" type="Relation_Trigger"/>
            <entity charOffset="92-104" id="miRNA-corp.d200.s3.e3" text="CNS disorders" type="Diseases"/>
            <entity charOffset="185-191" id="miRNA-corp.d200.s3.e4" text="targets" type="Relation_Trigger"/>
            <pair e1="miRNA-corp.d200.s3.e1" e2="miRNA-corp.d200.s3.e3" id="miRNA-corp.d200.s3.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
            <pair e1="miRNA-corp.d200.s3.e0" e2="miRNA-corp.d200.s3.e3" id="miRNA-corp.d200.s3.p1" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s4" origId="19536656.s2" text="Hundreds of non-coding regulatory RNA molecules called microRNAs (miRNAs) have been identified in the mammalian central nervous system (CNS) and are reported to mediate pivotal roles in many aspects of neuronal functions. ">
            <entity charOffset="55-63" id="miRNA-corp.d200.s4.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="66-71" id="miRNA-corp.d200.s4.e1" text="miRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="23-32" id="miRNA-corp.d200.s4.e2" text="regulatory" type="Relation_Trigger"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s5" origId="19536656.s1" text="In recent years, there has been a shift in the conventional paradigms for transcriptional and translational regulation as extensive sequencing efforts have yielded new insights into the landscape of the human genome and transcriptome. ">
            <entity charOffset="94-117" id="miRNA-corp.d200.s5.e0" text="translational regulation" type="Relation_Trigger"/>
            <entity charOffset="203-207" id="miRNA-corp.d200.s5.e1" text="human" type="Species"/>
        </sentence>
        <sentence id="miRNA-corp.d200.s6" origId="19536656.s0" text="microRNAs in CNS disorders.  ">
            <entity charOffset="0-8" id="miRNA-corp.d200.s6.e0" text="microRNAs" type="Non-Specific_miRNAs"/>
            <entity charOffset="13-25" id="miRNA-corp.d200.s6.e1" text="CNS disorders" type="Diseases"/>
            <pair e1="miRNA-corp.d200.s6.e0" e2="miRNA-corp.d200.s6.e1" id="miRNA-corp.d200.s6.p0" interaction="False" type="Non-Specific_miRNAs-Diseases"/>
        </sentence>
    </document>
</corpus>
